<SEC-DOCUMENT>0001564590-13-000015.txt : 20130513
<SEC-HEADER>0001564590-13-000015.hdr.sgml : 20130513
<ACCEPTANCE-DATETIME>20130513172258
ACCESSION NUMBER:		0001564590-13-000015
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20130331
FILED AS OF DATE:		20130513
DATE AS OF CHANGE:		20130513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		13838441

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>abio-10q_20130331.htm
<DESCRIPTION>FORM 10-Q
<TEXT>

<HTML>
<HEAD></HEAD>
<BODY BGCOLOR="WHITE">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:1.00pt;margin-bottom:-0.05pt;text-align:center;line-height:1.00pt;; border-top:solid 0.75pt;font-size:4.00pt;; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:1.00pt;margin-bottom:-0.05pt;text-align:center;line-height:1.00pt;; border-top:solid 1.00pt;font-size:4.00pt;; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:1.00pt;margin-bottom:-0.05pt;text-align:center;line-height:1.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:4.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:3.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 18.00pt; font-weight: Bold; ">UNITED STATES </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 18.00pt; font-weight: Bold; ">SECURITIES AND EXCHANGE COMMISSION </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 12.00pt; font-weight: Bold; ">WASHINGTON, D.C. 20549 </FONT></P>
<P STYLE="margin-top:4.00pt;margin-bottom:-0.05pt;text-align:center;line-height:4.00pt;; border-bottom:solid 1.00pt;margin-right:144.00pt;font-size:6.00pt;; margin-left:144.00pt; text-indent:0.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P><center></center>
<P STYLE="margin-top:4.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 18.00pt; font-weight: Bold; ">FORM 10-Q </FONT></P>
<P STYLE="margin-top:4.00pt;margin-bottom:-0.05pt;text-align:center;line-height:4.00pt;; border-bottom:solid 1.00pt;margin-right:144.00pt;font-size:6.00pt;; margin-left:144.00pt; text-indent:0.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P><center></center>
<P STYLE="margin-top:8.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(Mark One) </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Wingdings; font-size: 10.00pt; "></FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:8.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2013 </FONT></P>
<P STYLE="margin-top:8.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">OR </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:8.00pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Wingdings; font-size: 10.00pt; "></FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:8.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">FOR THE TRANSITION PERIOD FROM &nbsp;          </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; "> TO              </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Commission File Number 000-22873 </FONT></P>
<P STYLE="margin-top:4.00pt;margin-bottom:-0.05pt;text-align:center;line-height:4.00pt;; border-bottom:solid 1.00pt;margin-right:144.00pt;font-size:6.00pt;; margin-left:144.00pt; text-indent:0.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P><center></center>
<P STYLE="margin-top:4.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 24.00pt; font-weight: Bold; ">ARCA BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(Exact Name of Registrant as Specified in Its Charter) </FONT></P>
<P STYLE="margin-top:4.00pt;margin-bottom:-0.05pt;text-align:center;line-height:4.00pt;; border-bottom:solid 1.00pt;margin-right:144.00pt;font-size:6.00pt;; margin-left:144.00pt; text-indent:0.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P><center></center>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:50.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Delaware</FONT></P></TD>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:50.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">36-3855489</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:50.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">(State or Other Jurisdiction of</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Incorporation or Organization)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:50.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">(I.R.S. Employer</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Identification Number)</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:50.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">8001 Arista Place, Suite 430 Broomfield, CO</FONT></P></TD>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:50.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">80021</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:50.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">(Address of Principal Executive Offices)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:50.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">(Zip Code)</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">(720) 940-2200 </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">(Registrant&#146;s Telephone Number, including Area Code) </FONT></P>
<P STYLE="margin-top:4.00pt;margin-bottom:-0.05pt;text-align:center;line-height:4.00pt;; border-bottom:solid 1.00pt;margin-right:144.00pt;font-size:6.00pt;; margin-left:144.00pt; text-indent:0.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P><center></center>
<P STYLE="margin-top:4.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  </FONT><FONT STYLE="font-family: Wingdings; font-size: 10.00pt; "></FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>    <FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">No  </FONT><FONT STYLE="font-family: Wingdings; font-size: 10.00pt; "></FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  </FONT><FONT STYLE="font-family: Wingdings; font-size: 10.00pt; "></FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>    <FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">No   </FONT><FONT STYLE="font-family: Wingdings; font-size: 10.00pt; "></FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:4.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR>
   <TD VALIGN="center" STYLE="WIDTH:100.75pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Large accelerated filer</FONT></P></TD>
   <TD VALIGN="center" STYLE="WIDTH:26.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P></TD>
   <TD VALIGN="top" STYLE="WIDTH:268.85pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" STYLE="WIDTH:121.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Accelerated filer</FONT></P></TD>
   <TD VALIGN="center" STYLE="WIDTH:29.25pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P></TD></TR>
<TR STYLE="height:1.45pt">
   <TD VALIGN="bottom" STYLE="WIDTH:100.75pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Non-accelerated filer</FONT></P></TD>
   <TD VALIGN="bottom" STYLE="WIDTH:26.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P></TD>
   <TD VALIGN="bottom" STYLE="WIDTH:268.85pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(Do not check if smaller reporting company)</FONT></P></TD>
   <TD VALIGN="bottom" STYLE="WIDTH:121.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Smaller reporting company</FONT></P></TD>
   <TD VALIGN="bottom" STYLE="WIDTH:29.25pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </FONT><FONT STYLE="font-family: Wingdings; font-size: 10.00pt; "></FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> <FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">No </FONT><FONT STYLE="font-family: Wingdings; font-size: 10.00pt; "></FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:4.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Indicate the number of shares outstanding of each of the issuer&#146;s classes of common stock, as of the latest practicable date. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:99.84%; ">
<TR STYLE="height:4.50pt">
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:50.26%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Class</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:49.74%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Number of <BR>Shares Outstanding</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:50.26%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; border-top:solid 0.75pt;margin-right:124.55pt;font-size:1.00pt;; margin-left:124.55pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:49.74%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; border-top:solid 0.75pt;margin-right:93.60pt;font-size:1.00pt;; margin-left:93.60pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:12.00pt; text-indent:-12.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Common Stock $0.001 par value</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:49.74%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">On May 10, 2013: &nbsp;3,185,562</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:7.50pt;margin-bottom:-0.05pt;text-align:left;line-height:1.00pt;; border-top:solid 0.75pt;font-size:12.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:1.00pt;margin-bottom:-0.05pt;text-align:left;line-height:1.00pt;; margin-left:0.00pt; text-indent:-0.00pt; font-size:4.00pt">&nbsp;&nbsp;&nbsp; </P>
&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><A NAME="Break2"></A> </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:18.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ARCA BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">FORM 10-Q </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">FOR THE QUARTER ENDED MARCH 31, 2013 </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.32%; ">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:2.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:4.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:2.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:4.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">PAGE</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:1.00pt;; border-top:solid 1.00pt;font-size:4.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" COLSPAN="2" STYLE="WIDTH:92.36%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Part I Financial Information</FONT></P></TD>
   <TD VALIGN="bottom" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:2.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:4.00pt"></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_1"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 1. Consolidated Financial Statements (unaudited) </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_2"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 2. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">18</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_3"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 3. Quantitative and Qualitative Disclosures about Market Risk </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">23</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_4"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 4. Controls and Procedures </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">23</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" COLSPAN="2" STYLE="WIDTH:92.36%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Part II Other Information</FONT></P></TD>
   <TD VALIGN="bottom" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_1_II"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 1. Legal Proceedings </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">24</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_1A_II"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 1A. Risk Factors </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">24</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_2_II"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">42</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_3_II"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 3. Defaults Upon Senior Securities </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">42</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_4_II"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 4. Mine Safety Disclosures </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">42</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_5_II"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 5. Other Information </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">42</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:12.00pt; text-indent:-12.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#ITEM_6_II"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Item 6. Exhibits </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">43</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:5.14%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:87.20%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:7.64%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" COLSPAN="2" STYLE="WIDTH:92.36%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.00pt; text-indent:-12.00pt"><A HREF="#SIGNATURES"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Signature </FONT></A>&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:7.64%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">45</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;2&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break3"></A> </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">PART I. FINANCIAL INFORMATION </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:10.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="ITEM_1"></A><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM&nbsp;1.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">CONSOLIDATED FINANCIAL STATEMENTS</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:18.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ARCA BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(a development stage enterprise) </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">CONSOLIDATED BALANCE SHEETS </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(Unaudited) </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">March 31,</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">December 31,</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:13.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">2013&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:13.80%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">2012&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:7.20pt">
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(in thousands, except share and per share amounts)</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ASSETS</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Current assets:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:3.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Cash and cash equivalents</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3,537&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">2,920&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:3.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Other current assets</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">456&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">125&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Total current assets</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3,993&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3,045&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:-0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Property and equipment, net</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">22&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">23&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:-0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Other assets</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">124&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">144&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Total assets</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-top:solid 0.75pt #000000; border-bottom:double 1.50pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">4,139&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-top:solid 0.75pt #000000; border-bottom:double 1.50pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3,212&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:35.10pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">LIABILITIES AND STOCKHOLDERS&#146; EQUITY</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-top:double 1.50pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.80%; border-top:double 1.50pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:-0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Current liabilities:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:3.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Accounts payable</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">377&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">65&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:3.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Accrued compensation and employee benefits</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">60&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">103&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:3.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Accrued expenses and other liabilities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">383&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">121&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:3.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Deferred rent, current portion</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">8&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">16&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Total current liabilities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">828&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">305&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Total liabilities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">828&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">305&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:-0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Commitments and contingencies</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.80%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:-0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Stockholders&#146; equity:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:3.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Common stock, $0.001 par value; 100 million shares authorized at March 31, 2013</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:12.60pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">and December 31, 2012; &nbsp;3,185,562 and 2,660,315 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively.</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:3.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Additional paid-in capital</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">72,373&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">70</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,898&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:3.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Deficit accumulated during the development stage</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(69,065)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(67,994)</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Total stockholders&#146; equity</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3,311&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">2,907&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:66.92%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Total liabilities and stockholders&#146; equity</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.04%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.00%; border-top:solid 0.75pt #000000; border-bottom:double 1.50pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">4,139&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:3.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:13.80%; border-top:solid 0.75pt #000000; border-bottom:double 1.50pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3,212&nbsp;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">See accompanying notes to consolidated financial statements </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;3&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><A NAME="Break4"></A> </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ARCA BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(a development stage enterprise) </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(unaudited) </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:12.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR STYLE="height:35.25pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ROWSPAN="3" ALIGN="center" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">Period from December 17, 2001 (date of inception) to March 31, 2013</FONT></P></TD></TR>
<TR STYLE="height:27.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">Three Months Ended  <BR>March 31,</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:14.25pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">2013&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">2012&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:21.10pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" COLSPAN="5" ALIGN="center" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(in thousands, except share and  <BR>per share amounts)</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Costs and expenses:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:8.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Research and development</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">181&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">422&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">42,858&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:8.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Selling, general and administrative</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">889&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">984&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">43,472&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:8.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Merger transaction costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">5</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,470&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:8.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Restructuring expense, net</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">2</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,413&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:8.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Loss on impairment of in-process research and development</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">6</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,000&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Total costs and expenses</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">1,070&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">1,406&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">100,213&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Loss from operations</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,070)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,406)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(100,213)&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:35.10pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Gain on assignment of patent rights</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">2</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,000&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Gain on bargain purchase</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">25</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,282&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Interest and other income</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">2</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,028&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Interest and other expense</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(443)&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Loss before income taxes</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,071)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,407)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(71,346)&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Benefit from income taxes</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">2</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,281&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:35.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Net loss and comprehensive loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:double 2.25pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,071)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:double 2.25pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,407)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; border-bottom:double 2.25pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(69,065)&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.25pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:double 2.25pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:double 2.25pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:double 2.25pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Less: &nbsp;Accretion of redeemable convertible preferred stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">245</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">)&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:8.10pt; text-indent:-8.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Less: &nbsp;Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">781</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">)&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-top:solid 0.75pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Net loss attributable to common stockholders</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:double 2.25pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,071)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:double 2.25pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,407)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; border-bottom:double 2.25pt #000000; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(70,091)&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Net loss attributable to common stockholders per share:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:17.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Basic and diluted</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(0.35)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(0.69)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:7.20pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Weighted average shares outstanding:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.14%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:17.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Basic and diluted</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.62%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">3,034,763&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">2,027,716&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.60%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00%; padding-left:5.75pt; padding-right:5.75pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">See accompanying notes to consolidated financial statements </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;4&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><A NAME="Break5"></A> </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ARCA BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(a development stage enterprise) </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">CONSOLIDATED STATEMENTS OF PREFERRED STOCK AND STOCKHOLDERS&#146; EQUITY (DEFICIT) </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(unaudited) </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="WIDTH:250.60pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Preferred Stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="WIDTH:326.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Stockholders&#146; Equity (Deficit)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="WIDTH:250.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="WIDTH:326.20pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:7.65pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Series A</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Series B</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ROWSPAN="5" ALIGN="center" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Additional Paid In Capital</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ROWSPAN="5" ALIGN="center" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Deficit Accumulated During the Development Stage</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:3.50pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Redeemable</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Redeemable</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:3.50pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Convertible Preferred Stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Convertible Preferred Stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Common stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:3.50pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.30pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.30pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:118.35pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Shares</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Amount</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Shares</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Amount</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Shares</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Amount</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">Total</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:54.90pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:48.05pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:54.90pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:48.05pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:51.45pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:51.55pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:55.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:55.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:50.80pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:5.40pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="17" ALIGN="center" STYLE="WIDTH:590.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.00pt; font-weight: Bold; ">(in thousands, except share and per share amounts)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 17, 2001 (date of inception)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock to founders on December 31, 2002, for cash, at $0.36 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,588 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(116)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(116)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2003</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,588 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(116)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(115)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock on September 30, 2004, for cash, at $0.36 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">19,720 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">7 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">7 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(511)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(511)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2004</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">22,308 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">8 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(627)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(619)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock on January 3, 2005, for cash, at $0.36 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,922 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock on January 3, 2005, upon conversion of notes payable and related accrued interest at $0.36 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,978 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock on October 14, 2005, for intellectual property license rights, at $48.84 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">903 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">44 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">44 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock on October 14, 2005, upon conversion of notes payable and related accrued interest</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">31,095 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,354 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,354 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,459)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,459)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2005</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">60,206 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,408 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(2,086)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(678)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock on February 21, 2006, for intellectual property license rights, at $4.32 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">17,372 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">75 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">75 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"> <FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of Series A on February 22, 2006, for cash, at $1.6265 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">5,727,354 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">9,316 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of Series A on February 22, 2006, upon conversion of notes payable and related accrued interest, at $1.6265 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">420,817 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">684 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock upon exercise of stock options, for cash</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">8,019 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3 </FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;5&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break6"></A><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock on February 22, 2006, for intellectual property and product license rights, at $4.32 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">13,907 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">60 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">60 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock on June 23, 2006, for intellectual property license rights, at $5.40 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,505 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">15 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">15 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock on November 7, 2006, for intellectual property license rights, at $5.40 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">38 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of Series A on December 8, 2006, for cash, at $1.6265 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3,074,086 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">5,000 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Series A offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(98)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Share-based compensation</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">39 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">39 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accretion of offering costs of redeemable &nbsp;convertible preferred stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">17 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(17)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(17)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(5,241)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(5,241)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2006</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">9,222,257 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">14,919 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">102,047 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,583 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(7,327)</FONT></P></TD>
   <TD VALIGN="center" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(5,744)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of Series B convertible redeemable preferred stock, on May 31, 2007 for $2.439 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3,688,902 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">9,000 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of Series B convertible redeemable preferred stock, on December 28, 2007 for $3.253 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,766,677 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">9,000 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Series B offering Costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(147)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accretion of Series A offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">19 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(19)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(19)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accretion of Series B offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">18 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(18)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(18)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock for intellectual property license rights, on January 18, 2007 at $10.08 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,303 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">13 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">13 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock for intellectual property license rights, on June 30, 2007 at $10.80 per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">642 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">7 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">7 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock for commercial license rights, on July 19, 2007, vests upon achievement of specified criteria</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,783 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Share-based compensation</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">50 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">50 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of shares to executive on February 19, 2007, vesting upon achievement of specified criteria, subject to repurchase</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">13,915 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;6&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break7"></A><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock upon exercise of stock options for cash</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,227 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">16 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">both&#151;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">16 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(13,994)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(13,994)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2007</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">9,222,257 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">14,938 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">6,455,579 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">17,871 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">122,917 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,632 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(21,321)</FONT></P></TD>
   <TD VALIGN="center" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(19,689)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accretion of Series A offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">20 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(20)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(20)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accretion of Series B offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">36 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(36)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(36)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Share-based compensation</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">545 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">545 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Estimated fair value of warrants issued in connection with convertible notes payable</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">399 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">399 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock upon exercise of stock options, for cash</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">36,154 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">54 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">54 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(19,431)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(19,431)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2008</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">9,222,257 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">14,958 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">6,455,579 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">17,907 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">159,071</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,574 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(40,752)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(38,178)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Adjustment for fractional shares on common conversion</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(7)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Deemed preferred stock dividend for additional common shares issuable under anti-dilution provision</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">781 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(781)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(781)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accretion of Series A offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">42 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(42)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(42)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accretion of Series B offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">93 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(93)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(93)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Conversion of preferred stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(9,222,257)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(15,000)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(6,455,579)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(18,781)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">507,123</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">33,780 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">33,781 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Restricted stock release from restriction</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">75 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">75 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Conversion of convertible notes and related accrued interest</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">145,465</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">8,501 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">8,501 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Conversion of warrants for preferred stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">36 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">36 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Merger with Nuvelo, Inc.</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">447,826 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">11,913 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">11,913 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Adjustment for fractional shares</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(102)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Share-based compensation</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">845 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">845 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock upon exercise of stock options for cash</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">10,521 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">114 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">114 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">177 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Estimated fair value of warrants issued in connection with lease termination</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">377 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">377 </FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(9,138)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(9,138)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2009</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,270,074 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">57,301 </FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(49,890)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">7,412 </FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;7&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break8"></A><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock for cash, net of offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">194,100  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">7,182  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">7,182  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock upon exercise of stock options for cash</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">8,248  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">139  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">139  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Share-based compensation</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">458  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">458  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(8,420)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(8,420)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2010</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,472,422  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">65,080  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(58,310)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">6,771  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock for cash, net of offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">557,890  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">4,016  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">4,017  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock upon exercise of stock options for cash</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">188  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Share-based compensation</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">308&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">308  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(5,364)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(5,364)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2011</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,030,500  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">69,404  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(63,674)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">5,732  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock for cash, net of offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">629,815  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,188  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,189  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock upon exercise of stock options for cash</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Share-based compensation</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">306&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">306  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(4,320)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(4,320)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, December 31, 2012</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,660,315  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">70,898  &nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(67,994)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,907  &nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock for cash, net of offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:36.00pt; text-indent:-36.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">521,066&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,421&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,421&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Adjustment for fractional shares</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:36.00pt; text-indent:-36.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(64)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of common stock upon exercise of warrants for cash</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:36.00pt; text-indent:-36.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">4,245&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">12&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">12&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Share-based compensation</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:36.00pt; text-indent:-36.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">42&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">42&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:36.00pt; text-indent:-36.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,071)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,071)</FONT></P></TD></TR>
<TR STYLE="height:3.20pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:140.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Balance, March 31, 2013</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.90pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:48.05pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.45pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:7.00pt; text-indent:-7.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3,185,562&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:51.55pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">72,373&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:55.50pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(69,065)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:15.35pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:50.80pt; border-top:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3,311&nbsp;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:right; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt" ALIGN="right">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">See accompanying notes to consolidated financial statements </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;8&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break9"></A> </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:12.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ARCA BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(a development stage enterprise) </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">CONSOLIDATED STATEMENTS OF CASH FLOWS </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 9.00pt; font-weight: Bold; ">(unaudited) </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:4.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.50pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.50pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ROWSPAN="2" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Three Months Ended <BR>March 31,</FONT></P></TD>
   <TD VALIGN="bottom" ROWSPAN="5" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.50pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ROWSPAN="4" ALIGN="center" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;line-height:8.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Period from December 17, 2001 (date of inception) to March 31, 2013</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.50pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;line-height:1.00pt;; border-top:solid 1.00pt;font-size:4.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.50pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.50pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">2013&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.50pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">2012&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:7.50pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:7.50pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">(in thousands)</FONT></P></TD></TR>
<TR STYLE="height:4.50pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Cash flows used in operating activities:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,071)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,407)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(69,065)</FONT></P></TD></TR>
<TR STYLE="height:5.85pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:21.60pt; text-indent:-9.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Gain on patent rights assignment</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(2,000)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Gain on bargain purchase</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(25,282)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Depreciation and amortization</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">10&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">14&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,790&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Non-cash interest expense</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">211&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Share-based compensation</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">42&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">91&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,630&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Issuance of warrants for lease termination</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">377&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accretion of liabilities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">152&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Impairment of property and equipment</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">125&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Impairment of in-process research and development</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">6,000&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Write-off of deferred tax liability</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(2,281)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Gain on marketable securities available for sale</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(263)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(Gain) loss from disposal of property and equipment</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">83&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Other, net</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">267&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:32.85pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Change in operating assets and liabilities (net of amounts acquired):</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:39.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Other current assets</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(157)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(72)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,663&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:39.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Other assets</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">20&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">20&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">7,346&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:39.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accounts payable</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">312&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(134)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,813)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:39.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accrued expenses and other liabilities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">88&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(160)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(19,133)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:39.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Deferred rent</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(8)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(8)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">8&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:39.60pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:21.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Net cash used in operating activities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(764)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,656)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(98,185)</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:21.60pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Cash flows provided by (used in) investing activities:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Cash received from Merger</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">30,392&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Payment of deferred transaction costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,186)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Purchase of property and equipment</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(9)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,888)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Proceeds from sale of marketable securities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">15,369&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Proceeds from sale of property and equipment</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">358&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Proceeds from patent rights assignment</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,000&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:12.60pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:9.90pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Net cash provided by (used in) investing activities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(9)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">45,045&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:9.90pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Cash flows provided by (used in) financing activities:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Proceeds from issuance of convertible notes payable and</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; "> related warrants for common stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">10,841&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Proceeds from issuance of bank note payable</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">4,000&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Proceeds from stock subject to repurchase</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">38&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Proceeds from the issuance of preferred stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">32,316&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Preferred stock offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(246)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Proceeds from the issuance of common stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,741&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">15,850&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Payment of offering costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(308)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,634)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:13.50pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Payment of registration statement costs for subsequent resale registration of shares issued in equity offering</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(60)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(60)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Repayment of principal on bank note payable</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(4,000)</FONT></P></TD></TR>
<TR STYLE="height:4.50pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Repayment of principal on convertible notes payables</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(105)</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:12.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Repayment of principal on vendor finance agreement</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(43)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(323)</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:12.60pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:21.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Net cash provided by (used in) financing activities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1,390&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(60)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">56,677&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:21.60pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">617&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">(1,716)</FONT></P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3,537&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Cash and cash equivalents, beginning of period</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">2,920&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">5,943&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; font-weight: Bold; ">Cash and cash equivalents, end of period</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3,537&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">4,227&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">3,537&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Supplemental cash flow information:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:21.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Interest paid</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">1&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">116&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:21.60pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Supplemental disclosure of noncash investing and</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:8.10pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">financing transactions:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:21.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accrued interest on notes payable converted to equity</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">163&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:21.60pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:21.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Warrant issued in connection with credit facility</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">111&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:21.60pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:7.20pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:21.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Accrued deferred transaction costs</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">482&nbsp;</FONT></P></TD></TR>
<TR>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:21.60pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; border-top:double 1.50pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:59.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:21.60pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">Vendor finance agreement</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">131&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:10.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">134&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:2.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:8.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:16.00%; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 8.00pt; ">131&nbsp;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:4.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">See accompanying notes to consolidated financial statements </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:-0.00pt; font-size:10.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;9&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><A NAME="Break10"></A> </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:12.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ARCA BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(a development stage enterprise) </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(unaudited) </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(1) The Company and Summary of Significant Accounting Policies </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:12.20pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Description of Business </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">ARCA biopharma, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Broomfield, Colorado and is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; "><SUP style="vertical-align: baseline;position: relative;top: -0.4em;">TM</SUP></FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; "> (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, is being developed for the treatment and the prevention of atrial fibrillation, or AF, in patients with heart failure, or HF. The Company has identified common genetic variations in the cardiovascular system that it believes interact with Gencaro&#146;s pharmacology and may predict patient response to Gencaro treatment. The Company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with Gencaro based on genetic testing, which it believes will provide market exclusivity for these uses of Gencaro into at least 2026 in the U.S. and into 2025 in Europe. In addition, the Company believes that if Gencaro is approved, a Gencaro patent will be eligible for patent term extension based on our current clinical trial plans which, if granted, may provide market exclusivity for Gencaro into 2029 or 2030 in the US and Europe. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">ARCA believes that Gencaro has potential efficacy in reducing or preventing AF, and that this efficacy may be genetically regulated. The Company plans to test this hypothesis in a clinical trial of Gencaro, known as GENETIC-AF, which the Company plans to initiate pending receipt of the necessary funding. The Company has created an adaptive design for GENETIC-AF under which the trial is intended to be initiated as a Phase 2b study in approximately 200 patients with heart failure and left ventricular dysfunction, or HFREF. Depending on the results of the Phase 2b portion, the trial may then be expanded to a Phase 3 study by enrolling an estimated additional 420 patients. The Company anticipates that GENETIC-AF could begin approximately 6 months after the Company obtains sufficient funding. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">To support the continued development of Gencaro, including the planned GENETIC-AF clinical trial and ongoing operations, the Company will need to raise substantial additional funding through public or private equity transactions or a strategic combination or partnership. If the Company is delayed in obtaining funding or is unable to complete a strategic transaction, it may have to discontinue development activities on Gencaro or discontinue its operations. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:12.20pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Development Stage Risks, Liquidity and Going Concern </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The Company is in the development stage and devotes substantially all of its efforts towards obtaining regulatory approval, exploring strategic alternatives for further developing Gencaro, and raising capital necessary to fund its operations. The Company has not generated revenue to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has historically funded its operations through issuances of common and preferred stock, as well as through the business combination with Nuvelo, Inc, or Nuvelo. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Since ARCA was founded on December 17, 2001, or Inception, the Company has incurred substantial losses and negative cash flows from operations. Since Inception, the Company incurred a loss from operations of $100.2 million and had negative cash flows from operations of $98.2 million. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In light of the substantial additional time and costs associated with the development of Gencaro and the need to raise a significant amount of capital on acceptable terms to finance the planned clinical trial and the Company&#146;s ongoing operations, the Company is evaluating strategic alternatives for funding continued operations and development programs. The Company will need to complete a substantial equity financing, or a strategic transaction, such as a strategic combination or partnership to support the continued development of Gencaro, including the planned GENETIC-AF clinical trial. To date, the Company has completed two equity-financing transactions in 2013 and raised approximately $1.4 million, net of offering costs. These financings have allowed ARCA to continue operations while it continues to pursue financing options, a strategic combination, partnering, and licensing opportunities. If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or discontinue its operations. The Company currently believes its cash and cash equivalents balance as of March 31, 2013 will be sufficient to fund its operations through September 30, 2013. The Company is unable to assert that its current cash and cash equivalents are sufficient to fund operations beyond that date, and as a result, there is substantial doubt about the Company&#146;s ability to continue as a going concern beyond September 30, 2013. These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and <A NAME="Break11"></A> </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;10&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The Company&#146;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for Gencaro; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the market price of the Company&#146;s stock and the availability and cost of additional equity capital from existing and potential new investors; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the Company&#146;s ability to retain the listing of its common stock on the Nasdaq Capital Market; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">general economic and industry conditions affecting the availability and cost of capital; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the Company&#146;s ability to control costs associated with its operations; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the terms and conditions of the Company&#146;s existing collaborative and licensing agreements. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&#146;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&#146;s capital stock and could contain covenants that would restrict the Company&#146;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company in the near term, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Reverse Stock Split </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Basis of Presentation </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The accompanying unaudited consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim consolidated financial statements. The results of operations for the three months ended March 31, 2013 are not necessarily indicative of results expected for the full year ending December 31, 2013. The Company has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing Gencaro, and raising capital. Accordingly, the Company continues to be considered in the development stage at March 31, 2013. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto for the year ended December 31, 2012 included in the Company&#146;s Annual Report on Form 10-K filed with the Securities and Exchange Commission, as amended. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Concentrations of Credit Risk </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, money market fund accounts and debt securities with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break12"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;11&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Accrued Expenses </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&#146;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&#146;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(2) Loss Per Share </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The Company calculates basic loss per share by dividing loss attributable to common stockholders by the weighted average common shares outstanding during the period, excluding common stock subject to vesting provisions. Diluted loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company&#146;s potentially dilutive shares include options and warrants. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:9.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:11.25pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:160.35pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; "> Three Months Ended March 31,</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:73.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">2013&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:73.70pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">2012&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(In thousands, except shares and per share data)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:73.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:73.70pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Net loss</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(1,071)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.70pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(1,407)</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Net loss available to common shareholders</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.00pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(1,071)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.70pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(1,407)</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:73.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:73.70pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:2.50pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Weighted average shares of common stock outstanding</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3,037,546&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.70pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">2,030,499&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:5.40pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Less: &nbsp;Weighted-average shares of unvested common stock</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(2,783)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.70pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(2,783)</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ROWSPAN="2" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Total weighted-average shares used in computing net loss per share attributed to common stockholders</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:73.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:73.70pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3,034,763&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.70pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">2,027,716&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:13.50pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Basic and diluted loss per share</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.00pt; border-top:solid 0.75pt #000000; border-bottom:double 2.25pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(0.35)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:73.70pt; border-top:solid 0.75pt #000000; border-bottom:double 2.25pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(0.69)</FONT></P></TD></TR>
<TR STYLE="height:1.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:269.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:12.20pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:73.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:13.65pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:73.70pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">. </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Potentially dilutive securities representing 1.3 million and 604,000 weighted average shares of common stock were excluded for the three months ended March 31, 2013 and 2012, respectively, because including them would have an anti-dilutive effect on net loss per share. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(3) Merger with Nuvelo, Inc. on January 27, 2009 </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">On January 27, 2009, ARCA Colorado, Inc. (ARCA Colorado) completed the Merger with Nuvelo in accordance with the terms of the Merger Agreement, in which a wholly-owned subsidiary of Nuvelo merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Nuvelo. Immediately following the Merger, the Company changed its name from Nuvelo, Inc. to ARCA biopharma, Inc., and its common stock began trading on the Nasdaq Global Market under the symbol &#147;ABIO&#148; on January 28, 2009. On March 7, 2011, the listing of the Company&#146;s common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The Merger was treated as a reverse merger and accounted for as a business combination using the acquisition method of accounting in accordance with ASC 805. For accounting purposes, ARCA Colorado was considered to have acquired Nuvelo in the Merger, as the stockholders of ARCA Colorado prior to the Merger had a controlling interest in the combined company and the Company&#146;s management is the former management of ARCA Colorado. The results of operations and cash flows include the activities of Nuvelo since the date of the Merger. Pursuant to the rules and regulations of the United States Securities and Exchange Commission, or the SEC, the historical financial statements of ARCA Colorado replaced the historical financial statements of Nuvelo, and the disclosures in this report relating to the pre-Merger business of the Company, unless noted as being the business of Nuvelo prior to the Merger, pertain to the business of ARCA Colorado prior to the Merger. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The estimated total acquisition consideration of $11.9 million to acquire Nuvelo was based on the market capitalization of Nuvelo as of January 27, 2009 and the estimated fair values of its vested stock options and warrants outstanding on that date, as this was deemed the most reliable measure of the consideration effectively transferred to acquire Nuvelo on that date. The Company estimated the net assets acquired in the Merger to be $37.2 million, including $45.5 million of cash, cash equivalents and marketable securities. In accordance with ASC 805, any excess of fair value of net assets acquired in a business combination over the acquisition consideration results in a gain on bargain purchase, and as a result, the Company recorded a gain on bargain purchase of $25.3 million. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break13"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;12&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(4) Fair Value Disclosures </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">As of March 31, 2013, the Company had $3.5 million of cash equivalents consisting of money market funds with maturities of 90 days or less. The Company has the ability to liquidate these investments without restriction. The Company determines fair value for these money market funds and equity securities with Level 1 inputs through quoted market prices. There were no transfers of assets between fair value hierarchy levels during the three month period ended March 31, 2013. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Level 1&#151;Unadjusted quoted prices in active markets for identical assets or liabilities </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Level 2&#151;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Level 3&#151;Unobservable inputs for the asset or liability </FONT></TD></TR></TABLE>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Fair Value of Other Financial Instruments </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The carrying amount of other financial instruments, including cash, accounts payable, and short-term notes payable approximated fair value due to their short maturities. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(5) Property and Equipment </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:9.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Property and equipment consist of the following (in thousands): </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:24.00pt">
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:211.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:99.00pt; border-bottom:solid 0.75pt #000000; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Estimated Life</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:54.65pt; border-bottom:solid 0.75pt #000000; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">March 31, 2013</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:54.65pt; border-bottom:solid 0.75pt #000000; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">December 31, 2012</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:211.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Computer equipment</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:99.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3 years</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">87&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">104&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:211.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Lab equipment</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:99.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">5 years</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">142&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">142&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:211.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Furniture and fixtures</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:99.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">5 years</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">85&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">93&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:211.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Computer software</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:99.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3 years</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">176&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">176&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:25.50pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:211.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Leasehold improvements</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:99.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Lesser of useful life or life of the lease</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; border-bottom:solid 0.75pt #000000; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">18&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; border-bottom:solid 0.75pt #000000; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">18&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:211.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:99.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">508&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">533&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:211.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Less accumulated depreciation and amortization</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:99.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; border-bottom:solid 0.75pt #000000; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(486)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; border-bottom:solid 0.75pt #000000; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(510)</FONT></P></TD></TR>
<TR STYLE="height:13.50pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:211.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:99.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; border-top:solid 0.75pt #000000; border-bottom:double 1.50pt #000000; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">22&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:11.60pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.65pt; border-top:solid 0.75pt #000000; border-bottom:double 1.50pt #000000; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">23&nbsp;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:12.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">For the three months ended March 31, 2013 and 2012, and for the period from Inception through March 31, 2013, depreciation and amortization expense was $10,000, $14,000, and $1.8 million respectively. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(6) Commitments and Contingencies </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The Company has or is subject to the following commitments and contingencies: </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Employment Agreements </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The Company maintains employment agreements with several executive employees. Most of these agreements provide for payments to be made under certain conditions related to a change in control of the Company and entitle the employee to wages and certain benefits payments not exceeding one calendar year from the date of termination without cause or by the employee for good reason. The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Operating Lease </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">On February 8, 2008, the Company entered into a lease agreement for approximately 15,000 square feet of newly constructed office facilities in Broomfield, Colorado. The Company relocated to the new facility upon its completion in July 2008. The lease has a term of 5 years with rights to extend the term for two additional three year periods. On June 14, 2011, the Company entered into a first amendment (the &#147;Amendment&#148;) to the lease agreement. Under the terms of the Amendment, the Company and its landlord mutually agreed for the Company to relocate from its office suite of approximately 15,000 square feet, to another suite within the same building, comprising approximately 4,500 square feet. The office location serves as the Company&#146;s primary business office. The Amendment also modified the annual per square foot rate of rent and allows the Company to terminate with three months&#146; notice. As <A NAME="Break14"></A> </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;13&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">part of the agreement, the Company made a one-time payment to the landlord of $200,000, which the landlord agreed to use for the landlord&#146;s improvements in the new leased premises. The original five year term of the Lease remains unchanged. Per the lease agreement, base rent is subject to annual increases of approximately three percent per year. The rent expense for the lease is being recognized on a straight-line basis over the lease term. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Under the original lease, the Company received tenant improvement reimbursements from the landlord totaling $593,000 which were recorded as deferred rent and were amortized as reductions to rent expense. The $200,000 payment made to the landlord in conjunction with the Amendment was recorded against the existing deferred rent. The net deferred rent balance is being amortized as reductions to rent expense over the remaining term of the lease. The unamortized deferred rent balance as of March 31, 2013 was $8,000. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Rent expense under this lease for the three months ended March 31, 2013 and 2012 was $12,000, and was $527,000 from Inception through March 31, 2013. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The Company&#146;s facility lease in Broomfield, Colorado expires in June 2013. The remaining minimum lease payments committed under the lease through June 2013 are $20,000. The lease has an option to renew for an additional three year term under comparable terms, and the Company is in negotiations with the landlord regarding potential renewal of the lease. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Under the terms of its strategic license agreement with CPEC, a licensing subsidiary of Indevus Pharmaceuticals Inc. (a wholly owned subsidiary of Endo Pharmaceuticals), holding ownership rights to certain clinical trial data of Gencaro, the Company will incur milestone and royalty obligations upon the occurrence of certain events. In August 2008, the Company paid CPEC a milestone payment of $500,000 based on the July 31, 2008 submission of its NDA to the FDA. If the FDA grants marketing approval for Gencaro, the agreement provides that the Company will owe CPEC another milestone payment of $8.0 million within six months after FDA approval. The agreement also states that the Company has the obligation to make milestone payments of up to $5.0 million in the aggregate upon regulatory marketing approval in Europe and Japan. The agreement states that the Company&#146;s royalty obligation ranges from 12.5% to 25% of revenue from the related product based on achievement of specified product sales levels, including a 5% royalty that CPEC is obligated to pay under its original license agreement for Gencaro. The Company has the right to buy down the royalties to a range of 12.5% to 17% by making a payment to CPEC within six months of regulatory approval. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(7) </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Equity Financings and Warrants </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Private Investment in Public Equity (PIPE) Transaction </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">On January 22, 2013, the Company entered into a Subscription Agreement (the &#147;Purchase Agreement&#148;) with various accredited investors and its Chief Executive Officer in connection with a private placement of its common stock and warrants. Pursuant to the Purchase Agreement, the Company sold an aggregate of 356,430 shares of its common stock and warrants to purchase up to 249,501 additional shares of its common stock for aggregate gross proceeds of approximately $1 million, before deducting estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $805,000, and the private placement closed on January 25, 2013. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.70 shares of common stock. The purchase price for each unit was $2.81. The warrants were exercisable upon issuance, expire seven years from the date of issuance, and have an exercise price of $2.28 per share, equal to 100% of the closing bid price of ARCA&#146;s common stock on the Nasdaq Capital Market on January 22, 2013. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The Company filed a registration statement for the resale of the shares underlying the units sold in these private placements. That registration statement was declared effective by the Securities and Exchange Commission on February 14, 2013. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In connection with this transaction, the Company agreed that, subject to certain exceptions, it would not, while the warrants are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a &#147;variable rate transaction,&#148; which means a transaction in which the Company issues or sells any convertible securities either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. In addition, the Company agreed that, subject to certain exceptions, if it issues securities within one year following the closing of the offering, each investor would have the right to purchase its pro rata share of a specified portion of the securities in the future offering on the same terms, conditions and price provided for in the proposed issuance of securities. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break15"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;14&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Registered Direct Offering </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">On January 31, 2013, the Company entered into a subscription agreement with certain institutional investors (the &#147;Investors&#148;) in connection with its Registered Direct public offering (the &#147;Offering&#148;), pursuant to which the Company sold an aggregate of 164,636 shares of its common stock and warrants to purchase up to 65,855 additional shares of its common stock to the Investors for aggregate gross proceeds of approximately $730,000, before deducting placement agent fee and other estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $616,000, and the Offering closed on February 4, 2013. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase 0.40 shares of common stock. The purchase price for each unit was $4.43. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $4.13 per share, equal to the closing bid price of ARCA&#146;s common stock on the Nasdaq Capital Market on January 31, 2013. The Offering was effected as a takedown off the Company&#146;s S-3 Registration Statement, which became effective on April 4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February 1, 2013. The warrant agreements provide for settlement of the warrants in unregistered shares should an effective registration statement or current prospectus not be in place at the time a warrant is exercised. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Warrants </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">As of March 31, 2013, warrants to purchase 1.3 million shares of common stock were outstanding at exercise prices ranging from $1.80 to $116.89, with a weighted average exercise price per share of $7.25. These warrants, which were granted as part of various financing and business agreements, expire at various times between October 2013 and January 2020. Warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using the Black-Scholes option-pricing model. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(8) Share-based Compensation </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:9.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">For the three month periods ended March 31, 2013 and 2012 and for the period from Inception through March 31, 2013, the Company recognized the following non-cash, share-based compensation expense in the consolidated statement of operations (in thousands): </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:59.25pt">
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:137.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:137.15pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">Three Months Ended March 31,</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="WIDTH:64.30pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Period from December 17, 2001 (date of inception) to March 31, 2013</FONT></P></TD></TR>
<TR STYLE="height:15.75pt">
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:137.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:63.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">2013</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:63.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">2012</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:20.25pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:137.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:63.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:63.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:64.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:15.75pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:137.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Research and Development</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:63.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">15</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:63.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">26</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:64.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">605</FONT></P></TD></TR>
<TR STYLE="height:15.75pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:137.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Selling, General and Administrative</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:63.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">27</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:63.05pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">65</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:64.30pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">1</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,638</FONT></P></TD></TR>
<TR STYLE="height:15.75pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:137.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Restructuring Expense</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:63.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">0</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:63.05pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">0</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:64.30pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">387</FONT></P></TD></TR>
<TR STYLE="height:16.50pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:137.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Total</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:63.00pt; border-top:solid 0.75pt #000000; border-bottom:double 1.50pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">42</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:63.05pt; border-top:solid 0.75pt #000000; border-bottom:double 1.50pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">91</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:64.30pt; border-top:solid 0.75pt #000000; border-bottom:double 1.50pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">2</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">,630</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:24.45pt; text-indent:-24.45pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:24.45pt; text-indent:-24.45pt; font-size:12.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break16"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;15&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:9.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Stock option transactions for the three month period ended March 31, 2013 under all plans are as follows: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:77.25pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:62.10pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; "> # of Options</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:54.95pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">Weighted Average Exercise Price</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:62.95pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">Weighted Average Remaining Contractual Term  <BR>(in years)</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:62.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:54.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:62.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Options outstanding at December 31, 2012</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">144,019&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">18.28&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">4.91&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Changes during the period:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Granted</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">0.00&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Exercised</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">0.00&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Forfeited, cancelled or expired</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(6,259)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">16.53&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:15.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Options outstanding at March 31, 2013</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.10pt; border-top:solid 0.75pt #000000; border-bottom:double 2.25pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">137,760&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.95pt; border-bottom:double 2.25pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">18.36&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.95pt; border-bottom:double 2.25pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">4.89&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Options exercisable at March 31, 2013</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">123,408&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">18.</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">82&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">4.62&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:195.15pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Options vested and expected to vest</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.80pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">136,208&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:54.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">18.</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">39&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:11.10pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:62.95pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">4.88&nbsp;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:12.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">(9) Income Taxes </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In accordance with United States Generally Accepted Accounting Principles, a valuation allowance should be provided if it is more likely than not that some or all of the Company&#146;s deferred tax assets will not be realized. The Company&#146;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets. The Company believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has no reserve for uncertain tax positions. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:55.45pt; text-indent:-55.45pt"><A NAME="ITEM_2"></A><A NAME="Break17"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;16&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:9.00pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:11.00%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM 2.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.00%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">MANAGEMENT</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-style: Italic; ">This Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations contains &#147;forward-looking statements&#148; within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Private Securities Litigation Reform Act of 1995,These statements include, but are not limited to, statements regarding the Company&#146;s anticipated timing for initiation or completion of its clinical trials for any of its product candidates; the potential for Gencaro to be an effective potential treatment for atrial fibrillation and, the Company&#146;s ability to fund future operations. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the Company&#146;s ability to complete a strategic transaction to support the continued development Gencaro, and/or obtain additional financing; the Company&#146;s anticipated timing for initiation or completion of its clinical trials for any of its product candidates; the Company&#146;s ability to identify, develop and achieve commercial success for products and technologies; drug discovery and the regulatory approval process; estimated timelines for regulatory filings and the implications of interim or final results of the Company&#146;s clinical trials; the extent to which the Company&#146;s issued and pending patents may protect its products and technology; the potential of the Company&#146;s clinical development program to lead to the approval of the Company&#146;s New Drug Application for Gencaro; and, the impact of competitive products and technological changes. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors discussed herein and elsewhere. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December 31, 2012, as amended, the Company&#146;s Registration Statement on Form S-1 (Registration No. 333-187508), and subsequent filings. Forward-looking statements may be identified by words including &#147;will,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;intend,&#148; &#147;estimates,&#148; &#147;expect,&#148; &#147;should,&#148; &#147;may,&#148; &#147;potential&#148; and similar expressions. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The terms &#147;ARCA,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar terms refer to ARCA biopharma, Inc. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Overview </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">ARCA is a biopharmaceutical company whose principal focus is developing genetically-targeted therapies for cardiovascular diseases. Our lead product candidate is Gencaro&#153; (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator that we plan to evaluate in a new clinical trial for the treatment of atrial fibrillation, or AF, in patients with heart failure and left ventricular dysfunction, or HFREF. We have identified common genetic variations in receptors in the cardiovascular system that we believe interact with Gencaro&#146;s pharmacology and may predict patient response to the drug. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We plan to test this hypothesis in a Phase 2b/3 clinical trial of Gencaro, known as GENETIC-AF. We plan to pursue this indication for Gencaro because data from the previously conducted Phase 3 HF trial of Gencaro in 2,708 HF patients, or the BEST trial, suggest that Gencaro may be successful in reducing or preventing AF. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">AF is a disorder in which the normally regular and coordinated contraction pattern of the heart&#146;s two small upper chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke. AF is considered an epidemic cardiovascular disease with an estimated prevalence of at least 2.7 million Americans in 2010. The approved therapies for the treatment or prevention AF have certain disadvantages in HFREF patients, such as toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contra indicated or have warnings in their prescribing information for such patients. We believe there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in HFREF patients. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The GENETIC-AF trial is designed to compare Gencaro to the beta-blocker metoprolol CR/XL in patients with the beta-1 389 arginine homozygous genotype, which we believe responds most favorably to Gencaro. We believe data from the BEST trial indicate that Gencaro may have a genetically regulated effect in reducing or preventing AF, whereas we believe the therapeutic benefit of metoprolol CR/XL does not appear to be enhanced in patients with this genotype. A retrospective analysis of data from the BEST trial shows that the entire cohort of patients in the BEST trial treated with Gencaro had a 41% reduction in the risk of new onset AF (time-to-event) compared to placebo (p = 0.0004). In the BEST DNA substudy, patients with the beta-1 389 arginine homozygous genotype experienced a 74% (p = 0.0003) reduction in risk of AF when receiving Gencaro, based on the same analysis. The beta-1 389 arginine homozygous genotype was present in about 47% of the patients in the BEST pharmacogenetic substudy, and we estimate it is present in about 50% of the US general population. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">GENETIC-AF is planned as a multi-center, randomized, double-blind clinical trial designed to compare the safety and efficacy of Gencaro to an active comparator, metoprolol CR/XL, in beta-1 389 arginine homozygous genotype HFREF patients recently <A NAME="Break18"></A> </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;17&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">diagnosed with persistent AF. The primary endpoint will be measured over a twenty-four week period after the patient&#146;s AF has been electrically cardioverted through the administration of a direct current shock to restore normal heart rhythm. We have created an adaptive design for GENETIC-AF, which we plan to initiate with a Phase 2b study in approximately 200 HFREF patients with recent onset, persistent AF who also have a genetic variant of the beta-1 adrenergic receptor which we believe responds most favorably to Gencaro. The secondary endpoint of the proposed Phase 2b portion of the trial will be AF burden, as defined as a patient&#146;s actual percentage of time in AF, regardless of symptoms. Under the proposed design, all 200 patients in the Phase 2b portion of the trial will have AF burden measured by continuous monitoring, either by previously implanted cardiac resynchronization or defibrillation devices, or newly or previously inserted loop recorders. At the end of enrollment of the first 200 patients, the primary endpoint of the combination of recurrent symptomatic AF or all-cause mortality, and the secondary endpoint of AF burden will be evaluated by the trial&#146;s Data and Safety Monitoring Board for evidence of an efficacy signal. If a sufficient efficacy signal is detected and acceptable safety is observed, the trial could then proceed to the Phase 3 portion of the trial. We estimate that GENETIC-AF could begin approximately six months after we obtain sufficient funding and we believe the Phase 2b study would take approximately two years to complete after initiation. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, has entered into a Clinical Trial Collaboration Agreement, dated April 18, 2013 (the &#147;Agreement&#148;) with us to collaborate on the Phase 2b portion of GENETIC-AF. Under the collaboration, we plan, with the support of Medtronic, to conduct a substudy that will include continuous monitoring of the cardiac rhythms of all 200 patient enrolled during the Phase 2b portion of GENETIC-AF. Each patient will have heart rhythm monitoring via a Medtronic device, either a previously implanted cardiac resynchronization or defibrillation device, or a previously or newly inserted Reveal loop recorder. The collaboration substudy will measure AF burden, defined as a patient&#146;s actual time in AF regardless of symptoms. In determining the presence of an efficacy signal in the Phase 2b portion of the trial. AF burden will be evaluated along with time to mortality or recurrent AF, which will also be the Phase 3 primary endpoint. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The collaboration will be administered by a joint ARCA-Medtronic committee. Medtronic will use its proprietary CareLink System to collect and analyze the cardiac rhythm data from the implanted Medtronic devices and provide the data to ARCA at the close of the Phase 2b portion of the trial. The parties will negotiate in good faith to agree on the substudy protocol, specifying the elements of the substudy and of the cardiac rhythm data collection and analysis to be provided for the substudy by Medtronic by August 15, 2013. Medtronic will support the reimbursement process for patients enrolled in the Phase 2b portion, and will provide financial support of unreimbursed costs for a certain number of patients in the Phase 2b portion up to a certain maximum amount per patient. If GENETIC-AF proceeds to Phase 3, ARCA will seek to enroll an additional 100 patients in the substudy, and Medtronic will provide the agreed-on CareLink System cardiac rhythm data collection and analysis for the Phase 3 portion of the substudy, and support the reimbursement process. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We have been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with Gencaro based on genetic testing, which we believe will provide market exclusivity for these uses of Gencaro into at least 2026 in the U.S. and into 2025 in Europe. In addition, we believe that if Gencaro is approved, a Gencaro patent will be eligible for patent term extension based on our current clinical trial plans which, if granted, may provide market exclusivity for Gencaro into 2029 or 2030 in the U.S. and Europe. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">To support the continued development of Gencaro, including the planned GENETIC-AF clinical trial and our ongoing operations, we are pursuing a public equity offering to fund the Phase 2b portion of the GENETIC-AF trial and our general and administrative costs through its projected completion. We may also seek additional funding that could allow us to operate while we continue to pursue financing options, a strategic combination, partnering, and licensing opportunities. If we are delayed in obtaining funding or are unable to complete a strategic transaction, we may discontinue our development activities on Gencaro or discontinue our operations. We believe our cash and cash equivalents balance as of March 31, 2013 will be sufficient to fund our operations, at our current cost structure, through September 2013. We are unable to assert that our current cash and cash equivalents are sufficient to fund operations beyond that date, and as a result, there is substantial doubt about our ability to continue as a going concern beyond September 2013. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Results of Operations </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Research and Development Expenses </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Research and development, or R&D, expense is comprised of research & development, regulatory and manufacturing process development activities and costs. Our R&D expense continues to be almost entirely generated by our activities relating to the development of Gencaro. Research and Development expense for the three months ended March 31, 2013 was $181,000 compared to $422,000 for the corresponding period of 2012, a decrease of approximately $241,000. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break19"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;18&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Research & development expense decreased $135,000 for the three months ended March 31, 2013 due to reduced personnel costs from staff furloughs implemented in the third quarter of 2012 and decreased consulting costs attributable to reductions in our clinical development activities compared to the corresponding period of 2012. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Regulatory and manufacturing process costs decreased $105,000 for the three months ended March 31, 2013 compared to the corresponding periods of 2012. The decrease for the three months ended March 31,2013 compared to the corresponding period of 2012 is primarily due to reduced personnel costs from staff furloughs implemented in the third quarter of 2012. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our R&D expenses are contingent upon our ability to raise substantial additional funding or complete a strategic transaction. Should we receive funds from one or a combination of these sources, R&D expense in future periods could be substantially higher as we initiate our planned GENETIC-AF clinical trial. Until substantial additional funding is obtained, R&D expenses for the remainder of 2013 are expected to be comparable to those incurred in the respective quarters of 2012. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:12.20pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Selling, General and Administrative Expenses </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Selling, general and administrative expenses, or SG&A, primarily consist of personnel costs, consulting and professional fees, insurance, facilities and depreciation expenses, and various other administrative costs. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">SG&A expense was $889,000 for the three months ended March 31, 2013 as compared to $984,000 for the corresponding period in 2012, a decrease of $95,000. The decrease in the three months ended March 31, 2013 as compared to the corresponding period of 2012 is comprised of reduced personnel, travel and board of director costs of approximately $230,000 attributable to staff furloughs and other cost reduction efforts implemented in the third quarter of 2012. These decreases were partially offset by increased costs for accounting, legal, consulting, and outside support services of approximately $136,000, which increases are primarily attributable to the special proxy report and shareholder meeting held during the quarter to approve the 1 for 6 reverse split of the common stock. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">SG&A expenses for the remainder of 2013 are expected to be comparable to 2012 levels but are contingent upon our ability to raise substantial additional funding or complete a strategic transaction. Should we receive funds from one or a combination of these sources, SG&A expense in future periods could be substantially higher as we increase our activities to support initiation of our GENETIC-AF clinical trial. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Interest and Other Income </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Interest and other income was less than $1,000 in the three months ended March 31, 2013 and March 31, 2012. The amounts and related change between years are nominal to our overall operations. We expect interest income to continue to be nominal in 2013 due to low investment yields and declining cash and cash equivalent investment balances. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Interest and Other Expense </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Interest and other expense was approximately $1,000 in the three months ended March 31, 2013 and March 31, 2012. Based on our current capital structure, interest expense for 2013 is expected to be minimal. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Liquidity and Capital Resources </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:9.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-style: Italic; ">Cash and Cash Equivalents </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="WIDTH:176.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:71.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">March 31,</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:69.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">December 31,</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:71.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">2013</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:69.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">2012</FONT></P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:176.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:71.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:69.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:15.00pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:176.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:10.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Cash and cash equivalents</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:71.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">3,537</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:69.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">2,920</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">As of March 31, 2013, we had total cash and cash equivalents of approximately $3.5 million, as compared to $2.9 million as of December 31, 2012. The net increase of $.6 million in the three month period reflects the $1.4 million of net proceeds from our stock offerings completed during the quarter, less approximately $764,000 of cash used to fund operating activities for the three months ended March 31, 2013. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break20"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;19&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:9.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Cash Flows from Operating, Investing and Financing Activities </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR STYLE="height:15.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:229.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="WIDTH:168.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">Three Months Ended March 31,</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:229.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:77.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">2013&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:77.00pt; border-bottom:solid 0.75pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; color:#000000; ">2012&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:229.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:229.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:10.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Net cash (used in) provided by:</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:229.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:40.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Operating activities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">764)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">656)&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:229.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:40.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Investing activities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(9)&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#151;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:12.75pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:229.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:40.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Financing activities</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">1,390&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(60)&nbsp;</FONT></P></TD></TR>
<TR STYLE="height:13.50pt">
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:229.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:10.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">Net decrease in cash and cash equivalents</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; border-top:solid 0.75pt #000000; border-bottom:double 2.25pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">617&nbsp;&nbsp;</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:14.00pt; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="right" STYLE="WIDTH:77.00pt; border-top:solid 0.75pt #000000; border-bottom:double 2.25pt #000000; padding-left:5.40pt; padding-right:5.40pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; text-align:left;margin:0;padding:0;float:left">&nbsp;&nbsp;$ </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(1,</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">716)&nbsp;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Net cash used in operating activities for the three months ended March 31, 2013 decreased approximately $892,000 compared with the 2012 period primarily due to decreased R&D and SG&A expenses discussed above and due to increased trade payable and accrued liabilities. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Net cash used in investing activities for the three months ended March 31, 2013 was approximately $9,000 representing investment in capitalized equipment compared to $0 used in investing activities in the three months ended March 31, 2012. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Net cash provided by financing activities was $1.4 million for the three months ended March 31, 2013 representing the net proceeds from two equity financings completed during the quarter. Net cash used in financing activities of $60,000 for the three months ended March 31, 2012 were costs incurred in 2012 for preparing and filing the registration statement required for our equity financing completed in December 2011. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Sources and Uses of Capital </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our primary sources of liquidity to date have been capital raised from issuances of shares of our common and preferred stock and funds provided by the merger with Nuvelo. The primary uses of our capital resources to date have been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments, and spending on capital items. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Considering the substantial additional time and costs associated with the development of Gencaro and our need to raise a significant amount of capital on acceptable terms to finance the planned GENETIC-AF clinical trial and our ongoing operations, we are evaluating strategic alternatives for funding our operations and development programs. We plan to pursue a public equity offering to fund the Phase 2b portion of the GENETIC-AF trial and our general and administrative costs through its projected completion. We may also seek additional funding that could allow us to operate while we continue to pursue financing alternatives, a strategic combination, or partnership to support the continued clinical development of Gencaro, including the planned GENETIC-AF clinical trial. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">To date, we have completed two equity-financing transactions in 2013 and raised approximately $1.4 million, net of offering costs. These financings have allowed us to continue operations while we pursue financing options, a strategic combination, partnering, and licensing opportunities, and we may seek more interim funding in 2013. On January 22, 2013, we sold approximately $1 million of our common stock and warrants for common stock in a private placement transaction with accredited investors and our Chief Executive Officer. We issued 356,430 shares of common stock together with warrants to purchase 249,501 shares of common stock. The net proceeds, after deducting placement agent fees and other offering expenses, were approximately $805,000, and these proceeds are being used solely for general working capital purposes.  Each unit, consisting of a share of common stock and a warrant to purchase 0.70 shares of common stock, was sold at a purchase price of $2.81 per unit. The warrants were exercisable upon issuance, expire seven years from the date of issuance, and have an exercise price of $2.28 per share. Pursuant to the terms of the Registration Rights Agreements (the Rights Agreements) entered into as part of this and prior Private Placement transactions, we filed a registration statement for the resale of the shares underlying the units sold in these private placements. That registration statement was declared effective by the Securities and Exchange Commission on February 14, 2013. On January 31, 2013, we sold approximately $730,000 of ARCA&#146;s common stock and warrants for common stock in a Registered Direct Offering in which we issued 164,636 shares of common stock and warrants to purchase 65,855 shares of common stock. The net proceeds, after deducting placement agent fees and other offering expenses payable by us, was approximately $616,000, and these proceeds are being used solely for general working capital purposes. Each unit, consisting of a share of common stock and a warrant to purchase 0.40 shares of common stock, was sold at a purchase price of $4.43 per unit. The warrants were exercisable upon issuance, expire five years from the date of issuance, and have an exercise price of $4.13 per share. The Registered Direct Offering was effected pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February 1, 2013. The warrant agreements provide for settlement of the warrants in unregistered shares should an effective registration statement or current prospectus not be in place at the time a warrant is exercised. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break21"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;20&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">To support the continued development of Gencaro, including the planned GENETIC-AF clinical trial and our ongoing operations, we are pursuing a public equity offering to fund the Phase 2b portion of the GENETIC-AF trial and our general and administrative costs through the trial&#146;s projected completion. Our liquidity, and ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the costs and timing for GENETIC-AF clinical trial in order to gain possible FDA approval for Gencaro; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the market price of our stock and the availability and cost of additional equity capital from existing and potential new investors; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">our ability to retain the listing of our common stock on the Nasdaq Capital Market; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">general economic and industry conditions affecting the availability and cost of capital; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">potential receipt of government or third party funding to further develop Gencaro or rNAPc2; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">our ability to control costs associated with our operations; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:4.50pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the terms and conditions of our existing collaborative and licensing agreements. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to our existing stockholders. If we raise additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of our capital stock and could contain covenants that would restrict our operations. We also cannot predict what consideration might be available, if any, to us or our stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to us in the near term, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the normal course of business which may, among other alternatives, cause us to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We currently believe our cash and cash equivalents balance as of March 31, 2013 will be sufficient to fund our operations, at our current cost structure, through September 30, 2013. However, we are unable to assert that these funds are sufficient to fund operations beyond that date, and as a result, there is substantial doubt about our ability to continue as a going concern beyond September 30, 2013. The consolidated financial statements contained in this report have been prepared with the assumption that we will continue as a going concern and will be able to realize our assets and discharge our liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. We may not be able to raise sufficient capital on acceptable terms or at all to continue development of Gencaro or to continue operations and may not be able to execute any strategic transaction. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Critical Accounting Policies and Estimates </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires our management&#146;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our significant accounting policies are described in Note 1 of &#147;Notes to the Consolidated Financial Statements&#148; included within our 2012 Annual Report on Form 10-K filed with the Securities and Exchange Commission. Following is a discussion of the accounting policies that we believe involve the most difficult, subjective or complex judgments and estimates. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-style: Italic; ">Long-Lived Assets and Impairments </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We review long-lived assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. As a development stage company, we have not generated positive cash flows from operations, and such cash flows may not materialize for a significant period in the future, if ever. Additionally, we may make changes to our business plan that would result in changes to expected cash flows from long-lived assets. It is reasonably possible that future evaluations of long-lived assets, including changes from our current expected use of long-lived assets, may result in impairments. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-style: Italic; ">Accrued Expenses </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">As part of the process of preparing our financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our the Company&#146;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to our drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. We develop estimates of liabilities using our judgment based upon the facts and circumstances known at the time. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"><A NAME="Break22"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;21&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-style: Italic; ">Share-based Compensation </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our share-based compensation cost recognized includes: (a) compensation costs for current period vesting of all share-based awards granted prior to January 1, 2006, based on the intrinsic value method, and (b) compensation cost for current period vesting of all share-based awards granted or modified subsequent to January 1, 2006, based on the estimated grant date fair value. We recognize compensation costs for our share-based awards on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">From Inception through December 31, 2005, we accounted for issuances of share-based compensation under the intrinsic-value-based method of accounting. Under this method, compensation expense is generally recorded on the date of grant only if the estimated fair value of the underlying stock exceeds the exercise price. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Off-Balance Sheet Arrangements </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We have not participated in any transactions with unconsolidated entities, such as special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Indemnifications </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify certain parties from any losses incurred relating to the services they perform on our behalf or for losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. We have entered into indemnity agreements with each of our directors, officers and certain employees. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in Delaware law. We also maintain an insurance policy for our directors and executive officers insuring against certain liabilities arising in their capacities as such. </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:13.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:10.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="ITEM_3"></A><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM&nbsp;3.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Not applicable. </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:13.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:10.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="ITEM_4"></A><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM&nbsp;4.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">CONTROLS AND PROCEDURES</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Evaluation of Disclosure Controls and Procedures </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, an evaluation was carried out under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable level of assurance. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Changes in Internal Control over Financial Reporting </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">There has been no change in our internal control over financial reporting during our most recent fiscal quarter that would materially affect or is reasonably likely to materially affect, our internal control over financial reporting. </FONT></P>
<P STYLE="margin-top:18.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt" ALIGN="center">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;22&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><A NAME="Break23"></A> </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:12.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">PART II. OTHER INFORMATION </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:9.00pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:10.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="ITEM_1_II"></A><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM&nbsp;1.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">LEGAL PROCEEDINGS</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">None </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:10.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="ITEM_1A_II"></A><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Item&nbsp;1A.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">Risk Factors</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-style: Italic; ">An investment in ARCA&#146;s securities involves certain risks, including those set forth below and elsewhere in this report. In addition to the risks set forth below and elsewhere in this report, other risks and uncertainties not known to ARCA, that are beyond its control or that ARCA deems to be immaterial may also materially adversely affect ARCA&#146;s business operations. You should carefully consider the risks described below as well as other information and data included in this report. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Risks Related to Our Business and Financial Condition </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Our management and our independent registered public accountant, in their report on our financial statements as of and for the year ended December 31, 2012, have concluded that due to our need for additional capital, and the uncertainties surrounding our ability to raise such funding, substantial doubt exists as to our ability to continue as a going concern. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our audited financial statements for the fiscal year ended December 31, 2012 and for the three months ended March 31, 2013, were prepared assuming that we will continue as a going concern. The going concern basis of presentation assumes that we will continue in operation for the foreseeable future and will be able to realize our assets and discharge our liabilities and commitments in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from our inability to continue as a going concern. Our management and our independent registered public accountants have concluded that due to our need for additional capital, and the uncertainties surrounding our ability to raise such funding, substantial doubt exists as to our ability to continue as a going concern. We may be forced to reduce our operating expenses and raise additional funds to meet our working capital needs, principally through the additional sales of our securities or debt financings. However, we cannot guarantee that will be able to obtain sufficient additional funds when needed or that such funds, if available, will be obtainable on terms satisfactory to us. If we are unable to raise sufficient additional capital or complete a strategic transaction, we may be unable to continue to fund our operations, develop Gencaro or our other product candidates, or realize value from our assets and discharge our liabilities in the normal course of business. These uncertainties raise substantial doubt about our ability to continue as a going concern. If we become unable to continue as a going concern, we may have to liquidate our assets, and might realize significantly less than the values at which they are carried on our financial statements, and stockholders may lose all or part of their investment in our common stock. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We will need to raise substantial additional funds through public or private equity transactions complete one or more strategic transactions, to continue development of Gencaro. If we are unable to raise such financing or complete such a transaction, we may not be able to continue operations. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In light of the expected development timeline to potentially obtain FDA approval for Gencaro, if at all, the substantial additional costs associated with the development of Gencaro, including the costs associated with the planned GENETIC-AF clinical trial, the substantial cost of commercializing Gencaro, if it is approved, we will need to raise substantial additional funding through public or private r equity transactions or a strategic combination or partnership. If we are delayed in obtaining funding or are unable to complete a strategic transaction, we may discontinue our development activities on Gencaro or discontinue our operations. Even if we are able to fund continued development and Gencaro is approved, we expect that we will need to complete a strategic transaction or raise substantial additional funding through public or private debt or equity securities to successfully commercialize Gencaro. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We believe our cash and cash equivalents balance as of March 31, 2013 will be sufficient to fund our operations, at our current cost structure, through September 30, 2013. As a result of the significant additional development effort required for Gencaro, including the additional clinical trials, we may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or to continue operation and may not be able to execute any strategic transaction. We are unable to assert that our current cash and cash equivalents are sufficient to fund operations beyond that date, and as a result, there is substantial doubt about our ability to continue as a going concern beyond September 30, 2013. Changing circumstances may cause us to consume capital significantly faster or slower than we currently anticipate. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available financial resources sooner than we currently anticipate. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our liquidity, and our ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the costs and timing for additional clinical trials in order to gain possible FDA approval for Gencaro;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:48.95pt; text-indent:-18.35pt"><A NAME="Break24"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;23&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the market price of our stock and the availability and cost of additional equity capital from existing and potential new investors;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">our ability to retain the listing of our common stock on the Nasdaq Capital Market;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">general economic and industry conditions affecting the availability and cost of capital;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">our ability to control costs associated with our operations;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the terms and conditions of our existing collaborative and licensing agreements.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The sale of additional equity or convertible debt securities would likely result in substantial dilution to our stockholders. If we raise additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of our capital stock and could contain covenants that would restrict our operations. We also cannot predict what consideration might be available, if any, to us or our stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to us in the near term, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the normal course of business which may, among other alternatives, cause us to further delay, substantially reduce or discontinue operational activities to conserve our cash resources. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If we are not able to maintain the requirements for listing on the Nasdaq Capital Market, we could be delisted, which could have a materially adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of our common stock on the Nasdaq Capital Market we are required to meet certain listing requirements, including, among others, either: (i) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and stockholders&#146; equity of at least $2.5 million; or (ii) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and a total market value of listed securities of at least $35 million. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">During 2012 our stock price fell below the Nasdaq Capital Market&#146;s minimum bid price requirements and we became subject to delisting from the exchange. On March 4, 2013 we executed a 1 for 6 reverse split of our common stock and have subsequently regained compliance with the minimum bid price requirements. In future periods, if we do not meet the minimum stockholders&#146; equity, minimum closing bid price requirements, or any other listing requirements, we would be subject to delisting from the Nasdaq Capital Market. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">As of May10, 2013, the closing price of our common stock was $2.40 per share, and the total market value of our publicly held shares of our common stock (excluding shares held by our executive officers, directors and 10% or more stockholders) was approximately $6.0 million and the total market value of our listed securities was approximately $7.6 million. As of March 31, 2013, we had stockholders&#146; equity of $3.3 million. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Our failure to raise substantial additional funding or enter into a strategic transaction may materially and adversely affect our business. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Unless we are able to raise substantial additional funding through other means, we will need to complete a strategic transaction to continue the development of Gencaro or our other operations. The strategic transactions that we may consider include a potential combination or partnership. Our board of directors and management team has and will continue to devote substantial time and resources to obtaining additional capital or the consideration and implementation of any such strategic transaction. In addition, conditions in the financial markets may lead to an increased number of biotechnology companies that are also seeking to enter into strategic transactions, which may limit our ability to negotiate favorable terms for any such transaction. Further, our current employees do not have experience in the strategic transaction process, and our previous efforts to enter into a strategic transaction have not been successful. As a result of these and other factors, there is substantial risk that we may not be able to complete a strategic transaction on favorable terms, or at all. The failure to complete a strategic transaction may materially and adversely affect our business. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We may be limited in our ability to access sufficient funding through a private equity or convertible debt offering. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Nasdaq rules impose restrictions on our ability to raise funds through a private offering of our common stock, convertible debt or similar instruments without obtaining stockholder approval. Under Nasdaq rules, an offering of more than 20% of our total shares outstanding for less than the greater of book or market value requires stockholder approval unless the offering qualifies as a &#147;public offering&#148; for purposes of the Nasdaq rules. As of March 31, 2013, we had 3,185,562 shares of common stock outstanding, 20% of which is 637,112 shares. To the extent we seek to raise funds through a private offering of stock, convertible debt or similar instruments, we are limited in how much funding we could raise privately without requiring a stockholder vote. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break25"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;24&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In addition, we are currently subject to certain contractual rights of investors arising from our public and private equity financing transactions that limit the nature and price of future public and private financing transactions that we may effect. For example, in January 2013, we entered into separate subscription agreements with certain institutional investors in connection with a private investment in public equity, pursuant to which we sold shares of our common stock and warrants to purchase shares of our common stock to the investors. In connection with this transaction, we agreed that, subject to certain exceptions, we would not, while the warrants are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a &#147;variable rate transaction,&#148; which means a transaction in which we issue or sell any convertible securities either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. In addition, we agreed that, subject to certain exceptions, if we issue securities within one year following the closing of the offering, each investor would have the right to purchase its pro rata share of a specified portion of the securities in the future offering on the same terms, conditions and price provided for in the proposed issuance of securities. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The restrictions imposed by the terms of these offerings, and that could be imposed in future offerings, may limit our access to capital on agreeable terms and delay or make impossible certain otherwise available equity financing opportunities and could severely restrict our access to the capital necessary to conduct our business. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If we are not able to successfully develop, obtain FDA approval for and provide for the commercialization of Gencaro in a timely manner, we may not be able to continue our business operations. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We currently have no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly. We plan to conduct a Phase 2b/Phase 3 clinical study of Gencaro in approximately 620 HFREF patients with AF. Clinical trials are typically lengthy, complex and expensive and we do not currently have the resources to fund such a trial. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Failure to demonstrate that a product candidate, particularly Gencaro, is safe and effective, or significant delays in demonstrating such safety and efficacy, would adversely affect our business. Failure to obtain marketing approval of Gencaro from appropriate regulatory authorities, or significant delays in obtaining such approval, would also adversely affect our business and could, among other things, preclude us from completing a strategic transaction or obtaining additional financing necessary to continue as a going concern. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Even if approved for sale, a product candidate must be successfully commercialized to generate value. We do not currently have the capital resources or management expertise to commercialize Gencaro and, as a result, will need to complete a strategic transaction, or, alternatively, raise substantial additional funds to enable commercialization of Gencaro, if it is approved. Failure to successfully provide for the commercialization of Gencaro, if it is approved, would damage our business. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Our clinical trials for our product candidates may not yield results that will enable us to further develop our products and obtain the regulatory approvals necessary to sell them. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We will receive regulatory approval for our product candidates only if we can demonstrate in carefully designed and conducted clinical trials that the product candidate is safe and effective. We do not know whether any future clinical trials, including the planned GENETIC-AF clinical trial for Gencaro, will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products. For example, GENETIC-AF is designed to be an adaptive trial. If we do not see sufficient efficacy and safety in the Phase 2b portion of the trial, we will not complete the Phase 3 portion of the trial. Clinical trials are lengthy, complex and expensive processes with uncertain results. We have spent, and expect to continue to spend, significant amounts of time and money in the clinical development of our product candidates. We have never conducted a Phase 2 or Phase 3 clinical trial and do not currently have sufficient staff with the requisite experience to do so, and we therefore expect that we will have to rely on contract research organizations to conduct certain of our clinical trials. While certain of our employees have experience in designing and administering clinical trials, these employees have no such experience since being with us. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The results we obtain in preclinical testing and early clinical trials may not be predictive of results that are obtained in later studies. We may suffer significant setbacks in advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, we may decide to repeat or redesign a trial or discontinue development of one or more of our product candidates. If we fail to adequately demonstrate the safety and efficacy of our products under development, we will not be able to obtain the required regulatory approvals to commercialize our product candidates, and our business, results of operations and financial condition would be materially adversely affected. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break26"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;25&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Administering our product candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of our product candidates and could result in the FDA or other regulatory authorities denying approval of our product candidates for any or all targeted indications. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">If clinical trials for a product candidate are unsuccessful, we will be unable to commercialize the product candidate. If one or more of our clinical trials are delayed, we will be unable to meet our anticipated development timelines. Either circumstance could cause the market price of our common stock to decline. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We expect to rely on contract research organizations to conduct clinical trials, and as a result, will be unable to directly control the timing, conduct and expense of clinical trials. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We expect that we, or any strategic partners, will rely primarily on third parties to conduct clinical trials, including the AF clinical trial that we plan to conduct. As a result, we will have less control over the conduct of the clinical trials, the timing and completion of the trials, the required reporting of adverse events and the management of data developed through the trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our trials. We may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a contract research organization may lead us or any strategic partner to seek to terminate the relationship and use an alternative service provider. However, making this change may be costly and may delay ongoing trials, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable cost. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Even if we do use a contract research organization to conduct clinical trials, we will have to devote substantial resources and rely on the expertise of our employees to manage the work being done by the contract research organization. We have never conducted a clinical trial and do not currently have sufficient staff with the requisite experience to do so. The inability of our current staff to adequately manage any contract research organization that we hire may exacerbate the risks associated with relying on a contract research organization. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If we encounter difficulties enrolling patients in our clinical trials, our trials could be delayed or otherwise adversely affected. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Clinical trials for our product candidates require that we identify and enroll a large number of patients with the disorder or condition under investigation. We may not be able to enroll a sufficient number of patients to complete our clinical trials in a timely manner. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Patient enrollment is affected by factors including: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">design of the protocol;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the size of the patient population;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">eligibility criteria for the study in question;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">perceived risks and benefits of the drug under study;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">availability of competing therapies, including the off-</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">label use of therapies approved for related indications;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">efforts to facilitate timely enrollment in clinical trials;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the success of our personnel in making the arrangements with potential clinical trial sites necessary for those sites to begin enrolling patients;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">patient referral practices of physicians;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">availability of clinical trial sites; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">other clinical trials seeking to enroll subjects with similar profiles.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay or terminate ongoing or planned clinical trials, either of which would have a negative effect on our business. Delays in enrolling patients in our clinical trials would also adversely affect our ability to generate any product, milestone and royalty revenues under collaboration agreements, if any, and could impose significant additional costs on us or on any future collaborators. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We expect to depend on existing and future collaborations with third parties for the development of some of our product candidates. If those collaborations are not successful, we may not be able to complete the development of these product candidates. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break27"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;26&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We currently have a collaboration agreement with Medtronic, Inc. or Medtronic for the support of our GENETIC-AF trial. Medtronic can terminate its collaboration with us for various reasons including uncured material breach, an ARCA bankruptcy, if, after FDA communication, it is reasonably concluded that the FDA will not allow GENETIC-AF to enroll or proceed, if the trial has not begun by December 1, 2014, if the substudy protocol is not agreed to by August 15, 2013, or if Medtronic&#146;s obligations are unilaterally expanded. We may seek additional third party collaborators for the development of Gencaro or other product candidates. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Under our current arrangement with Medtronic, we have limited control over the amount and timing of resources that they dedicate to the development of Gencaro. This is also likely to be true in any future collaborations with third parties. Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Collaborations involving our product candidates pose the following risks to us: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#146;s strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">collaborators may elect to take over manufacturing rather than retain us as manufacturers and may encounter problems in starting up or gaining approval for their manufacturing facility and so be unable to continue development of product candidates; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">we may be required to undertake the expenditure of substantial operational, financial and management resources in connection with any collaboration; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">we may be required to issue equity securities to collaborators that would dilute our existing stockholders&#146; percentage ownership; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">we may be required to assume substantial actual or contingent liabilities; </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">collaborators may not commit adequate resources to the marketing and distribution of our product candidates, limiting our potential revenues from these products; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; margin-left:10.88%; margin-top:9.00pt; margin-bottom:0.00pt; WIDTH:89.12%;" BORDER="0" CELLPADDING="0" CELLSPACING="0" >
<TR>
   <TD WIDTH="3%" VALIGN="top" ><FONT STYLE="font-family: Symbol; font-size: 10">&#183;&nbsp;&nbsp;</FONT></TD>
   <TD WIDTH="97%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">collaborators may experience financial difficulties. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We face a number of challenges in seeking additional collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#146;s evaluation of a number of factors, such as the design or results of our clinical trials, the potential market for our product candidates, the costs and complexities of manufacturing and delivering our product candidates to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of our intellectual property, and industry and market conditions generally. If we were to determine that additional collaborations for our Gencaro development &nbsp;is necessary and were unable to enter into such collaborations on acceptable terms, we might elect to delay or scale back the development or commercialization of Gencaro in order to preserve our financial resources or to allow us adequate time to develop the required physical resources and systems and expertise ourselves. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break28"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;27&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Our planned GENETIC-AF clinical trial will require the use of a third-party diagnostic services provider to administer the genetic test needed to identify the patient receptor genotypes of clinical trial participants. We do not currently have a third-party diagnostic services provider identified to perform this work for our planned clinical trial. If we have difficulty getting an arrangement for administering the Gencaro Test, the launch of our clinical trial could be delayed. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The planned GENETIC-AF clinical trial we intend to conduct with Gencaro requires a companion test that identifies the patient&#146;s receptor genotype, or Gencaro Test, and the trial will only enroll those patients with the receptor that has the potential for enhanced efficacy, the beta-1 389 Arg receptor as detected by a beta-1 389 Arg/Arg genotype. Accordingly, the GENETIC-AF trial will require use of a third-party diagnostic service to perform the Gencaro Test. Previously we entered into a collaboration arrangement with LabCorp to develop and commercialize the Gencaro Test for the treatment of patients with HF. Under the terms of that collaboration, we licensed to LabCorp certain rights to commercialize a receptor genotype diagnostic for the beta-1 and alpha-2C polymorphisms. We currently intend to pursue a separate arrangement with LabCorp or another third party to provide the diagnostic services of the Gencaro Test needed to support our GENETIC-AF trial. Obtaining an arrangement with a third party for developing or administering the Gencaro Test for the clinical trial could delay the launch and/or affect the cost and complexity of our planned study. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Unless we are able to generate sufficient product revenue, we will continue to incur losses from operations and may not achieve or maintain profitability. We are years away from commercializing a product and generating product revenue. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our historical losses have had and will continue to have an adverse effect on our stockholders&#146; equity and working capital, among other things. We are years away from commercializing a product and generating any product revenue. As a result, we expect to continue to incur significant operating losses for the foreseeable future. Even if we ultimately receive regulatory approval for Gencaro or our other product candidates, sales of such products may not generate sufficient revenue for it to achieve or maintain profitability. Because of the numerous risks and uncertainties associated with developing therapeutic drugs, we may experience larger than expected future losses and may never reach profitability. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:12.20pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We may not achieve our projected development goals in the time frames we announce and expect. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We set goals for, and make public statements regarding, the timing of certain accomplishments, such as, the commencement and completion of clinical trials, particularly GENETIC-AF, the disclosure of trial results, the obtainment of regulatory approval and the sale of drug product, which we sometimes refer to as milestones. These milestones may not be achieved, and the actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our clinical trials, disagreements with current or future collaborative partners, the uncertainties inherent in the regulatory approval process and manufacturing scale-up and delays in achieving manufacturing or marketing arrangements sufficient to commercialize our products. FDA approval of Gencaro, if it occurs, is expected to require years of additional clinical development, including the completion of a new multi-year clinical study of Gencaro in approximately 200 patient and, depending on the outcome of the Phase 2b portion, may be expanded to a Phase 3 study with up to an estimated additional 420 patients. There can be no assurance that our clinical trials will be completed, or that we will make regulatory submissions or receive regulatory approvals as planned. If we fail to achieve one or more of these milestones as planned, our business will be materially adversely affected. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Our product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase our future development costs or impair our future revenue. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising, promotion, sale, marketing, and distribution, if approved, of our product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United States and elsewhere. These regulations also vary in important, meaningful ways from country to country. We are not permitted to market a potential drug in the United States until we receive approval of an NDA from the FDA. We have not received an NDA approval from the FDA for Gencaro or any of our other product candidates. There can be no guarantees with respect to our product candidates that clinical studies will adequately support an NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">To receive regulatory approval for the commercial sale of any product candidates, we must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through preclinical studies and adequate and well-controlled clinical trials of the product candidates. This process is expensive and can take many years, and failure can occur at any stage of the testing. Our failure to adequately demonstrate the safety and efficacy of our product candidates will prevent regulatory approval and commercialization of such products. In 2008, we submitted and the FDA accepted our NDA filing for Gencaro for the treatment of chronic HF. In 2009, the FDA issued a CRL in which the FDA stated that it could not approve the Gencaro NDA in its current form, and specified actions required for approval of the NDA, including conducting an additional Phase 3 clinical trial of Gencaro in patients with HF. We plan to conduct a clinical study of Gencaro in AF patients HREF to assess its efficacy in reducing or preventing AF. We anticipate that GENETIC-AF could begin approximately six months after we obtain sufficient funding. This trial is planned to begin as a Phase 2b study in approximately 200 patients and, depending on the outcome of the Phase 2b portion, may be expanded to a Phase 3 study with <A NAME="Break29"></A> </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;28&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">up to an estimated additional 420 patients. We believe the Phase 2b study would take approximately two years to complete. This product candidate will require years of clinical development. Even if we conduct additional studies in accordance with further FDA guidance and submit or file a new or amended NDA, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In the event that we or our collaborators conduct preclinical studies that do not comply with Good Laboratory Practices or GLP or incorrectly design or carry out human clinical trials in accordance with Good Clinical Practices or GCP or those clinical trials fail to demonstrate clinical significance, it is unlikely that we will be able to obtain FDA approval for product development candidates. Our inability to successfully and effectively complete clinical trials for any product candidate on schedule, or at all, will severely harm our business. Significant delays in clinical development could materially increase product development costs or allow our competitors to bring products to market before we do, impairing our ability to effectively commercialize any future product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to our product candidates or similar product candidates of our competitors or failure to follow regulatory guidelines;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidates for use in trials;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">delays or failures in reaching agreement on acceptable terms with prospective study sites;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">delays or failures in obtaining approval of our clinical trial protocol from an institutional review board, or IRB, to conduct a clinical trial at a prospective study site;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">delays in recruiting patients to participate in a clinical trial, which may be due to the size of the patient population, eligibility criteria, protocol design, perceived risks and benefits of the drug, availability of other approved and standard of care therapies, availability of clinical trial sites;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">other clinical trials seeking to enroll subjects with similar profile;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">failure of our clinical trials and clinical investigators to be in compliance with the FDA</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#146;s Good Clinical Practices;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">unforeseen safety issues, including negative results from ongoing preclinical studies;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">inability to monitor patients adequately during or after treatment;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">difficulty monitoring multiple study sites; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">failure of our third-party contract research organizations, clinical site organizations and other clinical trial managers, to satisfy their contractual duties, comply with regulations or meet expected deadlines.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In addition, any approvals we may obtain may not cover all of the clinical indications for which we seek approval or permit us to make claims of superiority over currently marketed competitive products. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks, we may be required to include as part of the NDA a proposed REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug&#146;s distribution, or a Medication Guide, to provide better information to consumers about the drug&#146;s risks and benefits. Finally, an approval could be conditioned on our commitment to conduct further clinical trials, which we may not have the resources to conduct or which may negatively impact our financial situation. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The manufacture and tableting of Gencaro is done by third party suppliers, who must also meet current Good Manufacturing Practices, or cGMP, requirements and pass a pre-approval inspection of their facilities before we can obtain marketing approval. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">All of our product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities in the United States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons, including, but not limited to: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Side effects;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:48.95pt; text-indent:-18.35pt"><A NAME="Break30"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;29&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Safety and efficacy;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Defects in the design of clinical trials;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">The fact that the FDA or other regulatory officials may not approve our or our third party manufacturer</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#146;s processes or facilities; or</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">The fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a product candidate.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In light of widely publicized events concerning the safety of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products, revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product&#146;s risk/benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability of the Gencaro NDA in a timely manner. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In pursuing clinical development of Gencaro for an AF indication, we would likely be required to amend the Gencaro HF NDA or prepare a new NDA. The FDA could approve Gencaro, but without including some or all of the prescribing information that we have requested. For instance, the FDA could approve Gencaro for AF in a more limited patient population or included additional warnings in the drug&#146;s label. This, in turn, could substantially and detrimentally impact our ability to successfully commercialize Gencaro and effectively protect our intellectual property rights in Gencaro. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If our product candidates receive regulatory approval, we would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit our ability to develop and commercialize other potential products. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">If a product candidate of ours is approved by the FDA or by another regulatory authority, we would be held to extensive regulatory requirements over product manufacturing, testing, distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing, promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly follow-up or post-marketing clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional regulatory controls or restrictions on the marketing or use of the product or the need for post marketing studies, and could include suspension or withdrawal of the products from the market. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Furthermore, our third-party manufacturers and the manufacturing facilities that they use to make our product candidates are regulated by the FDA. Quality control and manufacturing procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and/or other foreign authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by us or our collaborators, may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. We and our third-party manufacturers will also be subject to ongoing FDA requirements for submission of safety and other post-market information. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The marketing and advertising of our drug products by our collaborators or us will be regulated by the FDA, certain state agencies or foreign regulatory authorities. Violations of these laws and regulations, including promotion of our products for unapproved uses or failing to disclose risk information, are punishable by criminal and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, U.S. Department of Justice, state agencies, or foreign regulatory authorities that could jeopardize our ability to market the product. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In addition to the FDA, state or foreign regulations, the marketing of our drug products by us or our collaborators will be regulated by federal, state or foreign laws pertaining to health care &#147;fraud and abuse,&#148; such as the federal anti-kickback law prohibiting bribes, kickbacks or other remuneration for the order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid and Veterans Affairs healthcare programs. Because of the far-reaching nature of these laws, we may be required to discontinue one or more of our practices to be in compliance with these laws. Health care fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or <A NAME="Break31"></A> </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;30&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">prohibition has been violated. Any violations of these laws, or any action against us for violations of these laws, even if we successfully defend against it, could have a material adverse effect on our business, financial condition and results of operations. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We could also become subject to false claims litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. These false claims statutes include the False Claims Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have increased significantly in volume and breadth in recent years. Some of these suits have been brought on the basis of certain sales practices promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other federal and state healthcare programs as a result of an investigation arising out of such action. We may become subject to such litigation and, if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial condition and results of operations. We could also become subject to false claims litigation and consumer protection claims under state statutes, which also could lead to civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in state health care programs. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Of note, over the past few years there has been an increased focus on the sales and marketing practices of the pharmaceutical industry at both the federal and state level. Additionally, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be adopted that could prevent or delay regulatory approval of our product candidates or limit our ability to commercialize our products. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the U.S. or elsewhere. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">If we, our collaborators or our third-party manufacturers fail to comply with applicable continuing regulatory requirements, our business could be seriously harmed because a regulatory agency may: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">issue untitled or warning letters;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">suspend or withdraw our regulatory approval for approved products;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">seize or detain products or recommend a product recall of a drug or medical device, or issue a mandatory recall of a medical device;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">refuse to approve pending applications or supplements to approved applications filed by us;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">suspend our ongoing clinical trials;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">restrict our operations, including costly new manufacturing requirements, or restrict the sale, marketing and/or distribution of our products;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">seek an injunction;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">pursue criminal prosecutions;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">close the facilities of our contract manufacturers; or</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">impose civil or criminal penalties.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We will need to establish a collaborative arrangement with a third-party diagnostics services provider to obtain marketing clearance or approval of the companion Gencaro Test. There is no guarantee that the FDA will grant timely clearance or approval of the Gencaro Test, if at all, and failure to obtain such timely clearance or approval would adversely affect our ability to market Gencaro. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The drug label we intend to seek for Gencaro would identify the patient receptor genotype for which the drug is approved. Accordingly, we believe developing a Gencaro Test that is simple to administer and widely available will be critical to the successful commercialization of Gencaro and also to the ability to conduct our planned GENETIC-AF clinical trial. The Gencaro Test will be subject to regulation by the FDA and by comparable agencies in various foreign countries. The process of complying with the requirements of the FDA and comparable agencies is costly, time consuming and burdensome. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Despite the time and expense expended, regulatory clearance or approval is never guaranteed. If regulatory clearance or approval is delayed, or if a third-party diagnostic services provider is unable to obtain FDA approval of the Gencaro Test at all or in parallel with the approval of Gencaro, or is unable to commercialize the test successfully and in a manner that effectively supports the commercial efforts for Gencaro, or if the information concerning the differential response to Gencaro resulting from certain genetic variation is not included in the approval label for Gencaro, the commercial launch of Gencaro may be significantly and adversely affected. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break32"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;31&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Reliance on third parties to commercialize Gencaro could negatively impact our business. If we are required to establish a direct sales force in the U.S. and are unable to do so, our business may be harmed. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Commercialization of Gencaro, particularly the establishment of a sales organization, will require substantial additional capital resources. We currently intend to pursue a strategic partnership alternative for the commercialization of Gencaro, if it is approved, and we have suspended our efforts to build internal sales, marketing and distribution capabilities. If we elect to rely on third parties to sell Gencaro and any other products, then we may receive less revenue than if we sold such products directly. In addition, we may have little or no control over the sales efforts of those third parties. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">If we are unable to complete a strategic transaction, we would be unable to commercialize Gencaro or any other product candidate without substantial additional capital. Even if such capital were secured, we would be required to build internal sales, marketing and distribution capabilities to market Gencaro in the U.S. None of our current employees have experience in establishing and managing a sales force. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In the event we are unable to sell Gencaro and other selected product candidates, either directly or through third parties via a strategic transaction, the commercialization of Gencaro, if it is approved, may be delayed indefinitely. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:12.20pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Future sales of Gencaro may suffer if its marketplace acceptance is negatively affected by the Gencaro Test. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The Gencaro Test is an important component of the commercial strategy for Gencaro in addition to being required to proceed with our planned AF trial. We believe that the Gencaro Test helps predict patient response to Gencaro, and that this aspect of the drug is important to its ability to compete effectively with current therapies. The Gencaro Test adds an additional step in the prescribing process, an additional cost for the patient and payors, the risk that the test results may not be rapidly available and the possibility that it may not be available at all to hospitals and medical centers. Although we anticipate that Gencaro, if approved in a timely manner, would be the first genetically-targeted cardiovascular drug, Gencaro will be one of a number of successful drugs in the beta-blocker class currently on the market. Prescribers may be more familiar with these other beta-blockers, and may be resistant to prescribing Gencaro as an AF or HF therapy. Any one of these factors could affect prescriber behavior, which in turn may substantially impede market acceptance of the Gencaro Test, which could cause significant harm to Gencaro&#146;s ability to compete, and in turn harm our business. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:12.20pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We are dependent on our key personnel. </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The success of our business is highly dependent on the principal members of our board of directors and executive management, including our President and Chief Executive Officer, Michael R. Bristow. The loss of the services of any such individual might seriously harm our product development, partnering and financing efforts. Recruiting and training personnel with the requisite skills is challenging and we compete for talent with companies that are larger and have more financial resources. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We do not currently operate manufacturing facilities for clinical or commercial production of our product candidates, including their active pharmaceutical ingredients, or API. We have no experience in drug formulation or manufacturing, and we lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We do not intend to develop facilities for the manufacture of product candidates for clinical trials or commercial purposes in the foreseeable future. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We have contracted with Groupe Novasep to manufacture commercial quantities of the API for Gencaro. For drug production, we have contracted with Patheon, Inc. to manufacture the Gencaro tablets. These contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our products. In addition, these manufacturers may have staffing difficulties, may not be able to manufacture our products on a timely basis or may become financially distressed. In the event of errors in forecasting production quantities required to meet demand, natural disaster, equipment malfunctions or failures, technology malfunctions, strikes, lock-outs or work stoppages, regional power outages, product tampering, war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty, we may be unable to find an alternative third-party manufacturer in a timely manner and the production of our product candidates would be interrupted, resulting in delays and additional costs, which could impact our ability to commercialize and sell our product candidates. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We or our contract manufacturers may also fail to achieve and maintain required manufacturing standards, which could result in patient injury or death, product recalls or withdrawals, an order by governmental authorities to halt production, delays or failures in product testing or delivery, cost overruns or other problems that could seriously hurt our business. Contract manufacturers also often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. In addition, our contract manufacturers are subject to ongoing inspections and regulation by the FDA, the U.S. Drug Enforcement Agency and corresponding foreign and state agencies and they may fail to meet these agencies&#146; acceptable standards of compliance. If our contract manufacturers fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and documentation, we may not be able to continue production of the API or finished product. If the safety of <A NAME="Break33"></A> </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;32&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">any API or product supplied is compromised due to failure to adhere to applicable laws or for other reasons, this may jeopardize our regulatory approval for Gencaro and other product candidates, and we may be held liable for any injuries sustained as a result. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Upon the occurrence of one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the number of potential manufacturers is limited and we may not be able to negotiate agreements with alternative manufacturers on commercially reasonable terms, if at all;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">long lead times are often needed to manufacture drugs;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the manufacturing process is complex and may require a significant learning curve; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the FDA must approve any replacement prior to manufacturing, which requires new testing and compliance inspections.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If a third-party diagnostics provider responsible for the Gencaro Test or certain of its third-party suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements, or if there are unanticipated problems with the Gencaro Test, these products could be subject to restrictions or withdrawal from use in trial or from the market. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Any medical device for which a third-party diagnostics provider obtains clearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. With respect to the Gencaro Test, to the extent applicable, any third-party diagnostics provider and certain of its suppliers will be required to comply with the FDA&#146;s Quality System Regulation, or QSR, and International Standards Organization, or ISO, requirements which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which clearance or approval is obtained. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by a third-party diagnostics provider, or certain of its third-party manufacturers or suppliers, as the case may be, to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, enforcement actions. If any of these actions were to occur, it could harm our reputation and cause product sales and profitability of Gencaro to suffer and may prevent us from generating revenue or utilizing the Gencaro Test further in any clinical trial. Even if regulatory clearance or approval is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product and generate revenue from the product. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">A third-party diagnostics provider may need to conduct clinical trials to support current or future versions of the Gencaro Test. Delays or failures in any such clinical trials may prevent a third-party diagnostics provider from commercializing any modified or new versions of the Gencaro Test and will adversely affect our business, operating results and prospects. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Based on discussions with the FDA, we do not believe that additional clinical data are needed for the Gencaro Test submission. However, the FDA may require clinical data for the Gencaro Test submission and/or future products. Initiating and completing clinical trials necessary to support 510(k)s or PMAs, if required, for current or future products will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we or our third party suppliers advance into clinical trials may not have favorable results in later clinical trials. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Conducting successful clinical studies may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including: the size of the patient population; the number of patients to be enrolled; the nature of the trial protocol; the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects; the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites; and the patients&#146; ability to meet the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our products or if they determine that the treatments received under the trial protocol are not attractive or involve unacceptable risks or discomforts. In addition, patients participating in clinical trials may die before completion of the trial or suffer adverse medical events unrelated to investigational products. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required, and we or the third-party diagnostics provider may not adequately develop such protocols to support clearance and approval. The trials will require the submission and approval of an investigational device exemption, or IDE, from the FDA. There is no guarantee that the FDA will approve the third-party diagnostics provider&#146;s or our future IDE submissions. Further, the FDA may require them or us to submit data on a greater number of patients than originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of future products or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in such clinical trials, <A NAME="Break34"></A> </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;33&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">the FDA may not consider the data to be adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our or our third party suppliers&#146; business, operating results and prospects. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Transitioning from a developmental stage company will require successful completion of a number of steps, many of which are outside of our control and, consequently, we can provide no assurance of our successful and timely transition from a developmental stage company. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We are a development stage biopharmaceutical company with a limited operating history. To date we have not generated any product revenue and have historically funded our operations through investment capital. Our future growth depends on our ability to emerge from the developmental stage and successfully commercialize or provide for the commercialization of Gencaro and our other product candidates, which in turn, will depend, among other things, on our ability to: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">conduct an additional clinical trial and develop and obtain regulatory approval for Gencaro or other product candidates;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">successfully partner a companion genetic test with the commercial launch of Gencaro;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">enter into a strategic transaction enabling the continued development and commercialization of Gencaro, or alternatively, raise significant additional capital to enable these activities;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">pursue additional indications for Gencaro and develop other product candidates, including other cardiovascular therapies; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">obtain commercial quantities of Gencaro or other product candidates at acceptable cost levels.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Any one of these factors or other factors discussed in this report could affect our ability to successfully commercialize Gencaro and other product candidates, which could impact our ability to earn sufficient revenues to transition from a developmental stage company and continue our business. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If approved by the FDA, Gencaro will be entering a competitive marketplace and may not succeed. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Gencaro is a new type of beta-blocker and vasodilator being developed for AF. While we anticipate that this drug, if approved, would be the first genetically-targeted cardiovascular drug, and potentially the only beta-blocker approved for AF. Gencaro will be one of a number of successful drugs in the beta-blocker class currently on the market. For example, currently, there are three branded beta-blockers indicated for chronic HF in New York Health Association, or NYHA, class II-IV patients: Toprol-XL (once-a-day formulation), Coreg and Coreg CR (once-a-day). Toprol-XL and Coreg have generic equivalents commercially available in the U.S. (metoprolol succinate and carvedilol, respectively). The price of the generic forms of these drugs will be less than the anticipated price of Gencaro, if approved. As a result, Gencaro may not be successful in competing against these existing drugs. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than Gencaro. If products with any of these properties are developed, or any of the existing products are better marketed, then prescriptions of Gencaro by physicians and patient use of Gencaro could be significantly reduced or rendered obsolete and noncompetitive. Further, public announcements regarding the development of any such competing drugs could adversely affect the market price of our common stock and the value of our assets. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Future sales of our products may suffer if they are not accepted in the marketplace by physicians, patients and the medical community. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Gencaro or our other product candidates may not gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of Gencaro or our other product candidates will depend on a number of factors, such as its effectiveness and tolerability, as compared with competitive drugs. Also, prevalence and severity of side-effects could negatively affect market acceptance of Gencaro or our other product candidates. Failure to achieve market acceptance of Gencaro would significantly harm our business. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If we are unable to obtain acceptable prices or adequate reimbursement from third-party payors for Gencaro, or any other product candidates that we may seek to commercialize, then our revenues and prospects for profitability will suffer. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our or any strategic partner&#146;s ability to commercialize Gencaro, or any other product candidates that we may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">governmental payors, such as Medicare and Medicaid;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">private health insurers, including managed-care organizations; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">other third-party payors.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break35"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;34&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Many patients will not be capable of paying for our potential products themselves and will rely on third-party payors to pay for their medical needs. A primary current trend in the U.S. health care industry is toward cost containment. Large private payors, managed-care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, are challenging the prices charged for medical products and services, and many third-party payors limit reimbursement for newly approved health care products. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Cost-control initiatives could decrease the price we might establish for products, which could result in product revenues lower than anticipated. If the prices for our product candidates decrease, or if governmental and other third-party payors do not provide adequate coverage and reimbursement levels, then our revenue and prospects for profitability will suffer. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Health care reform measures could materially and adversely affect our business. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care. The U.S. Congress has enacted legislation to reform the health care system. While we anticipate that this legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations as well as expansion of the 340(B) Public Health Services drug discount program. In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion, including new fees or taxes on certain health-related industries, including medical device manufacturers. Beginning in 2013, each medical device manufacturer will have to pay an excise tax (or sales tax) in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices. Such excise taxes may impact any potential sales of the Gencaro Test if it is approved for marketing. In foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health care system. For example, in some countries other than the United States, pricing of prescription drugs is subject to government control and we expect to see continued efforts to reduce healthcare costs in international markets. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform in the future although we are unable to predict what additional legislation or regulation, if any, relating to the health care industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation or regulation would have on our business. We or any strategic partner&#146;s ability to commercialize Gencaro, or any other product candidates that we may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third-party payors, and any change in reimbursement levels could materially and adversely affect our business. Further, the pendency or approval of future proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to obtain strategic partnerships or licenses. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Our competitors may be better positioned in the marketplace and thereby may be more successful than us at developing, manufacturing and marketing approved products. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Many of our competitors currently have significantly greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, managing manufacturing and marketing approved products than us. Other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring therapies and therapy licenses complementary to our programs or advantageous to our business. We expect that our ability to compete effectively will depend upon our ability to: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">successfully and rapidly complete clinical trials for any product candidates and obtain all requisite regulatory approvals in a cost-effective manner;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">build an adequate sales and marketing infrastructure, raise additional funding, or enter into strategic transactions enabling the commercialization of our products;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">develop competitive formulations of our product candidates;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">attract and retain key personnel; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:48.95pt; text-indent:-18.35pt"><A NAME="Break36"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;35&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">identify and obtain other product candidates on commercially reasonable terms.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If we fail to identify and license or acquire other products or product candidates, then we may be unable to expand our business, and the acquisition or licensing of other products or product candidates may put a strain on our operations and will likely require us to seek additional financing. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">One of our strategies is to license or acquire clinical-stage products or product candidates and further develop them for commercialization. The market for licensing and acquiring products and product candidates is intensely competitive and many of our competitors may have greater resources than us. If we undertake any additional acquisitions, whether of product candidates or other biopharmaceutical companies, the process of integrating an acquired product candidate or complementary company into our business may put a strain on our operations, divert personnel, financial resources and management&#146;s attention. In 2013, we expect our research and development activities will be dedicated to Gencaro. If we are not able to substantially expand our research and development efforts, or identify, or license or acquire other products or product candidates or complete future acquisitions, then we will likely be unable expand our pipeline of product candidates. In addition, any future acquisition would give rise to additional operating costs and will likely require us to seek additional financing. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect our operating results. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We would be subject to applicable regulatory approval requirements of the foreign countries in which we market our products, which are costly and may prevent or delay us from marketing our products in those countries. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In addition to regulatory requirements in the United States, we would be subject to the regulatory approval requirements in each foreign country where we market our products. In addition, we might be required to identify one or more collaborators in these foreign countries to develop, seek approval for and manufacture our products and any companion genetic test for Gencaro. If we decide to pursue regulatory approvals and commercialization of our product candidates internationally, we may not be able to obtain the required foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause us to incur additional costs or prevent us from marketing our products in foreign countries, which may have a material adverse effect on our business, financial condition and results of operations. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If our internal control over financial reporting is not considered effective, our business and stock price could be adversely affected. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our internal control over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of our internal control over financial reporting in our annual report on Form 10-K for that fiscal year. Our management, including our chief executive officer and chief financial officer, does not expect that our internal control over financial reporting will prevent all error and all fraud. During the first quarter of 2011 there was a reduction in our workforce which included personnel involved in financial reporting and our internal control processes. Since that time we have continued to operate with a reduced staff for financial reporting. Though the process and design of our internal controls over financial reporting have not been altered, the reduced number of staff may limit our ability to properly segregate internal control procedures which could result in deficiencies or material weaknesses in our internal controls in the future. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and we cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. We cannot assure you that we or our independent registered public accounting firm will not identify a material weakness in our internal control over financial reporting in the future. A material weakness in our internal control over financial reporting would require management to consider our internal control over financial reporting as ineffective. If our internal control over financial reporting is not considered effective, we may experience a loss of public confidence, which could have an adverse effect on our business and on the market price of our common stock. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Risks Related to Intellectual Property and Other Legal Matters </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If product liability lawsuits are successfully brought against us, then we will incur substantial liabilities and may be required to limit commercialization of Gencaro or other product candidates. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break37"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;36&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We face product liability exposure related to the testing of our product candidates in human clinical trials, and may face exposure to claims by an even greater number of persons once we begin marketing and distributing our products commercially. If we cannot successfully defend against product liability claims, then we will incur substantial liabilities. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Regardless of merit or eventual outcome, liability claims may result in: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">decreased demand for our products and product candidates;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">injury to our reputation;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">withdrawal of clinical trial participants;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">costs of related litigation;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">substantial monetary awards to patients and others;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">loss of revenues; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the inability to commercialize our products and product candidates.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We have obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to us in sufficient amounts or at an acceptable cost, or at all. We may not be able to obtain commercially reasonable product liability insurance for any product candidate. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Defending against claims relating to improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our research and development of product candidates may involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from the materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may be sued or be required to pay fines for any injury or contamination that results from our use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">The loss of any rights to market key products would significantly impair our operating results. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We have licensed from CPEC, who has licensed rights in Gencaro from Bristol Meyers Squibb (BMS), the exclusive rights to Gencaro for all therapeutic and diagnostic uses in any country until the later of (i) 10 years from the first commercial sale of Gencaro in such country, or (ii) the termination of our commercial exclusivity in such country. This license includes a sublicense to us from BMS. We are obligated to use commercially reasonable efforts to develop and commercialize Gencaro, including obtaining regulatory approvals. Our ability to develop and commercialize Gencaro is dependent on numerous factors, including some factors that are outside of our control. CPEC has the right to terminate our license if we materially breach our obligations under the license agreement and fail to cure any such breach within the terms of the license. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">If our license agreement with CPEC is terminated for reasons related to non-payment of fees, or for any other breach, then we would have no further rights to develop and commercialize Gencaro for any indication. The termination of this license, or of any other agreement which enables us to market a key product or product candidate, could significantly and adversely affect our business. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Certain intellectual property licensed by us is the subject of additional licensing arrangements to which the party that has licensed rights to us is subject. If such parties were to breach the terms of such licenses or such licenses were otherwise to terminate, our and our partners&#146; rights to use such technology and develop and commercialize their products such as the Gencaro Test may terminate and our business would be materially harmed. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Third parties may own or control patents or patent applications that we may be required to license to commercialize our product candidates or that could result in litigation that would be costly and time consuming. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our or any strategic partner&#146;s ability to commercialize Gencaro and other product candidates depends upon our ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to the technologies owned by or licensed to us. We may choose to seek, or be required to seek, licenses under third party patents, which would likely require the payment of license fees or royalties or both. We may also be unaware of existing patents that may be infringed by Gencaro, the genetic testing we intend to use in connection with Gencaro or our other product candidates. Because patent applications can take many years to issue, there may be other currently pending applications that may later result in issued patents that are infringed by Gencaro or our other product candidates. Moreover, a license may not be available to us on commercially reasonable terms, or at all. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><A NAME="Break38"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;37&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we are infringing on its technology, then our business and results of operations could be harmed by a number of factors, including: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">infringement and other intellectual property claims, even if without merit, are expensive and time-consuming to litigate and can divert management</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#146;s attention from our core business;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">monetary damage awards for past infringement can be substantial;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">a court may prohibit us from selling or licensing product candidates unless the patent holder chooses to license the patent to us; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">if a license is available from a patent holder, we may have to pay substantial royalties.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We may also be forced to bring an infringement action if we believe that a competitor is infringing our protected intellectual property. Any such litigation will be costly, time-consuming and divert management&#146;s attention, and the outcome of any such litigation may not be favorable to us. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Our intellectual property rights may not preclude competitors from developing competing products and our business may suffer. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our competitive success will depend, in part, on our ability to obtain and maintain patent protection for our inventions, technologies and discoveries, including intellectual property that we license. The patent positions of biotechnology companies involve complex legal and factual questions, and we cannot be certain that our patents and licenses will successfully preclude others from using our technology. Consequently, we cannot be certain that any of our patents will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or invalid. In some cases, patent applications in the U.S. and certain other jurisdictions are maintained in secrecy until patents issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office to determine priority of invention or in opposition proceedings in a foreign patent office, any of which could result in substantial cost to us, even if the eventual outcome is favorable. There can be no assurance that a court of competent jurisdiction would hold any claims in any issued patent to be valid. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties or require us to cease using such technology. Regardless of merit, the listing of patents in the FDA Orange Book for Gencaro may be challenged as being improperly listed. We may have to defend against such claims and possible associated antitrust issues. We could also incur substantial costs in seeking to enforce our proprietary rights against infringement. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">While the composition of matter patents on the compound that comprises Gencaro have expired, we hold the intellectual property concerning the interaction of Gencaro with the polymorphisms of the &szlig;1 and 2C receptors. We have obtained patents that claim methods involving Gencaro after a patient&#146;s receptor genotype has been determined. Our NDA requested a label that will include a claim that efficacy varies based on receptor genotype and a recommendation in the prescribing information that prospective patients be tested for their receptor genotype. We believe that under applicable law, a generic bucindolol label would likely be required to include this recommendation as it pertains directly to the safe or efficacious use of the drug. Such a label may be considered as inducing infringement, carrying the same liability as direct infringement. If the label with the genotype information for Gencaro is not approved, or if generic labels are not required to copy the approved label, competitors could have an easier path to introduce competing products and our business may suffer. The approved label may not contain language covered by the patents, or we may be unsuccessful in enforcing them. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We may not be able to effectively protect our intellectual property rights in some foreign countries, as our patents are limited by jurisdiction and many countries do not offer the same level of legal protection for intellectual property as the U.S. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We require our employees, consultants, business partners and members of our scientific advisory board to execute confidentiality agreements upon the commencement of employment, consulting or business relationships with us. These agreements provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions resulting from work performed for us, utilizing the property or relating to our business and conceived or completed by the individual during employment shall be our exclusive property to the extent permitted by applicable law. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Third parties may breach these and other agreements with us regarding our intellectual property and we may not have adequate remedies for the breach. Third parties could also fail to take necessary steps to protect our licensed intellectual property, which could seriously harm our intellectual property position. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">If we are not able to protect our proprietary technology, trade secrets and know-how, then our competitors may develop competing products. Any issued patent may not be sufficient to prevent others from competing with us. Further, we have trade secrets relating to Gencaro, and such trade secrets may become known or independently discovered. Our issued patents and those that may <A NAME="Break39"></A> </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;38&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">issue in the future, or those licensed to us, may be challenged, opposed, invalidated or circumvented, which could allow competitors to market similar products or limit the patent protection term of our product candidates. All of these factors may affect our competitive position. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">If the manufacture, use or sale of our products infringe on the intellectual property rights of others, we could face costly litigation, which could cause us to pay substantial damages or licensing fees and limit our ability to sell some or all of our products. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know-how and determine the enforceability, scope and validity of certain proprietary rights. Litigation may even be necessary to defend disputes of inventorship or ownership of proprietary rights. The defense and prosecution of intellectual property lawsuits, U.S. Patent and Trademark Office interference proceedings, and related legal and administrative proceedings (e.g., a reexamination) in the U.S. and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time-consuming to pursue, and their outcome is uncertain. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Regardless of merit or outcome, our involvement in any litigation, interference or other administrative proceedings could cause us to incur substantial expense and could significantly divert the efforts of our technical and management personnel. Any public announcements related to litigation or interference proceedings initiated or threatened against us could cause our stock price to decline. Adverse outcomes in patent litigation may potentially subject us to antitrust litigation which, regardless of the outcome, would adversely affect our business. An adverse determination may subject us to the loss of our proprietary position or to significant liabilities, or require us to seek licenses that may include substantial cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent us from manufacturing and selling our products, if any. These outcomes could materially harm our business, financial condition and results of operations. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Risks Related to Stock Price Volatility </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Ownership of our common stock is highly concentrated, and it may prevent you and other stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause our stock price to decline. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our executive officers, directors and their affiliates beneficially owned approximately 29% of our outstanding common stock as of March 31, 2013. Accordingly, these executive officers, directors and their affiliates, acting individually or as a group, have substantial influence over the outcome of a corporate action of ours requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transaction. These stockholders may also delay or prevent a change in control of us, even if such change in control would benefit our other stockholders. The significant concentration of stock ownership may adversely affect the value of our common stock due to investors&#146; perception that conflicts of interest may exist or arise. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:12.20pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Our stock price is expected to be volatile. </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the regulatory status of Gencaro and the Gencaro Test, and whether and when they are approved for sale, if at all, and the labeling or other conditions of use imposed by the FDA;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">our ability to secure substantial additional funding or complete a strategic transaction or to complete development of and commercialize Gencaro;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">potential receipt of government or third party funding to further develop Gencaro;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the results of our future clinical trials and any future NDAs of our current and future product candidates;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the entry into, or termination of, key agreements, including key strategic alliance agreements;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the results and timing of regulatory reviews relating to our product candidates;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">failure of any of our product candidates, if approved, to achieve commercial success;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">general and industry-specific economic conditions that may affect our research and development expenditures;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the results of clinical trials conducted by others on drugs that would compete with our product candidates;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">issues in manufacturing our product candidates or any approved products;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:48.95pt; text-indent:-18.35pt"><A NAME="Break40"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;39&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the initiation of or material developments in or the conclusion of litigation to enforce or defend any of our intellectual property rights;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the loss of key employees;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the introduction of technological innovations or new commercial products by our competitors;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">changes in estimates or recommendations by securities analysts, if any, who cover our common stock;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">future sales of our common stock;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">changes in the structure of health care payment systems;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">period-</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">to-period fluctuations in our financial results; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">our ability to retain the listing of our common stock on the Nasdaq Capital Market.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a company&#146;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:12.20pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">Future sales or the possibility of future sales of our common stock may depress the market price of our common stock. </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Sales in the public market of substantial amounts of our common stock could depress prevailing market prices of our common stock. As of March 31, 2013, 3,185,562 shares of common stock were outstanding. All of these shares are freely transferable without restriction or further registration under the Securities Act, except for shares held by our directors, officers and other affiliates and unregistered shares held by non-affiliates. The sale of these additional shares, or the perception that such sales may occur, could depress the market price of our common stock. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">As of March 31, 2013 approximately 1.3 million shares of our common stock were issuable upon the exercise of outstanding warrants. Once a warrant is exercised, if the shares of our common stock issued upon the exercise of any such warrant are not available for sale in the open market without further registration under the Securities Act, then the holder can arrange for the resale of shares either by invoking any applicable registration rights, causing the shares to be registered under the Securities Act and thus freely transferable, or by relying on an exemption to the Securities Act. If these registration rights, or similar registration rights that may apply to securities we may issue in the future, are exercised, it could result in additional sales of our common stock in the market, which may have an adverse effect on our stock price. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">As of March 31, 2013, there were approximately 138,000 shares of our common stock which may be issued upon exercise of outstanding stock options. If and when these options are exercised, such shares will be available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options may negatively affect our ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options, and the prompt resale of shares of our common stock received, may also result in downward pressure on the price of our common stock. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">In the absence of a significant strategic transaction, we will need to raise significant additional capital to finance our capital requirements, including the research, development and commercialization of our drug products. If future securities offerings occur, they would dilute our current stockholders&#146; equity interests and could reduce the market price of our common stock. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We do not expect to pay cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We anticipate that we will retain our earnings, if any, for future growth and therefore do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our common stock will provide a return to stockholders. Investors seeking cash dividends should not invest in our common stock. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; font-style: Italic; ">We have implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to our stockholders. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">establish a classified board of directors so that not all members of our board may be elected at one time;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">authorize the issuance of up to 5 </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">million additional shares of preferred stock that could be issued by our board of directors to increase the number of outstanding shares and hinder a takeover attempt;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">limit who may call a special meeting of stockholders;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:48.95pt; text-indent:-18.35pt"><A NAME="Break41"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;40&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:95.00%;margin-left:5.00%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:3.64%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:96.36%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at a stockholder meeting.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Specifically, our certificate of incorporation provides that all stockholder action must be effected at a duly called meeting and not by a written consent. The bylaws provide, however, that our stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50% of our outstanding common stock. These provisions of our certificate of incorporation and bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. We designed these provisions to reduce our vulnerability to unsolicited acquisition proposals and to discourage certain tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for our shares. As a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We are permitted to issue shares of our preferred stock without stockholder approval upon such terms as our board of directors determines. Therefore, the rights of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of our preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the holdings of our current stockholders. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:24.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">We are subject to the Delaware anti-takeover laws regulating corporate takeovers. These anti-takeover laws prevent a Delaware corporation from engaging in a merger or sale of more than 10% of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15% or more of the corporation&#146;s outstanding voting stock, for three years following the date that the stockholder acquired 15% or more of the corporation&#146;s stock unless: </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:98.53%;margin-left:1.47%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:7.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:92.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">the board of directors approved the transaction where the stockholder acquired 15% or more of the corporation</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#146;s stock;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:98.53%;margin-left:1.47%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:7.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:92.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">after the transaction in which the stockholder acquired 15% or more of the corporation</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#146;s stock, the stockholder owned at least 85% of the corporation&#146;s outstanding voting stock, excluding shares owned by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:98.53%;margin-left:1.47%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:7.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:92.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">on or after this date, the merger or sale is approved by the board of directors and the holders of at least two-</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">thirds of the outstanding voting stock that is not owned by the stockholder.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:13.50pt; text-indent:-13.50pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The provisions of our governing documents and current Delaware law may, collectively: </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:98.53%;margin-left:1.47%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:7.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:92.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">lengthen the time required for a person or entity to acquire control of us through a proxy contest for the election of a majority of our board of directors;</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:98.53%;margin-left:1.47%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:7.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:92.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">discourage bids for our common stock at a premium over market price; and</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:98.53%;margin-left:1.47%; margin-top:4.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:7.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#149;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:92.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">generally deter efforts to obtain control of us.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:13.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:10.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="ITEM_2_II"></A><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM&nbsp;2.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Not applicable. </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:13.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:10.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="ITEM_3_II"></A><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM&nbsp;3.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">DEFAULTS UPON SENIOR SECURITIES</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Not applicable. </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:13.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:10.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="ITEM_4_II"></A><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM&nbsp;4.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">MINE SAFETY DISCLOSURES</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Not applicable. </FONT></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:13.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:10.92%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><A NAME="ITEM_5_II"></A><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM&nbsp;5.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.08%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">OTHER INFORMATION</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Not applicable. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:55.45pt; text-indent:-55.45pt"><A NAME="ITEM_6_II"></A><A NAME="Break42"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;41&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:11.00%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">ITEM&nbsp;6.</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:89.00%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold;  margin-left:-0.00pt;">EXHIBITS</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:7.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The following documents are filed as part of this quarterly report on Form 10-Q. The Company will furnish a copy of any exhibit listed to requesting stockholders upon payment of the Company&#146;s reasonable expenses in furnishing those materials. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Exhibit</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Number</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:1.00pt;; border-top:solid 1.00pt;font-size:4.00pt;; border-top:solid 1.00pt #000000; ; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:87.00%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Description</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:1.00pt;; border-top:solid 1.00pt;font-size:4.00pt;; border-top:solid 1.00pt #000000; ; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3.1</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Amended and Restated Certificate of Incorporation of the Registrant, as amended.(1)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3.1(a)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Certificate of Amendment to Restated Certificate of Incorporation.(2)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3.2</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Second Amended and Restated Bylaws of the Registrant, as amended.(3)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">4.1</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Form of Warrants to Purchase Shares of Common Stock.(5)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">4.2</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Form of Common Stock Purchase Warrant.(6)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">4.3</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Reference is made to Exhibits 3.1, 3.1(a) and 3.2.</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.1</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated as of April 18, 2013.(4)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.2</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Form of Subscription Agreement by and among the Company and the purchasers identified therein, dated January 22, 2013.(5)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.3</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Form of Registration Rights Agreement.(5)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.4</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Placement Agency Agreement by and between ARCA biopharma, Inc. and Dawson James Securities, Inc., dated January 31, 2013.(6)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.5</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Subscription Agreement.(6)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">31.1*</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">31.2*</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">32.1*</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.INS&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Instance Document ( furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.SCH&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Schema Document (furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.CAL&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Calculation Linkbase Document (furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.LAB&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Label Linkbase Document (furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.PRE&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Presentation Linkbase Document (furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.DEF&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Definition Linkbase Document (furnished electronically herewith)</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:-0.05pt;margin-bottom:3.00pt;text-align:left;line-height:6.00pt;; border-bottom:solid 0.75pt;margin-right:360.00pt;font-size:12.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(1)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from AR</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">CA biopharma, Inc&#146;s Form 10-K, filed March 27, 2009, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(2)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">ARCA biopharma, Inc&#146;s Form 8-K, filed on March 5, 2013, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.84%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(3)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.16%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">ARCA biopharma, Inc&#146;s Form 10-Q, filed November 16, 2009, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.84%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(4)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.16%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from ARCA biopharma, Inc</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#146;s Form 8-K, filed April 22, 2013, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.84%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(5)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.16%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from ARCA biopharma, Inc</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#146;s Form 8-K, filed January 23, 2013, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.84%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(6)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.16%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from ARCA biopharma, Inc</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#146;s Form 8-K, filed February 1, 2013, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">*</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Filed herewith.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:24.45pt; text-indent:-24.45pt"><A NAME="Break43"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;42&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><A NAME="SIGNATURES"></A><A NAME="Break44"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;43&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">SIGNATURE </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:40.00%; ">
<TR>
   <TD VALIGN="top" COLSPAN="2" ALIGN="left" STYLE="WIDTH:40.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">ARCA biopharma, Inc. (Registrant)</FONT></P></TD></TR>
<TR STYLE="height:12.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:5.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">By:</FONT></P></TD>
   <TD VALIGN="center" ALIGN="center" STYLE="WIDTH:35.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">/s/ Patrick M. Wheeler</FONT></P></TD></TR>
<TR STYLE="height:4.00pt">
   <TD VALIGN="top" STYLE="WIDTH:5.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:35.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:1.00pt;; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:9.00pt">
   <TD VALIGN="top" STYLE="WIDTH:5.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:12.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:35.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" STYLE="WIDTH:5.00%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:2.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:4.00pt"></P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:35.00%; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">Chief Financial Officer</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Dated: May 13, 2013 </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><A NAME="Break45"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;44&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18.00pt;margin-bottom:0.00pt;text-align:center; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; font-weight: Bold; ">EXHIBIT INDEX </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">The following documents are filed as part of this quarterly report on Form 10-Q. The Company will furnish a copy of any exhibit listed to requesting stockholders upon payment of the Company&#146;s reasonable expenses in furnishing those materials. </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:9.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Exhibit</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Number</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:1.00pt;; border-top:solid 1.00pt;font-size:4.00pt;; border-top:solid 1.00pt #000000; ; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:87.00%; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 7.50pt; font-weight: Bold; ">Description</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:1.00pt;; border-top:solid 1.00pt;font-size:4.00pt;; border-top:solid 1.00pt #000000; ; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3.1</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Amended and Restated Certificate of Incorporation of the Registrant, as amended.(1)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3.1(a)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Certificate of Amendment to Restated Certificate of Incorporation. (2)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">3.2</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Second Amended and Restated Bylaws of the Registrant, as amended.(3)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">4.1</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Form of Warrants to Purchase Shares of Common Stock. (5)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">4.2</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Form of Common Stock Purchase Warrant. (6)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">4.3</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Reference is made to Exhibits 3.1, 3.1(a) and 3.2.</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.1</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Clinical Trial Collaboration Agreement between ARCA biopharma, Inc. and Medtronic, Inc. dated as of April 18, 2013.(4)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.2</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Form of Subscription Agreement by and among the Company and the purchasers identified therein, dated January 22, 2013.(5)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.3</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Form of Registration Rights Agreement.(5)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.4</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Placement Agency Agreement by and between ARCA biopharma, Inc. and Dawson James Securities, Inc., dated January 31, 2013.(6)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">10.5</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Subscription Agreement.(6)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">31.1*</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">31.2*</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">32.1*</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.INS&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Instance Document (furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.SCH&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Schema Document (furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.CAL&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Calculation Linkbase Document (furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.LAB&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Label Linkbase Document (furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.PRE&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Presentation Linkbase Document (furnished electronically herewith)</FONT></P></TD></TR>
<TR STYLE="height:6.00pt">
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:6.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:7.20pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">101.DEF&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:auto; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">XBRL Taxonomy Extension Definition Linkbase Document (furnished electronically herewith)</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:-0.05pt;margin-bottom:3.00pt;text-align:left;line-height:6.00pt;; border-bottom:solid 0.75pt;margin-right:360.00pt;font-size:12.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%; ">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(1)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from AR</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">CA biopharma, Inc&#146;s Form 10-K, filed March 27, 2009, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(2)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; "> ARCA biopharma, Inc&#146;s Form 8-K, filed on March 5, 2013, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">(3)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Previously filed with the SEC as an </FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">Exhibit to and incorporated herein by reference from ARCA biopharma, Inc&#146;s Form 10-Q, filed November 16, 2009, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(4)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from ARCA biopharma, Inc</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#146;s Form 8-K, filed April 22, 2013, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(5)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from ARCA biopharma, Inc</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#146;s Form 8-K, filed January 23, 2013, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">(6)</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000;  margin-left:-0.00pt;">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from ARCA biopharma, Inc</FONT><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; color:#000000; ">&#146;s Form 8-K, filed February 1, 2013, File No. 000-22873.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:24.45pt; text-indent:-24.45pt"><A NAME="StopHere"></A><A NAME="Break46"></A> </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;45&nbsp; </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always">
<P>&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:1.50pt;margin-bottom:0.00pt;text-align:left; margin-left:24.45pt; text-indent:-24.45pt; font-size:12.00pt">&nbsp;&nbsp;&nbsp; </P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">*</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">Filed herewith.</FONT></P></TD></TR></TABLE></DIV> <DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:100.00%;  margin-top:1.50pt;">
<TR>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:4.86%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&#134;</FONT></P></TD>
   <TD VALIGN="top" ALIGN="left" STYLE="WIDTH:95.14%; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt;  margin-left:-0.00pt;">XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 10.00pt; ">&nbsp;46&nbsp; </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always"></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>abio-ex31_2013033039.htm
<DESCRIPTION>EX-31.1
<TEXT>

<HTML>
<HEAD></HEAD>
<BODY BGCOLOR="WHITE">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:right;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="right"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">Exhibit 31.1 </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">CERTIFICATION </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">I, Michael R. Bristow, certify that: </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">1. I have reviewed this quarterly report on Form 10-Q of ARCA biopharma, Inc.; </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">Date: May 13, 2013 </FONT></P>
<P STYLE="margin-top:-0.05pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:297.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; ">/s/ Michael R. Bristow</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:297.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:297.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">Michael R. Bristow</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:297.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-style: Italic; color:#000000; ">President and Chief Executive Officer</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:297.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-style: Italic; color:#000000; ">(Principal Executive Officer)</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always"></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>abio-ex31_2013033040.htm
<DESCRIPTION>EX-31.2
<TEXT>

<HTML>
<HEAD></HEAD>
<BODY BGCOLOR="WHITE">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:right;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="right"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">Exhibit 31.2 </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">CERTIFICATION </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">I, Patrick M. Wheeler, certify that: </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">1. I have reviewed this quarterly report on Form 10-Q of ARCA biopharma, Inc.; </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">c) Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></P>
<P STYLE="margin-top:4.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">Date: May 13, 2013 </FONT></P>
<P STYLE="margin-top:-0.05pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:301.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; ">/s/ Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:301.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:301.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:301.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-style: Italic; color:#000000; ">Chief Financial Officer</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-style: Italic; color:#000000; ">(Principal Financial and Accounting Officer)</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always"></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>abio-ex32_2013033041.htm
<DESCRIPTION>EX-32.1
<TEXT>

<HTML>
<HEAD></HEAD>
<BODY BGCOLOR="WHITE">
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt"> </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:right;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="right"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">Exhibit 32.1 </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">ARCA BIOPHARMA, INC. </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:center;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">CERTIFICATION PURSUANT TO </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">18 U.S.C. SEC. 1350 </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">AS ADOPTED PURSUANT TO </FONT></P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt" ALIGN="center"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Michael R. Bristow, Chief Executive Officer of ARCA biopharma, Inc. (the &#147;Company&#148;), and Patrick M. Wheeler, Chief Financial Officer of the Company, each hereby certifies that, to the best of his/her knowledge: </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">(1) The Company&#146;s Quarterly Report on Form 10-Q for the period ended March 31, 2013, to which this Certification is attached as Exhibit 32.1 (the &#147;Periodic Report&#148;) fully complies with the requirements of section 13(a) or 15(d) of the Exchange Act; and </FONT></P>
<P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">(2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </FONT></P>
<P STYLE="margin-top:13.50pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">In Witness Whereof</FONT><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">, the undersigned have set their hands hereto as of the 13<SUP style="vertical-align: baseline;position: relative;top: -0.4em;">th</SUP> day of May 2013. </FONT></P>
<P STYLE="margin-top:-0.05pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt;text-align:justify">&nbsp;</P><DIV ALIGN="center">
<TABLE CELLSPACING="0" CELLPADDING="0" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE;WIDTH:auto; ">
<TR>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:243.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:4.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="center" ALIGN="left" STYLE="WIDTH:256.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:243.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; ">/s/ Michael R. Bristow</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:4.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:256.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; ">/s/ Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:243.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:4.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:1.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:256.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; border-top:solid 0.75pt;font-size:1.00pt;; margin-left:0.00pt; text-indent:0.00pt">&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:243.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">Michael R. Bristow</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:4.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:256.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-weight: Bold; color:#000000; ">Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
   <TD VALIGN="top" ALIGN="center" STYLE="WIDTH:243.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-style: Italic; color:#000000; ">President and Chief Executive Officer</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-style: Italic; color:#000000; ">(Principal Executive Officer)</FONT></P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:4.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="left" STYLE="WIDTH:9.00pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:left;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp;</P></TD>
   <TD VALIGN="bottom" ALIGN="center" STYLE="WIDTH:256.50pt; padding-left:0.00pt; padding-right:0.00pt; padding-top:0.00pt; padding-bottom:0.00pt; ">
      <P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-style: Italic; color:#000000; ">Chief Financial Officer</FONT></P>
      <P STYLE="margin-top:0pt;margin-bottom:1pt;text-align:center;line-height:12.00pt;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; font-style: Italic; color:#000000; ">(Principal Financial and Accounting Officer)</FONT></P></TD></TR></TABLE></DIV>
 <P STYLE="margin-top:9.00pt;margin-bottom:0.00pt;text-align:left;line-height:auto;; ; margin-left:0.00pt; text-indent:0.00pt"><FONT STYLE="font-family: Times New Roman; font-size: 11.00pt; color:#000000; ">A signed original of this written statement required by Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. &#167;&nbsp;1350, as adopted) has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of ARCA biopharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. </FONT></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;text-align:left; margin-left:0.00pt; text-indent:0.00pt; font-size:10.00pt">&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0.00pt;margin-bottom:0.00pt;text-align:center; margin-left:0.00pt; text-indent:0.00pt"> </P><hr style="page-break-after:always"></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>abio-20130331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Instance Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2013-05-13T20:55:49.3389120+00:00 -->
<!-- Version            : 1.0.0.64 -->
<!-- Package ID         : 0EC0A1A677FC5574CCB8E2DAD25CAE4D-0000907654-001304 -->
<!-- Copyright (c) 2013 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:abio="http://www.arcabiopharma.com/20130331" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-roles="http://fasb.org/us-roles/2012-01-31" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="abio-20130331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217USD_xbrlishares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_abioPatients">
    <measure>abio:Patients</measure>
  </unit>
  <unit id="U_utrsqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="U_xbrlipure">
    <measure>pure</measure>
  </unit>
  <unit id="U_iso4217USD_abioUnit">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>abio:Unit</measure>
      </unitDenominator>
    </divide>
  </unit>
  <context id="C_0000907654_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20130510">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2013-05-10</instant>
    </period>
  </context>
  <context id="C_0000907654_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20120101_20120331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20011217_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2001-12-17</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20011218_20031231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-12-18</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20011218_20031231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2001-12-18</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20011218_20031231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-12-18</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20011218_20031231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-12-18</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20031231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20031231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20031231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20031231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20040101_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20040101_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20040101_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20040101_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20040101_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20040101_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20040101_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_20040101_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20040101_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20041231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeriesOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SeriesOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20060101_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20061231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioIssuanceOfCommonStockForCommercialLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:IssuanceOfCommonStockForCommercialLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioIssuanceOfSharesToExecutiveSubjectToRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:IssuanceOfSharesToExecutiveSubjectToRepurchaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20080101_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20081231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CommonConversionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:AccretionOfSeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CommonConversionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CommonConversionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CommonConversionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CommonConversionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioNotesAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:NotesAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioNotesAndRelatedAccruedInterestMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:NotesAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioNotesAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:NotesAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20090101_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20091231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20100101_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_20100101_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20100101_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20100101_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20100101_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20100101_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20100101_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20101231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20110101_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20110101_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_20110101_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20110101_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20110101_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20110101_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20110101_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20111231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20120101_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20120101_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_20120101_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20120101_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20120101_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20120101_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20120101_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:DeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20021231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2002-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20040930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-09-30</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050103">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:CashNetOfOfferingCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-01-03</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050103">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-01-03</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20051014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-10-14</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060221">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-02-21</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060222">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-02-22</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060623">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-06-23</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20061107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-11-07</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070118">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-01-18</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-06-30</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060222">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-02-22</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060222">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-02-22</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20061208">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-08</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-05-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20071228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abio:SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-28</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapPreferredStockMember_20011217_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-12-17</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20011217_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-12-17</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20120331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapRangeAxis_us-gaapMinimumMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapRangeAxis_us-gaapMaximumMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancingAxis">abio:TwoZeroOneThreeEquityFinancingsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20130204_20130304">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2013-02-04</startDate>
      <endDate>2013-03-04</endDate>
    </period>
  </context>
  <context id="C_0000907654_20090127">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2009-01-27</instant>
    </period>
  </context>
  <context id="C_0000907654_20090101_20090127">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-01-27</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerSoftwareIntangibleAssetMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerSoftwareIntangibleAssetMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerSoftwareIntangibleAssetMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20121231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="C_0000907654_20080208">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2008-02-08</instant>
    </period>
  </context>
  <context id="C_0000907654_20110614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2011-06-14</instant>
    </period>
  </context>
  <context id="C_0000907654_20080701_20080731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <startDate>2008-07-01</startDate>
      <endDate>2008-07-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_20080731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
    </entity>
    <period>
      <instant>2008-07-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130122">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SaleAxis">abio:PrivateInvestmentInPublicEquityTransactionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancingAxis">abio:TwoZeroOneThreeEquityFinancingsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-01-22</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130101_20130122">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SaleAxis">abio:PrivateInvestmentInPublicEquityTransactionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancingAxis">abio:TwoZeroOneThreeEquityFinancingsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-22</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130101_20130122">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancingAxis">abio:TwoZeroOneThreeEquityFinancingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SaleAxis">abio:PrivateInvestmentInPublicEquityTransactionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-22</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancingAxis">abio:TwoZeroOneThreeEquityFinancingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SaleAxis">abio:RegisteredDirectOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-01-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130101_20130131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancingAxis">abio:TwoZeroOneThreeEquityFinancingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SaleAxis">abio:RegisteredDirectOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneOneEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130101_20130131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancingAxis">abio:TwoZeroOneOneEquityFinancingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SaleAxis">abio:RegisteredDirectOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130101_20130131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancingAxis">abio:TwoZeroOneThreeEquityFinancingsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SaleAxis">abio:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_us-gaapRangeAxis_us-gaapMaximumMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_us-gaapRangeAxis_us-gaapMinimumMember_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapResearchAndDevelopmentExpenseMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapRestructuringChargesMember_20130101_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapResearchAndDevelopmentExpenseMember_20120101_20120331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20120101_20120331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapRestructuringChargesMember_20120101_20120331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapResearchAndDevelopmentExpenseMember_20011217_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-12-17</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20011217_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-12-17</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapRestructuringChargesMember_20011217_20130331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-12-17</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <dei:EntityRegistrantName id="F_000000" contextRef="C_0000907654_20130101_20130331">ARCA Biopharma, Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000001" contextRef="C_0000907654_20130101_20130331">0000907654</dei:EntityCentralIndexKey>
  <dei:DocumentType id="F_000002" contextRef="C_0000907654_20130101_20130331">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000003" contextRef="C_0000907654_20130101_20130331">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000004" contextRef="C_0000907654_20130101_20130331">2013-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalPeriodFocus id="F_000005" contextRef="C_0000907654_20130101_20130331">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="F_000006" contextRef="C_0000907654_20130101_20130331">2013</dei:DocumentFiscalYearFocus>
  <dei:CurrentFiscalYearEndDate id="F_000007" contextRef="C_0000907654_20130101_20130331">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000008" contextRef="C_0000907654_20130101_20130331">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000009" contextRef="C_0000907654_20130510" decimals="INF" unitRef="U_shares">3185562</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000010" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">3537000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000011" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">2920000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherAssetsCurrent id="F_000012" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">456000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="F_000013" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">125000</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000014" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">3993000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000015" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">3045000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000016" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">22000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000017" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">23000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000018" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">124000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000019" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">144000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000020" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">4139000</us-gaap:Assets>
  <us-gaap:Assets id="F_000021" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">3212000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000022" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">377000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000023" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">65000</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000024" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">60000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000025" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">103000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000026" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">383000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="F_000027" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">121000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000028" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000029" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000030" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">828000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000031" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">305000</us-gaap:LiabilitiesCurrent>
  <us-gaap:Liabilities id="F_000032" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">828000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000033" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">305000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000034" xsi:nil="true" contextRef="C_0000907654_20130331" unitRef="U_iso4217USD" />
  <us-gaap:CommitmentsAndContingencies id="F_000035" xsi:nil="true" contextRef="C_0000907654_20121231" unitRef="U_iso4217USD" />
  <us-gaap:CommonStockValue id="F_000036" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000037" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital id="F_000038" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">72373000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="F_000039" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">70898000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000040" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">-69065000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000041" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">-67994000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000042" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">3311000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000043" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">2907000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000044" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">4139000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000045" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">3212000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000046" contextRef="C_0000907654_20130331" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000047" contextRef="C_0000907654_20121231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000048" contextRef="C_0000907654_20130331" decimals="-6" unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000049" contextRef="C_0000907654_20121231" decimals="-6" unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000050" contextRef="C_0000907654_20130331" decimals="INF" unitRef="U_shares">3185562</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000051" contextRef="C_0000907654_20121231" decimals="INF" unitRef="U_shares">2660315</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000052" contextRef="C_0000907654_20130331" decimals="INF" unitRef="U_shares">3185562</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000053" contextRef="C_0000907654_20121231" decimals="INF" unitRef="U_shares">2660315</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000054" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">181000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000055" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">422000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000056" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">42858000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000057" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">889000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000058" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">984000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="F_000059" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">43472000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:BusinessCombinationAcquisitionRelatedCosts id="F_000060" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">5470000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
  <us-gaap:RestructuringCharges id="F_000061" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">2413000</us-gaap:RestructuringCharges>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill id="F_000062" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">6000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:OperatingExpenses id="F_000063" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">1070000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000064" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">1406000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000065" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">100213000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000066" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">-1070000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000067" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-1406000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000068" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-100213000</us-gaap:OperatingIncomeLoss>
  <abio:GainLossOnAssignmentOfPatentRights id="F_000069" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">2000000</abio:GainLossOnAssignmentOfPatentRights>
  <us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount id="F_000070" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">25282000</us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount>
  <us-gaap:InterestAndOtherIncome id="F_000071" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">2028000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestExpenseDebt id="F_000072" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="F_000073" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="F_000074" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">443000</us-gaap:InterestExpenseDebt>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="F_000075" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">-1071000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="F_000076" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-1407000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="F_000077" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-71346000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000078" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-2281000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="F_000079" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">-1071000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000080" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-1407000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000081" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-69065000</us-gaap:NetIncomeLoss>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount id="F_000082" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">245000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments id="F_000083" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">781000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000084" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">-1071000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000085" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-1407000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000086" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-70091000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000087" contextRef="C_0000907654_20130101_20130331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000088" contextRef="C_0000907654_20120101_20120331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000089" contextRef="C_0000907654_20130101_20130331" decimals="INF" unitRef="U_shares">3034763</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000090" contextRef="C_0000907654_20120101_20120331" decimals="INF" unitRef="U_shares">2027716</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000091" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20011218_20031231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000092" contextRef="C_0000907654_20011218_20031231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000093" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20011218_20031231" decimals="INF" unitRef="U_shares">2588</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:NetIncomeLoss id="F_000094" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20011218_20031231" decimals="-3" unitRef="U_iso4217USD">-116000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000095" contextRef="C_0000907654_20011218_20031231" decimals="-3" unitRef="U_iso4217USD">-116000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000096" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20031231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000097" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20031231" decimals="-3" unitRef="U_iso4217USD">-116000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000098" contextRef="C_0000907654_20031231" decimals="-3" unitRef="U_iso4217USD">-115000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000099" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20031231" decimals="INF" unitRef="U_shares">2588</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000100" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20040101_20041231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000101" contextRef="C_0000907654_20040101_20041231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000102" xsi:nil="true" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20040101_20041231" unitRef="U_shares" />
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000103" xsi:nil="true" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20040101_20041231" unitRef="U_shares" />
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000104" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20040101_20041231" decimals="INF" unitRef="U_shares">19720</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000105" xsi:nil="true" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20040101_20041231" unitRef="U_shares" />
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000106" xsi:nil="true" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20040101_20041231" unitRef="U_shares" />
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000107" xsi:nil="true" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_20040101_20041231" unitRef="U_shares" />
  <us-gaap:NetIncomeLoss id="F_000108" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20040101_20041231" decimals="-3" unitRef="U_iso4217USD">-511000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000109" contextRef="C_0000907654_20040101_20041231" decimals="-3" unitRef="U_iso4217USD">-511000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000110" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20041231" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000111" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20041231" decimals="-3" unitRef="U_iso4217USD">-627000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000112" contextRef="C_0000907654_20041231" decimals="-3" unitRef="U_iso4217USD">-619000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000113" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20041231" decimals="INF" unitRef="U_shares">22308</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000114" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000115" contextRef="C_0000907654_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000116" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050101_20051231" decimals="INF" unitRef="U_shares">2922</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000117" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000118" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000119" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050101_20051231" decimals="INF" unitRef="U_shares">2978</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000120" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">44000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000121" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">44000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000122" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050101_20051231" decimals="INF" unitRef="U_shares">903</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000123" xsi:nil="true" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050101_20051231" unitRef="U_iso4217USD" />
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000124" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">1354000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000125" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">1354000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000126" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050101_20051231" decimals="INF" unitRef="U_shares">31095</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000127" xsi:nil="true" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20050101_20051231" unitRef="U_shares" />
  <us-gaap:NetIncomeLoss id="F_000128" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">-1459000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000129" contextRef="C_0000907654_20050101_20051231" decimals="-3" unitRef="U_iso4217USD">-1459000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000130" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20051231" decimals="-3" unitRef="U_iso4217USD">1408000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000131" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20051231" decimals="-3" unitRef="U_iso4217USD">-2086000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000132" contextRef="C_0000907654_20051231" decimals="-3" unitRef="U_iso4217USD">-678000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000133" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20051231" decimals="INF" unitRef="U_shares">60206</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000134" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000135" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000136" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231" decimals="INF" unitRef="U_shares">17372</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000137" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">9316000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000138" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231" decimals="INF" unitRef="U_shares">5727354</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000139" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">684000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000140" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231" decimals="INF" unitRef="U_shares">420817</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000141" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000142" contextRef="C_0000907654_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000143" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231" decimals="INF" unitRef="U_shares">8019</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000144" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">60000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000145" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">60000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000146" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231" decimals="INF" unitRef="U_shares">13907</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000147" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000148" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000149" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231" decimals="INF" unitRef="U_shares">2505</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000150" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060101_20061231" decimals="INF" unitRef="U_shares">38</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000151" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000152" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231" decimals="INF" unitRef="U_shares">3074086</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000153" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeriesOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">-98000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000154" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">39000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000155" contextRef="C_0000907654_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">39000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000156" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">17000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000157" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">-17000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000158" contextRef="C_0000907654_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">-17000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:NetIncomeLoss id="F_000159" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">-5241000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000160" contextRef="C_0000907654_20060101_20061231" decimals="-3" unitRef="U_iso4217USD">-5241000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000161" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20061231" decimals="-3" unitRef="U_iso4217USD">14919000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000162" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20061231" decimals="-3" unitRef="U_iso4217USD">1583000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000163" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20061231" decimals="-3" unitRef="U_iso4217USD">-7327000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000164" contextRef="C_0000907654_20061231" decimals="-3" unitRef="U_iso4217USD">-5744000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000165" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20061231" decimals="INF" unitRef="U_shares">9222257</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="F_000166" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20061231" decimals="INF" unitRef="U_shares">102047</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000167" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">9000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000168" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231" decimals="INF" unitRef="U_shares">3688902</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000169" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">9000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000170" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231" decimals="INF" unitRef="U_shares">2766677</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000171" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">-147000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000172" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">19000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000173" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">-19000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000174" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">-19000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000175" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000176" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">-18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000177" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">-18000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000178" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000179" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000180" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231" decimals="INF" unitRef="U_shares">1303</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000181" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000182" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000183" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231" decimals="INF" unitRef="U_shares">642</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000184" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioIssuanceOfCommonStockForCommercialLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231" decimals="INF" unitRef="U_shares">2783</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000185" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">50000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000186" contextRef="C_0000907654_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">50000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000187" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioIssuanceOfSharesToExecutiveSubjectToRepurchaseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231" decimals="INF" unitRef="U_shares">13915</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000188" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000189" contextRef="C_0000907654_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000190" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070101_20071231" decimals="INF" unitRef="U_shares">2227</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:NetIncomeLoss id="F_000191" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">-13994000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000192" contextRef="C_0000907654_20070101_20071231" decimals="-3" unitRef="U_iso4217USD">-13994000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000193" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20071231" decimals="-3" unitRef="U_iso4217USD">14938000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000194" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20071231" decimals="-3" unitRef="U_iso4217USD">17871000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000195" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20071231" decimals="-3" unitRef="U_iso4217USD">1632000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000196" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20071231" decimals="-3" unitRef="U_iso4217USD">-21321000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000197" contextRef="C_0000907654_20071231" decimals="-3" unitRef="U_iso4217USD">-19689000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000198" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20071231" decimals="INF" unitRef="U_shares">9222257</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="F_000199" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20071231" decimals="INF" unitRef="U_shares">6455579</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="F_000200" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20071231" decimals="INF" unitRef="U_shares">122917</us-gaap:SharesOutstanding>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000201" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000202" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">-20000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000203" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">-20000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000204" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">36000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000205" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">-36000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000206" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">-36000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000207" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">545000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000208" contextRef="C_0000907654_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">545000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="F_000209" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued id="F_000210" contextRef="C_0000907654_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000211" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000212" contextRef="C_0000907654_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">54000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000213" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20080101_20081231" decimals="INF" unitRef="U_shares">36154</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:NetIncomeLoss id="F_000214" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">-19431000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000215" contextRef="C_0000907654_20080101_20081231" decimals="-3" unitRef="U_iso4217USD">-19431000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000216" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20081231" decimals="-3" unitRef="U_iso4217USD">14958000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000217" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20081231" decimals="-3" unitRef="U_iso4217USD">17907000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000218" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20081231" decimals="-3" unitRef="U_iso4217USD">2574000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000219" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20081231" decimals="-3" unitRef="U_iso4217USD">-40752000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000220" contextRef="C_0000907654_20081231" decimals="-3" unitRef="U_iso4217USD">-38178000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000221" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20081231" decimals="INF" unitRef="U_shares">9222257</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="F_000222" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20081231" decimals="INF" unitRef="U_shares">6455579</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="F_000223" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20081231" decimals="INF" unitRef="U_shares">159071</us-gaap:SharesOutstanding>
  <abio:AdjustmentForFractionalShares id="F_000224" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231" decimals="INF" unitRef="U_shares">-7</abio:AdjustmentForFractionalShares>
  <us-gaap:DividendsPreferredStockStock id="F_000225" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-781000</us-gaap:DividendsPreferredStockStock>
  <us-gaap:DividendsPreferredStockStock id="F_000226" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">781000</us-gaap:DividendsPreferredStockStock>
  <us-gaap:DividendsPreferredStockStock id="F_000227" contextRef="C_0000907654_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">781000</us-gaap:DividendsPreferredStockStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000228" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000229" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000230" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000231" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">93000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000232" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-93000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000233" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioAccretionOfSeriesBMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-93000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000234" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">15000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000235" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">18781000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000236" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000237" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-33780000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000238" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-33781000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits id="F_000239" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20090101_20091231" decimals="INF" unitRef="U_shares">9222257</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits id="F_000240" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20090101_20091231" decimals="INF" unitRef="U_shares">6455579</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits id="F_000241" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCommonConversionMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231" decimals="INF" unitRef="U_shares">-507123</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <abio:AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction id="F_000242" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">75000</abio:AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction>
  <abio:AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction id="F_000243" contextRef="C_0000907654_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">75000</abio:AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000244" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioNotesAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">8501000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000245" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioNotesAndRelatedAccruedInterestMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">8501000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000246" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioNotesAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231" decimals="INF" unitRef="U_shares">145465</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <abio:AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock id="F_000247" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">36000</abio:AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock>
  <abio:AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock id="F_000248" contextRef="C_0000907654_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">36000</abio:AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="F_000249" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">11913000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions id="F_000250" contextRef="C_0000907654_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">11913000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions id="F_000251" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231" decimals="INF" unitRef="U_shares">447826</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <abio:AdjustmentForFractionalShares id="F_000252" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231" decimals="INF" unitRef="U_shares">-102</abio:AdjustmentForFractionalShares>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000253" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">845000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000254" contextRef="C_0000907654_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">845000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000255" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">114000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000256" contextRef="C_0000907654_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">114000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000257" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231" decimals="INF" unitRef="U_shares">10521</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan id="F_000258" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan id="F_000259" contextRef="C_0000907654_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan id="F_000260" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20090101_20091231" decimals="INF" unitRef="U_shares">177</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
  <abio:AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued id="F_000261" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">377000</abio:AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued>
  <abio:AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued id="F_000262" contextRef="C_0000907654_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">377000</abio:AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued>
  <us-gaap:NetIncomeLoss id="F_000263" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-9138000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000264" contextRef="C_0000907654_20090101_20091231" decimals="-3" unitRef="U_iso4217USD">-9138000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000265" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20091231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000266" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20091231" decimals="-3" unitRef="U_iso4217USD">57301000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000267" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20091231" decimals="-3" unitRef="U_iso4217USD">-49890000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000268" contextRef="C_0000907654_20091231" decimals="-3" unitRef="U_iso4217USD">7412000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000269" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20091231" decimals="INF" unitRef="U_shares">1270074</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000270" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20100101_20101231" decimals="-3" unitRef="U_iso4217USD">7182000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000271" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_20100101_20101231" decimals="-3" unitRef="U_iso4217USD">7182000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000272" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20100101_20101231" decimals="INF" unitRef="U_shares">194100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000273" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20100101_20101231" decimals="-3" unitRef="U_iso4217USD">139000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000274" contextRef="C_0000907654_20100101_20101231" decimals="-3" unitRef="U_iso4217USD">139000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000275" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20100101_20101231" decimals="INF" unitRef="U_shares">8248</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000276" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20100101_20101231" decimals="-3" unitRef="U_iso4217USD">458000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000277" contextRef="C_0000907654_20100101_20101231" decimals="-3" unitRef="U_iso4217USD">458000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000278" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20100101_20101231" decimals="-3" unitRef="U_iso4217USD">-8420000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000279" contextRef="C_0000907654_20100101_20101231" decimals="-3" unitRef="U_iso4217USD">-8420000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000280" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20101231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000281" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20101231" decimals="-3" unitRef="U_iso4217USD">65080000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000282" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20101231" decimals="-3" unitRef="U_iso4217USD">-58310000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000283" contextRef="C_0000907654_20101231" decimals="-3" unitRef="U_iso4217USD">6771000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000284" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20101231" decimals="INF" unitRef="U_shares">1472422</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000285" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20110101_20111231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000286" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20110101_20111231" decimals="-3" unitRef="U_iso4217USD">4016000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000287" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_20110101_20111231" decimals="-3" unitRef="U_iso4217USD">4017000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000288" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20110101_20111231" decimals="INF" unitRef="U_shares">557890</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000289" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20110101_20111231" decimals="-3" unitRef="U_iso4217USD">188000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000290" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20110101_20111231" decimals="-3" unitRef="U_iso4217USD">308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000291" contextRef="C_0000907654_20110101_20111231" decimals="-3" unitRef="U_iso4217USD">308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000292" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20110101_20111231" decimals="-3" unitRef="U_iso4217USD">-5364000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000293" contextRef="C_0000907654_20110101_20111231" decimals="-3" unitRef="U_iso4217USD">-5364000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000294" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20111231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000295" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20111231" decimals="-3" unitRef="U_iso4217USD">69404000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000296" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20111231" decimals="-3" unitRef="U_iso4217USD">-63674000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000297" contextRef="C_0000907654_20111231" decimals="-3" unitRef="U_iso4217USD">5732000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000298" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20111231" decimals="INF" unitRef="U_shares">2030500</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000299" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20120101_20121231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000300" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20120101_20121231" decimals="-3" unitRef="U_iso4217USD">1188000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000301" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_20120101_20121231" decimals="-3" unitRef="U_iso4217USD">1189000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000302" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20120101_20121231" decimals="INF" unitRef="U_shares">629815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000303" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20120101_20121231" decimals="-3" unitRef="U_iso4217USD">306000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000304" contextRef="C_0000907654_20120101_20121231" decimals="-3" unitRef="U_iso4217USD">306000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000305" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20120101_20121231" decimals="-3" unitRef="U_iso4217USD">-4320000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000306" contextRef="C_0000907654_20120101_20121231" decimals="-3" unitRef="U_iso4217USD">-4320000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000307" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20121231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000308" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20121231" decimals="-3" unitRef="U_iso4217USD">70898000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000309" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20121231" decimals="-3" unitRef="U_iso4217USD">-67994000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000310" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20121231" decimals="INF" unitRef="U_shares">2660315</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000311" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">1421000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000312" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">1421000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000313" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20130331" decimals="INF" unitRef="U_shares">521066</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <abio:AdjustmentForFractionalShares id="F_000314" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20130331" decimals="INF" unitRef="U_shares">-64</abio:AdjustmentForFractionalShares>
  <abio:StockIssuedDuringPeriodValueWarrantsExercised id="F_000315" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">12000</abio:StockIssuedDuringPeriodValueWarrantsExercised>
  <abio:StockIssuedDuringPeriodValueWarrantsExercised id="F_000316" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">12000</abio:StockIssuedDuringPeriodValueWarrantsExercised>
  <abio:StockIssuedDuringPeriodSharesWarrantsExercised id="F_000317" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130101_20130331" decimals="INF" unitRef="U_shares">4245</abio:StockIssuedDuringPeriodSharesWarrantsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000318" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000319" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000320" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">-1071000</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="F_000321" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130331" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000322" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20130331" decimals="-3" unitRef="U_iso4217USD">72373000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000323" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_abioDeficitAccumulatedDuringDevelopmentStageMember_20130331" decimals="-3" unitRef="U_iso4217USD">-69065000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000324" contextRef="C_0000907654_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20130331" decimals="INF" unitRef="U_shares">3185562</us-gaap:SharesOutstanding>
  <abio:CommonStockMarketPricePerShare id="F_000325" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20021231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.36</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000326" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20040930" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.36</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000327" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioCashNetOfOfferingCostsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050103" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.36</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000328" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20050103" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.36</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000329" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20051014" decimals="INF" unitRef="U_iso4217USD_xbrlishares">48.84</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000330" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060221" decimals="INF" unitRef="U_iso4217USD_xbrlishares">4.32</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000331" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060222" decimals="INF" unitRef="U_iso4217USD_xbrlishares">4.32</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000332" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20060623" decimals="INF" unitRef="U_iso4217USD_xbrlishares">5.40</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000333" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20061107" decimals="INF" unitRef="U_iso4217USD_xbrlishares">5.40</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000334" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070118" decimals="INF" unitRef="U_iso4217USD_xbrlishares">10.08</abio:CommonStockMarketPricePerShare>
  <abio:CommonStockMarketPricePerShare id="F_000335" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20070630" decimals="INF" unitRef="U_iso4217USD_xbrlishares">10.80</abio:CommonStockMarketPricePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000336" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioFirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060222" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.6265</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000337" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20060222" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.6265</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000338" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesAMember_20061208" decimals="INF" unitRef="U_iso4217USD_xbrlishares">1.6265</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000339" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20070531" decimals="INF" unitRef="U_iso4217USD_xbrlishares">2.439</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000340" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_abioSecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapSeriesBMember_20071228" decimals="INF" unitRef="U_iso4217USD_xbrlishares">3.253</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:DepreciationAndAmortization id="F_000341" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000342" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000343" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">1790000</us-gaap:DepreciationAndAmortization>
  <us-gaap:PaidInKindInterest id="F_000344" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">211000</us-gaap:PaidInKindInterest>
  <us-gaap:ShareBasedCompensation id="F_000345" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">42000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000346" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000347" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">2630000</us-gaap:ShareBasedCompensation>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="F_000348" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">377000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:AccretionExpense id="F_000349" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">152000</us-gaap:AccretionExpense>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000350" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">125000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <abio:WriteOffOfDeferredTaxLiability id="F_000351" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">2281000</abio:WriteOffOfDeferredTaxLiability>
  <us-gaap:MarketableSecuritiesGainLoss id="F_000352" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">263000</us-gaap:MarketableSecuritiesGainLoss>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000353" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-83000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:OtherNoncashIncomeExpense id="F_000354" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-267000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="F_000355" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">157000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="F_000356" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">72000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets id="F_000357" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-2663000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000358" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">-20000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000359" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-20000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000360" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-7346000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000361" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">312000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000362" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-134000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000363" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-1813000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities id="F_000364" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">88000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities id="F_000365" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-160000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities id="F_000366" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-19133000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredCharges id="F_000367" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">-8000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInDeferredCharges id="F_000368" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-8000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInDeferredCharges id="F_000369" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">8000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000370" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">-764000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000371" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-1656000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000372" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">-98185000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:CashAcquiredFromAcquisition id="F_000373" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">30392000</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:OtherPaymentsToAcquireBusinesses id="F_000374" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">1186000</us-gaap:OtherPaymentsToAcquireBusinesses>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000375" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000376" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">1888000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000377" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">15369000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000378" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">358000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfIntangibleAssets id="F_000379" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">2000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000380" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">-9000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000381" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">45045000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000382" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">10841000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromNotesPayable id="F_000383" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">4000000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock id="F_000384" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">38000</us-gaap:ProceedsFromIssuanceOfRedeemablePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000385" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">32316000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000386" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapPreferredStockMember_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">246000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000387" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">1741000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000388" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">15850000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000389" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">308000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000390" contextRef="C_0000907654_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">1634000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000391" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">60000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000392" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">60000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:RepaymentsOfNotesPayable id="F_000393" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">4000000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RepaymentsOfConvertibleDebt id="F_000394" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">105000</us-gaap:RepaymentsOfConvertibleDebt>
  <abio:RepaymentOfPrincipalOnVendorFinanceAgreement id="F_000395" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">43000</abio:RepaymentOfPrincipalOnVendorFinanceAgreement>
  <abio:RepaymentOfPrincipalOnVendorFinanceAgreement id="F_000396" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">323000</abio:RepaymentOfPrincipalOnVendorFinanceAgreement>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000397" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">1390000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000398" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-60000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000399" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">56677000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000400" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">617000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000401" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">-1716000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000402" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">3537000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000403" contextRef="C_0000907654_20111231" decimals="-3" unitRef="U_iso4217USD">5943000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000404" contextRef="C_0000907654_20120331" decimals="-3" unitRef="U_iso4217USD">4227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InterestPaid id="F_000405" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="F_000406" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">116000</us-gaap:InterestPaid>
  <abio:AccruedInterestOnNotesPayableConvertedToEquity id="F_000407" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">163000</abio:AccruedInterestOnNotesPayableConvertedToEquity>
  <abio:WarrantIssuedInConnectionWithCreditFacility id="F_000408" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">111000</abio:WarrantIssuedInConnectionWithCreditFacility>
  <abio:AccruedDeferredTransactionCosts id="F_000409" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">482000</abio:AccruedDeferredTransactionCosts>
  <abio:VendorFinanceAgreement id="F_000410" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">131000</abio:VendorFinanceAgreement>
  <abio:VendorFinanceAgreement id="F_000411" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">134000</abio:VendorFinanceAgreement>
  <abio:VendorFinanceAgreement id="F_000412" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">131000</abio:VendorFinanceAgreement>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="F_000413" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:9pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(1) The Company and Summary of Significant Accounting Policies &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt 12.2pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Description of Business&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;ARCA &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;biopharma&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Broomfield, Colorado and is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&amp;#8217;s lead product candidate, &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:5pt; vertical-align:super"&gt;TM&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; (&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;bucindolol&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, is being developed for the treatment and the prevention of atrial fibrillation, or AF, in patients with heart failure, or HF. The Company has identified common genetic variations in the cardiovascular system that it believes interact with &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&amp;#8217;s&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; pharmacology and may predict patient response to &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; treatment. The Company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; based on genetic testing, which it believes will provide market exclusivity for these uses of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; into at least 2026 in the U.S. and into 2025 in Europe. In addition, the Company believes that if &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; is approved, a &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; patent will be eligible for patent term extension based on our current clinical trial plans which, if granted, may provide market exclusivity for &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; into 2029 or 2030 in the US and Europe. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:6pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;ARCA&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; believes that &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; has potential efficacy in reducing or preventing AF, and&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; that&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; this efficacy may be genetically regulated. The Company plans to test this hypothesis in a clinical trial of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, known as GENETIC-AF, which the Company plans to initiate pending receipt of the necessary funding. The Company has created an adaptive design for GENETIC-AF under which the trial is intended to be initiated as a Phase 2b study in approximately &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;200&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; patients with heart failure and left ventricular dysfunction, or HFREF. Depending on the results of the Phase 2b portion, the trial may then be expanded to a Phase 3 study by enrolling an estimated additional &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;420&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; patients. The Company anticipates that GENETIC-AF could begin approximately 6 months after the Company obtains sufficient funding&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;.&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;To support the continued development of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, including the planned GENETIC-AF clinical trial and ongoing operations, the Company will need to &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;raise&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; substantial additional funding through public or private equity transactions or a strategic combination or partnership. If the Company is delayed in obtaining funding or is unable to complete a strategic transaction, it may have to discontinue development activities on &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; or discontinue its operations. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt 12.2pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Development Stage Risks, Liquidity and Going Concern&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company is in the development stage and devotes substantially all of its efforts towards obtaining regulatory approval, exploring strategic alternatives for further developing &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, and raising capital necessary to fund its operations. The Company has not generated revenue to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has historically funded its operations through issuances of common and preferred stock, as well as through the business combination with &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Inc&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, or &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Since ARCA was founded on December&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;17, 2001, or Inception, the Company has incurred substantial losses and negative cash flows from operations. Since Inception, the Company incurred a loss from operations of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;100.2&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million and had negative cash flows from operations of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;98.2&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;In light of the substantial additional time and costs associated with the development of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; and the need to raise a significant amount of capital on acceptable terms to finance the planned clinical trial and the Company&amp;#8217;s ongoing operations, the Company is evaluating strategic alternatives for funding continued operations and development programs. The Company will need to complete a substantial equity financing, or a strategic transaction, such as a strategic combination or partnership to support the continued development of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, including the planned GENETIC-AF clinical trial. &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;To date&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the Company &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;has completed two equity-financing transactions in 2013 and &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;raised approximately $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;1.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;4&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million, net of offering costs&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;These financings &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;have &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;allow&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;ed&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; ARCA to continue operations&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; while it continues to pursue financing options, a strategic combination, partnering, and licensing opportunities. If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or discontinue its operations. The Company currently believes its cash and cash equivalents balance as of March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2013 &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;will be sufficient to fund its operations &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;through September&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;30, 2013. The Company is unable to assert that its current cash and cash equivalents are sufficient to fund operations beyond that date, and as a result, there is substantial doubt about the Company&amp;#8217;s ability to continue as a going concern beyond September&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;30, 2013. These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; or to otherwise continue operations and may not be able to execute any strategic transaction. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company&amp;#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: &lt;/font&gt;&lt;/p&gt;
			&lt;ul type="disc" style="margin:0pt; padding-left:0pt"&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the market price of the Company&amp;#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the Company&amp;#8217;s ability to retain the listing of its common stock on the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nasdaq&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; Capital Market; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;general economic and industry conditions affecting the availability and cost of capital; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the Company&amp;#8217;s ability to control costs associated with its operations; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; terms and conditions of the Company&amp;#8217;s existing collaborative and licensing agreements. &lt;/font&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&amp;#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&amp;#8217;s capital stock and could contain covenants that would restrict the Company&amp;#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company in the near term, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Reverse Stock Split &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;On &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;March 4&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, 2013&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; the Company &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;completed &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;a &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;1-for-6 reverse split&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; of its common stock&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Basis of Presentation &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The accompanying unaudited consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and Rule 10-01 of Regulation S-X.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim consolidated financial statements. The results of operations for the three months ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 are not necessarily indicative of results expected for the full year ending December&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2013&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company has generated &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;no&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; revenue to date a&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;nd its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, and raising capital. Accordingly, the Company continues to be considered in the development stage at March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto for the year ended &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;December&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2012 included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, as amended&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Concentrations of Credit Risk &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, money market fund accounts and debt securities with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Accrued Expenses &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&amp;#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&amp;#8217;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000414" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(2) Loss &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Per&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt; Share &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company calculates basic loss per share by dividing loss attributable to common stockholders by the weighted average common shares outstanding during the period, excluding common stock subject to vesting provisions. Diluted loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company&amp;#8217;s potentially dilutive shares include options and warrants. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: &lt;/font&gt;&lt;/p&gt;
			&lt;table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:76%"&gt;

					&lt;tr style="height:11.25pt"&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:160.35pt"&gt;
							&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt; Three Months Ended March 31, &lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;2013&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;2012&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
					&lt;/tr&gt;


					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(In thousands, except shares and per share data)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(1,071)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(1,407)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Net loss available to common shareholders&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(1,071)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(1,407)&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:2.5pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Weighted average shares of common stock outstanding&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;3,037,546&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2,030,499&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:5.4pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Less:&amp;#160; Weighted-average shares of unvested common stock&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(2,783)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(2,783)&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td rowspan="2" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Total weighted-average shares used in computing net loss per share attributed to common stockholders&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;3,034,763&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2,027,716&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:13.5pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(0.35)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(0.69)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:1pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
				&lt;!--[if !supportMisalignedColumns]&gt;&lt;tr style="height:0pt"&gt;
					&lt;td style="width:200.7pt; border:none"&gt;
					&lt;/td&gt;
					&lt;td style="width:11.2pt; border:none"&gt;
					&lt;/td&gt;
					&lt;td style="width:55.95pt; border:none"&gt;
					&lt;/td&gt;
					&lt;td style="width:12.25pt; border:none"&gt;
					&lt;/td&gt;
					&lt;td style="width:56.45pt; border:none"&gt;
					&lt;/td&gt;
				&lt;/tr&gt;&lt;![endif]--&gt;&lt;/table&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;.&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Potentially dilutive securities representing&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;1.3&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million and &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;604,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; weighted average shares of common stock were excluded for the three months ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 and 2012, respectively, because including them would have an anti-dilutive effect on net loss per share&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:BusinessCombinationDisclosureTextBlock id="F_000415" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(3) Merger with &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;, Inc. on January&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;27, 2009 &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;On January&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;27, 2009, ARCA Colorado, Inc. (ARCA Colorado) completed the Merger with &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; in accordance with the terms of the Merger Agreement, in which a wholly-owned subsidiary of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. Immediately following the Merger, the Company changed its name from &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, Inc. to ARCA &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;biopharma&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, Inc., and its common stock began trading on the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nasdaq&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; Global Market under the symbol &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#8220;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;ABIO&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#8221;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; on January&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;28, 2009. On March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;7, 2011, the listing of the Company&amp;#8217;s common stock was transferred from the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nasdaq&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; Global Market to the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nasdaq&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; Capital Market. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Merger was treated as a reverse merger and accounted for as a business combination using the acquisition method of accounting in accordance with ASC 805. For accounting purposes, ARCA Colorado was considered to have acquired &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; in the Merger, as the stockholders of ARCA Colorado prior to the Merger had a controlling interest in the combined company and the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Company&amp;#8217;s &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;management is the former management of ARCA Colorado. The results of operations and cash flows include the activities of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; since the date of the Merger. Pursuant to the rules and regulations of the United States Securities and Exchange Commission, or the SEC, the historical financial statements of ARCA Colorado replaced the historical financial statements of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, and the disclosures in this report relating to the pre-Merger business of the Company, unless noted as being the business of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; prior to the Merger, pertain to the business of ARCA Colorado prior to the Merger. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The estimated total acquisition consideration of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;11.9&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million to acquire &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; was based on the market capitalization of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; as of January&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;27, 2009 and the estimated fair values of its vested stock options and warrants outstanding on that date, as this was deemed the most reliable measure of the consideration effectively transferred to acquire &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; on that date.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company estimated the net assets acquired in the Merger to be $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;37.2&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million, including $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;45.5&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million of cash, cash equivalents and marketable securities. In accordance with ASC 805, any excess of fair value of net assets acquired in a business combination over the acquisition consideration results in a gain on bargain purchase, and as a result, the Company recorded a gain on bargain purchase of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;25.3&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000416" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(4) Fair Value Disclosures &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;As of March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013, the Company had $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;3&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;.5&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million of cash equivalents consisting of money market funds with maturities of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;90 days&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; or less. The Company has the ability to liquidate these investments without restriction. The Company determines fair value for these money ma&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;rket funds and equity securities with Level 1 inputs through quoted market prices. There were no transfers of assets between fair value &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;hierarchy&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; levels during the three month period ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: &lt;/font&gt;&lt;/p&gt;
			&lt;ul type="disc" style="margin:0pt; padding-left:0pt"&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets for identical assets or liabilities &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Level 2&amp;#8212;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Level 3&amp;#8212;Unobservable inputs for the asset or liability &lt;/font&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Fair Value of Other Financial Instruments &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The carrying amount of other financial instruments, including cash, accounts payable, and short-term notes payable approximated fair value due to their short maturities. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000417" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(5) Property and Equipment &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 9pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Property and equipment consist of the following (in thousands): &lt;/font&gt;&lt;/p&gt;
			&lt;table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:94.66%"&gt;
				&lt;tr style="height:24pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Estimated Life&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;March 31, 2013&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;December 31, 2012&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;3 years&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;87&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;104&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Lab equipment&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;5 years&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;142&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;142&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;5 years&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;85&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;93&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Computer software&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;3 years&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;176&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;176&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:25.5pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Lesser of useful life or life of the lease&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;508&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;533&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Less accumulated depreciation and &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;amortization&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(486)&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(510)&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:13.5pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;22&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;23&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
			&lt;/table&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:12pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;For the three months ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 and 2012, and for the period from Inception through March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013, depreciation and amortization expense was $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;10&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;14&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, and $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;1.8&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million respectively.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000418" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(6) Commitments and Contingencies &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company has or is subject to the following commitments and contingencies: &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Employment Agreements &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company maintains employment agreements with several executive employees. &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Most of these agreements provide for payments to be made under certain conditions related to a change in control of the Company and entitle the employee to wages and certain benefits payments not exceeding one calendar year from the date of termination without cause or by the employee for good reason. &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Operating Lease &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;On February&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;8, 2008, the Company entered into a lease agreement for approximately &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;15,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; square feet of newly constructed office facilities in Broomfield, Colorado. The Company relocated to the new facility upon its completion in July&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2008. The lease has a term of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;5&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;years&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; with rights to extend the term for &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;two additional &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;three year&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt; periods&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. On June&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;14, 2011, the Company entered into a first amendment (the &amp;#8220;Amendment&amp;#8221;) to the lease agreement. Under the terms of the Amendment, the Company and its landlord mutually agreed for the Company to relocate from its office suite of approximately 15,000 square feet, to another suite within the same building, comprising approximately &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;4,500&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; square feet. The office location serves as the Company&amp;#8217;s primary business office. The Amendment also modified the annual per square foot rate of rent and allows the Company to terminate with &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;three months&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#8217; notice. As part of the agreement, the Company made a one-time payment to the landlord of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;200,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, which the landlord agreed to use for the landlord&amp;#8217;s improvements in the new leased premises. The original five year term of the Lease remains unchanged. Per the lease agreement, base rent is subject to annual increases of approximately three percent per year. The rent expense for the lease is being recognized on a straight-line basis over the lease term.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Under the original lease, the Company received tenant improvement reimbursements from the landlord totaling $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;593,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; which were recorded as deferred rent and were amortized as reductions to rent expense. The $200,000 payment made to the landlord in conjunction with the Amendment was recorded against the existing deferred rent. The net deferred rent balance is being amortized as reductions to rent expense over the remaining term of the lease. The unamortized deferred rent balance as of March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 was $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;8&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Rent expense under this lease for the three months ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 and 2012 was $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;12&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, and&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; was&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;527&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;from Inception through March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company&amp;#8217;s facility lease in Broomfield, Colorado expires in &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;June 2013&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. The remaining minimum lease payments committed under the lease through June 2013 are $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;20,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. The lease has an option to renew for an additional three year term under comparable terms, &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;and &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the Company &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;is in negotiations with the landlord regarding potential renewal of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the lease. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Under the terms of its strategic license agreement with CPEC, a licensing subsidiary of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Indevus&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; Pharmaceuticals Inc. (a wholly owned subsidiary of Endo Pharmaceuticals), holding ownership rights to certain clinical trial data of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, the Company will incur milestone and royalty obligations upon the occurrence of certain events. In August 2008, the Company paid CPEC a milestone payment of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;500,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; based on the July&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2008 submission of its NDA to the FDA. If the FDA grants marketing approval for &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;agreement provides that the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Company will owe CPEC another milestone payment of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;8.0&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;million within six months after FDA approval. The &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;agreement also states that the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Company has the obligation to make milestone payments of up to $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;5.0&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million in the aggregate upon regulatory marketing approval in Europe and Japan. The &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;agreement states that the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Company&amp;#8217;s royalty obligation ranges from &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;12.5&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;% to &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;25&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;% of revenue from the related product based on achievement of specified product sales levels, including a &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;5&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;% royalty that CPEC is obligated to pay under its original license agreement for &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. The Company has the right to buy down the royalties to a range of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;12.5&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;% to &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;17&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;% by making a payment to CPEC within &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;six months&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; of regulatory approval. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <abio:EquityFinancingsAndWarrantsDisclosureTextBlock id="F_000419" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(7) &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Equity Financings and Warrants &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Private Investment in Public Equity (PIPE) Transaction &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;On January&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;22, 2013, the Company entered into a Subscription Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;) with various accredited investors and &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;its&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; Chief Executive Officer in connection with a private placement of its common stock and warrants. Pursuant to the Purchase Agreement, the Company sold an aggregate of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;356,430&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; shares of its common stock and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;249,501&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; additional shares of its common stock for aggregate gross proceeds of approximately $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;1&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million, before deducting estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;80&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;5&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, and the private placement closed on &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;January&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;25, 2013&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;0.70&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; shares of common stock. The purchase price for each unit was $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;2.81&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. The warrants were exercisable upon issuance, expire &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;seven&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; years from the date of issuance, and have an exercise price of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;2.28&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; per share, equal to &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;100%&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; of the closing bid price of ARCA&amp;#8217;s common stock on the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nasdaq&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; Capital Market on January&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;22, 2013.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company filed a registration statement for the resale of the shares underlying the units sold in these private placements. That registration statement was declared effective by the Securities and Exchange Commission on February&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;14, 2013. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;In connection with this transaction, the Company agreed that, subject to certain exceptions, it would not, while the warrants are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a &amp;#8220;variable rate transaction,&amp;#8221; which means a transaction in which the Company issues or sells any convertible securities either (A)&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B)&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. In addition, the Company agreed that, subject to certain exceptions, if it issues securities within one year following the closing of the offering, each investor would have the right to purchase its pro rata share of a specified portion of the securities in the future offering on the same terms, conditions and price provided for in the proposed issuance of securities. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Registered Direct Offering &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;On January&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013, the Company entered into a subscription agreement with certain institutional investors (the &amp;#8220;Investors&amp;#8221;) in connection with its Registered Direct public offering (the &amp;#8220;Offering&amp;#8221;), pursuant to which the Company sold an aggregate of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;164,636&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; shares of its common stock and warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;65,855&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; additional shares of its common stock to the Investors for aggregate gross proceeds of approximately $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;730,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, before deducting placement agent fee and other estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;616&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,000&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, and the Offering closed on &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;February&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;4, 2013&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;0.40&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; shares of common stock. The purchase price for each unit was $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;4.43&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. The warrants were exercisable upon issuance, expire &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;five&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; years from the date of issuance, and have an exercise price of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;4.13&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; per share, equal to the closing bid price of ARCA&amp;#8217;s common stock on the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nasdaq&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; Capital Market o&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;n&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; January&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013. The Offering was &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;effected&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; as a takedown off the Company&amp;#8217;s S-3 Registration Statement, which became effective on April&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;1, 2013. The warrant agreements provide for settlement of the warrants in unregistered shares should an effective registration statement or current prospectus not &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;be&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; in place at the time a warrant is exercised. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Warrants &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;As of March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013, warrants to purchase &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;1.3 million&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; shares of common stock were outstanding at exercise prices ranging from $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;1.80&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; to $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;116.89&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, with a weighted average exercise price per share of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;7.25&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. These warrants, which were granted as part of various financing and business agreements, expire at various times between October 2013 and &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;January 2020&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. Warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using the Black-Scholes option-pricing model. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</abio:EquityFinancingsAndWarrantsDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000420" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(8) Share-based Compensation &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 9pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;For the three month periods ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 and 2012 and for the period from Inception through March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013, the Company recognized the following non-cash, share-based compensation expense in the consolidated statement of operations (in thousands): &lt;/font&gt;&lt;/p&gt;
			&lt;div style="text-align:center"&gt;
				&lt;table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:84%"&gt;

						&lt;tr style="height:59.25pt"&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:137.15pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Three Months Ended March 31,&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Period from December 17, 2001 (date of inception) to March 31, 2013&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
						&lt;/tr&gt;
						&lt;tr style="height:15.75pt"&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;2013&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;2012&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
						&lt;/tr&gt;


						&lt;tr style="height:20.25pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
						&lt;tr style="height:15.75pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Research and Development&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;15&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;26&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;605&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
						&lt;tr style="height:15.75pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Selling, General and Administrative&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;27&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;65&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;1&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;638&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
						&lt;tr style="height:15.75pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Restructuring Expense&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;0&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;0&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;387&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
						&lt;tr style="height:16.5pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Total&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;42&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;91&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;630&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
					&lt;!--[if !supportMisalignedColumns]&gt;&lt;tr style="height:0pt"&gt;
						&lt;td style="width:143pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:67.55pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:11.55pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:68.5pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:12.3pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:69.05pt; border:none"&gt;
						&lt;/td&gt;
					&lt;/tr&gt;&lt;![endif]--&gt;&lt;/table&gt;
			&lt;/div&gt;
			&lt;p style="margin:4.5pt 0pt 0pt 24.5pt; text-indent:-24.5pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt 24.5pt; text-indent:-24.5pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:12pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Stock option transactions for the three month period ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 under all plans are as follows: &lt;/font&gt;&lt;/p&gt;
			&lt;div style="text-align:center"&gt;
				&lt;table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:84%"&gt;
					&lt;tr style="height:77.25pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt; # of Options &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Weighted Average Remaining Contractual Term &lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(in years)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Options outstanding at December&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2012&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;144,019&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18.28&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;4.91&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Changes during the period:&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Granted&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;-&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;0.00&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;-&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;0.00&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Forfeited, cancelled or expired&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(6,259)&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;16.53&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Options outstanding at March 31, 2013&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;137,760&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18.36&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;4.89&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Options exercisable at March 31, 2013&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;123,408&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;82&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;4.62&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Options vested and expected to vest&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;136,208&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;39&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;4.88&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
				&lt;/table&gt;
			&lt;/div&gt;
			&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000421" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(9) Income Taxes &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;In accordance with United States Generally Accepted Accounting Principles, a valuation allowance should be provided if it is more likely than not that some or all of the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Company&amp;#8217;s &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;deferred tax assets will not be realized. The &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Company&amp;#8217;s &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets. The Company believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;no&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; reserve for uncertain tax positions&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock id="F_000422" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:4.5pt 0pt 0pt 12.2pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Description of Business&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;ARCA &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;biopharma&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Broomfield, Colorado and is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&amp;#8217;s lead product candidate, &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:5pt; vertical-align:super"&gt;TM&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; (&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;bucindolol&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, is being developed for the treatment and the prevention of atrial fibrillation, or AF, in patients with heart failure, or HF. The Company has identified common genetic variations in the cardiovascular system that it believes interact with &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&amp;#8217;s&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; pharmacology and may predict patient response to &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; treatment. The Company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; based on genetic testing, which it believes will provide market exclusivity for these uses of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; into at least 2026 in the U.S. and into 2025 in Europe. In addition, the Company believes that if &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; is approved, a &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; patent will be eligible for patent term extension based on our current clinical trial plans which, if granted, may provide market exclusivity for &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; into 2029 or 2030 in the US and Europe. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:6pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;ARCA&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; believes that &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; has potential efficacy in reducing or preventing AF, and&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; that&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; this efficacy may be genetically regulated. The Company plans to test this hypothesis in a clinical trial of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, known as GENETIC-AF, which the Company plans to initiate pending receipt of the necessary funding. The Company has created an adaptive design for GENETIC-AF under which the trial is intended to be initiated as a Phase 2b study in approximately &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;200&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; patients with heart failure and left ventricular dysfunction, or HFREF. Depending on the results of the Phase 2b portion, the trial may then be expanded to a Phase 3 study by enrolling an estimated additional &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;420&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; patients. The Company anticipates that GENETIC-AF could begin approximately 6 months after the Company obtains sufficient funding&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;.&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;To support the continued development of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, including the planned GENETIC-AF clinical trial and ongoing operations, the Company will need to &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;raise&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; substantial additional funding through public or private equity transactions or a strategic combination or partnership. If the Company is delayed in obtaining funding or is unable to complete a strategic transaction, it may have to discontinue development activities on &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; or discontinue its operations. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
  <abio:DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock id="F_000423" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt 12.2pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Development Stage Risks, Liquidity and Going Concern&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company is in the development stage and devotes substantially all of its efforts towards obtaining regulatory approval, exploring strategic alternatives for further developing &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, and raising capital necessary to fund its operations. The Company has not generated revenue to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has historically funded its operations through issuances of common and preferred stock, as well as through the business combination with &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Inc&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, or &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nuvelo&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Since ARCA was founded on December&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;17, 2001, or Inception, the Company has incurred substantial losses and negative cash flows from operations. Since Inception, the Company incurred a loss from operations of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;100.2&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million and had negative cash flows from operations of $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;98.2&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;In light of the substantial additional time and costs associated with the development of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; and the need to raise a significant amount of capital on acceptable terms to finance the planned clinical trial and the Company&amp;#8217;s ongoing operations, the Company is evaluating strategic alternatives for funding continued operations and development programs. The Company will need to complete a substantial equity financing, or a strategic transaction, such as a strategic combination or partnership to support the continued development of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, including the planned GENETIC-AF clinical trial. &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;To date&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the Company &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;has completed two equity-financing transactions in 2013 and &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;raised approximately $&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;1.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;4&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; million, net of offering costs&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;These financings &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;have &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;allow&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;ed&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; ARCA to continue operations&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; while it continues to pursue financing options, a strategic combination, partnering, and licensing opportunities. If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or discontinue its operations. The Company currently believes its cash and cash equivalents balance as of March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2013 &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;will be sufficient to fund its operations &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;through September&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;30, 2013. The Company is unable to assert that its current cash and cash equivalents are sufficient to fund operations beyond that date, and as a result, there is substantial doubt about the Company&amp;#8217;s ability to continue as a going concern beyond September&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;30, 2013. These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; or to otherwise continue operations and may not be able to execute any strategic transaction. &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:9pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company&amp;#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: &lt;/font&gt;&lt;/p&gt;
			&lt;ul type="disc" style="margin:0pt; padding-left:0pt"&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the market price of the Company&amp;#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the Company&amp;#8217;s ability to retain the listing of its common stock on the &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Nasdaq&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; Capital Market; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;general economic and industry conditions affecting the availability and cost of capital; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the Company&amp;#8217;s ability to control costs associated with its operations; &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and &lt;/font&gt;&lt;/li&gt;
				&lt;li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;the&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; terms and conditions of the Company&amp;#8217;s existing collaborative and licensing agreements. &lt;/font&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;p style="margin:9pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&amp;#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&amp;#8217;s capital stock and could contain covenants that would restrict the Company&amp;#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company in the near term, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</abio:DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock>
  <abio:ReverseStockSplitPolicyTextBlock id="F_000424" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Reverse Stock Split &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;On &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;March 4&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, 2013&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; the Company &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;completed &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;a &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;1-for-6 reverse split&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; of its common stock&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</abio:ReverseStockSplitPolicyTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000425" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Basis of Presentation &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The accompanying unaudited consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and Rule 10-01 of Regulation S-X.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim consolidated financial statements. The results of operations for the three months ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 are not necessarily indicative of results expected for the full year ending December&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2013&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;The Company has generated &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; "&gt;no&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; revenue to date a&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;nd its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Gencaro&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, and raising capital. Accordingly, the Company continues to be considered in the development stage at March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto for the year ended &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;December&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2012 included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;, as amended&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000426" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Concentrations of Credit Risk &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, money market fund accounts and debt securities with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:ConcentrationRiskCreditRisk>
  <abio:AccruedExpensesPolicyTextBlock id="F_000427" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold; font-style:italic"&gt;Accrued Expenses &lt;/font&gt;&lt;/p&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&amp;#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&amp;#8217;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. &lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</abio:AccruedExpensesPolicyTextBlock>
  <us-gaap:ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock id="F_000428" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:9pt 0pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: &lt;/font&gt;&lt;/p&gt;
			&lt;table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:76%"&gt;

					&lt;tr style="height:11.25pt"&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:160.35pt"&gt;
							&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt; Three Months Ended March 31, &lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;2013&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
						&lt;th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;2012&lt;/font&gt;&lt;/p&gt;
						&lt;/th&gt;
					&lt;/tr&gt;


					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(In thousands, except shares and per share data)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(1,071)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(1,407)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Net loss available to common shareholders&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(1,071)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(1,407)&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:2.5pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Weighted average shares of common stock outstanding&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;3,037,546&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2,030,499&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:5.4pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Less:&amp;#160; Weighted-average shares of unvested common stock&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(2,783)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(2,783)&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td rowspan="2" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Total weighted-average shares used in computing net loss per share attributed to common stockholders&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:12.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;3,034,763&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2,027,716&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:13.5pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(0.35)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(0.69)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:1pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt"&gt;
							&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:1pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
				&lt;!--[if !supportMisalignedColumns]&gt;&lt;tr style="height:0pt"&gt;
					&lt;td style="width:200.7pt; border:none"&gt;
					&lt;/td&gt;
					&lt;td style="width:11.2pt; border:none"&gt;
					&lt;/td&gt;
					&lt;td style="width:55.95pt; border:none"&gt;
					&lt;/td&gt;
					&lt;td style="width:12.25pt; border:none"&gt;
					&lt;/td&gt;
					&lt;td style="width:56.45pt; border:none"&gt;
					&lt;/td&gt;
				&lt;/tr&gt;&lt;![endif]--&gt;&lt;/table&gt;
			&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000429" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:4.5pt 0pt 9pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Property and equipment consist of the following (in thousands): &lt;/font&gt;&lt;/p&gt;
			&lt;table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:94.66%"&gt;
				&lt;tr style="height:24pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Estimated Life&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;March 31, 2013&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;December 31, 2012&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;3 years&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;87&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;104&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Lab equipment&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;5 years&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;142&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;142&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;5 years&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;85&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;93&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Computer software&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;3 years&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;176&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;176&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:25.5pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Lesser of useful life or life of the lease&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;508&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;533&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:12.75pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Less accumulated depreciation and &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;amortization&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(486)&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(510)&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr style="height:13.5pt"&gt;
					&lt;td style="vertical-align:bottom; width:211.5pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:99pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;22&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="vertical-align:bottom; width:11.6pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; vertical-align:bottom; width:54.65pt"&gt;
						&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;23&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt; &lt;/font&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
			&lt;/table&gt;
			&lt;p style="margin:4.5pt 0pt 0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:12pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000430" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:4.5pt 0pt 9pt; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;For the three month periods ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 and 2012 and for the period from Inception through March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013, the Company recognized the following non-cash, share-based compensation expense in the consolidated statement of operations (in thousands): &lt;/font&gt;&lt;/p&gt;
			&lt;div style="text-align:center"&gt;
				&lt;table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:84%"&gt;

						&lt;tr style="height:59.25pt"&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:137.15pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Three Months Ended March 31,&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Period from December 17, 2001 (date of inception) to March 31, 2013&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
						&lt;/tr&gt;
						&lt;tr style="height:15.75pt"&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;2013&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt; text-align:center"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;2012&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
							&lt;th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/th&gt;
						&lt;/tr&gt;


						&lt;tr style="height:20.25pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
						&lt;tr style="height:15.75pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Research and Development&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;15&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;26&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;605&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
						&lt;tr style="height:15.75pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Selling, General and Administrative&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;27&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;65&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;1&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;638&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
						&lt;tr style="height:15.75pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Restructuring Expense&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;0&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;0&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;387&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
						&lt;tr style="height:16.5pt"&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Total&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;42&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;91&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
							&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt"&gt;
								&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;2&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;,&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;630&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
							&lt;/td&gt;
						&lt;/tr&gt;
					&lt;!--[if !supportMisalignedColumns]&gt;&lt;tr style="height:0pt"&gt;
						&lt;td style="width:143pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:67.55pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:11.55pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:68.5pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:12.3pt; border:none"&gt;
						&lt;/td&gt;
						&lt;td style="width:69.05pt; border:none"&gt;
						&lt;/td&gt;
					&lt;/tr&gt;&lt;![endif]--&gt;&lt;/table&gt;
			&lt;/div&gt;
			&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock id="F_000431" contextRef="C_0000907654_20130101_20130331">&lt;div&gt;
			&lt;p style="margin:9pt 0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Stock option transactions for the three month period ended March&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2013 under all plans are as follows: &lt;/font&gt;&lt;/p&gt;
			&lt;div style="text-align:center"&gt;
				&lt;table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:84%"&gt;
					&lt;tr style="height:77.25pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt; # of Options &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;Weighted Average Remaining Contractual Term &lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt; font-weight:bold"&gt;(in years)&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:Calibri; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Options outstanding at December&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;31, 2012&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;144,019&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18.28&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;4.91&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Changes during the period:&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Granted&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;-&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;0.00&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;-&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;0.00&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Forfeited, cancelled or expired&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;(6,259)&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;16.53&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Options outstanding at March 31, 2013&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;137,760&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18.36&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;4.89&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15.75pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Options exercisable at March 31, 2013&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;123,408&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;82&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;4.62&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
					&lt;tr style="height:15pt"&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;Options vested and expected to vest&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;136,208&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;$&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;18.&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;39&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt"&gt;
							&lt;p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
						&lt;td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt"&gt;
							&lt;p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;4.88&lt;/font&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/p&gt;
						&lt;/td&gt;
					&lt;/tr&gt;
				&lt;/table&gt;
			&lt;/div&gt;
			&lt;p style="margin:0pt"&gt;&lt;font style="font-family:&apos;Times New Roman&apos;; font-size:10pt"&gt;&amp;#xa0;&lt;/font&gt;&lt;/p&gt;
		&lt;/div&gt;
</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <abio:NumberOfPatientsCompanyPlansToEnroll id="F_000432" contextRef="C_0000907654_us-gaapRangeAxis_us-gaapMinimumMember_20130101_20130331" decimals="INF" unitRef="U_abioPatients">200</abio:NumberOfPatientsCompanyPlansToEnroll>
  <abio:NumberOfPatientsCompanyPlansToEnroll id="F_000433" contextRef="C_0000907654_us-gaapRangeAxis_us-gaapMaximumMember_20130101_20130331" decimals="INF" unitRef="U_abioPatients">420</abio:NumberOfPatientsCompanyPlansToEnroll>
  <abio:AnticipatedPeriodToStartAtrialFibrillationTrial id="F_000434" contextRef="C_0000907654_20130101_20130331">P6M</abio:AnticipatedPeriodToStartAtrialFibrillationTrial>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000435" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">1400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000436" contextRef="C_0000907654_20130204_20130304">1 for 6 reverse split</us-gaap:StockholdersEquityReverseStockSplit>
  <abio:RevenueGenerated id="F_000437" contextRef="C_0000907654_20130101_20130331" decimals="0" unitRef="U_iso4217USD">0</abio:RevenueGenerated>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000438" contextRef="C_0000907654_20130101_20130331" decimals="0" unitRef="U_shares">3037546</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000439" contextRef="C_0000907654_20120101_20120331" decimals="0" unitRef="U_shares">2030499</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment id="F_000440" contextRef="C_0000907654_20130101_20130331" decimals="0" unitRef="U_shares">-2783</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment id="F_000441" contextRef="C_0000907654_20120101_20120331" decimals="0" unitRef="U_shares">-2783</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic id="F_000442" contextRef="C_0000907654_20130101_20130331" decimals="0" unitRef="U_shares">3034763</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <us-gaap:WeightedAverageNumberOfSharesIssuedBasic id="F_000443" contextRef="C_0000907654_20120101_20120331" decimals="0" unitRef="U_shares">2027716</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000444" contextRef="C_0000907654_20130101_20130331" decimals="-5" unitRef="U_shares">1300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000445" contextRef="C_0000907654_20120101_20120331" decimals="0" unitRef="U_shares">604000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityPurchasePrice id="F_000446" contextRef="C_0000907654_20090127" decimals="-5" unitRef="U_iso4217USD">11900000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityPurchasePrice>
  <us-gaap:BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet id="F_000447" contextRef="C_0000907654_20090127" decimals="-5" unitRef="U_iso4217USD">37200000</us-gaap:BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet>
  <us-gaap:BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents id="F_000448" contextRef="C_0000907654_20090127" decimals="-5" unitRef="U_iso4217USD">45500000</us-gaap:BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents>
  <us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount id="F_000449" contextRef="C_0000907654_20090101_20090127" decimals="-5" unitRef="U_iso4217USD">25300000</us-gaap:BusinessCombinationBargainPurchaseGainRecognizedAmount>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000450" contextRef="C_0000907654_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_20130331" decimals="-5" unitRef="U_iso4217USD">3500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <abio:CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities id="F_000451" contextRef="C_0000907654_20130331">P90D</abio:CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities>
  <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount id="F_000452" contextRef="C_0000907654_20130101_20130331" decimals="0" unitRef="U_iso4217USD">0</abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000453" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20130101_20130331">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000454" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20130101_20130331">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000455" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20130101_20130331">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000456" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerSoftwareIntangibleAssetMember_20130101_20130331">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <abio:LeaseholdImprovementsUsefulLife id="F_000457" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20130101_20130331">Lesser of useful life or life of the lease</abio:LeaseholdImprovementsUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000458" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20130331" decimals="-3" unitRef="U_iso4217USD">87000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000459" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20121231" decimals="-3" unitRef="U_iso4217USD">104000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000460" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20130331" decimals="-3" unitRef="U_iso4217USD">142000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000461" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20121231" decimals="-3" unitRef="U_iso4217USD">142000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000462" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20130331" decimals="-3" unitRef="U_iso4217USD">85000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000463" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20121231" decimals="-3" unitRef="U_iso4217USD">93000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000464" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerSoftwareIntangibleAssetMember_20130331" decimals="-3" unitRef="U_iso4217USD">176000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000465" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerSoftwareIntangibleAssetMember_20121231" decimals="-3" unitRef="U_iso4217USD">176000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000466" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20130331" decimals="-3" unitRef="U_iso4217USD">18000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000467" contextRef="C_0000907654_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20121231" decimals="-3" unitRef="U_iso4217USD">18000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000468" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">508000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000469" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">533000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000470" contextRef="C_0000907654_20130331" decimals="-3" unitRef="U_iso4217USD">486000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000471" contextRef="C_0000907654_20121231" decimals="-3" unitRef="U_iso4217USD">510000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000472" contextRef="C_0000907654_20130101_20130331" decimals="0" unitRef="U_iso4217USD">10000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000473" contextRef="C_0000907654_20120101_20120331" decimals="0" unitRef="U_iso4217USD">14000</us-gaap:DepreciationDepletionAndAmortization>
  <abio:DepreciationAndAmortizationExpenseSinceInception id="F_000474" contextRef="C_0000907654_20011217_20130331" decimals="-5" unitRef="U_iso4217USD">1800000</abio:DepreciationAndAmortizationExpenseSinceInception>
  <us-gaap:AreaOfRealEstateProperty id="F_000475" contextRef="C_0000907654_20080208" decimals="0" unitRef="U_utrsqft">15000</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:AreaOfRealEstateProperty id="F_000476" contextRef="C_0000907654_20110614" decimals="0" unitRef="U_utrsqft">4500</us-gaap:AreaOfRealEstateProperty>
  <abio:LeaseTerm id="F_000477" contextRef="C_0000907654_20130101_20130331">P5Y</abio:LeaseTerm>
  <abio:ExtendedLeaseTerm id="F_000478" contextRef="C_0000907654_20130101_20130331">P3Y</abio:ExtendedLeaseTerm>
  <abio:RightsToExtendTerm id="F_000479" contextRef="C_0000907654_20130101_20130331">Two additional three year periods</abio:RightsToExtendTerm>
  <abio:AllowToTerminateAgreement id="F_000480" contextRef="C_0000907654_20130101_20130331">P3M</abio:AllowToTerminateAgreement>
  <abio:OneTimePaymentToLandlordForNewLeasedPremises id="F_000481" contextRef="C_0000907654_20130101_20130331" decimals="0" unitRef="U_iso4217USD">200000</abio:OneTimePaymentToLandlordForNewLeasedPremises>
  <us-gaap:TenantReimbursements id="F_000482" contextRef="C_0000907654_20130101_20130331" decimals="0" unitRef="U_iso4217USD">593000</us-gaap:TenantReimbursements>
  <us-gaap:DeferredRentCredit id="F_000483" contextRef="C_0000907654_20130331" decimals="0" unitRef="U_iso4217USD">8000</us-gaap:DeferredRentCredit>
  <us-gaap:OperatingLeasesRentExpenseNet id="F_000484" contextRef="C_0000907654_20130101_20130331" decimals="0" unitRef="U_iso4217USD">12000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet id="F_000485" contextRef="C_0000907654_20120101_20120331" decimals="0" unitRef="U_iso4217USD">12000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet id="F_000486" contextRef="C_0000907654_20011217_20130331" decimals="0" unitRef="U_iso4217USD">527000</us-gaap:OperatingLeasesRentExpenseNet>
  <abio:LeaseMonthExpirationDate id="F_000487" contextRef="C_0000907654_20130101_20130331">2013-06</abio:LeaseMonthExpirationDate>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="F_000488" contextRef="C_0000907654_20130331" decimals="0" unitRef="U_iso4217USD">20000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <abio:MilestonePaymentMadeByCompany id="F_000489" contextRef="C_0000907654_20080701_20080731" decimals="0" unitRef="U_iso4217USD">500000</abio:MilestonePaymentMadeByCompany>
  <abio:ExpectedMilestonePaymentsUponApproval id="F_000490" contextRef="C_0000907654_20080731" decimals="-5" unitRef="U_iso4217USD">8000000</abio:ExpectedMilestonePaymentsUponApproval>
  <abio:AnotherExpectedMilestonePaymentsUponApproval id="F_000491" contextRef="C_0000907654_20080731" decimals="-5" unitRef="U_iso4217USD">5000000</abio:AnotherExpectedMilestonePaymentsUponApproval>
  <abio:MinimumPercentageOfRoyaltyObligation id="F_000492" contextRef="C_0000907654_20080701_20080731" decimals="INF" unitRef="U_xbrlipure">0.125</abio:MinimumPercentageOfRoyaltyObligation>
  <abio:MaximumPercentageOfRoyaltyObligation id="F_000493" contextRef="C_0000907654_20080701_20080731" decimals="INF" unitRef="U_xbrlipure">0.25</abio:MaximumPercentageOfRoyaltyObligation>
  <abio:PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement id="F_000494" contextRef="C_0000907654_20080701_20080731" decimals="2" unitRef="U_xbrlipure">0.05</abio:PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement>
  <abio:MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown id="F_000495" contextRef="C_0000907654_20080701_20080731" decimals="INF" unitRef="U_xbrlipure">0.125</abio:MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown>
  <abio:MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown id="F_000496" contextRef="C_0000907654_20080701_20080731" decimals="INF" unitRef="U_xbrlipure">0.17</abio:MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown>
  <abio:MilestonePaymentDuePeriod id="F_000497" contextRef="C_0000907654_20080701_20080731">P6M</abio:MilestonePaymentDuePeriod>
  <us-gaap:CommonStockSharesIssued id="F_000498" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130122" decimals="INF" unitRef="U_shares">356430</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000499" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130122" decimals="INF" unitRef="U_shares">249501</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommonStockIncludingAdditionalPaidInCapital id="F_000500" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130122" decimals="-6" unitRef="U_iso4217USD">1000000</us-gaap:CommonStockIncludingAdditionalPaidInCapital>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000501" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130101_20130122" decimals="-3" unitRef="U_iso4217USD">805000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <abio:PrivateInvestmentInPublicEquityOfferingCloseDate id="F_000502" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130122">2013-01-25</abio:PrivateInvestmentInPublicEquityOfferingCloseDate>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000503" contextRef="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130101_20130122" decimals="2" unitRef="U_shares">0.70</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <abio:PurchasePriceOfCommonStockUnit id="F_000504" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130101_20130122" decimals="2" unitRef="U_iso4217USD_abioUnit">2.81</abio:PurchasePriceOfCommonStockUnit>
  <abio:ClassOfWarrantOrRightExercisableExpirationPeriod id="F_000505" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130101_20130122">P7Y</abio:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <abio:ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares id="F_000506" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130122" decimals="0" unitRef="U_xbrlipure">1</abio:ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000507" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioPrivateInvestmentInPublicEquityTransactionMember_20130122" decimals="INF" unitRef="U_iso4217USD_abioUnit">2.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:CommonStockSharesIssued id="F_000508" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130131" decimals="0" unitRef="U_shares">164636</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000509" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130131" decimals="INF" unitRef="U_shares">65855</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommonStockIncludingAdditionalPaidInCapital id="F_000510" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130131" decimals="0" unitRef="U_iso4217USD">730000</us-gaap:CommonStockIncludingAdditionalPaidInCapital>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000511" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130101_20130131" decimals="-3" unitRef="U_iso4217USD">616000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <abio:RegisteredDirectOfferingCloseDate id="F_000512" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneOneEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130101_20130131">2013-02-04</abio:RegisteredDirectOfferingCloseDate>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000513" contextRef="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130101_20130131" decimals="INF" unitRef="U_shares">0.40</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <abio:PurchasePriceOfCommonStockUnit id="F_000514" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130101_20130131" decimals="2" unitRef="U_iso4217USD_abioUnit">4.43</abio:PurchasePriceOfCommonStockUnit>
  <abio:ClassOfWarrantOrRightExercisableExpirationPeriod id="F_000515" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130101_20130131">P5Y</abio:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000516" contextRef="C_0000907654_us-gaapFinancingAxis_abioTwoZeroOneThreeEquityFinancingsMember_us-gaapSaleAxis_abioRegisteredDirectOfferingMember_20130131" decimals="INF" unitRef="U_iso4217USD_abioUnit">4.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000517" contextRef="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_20130331" decimals="INF" unitRef="U_shares">1300000.0</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000518" contextRef="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_20130331" decimals="2" unitRef="U_iso4217USD_abioUnit">7.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000519" contextRef="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_us-gaapRangeAxis_us-gaapMaximumMember_20130331" decimals="2" unitRef="U_iso4217USD_abioUnit">116.89</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="F_000520" contextRef="C_0000907654_us-gaapDebtInstrumentAxis_us-gaapWarrantMember_us-gaapRangeAxis_us-gaapMinimumMember_20130331" decimals="2" unitRef="U_iso4217USD_abioUnit">1.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000521" contextRef="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapResearchAndDevelopmentExpenseMember_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000522" contextRef="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000523" contextRef="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapRestructuringChargesMember_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000524" contextRef="C_0000907654_20130101_20130331" decimals="-3" unitRef="U_iso4217USD">42000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000525" contextRef="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapResearchAndDevelopmentExpenseMember_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000526" contextRef="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">65000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000527" contextRef="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapRestructuringChargesMember_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000528" contextRef="C_0000907654_20120101_20120331" decimals="-3" unitRef="U_iso4217USD">91000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000529" contextRef="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapResearchAndDevelopmentExpenseMember_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">605000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000530" contextRef="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">1638000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000531" contextRef="C_0000907654_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_us-gaapRestructuringChargesMember_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">387000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000532" contextRef="C_0000907654_20011217_20130331" decimals="-3" unitRef="U_iso4217USD">2630000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000533" contextRef="C_0000907654_20121231" decimals="INF" unitRef="U_shares">144019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000534" xsi:nil="true" contextRef="C_0000907654_20130101_20130331" unitRef="U_shares" />
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000535" xsi:nil="true" contextRef="C_0000907654_20130101_20130331" unitRef="U_shares" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="F_000536" contextRef="C_0000907654_20130101_20130331" decimals="INF" unitRef="U_shares">6259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000537" contextRef="C_0000907654_20130331" decimals="INF" unitRef="U_shares">137760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000538" contextRef="C_0000907654_20130331" decimals="INF" unitRef="U_shares">123408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000539" contextRef="C_0000907654_20130331" decimals="INF" unitRef="U_shares">136208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000540" contextRef="C_0000907654_20121231" decimals="2" unitRef="U_iso4217USD_xbrlishares">18.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000541" contextRef="C_0000907654_20130101_20130331" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000542" contextRef="C_0000907654_20130101_20130331" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="F_000543" contextRef="C_0000907654_20130101_20130331" decimals="2" unitRef="U_iso4217USD_xbrlishares">16.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000544" contextRef="C_0000907654_20130331" decimals="2" unitRef="U_iso4217USD_xbrlishares">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000545" contextRef="C_0000907654_20130331" decimals="2" unitRef="U_iso4217USD_xbrlishares">18.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000546" contextRef="C_0000907654_20130331" decimals="2" unitRef="U_iso4217USD_xbrlishares">18.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000547" contextRef="C_0000907654_20120101_20121231">P4Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000548" contextRef="C_0000907654_20130101_20130331">P4Y10M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000549" contextRef="C_0000907654_20130101_20130331">P4Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000550" contextRef="C_0000907654_20130101_20130331">P4Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:IncomeTaxExaminationLiabilityRecorded id="F_000551" contextRef="C_0000907654_20130331" decimals="0" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationLiabilityRecorded>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>abio-20130331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2013-05-13T20:55:49.3389120+00:00 -->
<!-- Version            : 1.0.0.64 -->
<!-- Package ID         : 0EC0A1A677FC5574CCB8E2DAD25CAE4D-0000907654-001304 -->
<!-- Copyright (c) 2013 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/role/TemplateLink" xlink:href="abio-20130331.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="abio-20130331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="abio-20130331.xsd#abio_DocumentDocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="abio_DocumentDocumentAndEntityInformationLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="abio_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_DocumentDocumentAndEntityInformationLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" xlink:type="locator" xlink:label="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" xlink:to="us-gaap_AssetsAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedBalanceSheetsParentheticalUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="abio-20130331.xsd#abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:type="locator" xlink:label="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:type="locator" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_GainLossOnAssignmentOfPatentRights" xlink:type="locator" xlink:label="abio_GainLossOnAssignmentOfPatentRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:type="locator" xlink:label="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="abio_GainLossOnAssignmentOfPatentRights" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="11320.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11560.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount" order="11760.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="11840.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnaudited">
    <loc xlink:href="abio-20130331.xsd#abio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="abio_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <loc xlink:href="abio-20130331.xsd#abio_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator" xlink:label="abio_StockIssuedDuringPeriodValueWarrantsExercised" />
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" xlink:type="locator" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" xlink:type="locator" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_li0l2" />
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" xlink:type="locator" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentForFractionalShares" xlink:type="locator" xlink:label="abio_AdjustmentForFractionalShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="abio-20130331.xsd#abio_NotesAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_NotesAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_CommonConversionMember" xlink:type="locator" xlink:label="abio_CommonConversionMember" />
    <loc xlink:href="abio-20130331.xsd#abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" xlink:type="locator" xlink:label="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" />
    <loc xlink:href="abio-20130331.xsd#abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_AccretionOfSeriesBMember" xlink:type="locator" xlink:label="abio_AccretionOfSeriesBMember" />
    <loc xlink:href="abio-20130331.xsd#abio_AccretionOfSeriesMember" xlink:type="locator" xlink:label="abio_AccretionOfSeriesMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SeriesOfferingCostsMember" xlink:type="locator" xlink:label="abio_SeriesOfferingCostsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_CashNetOfOfferingCostsMember" xlink:type="locator" xlink:label="abio_CashNetOfOfferingCostsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_DeficitAccumulatedDuringDevelopmentStageMember" xlink:type="locator" xlink:label="abio_DeficitAccumulatedDuringDevelopmentStageMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesBMember" xlink:type="locator" xlink:label="us-gaap_SeriesBMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesAMember" xlink:type="locator" xlink:label="us-gaap_SeriesAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesAMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesBMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abio_DeficitAccumulatedDuringDevelopmentStageMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_CashNetOfOfferingCostsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SeriesOfferingCostsMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_AccretionOfSeriesMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_AccretionOfSeriesBMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_CommonConversionMember" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_NotesAndRelatedAccruedInterestMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="17600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="20080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="20300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="26800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AdjustmentForFractionalShares" order="28300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStockStock" order="28520.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="29300.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="29600.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" order="29860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_li0l2" order="30100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="30340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" order="30560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="30800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="31040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" order="32180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="32420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" order="32640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_StockIssuedDuringPeriodValueWarrantsExercised" order="39920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_StockIssuedDuringPeriodSharesWarrantsExercised" order="40160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnauditedParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="abio-20130331.xsd#abio_CommonStockMarketPricePerShare" xlink:type="locator" xlink:label="abio_CommonStockMarketPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesBMember" xlink:type="locator" xlink:label="us-gaap_SeriesBMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesAMember" xlink:type="locator" xlink:label="us-gaap_SeriesAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_CashNetOfOfferingCostsMember" xlink:type="locator" xlink:label="abio_CashNetOfOfferingCostsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_CashNetOfOfferingCostsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesAMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesBMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_CommonStockMarketPricePerShare" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:href="abio-20130331.xsd#abio_VendorFinanceAgreement" xlink:type="locator" xlink:label="abio_VendorFinanceAgreement" />
    <loc xlink:href="abio-20130331.xsd#abio_AccruedDeferredTransactionCosts" xlink:type="locator" xlink:label="abio_AccruedDeferredTransactionCosts" />
    <loc xlink:href="abio-20130331.xsd#abio_WarrantIssuedInConnectionWithCreditFacility" xlink:type="locator" xlink:label="abio_WarrantIssuedInConnectionWithCreditFacility" />
    <loc xlink:href="abio-20130331.xsd#abio_AccruedInterestOnNotesPayableConvertedToEquity" xlink:type="locator" xlink:label="abio_AccruedInterestOnNotesPayableConvertedToEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="abio-20130331.xsd#abio_RepaymentOfPrincipalOnVendorFinanceAgreement" xlink:type="locator" xlink:label="abio_RepaymentOfPrincipalOnVendorFinanceAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <loc xlink:href="abio-20130331.xsd#abio_WriteOffOfDeferredTaxLiability" xlink:type="locator" xlink:label="abio_WriteOffOfDeferredTaxLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionExpense" xlink:type="locator" xlink:label="us-gaap_AccretionExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_GainLossOnAssignmentOfPatentRights" xlink:type="locator" xlink:label="abio_GainLossOnAssignmentOfPatentRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10410.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="abio_GainLossOnAssignmentOfPatentRights" order="10840.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" order="10900.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionExpense" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="abio_WriteOffOfDeferredTaxLiability" order="11580.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="11660.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="11740.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="11820.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="12020.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="12140.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="12940.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="13020.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="13120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" order="13280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="13360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="13460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="13580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="13660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" order="13740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="13820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="13900.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="13980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="14280.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="14360.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="abio_RepaymentOfPrincipalOnVendorFinanceAgreement" order="14440.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="14540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="14660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="14780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" order="14860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="14940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="15060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="15160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="abio_AccruedInterestOnNotesPayableConvertedToEquity" order="15280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="abio_WarrantIssuedInConnectionWithCreditFacility" order="15360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="abio_AccruedDeferredTransactionCosts" order="15440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="abio_VendorFinanceAgreement" order="15520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="abio-20130331.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShare" xlink:href="abio-20130331.xsd#Role_DisclosureLossPerShare" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShare">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009" xlink:href="abio-20130331.xsd#Role_DisclosureMergerWithNuveloIncOnJanuary272009" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosures" xlink:href="abio-20130331.xsd#Role_DisclosureFairValueDisclosures" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosures">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="abio-20130331.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipment">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="abio-20130331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrants" xlink:href="abio-20130331.xsd#Role_DisclosureEquityFinancingsAndWarrants" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrants">
    <loc xlink:href="abio-20130331.xsd#abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="abio-20130331.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="abio-20130331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxes">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="abio-20130331.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:href="abio-20130331.xsd#abio_AccruedExpensesPolicyTextBlock" xlink:type="locator" xlink:label="abio_AccruedExpensesPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <loc xlink:href="abio-20130331.xsd#abio_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="abio_ReverseStockSplitPolicyTextBlock" />
    <loc xlink:href="abio-20130331.xsd#abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_ReverseStockSplitPolicyTextBlock" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AccruedExpensesPolicyTextBlock" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareTables" xlink:href="abio-20130331.xsd#Role_DisclosureLossPerShareTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="abio-20130331.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="abio-20130331.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="abio-20130331.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:href="abio-20130331.xsd#abio_RevenueGenerated" xlink:type="locator" xlink:label="abio_RevenueGenerated" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="abio-20130331.xsd#abio_TwoZeroOneThreeEquityFinancingsMember" xlink:type="locator" xlink:label="abio_TwoZeroOneThreeEquityFinancingsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingDomain" xlink:type="locator" xlink:label="us-gaap_FinancingDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingAxis" xlink:type="locator" xlink:label="us-gaap_FinancingAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="abio-20130331.xsd#abio_AnticipatedPeriodToStartAtrialFibrillationTrial" xlink:type="locator" xlink:label="abio_AnticipatedPeriodToStartAtrialFibrillationTrial" />
    <loc xlink:href="abio-20130331.xsd#abio_NumberOfPatientsCompanyPlansToEnroll" xlink:type="locator" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll" />
    <loc xlink:href="abio-20130331.xsd#abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:type="locator" xlink:label="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:to="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="abio_NumberOfPatientsCompanyPlansToEnroll" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="abio_AnticipatedPeriodToStartAtrialFibrillationTrial" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FinancingAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingAxis" xlink:to="us-gaap_FinancingDomain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingDomain" xlink:to="abio_TwoZeroOneThreeEquityFinancingsMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="abio_RevenueGenerated" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetails" xlink:href="abio-20130331.xsd#Role_DisclosureLossPerShareDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="abio-20130331.xsd#abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:type="locator" xlink:label="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureLossPerShareDetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureLossPerShareDetailsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_DisclosureLossPerShareDetailsLineItems" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DisclosureLossPerShareDetailsLineItems" xlink:to="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetailsTextual" xlink:href="abio-20130331.xsd#Role_DisclosureLossPerShareDetailsTextual" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetailsTextual">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_EarningsLossPerShareTextualAbstract" xlink:type="locator" xlink:label="abio_EarningsLossPerShareTextualAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureLossPerShareDetailsTextualLineItems" xlink:type="locator" xlink:label="abio_DisclosureLossPerShareDetailsTextualLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_DisclosureLossPerShareDetailsTextualLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DisclosureLossPerShareDetailsTextualLineItems" xlink:to="abio_EarningsLossPerShareTextualAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EarningsLossPerShareTextualAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009Details" xlink:href="abio-20130331.xsd#Role_DisclosureMergerWithNuveloIncOnJanuary272009Details" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009Details">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice" />
    <loc xlink:href="abio-20130331.xsd#abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:type="locator" xlink:label="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" xlink:to="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:to="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosuresDetails" xlink:href="abio-20130331.xsd#Role_DisclosureFairValueDisclosuresDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosuresDetails">
    <loc xlink:href="abio-20130331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" xlink:type="locator" xlink:label="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" />
    <loc xlink:href="abio-20130331.xsd#abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:type="locator" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="abio-20130331.xsd#abio_FairValueDisclosuresTextualAbstract" xlink:type="locator" xlink:label="abio_FairValueDisclosuresTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="abio_FairValueDisclosuresTextualAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_FairValueDisclosuresTextualAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="abio_FairValueDisclosuresAdditionalTextualAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetails" xlink:href="abio-20130331.xsd#Role_DisclosurePropertyAndEquipmentDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="abio-20130331.xsd#abio_LeaseholdImprovementsUsefulLife" xlink:type="locator" xlink:label="abio_LeaseholdImprovementsUsefulLife" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="abio-20130331.xsd#abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:type="locator" xlink:label="abio_ComponentsOfPropertyAndEquipmentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="abio_ComponentsOfPropertyAndEquipmentAbstract" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="abio_LeaseholdImprovementsUsefulLife" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="11220.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual" xlink:href="abio-20130331.xsd#Role_DisclosurePropertyAndEquipmentDetailsTextual" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual">
    <loc xlink:href="abio-20130331.xsd#abio_DepreciationAndAmortizationExpenseSinceInception" xlink:type="locator" xlink:label="abio_DepreciationAndAmortizationExpenseSinceInception" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="abio-20130331.xsd#abio_PropertyAndEquipmentTextualAbstract" xlink:type="locator" xlink:label="abio_PropertyAndEquipmentTextualAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" xlink:type="locator" xlink:label="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" xlink:to="abio_PropertyAndEquipmentTextualAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_PropertyAndEquipmentTextualAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_PropertyAndEquipmentTextualAbstract" xlink:to="abio_DepreciationAndAmortizationExpenseSinceInception" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails" xlink:href="abio-20130331.xsd#Role_DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails">
    <loc xlink:href="abio-20130331.xsd#abio_MilestonePaymentDuePeriod" xlink:type="locator" xlink:label="abio_MilestonePaymentDuePeriod" />
    <loc xlink:href="abio-20130331.xsd#abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <loc xlink:href="abio-20130331.xsd#abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <loc xlink:href="abio-20130331.xsd#abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" xlink:type="locator" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" />
    <loc xlink:href="abio-20130331.xsd#abio_MaximumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRoyaltyObligation" />
    <loc xlink:href="abio-20130331.xsd#abio_MinimumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRoyaltyObligation" />
    <loc xlink:href="abio-20130331.xsd#abio_AnotherExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval" />
    <loc xlink:href="abio-20130331.xsd#abio_ExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_ExpectedMilestonePaymentsUponApproval" />
    <loc xlink:href="abio-20130331.xsd#abio_MilestonePaymentMadeByCompany" xlink:type="locator" xlink:label="abio_MilestonePaymentMadeByCompany" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="abio-20130331.xsd#abio_LeaseMonthExpirationDate" xlink:type="locator" xlink:label="abio_LeaseMonthExpirationDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TenantReimbursements" xlink:type="locator" xlink:label="us-gaap_TenantReimbursements" />
    <loc xlink:href="abio-20130331.xsd#abio_OneTimePaymentToLandlordForNewLeasedPremises" xlink:type="locator" xlink:label="abio_OneTimePaymentToLandlordForNewLeasedPremises" />
    <loc xlink:href="abio-20130331.xsd#abio_AllowToTerminateAgreement" xlink:type="locator" xlink:label="abio_AllowToTerminateAgreement" />
    <loc xlink:href="abio-20130331.xsd#abio_RightsToExtendTerm" xlink:type="locator" xlink:label="abio_RightsToExtendTerm" />
    <loc xlink:href="abio-20130331.xsd#abio_ExtendedLeaseTerm" xlink:type="locator" xlink:label="abio_ExtendedLeaseTerm" />
    <loc xlink:href="abio-20130331.xsd#abio_LeaseTerm" xlink:type="locator" xlink:label="abio_LeaseTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <loc xlink:href="abio-20130331.xsd#abio_CommitmentsAndContingenciesTextualAbstract" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" xlink:to="abio_CommitmentsAndContingenciesTextualAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_LeaseTerm" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_ExtendedLeaseTerm" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_RightsToExtendTerm" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_AllowToTerminateAgreement" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_OneTimePaymentToLandlordForNewLeasedPremises" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_TenantReimbursements" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_DeferredRentCredit" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_LeaseMonthExpirationDate" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MilestonePaymentMadeByCompany" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_ExpectedMilestonePaymentsUponApproval" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_AnotherExpectedMilestonePaymentsUponApproval" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MinimumPercentageOfRoyaltyObligation" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MaximumPercentageOfRoyaltyObligation" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MilestonePaymentDuePeriod" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetails" xlink:href="abio-20130331.xsd#Role_DisclosureEquityFinancingsAndWarrantsDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_RegisteredDirectOfferingCloseDate" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingCloseDate" />
    <loc xlink:href="abio-20130331.xsd#abio_TwoZeroOneOneEquityFinancingsMember" xlink:type="locator" xlink:label="abio_TwoZeroOneOneEquityFinancingsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_RegisteredDirectOfferingMember" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <loc xlink:href="abio-20130331.xsd#abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" />
    <loc xlink:href="abio-20130331.xsd#abio_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" />
    <loc xlink:href="abio-20130331.xsd#abio_PurchasePriceOfCommonStockUnit" xlink:type="locator" xlink:label="abio_PurchasePriceOfCommonStockUnit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_PrivateInvestmentInPublicEquityOfferingCloseDate" xlink:type="locator" xlink:label="abio_PrivateInvestmentInPublicEquityOfferingCloseDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="abio-20130331.xsd#abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <loc xlink:href="abio-20130331.xsd#abio_TwoZeroOneThreeEquityFinancingsMember" xlink:type="locator" xlink:label="abio_TwoZeroOneThreeEquityFinancingsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingDomain" xlink:type="locator" xlink:label="us-gaap_FinancingDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingAxis" xlink:type="locator" xlink:label="us-gaap_FinancingAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_PrivateInvestmentInPublicEquityTransactionMember" xlink:type="locator" xlink:label="abio_PrivateInvestmentInPublicEquityTransactionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleDomain" xlink:type="locator" xlink:label="us-gaap_SaleDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleAxis" xlink:type="locator" xlink:label="us-gaap_SaleAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SaleAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleAxis" xlink:to="us-gaap_SaleDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleDomain" xlink:to="abio_PrivateInvestmentInPublicEquityTransactionMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_FinancingAxis" order="10020.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingAxis" xlink:to="us-gaap_FinancingDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingDomain" xlink:to="abio_TwoZeroOneThreeEquityFinancingsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapital" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PrivateInvestmentInPublicEquityOfferingCloseDate" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10020.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_WarrantMember" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="abio_EquityFinancingsAndWarrantsTextualAbstract" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PurchasePriceOfCommonStockUnit" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleDomain" xlink:to="abio_RegisteredDirectOfferingMember" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancingDomain" xlink:to="abio_TwoZeroOneOneEquityFinancingsMember" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_RegisteredDirectOfferingCloseDate" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RangeAxis" order="10020.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="12790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="12810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails" xlink:href="abio-20130331.xsd#Role_DisclosureShareBasedCompensationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:type="locator" xlink:label="us-gaap_RestructuringChargesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" order="10020.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_RestructuringChargesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails1" xlink:href="abio-20130331.xsd#Role_DisclosureShareBasedCompensationDetails1" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails1">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureShareBasedCompensationDetails1LineItems" xlink:type="locator" xlink:label="abio_DisclosureShareBasedCompensationDetails1LineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_DisclosureShareBasedCompensationDetails1LineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DisclosureShareBasedCompensationDetails1LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10540.00" priority="2" use="optional" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxesDetails" xlink:href="abio-20130331.xsd#Role_DisclosureIncomeTaxesDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExaminationLiabilityRecorded" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRecorded" />
    <loc xlink:href="abio-20130331.xsd#abio_IncomeTaxesTextualAbstract" xlink:type="locator" xlink:label="abio_IncomeTaxesTextualAbstract" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureIncomeTaxesDetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureIncomeTaxesDetailsLineItems" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="abio_DisclosureIncomeTaxesDetailsLineItems" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_DisclosureIncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesTextualAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRecorded" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>abio-20130331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2013-05-13T20:55:49.3389120+00:00 -->
<!-- Version            : 1.0.0.64 -->
<!-- Package ID         : 0EC0A1A677FC5574CCB8E2DAD25CAE4D-0000907654-001304 -->
<!-- Copyright (c) 2013 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://xbrl.us/us-gaap/role/label/negated" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" xlink:type="simple" />
  <roleRef roleURI="http://xbrl.us/us-gaap/role/label/negatedTotal" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negatedTotal" xlink:type="simple" />
  <roleRef roleURI="http://xbrl.us/us-gaap/role/label/negatedPeriodEnd" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negatedPeriodEnd" xlink:type="simple" />
  <roleRef roleURI="http://xbrl.us/us-gaap/role/label/negatedPeriodStart" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negatedPeriodStart" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="abio-20130331.xsd#abio_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="abio_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="abio_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document and entity information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DocumentAndEntityInformationAbstract" xlink:to="abio_DocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Abstract]</label>
    <loc xlink:href="abio-20130331.xsd#abio_DocumentDocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="abio_DocumentDocumentAndEntityInformationLineItems" />
    <label xml:lang="en-US" xlink:label="abio_DocumentDocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document - Document and Entity Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="abio_DocumentDocumentAndEntityInformationLineItems_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</label>
    <label xml:lang="en-US" xlink:label="abio_DocumentDocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Document And Entity Information [Line Items]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="abio-20130331.xsd#abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" xlink:type="locator" xlink:label="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" />
    <label xml:lang="en-US" xlink:label="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement - Consolidated Balance Sheets (unaudited) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" xlink:to="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Consolidated Balance Sheets Unaudited [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 100 million shares authorized at March 31, 2013 and December 31, 2012; 3,185,562 and 2,660,315 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deficit accumulated during the development stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="abio-20130331.xsd#abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:type="locator" xlink:label="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" />
    <label xml:lang="en-US" xlink:label="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement - Consolidated Balance Sheets (Parenthetical) (unaudited) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Consolidated Balance Sheets Parenthetical Unaudited [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="abio-20130331.xsd#abio_GainLossOnAssignmentOfPatentRights" xlink:type="locator" xlink:label="abio_GainLossOnAssignmentOfPatentRights" />
    <label xml:lang="en-US" xlink:label="abio_GainLossOnAssignmentOfPatentRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The gain or loss on transfer of all or part of the rights and interests in certain patents and patent applications.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_GainLossOnAssignmentOfPatentRights" xlink:to="abio_GainLossOnAssignmentOfPatentRights_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <loc xlink:href="abio-20130331.xsd#abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:type="locator" xlink:label="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" />
    <label xml:lang="en-US" xlink:label="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement - Consolidated Statements of Operations and Comprehensive Loss (unaudited) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Consolidated Statements Of Operations And Comprehensive Loss Unaudited [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs And Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Acquisition Related Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on impairment of in-process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Excluding Goodwill</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <label xml:lang="en-US" xlink:label="abio_GainLossOnAssignmentOfPatentRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on assignment of patent rights</label>
    <label xml:lang="en-US" xlink:label="abio_GainLossOnAssignmentOfPatentRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Assignment Of Patent Rights</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on bargain purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:to="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Bargain Purchase Gain Recognized Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Interest and other expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Benefit from income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:type="locator" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Less: Accretion of redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Accretion Of Redemption Discount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Less: Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends And Other Adjustments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Of Stockholders Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesAMember" xlink:type="locator" xlink:label="us-gaap_SeriesAMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAMember" xlink:to="us-gaap_SeriesAMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesBMember" xlink:type="locator" xlink:label="us-gaap_SeriesBMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBMember" xlink:to="us-gaap_SeriesBMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_DeficitAccumulatedDuringDevelopmentStageMember" xlink:type="locator" xlink:label="abio_DeficitAccumulatedDuringDevelopmentStageMember" />
    <label xml:lang="en-US" xlink:label="abio_DeficitAccumulatedDuringDevelopmentStageMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deficit accumulated during development stage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeficitAccumulatedDuringDevelopmentStageMember" xlink:to="abio_DeficitAccumulatedDuringDevelopmentStageMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DeficitAccumulatedDuringDevelopmentStageMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deficit Accumulated During the Development Stage</label>
    <label xml:lang="en-US" xlink:label="abio_DeficitAccumulatedDuringDevelopmentStageMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deficit Accumulated During Development Stage [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</label>
    <loc xlink:href="abio-20130331.xsd#abio_CashNetOfOfferingCostsMember" xlink:type="locator" xlink:label="abio_CashNetOfOfferingCostsMember" />
    <label xml:lang="en-US" xlink:label="abio_CashNetOfOfferingCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, net of offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashNetOfOfferingCostsMember" xlink:to="abio_CashNetOfOfferingCostsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_CashNetOfOfferingCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Net of Offering Costs</label>
    <label xml:lang="en-US" xlink:label="abio_CashNetOfOfferingCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Net Of Offering Costs [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <label xml:lang="en-US" xlink:label="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First issuance for notes payable and related accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:to="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Notes Payable and Related Accrued Interest on January 3, 2005</label>
    <label xml:lang="en-US" xlink:label="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Issuance For Notes Payable And Related Accrued Interest [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <label xml:lang="en-US" xlink:label="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First issuance of stock for intellectual property license rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:to="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Intellectual Property License Rights on October 14, 2005</label>
    <label xml:lang="en-US" xlink:label="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Issuance Of Stock For Intellectual Property License Rights [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second issuance for notes payable and related accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:to="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Notes Payable and Related Accrued Interest on October 14, 2005</label>
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Issuance For Notes Payable And Related Accrued Interest [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second issuance of stock for intellectual property license rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:to="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Intellectual Property License Rights on February 21, 2006</label>
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Issuance Of Stock For Intellectual Property License Rights [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First issuance of series convertible redeemable preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:to="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A on February 22, 2006</label>
    <label xml:lang="en-US" xlink:label="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Issuance Of Series Convertible Redeemable Preferred Stock [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <label xml:lang="en-US" xlink:label="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Third issuance for notes payable and related accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:to="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Issuance for Notes Payable and Related Accrued Interest</label>
    <label xml:lang="en-US" xlink:label="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Third Issuance For Notes Payable And Related Accrued Interest [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <label xml:lang="en-US" xlink:label="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Third issuance of stock for intellectual property license rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:to="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Intellectual Property License Rights on February 22, 2006</label>
    <label xml:lang="en-US" xlink:label="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Third Issuance Of Stock For Intellectual Property License Rights [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <label xml:lang="en-US" xlink:label="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fourth issuance of stock for intellectual property license rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:to="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Intellectual Property License Rights on June 23, 2006</label>
    <label xml:lang="en-US" xlink:label="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fourth Issuance Of Stock For Intellectual Property License Rights [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <label xml:lang="en-US" xlink:label="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fifth issuance of stock for intellectual property license rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:to="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Intellectual Property License Rights on November 7, 2006</label>
    <label xml:lang="en-US" xlink:label="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fifth Issuance Of Stock For Intellectual Property License Rights [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second issuance of series convertible redeemable preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:to="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A on December 8, 2006</label>
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Issuance Of Series Convertible Redeemable Preferred Stock [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_SeriesOfferingCostsMember" xlink:type="locator" xlink:label="abio_SeriesOfferingCostsMember" />
    <label xml:lang="en-US" xlink:label="abio_SeriesOfferingCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A offering costs..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeriesOfferingCostsMember" xlink:to="abio_SeriesOfferingCostsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_SeriesOfferingCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A offering costs</label>
    <label xml:lang="en-US" xlink:label="abio_SeriesOfferingCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series Offering Costs [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Third issuance of series B convertible redeemable preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:to="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Series B on May 31, 2007</label>
    <label xml:lang="en-US" xlink:label="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Third Issuance Of Series B Convertible Redeemable Preferred Stock [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second issuance of series B convertible redeemable preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:to="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Series B on December 28, 2007</label>
    <label xml:lang="en-US" xlink:label="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Issuance Of Series B Convertible Redeemable Preferred Stock [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_AccretionOfSeriesMember" xlink:type="locator" xlink:label="abio_AccretionOfSeriesMember" />
    <label xml:lang="en-US" xlink:label="abio_AccretionOfSeriesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of series A.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccretionOfSeriesMember" xlink:to="abio_AccretionOfSeriesMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AccretionOfSeriesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of Series A</label>
    <label xml:lang="en-US" xlink:label="abio_AccretionOfSeriesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Series [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_AccretionOfSeriesBMember" xlink:type="locator" xlink:label="abio_AccretionOfSeriesBMember" />
    <label xml:lang="en-US" xlink:label="abio_AccretionOfSeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of series B.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccretionOfSeriesBMember" xlink:to="abio_AccretionOfSeriesBMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AccretionOfSeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of Series B</label>
    <label xml:lang="en-US" xlink:label="abio_AccretionOfSeriesBMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Series B [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <label xml:lang="en-US" xlink:label="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sixth issuance of stock for intellectual property license rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:to="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Intellectual Property License Rights on January 18, 2007</label>
    <label xml:lang="en-US" xlink:label="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sixth Issuance Of Stock For Intellectual Property License Rights [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <label xml:lang="en-US" xlink:label="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Seventh issuance of stock for intellectual property license rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:to="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance for Intellectual Property License Rights on June 30, 2007</label>
    <label xml:lang="en-US" xlink:label="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Seventh Issuance Of Stock For Intellectual Property License Rights [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" />
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for commercial license rights.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" xlink:to="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Common Stock for Commercial License Rights, on July 19, 2007</label>
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock For Commercial License Rights [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" xlink:type="locator" xlink:label="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" />
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of shares to executive subject to repurchase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" xlink:to="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Shares to Executive Subject to Repurchase</label>
    <label xml:lang="en-US" xlink:label="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Shares To Executive Subject To Repurchase [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_CommonConversionMember" xlink:type="locator" xlink:label="abio_CommonConversionMember" />
    <label xml:lang="en-US" xlink:label="abio_CommonConversionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common conversion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonConversionMember" xlink:to="abio_CommonConversionMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_CommonConversionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Conversion</label>
    <label xml:lang="en-US" xlink:label="abio_CommonConversionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Conversion [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_NotesAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_NotesAndRelatedAccruedInterestMember" />
    <label xml:lang="en-US" xlink:label="abio_NotesAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes and related accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NotesAndRelatedAccruedInterestMember" xlink:to="abio_NotesAndRelatedAccruedInterestMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_NotesAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes and Related Accrued Interest</label>
    <label xml:lang="en-US" xlink:label="abio_NotesAndRelatedAccruedInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes And Related Accrued Interest [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock for cash, net of offering costs, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock for cash, net of offering costs, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, value</label>
    <label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, for cash, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, for cash, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of warrants issued in connection with convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Warrant Issued</label>
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentForFractionalShares" xlink:type="locator" xlink:label="abio_AdjustmentForFractionalShares" />
    <label xml:lang="en-US" xlink:label="abio_AdjustmentForFractionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment for fractional shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AdjustmentForFractionalShares" xlink:to="abio_AdjustmentForFractionalShares_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AdjustmentForFractionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment for fractional shares</label>
    <label xml:lang="en-US" xlink:label="abio_AdjustmentForFractionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment For Fractional Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Deemed preferred stock dividend for additional common shares issuable under anti-dilution provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Preferred Stock Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Conversion of preferred stock and convertible notes and related accrued interest, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Conversion of preferred stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Units</label>
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" xlink:type="locator" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" />
    <label xml:lang="en-US" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The adjustment to additional paid in capital to record the release of restriction agreements on stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" xlink:to="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock release from restriction</label>
    <label xml:lang="en-US" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment To Additional Paid In Capital Restricted Stock Release From Restriction</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock and convertible notes and related accrued interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</label>
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" xlink:type="locator" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" />
    <label xml:lang="en-US" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount recorded to additional Paid in Capital account as a result of the conversion of warrants for preferred stock to outstanding common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" xlink:to="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of warrants for preferred stock</label>
    <label xml:lang="en-US" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment To Additional Paid In Capital Conversion Of Warrants For Preferred Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger with Nuvelo, Inc., value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Acquisitions</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger with Nuvelo, Inc., shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Acquisitions</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Ownership Plan</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Ownership Plan</label>
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" xlink:type="locator" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" />
    <label xml:lang="en-US" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment to additional paid in capital estimated fair value of warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" xlink:to="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of warrants issued in connection with lease termination</label>
    <label xml:lang="en-US" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment To Additional Paid In Capital Estimated Fair Value Of Warrants Issued</label>
    <loc xlink:href="abio-20130331.xsd#abio_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator" xlink:label="abio_StockIssuedDuringPeriodValueWarrantsExercised" />
    <label xml:lang="en-US" xlink:label="abio_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="abio_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="abio_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants for cash, value</label>
    <label xml:lang="en-US" xlink:label="abio_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Warrants Exercised</label>
    <loc xlink:href="abio-20130331.xsd#abio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="abio_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <label xml:lang="en-US" xlink:label="abio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="abio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="abio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of warrants for cash, shares</label>
    <label xml:lang="en-US" xlink:label="abio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrants Exercised</label>
    <loc xlink:href="abio-20130331.xsd#abio_CommonStockMarketPricePerShare" xlink:type="locator" xlink:label="abio_CommonStockMarketPricePerShare" />
    <label xml:lang="en-US" xlink:label="abio_CommonStockMarketPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock market price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockMarketPricePerShare" xlink:to="abio_CommonStockMarketPricePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="abio_CommonStockMarketPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock market price per share</label>
    <label xml:lang="en-US" xlink:label="abio_CommonStockMarketPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Market Price Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="abio-20130331.xsd#abio_RepaymentOfPrincipalOnVendorFinanceAgreement" xlink:type="locator" xlink:label="abio_RepaymentOfPrincipalOnVendorFinanceAgreement" />
    <label xml:lang="en-US" xlink:label="abio_RepaymentOfPrincipalOnVendorFinanceAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment of principal on vendor finance agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RepaymentOfPrincipalOnVendorFinanceAgreement" xlink:to="abio_RepaymentOfPrincipalOnVendorFinanceAgreement_lbl" />
    <loc xlink:href="abio-20130331.xsd#abio_WriteOffOfDeferredTaxLiability" xlink:type="locator" xlink:label="abio_WriteOffOfDeferredTaxLiability" />
    <label xml:lang="en-US" xlink:label="abio_WriteOffOfDeferredTaxLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The write off of deferred tax liability associated with the impairment of the in-process research and development asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WriteOffOfDeferredTaxLiability" xlink:to="abio_WriteOffOfDeferredTaxLiability_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_GainLossOnAssignmentOfPatentRights_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Gain on patent rights assignment</label>
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Gain on bargain purchase</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paid In Kind Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants for lease termination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock And Warrants For Services Or Claims</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionExpense" xlink:type="locator" xlink:label="us-gaap_AccretionExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</label>
    <label xml:lang="en-US" xlink:label="abio_WriteOffOfDeferredTaxLiability_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Write-off of deferred tax liability</label>
    <label xml:lang="en-US" xlink:label="abio_WriteOffOfDeferredTaxLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Write Off Of Deferred Tax Liability</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Gain on marketable securities available for sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Gain Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">(Gain) loss from disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Other, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities (net of amounts acquired):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Charges</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows provided by (used in) investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received from Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired From Acquisition</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Payment of deferred transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Payments To Acquire Businesses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from patent rights assignment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Intangible Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows provided by (used in) financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible notes payable and related warrants for common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of bank note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Notes Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from stock subject to repurchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Redeemable Preferred Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Payment of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Repayment of principal on bank note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Notes Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Repayment of principal on convertible notes payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Convertible Debt</label>
    <label xml:lang="en-US" xlink:label="abio_RepaymentOfPrincipalOnVendorFinanceAgreement_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Repayment of principal on vendor finance agreement</label>
    <label xml:lang="en-US" xlink:label="abio_RepaymentOfPrincipalOnVendorFinanceAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayment Of Principal On Vendor Finance Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and financing transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <loc xlink:href="abio-20130331.xsd#abio_AccruedInterestOnNotesPayableConvertedToEquity" xlink:type="locator" xlink:label="abio_AccruedInterestOnNotesPayableConvertedToEquity" />
    <label xml:lang="en-US" xlink:label="abio_AccruedInterestOnNotesPayableConvertedToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of the interest accrued on notes payable that was recorded by the Company but converted by the holder to equity during the period that resulted in a noncash transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedInterestOnNotesPayableConvertedToEquity" xlink:to="abio_AccruedInterestOnNotesPayableConvertedToEquity_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AccruedInterestOnNotesPayableConvertedToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest on notes payable converted to equity</label>
    <label xml:lang="en-US" xlink:label="abio_AccruedInterestOnNotesPayableConvertedToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest On Notes Payable Converted To Equity</label>
    <loc xlink:href="abio-20130331.xsd#abio_WarrantIssuedInConnectionWithCreditFacility" xlink:type="locator" xlink:label="abio_WarrantIssuedInConnectionWithCreditFacility" />
    <label xml:lang="en-US" xlink:label="abio_WarrantIssuedInConnectionWithCreditFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The non-cash value of warrants issued in connection with a bank credit facility.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WarrantIssuedInConnectionWithCreditFacility" xlink:to="abio_WarrantIssuedInConnectionWithCreditFacility_lbl" />
    <label xml:lang="en-US" xlink:label="abio_WarrantIssuedInConnectionWithCreditFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued in connection with credit facility</label>
    <label xml:lang="en-US" xlink:label="abio_WarrantIssuedInConnectionWithCreditFacility_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Issued In Connection With Credit Facility</label>
    <loc xlink:href="abio-20130331.xsd#abio_AccruedDeferredTransactionCosts" xlink:type="locator" xlink:label="abio_AccruedDeferredTransactionCosts" />
    <label xml:lang="en-US" xlink:label="abio_AccruedDeferredTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred transaction costs accrued at the end of the respective period and applied to proceeds in the subsequent period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedDeferredTransactionCosts" xlink:to="abio_AccruedDeferredTransactionCosts_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AccruedDeferredTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued deferred transaction costs</label>
    <label xml:lang="en-US" xlink:label="abio_AccruedDeferredTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Deferred Transaction Costs</label>
    <loc xlink:href="abio-20130331.xsd#abio_VendorFinanceAgreement" xlink:type="locator" xlink:label="abio_VendorFinanceAgreement" />
    <label xml:lang="en-US" xlink:label="abio_VendorFinanceAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vendor finance agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_VendorFinanceAgreement" xlink:to="abio_VendorFinanceAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="abio_VendorFinanceAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vendor finance agreement</label>
    <label xml:lang="en-US" xlink:label="abio_VendorFinanceAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vendor Finance Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger with Nuvelo, Inc. on January 27, 2009</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</label>
    <loc xlink:href="abio-20130331.xsd#abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity financings and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:to="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Financings and Warrants</label>
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financings And Warrants Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Accounting Policies [Text Block]</label>
    <loc xlink:href="abio-20130331.xsd#abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development stage risks liquidity and going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Stage Risks, Liquidity and Going Concern</label>
    <label xml:lang="en-US" xlink:label="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Stage Risks Liquidity And Going Concern Policy [Text Block]</label>
    <loc xlink:href="abio-20130331.xsd#abio_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="abio_ReverseStockSplitPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="abio_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ReverseStockSplitPolicyTextBlock" xlink:to="abio_ReverseStockSplitPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</label>
    <label xml:lang="en-US" xlink:label="abio_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</label>
    <loc xlink:href="abio-20130331.xsd#abio_AccruedExpensesPolicyTextBlock" xlink:type="locator" xlink:label="abio_AccruedExpensesPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="abio_AccruedExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for estimating costs incurred that have not yet been billed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedExpensesPolicyTextBlock" xlink:to="abio_AccruedExpensesPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AccruedExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</label>
    <label xml:lang="en-US" xlink:label="abio_AccruedExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" xlink:to="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Calculation Of Numerator And Denominator In Earnings Per Share Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash, Share-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <loc xlink:href="abio-20130331.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" />
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Company and Summary of Significant Accounting Policies Table [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems_lbl" />
    <loc xlink:href="abio-20130331.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" />
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Company and summary of significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company And Summary Of Significant Accounting Policies [Table]</label>
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Company And Summary Of Significant Accounting Policies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company And Summary Of Significant Accounting Policies Table [Line Items]</label>
    <label xml:lang="en-US" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Company And Summary Of Significant Accounting Policies Table [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:type="locator" xlink:label="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Company development stage, and basis of presentation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company Development Stage and Basis of Presentation (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Company Development Stage And Basis Of Presentation Textual [Abstract]</label>
    <loc xlink:href="abio-20130331.xsd#abio_NumberOfPatientsCompanyPlansToEnroll" xlink:type="locator" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll" />
    <label xml:lang="en-US" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of patients company plans to enroll.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfPatientsCompanyPlansToEnroll" xlink:to="abio_NumberOfPatientsCompanyPlansToEnroll_lbl" />
    <label xml:lang="en-US" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of patients company plans to enroll</label>
    <label xml:lang="en-US" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Patients Company Plans To Enroll</label>
    <loc xlink:href="abio-20130331.xsd#abio_AnticipatedPeriodToStartAtrialFibrillationTrial" xlink:type="locator" xlink:label="abio_AnticipatedPeriodToStartAtrialFibrillationTrial" />
    <label xml:lang="en-US" xlink:label="abio_AnticipatedPeriodToStartAtrialFibrillationTrial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Anticipated period to start atrial fibrillation trial.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AnticipatedPeriodToStartAtrialFibrillationTrial" xlink:to="abio_AnticipatedPeriodToStartAtrialFibrillationTrial_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AnticipatedPeriodToStartAtrialFibrillationTrial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anticipated time to start AF Trial</label>
    <label xml:lang="en-US" xlink:label="abio_AnticipatedPeriodToStartAtrialFibrillationTrial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Anticipated Period To Start Atrial Fibrillation Trial</label>
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingAxis" xlink:type="locator" xlink:label="us-gaap_FinancingAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingAxis" xlink:to="us-gaap_FinancingAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financing [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingDomain" xlink:type="locator" xlink:label="us-gaap_FinancingDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingDomain" xlink:to="us-gaap_FinancingDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financing [Domain]</label>
    <loc xlink:href="abio-20130331.xsd#abio_TwoZeroOneThreeEquityFinancingsMember" xlink:type="locator" xlink:label="abio_TwoZeroOneThreeEquityFinancingsMember" />
    <label xml:lang="en-US" xlink:label="abio_TwoZeroOneThreeEquityFinancingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2013 Equity Financings.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoZeroOneThreeEquityFinancingsMember" xlink:to="abio_TwoZeroOneThreeEquityFinancingsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_TwoZeroOneThreeEquityFinancingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Equity Financings</label>
    <label xml:lang="en-US" xlink:label="abio_TwoZeroOneThreeEquityFinancingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero One Three Equity Financings [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fund raised through sale of common stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</label>
    <loc xlink:href="abio-20130331.xsd#abio_RevenueGenerated" xlink:type="locator" xlink:label="abio_RevenueGenerated" />
    <label xml:lang="en-US" xlink:label="abio_RevenueGenerated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue generated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RevenueGenerated" xlink:to="abio_RevenueGenerated_lbl" />
    <label xml:lang="en-US" xlink:label="abio_RevenueGenerated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue generated by the company</label>
    <label xml:lang="en-US" xlink:label="abio_RevenueGenerated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Generated</label>
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureLossPerShareDetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureLossPerShareDetailsLineItems" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureLossPerShareDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Loss Per Share (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DisclosureLossPerShareDetailsLineItems" xlink:to="abio_DisclosureLossPerShareDetailsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureLossPerShareDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Loss Per Share Details [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:type="locator" xlink:label="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reconciliation of numerator and denominator used in the calculation of basic and diluted loss per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of basic and diluted loss per share</label>
    <label xml:lang="en-US" xlink:label="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Numerator And Denominator Used In Calculation Of Basic And Diluted Loss Per Share [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Weighted-average shares of unvested common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total weighted-average shares used in computing net loss per share attributed to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Issued Basic</label>
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic and diluted loss per share</label>
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureLossPerShareDetailsTextualLineItems" xlink:type="locator" xlink:label="abio_DisclosureLossPerShareDetailsTextualLineItems" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureLossPerShareDetailsTextualLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Loss Per Share (Details Textual) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DisclosureLossPerShareDetailsTextualLineItems" xlink:to="abio_DisclosureLossPerShareDetailsTextualLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureLossPerShareDetailsTextualLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Loss Per Share Details Textual [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_EarningsLossPerShareTextualAbstract" xlink:type="locator" xlink:label="abio_EarningsLossPerShareTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_EarningsLossPerShareTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnings loss per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EarningsLossPerShareTextualAbstract" xlink:to="abio_EarningsLossPerShareTextualAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_EarningsLossPerShareTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings (Loss) Per Share (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_EarningsLossPerShareTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Loss Per Share Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Merger with Nuvelo, Inc. on January 27, 2009 (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" xlink:to="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Merger With Nuvelo Inc On January272009 Details [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:type="locator" xlink:label="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger on January 27, 2009.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:to="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger with Nuvelo, Inc. On January 27, 2009 (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Merger On January Two Seven Two Zero Zero Nine Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated total acquisition consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Cost Of Acquired Entity Purchase Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net assets acquired in the Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Purchase Price Allocation Assets Acquired Liabilities Assumed Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net assets acquired, including cash, cash equivalents and marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Purchase Price Allocation Current Assets Cash And Cash Equivalents</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Balance Sheet Grouping [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Asset Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_FairValueDisclosuresTextualAbstract" xlink:type="locator" xlink:label="abio_FairValueDisclosuresTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_FairValueDisclosuresTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosures (Textual) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresTextualAbstract" xlink:to="abio_FairValueDisclosuresTextualAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FairValueDisclosuresTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents consisting of money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</label>
    <loc xlink:href="abio-20130331.xsd#abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:type="locator" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Disclosures (Additional Textual) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="abio_FairValueDisclosuresAdditionalTextualAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosures (Additional Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures Additional Textual [Abstract]</label>
    <loc xlink:href="abio-20130331.xsd#abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" xlink:type="locator" xlink:label="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" />
    <label xml:lang="en-US" xlink:label="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents consisting of money market funds with maturities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" xlink:to="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities_lbl" />
    <label xml:lang="en-US" xlink:label="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents consisting of money market funds with maturities</label>
    <label xml:lang="en-US" xlink:label="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents Consisting Of Money Market Funds With Maturities</label>
    <loc xlink:href="abio-20130331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" />
    <label xml:lang="en-US" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets between hierarchy levels transfers amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" />
    <label xml:lang="en-US" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers of assets between fair value hierarchy levels</label>
    <label xml:lang="en-US" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Between Hierarchy Levels Transfers Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software Intangible Asset [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:type="locator" xlink:label="abio_ComponentsOfPropertyAndEquipmentAbstract" />
    <label xml:lang="en-US" xlink:label="abio_ComponentsOfPropertyAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Components of Property and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="abio_ComponentsOfPropertyAndEquipmentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ComponentsOfPropertyAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Property and equipment</label>
    <label xml:lang="en-US" xlink:label="abio_ComponentsOfPropertyAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Property And Equipment [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</label>
    <loc xlink:href="abio-20130331.xsd#abio_LeaseholdImprovementsUsefulLife" xlink:type="locator" xlink:label="abio_LeaseholdImprovementsUsefulLife" />
    <label xml:lang="en-US" xlink:label="abio_LeaseholdImprovementsUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Leasehold improvements useful life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LeaseholdImprovementsUsefulLife" xlink:to="abio_LeaseholdImprovementsUsefulLife_lbl" />
    <label xml:lang="en-US" xlink:label="abio_LeaseholdImprovementsUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</label>
    <label xml:lang="en-US" xlink:label="abio_LeaseholdImprovementsUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements Useful Life</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Less accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</label>
    <loc xlink:href="abio-20130331.xsd#abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" xlink:type="locator" xlink:label="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" />
    <label xml:lang="en-US" xlink:label="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Property and Equipment (Details Textual) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" xlink:to="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Property And Equipment Details Textual [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_PropertyAndEquipmentTextualAbstract" xlink:type="locator" xlink:label="abio_PropertyAndEquipmentTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_PropertyAndEquipmentTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PropertyAndEquipmentTextualAbstract" xlink:to="abio_PropertyAndEquipmentTextualAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PropertyAndEquipmentTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_PropertyAndEquipmentTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</label>
    <loc xlink:href="abio-20130331.xsd#abio_DepreciationAndAmortizationExpenseSinceInception" xlink:type="locator" xlink:label="abio_DepreciationAndAmortizationExpenseSinceInception" />
    <label xml:lang="en-US" xlink:label="abio_DepreciationAndAmortizationExpenseSinceInception_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Depreciation and amortization expense since inception.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DepreciationAndAmortizationExpenseSinceInception" xlink:to="abio_DepreciationAndAmortizationExpenseSinceInception_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DepreciationAndAmortizationExpenseSinceInception_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense since inception</label>
    <label xml:lang="en-US" xlink:label="abio_DepreciationAndAmortizationExpenseSinceInception_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization Expense Since Inception</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" xlink:to="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Commitments And Contingencies Details [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_CommitmentsAndContingenciesTextualAbstract" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_CommitmentsAndContingenciesTextualAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office facilities taken on lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Real Estate Property</label>
    <loc xlink:href="abio-20130331.xsd#abio_LeaseTerm" xlink:type="locator" xlink:label="abio_LeaseTerm" />
    <label xml:lang="en-US" xlink:label="abio_LeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LeaseTerm" xlink:to="abio_LeaseTerm_lbl" />
    <label xml:lang="en-US" xlink:label="abio_LeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</label>
    <label xml:lang="en-US" xlink:label="abio_LeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Term</label>
    <loc xlink:href="abio-20130331.xsd#abio_ExtendedLeaseTerm" xlink:type="locator" xlink:label="abio_ExtendedLeaseTerm" />
    <label xml:lang="en-US" xlink:label="abio_ExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Extended lease term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExtendedLeaseTerm" xlink:to="abio_ExtendedLeaseTerm_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended lease term</label>
    <label xml:lang="en-US" xlink:label="abio_ExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Extended Lease Term</label>
    <loc xlink:href="abio-20130331.xsd#abio_RightsToExtendTerm" xlink:type="locator" xlink:label="abio_RightsToExtendTerm" />
    <label xml:lang="en-US" xlink:label="abio_RightsToExtendTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rights to extend term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RightsToExtendTerm" xlink:to="abio_RightsToExtendTerm_lbl" />
    <label xml:lang="en-US" xlink:label="abio_RightsToExtendTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rights to extend term</label>
    <label xml:lang="en-US" xlink:label="abio_RightsToExtendTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rights To Extend Term</label>
    <loc xlink:href="abio-20130331.xsd#abio_AllowToTerminateAgreement" xlink:type="locator" xlink:label="abio_AllowToTerminateAgreement" />
    <label xml:lang="en-US" xlink:label="abio_AllowToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Allow to terminate agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AllowToTerminateAgreement" xlink:to="abio_AllowToTerminateAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AllowToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allow to terminate agreement notice period</label>
    <label xml:lang="en-US" xlink:label="abio_AllowToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allow To Terminate Agreement</label>
    <loc xlink:href="abio-20130331.xsd#abio_OneTimePaymentToLandlordForNewLeasedPremises" xlink:type="locator" xlink:label="abio_OneTimePaymentToLandlordForNewLeasedPremises" />
    <label xml:lang="en-US" xlink:label="abio_OneTimePaymentToLandlordForNewLeasedPremises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">One-time payment to landlord for new leased premises.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OneTimePaymentToLandlordForNewLeasedPremises" xlink:to="abio_OneTimePaymentToLandlordForNewLeasedPremises_lbl" />
    <label xml:lang="en-US" xlink:label="abio_OneTimePaymentToLandlordForNewLeasedPremises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement payment</label>
    <label xml:lang="en-US" xlink:label="abio_OneTimePaymentToLandlordForNewLeasedPremises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">One Time Payment To Landlord For New Leased Premises</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TenantReimbursements" xlink:type="locator" xlink:label="us-gaap_TenantReimbursements" />
    <label xml:lang="en-US" xlink:label="us-gaap_TenantReimbursements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantReimbursements" xlink:to="us-gaap_TenantReimbursements_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TenantReimbursements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Reimbursements</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</label>
    <loc xlink:href="abio-20130331.xsd#abio_LeaseMonthExpirationDate" xlink:type="locator" xlink:label="abio_LeaseMonthExpirationDate" />
    <label xml:lang="en-US" xlink:label="abio_LeaseMonthExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease month expiration date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LeaseMonthExpirationDate" xlink:to="abio_LeaseMonthExpirationDate_lbl" />
    <label xml:lang="en-US" xlink:label="abio_LeaseMonthExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiry period</label>
    <label xml:lang="en-US" xlink:label="abio_LeaseMonthExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Month Expiration Date</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</label>
    <loc xlink:href="abio-20130331.xsd#abio_MilestonePaymentMadeByCompany" xlink:type="locator" xlink:label="abio_MilestonePaymentMadeByCompany" />
    <label xml:lang="en-US" xlink:label="abio_MilestonePaymentMadeByCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment made by company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MilestonePaymentMadeByCompany" xlink:to="abio_MilestonePaymentMadeByCompany_lbl" />
    <label xml:lang="en-US" xlink:label="abio_MilestonePaymentMadeByCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</label>
    <label xml:lang="en-US" xlink:label="abio_MilestonePaymentMadeByCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Made By Company</label>
    <loc xlink:href="abio-20130331.xsd#abio_ExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_ExpectedMilestonePaymentsUponApproval" />
    <label xml:lang="en-US" xlink:label="abio_ExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected milestone payments upon approval.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExpectedMilestonePaymentsUponApproval" xlink:to="abio_ExpectedMilestonePaymentsUponApproval_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected milestone payments upon approval</label>
    <label xml:lang="en-US" xlink:label="abio_ExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Milestone Payments Upon Approval</label>
    <loc xlink:href="abio-20130331.xsd#abio_AnotherExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval" />
    <label xml:lang="en-US" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Another expected milestone payments upon approval.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AnotherExpectedMilestonePaymentsUponApproval" xlink:to="abio_AnotherExpectedMilestonePaymentsUponApproval_lbl" />
    <label xml:lang="en-US" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Another expected milestone payments upon approval</label>
    <label xml:lang="en-US" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Another Expected Milestone Payments Upon Approval</label>
    <loc xlink:href="abio-20130331.xsd#abio_MinimumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRoyaltyObligation" />
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of royalty obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfRoyaltyObligation" xlink:to="abio_MinimumPercentageOfRoyaltyObligation_lbl" />
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of royalty obligation</label>
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Royalty Obligation</label>
    <loc xlink:href="abio-20130331.xsd#abio_MaximumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRoyaltyObligation" />
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of royalty obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MaximumPercentageOfRoyaltyObligation" xlink:to="abio_MaximumPercentageOfRoyaltyObligation_lbl" />
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of royalty obligation</label>
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRoyaltyObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Royalty Obligation</label>
    <loc xlink:href="abio-20130331.xsd#abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" xlink:type="locator" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" />
    <label xml:lang="en-US" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty obligated to pay under its original license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" xlink:to="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product sales levels royalty</label>
    <label xml:lang="en-US" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Obligated To Pay Under Its Original License Agreement</label>
    <loc xlink:href="abio-20130331.xsd#abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of range of royalties that can be buy down.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:to="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" />
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of range of royalties that can be buy down</label>
    <label xml:lang="en-US" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Range Of Royalties That Can Be Buy Down</label>
    <loc xlink:href="abio-20130331.xsd#abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of range of royalties that can be buy down.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:to="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" />
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of range of royalties that can be buy down</label>
    <label xml:lang="en-US" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Range Of Royalties That Can Be Buy Down</label>
    <loc xlink:href="abio-20130331.xsd#abio_MilestonePaymentDuePeriod" xlink:type="locator" xlink:label="abio_MilestonePaymentDuePeriod" />
    <label xml:lang="en-US" xlink:label="abio_MilestonePaymentDuePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment due period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MilestonePaymentDuePeriod" xlink:to="abio_MilestonePaymentDuePeriod_lbl" />
    <label xml:lang="en-US" xlink:label="abio_MilestonePaymentDuePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment due period</label>
    <label xml:lang="en-US" xlink:label="abio_MilestonePaymentDuePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleAxis" xlink:type="locator" xlink:label="us-gaap_SaleAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleAxis" xlink:to="us-gaap_SaleAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleDomain" xlink:type="locator" xlink:label="us-gaap_SaleDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleDomain" xlink:to="us-gaap_SaleDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale [Domain]</label>
    <loc xlink:href="abio-20130331.xsd#abio_PrivateInvestmentInPublicEquityTransactionMember" xlink:type="locator" xlink:label="abio_PrivateInvestmentInPublicEquityTransactionMember" />
    <label xml:lang="en-US" xlink:label="abio_PrivateInvestmentInPublicEquityTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Private investment in public equity transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PrivateInvestmentInPublicEquityTransactionMember" xlink:to="abio_PrivateInvestmentInPublicEquityTransactionMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PrivateInvestmentInPublicEquityTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PIPE Transaction</label>
    <label xml:lang="en-US" xlink:label="abio_PrivateInvestmentInPublicEquityTransactionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Investment In Public Equity Transaction [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Financings And Warrants (Textual) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_EquityFinancingsAndWarrantsTextualAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapital" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapital" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapital_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Including Additional Paid In Capital</label>
    <loc xlink:href="abio-20130331.xsd#abio_PrivateInvestmentInPublicEquityOfferingCloseDate" xlink:type="locator" xlink:label="abio_PrivateInvestmentInPublicEquityOfferingCloseDate" />
    <label xml:lang="en-US" xlink:label="abio_PrivateInvestmentInPublicEquityOfferingCloseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Private investment in public equity offering close date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PrivateInvestmentInPublicEquityOfferingCloseDate" xlink:to="abio_PrivateInvestmentInPublicEquityOfferingCloseDate_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PrivateInvestmentInPublicEquityOfferingCloseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Equity Offering Close Date</label>
    <label xml:lang="en-US" xlink:label="abio_PrivateInvestmentInPublicEquityOfferingCloseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Investment In Public Equity Offering Close Date</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</label>
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity financings and warrants (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Financings And Warrants Textual [Abstract]</label>
    <loc xlink:href="abio-20130331.xsd#abio_PurchasePriceOfCommonStockUnit" xlink:type="locator" xlink:label="abio_PurchasePriceOfCommonStockUnit" />
    <label xml:lang="en-US" xlink:label="abio_PurchasePriceOfCommonStockUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price of common stock unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchasePriceOfCommonStockUnit" xlink:to="abio_PurchasePriceOfCommonStockUnit_lbl" />
    <label xml:lang="en-US" xlink:label="abio_PurchasePriceOfCommonStockUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price for common stock unit</label>
    <label xml:lang="en-US" xlink:label="abio_PurchasePriceOfCommonStockUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Price Of Common Stock Unit</label>
    <loc xlink:href="abio-20130331.xsd#abio_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" />
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right exercisable expiration period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:to="abio_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants were exercisable upon issuance, expiry year</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercisable Expiration Period</label>
    <loc xlink:href="abio-20130331.xsd#abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" />
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right exercise price of share percentage of closing bid price of common shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" xlink:to="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares_lbl" />
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing bid price of the common stock</label>
    <label xml:lang="en-US" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Share Percentage Of Closing Bid Price Of Common Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
    <loc xlink:href="abio-20130331.xsd#abio_RegisteredDirectOfferingMember" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingMember" />
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Registered direct offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RegisteredDirectOfferingMember" xlink:to="abio_RegisteredDirectOfferingMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registered Direct Offering</label>
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Registered Direct Offering [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_TwoZeroOneOneEquityFinancingsMember" xlink:type="locator" xlink:label="abio_TwoZeroOneOneEquityFinancingsMember" />
    <label xml:lang="en-US" xlink:label="abio_TwoZeroOneOneEquityFinancingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2011 Equity Financings.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoZeroOneOneEquityFinancingsMember" xlink:to="abio_TwoZeroOneOneEquityFinancingsMember_lbl" />
    <label xml:lang="en-US" xlink:label="abio_TwoZeroOneOneEquityFinancingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2011 Equity Financings</label>
    <label xml:lang="en-US" xlink:label="abio_TwoZeroOneOneEquityFinancingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero One One Equity Financings [Member]</label>
    <loc xlink:href="abio-20130331.xsd#abio_RegisteredDirectOfferingCloseDate" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingCloseDate" />
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectOfferingCloseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Registered direct offering close date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RegisteredDirectOfferingCloseDate" xlink:to="abio_RegisteredDirectOfferingCloseDate_lbl" />
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectOfferingCloseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registered Direct Offering Close Date</label>
    <label xml:lang="en-US" xlink:label="abio_RegisteredDirectOfferingCloseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Registered Direct Offering Close Date</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs By Report Line [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs Report Line [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Selling, General and Administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:type="locator" xlink:label="us-gaap_RestructuringChargesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringChargesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringChargesMember" xlink:to="us-gaap_RestructuringChargesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringChargesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash, share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Aggregate Disclosures [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureShareBasedCompensationDetails1LineItems" xlink:type="locator" xlink:label="abio_DisclosureShareBasedCompensationDetails1LineItems" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureShareBasedCompensationDetails1LineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Share-based Compensation (Details 1) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DisclosureShareBasedCompensationDetails1LineItems" xlink:to="abio_DisclosureShareBasedCompensationDetails1LineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureShareBasedCompensationDetails1LineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Share Based Compensation Details1 [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option activities of company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated">Number of Options Forfeited, cancelled or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding end of the period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, end of period, Number of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest, Number of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average exercise Price, Options Outstanding, Beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited, cancelled or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average exercise Price, Options Outstanding, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Options exercisable, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average exercise Price, Options vested and expected to vest, end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Remaining Contractual Term (in years) Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable at March 31, 2013, Weighted Average Remaining Contractual Term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest, Weighted Average Remaining Contractual Term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureIncomeTaxesDetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureIncomeTaxesDetailsLineItems" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureIncomeTaxesDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DisclosureIncomeTaxesDetailsLineItems" xlink:to="abio_DisclosureIncomeTaxesDetailsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="abio_DisclosureIncomeTaxesDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Income Taxes Details [Line Items]</label>
    <loc xlink:href="abio-20130331.xsd#abio_IncomeTaxesTextualAbstract" xlink:type="locator" xlink:label="abio_IncomeTaxesTextualAbstract" />
    <label xml:lang="en-US" xlink:label="abio_IncomeTaxesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes (Textual) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="abio_IncomeTaxesTextualAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="abio_IncomeTaxesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes (Textual) [Abstract]</label>
    <label xml:lang="en-US" xlink:label="abio_IncomeTaxesTextualAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Textual [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExaminationLiabilityRecorded" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRecorded" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRecorded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserve for uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLiabilityRecorded" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRecorded_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRecorded_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Liability Recorded</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>abio-20130331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2013-05-13T20:55:49.3389120+00:00 -->
<!-- Version            : 1.0.0.64 -->
<!-- Package ID         : 0EC0A1A677FC5574CCB8E2DAD25CAE4D-0000907654-001304 -->
<!-- Copyright (c) 2013 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="abio-20130331.xsd#TemplateLink" roleURI="http://www.arcabiopharma.com/20130331/role/TemplateLink" />
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="abio-20130331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_DocumentDocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="abio_DocumentDocumentAndEntityInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DocumentDocumentAndEntityInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10630.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" xlink:type="locator" xlink:label="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" xlink:to="us-gaap_AssetsAbstract" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12010.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedBalanceSheetsParentheticalUnaudited" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:type="locator" xlink:label="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10330.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:type="locator" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_GainLossOnAssignmentOfPatentRights" xlink:type="locator" xlink:label="abio_GainLossOnAssignmentOfPatentRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:type="locator" xlink:label="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="10610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="abio_GainLossOnAssignmentOfPatentRights" order="11090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" order="11170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="11250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="11330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="11450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount" order="11770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="11850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="11930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="12050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="12170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="12270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="12390.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnaudited">
    <loc xlink:href="abio-20130331.xsd#abio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="abio_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <loc xlink:href="abio-20130331.xsd#abio_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator" xlink:label="abio_StockIssuedDuringPeriodValueWarrantsExercised" />
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" xlink:type="locator" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" xlink:type="locator" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" xlink:type="locator" xlink:label="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DividendsPreferredStockStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <loc xlink:href="abio-20130331.xsd#abio_AdjustmentForFractionalShares" xlink:type="locator" xlink:label="abio_AdjustmentForFractionalShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="abio-20130331.xsd#abio_NotesAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_NotesAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_CommonConversionMember" xlink:type="locator" xlink:label="abio_CommonConversionMember" />
    <loc xlink:href="abio-20130331.xsd#abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" xlink:type="locator" xlink:label="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" />
    <loc xlink:href="abio-20130331.xsd#abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" xlink:type="locator" xlink:label="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_AccretionOfSeriesBMember" xlink:type="locator" xlink:label="abio_AccretionOfSeriesBMember" />
    <loc xlink:href="abio-20130331.xsd#abio_AccretionOfSeriesMember" xlink:type="locator" xlink:label="abio_AccretionOfSeriesMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SeriesOfferingCostsMember" xlink:type="locator" xlink:label="abio_SeriesOfferingCostsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_CashNetOfOfferingCostsMember" xlink:type="locator" xlink:label="abio_CashNetOfOfferingCostsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_DeficitAccumulatedDuringDevelopmentStageMember" xlink:type="locator" xlink:label="abio_DeficitAccumulatedDuringDevelopmentStageMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesBMember" xlink:type="locator" xlink:label="us-gaap_SeriesBMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesAMember" xlink:type="locator" xlink:label="us-gaap_SeriesAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesAMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesBMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abio_DeficitAccumulatedDuringDevelopmentStageMember" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_CashNetOfOfferingCostsMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SeriesOfferingCostsMember" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" order="10730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_AccretionOfSeriesMember" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_AccretionOfSeriesBMember" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_CommonConversionMember" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_NotesAndRelatedAccruedInterestMember" order="11070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="11210.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="11230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="11250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="11450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="17610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="20090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="20310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="26810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AdjustmentForFractionalShares" order="28310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStockStock" order="28530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="29310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="29610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" order="29870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="30350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" order="30570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="30810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="31050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan" order="32190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="32430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" order="32650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_StockIssuedDuringPeriodValueWarrantsExercised" order="39930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_StockIssuedDuringPeriodSharesWarrantsExercised" order="40170.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnauditedParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="abio-20130331.xsd#abio_CommonStockMarketPricePerShare" xlink:type="locator" xlink:label="abio_CommonStockMarketPricePerShare" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesBMember" xlink:type="locator" xlink:label="us-gaap_SeriesBMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeriesAMember" xlink:type="locator" xlink:label="us-gaap_SeriesAMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" />
    <loc xlink:href="abio-20130331.xsd#abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" xlink:type="locator" xlink:label="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" xlink:type="locator" xlink:label="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" />
    <loc xlink:href="abio-20130331.xsd#abio_CashNetOfOfferingCostsMember" xlink:type="locator" xlink:label="abio_CashNetOfOfferingCostsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_CashNetOfOfferingCostsMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesAMember" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_SeriesBMember" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10750.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_CommonStockMarketPricePerShare" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11330.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:href="abio-20130331.xsd#abio_VendorFinanceAgreement" xlink:type="locator" xlink:label="abio_VendorFinanceAgreement" />
    <loc xlink:href="abio-20130331.xsd#abio_AccruedDeferredTransactionCosts" xlink:type="locator" xlink:label="abio_AccruedDeferredTransactionCosts" />
    <loc xlink:href="abio-20130331.xsd#abio_WarrantIssuedInConnectionWithCreditFacility" xlink:type="locator" xlink:label="abio_WarrantIssuedInConnectionWithCreditFacility" />
    <loc xlink:href="abio-20130331.xsd#abio_AccruedInterestOnNotesPayableConvertedToEquity" xlink:type="locator" xlink:label="abio_AccruedInterestOnNotesPayableConvertedToEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" xlink:label="us-gaap_InterestPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="abio-20130331.xsd#abio_RepaymentOfPrincipalOnVendorFinanceAgreement" xlink:type="locator" xlink:label="abio_RepaymentOfPrincipalOnVendorFinanceAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <loc xlink:href="abio-20130331.xsd#abio_WriteOffOfDeferredTaxLiability" xlink:type="locator" xlink:label="abio_WriteOffOfDeferredTaxLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionExpense" xlink:type="locator" xlink:label="us-gaap_AccretionExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_GainLossOnAssignmentOfPatentRights" xlink:type="locator" xlink:label="abio_GainLossOnAssignmentOfPatentRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10510.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="abio_GainLossOnAssignmentOfPatentRights" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" order="11090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionExpense" order="11370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="11450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="11530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="abio_WriteOffOfDeferredTaxLiability" order="11590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="11670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="11750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="11830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="12030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="12150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="12270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="12390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="12510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="12750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="12870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="12950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="13030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="13130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="13210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" order="13290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="13370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="13470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="13590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="13670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" order="13750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="13830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="13910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="13990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="14290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="14370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="abio_RepaymentOfPrincipalOnVendorFinanceAgreement" order="14450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="14550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="14670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="14790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="14950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="15070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="15170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="abio_AccruedInterestOnNotesPayableConvertedToEquity" order="15290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="abio_WarrantIssuedInConnectionWithCreditFacility" order="15370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="abio_AccruedDeferredTransactionCosts" order="15450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="abio_VendorFinanceAgreement" order="15530.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="abio-20130331.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShare" xlink:href="abio-20130331.xsd#Role_DisclosureLossPerShare" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShare">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009" xlink:href="abio-20130331.xsd#Role_DisclosureMergerWithNuveloIncOnJanuary272009" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosures" xlink:href="abio-20130331.xsd#Role_DisclosureFairValueDisclosures" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosures">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="abio-20130331.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipment">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="abio-20130331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrants" xlink:href="abio-20130331.xsd#Role_DisclosureEquityFinancingsAndWarrants" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrants">
    <loc xlink:href="abio-20130331.xsd#abio_EquityFinancingsAndWarrantsDisclosureTextBlock" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensation" xlink:href="abio-20130331.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="abio-20130331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxes">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="abio-20130331.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:href="abio-20130331.xsd#abio_AccruedExpensesPolicyTextBlock" xlink:type="locator" xlink:label="abio_AccruedExpensesPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <loc xlink:href="abio-20130331.xsd#abio_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="abio_ReverseStockSplitPolicyTextBlock" />
    <loc xlink:href="abio-20130331.xsd#abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_ReverseStockSplitPolicyTextBlock" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_AccruedExpensesPolicyTextBlock" order="10490.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareTables" xlink:href="abio-20130331.xsd#Role_DisclosureLossPerShareTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="abio-20130331.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationTables" xlink:href="abio-20130331.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="10170.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="abio-20130331.xsd#Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:href="abio-20130331.xsd#abio_RevenueGenerated" xlink:type="locator" xlink:label="abio_RevenueGenerated" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="abio-20130331.xsd#abio_TwoZeroOneThreeEquityFinancingsMember" xlink:type="locator" xlink:label="abio_TwoZeroOneThreeEquityFinancingsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingDomain" xlink:type="locator" xlink:label="us-gaap_FinancingDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingDomain" xlink:type="locator" xlink:label="us-gaap_FinancingDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingAxis" xlink:type="locator" xlink:label="us-gaap_FinancingAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="abio-20130331.xsd#abio_AnticipatedPeriodToStartAtrialFibrillationTrial" xlink:type="locator" xlink:label="abio_AnticipatedPeriodToStartAtrialFibrillationTrial" />
    <loc xlink:href="abio-20130331.xsd#abio_NumberOfPatientsCompanyPlansToEnroll" xlink:type="locator" xlink:label="abio_NumberOfPatientsCompanyPlansToEnroll" />
    <loc xlink:href="abio-20130331.xsd#abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:type="locator" xlink:label="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:to="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" order="10120.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" xlink:to="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="abio_NumberOfPatientsCompanyPlansToEnroll" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="abio_AnticipatedPeriodToStartAtrialFibrillationTrial" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FinancingAxis" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancingAxis" xlink:to="us-gaap_FinancingDomain_2" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingAxis" xlink:to="us-gaap_FinancingDomain" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingDomain" xlink:to="abio_TwoZeroOneThreeEquityFinancingsMember" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" xlink:to="abio_RevenueGenerated" order="10930.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetails" xlink:href="abio-20130331.xsd#Role_DisclosureLossPerShareDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="abio-20130331.xsd#abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:type="locator" xlink:label="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureLossPerShareDetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureLossPerShareDetailsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_DisclosureLossPerShareDetailsLineItems" xlink:to="us-gaap_StatementTable" order="10080.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DisclosureLossPerShareDetailsLineItems" xlink:to="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10520.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetailsTextual" xlink:href="abio-20130331.xsd#Role_DisclosureLossPerShareDetailsTextual" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetailsTextual">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_EarningsLossPerShareTextualAbstract" xlink:type="locator" xlink:label="abio_EarningsLossPerShareTextualAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureLossPerShareDetailsTextualLineItems" xlink:type="locator" xlink:label="abio_DisclosureLossPerShareDetailsTextualLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_DisclosureLossPerShareDetailsTextualLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DisclosureLossPerShareDetailsTextualLineItems" xlink:to="abio_EarningsLossPerShareTextualAbstract" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EarningsLossPerShareTextualAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10170.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009Details" xlink:href="abio-20130331.xsd#Role_DisclosureMergerWithNuveloIncOnJanuary272009Details" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009Details">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice" />
    <loc xlink:href="abio-20130331.xsd#abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:type="locator" xlink:label="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" xlink:to="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" xlink:to="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" order="10430.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosuresDetails" xlink:href="abio-20130331.xsd#Role_DisclosureFairValueDisclosuresDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosuresDetails">
    <loc xlink:href="abio-20130331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" xlink:type="locator" xlink:label="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" />
    <loc xlink:href="abio-20130331.xsd#abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:type="locator" xlink:label="abio_FairValueDisclosuresAdditionalTextualAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="abio-20130331.xsd#abio_FairValueDisclosuresTextualAbstract" xlink:type="locator" xlink:label="abio_FairValueDisclosuresTextualAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10100.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="abio_FairValueDisclosuresTextualAbstract" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresTextualAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="abio_FairValueDisclosuresAdditionalTextualAbstract" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresAdditionalTextualAbstract" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="10420.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetails" xlink:href="abio-20130331.xsd#Role_DisclosurePropertyAndEquipmentDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="abio-20130331.xsd#abio_LeaseholdImprovementsUsefulLife" xlink:type="locator" xlink:label="abio_LeaseholdImprovementsUsefulLife" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="abio-20130331.xsd#abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:type="locator" xlink:label="abio_ComponentsOfPropertyAndEquipmentAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10180.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="dei_LegalEntityAxis" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="abio_ComponentsOfPropertyAndEquipmentAbstract" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="abio_LeaseholdImprovementsUsefulLife" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="11230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ComponentsOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="11310.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual" xlink:href="abio-20130331.xsd#Role_DisclosurePropertyAndEquipmentDetailsTextual" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual">
    <loc xlink:href="abio-20130331.xsd#abio_DepreciationAndAmortizationExpenseSinceInception" xlink:type="locator" xlink:label="abio_DepreciationAndAmortizationExpenseSinceInception" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="abio-20130331.xsd#abio_PropertyAndEquipmentTextualAbstract" xlink:type="locator" xlink:label="abio_PropertyAndEquipmentTextualAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" xlink:type="locator" xlink:label="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" xlink:to="abio_PropertyAndEquipmentTextualAbstract" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PropertyAndEquipmentTextualAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PropertyAndEquipmentTextualAbstract" xlink:to="abio_DepreciationAndAmortizationExpenseSinceInception" order="10310.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails" xlink:href="abio-20130331.xsd#Role_DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails">
    <loc xlink:href="abio-20130331.xsd#abio_MilestonePaymentDuePeriod" xlink:type="locator" xlink:label="abio_MilestonePaymentDuePeriod" />
    <loc xlink:href="abio-20130331.xsd#abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <loc xlink:href="abio-20130331.xsd#abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" />
    <loc xlink:href="abio-20130331.xsd#abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" xlink:type="locator" xlink:label="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" />
    <loc xlink:href="abio-20130331.xsd#abio_MaximumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MaximumPercentageOfRoyaltyObligation" />
    <loc xlink:href="abio-20130331.xsd#abio_MinimumPercentageOfRoyaltyObligation" xlink:type="locator" xlink:label="abio_MinimumPercentageOfRoyaltyObligation" />
    <loc xlink:href="abio-20130331.xsd#abio_AnotherExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_AnotherExpectedMilestonePaymentsUponApproval" />
    <loc xlink:href="abio-20130331.xsd#abio_ExpectedMilestonePaymentsUponApproval" xlink:type="locator" xlink:label="abio_ExpectedMilestonePaymentsUponApproval" />
    <loc xlink:href="abio-20130331.xsd#abio_MilestonePaymentMadeByCompany" xlink:type="locator" xlink:label="abio_MilestonePaymentMadeByCompany" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="abio-20130331.xsd#abio_LeaseMonthExpirationDate" xlink:type="locator" xlink:label="abio_LeaseMonthExpirationDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TenantReimbursements" xlink:type="locator" xlink:label="us-gaap_TenantReimbursements" />
    <loc xlink:href="abio-20130331.xsd#abio_OneTimePaymentToLandlordForNewLeasedPremises" xlink:type="locator" xlink:label="abio_OneTimePaymentToLandlordForNewLeasedPremises" />
    <loc xlink:href="abio-20130331.xsd#abio_AllowToTerminateAgreement" xlink:type="locator" xlink:label="abio_AllowToTerminateAgreement" />
    <loc xlink:href="abio-20130331.xsd#abio_RightsToExtendTerm" xlink:type="locator" xlink:label="abio_RightsToExtendTerm" />
    <loc xlink:href="abio-20130331.xsd#abio_ExtendedLeaseTerm" xlink:type="locator" xlink:label="abio_ExtendedLeaseTerm" />
    <loc xlink:href="abio-20130331.xsd#abio_LeaseTerm" xlink:type="locator" xlink:label="abio_LeaseTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <loc xlink:href="abio-20130331.xsd#abio_CommitmentsAndContingenciesTextualAbstract" xlink:type="locator" xlink:label="abio_CommitmentsAndContingenciesTextualAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" xlink:to="abio_CommitmentsAndContingenciesTextualAbstract" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_LeaseTerm" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_ExtendedLeaseTerm" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_RightsToExtendTerm" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_AllowToTerminateAgreement" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_OneTimePaymentToLandlordForNewLeasedPremises" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_TenantReimbursements" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_DeferredRentCredit" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="11150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_LeaseMonthExpirationDate" order="11410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="11470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MilestonePaymentMadeByCompany" order="11670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_ExpectedMilestonePaymentsUponApproval" order="11730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_AnotherExpectedMilestonePaymentsUponApproval" order="11790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MinimumPercentageOfRoyaltyObligation" order="11850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MaximumPercentageOfRoyaltyObligation" order="11910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" order="11970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" order="12030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" order="12090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsAndContingenciesTextualAbstract" xlink:to="abio_MilestonePaymentDuePeriod" order="12150.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetails" xlink:href="abio-20130331.xsd#Role_DisclosureEquityFinancingsAndWarrantsDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_RegisteredDirectOfferingCloseDate" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingCloseDate" />
    <loc xlink:href="abio-20130331.xsd#abio_TwoZeroOneOneEquityFinancingsMember" xlink:type="locator" xlink:label="abio_TwoZeroOneOneEquityFinancingsMember" />
    <loc xlink:href="abio-20130331.xsd#abio_RegisteredDirectOfferingMember" xlink:type="locator" xlink:label="abio_RegisteredDirectOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <loc xlink:href="abio-20130331.xsd#abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" />
    <loc xlink:href="abio-20130331.xsd#abio_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:type="locator" xlink:label="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" />
    <loc xlink:href="abio-20130331.xsd#abio_PurchasePriceOfCommonStockUnit" xlink:type="locator" xlink:label="abio_PurchasePriceOfCommonStockUnit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_PrivateInvestmentInPublicEquityOfferingCloseDate" xlink:type="locator" xlink:label="abio_PrivateInvestmentInPublicEquityOfferingCloseDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="abio-20130331.xsd#abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:type="locator" xlink:label="abio_EquityFinancingsAndWarrantsTextualAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <loc xlink:href="abio-20130331.xsd#abio_TwoZeroOneThreeEquityFinancingsMember" xlink:type="locator" xlink:label="abio_TwoZeroOneThreeEquityFinancingsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingDomain" xlink:type="locator" xlink:label="us-gaap_FinancingDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FinancingAxis" xlink:type="locator" xlink:label="us-gaap_FinancingAxis" />
    <loc xlink:href="abio-20130331.xsd#abio_PrivateInvestmentInPublicEquityTransactionMember" xlink:type="locator" xlink:label="abio_PrivateInvestmentInPublicEquityTransactionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleDomain" xlink:type="locator" xlink:label="us-gaap_SaleDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleDomain" xlink:type="locator" xlink:label="us-gaap_SaleDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleAxis" xlink:type="locator" xlink:label="us-gaap_SaleAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SaleAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SaleAxis" xlink:to="us-gaap_SaleDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SaleAxis" xlink:to="us-gaap_SaleDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleDomain" xlink:to="abio_PrivateInvestmentInPublicEquityTransactionMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_FinancingAxis" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancingAxis" xlink:to="us-gaap_FinancingDomain" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingDomain" xlink:to="abio_TwoZeroOneThreeEquityFinancingsMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10310.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapital" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PrivateInvestmentInPublicEquityOfferingCloseDate" order="10590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10920.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_WarrantMember" order="10960.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="abio_EquityFinancingsAndWarrantsTextualAbstract" order="11020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_PurchasePriceOfCommonStockUnit" order="11160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" order="11280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="11340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleDomain" xlink:to="abio_RegisteredDirectOfferingMember" order="11450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancingDomain" xlink:to="abio_TwoZeroOneOneEquityFinancingsMember" order="11660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="abio_RegisteredDirectOfferingCloseDate" order="12040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RangeAxis" order="12760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="12780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="12800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="12820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsAndWarrantsTextualAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="13090.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails" xlink:href="abio-20130331.xsd#Role_DisclosureShareBasedCompensationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:type="locator" xlink:label="us-gaap_RestructuringChargesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_2" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="us-gaap_RestructuringChargesMember" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10140.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10420.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails1" xlink:href="abio-20130331.xsd#Role_DisclosureShareBasedCompensationDetails1" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails1">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureShareBasedCompensationDetails1LineItems" xlink:type="locator" xlink:label="abio_DisclosureShareBasedCompensationDetails1LineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_DisclosureShareBasedCompensationDetails1LineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DisclosureShareBasedCompensationDetails1LineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="11470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12330.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxesDetails" xlink:href="abio-20130331.xsd#Role_DisclosureIncomeTaxesDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExaminationLiabilityRecorded" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLiabilityRecorded" />
    <loc xlink:href="abio-20130331.xsd#abio_IncomeTaxesTextualAbstract" xlink:type="locator" xlink:label="abio_IncomeTaxesTextualAbstract" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="abio-20130331.xsd#abio_DisclosureIncomeTaxesDetailsLineItems" xlink:type="locator" xlink:label="abio_DisclosureIncomeTaxesDetailsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_DisclosureIncomeTaxesDetailsLineItems" xlink:to="us-gaap_StatementTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DisclosureIncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesTextualAbstract" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesTextualAbstract" xlink:to="us-gaap_IncomeTaxExaminationLiabilityRecorded" order="10130.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>abio-20130331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Linkbase Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2013-05-13T20:55:49.3389120+00:00 -->
<!-- Version            : 1.0.0.64 -->
<!-- Package ID         : 0EC0A1A677FC5574CCB8E2DAD25CAE4D-0000907654-001304 -->
<!-- Copyright (c) 2013 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20130331.xsd#TemplateLink" roleURI="http://www.arcabiopharma.com/20130331/role/TemplateLink" />
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_GainLossOnAssignmentOfPatentRights" xlink:type="locator" xlink:label="abio_GainLossOnAssignmentOfPatentRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:type="locator" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="abio_GainLossOnAssignmentOfPatentRights" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_InterestAndOtherIncome" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_InterestExpenseDebt" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="10160.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="abio-20130331.xsd#Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
    <loc xlink:href="abio-20130331.xsd#abio_WriteOffOfDeferredTaxLiability" xlink:type="locator" xlink:label="abio_WriteOffOfDeferredTaxLiability" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccretionExpense" xlink:type="locator" xlink:label="us-gaap_AccretionExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaidInKindInterest" xlink:type="locator" xlink:label="us-gaap_PaidInKindInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" />
    <loc xlink:href="abio-20130331.xsd#abio_GainLossOnAssignmentOfPatentRights" xlink:type="locator" xlink:label="abio_GainLossOnAssignmentOfPatentRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="locator" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <loc xlink:href="abio-20130331.xsd#abio_RepaymentOfPrincipalOnVendorFinanceAgreement" xlink:type="locator" xlink:label="abio_RepaymentOfPrincipalOnVendorFinanceAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="abio_RepaymentOfPrincipalOnVendorFinanceAgreement" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="abio_GainLossOnAssignmentOfPatentRights" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10240.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PaidInKindInterest" order="10250.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10260.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10270.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionExpense" order="10280.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10290.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="10300.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="abio_WriteOffOfDeferredTaxLiability" order="10310.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="10320.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10330.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10340.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10350.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10360.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10370.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="10380.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="10390.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetails" xlink:href="abio-20130331.xsd#Role_DisclosureLossPerShareDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetails" xlink:href="abio-20130331.xsd#Role_DisclosurePropertyAndEquipmentDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10450.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>abio-20130331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- RRD ActiveDisclosure(SM) XBRL Schema Document - http://www.financial.rrd.com/ -->
<!-- Creation Date      : 2013-05-13T20:55:49.3389120+00:00 -->
<!-- Version            : 1.0.0.64 -->
<!-- Package ID         : 0EC0A1A677FC5574CCB8E2DAD25CAE4D-0000907654-001304 -->
<!-- Copyright (c) 2013 R. R. Donnelley & Sons Company. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:abio="http://www.arcabiopharma.com/20130331" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arcabiopharma.com/20130331" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" namespace="http://fasb.org/us-types/2012-01-31" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" namespace="http://fasb.org/us-gaap/2012-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd" namespace="http://xbrl.sec.gov/country/2012-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2012-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2012-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2012/exch-2012-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2012-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2012-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arcabiopharma.com/20130331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20130331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20130331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20130331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abio-20130331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited" id="Role_StatementConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited" id="Role_StatementConsolidatedBalanceSheetsParentheticalUnaudited">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical) (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnaudited" id="Role_StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnaudited">
        <link:definition>100040 - Statement - Consolidated Statements of Preferred Stock and Stockholders&apos; Equity (Deficit) (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnauditedParenthetical" id="Role_StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnauditedParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Preferred Stock and Stockholders&apos; Equity (Deficit) (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - The Company and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShare" id="Role_DisclosureLossPerShare">
        <link:definition>100080 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009" id="Role_DisclosureMergerWithNuveloIncOnJanuary272009">
        <link:definition>100090 - Disclosure - Merger with Nuvelo, Inc. on January 27, 2009</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosures" id="Role_DisclosureFairValueDisclosures">
        <link:definition>100100 - Disclosure - Fair Value Disclosures</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100110 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrants" id="Role_DisclosureEquityFinancingsAndWarrants">
        <link:definition>100130 - Disclosure - Equity Financings and Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100140 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100160 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareTables" id="Role_DisclosureLossPerShareTables">
        <link:definition>100170 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100180 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100190 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails" id="Role_DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>100200 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetails" id="Role_DisclosureLossPerShareDetails">
        <link:definition>100210 - Disclosure - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetailsTextual" id="Role_DisclosureLossPerShareDetailsTextual">
        <link:definition>100220 - Disclosure - Loss Per Share (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009Details" id="Role_DisclosureMergerWithNuveloIncOnJanuary272009Details">
        <link:definition>100230 - Disclosure - Merger with Nuvelo, Inc. on January 27, 2009 (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosuresDetails" id="Role_DisclosureFairValueDisclosuresDetails">
        <link:definition>100240 - Disclosure - Fair Value Disclosures (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentDetails">
        <link:definition>100250 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual" id="Role_DisclosurePropertyAndEquipmentDetailsTextual">
        <link:definition>100260 - Disclosure - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails" id="Role_DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>100270 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetails" id="Role_DisclosureEquityFinancingsAndWarrantsDetails">
        <link:definition>100280 - Disclosure - Equity Financings and Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails" id="Role_DisclosureShareBasedCompensationDetails">
        <link:definition>100290 - Disclosure - Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails1" id="Role_DisclosureShareBasedCompensationDetails1">
        <link:definition>100300 - Disclosure - Share-based Compensation (Details 1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesDetails">
        <link:definition>100310 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="abio_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_DocumentDocumentAndEntityInformationLineItems" name="DocumentDocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_StatementConsolidatedBalanceSheetsUnauditedLineItems" name="StatementConsolidatedBalanceSheetsUnauditedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" name="StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_GainLossOnAssignmentOfPatentRights" name="GainLossOnAssignmentOfPatentRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" name="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_DeficitAccumulatedDuringDevelopmentStageMember" name="DeficitAccumulatedDuringDevelopmentStageMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CashNetOfOfferingCostsMember" name="CashNetOfOfferingCostsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" name="FirstIssuanceForNotesPayableAndRelatedAccruedInterestMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" name="FirstIssuanceOfStockForIntellectualPropertyLicenseRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" name="SecondIssuanceForNotesPayableAndRelatedAccruedInterestMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" name="SecondIssuanceOfStockForIntellectualPropertyLicenseRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" name="FirstIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" name="ThirdIssuanceForNotesPayableAndRelatedAccruedInterestMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" name="ThirdIssuanceOfStockForIntellectualPropertyLicenseRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" name="FourthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" name="FifthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" name="SecondIssuanceOfSeriesConvertibleRedeemablePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_SeriesOfferingCostsMember" name="SeriesOfferingCostsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" name="ThirdIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" name="SecondIssuanceOfSeriesBConvertibleRedeemablePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_AccretionOfSeriesMember" name="AccretionOfSeriesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_AccretionOfSeriesBMember" name="AccretionOfSeriesBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" name="SixthIssuanceOfStockForIntellectualPropertyLicenseRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" name="SeventhIssuanceOfStockForIntellectualPropertyLicenseRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_IssuanceOfCommonStockForCommercialLicenseRightsMember" name="IssuanceOfCommonStockForCommercialLicenseRightsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" name="IssuanceOfSharesToExecutiveSubjectToRepurchaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CommonConversionMember" name="CommonConversionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_NotesAndRelatedAccruedInterestMember" name="NotesAndRelatedAccruedInterestMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_AdjustmentForFractionalShares" name="AdjustmentForFractionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" name="AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" name="AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" name="AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_CommonStockMarketPricePerShare" name="CommonStockMarketPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="abio_RepaymentOfPrincipalOnVendorFinanceAgreement" name="RepaymentOfPrincipalOnVendorFinanceAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_WriteOffOfDeferredTaxLiability" name="WriteOffOfDeferredTaxLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_AccruedInterestOnNotesPayableConvertedToEquity" name="AccruedInterestOnNotesPayableConvertedToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="abio_WarrantIssuedInConnectionWithCreditFacility" name="WarrantIssuedInConnectionWithCreditFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="abio_AccruedDeferredTransactionCosts" name="AccruedDeferredTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="abio_VendorFinanceAgreement" name="VendorFinanceAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="abio_EquityFinancingsAndWarrantsDisclosureTextBlock" name="EquityFinancingsAndWarrantsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" name="DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" name="CompanyAndSummaryOfSignificantAccountingPoliciesTableLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CompanyAndSummaryOfSignificantAccountingPoliciesTable" name="CompanyAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" name="CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_NumberOfPatientsCompanyPlansToEnroll" name="NumberOfPatientsCompanyPlansToEnroll" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_AnticipatedPeriodToStartAtrialFibrillationTrial" name="AnticipatedPeriodToStartAtrialFibrillationTrial" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_TwoZeroOneThreeEquityFinancingsMember" name="TwoZeroOneThreeEquityFinancingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_RevenueGenerated" name="RevenueGenerated" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_DisclosureLossPerShareDetailsLineItems" name="DisclosureLossPerShareDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" name="ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_DisclosureLossPerShareDetailsTextualLineItems" name="DisclosureLossPerShareDetailsTextualLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_EarningsLossPerShareTextualAbstract" name="EarningsLossPerShareTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" name="DisclosureMergerWithNuveloIncOnJanuary272009DetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" name="MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FairValueDisclosuresTextualAbstract" name="FairValueDisclosuresTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_FairValueDisclosuresAdditionalTextualAbstract" name="FairValueDisclosuresAdditionalTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" name="CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" name="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_ComponentsOfPropertyAndEquipmentAbstract" name="ComponentsOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_LeaseholdImprovementsUsefulLife" name="LeaseholdImprovementsUsefulLife" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_DisclosurePropertyAndEquipmentDetailsTextualLineItems" name="DisclosurePropertyAndEquipmentDetailsTextualLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_PropertyAndEquipmentTextualAbstract" name="PropertyAndEquipmentTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_DepreciationAndAmortizationExpenseSinceInception" name="DepreciationAndAmortizationExpenseSinceInception" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="abio_DisclosureCommitmentsAndContingenciesDetailsLineItems" name="DisclosureCommitmentsAndContingenciesDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_LeaseTerm" name="LeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ExtendedLeaseTerm" name="ExtendedLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_RightsToExtendTerm" name="RightsToExtendTerm" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_AllowToTerminateAgreement" name="AllowToTerminateAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_OneTimePaymentToLandlordForNewLeasedPremises" name="OneTimePaymentToLandlordForNewLeasedPremises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_LeaseMonthExpirationDate" name="LeaseMonthExpirationDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_MilestonePaymentMadeByCompany" name="MilestonePaymentMadeByCompany" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_ExpectedMilestonePaymentsUponApproval" name="ExpectedMilestonePaymentsUponApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_AnotherExpectedMilestonePaymentsUponApproval" name="AnotherExpectedMilestonePaymentsUponApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="abio_MinimumPercentageOfRoyaltyObligation" name="MinimumPercentageOfRoyaltyObligation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_MaximumPercentageOfRoyaltyObligation" name="MaximumPercentageOfRoyaltyObligation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" name="PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" name="MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" name="MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_MilestonePaymentDuePeriod" name="MilestonePaymentDuePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_PrivateInvestmentInPublicEquityTransactionMember" name="PrivateInvestmentInPublicEquityTransactionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_EquityFinancingsAndWarrantsTextualAbstract" name="EquityFinancingsAndWarrantsTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_PrivateInvestmentInPublicEquityOfferingCloseDate" name="PrivateInvestmentInPublicEquityOfferingCloseDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="abio_PurchasePriceOfCommonStockUnit" name="PurchasePriceOfCommonStockUnit" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ClassOfWarrantOrRightExercisableExpirationPeriod" name="ClassOfWarrantOrRightExercisableExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" name="ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="abio_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_TwoZeroOneOneEquityFinancingsMember" name="TwoZeroOneOneEquityFinancingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_RegisteredDirectOfferingCloseDate" name="RegisteredDirectOfferingCloseDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="abio_DisclosureShareBasedCompensationDetails1LineItems" name="DisclosureShareBasedCompensationDetails1LineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_DisclosureIncomeTaxesDetailsLineItems" name="DisclosureIncomeTaxesDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="abio_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E4FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Disclosures (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresAdditionalTextualAbstract', window );"><strong>Fair Value Disclosures (Additional Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities', window );">Cash equivalents consisting of money market funds with maturities</a></td>
        <td class="text">90 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount', window );">Transfers of assets between fair value hierarchy levels</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money Market Funds</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresTextualAbstract', window );"><strong>Fair Value Disclosures (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents consisting of money market funds</a></td>
        <td class="nump">$ 3,500,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash equivalents consisting of money market funds with maturities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_CashEquivalentsConsistingOfMoneyMarketFundsWithMaturities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value assets between hierarchy levels transfers amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueDisclosuresAdditionalTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_FairValueDisclosuresAdditionalTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueDisclosuresTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_FairValueDisclosuresTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Company may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8<br><br> -Footnote 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 8, 9, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(2) Loss </font><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Per</font><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> Share </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The Company calculates basic loss per share by dividing loss attributable to common stockholders by the weighted average common shares outstanding during the period, excluding common stock subject to vesting provisions. Diluted loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. The Company&#8217;s potentially dilutive shares include options and warrants. </font></p>
			<p style="margin:9pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: </font></p>
			<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:76%">

					<tr style="height:11.25pt">
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</th>
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</th>
						<th colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:160.35pt">
							<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> Three Months Ended March 31, </font></p>
						</th>
					</tr>
					<tr style="height:12.75pt">
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</th>
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</th>
						<th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">2013</font></p>
						</th>
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</th>
						<th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">2012</font></p>
						</th>
					</tr>


					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(In thousands, except shares and per share data)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Net loss</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(1,071)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(1,407)</font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Net loss available to common shareholders</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(1,071)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(1,407)</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:2.5pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Weighted average shares of common stock outstanding</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">3,037,546</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">2,030,499</font></p>
						</td>
					</tr>
					<tr style="height:5.4pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Less:&#160; Weighted-average shares of unvested common stock</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(2,783)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(2,783)</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td rowspan="2" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Total weighted-average shares used in computing net loss per share attributed to common stockholders</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">3,034,763</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">2,027,716</font></p>
						</td>
					</tr>
					<tr style="height:13.5pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Basic and diluted loss per share</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(0.35)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(0.69)</font></p>
						</td>
					</tr>
					<tr style="height:1pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
					</tr>
				<!--[if !supportMisalignedColumns]><tr style="height:0pt">
					<td style="width:200.7pt; border:none">
					</td>
					<td style="width:11.2pt; border:none">
					</td>
					<td style="width:55.95pt; border:none">
					</td>
					<td style="width:12.25pt; border:none">
					</td>
					<td style="width:56.45pt; border:none">
					</td>
				</tr><![endif]--></table>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">.</font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Potentially dilutive securities representing</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt; ">1.3</font><font style="font-family:'Times New Roman'; font-size:10pt"> million and </font><font style="font-family:'Times New Roman'; font-size:10pt; ">604,000</font><font style="font-family:'Times New Roman'; font-size:10pt"> weighted average shares of common stock were excluded for the three months ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 and 2012, respectively, because including them would have an anti-dilutive effect on net loss per share</font><font style="font-family:'Times New Roman'; font-size:10pt">. </font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16381557&amp;loc=d3e4984-109258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y
M-3@Q,#EC-#0X-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(P
M9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T.#<T+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S7W5N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?4')E
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L
M:61A=&5D7U-T871E;65N='-?;V9?4')E,3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F
M7T-A<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E1H
M95]#;VUP86YY7V%N9%]3=6UM87)Y7V]F7U-I9SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DQO<W-?4&5R7U-H87)E/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^365R9V5R7W=I=&A?3G5V
M96QO7TEN8U]O;E]*86YU/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1F%I<E]686QU95]$:7-C;&]S=7)E<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE
M;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM
M:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D5Q=6ET>5]&:6YA;F-I;F=S7V%N9%]787)R
M86YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-H
M87)E0F%S961?0V]M<&5N<V%T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^5&AE7T-O;7!A;GE?86YD7U-U;6UA<GE?
M;V9?4VEG,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/DQO<W-?4&5R7U-H87)E7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G1?5&%B;&5S
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4VAA<F5B
M87-E9%]#;VUP96YS871I;VY?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^5&AE7T-O;7!A;GE?86YD7U-U;6UA<GE?;V9?
M4VEG,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQO
M<W-?4&5R7U-H87)E7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y,;W-S7U!E<E]3:&%R95]$971A:6QS7U1E>'1U86P\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y-97)G97)?
M=VET:%].=79E;&]?26YC7V]N7TIA;G4Q/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]$:7-C;&]S=7)E<U]$971A
M:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O
M<&5R='E?86YD7T5Q=6EP;65N=%]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N=%]$
M971A:6QS,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5Q=6ET>5]&:6YA;F-I;F=S7V%N
M9%]787)R86YT<S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,CDN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y3:&%R96)A<V5D7T-O;7!E;G-A=&EO;E]$971A:6P\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,S`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3:&%R96)A<V5D7T-O;7!E
M;G-A=&EO;E]$971A:6PQ/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,Q+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^26YC;VUE7U1A>&5S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S(N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7
M;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T
M<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E
M4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C
M=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O
M=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME
M;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@
M<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N
M97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X-S0-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(P9F(U8V1?-3<T85\T,C=E
M7V(U861?.34X,3`Y8S0T.#<T+U=O<FMS:&5E=',O4VAE970P,2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P13)!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@
M86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA>2`Q,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="`M($1O8W5M96YT(&%N
M9"!%;G1I='D@26YF;W)M871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R
M86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D%20T$@
M0FEO<&AA<FUA+"!);F,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P,#`Y,#<V-30\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M
M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P+5$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y-87(@,S$L#0H)"3(P,3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT
M($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/E$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C`Q,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@
M665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y3;6%L;&5R(%)E<&]R=&EN9R!#;VUP86YY/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3@U+#4V,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V(P9F(U8V1?-3<T85\T
M,C=E7V(U861?.34X,3`Y8S0T.#<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"]7
M;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$505T%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H
M=6YA=61I=&5D*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T
M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E=',Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@
M86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RPU,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(L.3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!C=7)R96YT(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L.3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPP-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,3,Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPR,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0W5R<F5N="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y
M86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8W)U960@8V]M<&5N<V%T:6]N(&%N9"!E;7!L;WEE92!B96YE9FET<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP
M96YS97,@86YD(&]T:&5R(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0L(&-U<G)E;G0@
M<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@
M86YD(&-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO
M;&1E<G/B@)D@97%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[
M(#$P,"!M:6QL:6]N('-H87)E<R!A=71H;W)I>F5D(&%T($UA<F-H(#,Q+"`R
M,#$S(&%N9"!$96-E;6)E<B`S,2P@,C`Q,CL@,RPQ.#4L-38R(&%N9"`R+#8V
M,"PS,34@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@870@36%R8V@@
M,S$L(#(P,3,@86YD($1E8V5M8F5R(#,Q+"`R,#$R+"!R97-P96-T:79E;'DN
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA
M;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<R+#,W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<P+#@Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5F:6-I="!A8V-U;75L871E9"!D=7)I;F<@
M=&AE(&1E=F5L;W!M96YT('-T86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@V.2PP-C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-C<L.3DT*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<^*`
MF2!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S$Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPY,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)SXH"9
M(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#$S
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,RPR,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C9%\U-S1A7S0R-V5?
M8C5A9%\Y-3@Q,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%04=!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS;VQI9&%T
M960@0F%L86YC92!3:&5E=',@*%!A<F5N=&AE=&EC86PI("AU;F%U9&ET960I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T871E;65N="`M($-O;G-O;&ED871E
M9"!"86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;"D@*'5N875D:71E9"D@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#$X-2PU-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#8V,"PS,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U
M='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$X
M-2PU-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#8V,"PS,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W
M-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C9%\U-S1A
M7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E=#`T+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%0DQ!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS
M;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS(&%N9"!#;VUP<F5H
M96YS:79E($QO<W,@*'5N875D:71E9"D@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I
M9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3,U($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;W-T<R!A;F0@97AP96YS97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H
M(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#0R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-#(L.#4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y396QL:6YG+"!G96YE<F%L(&%N9"!A
M9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#,L-#<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y-97)G97(@=')A;G-A8W1I;VX@8V]S=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-#<P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<G5C='5R:6YG
M(&5X<&5N<V4L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPT,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQO<W,@;VX@:6UP86ER;65N="!O9B!I;BUP<F]C97-S(')E<V5A
M<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!C;W-T<R!A;F0@97AP96YS97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#<P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,C$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L,#<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L-#`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$P,"PR,3,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'86EN(&]N(&%S<VEG;FUE
M;G0@;V8@<&%T96YT(')I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D=A:6X@;VX@8F%R9V%I;B!P=7)C:&%S93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,C@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!A;F0@
M;W1H97(@:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#`R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YT97)E<W0@86YD(&]T:&5R(&5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-#,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!B969O<F4@:6YC
M;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`W
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#0P-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@W,2PS-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"96YE9FET(&9R;VT@:6YC;VUE('1A>&5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(X,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M(&%N9"!C;VUP<F5H96YS:79E(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L,#<Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L-#`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#8Y+#`V-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,Z($%C8W)E=&EO
M;B!O9B!R961E96UA8FQE(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C0U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5S<SH@1&5E
M;65D('!R969E<G)E9"!S=&]C:R!D:79I9&5N9"!F;W(@861D:71I;VYA;"!C
M;VUM;VX@<VAA<F5S(&ES<W5A8FQE('5N9&5R(&%N=&DM9&EL=71I;VX@<')O
M=FES:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S@Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!L;W-S(&%T=')I8G5T86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L,#<Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PT
M,#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@W,"PP.3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYE="!L;W-S(&%T=')I8G5T86)L92!T
M;R!C;VUM;VX@<W1O8VMH;VQD97)S('!E<B!S:&%R93H\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XS-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N
M-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E=E:6=H=&5D(&%V97)A9V4@<VAA<F5S(&]U='-T86YD
M:6YG.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPP,S0L-S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPP,C<L-S$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y
M-3@Q,#EC-#0X-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(P
M9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T.#<T+U=O<FMS:&5E=',O
M4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14I:3E(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@4')E9F5R<F5D(%-T
M;V-K(&%N9"!3=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5F:6-I="D@*'5N875D
M:71E9"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D
M871A/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5&]T
M86P\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y#87-H+"!.970@;V8@3V9F97)I;F<@0V]S=',\8G(^55-$("@D*3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y)<W-U86YC92!F;W(@3F]T
M97,@4&%Y86)L92!A;F0@4F5L871E9"!!8V-R=65D($EN=&5R97-T(&]N($IA
M;G5A<GD@,RP@,C`P-3QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DES<W5A;F-E(&9O<B!);G1E;&QE8W1U86P@4')O<&5R
M='D@3&EC96YS92!2:6=H=',@;VX@3V-T;V)E<B`Q-"P@,C`P-3QB<CY54T0@
M*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DES<W5A;F-E
M(&9O<B!.;W1E<R!087EA8FQE(&%N9"!296QA=&5D($%C8W)U960@26YT97)E
M<W0@;VX@3V-T;V)E<B`Q-"P@,C`P-3QB<CY54T0@*"0I/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DES<W5A;F-E(&9O<B!);G1E;&QE8W1U
M86P@4')O<&5R='D@3&EC96YS92!2:6=H=',@;VX@1F5B<G5A<GD@,C$L(#(P
M,#8\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y)<W-U86YC92!F;W(@26YT96QL96-T=6%L(%!R;W!E<G1Y($QI8V5N<V4@
M4FEG:'1S(&]N($9E8G)U87)Y(#(R+"`R,#`V/&)R/E531"`H)"D\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^27-S=6%N8V4@9F]R($EN=&5L
M;&5C='5A;"!0<F]P97)T>2!,:6-E;G-E(%)I9VAT<R!O;B!*=6YE(#(S+"`R
M,#`V/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^06-C<F5T:6]N(&]F(%-E<FEE<R!!/&)R/E531"`H)"D\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^06-C<F5T:6]N(&]F(%-E<FEE<R!"
M/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M27-S=6%N8V4@9F]R($EN=&5L;&5C='5A;"!0<F]P97)T>2!,:6-E;G-E(%)I
M9VAT<R!O;B!*86YU87)Y(#$X+"`R,#`W/&)R/E531"`H)"D\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^27-S=6%N8V4@9F]R($EN=&5L;&5C
M='5A;"!0<F]P97)T>2!,:6-E;G-E(%)I9VAT<R!O;B!*=6YE(#,P+"`R,#`W
M/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M0V]M;6]N($-O;G9E<G-I;VX\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y.;W1E<R!A;F0@4F5L871E9"!!8V-R=65D($EN
M=&5R97-T/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5R:65S($$\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397)I97,@03QB<CY#87-H+"!.970@;V8@3V9F97)I
M;F<@0V]S=',\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R
M:65S($$\8G(^27-S=6%N8V4@;V8@4V5R:65S($$@;VX@1F5B<G5A<GD@,C(L
M(#(P,#8\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397)I97,@03QB<CY4:&ER9"!)<W-U86YC92!F;W(@3F]T97,@4&%Y
M86)L92!A;F0@4F5L871E9"!!8V-R=65D($EN=&5R97-T/&)R/E531"`H)"D\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R:65S($$\8G(^
M27-S=6%N8V4@;V8@4V5R:65S($$@;VX@1&5C96UB97(@."P@,C`P-CQB<CY5
M4T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<FEE
M<R!!/&)R/E-E<FEE<R!!(&]F9F5R:6YG(&-O<W1S/&)R/E531"`H)"D\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R:65S($$\8G(^06-C
M<F5T:6]N(&]F(%-E<FEE<R!!/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5R:65S($$\8G(^0V]M;6]N($-O;G9E<G-I
M;VX\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397)I97,@0CQB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<FEE<R!"/&)R/D-A<V@L($YE="!O9B!/9F9E<FEN9R!#
M;W-T<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397)I97,@
M0CQB<CY)<W-U86YC92!F;W(@4V5R:65S($(@;VX@36%Y(#,Q+"`R,#`W/&)R
M/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R
M:65S($(\8G(^27-S=6%N8V4@9F]R(%-E<FEE<R!"(&]N($1E8V5M8F5R(#(X
M+"`R,#`W/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5R:65S($(\8G(^06-C<F5T:6]N(&]F(%-E<FEE<R!"/&)R/E53
M1"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R:65S
M($(\8G(^0V]M;6]N($-O;G9E<G-I;VX\8G(^55-$("@D*3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL\8G(^55-$("@D
M*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O
M8VL\8G(^0V%S:"P@3F5T(&]F($]F9F5R:6YG($-O<W1S/&)R/E531"`H)"D\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K
M/&)R/DES<W5A;F-E(&9O<B!.;W1E<R!087EA8FQE(&%N9"!296QA=&5D($%C
M8W)U960@26YT97)E<W0@;VX@2F%N=6%R>2`S+"`R,#`U/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C:SQB<CY)<W-U86YC
M92!F;W(@26YT96QL96-T=6%L(%!R;W!E<G1Y($QI8V5N<V4@4FEG:'1S(&]N
M($]C=&]B97(@,30L(#(P,#4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^0V]M;6]N(%-T;V-K/&)R/DES<W5A;F-E(&9O<B!.;W1E<R!087EA
M8FQE(&%N9"!296QA=&5D($%C8W)U960@26YT97)E<W0@;VX@3V-T;V)E<B`Q
M-"P@,C`P-3QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D-O;6UO;B!3=&]C:SQB<CY)<W-U86YC92!F;W(@26YT96QL96-T
M=6%L(%!R;W!E<G1Y($QI8V5N<V4@4FEG:'1S(&]N($9E8G)U87)Y(#(Q+"`R
M,#`V/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3
M=&]C:SQB<CY)<W-U86YC92!F;W(@26YT96QL96-T=6%L(%!R;W!E<G1Y($QI
M8V5N<V4@4FEG:'1S(&]N($9E8G)U87)Y(#(R+"`R,#`V/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C:SQB<CY)<W-U86YC
M92!F;W(@26YT96QL96-T=6%L(%!R;W!E<G1Y($QI8V5N<V4@4FEG:'1S(&]N
M($IU;F4@,C,L(#(P,#8\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^0V]M;6]N(%-T;V-K/&)R/DES<W5A;F-E(&9O<B!);G1E;&QE8W1U86P@
M4')O<&5R='D@3&EC96YS92!2:6=H=',@;VX@3F]V96UB97(@-RP@,C`P-CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL\
M8G(^27-S=6%N8V4@9F]R($EN=&5L;&5C='5A;"!0<F]P97)T>2!,:6-E;G-E
M(%)I9VAT<R!O;B!*86YU87)Y(#$X+"`R,#`W/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C:SQB<CY)<W-U86YC92!F;W(@
M26YT96QL96-T=6%L(%!R;W!E<G1Y($QI8V5N<V4@4FEG:'1S(&]N($IU;F4@
M,S`L(#(P,#<\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M
M;6]N(%-T;V-K/&)R/DES<W5A;F-E(&]F($-O;6UO;B!3=&]C:R!F;W(@0V]M
M;65R8VEA;"!,:6-E;G-E(%)I9VAT<RP@;VX@2G5L>2`Q.2P@,C`P-SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL\8G(^
M27-S=6%N8V4@;V8@4VAA<F5S('1O($5X96-U=&EV92!3=6)J96-T('1O(%)E
M<'5R8VAA<V4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M
M;6]N(%-T;V-K/&)R/D-O;6UO;B!#;VYV97)S:6]N/&)R/E531"`H)"D\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K/&)R
M/DYO=&5S(&%N9"!296QA=&5D($%C8W)U960@26YT97)E<W0\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA;"!086ED($EN($-A
M<&ET86P\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y!9&1I=&EO;F%L(%!A:60@26X@0V%P:71A;#QB<CY#87-H+"!.970@
M;V8@3V9F97)I;F<@0V]S=',\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60@26X@0V%P:71A;#QB
M<CY)<W-U86YC92!F;W(@3F]T97,@4&%Y86)L92!A;F0@4F5L871E9"!!8V-R
M=65D($EN=&5R97-T(&]N($IA;G5A<GD@,RP@,C`P-3QB<CY54T0@*"0I/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I
M9"!);B!#87!I=&%L/&)R/DES<W5A;F-E(&9O<B!);G1E;&QE8W1U86P@4')O
M<&5R='D@3&EC96YS92!2:6=H=',@;VX@3V-T;V)E<B`Q-"P@,C`P-3QB<CY5
M4T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET
M:6]N86P@4&%I9"!);B!#87!I=&%L/&)R/DES<W5A;F-E(&9O<B!.;W1E<R!0
M87EA8FQE(&%N9"!296QA=&5D($%C8W)U960@26YT97)E<W0@;VX@3V-T;V)E
M<B`Q-"P@,C`P-3QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"!);B!#87!I=&%L/&)R/DES<W5A
M;F-E(&9O<B!);G1E;&QE8W1U86P@4')O<&5R='D@3&EC96YS92!2:6=H=',@
M;VX@1F5B<G5A<GD@,C$L(#(P,#8\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60@26X@0V%P:71A
M;#QB<CY)<W-U86YC92!F;W(@26YT96QL96-T=6%L(%!R;W!E<G1Y($QI8V5N
M<V4@4FEG:'1S(&]N($9E8G)U87)Y(#(R+"`R,#`V/&)R/E531"`H)"D\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA;"!086ED
M($EN($-A<&ET86P\8G(^27-S=6%N8V4@9F]R($EN=&5L;&5C='5A;"!0<F]P
M97)T>2!,:6-E;G-E(%)I9VAT<R!O;B!*=6YE(#(S+"`R,#`V/&)R/E531"`H
M)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA
M;"!086ED($EN($-A<&ET86P\8G(^06-C<F5T:6]N(&]F(%-E<FEE<R!!/&)R
M/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D
M:71I;VYA;"!086ED($EN($-A<&ET86P\8G(^06-C<F5T:6]N(&]F(%-E<FEE
M<R!"/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^061D:71I;VYA;"!086ED($EN($-A<&ET86P\8G(^27-S=6%N8V4@9F]R
M($EN=&5L;&5C='5A;"!0<F]P97)T>2!,:6-E;G-E(%)I9VAT<R!O;B!*86YU
M87)Y(#$X+"`R,#`W/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^061D:71I;VYA;"!086ED($EN($-A<&ET86P\8G(^27-S
M=6%N8V4@9F]R($EN=&5L;&5C='5A;"!0<F]P97)T>2!,:6-E;G-E(%)I9VAT
M<R!O;B!*=6YE(#,P+"`R,#`W/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^061D:71I;VYA;"!086ED($EN($-A<&ET86P\
M8G(^0V]M;6]N($-O;G9E<G-I;VX\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L(%!A:60@26X@0V%P:71A
M;#QB<CY.;W1E<R!A;F0@4F5L871E9"!!8V-R=65D($EN=&5R97-T/&)R/E53
M1"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5F:6-I
M="!!8V-U;75L871E9"!$=7)I;F<@=&AE($1E=F5L;W!M96YT(%-T86=E/&)R
M/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5F
M:6-I="!!8V-U;75L871E9"!$=7)I;F<@=&AE($1E=F5L;W!M96YT(%-T86=E
M/&)R/D-A<V@L($YE="!O9B!/9F9E<FEN9R!#;W-T<SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$969I8VET($%C8W5M=6QA=&5D($1U<FEN
M9R!T:&4@1&5V96QO<&UE;G0@4W1A9V4\8G(^27-S=6%N8V4@9F]R($YO=&5S
M(%!A>6%B;&4@86YD(%)E;&%T960@06-C<G5E9"!);G1E<F5S="!O;B!/8W1O
M8F5R(#$T+"`R,#`U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"96=I;FYI;F<@0F%L86YC92P@=F%L=64@870@1&5C+B`Q-RP@,C`P
M,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O
M9B!S=&]C:R!F;W(@8V%S:"P@;F5T(&]F(&]F9F5R:6YG(&-O<W1S+"!V86QU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U
M86YC92!O9B!S=&]C:R!F;W(@8V%S:"P@;F5T(&]F(&]F9F5R:6YG(&-O<W1S
M+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3@X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$Q-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N9&EN9R!"86QA;F-E+"!V86QU92!A="!$96,N(#,Q+"`R,#`S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,34I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M9&EN9R!"86QA;F-E+"!S:&%R97,@870@1&5C+B`S,2P@,C`P,SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU.#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F('-T
M;V-K(&9O<B!C87-H+"!N970@;V8@;V9F97)I;F<@8V]S=',L('9A;'5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M<W1O8VL@9F]R(&-A<V@L(&YE="!O9B!O9F9E<FEN9R!C;W-T<RP@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PW,C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@U,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-3$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L('9A;'5E(&%T($1E8RX@
M,S$L(#(P,#0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8Q.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-C(W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0F5G:6YN:6YG($)A;&%N8V4L('-H87)E<R!A="!$96,N(#,Q+"`R
M,#`T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPS,#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES
M<W5A;F-E(&]F('-T;V-K(&9O<B!C87-H+"!N970@;V8@;V9F97)I;F<@8V]S
M=',L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PS-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS-30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F('-T;V-K
M(&9O<B!C87-H+"!N970@;V8@;V9F97)I;F<@8V]S=',L('-H87)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY,C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DW.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#`Y
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L-#4Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L-#4Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L('9A;'5E
M(&%T($1E8RX@,S$L(#(P,#4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8W."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#0P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(L,#@V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L('-H87)E<R!A
M="!$96,N(#,Q+"`R,#`U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,"PR,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&]F('-T;V-K(&9O<B!C87-H+"!N970@;V8@
M;V9F97)I;F<@8V]S=',L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY+#,Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!S
M=&]C:R!F;W(@8V%S:"P@;F5T(&]F(&]F9F5R:6YG(&-O<W1S+"!S:&%R97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-S(W+#,U-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#<T
M+#`X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$W+#,W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$S+#DP-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-3`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@U+#(T,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#(T,2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&-O;6UO;B!S=&]C:R!U<&]N(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,L
M(&9O<B!C87-H+"!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U<&]N(&5X97)C
M:7-E(&]F('-T;V-K(&]P=&EO;G,L(&9O<B!C87-H+"!S:&%R97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R,"PX,3<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`Q.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3V9F97)I
M;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E+"!V86QU
M92!A="!$96,N(#,Q+"`R,#`V/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@U+#<T-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-"PY,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#4X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#<L,S(W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L
M('-H87)E<R!A="!$96,N(#,Q+"`R,#`V/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY+#(R,BPR-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,#(L,#0W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!S=&]C
M:R!F;W(@8V%S:"P@;F5T(&]F(&]F9F5R:6YG(&-O<W1S+"!V86QU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M27-S=6%N8V4@;V8@<W1O8VL@9F]R(&-A<V@L(&YE="!O9B!O9F9E<FEN9R!C
M;W-T<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#8X."PY,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#<V-BPV-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#,P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8T,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S@S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L.3$U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,L.3DT*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$S+#DY
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U<&]N(&5X97)C:7-E(&]F
M('-T;V-K(&]P=&EO;G,L(&9O<B!C87-H+"!V86QU93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T
M;V-K('5P;VX@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@9F]R(&-A<V@L
M('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,C<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$T-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I
M;F<@0F%L86YC92P@=F%L=64@870@1&5C+B`S,2P@,C`P-SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3DL-C@Y*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#DS.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#@W,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C,R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C$L,S(Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YD:6YG($)A;&%N8V4L('-H87)E<R!A="!$96,N(#,Q+"`R
M,#`W/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#(R,BPR-3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#0U-2PU-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,C(L.3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3DL-#,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$Y+#0S,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO
M;B!S=&]C:R!U<&]N(&5X97)C:7-E(&]F('-T;V-K(&]P=&EO;G,L(&9O<B!C
M87-H+"!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5P;VX@97AE<F-I<V4@;V8@
M<W1O8VL@;W!T:6]N<RP@9F]R(&-A<V@L('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S8L,34T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9E<FEN9R!C;W-T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S8I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!F86ER('9A;'5E(&]F('=A
M<G)A;G1S(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@8V]N=F5R=&EB;&4@
M;F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,SDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,SDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;F1I;F<@0F%L86YC92P@=F%L=64@870@1&5C+B`S,2P@,C`P
M.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S@L,3<X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#DU
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$W+#DP-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-3<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-#`L-S4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L('-H87)E<R!A
M="!$96,N(#,Q+"`R,#`X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY+#(R,BPR-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#0U-2PU-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3DL,#<Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PQ,S@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PQ,S@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC
M92!O9B!C;VUM;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O<'1I
M;VYS+"!F;W(@8V%S:"P@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5P;VX@
M97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@9F]R(&-A<V@L('-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L-3(Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9E<FEN
M9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#0R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#DS*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D:G5S=&UE;G0@9F]R
M(&9R86-T:6]N86P@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E96UE9"!P<F5F97)R960@<W1O8VL@9&EV:61E;F0@
M9F]R(&%D9&ET:6]N86P@8V]M;6]N('-H87)E<R!I<W-U86)L92!U;F1E<B!A
M;G1I+61I;'5T:6]N('!R;W9I<VEO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-S@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#<X,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G-I;VX@;V8@<')E9F5R<F5D
M('-T;V-K(&%N9"!C;VYV97)T:6)L92!N;W1E<R!A;F0@<F5L871E9"!A8V-R
M=65D(&EN=&5R97-T+"!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S,L-S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH."PU,#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,34L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$X+#<X,2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L-S@P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PU,#$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VYV97)S:6]N(&]F('!R969E<G)E9"!S=&]C:RP@<VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y+#(R,BPR-3<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPT-34L-3<Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4P-RPQ,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@<F5L96%S92!F<F]M(')E<W1R
M:6-T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)S:6]N(&]F('!R969E<G)E9"!S=&]C:R!A;F0@8V]N=F5R=&EB;&4@
M;F]T97,@86YD(')E;&%T960@86-C<G5E9"!I;G1E<F5S=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,S,L-S@Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-3`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L-S@Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S,RPW.#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^."PU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!O9B!C;VUM;VX@<W1O8VL@<'5R8VAA
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#4L-#8U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)S:6]N(&]F('=A<G)A;G1S(&9O<B!P<F5F97)R960@<W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUE<F=E<B!W:71H
M($YU=F5L;RP@26YC+BP@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q+#DQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$Q+#DQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^365R9V5R('=I=&@@3G5V96QO+"!);F,N
M+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T-RPX
M,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U;F1E<B!E;7!L;WEE92!S
M=&]C:R!P=7)C:&%S92!P;&%N(&%N9"!U<&]N('9E<W1I;F<@;V8@<F5S=')I
M8W1E9"!S=&]C:R!U;FET<RP@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=6YD97(@
M96UP;&]Y964@<W1O8VL@<'5R8VAA<V4@<&QA;B!A;F0@=7!O;B!V97-T:6YG
M(&]F(')E<W1R:6-T960@<W1O8VL@=6YI=',L('-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@9F%I<B!V86QU
M92!O9B!W87)R86YT<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H(&QE87-E
M('1E<FUI;F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N9&EN9R!"86QA;F-E+"!V86QU92!A="!$96,N(#,Q+"`R,#`Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#0Q,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-RPS,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T
M.2PX.3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;F1I;F<@0F%L86YC92P@<VAA<F5S(&%T($1E8RX@,S$L(#(P
M,#D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C<P+#`W-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M27-S=6%N8V4@;V8@<W1O8VL@9F]R(&-A<V@L(&YE="!O9B!O9F9E<FEN9R!C
M;W-T<RP@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L
M,3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPQ.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&]F('-T;V-K(&9O<B!C87-H+"!N970@;V8@
M;V9F97)I;F<@8V]S=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3DT+#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#@L-#(P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#@L-#(P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N
M('-T;V-K('5P;VX@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@9F]R(&-A
M<V@L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U<&]N(&5X97)C:7-E(&]F
M('-T;V-K(&]P=&EO;G,L(&9O<B!C87-H+"!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@L,C0X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YD:6YG($)A;&%N8V4L('9A;'5E(&%T($1E8RX@,S$L(#(P,3`\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-S<Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8U+#`X,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4X+#,Q,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N9&EN9R!"86QA;F-E+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q,#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-S(L-#(R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC
M92!O9B!S=&]C:R!F;W(@8V%S:"P@;F5T(&]F(&]F9F5R:6YG(&-O<W1S+"!V
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP,3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP
M,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F('-T;V-K(&9O<B!C87-H+"!N970@;V8@;V9F97)I
M;F<@8V]S=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-34W+#@Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#4L,S8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#4L,S8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K
M('5P;VX@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@9F]R(&-A<V@L('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92P@=F%L=64@870@1&5C+B`S
M,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW,S(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-CDL-#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-C,L-C<T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4L('-H87)E<R!A="!$96,N
M(#,Q+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`S
M,"PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5A;F-E(&]F('-T;V-K(&9O<B!C87-H+"!N970@;V8@;V9F
M97)I;F<@8V]S=',L('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#$X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@<W1O8VL@9F]R(&-A<V@L
M(&YE="!O9B!O9F9E<FEN9R!C;W-T<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,CDL.#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-"PS,C`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PS,C`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E
M9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YD:6YG($)A;&%N8V4L('9A;'5E(&%T($1E8RX@,S$L(#(P
M,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3`W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#@Y
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#8W+#DY-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E+"!S:&%R97,@870@1&5C+B`S,2P@
M,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV-C`L,S$U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!S=&]C:R!F;W(@8V%S:"P@;F5T(&]F(&]F9F5R:6YG
M(&-O<W1S+"!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PT,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#0R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^27-S=6%N8V4@;V8@<W1O8VL@9F]R(&-A<V@L(&YE="!O
M9B!O9F9E<FEN9R!C;W-T<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,C$L,#8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,2PP-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,2PP-S$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM
M;VX@<W1O8VL@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS+"!F;W(@
M8V%S:"P@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061J=7-T;65N="!F;W(@
M9G)A8W1I;VYA;"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5P;VX@97AE<F-I
M<V4@;V8@=V%R<F%N=',@9F]R(&-A<V@L('9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O
M8VL@=7!O;B!E>&5R8VES92!O9B!W87)R86YT<R!F;W(@8V%S:"P@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(T-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG
M($)A;&%N8V4L('9A;'5E(&%T($UA<BX@,S$L(#(P,3,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPS,3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<R+#,W,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-CDL,#8U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YD:6YG($)A;&%N8V4L('-H87)E<R!A="!-87(N(#,Q+"`R,#$S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$X-2PU-C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-B,&9B-6-D7S4W
M-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X
M-S0O5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%345!1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O
M9B!0<F5F97)R960@4W1O8VL@86YD(%-T;V-K:&]L9&5R<R<@17%U:71Y("A$
M969I8VET*2`H=6YA=61I=&5D*2`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN
M(#`S+"`R,#`U/&)R/D-A<V@L($YE="!O9B!/9F9E<FEN9R!#;W-T<SQB<CY#
M;VUM;VX@4W1O8VL\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`P-#QB<CY#87-H+"!.970@;V8@3V9F97)I;F<@0V]S=',\
M8G(^0V]M;6]N(%-T;V-K/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,#(\8G(^0V%S:"P@3F5T(&]F($]F9F5R:6YG($-O
M<W1S/&)R/D-O;6UO;B!3=&]C:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*86XN(#`S+"`R,#`U/&)R/DES<W5A;F-E(&9O<B!.;W1E<R!0
M87EA8FQE(&%N9"!296QA=&5D($%C8W)U960@26YT97)E<W0@;VX@2F%N=6%R
M>2`S+"`R,#`U/&)R/D-O;6UO;B!3=&]C:SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y/8W0N(#$T+"`R,#`U/&)R/DES<W5A;F-E(&9O<B!)
M;G1E;&QE8W1U86P@4')O<&5R='D@3&EC96YS92!2:6=H=',@;VX@3V-T;V)E
M<B`Q-"P@,C`P-3QB<CY#;VUM;VX@4W1O8VL\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1F5B+B`R,2P@,C`P-CQB<CY)<W-U86YC92!F;W(@
M26YT96QL96-T=6%L(%!R;W!E<G1Y($QI8V5N<V4@4FEG:'1S(&]N($9E8G)U
M87)Y(#(Q+"`R,#`V/&)R/D-O;6UO;B!3=&]C:SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y&96(N(#(R+"`R,#`V/&)R/DES<W5A;F-E(&]F
M(%-E<FEE<R!!(&]N($9E8G)U87)Y(#(R+"`R,#`V/&)R/E-E<FEE<R!!/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C(L(#(P,#8\
M8G(^5&AI<F0@27-S=6%N8V4@9F]R($YO=&5S(%!A>6%B;&4@86YD(%)E;&%T
M960@06-C<G5E9"!);G1E<F5S=#QB<CY397)I97,@03QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(R+"`R,#`V/&)R/DES<W5A;F-E
M(&9O<B!);G1E;&QE8W1U86P@4')O<&5R='D@3&EC96YS92!2:6=H=',@;VX@
M1F5B<G5A<GD@,C(L(#(P,#8\8G(^0V]M;6]N(%-T;V-K/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,C,L(#(P,#8\8G(^27-S=6%N
M8V4@9F]R($EN=&5L;&5C='5A;"!0<F]P97)T>2!,:6-E;G-E(%)I9VAT<R!O
M;B!*=6YE(#(S+"`R,#`V/&)R/D-O;6UO;B!3=&]C:SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#`W+"`R,#`V/&)R/DES<W5A;F-E
M(&9O<B!);G1E;&QE8W1U86P@4')O<&5R='D@3&EC96YS92!2:6=H=',@;VX@
M3F]V96UB97(@-RP@,C`P-CQB<CY#;VUM;VX@4W1O8VL\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`P."P@,C`P-CQB<CY)<W-U86YC
M92!O9B!397)I97,@02!O;B!$96-E;6)E<B`X+"`R,#`V/&)R/E-E<FEE<R!!
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`S,2P@,C`P
M-SQB<CY)<W-U86YC92!F;W(@4V5R:65S($(@;VX@36%Y(#,Q+"`R,#`W/&)R
M/E-E<FEE<R!"/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,C@L(#(P,#<\8G(^27-S=6%N8V4@9F]R(%-E<FEE<R!"(&]N($1E8V5M
M8F5R(#(X+"`R,#`W/&)R/E-E<FEE<R!"/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIA;BX@,3@L(#(P,#<\8G(^27-S=6%N8V4@9F]R($EN
M=&5L;&5C='5A;"!0<F]P97)T>2!,:6-E;G-E(%)I9VAT<R!O;B!*86YU87)Y
M(#$X+"`R,#`W/&)R/D-O;6UO;B!3=&]C:SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#`W/&)R/DES<W5A;F-E(&9O<B!)
M;G1E;&QE8W1U86P@4')O<&5R='D@3&EC96YS92!2:6=H=',@;VX@2G5N92`S
M,"P@,C`P-SQB<CY#;VUM;VX@4W1O8VL\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!M87)K970@<')I8V4@<&5R
M('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,S8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0X+C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+C,R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+C,R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,3`N,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-C(V-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XV,C8U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+C8R-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(N-#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S+C(U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X
M,3`Y8S0T.#<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B,&9B
M-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"]7;W)K<VAE971S+U-H
M965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$531T))/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-A<V@@1FQO=W,@*'5N
M875D:71E9"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,S4@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@=7-E
M9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,2PP-S$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#0P-RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8Y+#`V-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O
M(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@
M<&%T96YT(')I9VAT<R!A<W-I9VYM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@8F%R9V%I;B!P=7)C:&%S93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4L,C@R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C
M:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#<Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6-A<V@@:6YT97)E<W0@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB
M87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#8S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@=V%R<F%N=',@9F]R(&QE87-E
M('1E<FUI;F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8W)E=&EO;B!O9B!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);7!A:7)M96YT(&]F('!R;W!E<G1Y(&%N
M9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&]S<R!O;B!I;7!A:7)M96YT(&]F(&EN+7!R;V-E<W,@<F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5W)I=&4M;V9F(&]F(&1E9F5R<F5D('1A>"!L:6%B:6QI='D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,C@Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O
M;B!M87)K971A8FQE('-E8W5R:71I97,@879A:6QA8FQE(&9O<B!S86QE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-C,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XH1V%I;BD@;&]S
M<R!F<F]M(&1I<W!O<V%L(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<BP@;F5T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA
M;F=E(&EN(&]P97)A=&EN9R!A<W-E=',@86YD(&QI86)I;&ET:65S("AN970@
M;V8@86UO=6YT<R!A8W%U:7)E9"DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-3<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV-C,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L
M,S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,S0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,2PX,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S(&%N9"!O
M=&AE<B!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3DL,3,S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!U<V5D(&EN(&]P
M97)A=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@W-C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PV-38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.3@L,3@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S('!R
M;W9I9&5D(&)Y("AU<V5D(&EN*2!I;G9E<W1I;F<@86-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!R
M96-E:79E9"!F<F]M($UE<F=E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S`L,SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y087EM96YT(&]F(&1E9F5R<F5D('1R86YS86-T:6]N
M(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$X-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!U<F-H87-E(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PX.#@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M
M('-A;&4@;V8@;6%R:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-2PS-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L92!O
M9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<&%T96YT(')I9VAT<R!A
M<W-I9VYM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!I;G9E<W1I;F<@
M86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-2PP-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!P<F]V:61E9"!B>2`H=7-E9"!I
M;BD@9FEN86YC:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@
M;V8@8V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L92!A;F0@<F5L871E9"!W87)R
M86YT<R!F;W(@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,"PX-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8F%N
M:R!N;W1E('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]C965D<R!F<F]M('-T;V-K('-U8FIE8W0@=&\@<F5P=7)C
M:&%S93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E
M961S(&9R;VT@=&AE(&ES<W5A;F-E(&]F('!R969E<G)E9"!S=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(L,S$V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT(&]F
M(&]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@V,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&-O;6UO
M;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW-#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-2PX-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E<&%Y;65N="!O9B!P<FEN8VEP86P@;VX@8F%N:R!N;W1E('!A
M>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L,#`P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5P87EM96YT(&]F('!R:6YC:7!A;"!O;B!C;VYV97)T:6)L92!N;W1E<R!P
M87EA8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5P87EM96YT(&]F('!R:6YC:7!A;"!O;B!V96YD;W(@9FEN86YC92!A9W)E
M96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0S*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,R,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@9FEN86YC:6YG(&%C
M=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,SDP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-38L-C<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T("AD96-R96%S92D@:6YC<F5A<V4@:6X@8V%S:"!A
M;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PW,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPU,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',L(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L.3(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2PY-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',L(&5N9"!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-3,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PR,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#4S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@8V%S
M:"!F;&]W(&EN9F]R;6%T:6]N.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!P86ED/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D
M:7-C;&]S=7)E(&]F(&YO;F-A<V@@:6YV97-T:6YG(&%N9"!F:6YA;F-I;F<@
M=')A;G-A8W1I;VYS.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T(&]N(&YO=&5S('!A>6%B;&4@
M8V]N=F5R=&5D('1O(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@
M8W)E9&ET(&9A8VEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@9&5F97)R960@=')A;G-A8W1I;VX@8V]S=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5N9&]R(&9I;F%N
M8V4@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@<')O=FED960@8GD@
M*'5S960@:6XI(&9I;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT(&]F(&]F9F5R
M:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-#8I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#87-H(&9L;W=S('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!F
M:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&%Y;65N="!O9B!O9F9E<FEN9R!C;W-T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S,#@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#8S-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-B,&9B
M-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q
M,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^5&AE($-O;7!A;GD@86YD(%-U;6UA
M<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4:&4@0V]M<&%N>2!A
M;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.CEP="`P<'0@,'!T.R!P86=E+6)R96%K+6%F=&5R
M.F%V;VED)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[(&9O;G0M=V5I9VAT.F)O;&0G/B@Q
M*2!4:&4@0V]M<&%N>2!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O
M=6YT:6YG(%!O;&EC:65S(#PO9F]N=#X\+W`^#0H)"0D\<"!S='EL93TS1"=M
M87)G:6XZ-"XU<'0@,'!T(#!P="`Q,BXR<'0[('!A9V4M8G)E86LM869T97(Z
M879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9#L@9F]N
M="US='EL93II=&%L:6,G/D1E<V-R:7!T:6]N(&]F($)U<VEN97-S/"]F;VYT
M/CPO<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T)SX\
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M;&]G>2!A;F0@;6%Y('!R961I8W0@<&%T:65N="!R97-P;VYS92!T;R`\+V9O
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M="!L96%S="`R,#(V(&EN('1H92!5+E,N(&%N9"!I;G1O(#(P,C4@:6X@175R
M;W!E+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@8F5L:65V97,@=&AA="!I
M9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
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M(&9O<B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY'96YC87)O/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^(&EN=&\@,C`R.2!O<B`R,#,P(&EN('1H92!54R!A
M;F0@175R;W!E+B`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C9P="`P<'0@,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM
M97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/D%20T$\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SX@8F5L:65V97,@=&AA="`\+V9O;G0^/&9O;G0@<W1Y
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M9'D@:6X@87!P<F]X:6UA=&5L>2`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G
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M:6UA=&5L>2`V(&UO;G1H<R!A9G1E<B!T:&4@0V]M<&%N>2!O8G1A:6YS('-U
M9F9I8VEE;G0@9G5N9&EN9SPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/BX\+V9O
M;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.CEP="`P<'0@,'!T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@
M9F]N="US:7IE.C$P<'0G/E1O('-U<'!O<G0@=&AE(&-O;G1I;G5E9"!D979E
M;&]P;65N="!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
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M<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHQ,RXU<'0@,'!T(#!P="`Q,BXR
M<'0[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@
M9F]N="UW96EG:'0Z8F]L9#L@9F]N="US='EL93II=&%L:6,G/D1E=F5L;W!M
M96YT(%-T86=E(%)I<VMS+"!,:7%U:61I='D@86YD($=O:6YG($-O;F-E<FX\
M+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C0N-7!T(#!P="`P
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M<W,@8V]M8FEN871I;VX@=VET:"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
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M,3!P="<^+B`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.CEP
M="`P<'0@,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/E-I;F-E($%20T$@=V%S(&9O
M=6YD960@;VX@1&5C96UB97(\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA
M,#L\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ-RP@,C`P,2P@;W(@26YC97!T
M:6]N+"!T:&4@0V]M<&%N>2!H87,@:6YC=7)R960@<W5B<W1A;G1I86P@;&]S
M<V5S(&%N9"!N96=A=&EV92!C87-H(&9L;W=S(&9R;VT@;W!E<F%T:6]N<RX@
M4VEN8V4@26YC97!T:6]N+"!T:&4@0V]M<&%N>2!I;F-U<G)E9"!A(&QO<W,@
M9G)O;2!O<&5R871I;VYS(&]F("0\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G
M/C$P,"XR/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^(&UI;&QI;VX@86YD(&AA
M9"!N96=A=&EV92!C87-H(&9L;W=S(&9R;VT@;W!E<F%T:6]N<R!O9B`D/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXY."XR/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^(&UI;&QI;VXN(#PO9F]N=#X\+W`^#0H)"0D\<"!S='EL93TS1"=M
M87)G:6XZ.7!T(#!P="`P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^26X@;&EG:'0@
M;V8@=&AE('-U8G-T86YT:6%L(&%D9&ET:6]N86P@=&EM92!A;F0@8V]S=',@
M87-S;V-I871E9"!W:71H('1H92!D979E;&]P;65N="!O9B`\+V9O;G0^/&9O
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M('1O('-U<'!O<G0@=&AE(&-O;G1I;G5E9"!D979E;&]P;65N="!O9B`\+V9O
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M;F%N8VEN9R!T<F%N<V%C=&EO;G,@:6X@,C`Q,R!A;F0@/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^<F%I<V5D(&%P<')O>&EM871E;'D@)#PO9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0[("<^,2X\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C0\
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M="US:7IE.C$P<'0G/B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY4:&5S92!F
M:6YA;F-I;F=S(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG
M5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/FAA=F4@/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P="<^86QL;W<\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SYE9#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B!!4D-!('1O(&-O;G1I;G5E
M(&]P97)A=&EO;G,\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SX@=VAI;&4@:70@
M8V]N=&EN=65S('1O('!U<G-U92!F:6YA;F-I;F<@;W!T:6]N<RP@82!S=')A
M=&5G:6,@8V]M8FEN871I;VXL('!A<G1N97)I;F<L(&%N9"!L:6-E;G-I;F<@
M;W!P;W)T=6YI=&EE<RX@268@=&AE($-O;7!A;GD@:7,@9&5L87EE9"!I;B!C
M;VUP;&5T:6YG(&]R(&ES('5N86)L92!T;R!C;VUP;&5T92!A9&1I=&EO;F%L
M(&9U;F1I;F<@86YD+V]R(&$@<W1R871E9VEC('1R86YS86-T:6]N+"!T:&4@
M0V]M<&%N>2!M87D@9&ES8V]N=&EN=64@:71S(&1E=F5L;W!M96YT(&%C=&EV
M:71I97,@;W(@9&ES8V]N=&EN=64@:71S(&]P97)A=&EO;G,N(%1H92!#;VUP
M86YY(&-U<G)E;G1L>2!B96QI979E<R!I=',@8V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<R!B86QA;F-E(&%S(&]F($UA<F-H/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
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M,'!T)SXS,"P@,C`Q,RX@5&AE($-O;7!A;GD@:7,@=6YA8FQE('1O(&%S<V5R
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M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^,S`L(#(P,3,N(%1H97-E(&-O;G-O;&ED871E9"!F:6YA;F-I86P@
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M:&4@9F]L;&]W:6YG.B`\+V9O;G0^/"]P/@T*"0D)/'5L('1Y<&4],T1D:7-C
M('-T>6QE/3-$)VUA<F=I;CHP<'0[('!A9&1I;F<M;&5F=#HP<'0G/@T*"0D)
M"3QL:2!S='EL93TS1"=M87)G:6XZ(#0N-7!T(#!P="`P<'0@-3DN,3)P=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@<&%D9&EN9RUL969T.B`W+C0X<'0[(&9O;G0M
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M87)G:6XZ(#0N-7!T(#!P="`P<'0@-3DN,3)P=#L@=&5X="UI;F1E;G0Z(#!P
M=#L@<&%D9&EN9RUL969T.B`W+C0X<'0[(&9O;G0M<VEZ93H@,3)P=#LG/CQF
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M"3QL:2!S='EL93TS1"=M87)G:6XZ(#0N-7!T(#!P="`P<'0@-3DN,3)P=#L@
M=&5X="UI;F1E;G0Z(#!P=#L@<&%D9&EN9RUL969T.B`W+C0X<'0[(&9O;G0M
M<VEZ93H@,3)P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^=&AE($-O;7!A;GDF(S@R
M,3<[<R!A8FEL:71Y('1O(')E=&%I;B!T:&4@;&ES=&EN9R!O9B!I=',@8V]M
M;6]N('-T;V-K(&]N('1H92`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY.87-D
M87$\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SX@0V%P:71A;"!-87)K970[(#PO
M9F]N=#X\+VQI/@T*"0D)"3QL:2!S='EL93TS1"=M87)G:6XZ(#0N-7!T(#!P
M="`P<'0@-3DN,3)P=#L@=&5X="UI;F1E;G0Z(#!P=#L@<&%D9&EN9RUL969T
M.B`W+C0X<'0[(&9O;G0M<VEZ93H@,3)P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M9V5N97)A;"!E8V]N;VUI8R!A;F0@:6YD=7-T<GD@8V]N9&ET:6]N<R!A9F9E
M8W1I;F<@=&AE(&%V86EL86)I;&ET>2!A;F0@8V]S="!O9B!C87!I=&%L.R`\
M+V9O;G0^/"]L:3X-"@D)"0D\;&D@<W1Y;&4],T0G;6%R9VEN.B`T+C5P="`P
M<'0@,'!T(#4Y+C$R<'0[('1E>'0M:6YD96YT.B`P<'0[('!A9&1I;F<M;&5F
M=#H@-RXT.'!T.R!F;VYT+7-I>F4Z(#$R<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/G1H92!#;VUP86YY)B,X,C$W.W,@86)I;&ET>2!T;R!C;VYT<F]L(&-O<W1S
M(&%S<V]C:6%T960@=VET:"!I=',@;W!E<F%T:6]N<SL@/"]F;VYT/CPO;&D^
M#0H)"0D)/&QI('-T>6QE/3-$)VUA<F=I;CH@-"XU<'0@,'!T(#!P="`U.2XQ
M,G!T.R!T97AT+6EN9&5N=#H@,'!T.R!P861D:6YG+6QE9G0Z(#<N-#AP=#L@
M9F]N="US:7IE.B`Q,G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SYT:&4@8V]S=',@
M;V8@9FEL:6YG+"!P<F]S96-U=&EN9RP@9&5F96YD:6YG(&%N9"!E;F9O<F-I
M;F<@86YY('!A=&5N="!C;&%I;7,@86YD(&]T:&5R(&EN=&5L;&5C='5A;"!P
M<F]P97)T>2!R:6=H=',[(&%N9"`\+V9O;G0^/"]L:3X-"@D)"0D\;&D@<W1Y
M;&4],T0G;6%R9VEN.B`T+C5P="`P<'0@,'!T(#4Y+C$R<'0[('1E>'0M:6YD
M96YT.B`P<'0[('!A9&1I;F<M;&5F=#H@-RXT.'!T.R!F;VYT+7-I>F4Z(#$R
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M96UE;G1S+B`\+V9O;G0^/"]L:3X-"@D)"3PO=6P^#0H)"0D\<"!S='EL93TS
M1"=M87)G:6XZ.7!T(#!P="`P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^5&AE('-A
M;&4@;V8@861D:71I;VYA;"!E<75I='D@;W(@8V]N=F5R=&EB;&4@9&5B="!S
M96-U<FET:65S('=O=6QD(&QI:V5L>2!R97-U;'0@:6X@<W5B<W1A;G1I86P@
M861D:71I;VYA;"!D:6QU=&EO;B!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS('-T
M;V-K:&]L9&5R<RX@268@=&AE($-O;7!A;GD@<F%I<V5S(&%D9&ET:6]N86P@
M9G5N9',@=&AR;W5G:"!T:&4@:6YC=7)R96YC92!O9B!I;F1E8G1E9&YE<W,L
M('1H92!O8FQI9V%T:6]N<R!R96QA=&5D('1O('-U8V@@:6YD96)T961N97-S
M('=O=6QD(&)E('-E;FEO<B!T;R!R:6=H=',@;V8@:&]L9&5R<R!O9B!T:&4@
M0V]M<&%N>28C.#(Q-SMS(&-A<&ET86P@<W1O8VL@86YD(&-O=6QD(&-O;G1A
M:6X@8V]V96YA;G1S('1H870@=V]U;&0@<F5S=')I8W0@=&AE($-O;7!A;GDF
M(S@R,3<[<R!O<&5R871I;VYS+B!4:&4@0V]M<&%N>2!A;'-O(&-A;FYO="!P
M<F5D:6-T('=H870@8V]N<VED97)A=&EO;B!M:6=H="!B92!A=F%I;&%B;&4L
M(&EF(&%N>2P@=&\@=&AE($-O;7!A;GD@;W(@:71S('-T;V-K:&]L9&5R<RP@
M:6X@8V]N;F5C=&EO;B!W:71H(&%N>2!S=')A=&5G:6,@=')A;G-A8W1I;VXN
M(%-H;W5L9"!S=')A=&5G:6,@86QT97)N871I=F5S(&]R(&%D9&ET:6]N86P@
M8V%P:71A;"!N;W0@8F4@879A:6QA8FQE('1O('1H92!#;VUP86YY(&EN('1H
M92!N96%R('1E<FTL(&]R(&YO="!B92!A=F%I;&%B;&4@;VX@86-C97!T86)L
M92!T97)M<RP@=&AE($-O;7!A;GD@;6%Y(&)E('5N86)L92!T;R!R96%L:7IE
M('9A;'5E(&9R;VT@:71S(&%S<V5T<R!A;F0@9&ES8VAA<F=E(&ET<R!L:6%B
M:6QI=&EE<R!I;B!T:&4@;F]R;6%L(&-O=7)S92!O9B!B=7-I;F5S<R!W:&EC
M:"!M87DL(&%M;VYG(&]T:&5R(&%L=&5R;F%T:79E<RP@8V%U<V4@=&AE($-O
M;7!A;GD@=&\@9G5R=&AE<B!D96QA>2P@<W5B<W1A;G1I86QL>2!R961U8V4@
M;W(@9&ES8V]N=&EN=64@;W!E<F%T:6]N86P@86-T:79I=&EE<R!T;R!C;VYS
M97)V92!I=',@8V%S:"!R97-O=7)C97,N(#PO9F]N=#X\+W`^#0H)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,3,N-7!T(#!P="`P<'0[('!A9V4M8G)E86LM869T
M97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9#L@
M9F]N="US='EL93II=&%L:6,G/E)E=F5R<V4@4W1O8VL@4W!L:70@/"]F;VYT
M/CPO<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T)SX\
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M97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/F-O;7!L971E9"`\+V9O
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M(#PO9F]N=#X\+W`^#0H)"0D\<"!S='EL93TS1"=M87)G:6XZ-"XU<'0@,'!T
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M;R!&;W)M(#$P+5$@86YD(%)U;&4@,3`M,#$@;V8@4F5G=6QA=&EO;B!3+5@N
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T
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M;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M,S$L(#(P,3,@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F(')E
M<W5L=',@97AP96-T960@9F]R('1H92!F=6QL('EE87(@96YD:6YG($1E8V5M
M8F5R/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT
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M="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^5&AE($-O;7!A;GD@
M:&%S(&=E;F5R871E9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/FYO/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^(')E=F5N=64@=&\@9&%T92!A/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P="<^;F0@:71S(&%C=&EV:71I97,@:&%V92!C;VYS
M:7-T960@;V8@<V5E:VEN9R!R96=U;&%T;W)Y(&%P<')O=F%L+"!R97-E87)C
M:"!A;F0@9&5V96QO<&UE;G0L(&5X<&QO<FEN9R!S=')A=&5G:6,@86QT97)N
M871I=F5S(&9O<B!F=7)T:&5R(&1E=F5L;W!I;F<@86YD(&-O;6UE<F-I86QI
M>FEN9R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
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M+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^,S$L
M(#(P,3,N(%1H97-E('5N875D:71E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L
M('-T871E;65N=',@<VAO=6QD(&)E(')E860@:6X@8V]N:G5N8W1I;VX@=VET
M:"!T:&4@875D:71E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N
M=',@86YD(&9O;W1N;W1E<R!T:&5R971O(&9O<B!T:&4@>65A<B!E;F1E9"`\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2
M;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY$96-E;6)E<CPO9F]N=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US
M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/C,Q+"`R
M,#$R(&EN8VQU9&5D(&EN('1H92!#;VUP86YY)B,X,C$W.W,@06YN=6%L(%)E
M<&]R="!O;B!&;W)M(#$P+4L@9FEL960@=VET:"!T:&4@4V5C=7)I=&EE<R!A
M;F0@17AC:&%N9V4@0V]M;6ES<VEO;CPO9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/BP@87,@86UE;F1E9#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/BX@06UO=6YT
M<R!P<F5S96YT960@87)E(')O=6YD960@=&\@=&AE(&YE87)E<W0@=&AO=7-A
M;F0L('=H97)E(&EN9&EC871E9"P@97AC97!T('!E<B!S:&%R92!D871A(&%N
M9"!P87(@=F%L=65S+B`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C$S+C5P="`P<'0@,'!T.R!P86=E+6)R96%K+6%F=&5R.F%V;VED)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@
M9F]N="US:7IE.C$P<'0[(&9O;G0M=V5I9VAT.F)O;&0[(&9O;G0M<W1Y;&4Z
M:71A;&EC)SY#;VYC96YT<F%T:6]N<R!O9B!#<F5D:70@4FES:R`\+V9O;G0^
M/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C0N-7!T(#!P="`P<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,7!T)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C0N-7!T(#!P="`P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
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M>2!A="!T:6UE<R!E>&-E960@=&AE(&EN<W5R960@86UO=6YT+B`\+V9O;G0^
M/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C$S+C5P="`P<'0@,'!T.R!P
M86=E+6)R96%K+6%F=&5R.F%V;VED)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[(&9O;G0M
M=V5I9VAT.F)O;&0[(&9O;G0M<W1Y;&4Z:71A;&EC)SY!8V-R=65D($5X<&5N
M<V5S(#PO9F]N=#X\+W`^#0H)"0D\<"!S='EL93TS1"=M87)G:6XZ-"XU<'0@
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M(&9A8W1S(&%N9"!C:7)C=6US=&%N8V5S(&MN;W=N(&%T('1H92!T:6UE+B`\
M+V9O;G0^/"]P/@T*"0D\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X
M,3`Y8S0T.#<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B,&9B
M-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"]7;W)K<VAE971S+U-H
M965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY,;W-S(%!E<B!3:&%R93QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;W-S(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=CX-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHQ,RXU
M<'0@,'!T(#!P=#L@<&%G92UB<F5A:RUA9G1E<CIA=F]I9"<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T.R!F;VYT+7=E:6=H=#IB;VQD)SXH,BD@3&]S<R`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T.R!F;VYT+7=E:6=H=#IB;VQD)SY097(\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T.R!F;VYT+7=E:6=H=#IB;VQD)SX@4VAA<F4@/"]F;VYT
M/CPO<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T)SX\
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M;G1S+B`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.CEP="`P
M<'0[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M02!R96-O;F-I;&EA=&EO;B!O9B!T:&4@;G5M97)A=&]R(&%N9"!D96YO;6EN
M871O<B!U<V5D(&EN('1H92!C86QC=6QA=&EO;B!O9B!B87-I8R!A;F0@9&EL
M=71E9"!L;W-S('!E<B!S:&%R92!F;VQL;W=S.B`\+V9O;G0^/"]P/@T*"0D)
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4]
M,T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!M87)G:6XM;&5F=#HP<'0[
M('=I9'1H.C<V)2<^#0H)"0D)#0H)"0D)"3QT<CX-"@D)"0D)"3QT:"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[
M('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z,C8Y+CAP="<^#0H)"0D)
M"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UW96EG:'0Z8F]L9"<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&@^
M#0H)"0D)"0D\=&@@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D
M:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H
M.C$R+C)P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&@^#0H)
M"0D)"0D\=&@@8V]L<W!A;CTS1#,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC
M;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.G-O;&ED.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P861D:6YG+6QE9G0Z-2XT<'0[('!A
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M=#X\+W`^#0H)"0D)"0D\+W1H/@T*"0D)"0D\+W1R/@T*"0D)"0D\='(^#0H)
M"0D)"0D\=&@@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG
M+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C(V
M.2XX<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US
M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1H/@T*"0D)
M"0D)/'1H('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR
M:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ,BXR
M<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE
M.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1H/@T*"0D)"0D)
M/'1H('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(S`P,#`P,#L@8F]R
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M:6=N.F)O='1O;3L@=VED=&@Z,3,N-C5P="<^#0H)"0D)"0D)/'`@<W1Y;&4]
M,T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO
M<#X-"@D)"0D)"3PO=&@^#0H)"0D)"0D\=&@@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.G-O;&ED
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P861D:6YG+6QE9G0Z-2XT
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M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
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M.C$R+C)P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)
M"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG
M+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C<S
M<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE
M.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)
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M;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY.970@;&]S<SPO9F]N=#X\+W`^#0H)
M"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU
M+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.R!W:61T:#HQ,BXR<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN
M.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)
M"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(S`P,#`P,#L@8F]R9&5R+6)O='1O;2US='EL93IS;VQI9#L@8F]R9&5R
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M="<^*#$L,#<Q*3PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D
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M='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB
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M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^*#$L-#`W*3PO9F]N=#X\
M+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)"0D\='(^#0H)"0D)
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M/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[
M/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!B;W)D97(M
M=&]P+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUT;W`M<W1Y;&4Z<V]L:60[(&)O
M<F1E<BUT;W`M=VED=&@Z,"XU<'0[('!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D
M9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T
M:#HW,W!T)SX-"@D)"0D)"0D\<"!S='EL93TS1&UA<F=I;CHP<'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M
M<VEZ93HQ,'!T)SXD/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/B@Q+#`W,2D\+V9O;G0^/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT
M9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z
M-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z,3,N-C5P="<^
M#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T
M.R!B;W)D97(M=&]P+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUT;W`M<W1Y;&4Z
M<V]L:60[(&)O<F1E<BUT;W`M=VED=&@Z,"XU<'0[('!A9&1I;F<M;&5F=#HU
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M;VYT+7-I>F4Z,3!P="<^*#$L-#`W*3PO9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/B`\+V9O;G0^/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)/"]T<CX-"@D)"0D)
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M-S-P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)
M"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I
M9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$S+C8U
M<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE
M.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)
M/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H
M=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HW,RXW<'0G
M/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R
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M<F5S(&]F(&-O;6UO;B!S=&]C:R!O=71S=&%N9&EN9SPO9F]N=#X\+W`^#0H)
M"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU
M+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.R!W:61T:#HQ,BXR<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN
M.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)
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M+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M
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M,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXR+#`S
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M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z<V]L:60[(&)O
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M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^*#(L-S@S*3PO9F]N=#X\+W`^
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M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z<V]L:60[(&)O
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M,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXH,BPW.#,I/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^(#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)
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M/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[
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M9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.R!W:61T:#HW,RXW<'0G/@T*"0D)"0D)"3QP('-T
M>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG
M5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N
M=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)"0D\='(^#0H)
M"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG
M+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$R
M+C)P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[
M(&9O;G0M<VEZ93HQ,'!T)SXS+#`S-"PW-C,\+V9O;G0^/"]P/@T*"0D)"0D)
M/"]T9#X-"@D)"0D)"3QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[
M('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@
M=VED=&@Z,3,N-C5P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO
M=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P
M861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I
M9'1H.C<S+C=P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/C(L,#(W+#<Q-CPO9F]N=#X\
M+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)"0D\='(^#0H)"0D)
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M;&EG;CIB;W1T;VT[('=I9'1H.C$R+C)P="<^#0H)"0D)"0D)/'`@<W1Y;&4]
M,T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO
M<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.F1O=6)L
M93L@8F]R9&5R+6)O='1O;2UW:61T:#HR+C(U<'0[(&)O<F1E<BUT;W`M8V]L
M;W(Z(S`P,#`P,#L@8F]R9&5R+71O<"US='EL93IS;VQI9#L@8F]R9&5R+71O
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M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^*#`N
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M.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(S`P,#`P,#L@8F]R9&5R+6)O='1O;2US
M='EL93ID;W5B;&4[(&)O<F1E<BUB;W1T;VTM=VED=&@Z,BXR-7!T.R!B;W)D
M97(M=&]P+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUT;W`M<W1Y;&4Z<V]L:60[
M(&)O<F1E<BUT;W`M=VED=&@Z,"XU<'0[('!A9&1I;F<M;&5F=#HU+C1P=#L@
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M>F4Z,3!P="<^*#`N-CDI/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)
M"3PO='(^#0H)"0D)"3QT<CX-"@D)"0D)"3QT9"!S='EL93TS1"=P861D:6YG
M+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L
M:6=N.F)O='1O;3L@=VED=&@Z,C8Y+CAP="<^#0H)"0D)"0D)/'`@<W1Y;&4]
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M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)
M"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU
M+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.R!W:61T:#HW,W!T)SX-"@D)"0D)"0D\<"!S='EL93TS1&UA<F=I;CHP
M<'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\
M+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@
M<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W
M:61T:#HQ,RXV-7!T)SX-"@D)"0D)"0D\<"!S='EL93TS1&UA<F=I;CHP<'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[
M(&9O;G0M<VEZ93HQ<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D
M/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D
M9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T
M:#HW,RXW<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C%P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)
M"0D)"3PO='(^#0H)"0D)/"$M+5MI9B`A<W5P<&]R=$UI<V%L:6=N961#;VQU
M;6YS73X\='(^#0H)"0D)"3QT9"!S='EL93TS1"=W:61T:#HR,#`N-W!T.R!B
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M<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/E!O=&5N=&EA;&QY(&1I;'5T:79E('-E8W5R:71I97,@
M<F5P<F5S96YT:6YG/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F
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M,#0L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^('=E:6=H=&5D(&%V97)A
M9V4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W97)E(&5X8VQU9&5D(&9O<B!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
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M/CPO<#X-"@D)/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T
M-#@W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C9%\U
M-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E=#$P
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^365R
M9V5R('=I=&@@3G5V96QO+"!);F,N(&]N($IA;G5A<GD@,C<L(#(P,#D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^365R9V5R('=I
M=&@@3G5V96QO+"!);F,N(&]N($IA;G5A<GD@,C<L(#(P,#D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,3,N-7!T(#!P="`P<'0[('!A9V4M8G)E86LM869T97(Z879O:60G
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M=#L@9F]N="UW96EG:'0Z8F]L9"<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^,C<L(#(P,#D@/"]F;VYT/CPO<#X-
M"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US
M:7IE.C$P<'0G/D]N($IA;G5A<GD\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF
M(WAA,#L\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXR-RP@,C`P.2P@05)#02!#
M;VQO<F%D;RP@26YC+B`H05)#02!#;VQO<F%D;RD@8V]M<&QE=&5D('1H92!-
M97)G97(@=VET:"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY.=79E;&\\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ,'!T)SX@:6X@86-C;W)D86YC92!W:71H('1H92!T
M97)M<R!O9B!T:&4@365R9V5R($%G<F5E;65N="P@:6X@=VAI8V@@82!W:&]L
M;'DM;W=N960@<W5B<VED:6%R>2!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
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M92!#;VUP86YY(&-H86YG960@:71S(&YA;64@9G)O;2`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M
M<VEZ93HQ,'!T)SY.=79E;&\\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXL($EN
M8RX@=&\@05)#02`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
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M;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXR."P@,C`P.2X@3VX@36%R8V@\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA,#L\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ
M,'!T)SXW+"`R,#$Q+"!T:&4@;&ES=&EN9R!O9B!T:&4@0V]M<&%N>28C.#(Q
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M0R`X,#4N($9O<B!A8V-O=6YT:6YG('!U<G!O<V5S+"!!4D-!($-O;&]R861O
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M;G,@86YD(&-A<V@@9FQO=W,@:6YC;'5D92!T:&4@86-T:79I=&EE<R!O9B`\
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M(&)E:6YG('1H92!B=7-I;F5S<R!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SY.=79E;&\\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SX@<')I;W(@=&\@=&AE
M($UE<F=E<BP@<&5R=&%I;B!T;R!T:&4@8G5S:6YE<W,@;V8@05)#02!#;VQO
M<F%D;R!P<FEO<B!T;R!T:&4@365R9V5R+B`\+V9O;G0^/"]P/@T*"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.CEP="`P<'0@,'!T)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/E1H92!E<W1I;6%T960@=&]T86P@86-Q=6ES:71I;VX@8V]N<VED97)A=&EO
M;B!O9B`D/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXQ,2XY/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^(&UI;&QI;VX@=&\@86-Q=6ER92`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SY.=79E;&\\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SX@
M=V%S(&)A<V5D(&]N('1H92!M87)K970@8V%P:71A;&EZ871I;VX@;V8@/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^3G5V96QO/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^(&%S(&]F($IA;G5A<GD\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF
M(WAA,#L\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXR-RP@,C`P.2!A;F0@=&AE
M(&5S=&EM871E9"!F86ER('9A;'5E<R!O9B!I=',@=F5S=&5D('-T;V-K(&]P
M=&EO;G,@86YD('=A<G)A;G1S(&]U='-T86YD:6YG(&]N('1H870@9&%T92P@
M87,@=&AI<R!W87,@9&5E;65D('1H92!M;W-T(')E;&EA8FQE(&UE87-U<F4@
M;V8@=&AE(&-O;G-I9&5R871I;VX@969F96-T:79E;'D@=')A;G-F97)R960@
M=&\@86-Q=6ER92`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY.=79E;&\\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ,'!T)SX@;VX@=&AA="!D871E+CPO9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY4:&4@0V]M
M<&%N>2!E<W1I;6%T960@=&AE(&YE="!A<W-E=',@86-Q=6ER960@:6X@=&AE
M($UE<F=E<B!T;R!B92`D/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXS-RXR
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^(&UI;&QI;VXL(&EN8VQU9&EN9R`D
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M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^+B`\
M+V9O;G0^/"]P/@T*"0D\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X
M,3`Y8S0T.#<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B,&9B
M-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"]7;W)K<VAE971S+U-H
M965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY&86ER(%9A;'5E($1I<V-L;W-U<F5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@1&ES8VQO<W5R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,3,N-7!T(#!P="`P<'0[('!A9V4M8G)E86LM869T97(Z
M879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^*#0I
M($9A:7(@5F%L=64@1&ES8VQO<W5R97,@/"]F;VYT/CPO<#X-"@D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/D%S(&]F($UA<F-H/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^,S$L(#(P,3,L('1H92!#;VUP86YY(&AA
M9"`D/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
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M.C$P<'0[("<^.3`@9&%Y<SPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A
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M.C$P<'0G/C,Q+"`R,#$S+B`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.CEP="`P<'0@,'!T.R!P86=E+6)R96%K+6%F=&5R.F%V;VED)SX\
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M,'!T)SX-"@D)"0D\;&D@<W1Y;&4],T0G;6%R9VEN.B`T+C5P="`P<'0@,'!T
M(#4Y+C$R<'0[('1E>'0M:6YD96YT.B`P<'0[('!A9&1I;F<M;&5F=#H@-RXT
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M="`P<'0@-3DN,3)P=#L@=&5X="UI;F1E;G0Z(#!P=#L@<&%D9&EN9RUL969T
M.B`W+C0X<'0[(&9O;G0M<VEZ93H@,3)P=#LG/CQF;VYT('-T>6QE/3-$)V9O
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M86)I;&ET>2`\+V9O;G0^/"]L:3X-"@D)"0D\;&D@<W1Y;&4],T0G;6%R9VEN
M.B`T+C5P="`P<'0@,'!T(#4Y+C$R<'0[('1E>'0M:6YD96YT.B`P<'0[('!A
M9&1I;F<M;&5F=#H@-RXT.'!T.R!F;VYT+7-I>F4Z(#$R<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US
M:7IE.C$P<'0G/DQE=F5L(#,F(S@R,3([56YO8G-E<G9A8FQE(&EN<'5T<R!F
M;W(@=&AE(&%S<V5T(&]R(&QI86)I;&ET>2`\+V9O;G0^/"]L:3X-"@D)"3PO
M=6P^#0H)"0D\<"!S='EL93TS1"=M87)G:6XZ,3,N-7!T(#!P="`P<'0[('!A
M9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW
M96EG:'0Z8F]L9#L@9F]N="US='EL93II=&%L:6,G/D9A:7(@5F%L=64@;V8@
M3W1H97(@1FEN86YC:6%L($EN<W1R=6UE;G1S(#PO9F]N=#X\+W`^#0H)"0D\
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M=#X\+W`^#0H)"3PO9&EV/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC
M-#0X-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(P9F(U8V1?
M-3<T85\T,C=E7V(U861?.34X,3`Y8S0T.#<T+U=O<FMS:&5E=',O4VAE970Q
M,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R
M;W!E<G1Y(&%N9"!%<75I<&UE;G0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"@D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHQ,RXU<'0@,'!T(#!P=#L@<&%G92UB<F5A:RUA9G1E<CIA=F]I
M9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+7=E:6=H=#IB;VQD)SXH-2D@4')O
M<&5R='D@86YD($5Q=6EP;65N="`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C0N-7!T(#!P="`Y<'0[('!A9V4M8G)E86LM869T97(Z879O
M:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^4')O<&5R='D@86YD(&5Q=6EP;65N="!C
M;VYS:7-T(&]F('1H92!F;VQL;W=I;F<@*&EN('1H;W5S86YD<RDZ(#PO9F]N
M=#X\+W`^#0H)"0D\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[(&UA<F=I
M;BUL969T.C!P=#L@=VED=&@Z.30N-C8E)SX-"@D)"0D\='(^#0H)"0D)"3QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C(Q,2XU
M<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG
M;CIC96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-
M"@D)"0D)/"]T9#X-"@D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(S`P,#`P,#L@8F]R9&5R+6)O='1O;2US='EL93IS;VQI9#L@8F]R
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M9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^
M#0H)"0D)"3QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P
M,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z<V]L:60[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z,"XU<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-30N
M-C5P="<^#0H)"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.R!T97AT+6%L
M:6=N.F-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+7=E:6=H=#IB;VQD
M)SY-87)C:"`S,2P@,C`Q,SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)
M"3QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q
M+C9P="<^#0H)"0D)"0D\<"!S='EL93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D)"0D\+W1D/@T*"0D)"0D\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N
M-7!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T+C8U<'0G/@T*
M"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT
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M9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.CDY<'0G/@T*"0D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT97(G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^,R!Y96%R<SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)
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M/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[
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M.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM
M97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/C$P-#PO9F]N=#X\+W`^
M#0H)"0D)"3PO=&0^#0H)"0D)/"]T<CX-"@D)"0D\='(^#0H)"0D)"3QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C(Q,2XU<'0G
M/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^3&%B(&5Q=6EP;65N=#PO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)
M"3QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.CDY
M<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG
M;CIC96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^-2!Y96%R<SPO9F]N=#X\+W`^
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M.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ-#(\+V9O
M;G0^/"]P/@T*"0D)"0D\+W1D/@T*"0D)"0D\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ,2XV<'0G/@T*"0D)"0D)/'`@<W1Y
M;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T+C8U<'0G
M/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\
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M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)
M"3QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T
M+C8U<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
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M<B!S;V9T=V%R93PO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.CDY<'0G/@T*
M"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT
M97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^,R!Y96%R<SPO9F]N=#X\+W`^#0H)"0D)
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M.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ-S8\+V9O;G0^/"]P
M/@T*"0D)"0D\+W1D/@T*"0D)"0D\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.R!W:61T:#HQ,2XV<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T1M
M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-
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M86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ,2XV<'0G/@T*"0D)"0D)/'`@<W1Y
M;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT
M/CPO<#X-"@D)"0D)/"]T9#X-"@D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(S`P,#`P,#L@8F]R9&5R+6)O='1O;2US='EL93IS;VQI
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M.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ.#PO9F]N
M=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C9P="<^#0H)"0D)"0D\<"!S='EL
M93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA,#L\+V9O;G0^
M/"]P/@T*"0D)"0D\+W1D/@T*"0D)"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.G-O;&ED
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[('=I9'1H.C4T+C8U<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G
M:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S
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M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SXU,#@\+V9O;G0^/"]P/@T*"0D)"0D\+W1D/@T*"0D)
M"0D\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ
M,2XV<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)/"]T9#X-"@D)"0D)
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-30N
M-C5P="<^#0H)"0D)"0D\<"!S='EL93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^-3,S/"]F;VYT/CPO<#X-"@D)"0D)/"]T
M9#X-"@D)"0D\+W1R/@T*"0D)"3QT<CX-"@D)"0D)/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z,C$Q+C5P="<^#0H)"0D)"0D\
M<"!S='EL93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY,97-S(&%C
M8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^86UO<G1I>F%T:6]N/"]F;VYT/CPO<#X-"@D)"0D)/"]T9#X-"@D)
M"0D)/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z
M.3EP="<^#0H)"0D)"0D\<"!S='EL93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D)"0D\+W1D/@T*"0D)"0D\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ,2XV
M<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)/"]T9#X-"@D)"0D)/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(S`P,#`P,#L@8F]R9&5R
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M
M<VEZ93HQ,'!T)SXH-#@V*3PO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)
M"3QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q
M+C9P="<^#0H)"0D)"0D\<"!S='EL93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D)"0D\+W1D/@T*"0D)"0D\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N
M-7!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T+C8U<'0G/@T*
M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/B@U,3`I/"]F;VYT/CPO<#X-"@D)"0D)/"]T9#X-"@D)
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M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^
M#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CIB;W1T;VT[('=I9'1H.C$Q+C9P="<^#0H)"0D)"0D\<"!S='EL93TS1&UA
M<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA,#L\+V9O;G0^/"]P/@T*
M"0D)"0D\+W1D/@T*"0D)"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC
M;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.F1O=6)L93L@8F]R
M9&5R+6)O='1O;2UW:61T:#HQ+C5P=#L@8F]R9&5R+71O<"UC;VQO<CHC,#`P
M,#`P.R!B;W)D97(M=&]P+7-T>6QE.G-O;&ED.R!B;W)D97(M=&]P+7=I9'1H
M.C`N-7!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T+C8U<'0G
M/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\
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M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)
M"3QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z9&]U8FQE.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.C$N-7!T.R!B;W)D97(M=&]P+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUT;W`M
M<W1Y;&4Z<V]L:60[(&)O<F1E<BUT;W`M=VED=&@Z,"XU<'0[('9E<G1I8V%L
M+6%L:6=N.F)O='1O;3L@=VED=&@Z-30N-C5P="<^#0H)"0D)"0D\<"!S='EL
M93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXD/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/C(S/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^(#PO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)/"]T<CX-"@D)
M"3PO=&%B;&4^#0H)"0D\<"!S='EL93TS1"=M87)G:6XZ-"XU<'0@,'!T(#!P
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ,G!T)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C0N-7!T(#!P="`P<'0G/CQF;VYT('-T>6QE/3-$
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M,2P@,C`Q,R!A;F0@,C`Q,BP@86YD(&9O<B!T:&4@<&5R:6]D(&9R;VT@26YC
M97!T:6]N('1H<F]U9V@@36%R8V@\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF
M(WAA,#L\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXS,2P@,C`Q,RP@9&5P<F5C
M:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX@97AP96YS92!W87,@)#PO9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@
M9F]N="US:7IE.C$P<'0[("<^,3`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G
M/BPP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXL("0\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M
M<VEZ93HQ,'!T.R`G/C$T/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXL,#`P
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^+"!A;F0@)#PO9F]N=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US
M:7IE.C$P<'0[("<^,2XX/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^(&UI;&QI
M;VX@<F5S<&5C=&EV96QY+CPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B`\+V9O
M;G0^/"]P/@T*"0D\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y
M8S0T.#<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B,&9B-6-D
M7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"]7;W)K<VAE971S+U-H965T
M,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#
M;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-
M"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHQ,RXU<'0@,'!T(#!P=#L@<&%G92UB
M<F5A:RUA9G1E<CIA=F]I9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+7=E:6=H
M=#IB;VQD)SXH-BD@0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@/"]F
M;VYT/CPO<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T
M.R!P86=E+6)R96%K+6%F=&5R.F%V;VED)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/E1H
M92!#;VUP86YY(&AA<R!O<B!I<R!S=6)J96-T('1O('1H92!F;VQL;W=I;F<@
M8V]M;6ET;65N=',@86YD(&-O;G1I;F=E;F-I97,Z(#PO9F]N=#X\+W`^#0H)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,3,N-7!T(#!P="`P<'0[('!A9V4M8G)E
M86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z
M8F]L9#L@9F]N="US='EL93II=&%L:6,G/D5M<&QO>6UE;G0@06=R965M96YT
M<R`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C0N-7!T(#!P
M="`P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
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M=W)I='1E;B!N;W1I8V4@=&\@=&AE(&5M<&QO>65E+B`\+V9O;G0^/"]P/@T*
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C$S+C5P="`P<'0@,'!T.R!P86=E+6)R
M96%K+6%F=&5R.F%V;VED)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG
M5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[(&9O;G0M=V5I9VAT
M.F)O;&0[(&9O;G0M<W1Y;&4Z:71A;&EC)SY/<&5R871I;F<@3&5A<V4@/"]F
M;VYT/CPO<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0G/D]N($9E8G)U87)Y/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^."P@,C`P
M."P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;&5A<V4@86=R965M96YT
M(&9O<B!A<'!R;WAI;6%T96QY(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[("<^
M,34L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
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M,'!T)SXR,#`X+B!4:&4@;&5A<V4@:&%S(&$@=&5R;2!O9B`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T.R`G/C4\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/B8C
M>&$P.SPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[("<^>65A<G,\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SX@=VET:"!R:6=H=',@=&\@97AT96YD('1H92!T97)M
M(&9O<B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/G1W;R!A9&1I=&EO;F%L
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M;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ-"P@,C`Q,2P@=&AE($-O;7!A;GD@
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M871E;'D@,34L,#`P('-Q=6%R92!F965T+"!T;R!A;F]T:&5R('-U:71E('=I
M=&AI;B!T:&4@<V%M92!B=6EL9&EN9RP@8V]M<')I<VEN9R!A<'!R;WAI;6%T
M96QY(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[("<^-"PU,#`\+V9O;G0^/&9O
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M<R!T:&4@0V]M<&%N>2!T;R!T97)M:6YA=&4@=VET:"`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M
M<VEZ93HQ,'!T.R`G/G1H<F5E(&UO;G1H<SPO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/B8C.#(Q-SL@;F]T:6-E+B!!<R!P87)T(&]F('1H92!A9W)E96UE;G0L
M('1H92!#;VUP86YY(&UA9&4@82!O;F4M=&EM92!P87EM96YT('1O('1H92!L
M86YD;&]R9"!O9B`D/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXR,#`L,#`P
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M.C$P<'0G/B`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.CEP
M="`P<'0@,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/E5N9&5R('1H92!O<FEG:6YA
M;"!L96%S92P@=&AE($-O;7!A;GD@<F5C96EV960@=&5N86YT(&EM<')O=F5M
M96YT(')E:6UB=7)S96UE;G1S(&9R;VT@=&AE(&QA;F1L;W)D('1O=&%L:6YG
M("0\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C4Y,RPP,#`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SX@=VAI8V@@=V5R92!R96-O<F1E9"!A<R!D969E<G)E
M9"!R96YT(&%N9"!W97)E(&%M;W)T:7IE9"!A<R!R961U8W1I;VYS('1O(')E
M;G0@97AP96YS92X@5&AE("0R,#`L,#`P('!A>6UE;G0@;6%D92!T;R!T:&4@
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M+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^,S$L
M(#(P,3,@=V%S("0\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C@\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[
M(&9O;G0M<VEZ93HQ,'!T.R`G/BPP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SXN(#PO9F]N=#X\+W`^#0H)"0D\<"!S='EL93TS1"=M87)G:6XZ.7!T(#!P
M="`P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
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M,'!T)SXS,2P@,C`Q,R!A;F0@,C`Q,B!W87,@)#PO9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE
M.C$P<'0[("<^,3(\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/BPP,#`\+V9O
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M,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
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M,2P@,C`Q,RX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
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M:71T960@=6YD97(@=&AE(&QE87-E('1H<F]U9V@@2G5N92`R,#$S(&%R92`D
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXR,"PP,#`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M
M<VEZ93HQ,'!T)SXN(%1H92!L96%S92!H87,@86X@;W!T:6]N('1O(')E;F5W
M(&9O<B!A;B!A9&1I=&EO;F%L('1H<F5E('EE87(@=&5R;2!U;F1E<B!C;VUP
M87)A8FQE('1E<FUS+"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
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M;W)D(')E9V%R9&EN9R!P;W1E;G1I86P@<F5N97=A;"!O9B`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SYT:&4@;&5A<V4N(#PO9F]N=#X\+W`^#0H)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,3,N-7!T(#!P="`P<'0[('!A9V4M8G)E86LM869T
M97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9#L@
M9F]N="US='EL93II=&%L:6,G/D-A<F1I;W9A<V-U;&%R(%!H87)M86-O;&]G
M>2!A;F0@16YG:6YE97)I;F<@0V]N<W5L=&%N=',L($Q,0RP@;W(@0U!%0R`\
M+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C0N-7!T(#!P="`P
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M($EN($%U9W5S="`R,#`X+"!T:&4@0V]M<&%N>2!P86ED($-014,@82!M:6QE
M<W1O;F4@<&%Y;65N="!O9B`D/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXU
M,#`L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^(&)A<V5D(&]N('1H92!*
M=6QY/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT
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M/F%G<F5E;65N="!P<F]V:61E<R!T:&%T('1H92`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T)SY#;VUP86YY('=I;&P@;W=E($-014,@86YO=&AE<B!M:6QE<W1O
M;F4@<&%Y;65N="!O9B`D/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXX+C`\
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M="!A;'-O('-T871E<R!T:&%T('1H92`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SY#;VUP86YY(&AA<R!T:&4@;V)L:6=A=&EO;B!T;R!M86ME(&UI;&5S=&]N
M92!P87EM96YT<R!O9B!U<"!T;R`D/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@
M)SXU+C`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SX@;6EL;&EO;B!I;B!T:&4@
M86=G<F5G871E('5P;VX@<F5G=6QA=&]R>2!M87)K971I;F<@87!P<F]V86P@
M:6X@175R;W!E(&%N9"!*87!A;BX@5&AE(#PO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/F%G<F5E;65N="!S=&%T97,@=&AA="!T:&4@/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^0V]M<&%N>28C.#(Q-SMS(')O>6%L='D@;V)L:6=A=&EO;B!R
M86YG97,@9G)O;2`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C$R+C4\+V9O
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M;R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C$W/"]F;VYT/CQF;VYT('-T
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M9F]N="US:7IE.C$P<'0G/B!O9B!R96=U;&%T;W)Y(&%P<')O=F%L+B`\+V9O
M;G0^/"]P/@T*"0D\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y
M8S0T.#<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B,&9B-6-D
M7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"]7;W)K<VAE971S+U-H965T
M,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%
M<75I='D@1FEN86YC:6YG<R!A;F0@5V%R<F%N=',\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U:71Y($9I;F%N8VEN9W,@86YD
M(%=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C$S+C5P="`P<'0@,'!T.R!P86=E
M+6)R96%K+6%F=&5R.F%V;VED)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[(&9O;G0M=V5I
M9VAT.F)O;&0G/B@W*2`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+7=E
M:6=H=#IB;VQD.R!F;VYT+7-T>6QE.FET86QI8R<^17%U:71Y($9I;F%N8VEN
M9W,@86YD(%=A<G)A;G1S(#PO9F]N=#X\+W`^#0H)"0D\<"!S='EL93TS1"=M
M87)G:6XZ-"XU<'0@,'!T(#!P=#L@<&%G92UB<F5A:RUA9G1E<CIA=F]I9"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[
M(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+7=E:6=H=#IB;VQD.R!F;VYT+7-T>6QE
M.FET86QI8R<^4')I=F%T92!);G9E<W1M96YT(&EN(%!U8FQI8R!%<75I='D@
M*%!)4$4I(%1R86YS86-T:6]N(#PO9F]N=#X\+W`^#0H)"0D\<"!S='EL93TS
M1"=M87)G:6XZ-"XU<'0@,'!T(#!P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY/;B!*
M86YU87)Y/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^,C(L(#(P,3,L('1H92!#;VUP86YY(&5N=&5R960@
M:6YT;R!A(%-U8G-C<FEP=&EO;B!!9W)E96UE;G0@*'1H92`F(S@R,C`[4'5R
M8VAA<V4@06=R965M96YT)B,X,C(Q.RD@=VET:"!V87)I;W5S(&%C8W)E9&ET
M960@:6YV97-T;W)S(&%N9"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M=&]C:R!A;F0@=V%R<F%N=',@=&\@<'5R8VAA<V4@=7`@=&\@/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P=#L@)SXR-#DL-3`Q/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^(&%D9&ET:6]N86P@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@9F]R
M(&%G9W)E9V%T92!G<F]S<R!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2
M;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C$\+V9O;G0^/&9O;G0@<W1Y;&4]
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M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[("<^.#`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T.R`G/C4\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXL,#`P/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P="<^+"!A;F0@=&AE('!R:79A=&4@<&QA8V5M96YT
M(&-L;W-E9"!O;B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/DIA;G5A<GD\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2
M;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/B8C>&$P.SPO9F]N=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US
M:7IE.C$P<'0[("<^,C4L(#(P,3,\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXN
M(#PO9F]N=#X\+W`^#0H)"0D\<"!S='EL93TS1"=M87)G:6XZ.7!T(#!P="`P
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M;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[("<^,3`P
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M,C`Q,RX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
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M;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ-"P@,C`Q,RX@/"]F;VYT/CPO<#X-"@D)
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M;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
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M<F=I;CHT+C5P="`P<'0@,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/D]N($IA;G5A
M<GD\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA,#L\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M
M<VEZ93HQ,'!T)SXS,2P@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O
M(&$@<W5B<V-R:7!T:6]N(&%G<F5E;65N="!W:71H(&-E<G1A:6X@:6YS=&ET
M=71I;VYA;"!I;G9E<W1O<G,@*'1H92`F(S@R,C`[26YV97-T;W)S)B,X,C(Q
M.RD@:6X@8V]N;F5C=&EO;B!W:71H(&ET<R!296=I<W1E<F5D($1I<F5C="!P
M=6)L:6,@;V9F97)I;F<@*'1H92`F(S@R,C`[3V9F97)I;F<F(S@R,C$[*2P@
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M(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S92!U<"!T;R`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M
M<VEZ93HQ,'!T.R`G/C8U+#@U-3PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B!A
M9&1I=&EO;F%L('-H87)E<R!O9B!I=',@8V]M;6]N('-T;V-K('1O('1H92!)
M;G9E<W1O<G,@9F]R(&%G9W)E9V%T92!G<F]S<R!P<F]C965D<R!O9B!A<'!R
M;WAI;6%T96QY("0\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C<S,"PP,#`\
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M;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C8Q-CPO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/BPP,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXL(&%N9"!T:&4@3V9F
M97)I;F<@8VQO<V5D(&]N(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0[("<^1F5B
M<G5A<GD\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/B8C>&$P.SPO9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@
M9F]N="US:7IE.C$P<'0[("<^-"P@,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS
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M=7)C:&%S92!P<FEC92!F;W(@96%C:"!U;FET('=A<R`D/"]F;VYT/CQF;VYT
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M;G0M<VEZ93HQ,'!T.R`G/C0N,3,\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
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M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXS,2P@,C`Q,RX@
M5&AE($]F9F5R:6YG('=A<R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M-"P@,C`Q,2P@<'5R<W5A;G0@=&\@82!P<F]S<&5C='5S('-U<'!L96UE;G0@
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M='5S(&YO="`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SYB93PO9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/B!I;B!P;&%C92!A="!T:&4@=&EM92!A('=A<G)A;G0@
M:7,@97AE<F-I<V5D+B`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C$S+C5P="`P<'0@,'!T.R!P86=E+6)R96%K+6%F=&5R.F%V;VED)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@
M9F]N="US:7IE.C$P<'0[(&9O;G0M=V5I9VAT.F)O;&0[(&9O;G0M<W1Y;&4Z
M:71A;&EC)SY787)R86YT<R`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C0N-7!T(#!P="`P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^07,@;V8@
M36%R8V@\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA,#L\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SXS,2P@,C`Q,RP@=V%R<F%N=',@=&\@<'5R8VAA<V4@
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXQ+C,@;6EL;&EO;CPO9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@
M9F]N="US:7IE.C$P<'0G/B!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=E<F4@
M;W5T<W1A;F1I;F<@870@97AE<F-I<V4@<')I8V5S(')A;F=I;F<@9G)O;2`D
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@)SXQ+C@P/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^('1O("0\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C$Q-BXX
M.3PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/BP@=VET:"!A('=E:6=H=&5D(&%V
M97)A9V4@97AE<F-I<V4@<')I8V4@<&5R('-H87)E(&]F("0\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T.R`G/C<N,C4\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
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M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/DIA;G5A<GD@,C`R,#PO9F]N
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M9F]N=#X\+W`^#0H)"3PO9&EV/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q
M,#EC-#0X-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(P9F(U
M8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T.#<T+U=O<FMS:&5E=',O4VAE
M970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E-H87)E+4)A<V5D($-O;7!E;G-A=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,3,N-7!T(#!P="`P<'0[('!A9V4M8G)E86LM869T
M97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^
M*#@I(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B`\+V9O;G0^/"]P/@T*"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C0N-7!T(#!P="`Y<'0[('!A9V4M8G)E86LM
M869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^1F]R('1H92!T:')E92!M
M;VYT:"!P97)I;V1S(&5N9&5D($UA<F-H/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
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M(&9O;G0M<VEZ93HQ,'!T)SXS,2P@,C`Q,RP@=&AE($-O;7!A;GD@<F5C;V=N
M:7IE9"!T:&4@9F]L;&]W:6YG(&YO;BUC87-H+"!S:&%R92UB87-E9"!C;VUP
M96YS871I;VX@97AP96YS92!I;B!T:&4@8V]N<V]L:61A=&5D('-T871E;65N
M="!O9B!O<&5R871I;VYS("AI;B!T:&]U<V%N9',I.B`\+V9O;G0^/"]P/@T*
M"0D)/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R/@T*"0D)"3QT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V)O
M<F1E<BUC;VQL87!S93IC;VQL87!S93L@;6%R9VEN.C`@875T;SL@=VED=&@Z
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M+W`^#0H)"0D)"0D)/"]T:#X-"@D)"0D)"0D\=&@@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P
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M.'!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^)B-X83`[/"]F;VYT/CPO<#X-
M"@D)"0D)"0D\+W1H/@T*"0D)"0D)"3QT:"!R;W=S<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z<V]L:60[(&)O<F1E<BUB;W1T;VTM=VED=&@Z,"XU<'0[('!A9&1I
M;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.R!W:61T:#HV-"XS<'0G/@T*"0D)"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.R!T97AT+6%L:6=N.F-E;G1E<B<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T.R!F;VYT+7=E:6=H=#IB;VQD)SY097)I;V0@9G)O;2!$96-E;6)E
M<B`Q-RP@,C`P,2`H9&%T92!O9B!I;F-E<'1I;VXI('1O($UA<F-H(#,Q+"`R
M,#$S/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1H/@T*"0D)"0D)/"]T<CX-"@D)
M"0D)"3QT<CX-"@D)"0D)"0D\=&@@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N
M-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIT;W`[
M('=I9'1H.C$S-RXQ-7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#L@=&5X="UA;&EG;CIC96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UW96EG:'0Z8F]L9"<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1H
M/@T*"0D)"0D)"3QT:"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z<V]L:60[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z,"XU<'0[('!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR
M:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HV,W!T
M)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG
M;CIC96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^
M,C`Q,SPO9F]N=#X\+W`^#0H)"0D)"0D)/"]T:#X-"@D)"0D)"0D\=&@@<W1Y
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M9F]N=#X\+W`^#0H)"0D)"0D)/"]T:#X-"@D)"0D)"0D\=&@@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P861D:6YG
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M.F)O;&0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)
M"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I
M9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIT;W`[('=I9'1H.C8S<'0G/@T*
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M86PM86QI9VXZ=&]P.R!W:61T:#HV,RXP-7!T)SX-"@D)"0D)"0D)/'`@<W1Y
M;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z
M8F]L9"<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)
M"3QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG
M:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.G1O<#L@=VED=&@Z,3$N.'!T)SX-
M"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)"3QT
M9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z
M-2XT<'0[('9E<G1I8V%L+6%L:6=N.G1O<#L@=VED=&@Z-C0N,W!T)SX-"@D)
M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)/"]T<CX-
M"@D)"0D)"3QT<CX-"@D)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIT
M;W`[('=I9'1H.C$S-RXQ-7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G
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M"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X
M83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)"3QT9"!S='EL
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M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)"3QT9"!S
M='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT
M<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-C0N,W!T)SX-"@D)
M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
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M;CIT;W`[('=I9'1H.C$S-RXQ-7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M
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M,W!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/C(W/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\
M+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)"0D)"3QP('-T>6QE
M/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM
M97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\
M+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[('=I9'1H.C8S+C`U<'0G/@T*"0D)"0D)"0D\<"!S='EL
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M.'!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)
M"0D)"3QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M
M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-C0N
M,W!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
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M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
M9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"3PO='(^#0H)"0D)"0D\
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M+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.G-O
M;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P861D:6YG+6QE9G0Z
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M,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXP/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T
M.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)
M"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C
M>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ
M,'!T)SXP/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-
M"@D)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D
M:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H
M.C$Q+CAP="<^#0H)"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-
M"@D)"0D)"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P
M,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.C`N-7!T.R!P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG
M:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-C0N,W!T
M)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0G/C,X-SPO9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]P
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M93HQ,'!T)SY4;W1A;#PO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)
M"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.F1O=6)L93L@8F]R9&5R+6)O='1O;2UW:61T
M:#HQ+C5P=#L@8F]R9&5R+71O<"UC;VQO<CHC,#`P,#`P.R!B;W)D97(M=&]P
M+7-T>6QE.G-O;&ED.R!B;W)D97(M=&]P+7=I9'1H.C`N-7!T.R!P861D:6YG
M+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L
M:6=N.F)O='1O;3L@=VED=&@Z-C-P="<^#0H)"0D)"0D)"3QP('-T>6QE/3-$
M;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B0\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^-#(\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#L@/"]F;VYT/CPO
M<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)"3QT9"!S='EL93TS1"=P861D:6YG
M+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L
M:6=N.F)O='1O;3L@=VED=&@Z,3$N,7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4]
M,T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO
M<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)"3QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z9&]U
M8FQE.R!B;W)D97(M8F]T=&]M+7=I9'1H.C$N-7!T.R!B;W)D97(M=&]P+6-O
M;&]R.B,P,#`P,#`[(&)O<F1E<BUT;W`M<W1Y;&4Z<V]L:60[(&)O<F1E<BUT
M;W`M=VED=&@Z,"XU<'0[('!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR
M:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HV,RXP
M-7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG
M5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SXY,3PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]P/@T*"0D)"0D)"3PO=&0^#0H)
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M"0D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;2US='EL93ID;W5B;&4[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z,2XU<'0[(&)O<F1E<BUT;W`M8V]L;W(Z(S`P,#`P,#L@8F]R9&5R
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M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXV,S`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#L@/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)/"]T<CX-"@D)
M"0D)/"$M+5MI9B`A<W5P<&]R=$UI<V%L:6=N961#;VQU;6YS73X\='(^#0H)
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M:78^#0H)"0D\<"!S='EL93TS1"=M87)G:6XZ-"XU<'0@,'!T(#!P="`R-"XU
M<'0[('1E>'0M:6YD96YT.BTR-"XU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X
M83`[/"]F;VYT/CPO<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P
M<'0@,'!T(#(T+C5P=#L@=&5X="UI;F1E;G0Z+3(T+C5P="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,G!T)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.CEP="`P<'0[('!A9V4M8G)E86LM:6YS:61E.F%V;VED.R!P86=E+6)R
M96%K+6%F=&5R.F%V;VED)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG
M5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/E-T;V-K(&]P=&EO
M;B!T<F%N<V%C=&EO;G,@9F]R('1H92!T:')E92!M;VYT:"!P97)I;V0@96YD
M960@36%R8V@\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA,#L\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[
M(&9O;G0M<VEZ93HQ,'!T)SXS,2P@,C`Q,R!U;F1E<B!A;&P@<&QA;G,@87)E
M(&%S(&9O;&QO=W,Z(#PO9F]N=#X\+W`^#0H)"0D\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIC96YT97(^#0H)"0D)/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA
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M"0D)"3QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[
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M(R!O9B!/<'1I;VYS(#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)
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M='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB
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M079E<F%G92!%>&5R8VES92!0<FEC93PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D
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M"0D)"3QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[
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M5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2`\
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M+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.R!W:61T:#HQ,2XX<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[('!A9V4M8G)E86LM:6YS:61E.F%V;VED.R!P86=E+6)R
M96%K+6%F=&5R.F%V;VED)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3I#
M86QI8G)I.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)
M"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N
M-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[('=I9'1H.C8R+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
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M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU
M+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ,2XQ<'0G/@T*
M"0D)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[('!A9V4M8G)E86LM:6YS
M:61E.F%V;VED.R!P86=E+6)R96%K+6%F=&5R.F%V;VED)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3I#86QI8G)I.R!F;VYT+7-I>F4Z,3!P="<^)B-X
M83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C8R+CDU<'0G/@T*"0D)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[('!A9V4M8G)E86LM:6YS:61E.F%V
M;VED.R!P86=E+6)R96%K+6%F=&5R.F%V;VED)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3I#86QI8G)I.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F
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M;G0M<VEZ93HQ,'!T)SXS,2P@,C`Q,CPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D
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M)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\
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M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T)SXQ-#0L,#$Y/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)
M"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I
M9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P
M="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A
M:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)
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M:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[
M('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X
M83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4]
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M.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXT+CDQ/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)
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M<&5R:6]D.CPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D
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M.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)
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M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)
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M=&@Z-C(N.35P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@
M<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O
M:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)
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M,38P.R8C,38P.R`\+V9O;G0^/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT
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M="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG
M;CIR:6=H=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM
M869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/C`N
M,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
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M="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A
M:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)
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M=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)"0D\='(^#0H)
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]P/@T*"0D)"0D)
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M;3L@=VED=&@Z-30N.35P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#L@=&5X="UA;&EG;CIR:6=H=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O
M:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/C`N,#`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T
M97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R
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M+CAP="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB
M<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^
M#0H)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D
M:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H
M.C8R+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X
M="UA;&EG;CIR:6=H=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M
M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS
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M9'1H.C$Q+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@
M<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O
M:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M
M<VEZ93HQ,'!T)SXQ-BXU,SPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]P/@T*"0D)
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M='1O;3L@=VED=&@Z-C(N.35P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#L@=&5X="UA;&EG;CIR:6=H=#L@<&%G92UB<F5A:RUI;G-I9&4Z
M879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"3PO='(^
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M.B,P,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z9&]U8FQE.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.C(N,C5P=#L@8F]R9&5R+71O<"UC;VQO<CHC,#`P,#`P
M.R!B;W)D97(M=&]P+7-T>6QE.G-O;&ED.R!B;W)D97(M=&]P+7=I9'1H.C`N
M-7!T.R!P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[
M('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-C(N,7!T)SX-"@D)"0D)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.R!T97AT+6%L:6=N.G)I9VAT.R!P
M86=E+6)R96%K+6EN<VED93IA=F]I9#L@<&%G92UB<F5A:RUA9G1E<CIA=F]I
M9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#L@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^,3,W+#<V,#PO9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R`\+V9O;G0^/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT9"!S
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M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O<F1E
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M;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM
M869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO
M<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.F1O=6)L
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]P/@T*
M"0D)"0D)/"]T9#X-"@D)"0D)/"]T<CX-"@D)"0D)/'1R/@T*"0D)"0D)/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU
M+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ.34N,35P="<^
M#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI
M;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)
M"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I
M9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+CAP
M="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A
M:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)
M"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG
M+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C8R
M+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB
M<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^
M#0H)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D
M:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H
M.C$Q+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G
M92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO
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M;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)
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M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)
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M="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A
M:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^3W!T:6]N<R!E>&5R8VES86)L92!A="!-87)C:"`S,2P@
M,C`Q,SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE
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M/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P
M=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HV,BXQ<'0G/@T*"0D)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[('1E>'0M86QI9VXZ<FEG:'0[
M('!A9V4M8G)E86LM:6YS:61E.F%V;VED.R!P86=E+6)R96%K+6%F=&5R.F%V
M;VED)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ,C,L-#`X/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D
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M.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)
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M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/C$X+CPO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/C@R/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*
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M9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D
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M,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]P/@T*"0D)"0D)/"]T
M9#X-"@D)"0D)/"]T<CX-"@D)"0D)/'1R/@T*"0D)"0D)/'1D('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R
M=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ.34N,35P="<^#0H)"0D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O
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M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O
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M8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-30N.35P="<^#0H)"0D)"0D)/'`@
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M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y
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M,38P.R`\+V9O;G0^/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT9"!S='EL
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M"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIR:6=H
M=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z
M879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
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M#0H)"0D)/"]T86)L93X-"@D)"3PO9&EV/@T*"0D)/'`@<W1Y;&4],T1M87)G
M:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)
M/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C9%\U-S1A7S0R-V5?
M8C5A9%\Y-3@Q,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M
M92!487AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-
M"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHQ,RXU<'0@,'!T(#!P=#L@<&%G92UB
M<F5A:RUA9G1E<CIA=F]I9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+7=E:6=H
M=#IB;VQD)SXH.2D@26YC;VUE(%1A>&5S(#PO9F]N=#X\+W`^#0H)"0D\<"!S
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M9F]N="US:7IE.C$P<'0G/D-O;7!A;GDF(S@R,3<[<R`\+V9O;G0^/&9O;G0@
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M/CPO<#X-"@D)/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T
M-#@W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C9%\U
M-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E=#$W
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%34-!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY4
M:&4@0V]M<&%N>2!A;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S("A0;VQI8VEE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H)"0D\<"!S='EL
M93TS1"=M87)G:6XZ-"XU<'0@,'!T(#!P="`Q,BXR<'0[('!A9V4M8G)E86LM
M869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L
M9#L@9F]N="US='EL93II=&%L:6,G/D1E<V-R:7!T:6]N(&]F($)U<VEN97-S
M/"]F;VYT/CPO<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@
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M;R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
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M:6YT;R!A="!L96%S="`R,#(V(&EN('1H92!5+E,N(&%N9"!I;G1O(#(P,C4@
M:6X@175R;W!E+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@8F5L:65V97,@
M=&AA="!I9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
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M<VEV:71Y(&9O<B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY'96YC87)O/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^(&EN=&\@,C`R.2!O<B`R,#,P(&EN('1H
M92!54R!A;F0@175R;W!E+B`\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C9P="`P<'0@,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/D%20T$\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ,'!T)SX@8F5L:65V97,@=&AA="`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SY'96YC87)O/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M(&AA<R!P;W1E;G1I86P@969F:6-A8WD@:6X@<F5D=6-I;F<@;W(@<')E=F5N
M=&EN9R!!1BP@86YD/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^('1H870\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ,'!T)SX@=&AI<R!E9F9I8V%C>2!M87D@8F4@9V5N
M971I8V%L;'D@<F5G=6QA=&5D+B!4:&4@0V]M<&%N>2!P;&%N<R!T;R!T97-T
M('1H:7,@:'EP;W1H97-I<R!I;B!A(&-L:6YI8V%L('1R:6%L(&]F(#PO9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0G/D=E;F-A<F\\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ
M,'!T)SXL(&MN;W=N(&%S($=%3D5424,M048L('=H:6-H('1H92!#;VUP86YY
M('!L86YS('1O(&EN:71I871E('!E;F1I;F<@<F5C96EP="!O9B!T:&4@;F5C
M97-S87)Y(&9U;F1I;F<N(%1H92!#;VUP86YY(&AA<R!C<F5A=&5D(&%N(&%D
M87!T:79E(&1E<VEG;B!F;W(@1T5.151)0RU!1B!U;F1E<B!W:&EC:"!T:&4@
M=')I86P@:7,@:6YT96YD960@=&\@8F4@:6YI=&EA=&5D(&%S(&$@4&AA<V4@
M,F(@<W1U9'D@:6X@87!P<F]X:6UA=&5L>2`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ
M,'!T.R`G/C(P,#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG
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M87!P<F]X:6UA=&5L>2`V(&UO;G1H<R!A9G1E<B!T:&4@0V]M<&%N>2!O8G1A
M:6YS('-U9F9I8VEE;G0@9G5N9&EN9SPO9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/BX\+V9O;G0^/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.CEP="`P<'0@
M,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/E1O('-U<'!O<G0@=&AE(&-O;G1I;G5E
M9"!D979E;&]P;65N="!O9B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M;VYT/CPO<#X-"@D)/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E=F5L;W!M96YT(%-T86=E(%)I<VMS
M+"!,:7%U:61I='D@86YD($=O:6YG($-O;F-E<FX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^#0H)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,3,N-7!T(#!P="`P<'0@,3(N,G!T.R!P86=E+6)R96%K+6%F=&5R.F%V;VED
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0[(&9O;G0M=V5I9VAT.F)O;&0[(&9O;G0M<W1Y
M;&4Z:71A;&EC)SY$979E;&]P;65N="!3=&%G92!2:7-K<RP@3&EQ=6ED:71Y
M(&%N9"!';VEN9R!#;VYC97)N/"]F;VYT/CPO<#X-"@D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHT+C5P="`P<'0@,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
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M="<^+"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
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M;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M,3<L(#(P,#$L(&]R($EN8V5P=&EO;BP@=&AE($-O;7!A;GD@:&%S(&EN8W5R
M<F5D('-U8G-T86YT:6%L(&QO<W-E<R!A;F0@;F5G871I=F4@8V%S:"!F;&]W
M<R!F<F]M(&]P97)A=&EO;G,N(%-I;F-E($EN8V5P=&EO;BP@=&AE($-O;7!A
M;GD@:6YC=7)R960@82!L;W-S(&9R;VT@;W!E<F%T:6]N<R!O9B`D/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P=#L@)SXQ,#`N,CPO9F]N=#X\9F]N="!S='EL93TS
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M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B!M:6QL:6]N+B`\+V9O;G0^/"]P
M/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.CEP="`P<'0@,'!T)SX\9F]N="!S
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M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R`G/C$N/"]F;VYT/CQF
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M+7-I>F4Z,3!P="<^5&AE<V4@9FEN86YC:6YG<R`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T)SYH879E(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/F%L;&]W/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^960\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SX@05)#02!T;R!C;VYT:6YU92!O<&5R871I;VYS/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^('=H:6QE(&ET(&-O;G1I;G5E<R!T;R!P=7)S=64@9FEN86YC
M:6YG(&]P=&EO;G,L(&$@<W1R871E9VEC(&-O;6)I;F%T:6]N+"!P87)T;F5R
M:6YG+"!A;F0@;&EC96YS:6YG(&]P<&]R='5N:71I97,N($EF('1H92!#;VUP
M86YY(&ES(&1E;&%Y960@:6X@8V]M<&QE=&EN9R!O<B!I<R!U;F%B;&4@=&\@
M8V]M<&QE=&4@861D:71I;VYA;"!F=6YD:6YG(&%N9"]O<B!A('-T<F%T96=I
M8R!T<F%N<V%C=&EO;BP@=&AE($-O;7!A;GD@;6%Y(&1I<V-O;G1I;G5E(&ET
M<R!D979E;&]P;65N="!A8W1I=FET:65S(&]R(&1I<V-O;G1I;G5E(&ET<R!O
M<&5R871I;VYS+B!4:&4@0V]M<&%N>2!C=7)R96YT;'D@8F5L:65V97,@:71S
M(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@8F%L86YC92!A<R!O9B!-87)C
M:#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US
M:7IE.C$P<'0G/C,Q+"`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
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M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^,S`L(#(P,3,N(%1H92!#;VUP86YY
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M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/C,P+"`R,#$S+B!4:&5S92!C;VYS
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M=')A=&5G:6,@=')A;G-A8W1I;VXN(#PO9F]N=#X\+W`^#0H)"0D\<"!S='EL
M93TS1"=M87)G:6XZ.7!T(#!P="`P<'0[('!A9V4M8G)E86LM869T97(Z879O
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M:6YG+6QE9G0Z,'!T)SX-"@D)"0D\;&D@<W1Y;&4],T0G;6%R9VEN.B`T+C5P
M="`P<'0@,'!T(#4Y+C$R<'0[('1E>'0M:6YD96YT.B`P<'0[('!A9&1I;F<M
M;&5F=#H@-RXT.'!T.R!F;VYT+7-I>F4Z(#$R<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/G1H92!C;W-T<R!A;F0@=&EM:6YG(&9O<B!T:&4@<&QA;FYE9"!'14Y%
M5$E#+4%&(&-L:6YI8V%L('1R:6%L(&EN(&]R9&5R('1O(&=A:6X@<&]S<VEB
M;&4@1D1!(&%P<')O=F%L(&9O<B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SY'
M96YC87)O/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^.R`\+V9O;G0^/"]L:3X-
M"@D)"0D\;&D@<W1Y;&4],T0G;6%R9VEN.B`T+C5P="`P<'0@,'!T(#4Y+C$R
M<'0[('1E>'0M:6YD96YT.B`P<'0[('!A9&1I;F<M;&5F=#H@-RXT.'!T.R!F
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M.R`\+V9O;G0^/"]L:3X-"@D)"0D\;&D@<W1Y;&4],T0G;6%R9VEN.B`T+C5P
M="`P<'0@,'!T(#4Y+C$R<'0[('1E>'0M:6YD96YT.B`P<'0[('!A9&1I;F<M
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M($-A<&ET86P@36%R:V5T.R`\+V9O;G0^/"]L:3X-"@D)"0D\;&D@<W1Y;&4]
M,T0G;6%R9VEN.B`T+C5P="`P<'0@,'!T(#4Y+C$R<'0[('1E>'0M:6YD96YT
M.B`P<'0[('!A9&1I;F<M;&5F=#H@-RXT.'!T.R!F;VYT+7-I>F4Z(#$R<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0G/F=E;F5R86P@96-O;F]M:6,@86YD(&EN9'5S
M=')Y(&-O;F1I=&EO;G,@869F96-T:6YG('1H92!A=F%I;&%B:6QI='D@86YD
M(&-O<W0@;V8@8V%P:71A;#L@/"]F;VYT/CPO;&D^#0H)"0D)/&QI('-T>6QE
M/3-$)VUA<F=I;CH@-"XU<'0@,'!T(#!P="`U.2XQ,G!T.R!T97AT+6EN9&5N
M=#H@,'!T.R!P861D:6YG+6QE9G0Z(#<N-#AP=#L@9F]N="US:7IE.B`Q,G!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA
M;B<[(&9O;G0M<VEZ93HQ,'!T)SYT:&4@0V]M<&%N>28C.#(Q-SMS(&%B:6QI
M='D@=&\@8V]N=')O;"!C;W-T<R!A<W-O8VEA=&5D('=I=&@@:71S(&]P97)A
M=&EO;G,[(#PO9F]N=#X\+VQI/@T*"0D)"3QL:2!S='EL93TS1"=M87)G:6XZ
M(#0N-7!T(#!P="`P<'0@-3DN,3)P=#L@=&5X="UI;F1E;G0Z(#!P=#L@<&%D
M9&EN9RUL969T.B`W+C0X<'0[(&9O;G0M<VEZ93H@,3)P=#LG/CQF;VYT('-T
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M="`U.2XQ,G!T.R!T97AT+6EN9&5N=#H@,'!T.R!P861D:6YG+6QE9G0Z(#<N
M-#AP=#L@9F]N="US:7IE.B`Q,G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M+W5L/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.CEP="`P<'0@,'!T)SX\9F]N
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M(&%C=&EV:71I97,@=&\@8V]N<V5R=F4@:71S(&-A<V@@<F5S;W5R8V5S+B`\
M+V9O;G0^/"]P/@T*"0D\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V97)S92!3=&]C:R!3<&QI=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"@D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHQ,RXU<'0@,'!T(#!P=#L@<&%G92UB<F5A:RUA9G1E
M<CIA=F]I9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+7=E:6=H=#IB;VQD.R!F
M;VYT+7-T>6QE.FET86QI8R<^4F5V97)S92!3=&]C:R!3<&QI="`\+V9O;G0^
M/"]P/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C0N-7!T(#!P="`P<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^3VX@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^36%R
M8V@@-#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/BP@,C`Q,SPO9F]N=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/BP\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SX@=&AE($-O
M;7!A;GD@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^8V]M<&QE=&5D(#PO9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0G/F$@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@
M)SXQ+69O<BTV(')E=F5R<V4@<W!L:70\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SX@;V8@:71S(&-O;6UO;B!S=&]C:SPO9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/BX@06QL(&-O;6UO;B!S:&%R97,@86YD('!E<B!C;VUM;VX@<VAA<F4@86UO
M=6YT<R!I;B!T:&4@9FEN86YC:6%L('-T871E;65N=',@86YD(&9O;W1N;W1E
M<R!H879E(&)E96X@861J=7-T960@<F5T<F]A8W1I=F5L>2!T;R!R969L96-T
M('1H92!E9F9E8W1S(&]F('1H:7,@86-T:6]N+B`\+V9O;G0^/"]P/@T*"0D\
M+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C$S+C5P="`P<'0@,'!T.R!P86=E+6)R96%K+6%F=&5R.F%V;VED)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0[(&9O;G0M=V5I9VAT.F)O;&0[(&9O;G0M<W1Y;&4Z:71A
M;&EC)SY"87-I<R!O9B!0<F5S96YT871I;VX@/"]F;VYT/CPO<#X-"@D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T)SX\9F]N="!S='EL93TS
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M<FUA=&EO;B!A;F0@:6YS=')U8W1I;VYS('1O($9O<FT@,3`M42!A;F0@4G5L
M92`Q,"TP,2!O9B!296=U;&%T:6]N(%,M6"X\+V9O;G0^/&9O;G0@<W1Y;&4]
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M)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^26X@=&AE(&]P:6YI;VX@
M;V8@;6%N86=E;65N="P@=&AE<V4@9FEN86YC:6%L('-T871E;65N=',@:6YC
M;'5D92!A;&P@;F]R;6%L(&%N9"!R96-U<G)I;F<@861J=7-T;65N=',@8V]N
M<VED97)E9"!N96-E<W-A<GD@9F]R(&$@9F%I<B!P<F5S96YT871I;VX@;V8@
M=&AE<V4@:6YT97)I;2!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N
M=',N(%1H92!R97-U;'1S(&]F(&]P97)A=&EO;G,@9F]R('1H92!T:')E92!M
M;VYT:',@96YD960@36%R8V@\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA
M,#L\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXS,2P@,C`Q,R!A<F4@;F]T(&YE
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M86XG.R!F;VYT+7-I>F4Z,3!P="<^,C`Q,SPO9F]N=#X\9F]N="!S='EL93TS
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M;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXS,2P@,C`Q,RX@5&AE<V4@=6YA=61I
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M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^,S$L(#(P,3(@:6YC;'5D960@:6X@=&AE
M($-O;7!A;GDF(S@R,3<[<R!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2R!F
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M=#X\+W`^#0H)"3PO9&EV/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYC96YT<F%T:6]N<R!O9B!#<F5D:70@
M4FES:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"@D)
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M+C5P="`P<'0@,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM
M97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C%P="<^)B-X83`[/"]F;VYT/CPO
M<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T)SX\9F]N
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M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@17AP
M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H)
M"0D\<"!S='EL93TS1"=M87)G:6XZ,3,N-7!T(#!P="`P<'0[('!A9V4M8G)E
M86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z
M8F]L9#L@9F]N="US='EL93II=&%L:6,G/D%C8W)U960@17AP96YS97,@/"]F
M;VYT/CPO<#X-"@D)"3QP('-T>6QE/3-$)VUA<F=I;CHT+C5P="`P<'0@,'!T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0G/D%S('!A<G0@;V8@=&AE('!R;V-E<W,@;V8@
M<')E<&%R:6YG(&ET<R!F:6YA;F-I86P@<W1A=&5M96YT<RP@=&AE($-O;7!A
M;GD@:7,@<F5Q=6ER960@=&\@97-T:6UA=&4@86-C<G5E9"!E>'!E;G-E<RX@
M5&AI<R!P<F]C97-S(&EN=F]L=F5S(&ED96YT:69Y:6YG('-E<G9I8V5S('1H
M870@=&AI<F0@<&%R=&EE<R!H879E('!E<F9O<FUE9"!O;B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&)E:&%L9B!A;F0@97-T:6UA=&EN9R!T:&4@;&5V96P@;V8@
M<V5R=FEC92!P97)F;W)M960@86YD('1H92!A<W-O8VEA=&5D(&-O<W0@:6YC
M=7)R960@9F]R('1H97-E('-E<G9I8V5S(&%S(&]F('1H92!B86QA;F-E('-H
M965T(&1A=&4N($5X86UP;&5S(&]F(&5S=&EM871E9"!A8V-R=65D(&5X<&5N
M<V5S(&EN8VQU9&4@8V]N=')A8W0@<V5R=FEC92!F965S+"!S=6-H(&%S(&9E
M97,@<&%Y86)L92!T;R!C;VYT<F%C="!M86YU9F%C='5R97)S(&EN(&-O;FYE
M8W1I;VX@=VET:"!T:&4@<')O9'5C=&EO;B!O9B!M871E<FEA;',@<F5L871E
M9"!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS(&1R=6<@<')O9'5C="P@86YD('!R
M;V9E<W-I;VYA;"!S97)V:6-E(&9E97,L('-U8V@@87,@871T;W)N97ES+"!C
M;VYS=6QT86YT<RP@86YD(&-L:6YI8V%L(')E<V5A<F-H(&]R9V%N:7IA=&EO
M;G,N(%1H92!#;VUP86YY(&1E=F5L;W!S(&5S=&EM871E<R!O9B!L:6%B:6QI
M=&EE<R!U<VEN9R!I=',@:G5D9VUE;G0@8F%S960@=7!O;B!T:&4@9F%C=',@
M86YD(&-I<F-U;7-T86YC97,@:VYO=VX@870@=&AE('1I;64N(#PO9F]N=#X\
M+W`^#0H)"3PO9&EV/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X
M-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(P9F(U8V1?-3<T
M85\T,C=E7V(U861?.34X,3`Y8S0T.#<T+U=O<FMS:&5E=',O4VAE970Q."YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQO<W,@
M4&5R(%-H87)E("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@0F%S:6,@86YD($1I;'5T960@3&]S
M<R!097(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
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M('-H87)E(&9O;&QO=W,Z(#PO9F]N=#X\+W`^#0H)"0D\=&%B;&4@8V5L;'-P
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M<&%N/3-$,R!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z<V]L:60[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z,"XU<'0[('!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU
M+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ-C`N,S5P="<^
M#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC
M96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^(%1H
M<F5E($UO;G1H<R!%;F1E9"!-87)C:"`S,2P@/"]F;VYT/CPO<#X-"@D)"0D)
M"3PO=&@^#0H)"0D)"3PO='(^#0H)"0D)"3QT<CX-"@D)"0D)"3QT:"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[
M('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z,C8Y+CAP="<^#0H)"0D)
M"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X
M83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&@^#0H)"0D)"0D\=&@@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$R+C)P="<^#0H)"0D)"0D)
M/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[
M/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&@^#0H)"0D)"0D\=&@@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P861D:6YG
M+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L
M:6=N.F)O='1O;3L@=VED=&@Z-S-P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT97(G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M=#L@9F]N="UW96EG:'0Z8F]L9"<^,C`Q,SPO9F]N=#X\+W`^#0H)"0D)"0D\
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M,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z<V]L:60[(&)O<F1E<BUB;W1T
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M/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[
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M9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC
M86PM86QI9VXZ8F]T=&]M.R!W:61T:#HW,RXW<'0G/@T*"0D)"0D)"3QP('-T
M>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG
M5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N
M=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)"0D\='(^#0H)
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M+C)P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)
M"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.C`N-7!T.R!P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT
M<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-S-P="<^#0H)"0D)
M"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)#PO
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
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M=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(S`P,#`P,#L@8F]R9&5R+6)O='1O;2US='EL93IS
M;VQI9#L@8F]R9&5R+6)O='1O;2UW:61T:#HP+C5P=#L@<&%D9&EN9RUL969T
M.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB
M;W1T;VT[('=I9'1H.C<S+C=P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G
M:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)#PO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^
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M/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
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M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z<V]L:60[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z,"XU<'0[(&)O<F1E<BUT;W`M8V]L;W(Z(S`P
M,#`P,#L@8F]R9&5R+71O<"US='EL93IS;VQI9#L@8F]R9&5R+71O<"UW:61T
M:#HP+C5P=#L@<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N
M-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C<S<'0G/@T*"0D)
M"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B0\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2
M;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#L@/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^*#$L,#<Q*3PO
M9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A
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M97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M<V]L:60[(&)O<F1E<BUB;W1T;VTM=VED=&@Z,"XU<'0[(&)O<F1E<BUT;W`M
M8V]L;W(Z(S`P,#`P,#L@8F]R9&5R+71O<"US='EL93IS;VQI9#L@8F]R9&5R
M+71O<"UW:61T:#HP+C5P=#L@<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG
M+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C<S
M+C=P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG
M5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SXH,2PT,#<I/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^(#PO9F]N=#X\+W`^
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU
M+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ,BXR<'0G/@T*
M"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T
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M/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[
M/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T
M:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C<S+C=P="<^#0H)"0D)"0D)/'`@
M<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F
M;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"3PO='(^#0H)"0D)"3QT<CX-
M"@D)"0D)"3QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I
M;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z
M,C8Y+CAP="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT
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M+C)P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[
M(&9O;G0M<VEZ93HQ,'!T)SXS+#`S-RPU-#8\+V9O;G0^/"]P/@T*"0D)"0D)
M/"]T9#X-"@D)"0D)"3QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[
M('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@
M=VED=&@Z,3,N-C5P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO
M=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P
M861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I
M9'1H.C<S+C=P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/C(L,#,P+#0Y.3PO9F]N=#X\
M+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)"0D\='(^#0H)"0D)
M"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I
M9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C(V.2XX
M<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE
M.C$P<'0G/DQE<W,Z)B,Q-C`[(%=E:6=H=&5D+6%V97)A9V4@<VAA<F5S(&]F
M('5N=F5S=&5D(&-O;6UO;B!S=&]C:SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D
M/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D
M9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T
M:#HQ,BXR<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*
M"0D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(S`P,#`P
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M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O
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M="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*
M"0D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;2US='EL93IS;VQI9#L@8F]R9&5R+6)O='1O;2UW
M:61T:#HP+C5P=#L@<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT
M.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C<S+C=P="<^
M#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\
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M:6=N.F)O='1O;3L@=VED=&@Z,C8Y+CAP="<^#0H)"0D)"0D)/'`@<W1Y;&4]
M,T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^5&]T86P@=V5I9VAT960M
M879E<F%G92!S:&%R97,@=7-E9"!I;B!C;VUP=71I;F<@;F5T(&QO<W,@<&5R
M('-H87)E(&%T=')I8G5T960@=&\@8V]M;6]N('-T;V-K:&]L9&5R<SPO9F]N
M=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I
M;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM
M86QI9VXZ8F]T=&]M.R!W:61T:#HQ,BXR<'0G/@T*"0D)"0D)"3QP('-T>6QE
M/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM
M97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\
M+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M
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M='1O;3L@=VED=&@Z,3,N-C5P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G
M:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)
M"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N
M-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[('=I9'1H.C<S+C=P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ
M,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)
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M<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-S-P="<^#0H)"0D)"0D)/'`@
M<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/C,L,#,T+#<V,SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)
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M/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
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M,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z9&]U8FQE.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.C(N,C5P=#L@8F]R9&5R+71O<"UC;VQO<CHC,#`P,#`P.R!B
M;W)D97(M=&]P+7-T>6QE.G-O;&ED.R!B;W)D97(M=&]P+7=I9'1H.C`N-7!T
M.R!P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E
M<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-S-P="<^#0H)"0D)"0D)/'`@
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M,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S
M($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXH,"XS-2D\+V9O;G0^/"]P
M/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N
M.F)O='1O;3L@=VED=&@Z,3,N-C5P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T1M
M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-
M"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.F1O=6)L93L@
M8F]R9&5R+6)O='1O;2UW:61T:#HR+C(U<'0[(&)O<F1E<BUT;W`M8V]L;W(Z
M(S`P,#`P,#L@8F]R9&5R+71O<"US='EL93IS;VQI9#L@8F]R9&5R+71O<"UW
M:61T:#HP+C5P=#L@<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT
M.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C<S+C=P="<^
M#0H)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M(&9O;G0M<VEZ93HQ<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D
M/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D
M9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T
M:#HQ,BXR<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C%P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)
M"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG
M+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C<S
M<'0G/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE
M.C%P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT
M.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$S+C8U<'0G
M/@T*"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C%P
M="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N
M-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C<S+C=P="<^#0H)
M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
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M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"3PO9&EV/@T*/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C!F8C5C9%\U
M-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X-S0-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T
M.#<T+U=O<FMS:&5E=',O4VAE970Q.2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@*%1A
M8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W5M;6%R>2!O9B!0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C0N-7!T(#!P="`Y<'0[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^4')O<&5R='D@86YD(&5Q=6EP;65N="!C;VYS:7-T
M(&]F('1H92!F;VQL;W=I;F<@*&EN('1H;W5S86YD<RDZ(#PO9F]N=#X\+W`^
M#0H)"0D\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S
M='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[(&UA<F=I;BUL969T
M.C!P=#L@=VED=&@Z.30N-C8E)SX-"@D)"0D\='(^#0H)"0D)"3QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C(Q,2XU<'0G/@T*
M"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT
M97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)
M/"]T9#X-"@D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;2US='EL93IS;VQI9#L@8F]R9&5R+6)O
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M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)
M"3QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O
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M:"`S,2P@,C`Q,SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C9P="<^
M#0H)"0D)"0D\<"!S='EL93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D)"0D\+W1D/@T*"0D)"0D\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T+C8U<'0G/@T*"0D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT97(G/CQF
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M+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[('=I9'1H.CDY<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT97(G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^,R!Y96%R<SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S
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M86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ,2XV<'0G/@T*"0D)"0D)/'`@<W1Y
M;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT
M/CPO<#X-"@D)"0D)/"]T9#X-"@D)"0D)/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.F)O='1O;3L@=VED=&@Z-30N-C5P="<^#0H)"0D)"0D\<"!S='EL
M93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXD/"]F;VYT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/C$P-#PO9F]N=#X\+W`^#0H)"0D)
M"3PO=&0^#0H)"0D)/"]T<CX-"@D)"0D\='(^#0H)"0D)"3QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C(Q,2XU<'0G/@T*"0D)
M"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^3&%B
M(&5Q=6EP;65N=#PO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.CDY<'0G/@T*
M"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT
M97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^-2!Y96%R<SPO9F]N=#X\+W`^#0H)"0D)
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M.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ-#(\+V9O;G0^/"]P
M/@T*"0D)"0D\+W1D/@T*"0D)"0D\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.R!W:61T:#HQ,2XV<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T1M
M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-
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M>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T+C8U<'0G/@T*"0D)
M"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T+C8U<'0G
M/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\
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M=V%R93PO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.CDY<'0G/@T*"0D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT97(G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^,R!Y96%R<SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^
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M.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ-S8\+V9O;G0^/"]P/@T*"0D)
M"0D\+W1D/@T*"0D)"0D\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T
M=&]M.R!W:61T:#HQ,2XV<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ
M,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)
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M9VXZ8F]T=&]M.R!W:61T:#HQ,2XV<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T1M
M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-
M"@D)"0D)/"]T9#X-"@D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(S`P,#`P,#L@8F]R9&5R+6)O='1O;2US='EL93IS;VQI9#L@8F]R
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M.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXQ.#PO9F]N=#X\+W`^
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M;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.G-O;&ED.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M('=I9'1H.C4T+C8U<'0G/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM
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M>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S='EL93TS
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M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ
M93HQ,'!T)SXU,#@\+V9O;G0^/"]P/@T*"0D)"0D\+W1D/@T*"0D)"0D\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ,2XV<'0G
M/@T*"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)/"]T9#X-"@D)"0D)/'1D('-T
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M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)/"]T9#X-"@D)"0D)/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(S`P,#`P,#L@8F]R9&5R+6)O='1O
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ
M,'!T)SXH-#@V*3PO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C9P="<^
M#0H)"0D)"0D\<"!S='EL93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D)"0D\+W1D/@T*"0D)"0D\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T+C8U<'0G/@T*"0D)"0D)
M/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE
M.C$P<'0G/B@U,3`I/"]F;VYT/CPO<#X-"@D)"0D)/"]T9#X-"@D)"0D\+W1R
M/@T*"0D)"3QT<CX-"@D)"0D)/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.F)O='1O;3L@=VED=&@Z,C$Q+C5P="<^#0H)"0D)"0D\<"!S='EL93TS1&UA
M<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA,#L\+V9O;G0^/"]P/@T*
M"0D)"0D\+W1D/@T*"0D)"0D\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M8F]T=&]M.R!W:61T:#HY.7!T)SX-"@D)"0D)"3QP('-T>6QE/3-$;6%R9VEN
M.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)
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M,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.F1O=6)L93L@8F]R9&5R+6)O
M='1O;2UW:61T:#HQ+C5P=#L@8F]R9&5R+71O<"UC;VQO<CHC,#`P,#`P.R!B
M;W)D97(M=&]P+7-T>6QE.G-O;&ED.R!B;W)D97(M=&]P+7=I9'1H.C`N-7!T
M.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C4T+C8U<'0G/@T*"0D)
M"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)"3QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z9&]U8FQE.R!B;W)D97(M8F]T=&]M+7=I9'1H.C$N-7!T
M.R!B;W)D97(M=&]P+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUT;W`M<W1Y;&4Z
M<V]L:60[(&)O<F1E<BUT;W`M=VED=&@Z,"XU<'0[('9E<G1I8V%L+6%L:6=N
M.F)O='1O;3L@=VED=&@Z-30N-C5P="<^#0H)"0D)"0D\<"!S='EL93TS1&UA
M<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXD/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0G/C(S/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M(#PO9F]N=#X\+W`^#0H)"0D)"3PO=&0^#0H)"0D)/"]T<CX-"@D)"3PO=&%B
M;&4^#0H)"0D\<"!S='EL93TS1"=M87)G:6XZ-"XU<'0@,'!T(#!P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,G!T)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D\+V1I=CX-"CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V(P9F(U
M8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T.#<T#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P
M.6,T-#@W-"]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5013X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I
M;VX@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F]N+6-A<V@L(%-H87)E+4)A<V5D($-O;7!E;G-A=&EO;B!%>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C0N-7!T(#!P="`Y<'0[('!A9V4M8G)E86LM
M869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^1F]R('1H92!T:')E92!M
M;VYT:"!P97)I;V1S(&5N9&5D($UA<F-H/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
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M(&9O;G0M<VEZ93HQ,'!T)SXS,2P@,C`Q,RP@=&AE($-O;7!A;GD@<F5C;V=N
M:7IE9"!T:&4@9F]L;&]W:6YG(&YO;BUC87-H+"!S:&%R92UB87-E9"!C;VUP
M96YS871I;VX@97AP96YS92!I;B!T:&4@8V]N<V]L:61A=&5D('-T871E;65N
M="!O9B!O<&5R871I;VYS("AI;B!T:&]U<V%N9',I.B`\+V9O;G0^/"]P/@T*
M"0D)/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R/@T*"0D)"3QT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V)O
M<F1E<BUC;VQL87!S93IC;VQL87!S93L@;6%R9VEN.C`@875T;SL@=VED=&@Z
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M+W`^#0H)"0D)"0D)/"]T:#X-"@D)"0D)"0D\=&@@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P
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M.'!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^)B-X83`[/"]F;VYT/CPO<#X-
M"@D)"0D)"0D\+W1H/@T*"0D)"0D)"3QT:"!R;W=S<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB;W1T;VTM
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M<B`Q-RP@,C`P,2`H9&%T92!O9B!I;F-E<'1I;VXI('1O($UA<F-H(#,Q+"`R
M,#$S/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1H/@T*"0D)"0D)/"]T<CX-"@D)
M"0D)"3QT<CX-"@D)"0D)"0D\=&@@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N
M-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIT;W`[
M('=I9'1H.C$S-RXQ-7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#L@=&5X="UA;&EG;CIC96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UW96EG:'0Z8F]L9"<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1H
M/@T*"0D)"0D)"3QT:"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B,P
M,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z<V]L:60[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z,"XU<'0[('!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR
M:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HV,W!T
M)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG
M;CIC96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^
M,C`Q,SPO9F]N=#X\+W`^#0H)"0D)"0D)/"]T:#X-"@D)"0D)"0D\=&@@<W1Y
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M9F]N=#X\+W`^#0H)"0D)"0D)/"]T:#X-"@D)"0D)"0D\=&@@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P861D:6YG
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M.F)O;&0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)
M"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I
M9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIT;W`[('=I9'1H.C8S<'0G/@T*
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M86PM86QI9VXZ=&]P.R!W:61T:#HV,RXP-7!T)SX-"@D)"0D)"0D)/'`@<W1Y
M;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z
M8F]L9"<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)
M"3QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG
M:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.G1O<#L@=VED=&@Z,3$N.'!T)SX-
M"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)"3QT
M9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z
M-2XT<'0[('9E<G1I8V%L+6%L:6=N.G1O<#L@=VED=&@Z-C0N,W!T)SX-"@D)
M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)/"]T<CX-
M"@D)"0D)"3QT<CX-"@D)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIT
M;W`[('=I9'1H.C$S-RXQ-7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G
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M"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X
M83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)"3QT9"!S='EL
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M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)"3QT9"!S
M='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT
M<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-C0N,W!T)SX-"@D)
M"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W
M(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
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M;CIT;W`[('=I9'1H.C$S-RXQ-7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M
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M,W!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/C(W/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\
M+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)"0D)"3QP('-T>6QE
M/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM
M97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\
M+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[('=I9'1H.C8S+C`U<'0G/@T*"0D)"0D)"0D\<"!S='EL
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M.'!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)
M"0D)"3QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M
M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-C0N
M,W!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
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M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
M9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"3PO='(^#0H)"0D)"0D\
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M+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.G-O
M;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P861D:6YG+6QE9G0Z
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M,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXP/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T
M.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)
M"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C
M>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)"0D\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P
M861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I
M8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-C,N,#5P="<^#0H)"0D)"0D)"3QP
M('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ
M,'!T)SXP/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-
M"@D)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D
M:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H
M.C$Q+CAP="<^#0H)"0D)"0D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-
M"@D)"0D)"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P
M,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.C`N-7!T.R!P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG
M:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-C0N,W!T
M)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N
M)SL@9F]N="US:7IE.C$P<'0G/C,X-SPO9F]N=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G
M/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]P
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M93HQ,'!T)SY4;W1A;#PO9F]N=#X\+W`^#0H)"0D)"0D)/"]T9#X-"@D)"0D)
M"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.F1O=6)L93L@8F]R9&5R+6)O='1O;2UW:61T
M:#HQ+C5P=#L@8F]R9&5R+71O<"UC;VQO<CHC,#`P,#`P.R!B;W)D97(M=&]P
M+7-T>6QE.G-O;&ED.R!B;W)D97(M=&]P+7=I9'1H.C`N-7!T.R!P861D:6YG
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M:6=N.F)O='1O;3L@=VED=&@Z,3$N,7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4]
M,T1M87)G:6XZ,'!T/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO
M<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)"3QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M+6-O;&]R.B,P,#`P,#`[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z9&]U
M8FQE.R!B;W)D97(M8F]T=&]M+7=I9'1H.C$N-7!T.R!B;W)D97(M=&]P+6-O
M;&]R.B,P,#`P,#`[(&)O<F1E<BUT;W`M<W1Y;&4Z<V]L:60[(&)O<F1E<BUT
M;W`M=VED=&@Z,"XU<'0[('!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR
M:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HV,RXP
M-7!T)SX-"@D)"0D)"0D)/'`@<W1Y;&4],T1M87)G:6XZ,'!T/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG
M5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SXY,3PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@
M3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P<'0G/B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]P/@T*"0D)"0D)"3PO=&0^#0H)
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M"0D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(S`P,#`P
M,#L@8F]R9&5R+6)O='1O;2US='EL93ID;W5B;&4[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z,2XU<'0[(&)O<F1E<BUT;W`M8V]L;W(Z(S`P,#`P,#L@8F]R9&5R
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M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXV,S`\+V9O;G0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O
M;G0M<VEZ93HQ,'!T)SXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#L@/"]F;VYT/CPO<#X-"@D)"0D)"0D\+W1D/@T*"0D)"0D)/"]T<CX-"@D)
M"0D)/"$M+5MI9B`A<W5P<&]R=$UI<V%L:6=N961#;VQU;6YS73X\='(^#0H)
M"0D)"0D\=&0@<W1Y;&4],T0G=VED=&@Z,30S<'0[(&)O<F1E<CIN;VYE)SX-
M"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G=VED=&@Z-C<N-35P
M=#L@8F]R9&5R.FYO;F4G/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT9"!S='EL
M93TS1"=W:61T:#HQ,2XU-7!T.R!B;W)D97(Z;F]N92<^#0H)"0D)"0D\+W1D
M/@T*"0D)"0D)/'1D('-T>6QE/3-$)W=I9'1H.C8X+C5P=#L@8F]R9&5R.FYO
M;F4G/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT9"!S='EL93TS1"=W:61T:#HQ
M,BXS<'0[(&)O<F1E<CIN;VYE)SX-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@
M<W1Y;&4],T0G=VED=&@Z-CDN,#5P=#L@8F]R9&5R.FYO;F4G/@T*"0D)"0D)
M/"]T9#X-"@D)"0D)/"]T<CX\(5ME;F1I9ETM+3X\+W1A8FQE/@T*"0D)/"]D
M:78^#0H)"0D\<"!S='EL93TS1&UA<F=I;CHP<'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SXF(WAA,#L\+V9O;G0^/"]P/@T*"0D\+V1I=CX-"CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!3
M=&]C:R!/<'1I;VX@06-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
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M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^,S$L(#(P,3,@=6YD97(@86QL('!L86YS(&%R92!A<R!F;VQL;W=S
M.B`\+V9O;G0^/"]P/@T*"0D)/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N
M=&5R/@T*"0D)"3QT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@;6%R9VEN
M.C`@875T;SL@=VED=&@Z.#0E)SX-"@D)"0D)/'1R/@T*"0D)"0D)/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P
M=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ.34N,35P="<^#0H)
M"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I
M9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^)B-X83`[/"]F;VYT/CPO<#X-"@D)
M"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N
M-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T
M;VT[('=I9'1H.C$Q+CAP="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T
M97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^
M)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P
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M<R`\+V9O;G0^/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT9"!S='EL93TS
M1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E
M<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z,3$N,7!T)SX-"@D)"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.R!T97AT+6%L:6=N.F-E;G1E<CL@<&%G
M92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^)B-X83`[/"]F
M;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P861D:6YG+6QE
M9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N
M.F)O='1O;3L@=VED=&@Z-30N.35P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT97([('!A9V4M8G)E86LM:6YS
M:61E.F%V;VED.R!P86=E+6)R96%K+6%F=&5R.F%V;VED)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE
M.C$P<'0[(&9O;G0M=V5I9VAT.F)O;&0G/E=E:6=H=&5D($%V97)A9V4@17AE
M<F-I<V4@4')I8V4\+V9O;G0^/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT
M9"!S='EL93TS1"=P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z
M-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z,3$N,7!T)SX-
M"@D)"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.R!T97AT+6%L:6=N.F-E
M;G1E<CL@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T
M97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^
M)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.G-O;&ED.R!B;W)D97(M8F]T=&]M+7=I9'1H.C`N-7!T.R!P
M861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I;F<M<FEG:'0Z-2XT<'0[('9E<G1I
M8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z-C(N.35P="<^#0H)"0D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIC96YT97([('!A9V4M
M8G)E86LM:6YS:61E.F%V;VED.R!P86=E+6)R96%K+6%F=&5R.F%V;VED)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@
M9F]N="US:7IE.C$P<'0[(&9O;G0M=V5I9VAT.F)O;&0G/E=E:6=H=&5D($%V
M97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@/"]F;VYT/CQB<B`O
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UW96EG:'0Z8F]L9"<^*&EN('EE87)S
M*3PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)"0D\
M='(^#0H)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P
M861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIT;W`[('=I9'1H
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M="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*
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M,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT
M.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^
M#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI
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M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z
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M+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#HU+C1P=#L@<&%D9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI
M9VXZ8F]T=&]M.R!W:61T:#HV,BXY-7!T)SX-"@D)"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.R!P86=E+6)R96%K+6EN<VED93IA=F]I9#L@<&%G92UB
M<F5A:RUA9G1E<CIA=F]I9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M0V%L:6)R:3L@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)
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M.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CQF;VYT('-T>6QE/3-$
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M+#`Q.3PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE
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M/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T
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M="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@
M9F]N="US:7IE.C$P<'0G/C$X+C(X/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\+W`^
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M+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^
M/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)/"]T<CX-"@D)"0D)/'1R/@T*"0D)
M"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D9&EN9RUR
M:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T:#HQ.34N
M,35P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB
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M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z
M879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P
M="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N
M-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)
M"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I
M9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z
M,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\
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M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)
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M:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+CAP="<^#0H)"0D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[
M('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X
M83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V
M97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C8R+C%P="<^#0H)"0D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIR:6=H=#L@<&%G
M92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM
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M:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[
M('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X
M83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4]
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M.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I
M;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXP+C`P/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE
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M/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T
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M"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I
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M="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A
M:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)
M"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG
M+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C8R
M+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA
M;&EG;CIR:6=H=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E
M86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F
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M="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A
M:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT
M+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)
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M,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T
M)SXP+C`P/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE
M<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*
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M9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D
M/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D
M9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T
M:#HV,BXY-7!T)SX-"@D)"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.R!T
M97AT+6%L:6=N.G)I9VAT.R!P86=E+6)R96%K+6EN<VED93IA=F]I9#L@<&%G
M92UB<F5A:RUA9G1E<CIA=F]I9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXF(WAA,#L\
M+V9O;G0^/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)/"]T<CX-"@D)"0D)/'1R
M/@T*"0D)"0D)/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#HU+C1P=#L@<&%D
M9&EN9RUR:6=H=#HU+C1P=#L@=F5R=&EC86PM86QI9VXZ8F]T=&]M.R!W:61T
M:#HQ.34N,35P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@
M<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O
M:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^1F]R9F5I=&5D+"!C86YC96QL960@;W(@
M97AP:7)E9#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D
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M.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXH-BPR-3DI
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@
M4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)
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M:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)
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M+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB
M<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F
M;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^
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M9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)"0D\='(^
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M<F-H(#,Q+"`R,#$S/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT
M.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+CAP="<^
M#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI
M;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)
M"0D\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.F1O=6)L93L@8F]R9&5R+6)O='1O;2UW:61T
M:#HR+C(U<'0[(&)O<F1E<BUT;W`M8V]L;W(Z(S`P,#`P,#L@8F]R9&5R+71O
M<"US='EL93IS;VQI9#L@8F]R9&5R+71O<"UW:61T:#HP+C5P=#L@<&%D9&EN
M9RUL969T.C4N-'!T.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA
M;&EG;CIB;W1T;VT[('=I9'1H.C8R+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIR:6=H=#L@<&%G92UB<F5A:RUI
M;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
M9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O
M;6%N)SL@9F]N="US:7IE.C$P<'0G/C$S-RPW-C`\+V9O;G0^/&9O;G0@<W1Y
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M;"UA;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A
M9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[
M/"]F;VYT/CPO<#X-"@D)"0D)"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;2UC;VQO<CHC,#`P,#`P.R!B;W)D97(M8F]T=&]M+7-T
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M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.C$P
M<'0G/C$X+C,V/"]F;VYT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4
M:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\+W`^#0H)"0D)"0D\+W1D
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M)SL@9F]N="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\
M+W1D/@T*"0D)"0D)/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(S`P,#`P,#L@8F]R9&5R+6)O='1O;2US='EL93ID;W5B;&4[(&)O<F1E<BUB
M;W1T;VTM=VED=&@Z,BXR-7!T.R!P861D:6YG+6QE9G0Z-2XT<'0[('!A9&1I
M;F<M<FEG:'0Z-2XT<'0[('9E<G1I8V%L+6%L:6=N.F)O='1O;3L@=VED=&@Z
M-C(N.35P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X
M="UA;&EG;CIR:6=H=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M
M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS
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M>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T>6QE
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M/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D('-T
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M<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)/'1D
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M.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D)
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M-C(N.35P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@<&%G
M92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O:60G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG
M.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)"3PO
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\
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M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIR:6=H=#L@<&%G
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M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/&9O;G0@
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M.R8C,38P.R`\+V9O;G0^/"]P/@T*"0D)"0D)/"]T9#X-"@D)"0D)"3QT9"!S
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M#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@=&5X="UA;&EG;CIR
M:6=H=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T
M97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A
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M9'1H.C$Q+CAP="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#L@
M<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T97(Z879O
M:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M
M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-"@D)"0D)
M"3PO=&0^#0H)"0D)"0D\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.C4N-'!T
M.R!P861D:6YG+7)I9VAT.C4N-'!T.R!V97)T:6-A;"UA;&EG;CIB;W1T;VT[
M('=I9'1H.C8R+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#L@=&5X="UA;&EG;CIR:6=H=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[
M('!A9V4M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\9F]N="!S
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M;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M8G)E86LM869T
M97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.
M97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F;VYT/CPO<#X-
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M;&EG;CIB;W1T;VT[('=I9'1H.C$Q+C%P="<^#0H)"0D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#L@<&%G92UB<F5A:RUI;G-I9&4Z879O:60[('!A9V4M
M8G)E86LM869T97(Z879O:60G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I>F4Z,3!P="<^)B-X83`[/"]F
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M.R`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ)U1I;65S($YE
M=R!2;VUA;B<[(&9O;G0M<VEZ93HQ,'!T)SXT+C@X/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG.R!F;VYT+7-I
M>F4Z,3!P="<^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[(#PO
M9F]N=#X\+W`^#0H)"0D)"0D\+W1D/@T*"0D)"0D\+W1R/@T*"0D)"3PO=&%B
M;&4^#0H)"0D\+V1I=CX-"@D)"3QP('-T>6QE/3-$;6%R9VEN.C!P=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)SL@9F]N
M="US:7IE.C$P<'0G/B8C>&$P.SPO9F]N=#X\+W`^#0H)"3PO9&EV/@T*/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C!F8C5C
M9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X-S0-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y
M8S0T.#<T+U=O<FMS:&5E=',O4VAE970R,2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139)04<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^5&AE($-O;7!A;GD@86YD(%-U;6UA
M<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3,U
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#`T+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O
M;7!A;GD@1&5V96QO<&UE;G0@4W1A9V4@86YD($)A<VES(&]F(%!R97-E;G1A
M=&EO;B`H5&5X='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I8VEP871E9"!T:6UE('1O('-T
M87)T($%&(%1R:6%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV
M(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,2PP-S`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PT,#8L,#`P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3`P
M+#(Q,RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H(&9L;W=S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S8T+#`P,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#8U-BPP,#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3@L
M,3@U+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9U;F0@<F%I<V5D('1H<F]U9V@@<V%L92!O9B!C;VUM;VX@
M<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S0Q+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#@U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E=F5R<V4@<W1O8VL@<W!L:70\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C$@9F]R(#8@<F5V97)S92!S<&QI=#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V
M96YU92!G96YE<F%T960@8GD@=&AE(&-O;7!A;GD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3,@17%U:71Y($9I;F%N8VEN9W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUP86YY
M($1E=F5L;W!M96YT(%-T86=E(&%N9"!"87-I<R!O9B!0<F5S96YT871I;VX@
M*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1G5N9"!R86ES960@=&AR;W5G:"!S86QE(&]F
M(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#;VUP86YY($1E=F5L;W!M96YT(%-T86=E(&%N
M9"!"87-I<R!O9B!0<F5S96YT871I;VX@*%1E>'1U86PI(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R(&]F('!A=&EE;G1S(&-O;7!A;GD@<&QA;G,@=&\@96YR;VQL/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUP86YY($1E
M=F5L;W!M96YT(%-T86=E(&%N9"!"87-I<R!O9B!0<F5S96YT871I;VX@*%1E
M>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('!A=&EE;G1S(&-O;7!A;GD@<&QA
M;G,@=&\@96YR;VQL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-B
M,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y
M-3@Q,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M5E1!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,;W-S(%!E<B!3:&%R92`H
M1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R
M92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#D^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,C0@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3,U($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P.3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`X/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#<\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P-CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`U/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#0\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U;6UA<GD@;V8@8F%S:6,@86YD(&1I;'5T960@;&]S<R!P97(@<VAA
M<F4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PP
M-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@Q+#0P-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#0L,S(P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H-2PS-C0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X+#0R,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#DL,3,X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,3DL-#,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,3,L.3DT*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H-2PR-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#0U.2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4Q,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$Q-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#8Y+#`V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@;&]S<R!A='1R:6)U=&%B;&4@=&\@8V]M;6]N('-T
M;V-K:&]L9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q
M+#`W,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#$L-#`W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H-S`L,#DQ*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#`S-RPU-#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`S,"PT.3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,Z(%=E
M:6=H=&5D+6%V97)A9V4@<VAA<F5S(&]F('5N=F5S=&5D(&-O;6UO;B!S=&]C
M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPW.#,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPW.#,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@=V5I9VAT960M879E<F%G92!S:&%R97,@=7-E9"!I;B!C;VUP
M=71I;F<@;F5T(&QO<W,@<&5R('-H87)E(&%T=')I8G5T960@=&\@8V]M;6]N
M('-T;V-K:&]L9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPP,S0L-S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPP,C<L-S$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!L;W-S('!E
M<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C,U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,"XV.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C9%\U-S1A7S0R-V5?
M8C5A9%\Y-3@Q,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E=#(S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%2$@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&]S<R!097(@4VAA
M<F4@*$1E=&%I;',@5&5X='5A;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5A<FYI;F=S("A,;W-S*2!097(@
M4VAA<F4@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K+"!$:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#0L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C!F8C5C9%\U-S1A7S0R-V5?
M8C5A9%\Y-3@Q,#EC-#0X-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T.#<T+U=O<FMS
M:&5E=',O4VAE970R-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14E&04,^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^365R9V5R('=I=&@@3G5V96QO+"!);F,N(&]N($IA;G5A
M<GD@,C<L(#(P,#D@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ,S4@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,C<L(#(P,#D\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY-97)G97(@=VET:"!.=79E;&\L($EN8RX@3VX@2F%N=6%R>2`R-RP@,C`P
M.2`H5&5X='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@=&]T86P@86-Q=6ES:71I
M;VX@8V]N<VED97)A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,2PY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@87-S971S(&%C<75I<F5D(&EN('1H92!-
M97)G97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#(P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!A<W-E=',@86-Q=6ER960L(&EN8VQU9&EN9R!C87-H+"!C87-H
M(&5Q=6EV86QE;G1S(&%N9"!M87)K971A8FQE('-E8W5R:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+#4P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@
M8F%R9V%I;B!P=7)C:&%S93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R-2PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R-2PR.#(L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A
M9%\Y-3@Q,#EC-#0X-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T.#<T+U=O<FMS:&5E
M=',O4VAE970R-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P131&04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^1F%I<B!686QU92!$:7-C;&]S=7)E<R`H1&5T86EL<RD@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9A:7(@5F%L=64@1&ES8VQO<W5R97,@*$%D9&ET:6]N86P@5&5X
M='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H(&5Q=6EV86QE;G1S(&-O;G-I<W1I;F<@;V8@
M;6]N97D@;6%R:V5T(&9U;F1S('=I=&@@;6%T=7)I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^.3`@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A;G-F97)S(&]F(&%S
M<V5T<R!B971W965N(&9A:7(@=F%L=64@:&EE<F%R8VAY(&QE=F5L<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-;VYE>2!-87)K970@
M1G5N9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY&86ER(%9A;'5E($1I<V-L;W-U<F5S("A497AT=6%L*2!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@97%U:79A;&5N=',@8V]N<VES=&EN9R!O9B!M;VYE>2!M87)K970@9G5N
M9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPU,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C!F
M8C5C9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X-S0-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X
M,3`Y8S0T.#<T+U=O<FMS:&5E=',O4VAE970R-BYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14E*
M04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP
M;65N="`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-O;7!O;F5N=',@;V8@4')O<&5R='D@86YD
M(&5Q=6EP;65N=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT+"!'<F]S<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4S,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5S<R!A8V-U
M;75L871E9"!D97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#@V*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4Q,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A
M;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;7!U=&5R(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;7!O;F5N=',@;V8@4')O<&5R
M='D@86YD(&5Q=6EP;65N=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@3&EF93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD($5Q=6EP;65N
M="P@1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,86(@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0V]M<&]N96YT<R!O9B!0<F]P97)T>2!A;F0@97%U:7!M
M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5S=&EM871E9"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT+"!'<F]S<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=7)N:71U<F4@
M86YD(&9I>'1U<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0V]M<&]N96YT<R!O9B!0<F]P97)T>2!A;F0@97%U:7!M96YT
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S
M=&EM871E9"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT+"!'<F]S<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<'5T97(@<V]F='=A
M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M;VUP;VYE;G1S(&]F(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D($QI
M9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;W!E<G1Y(&%N9"!%<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E:&]L9"!I;7!R;W9E;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUP
M;VYE;G1S(&]F(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD(&EM<')O
M=F5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3&5S<V5R
M(&]F('5S969U;"!L:69E(&]R(&QI9F4@;V8@=&AE(&QE87-E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T
M>2!A;F0@17%U:7!M96YT+"!'<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T
M-#@W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C9%\U
M-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E=#(W
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%2D5!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0
M<F]P97)T>2!A;F0@17%U:7!M96YT("A$971A:6QS(%1E>'1U86PI("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,S4@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@
M*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I
M;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX@
M97AP96YS92!S:6YC92!I;F-E<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2PX,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]C8C!F8C5C9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q
M,#EC-#0X-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(P9F(U
M8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T.#<T+U=O<FMS:&5E=',O4VAE
M970R."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14%)0D<^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*$1E=&%I;',I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$S-2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`P.#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#$T+"`R,#$Q/&)R/G-Q9G0\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`P."P@,C`P.#QB
M<CYS<69T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A497AT=6%L
M*2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%R96$@;V8@;V9F:6-E(&9A8VEL:71I97,@=&%K96X@;VX@
M;&5A<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,96%S92!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>'1E;F1E9"!L96%S92!T97)M/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XS('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:6=H=',@=&\@97AT96YD('1E
M<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E1W;R!A9&1I=&EO
M;F%L('1H<F5E('EE87(@<&5R:6]D<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;W<@=&\@=&5R;6EN871E(&%G
M<F5E;65N="!N;W1I8V4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XS(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&5A<V4@86=R965M96YT('!A>6UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&5N86YT
M(&EM<')O=F5M96YT(')E:6UB=7)S96UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU.3,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F%M;W)T:7IE9"!D969E<G)E9"!R
M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y296YT(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4R-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E(&5X<&ER>2!P97)I;V0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P,3,M,#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@
M;&5A<V4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36EL97-T;VYE('!A>6UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&UI;&5S=&]N
M92!P87EM96YT<R!U<&]N(&%P<')O=F%L/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N;W1H97(@97AP96-T960@;6EL97-T
M;VYE('!A>6UE;G1S('5P;VX@87!P<F]V86P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M('!E<F-E;G1A9V4@
M;V8@<F]Y86QT>2!O8FQI9V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,BXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@<&5R8V5N=&%G92!O9B!R;WEA;'1Y
M(&]B;&EG871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O9'5C="!S86QE<R!L979E;',@<F]Y86QT>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@<&5R8V5N=&%G
M92!O9B!R86YG92!O9B!R;WEA;'1I97,@=&AA="!C86X@8F4@8G5Y(&1O=VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C4P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU
M;2!P97)C96YT86=E(&]F(')A;F=E(&]F(')O>6%L=&EE<R!T:&%T(&-A;B!B
M92!B=7D@9&]W;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-:6QE<W1O;F4@<&%Y;65N="!D=64@<&5R:6]D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XV(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V(P9F(U8V1?-3<T85\T,C=E7V(U
M861?.34X,3`Y8S0T.#<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"]7;W)K<VAE
M971S+U-H965T,CDN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V14%)/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D5Q=6ET>2!&:6YA;F-I;F=S(&%N9"!787)R86YT<R`H1&5T
M86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$S-2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0U/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3,\8G(^5V%R<F%N=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$S/&)R/E=A<G)A;G0\8G(^36%X:6UU;3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R
M/E=A<G)A;G0\8G(^36EN:6UU;3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/C(P,3,@17%U:71Y($9I;F%N8VEN
M9W,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`R,BP@
M,C`Q,SQB<CY025!%(%1R86YS86-T:6]N/&)R/C(P,3,@17%U:71Y($9I;F%N
M8VEN9W,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`R
M,BP@,C`Q,SQB<CY025!%(%1R86YS86-T:6]N/&)R/C(P,3,@17%U:71Y($9I
M;F%N8VEN9W,\8G(^5V%R<F%N=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*86XN(#,Q+"`R,#$S/&)R/E)E9VES=&5R960@1&ER96-T($]F
M9F5R:6YG/&)R/C(P,3,@17%U:71Y($9I;F%N8VEN9W,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q,SQB<CY296=I<W1E
M<F5D($1I<F5C="!/9F9E<FEN9SQB<CXR,#$S($5Q=6ET>2!&:6YA;F-I;F=S
M/&)R/E=A<G)A;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2F%N+B`S,2P@,C`Q,SQB<CY296=I<W1E<F5D($1I<F5C="!/9F9E<FEN9SQB
M<CXR,#$Q($5Q=6ET>2!&:6YA;F-I;F=S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5Q=6ET>2!F:6YA;F-I;F=S(&%N
M9"!W87)R86YT<R`H5&5X='5A;"D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H
M87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,3@U+#4V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,3@U+#4V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-C8P+#,Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U-BPT,S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C0L-C,V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I
M=&EO;F%L('-H87)E<R!P=7)C:&%S960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(T.2PU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV-2PX-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!G<F]S<R!P<F]C
M965D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#<S,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&-O
M;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+#<T,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$U+#@U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#`U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C$V
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4'5B;&EC($5Q=6ET>2!/9F9E<FEN9R!#;&]S92!$871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*86X@,C4L#0H)"3(P,3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL@<'5R8VAA<V5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E('!R:6-E(&9O<B!C
M;VUM;VX@<W1O8VL@=6YI=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BXX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0N-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S('=E<F4@97AE<F-I<V%B;&4@=7!O;B!I
M<W-U86YC92P@97AP:7)Y('EE87(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C<@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&]S:6YG(&)I9"!P<FEC92!O9B!T
M:&4@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT('!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RXR-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-BXX.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N,C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+C$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M96=I<W1E<F5D($1I<F5C="!/9F9E<FEN9R!#;&]S92!$871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y&96(@-"P-"@D),C`Q,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F('=A<G)A;G1S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P
M.6,T-#@W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C!F8C5C
M9%\U-S1A7S0R-V5?8C5A9%\Y-3@Q,#EC-#0X-S0O5V]R:W-H965T<R]3:&5E
M=#,P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3E-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@*$1E=&%I;',I("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3,U($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY.;VXM8V%S:"P@<VAA<F4M8F%S960@8V]M<&5N<V%T
M:6]N(&5X<&5N<V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R+#8S,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD($1E=F5L
M;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3F]N+6-A<V@L('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y396QL:6YG+"!'96YE<F%L(&%N9"!!9&UI;FES=')A=&EV93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO;BUC
M87-H+"!S:&%R92UB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C,X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-T<G5C='5R:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3F]N+6-A<V@L('-H87)E+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y
M8S0T.#<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B,&9B-6-D
M7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"]7;W)K<VAE971S+U-H965T
M,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5*44%%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL<R`Q*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=&]C:R!O<'1I;VX@86-T:79I=&EE<R!O9B!C
M;VUP86YY/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@;W5T<W1A;F1I;F<@8F5G:6YN:6YG(&]F('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30T+#`Q.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F($]P=&EO;G,@1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@
M=7!O;B!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS+"!F;W(@8V%S:"P@<VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!/<'1I;VYS($9O<F9E:71E9"P@8V%N8V5L;&5D(&]R
M(&5X<&ER960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L,C4Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!T:6]N<R!O=71S=&%N9&EN9R!E;F0@;V8@=&AE('!E<FEO9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,W+#<V,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-"PP,3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M=&EO;G,@97AE<F-I<V%B;&4L(&5N9"!O9B!P97)I;V0L($YU;6)E<B!O9B!/
M<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C,L-#`X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS('9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="P@3G5M8F5R
M(&]F($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S
M-BPR,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@97AE<F-I<V4@4')I8V4L($]P=&EO
M;G,@3W5T<W1A;F1I;F<L($)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@N,C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A
M9V4@97AE<F-I<V4@<')I8V4L($=R86YT960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!E>&5R8VES92!P
M<FEC92P@17AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@97AE<F-I<V4@<')I8V4L($9O<F9E
M:71E9"P@8V%N8V5L;&5D(&]R(&5X<&ER960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,38N-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@97AE<F-I
M<V4@4')I8V4L($]P=&EO;G,@3W5T<W1A;F1I;F<L(&5N9"!O9B!P97)I;V0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@N,S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$X+C(X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"!A=F5R86=E(&5X97)C:7-E('!R:6-E+"!/<'1I;VYS(&5X
M97)C:7-A8FQE+"!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$X+C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(&5X97)C:7-E
M(%!R:6-E+"!/<'1I;VYS('9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S="P@
M96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q."XS.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U
M86P@5&5R;2`H:6X@>65A<G,I($]P=&EO;G,@3W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,@,3`@;6]N=&AS(#(Q
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XT('EE87)S(#$P(&UO;G1H<R`R."!D87ES/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&5X97)C
M:7-A8FQE(&%T($UA<F-H(#,Q+"`R,#$S+"!796EG:'1E9"!!=F5R86=E(%)E
M;6%I;FEN9R!#;VYT<F%C='5A;"!497)M("AI;B!Y96%R<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,@-R!M;VYT:',@,3,@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!T:6]N<R!V97-T960@86YD(&5X<&5C=&5D('1O('9E<W0L(%=E:6=H
M=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FT@*&EN('EE
M87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R<R`Q
M,"!M;VYT:',@,3<@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T
M.#<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B,&9B-6-D7S4W
M-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"]7;W)K<VAE971S+U-H965T,S(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5413X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY);F-O
M;64@5&%X97,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);F-O;64@
M5&%X97,@*%1E>'1U86PI(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S97)V92!F;W(@=6YC97)T86EN
M('1A>"!P;W-I=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M8V(P9F(U8V1?-3<T85\T,C=E7V(U861?.34X,3`Y8S0T.#<T#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B,&9B-6-D7S4W-&%?-#(W95]B-6%D
M7SDU.#$P.6,T-#@W-"]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL
M('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z
M;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,C`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,S(N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7V-B,&9B
C-6-D7S4W-&%?-#(W95]B-6%D7SDU.#$P.6,T-#@W-"TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6EAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Financings and Warrants (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">135 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="5">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Warrant

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Warrant

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>2013 Equity Financings</div>
        </th>
        <th class="th">
          <div>Jan. 22, 2013

</div>
          <div>PIPE Transaction

</div>
          <div>2013 Equity Financings</div>
        </th>
        <th class="th">
          <div>Jan. 22, 2013

</div>
          <div>PIPE Transaction

</div>
          <div>2013 Equity Financings

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013

</div>
          <div>Registered Direct Offering

</div>
          <div>2013 Equity Financings</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013

</div>
          <div>Registered Direct Offering

</div>
          <div>2013 Equity Financings

</div>
          <div>Warrant</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013

</div>
          <div>Registered Direct Offering

</div>
          <div>2011 Equity Financings</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsTextualAbstract', window );"><strong>Equity financings and warrants (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">3,185,562<span></span></td>
        <td class="nump">3,185,562<span></span></td>
        <td class="nump">2,660,315<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">356,430<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">164,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Additional shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">249,501<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">65,855<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapital', window );">Aggregate gross proceeds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 730,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="nump">$ 1,741,000<span></span></td>
        <td class="nump">$ 15,850,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,400,000<span></span></td>
        <td class="nump">$ 805,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 616,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PrivateInvestmentInPublicEquityOfferingCloseDate', window );">Public Equity Offering Close Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 25,
         2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares of common stock purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.70<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PurchasePriceOfCommonStockUnit', window );">Purchase price for common stock unit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.81<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.43<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClassOfWarrantOrRightExercisableExpirationPeriod', window );">Warrants were exercisable upon issuance, expiry year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares', window );">Closing bid price of the common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Warrant price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7.25<span></span></td>
        <td class="nump">116.89<span></span></td>
        <td class="nump">1.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.28<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RegisteredDirectOfferingCloseDate', window );">Registered Direct Offering Close Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Feb.
        04,
         2013<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300,000.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClassOfWarrantOrRightExercisableExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of warrant or right exercisable expiration period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_ClassOfWarrantOrRightExercisableExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of warrant or right exercise price of share percentage of closing bid price of common shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_ClassOfWarrantOrRightExercisePriceOfSharePercentageOfClosingBidPriceOfCommonShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingsAndWarrantsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_EquityFinancingsAndWarrantsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PrivateInvestmentInPublicEquityOfferingCloseDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Private investment in public equity offering close date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_PrivateInvestmentInPublicEquityOfferingCloseDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PurchasePriceOfCommonStockUnit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase price of common stock unit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_PurchasePriceOfCommonStockUnit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RegisteredDirectOfferingCloseDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Registered direct offering close date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_RegisteredDirectOfferingCloseDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate amount of each class of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockIncludingAdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate of par value plus amounts in excess of par value or issuance value (in cases of no-par value stock) for common stock held by shareholders. Aggregate value for common stock issued and outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30, 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29,30(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockIncludingAdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAIBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">135 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2008</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 14, 2011

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Feb. 08, 2008

</div>
          <div>sqft</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office facilities taken on lease</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,500<span></span></td>
        <td class="nump">15,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LeaseTerm', window );">Lease term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ExtendedLeaseTerm', window );">Extended lease term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RightsToExtendTerm', window );">Rights to extend term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Two additional three year periods<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AllowToTerminateAgreement', window );">Allow to terminate agreement notice period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OneTimePaymentToLandlordForNewLeasedPremises', window );">Lease agreement payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantReimbursements', window );">Tenant improvement reimbursements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">593,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Unamortized deferred rent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,000<span></span></td>
        <td class="nump">12,000<span></span></td>
        <td class="nump">527,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LeaseMonthExpirationDate', window );">Lease expiry period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2013-06<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Minimum lease payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MilestonePaymentMadeByCompany', window );">Milestone payment</a></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ExpectedMilestonePaymentsUponApproval', window );">Expected milestone payments upon approval</a></td>
        <td class="nump">8,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AnotherExpectedMilestonePaymentsUponApproval', window );">Another expected milestone payments upon approval</a></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfRoyaltyObligation', window );">Minimum percentage of royalty obligation</a></td>
        <td class="nump">12.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MaximumPercentageOfRoyaltyObligation', window );">Maximum percentage of royalty obligation</a></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement', window );">Product sales levels royalty</a></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown', window );">Minimum percentage of range of royalties that can be buy down</a></td>
        <td class="nump">12.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown', window );">Maximum percentage of range of royalties that can be buy down</a></td>
        <td class="nump">17.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MilestonePaymentDuePeriod', window );">Milestone payment due period</a></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AllowToTerminateAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allow to terminate agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AllowToTerminateAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AnotherExpectedMilestonePaymentsUponApproval">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Another expected milestone payments upon approval.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AnotherExpectedMilestonePaymentsUponApproval</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_CommitmentsAndContingenciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ExpectedMilestonePaymentsUponApproval">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected milestone payments upon approval.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_ExpectedMilestonePaymentsUponApproval</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ExtendedLeaseTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Extended lease term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_ExtendedLeaseTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LeaseMonthExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease month expiration date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_LeaseMonthExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LeaseTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_LeaseTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum percentage of range of royalties that can be buy down.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_MaximumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MaximumPercentageOfRoyaltyObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum percentage of royalty obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_MaximumPercentageOfRoyaltyObligation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MilestonePaymentDuePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment due period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_MilestonePaymentDuePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MilestonePaymentMadeByCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment made by company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_MilestonePaymentMadeByCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum percentage of range of royalties that can be buy down.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_MinimumPercentageOfRangeOfRoyaltiesThatCanBeBuyDown</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfRoyaltyObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum percentage of royalty obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_MinimumPercentageOfRoyaltyObligation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OneTimePaymentToLandlordForNewLeasedPremises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One-time payment to landlord for new leased premises.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_OneTimePaymentToLandlordForNewLeasedPremises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of royalty obligated to pay under its original license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_PercentageOfRoyaltyObligatedToPayUnderItsOriginalLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RightsToExtendTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rights to extend term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_RightsToExtendTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area of a real estate property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AreaOfRealEstateProperty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Technical Bulletin (FTB)<br><br> -Number 85-3<br><br> -Paragraph 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 16<br><br> -Subparagraph b(i)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 122<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesRentExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantReimbursements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In accordance with the provisions of their lease agreement, this element represents allowable charges due a landlord from its tenant. In retail store and office building leases, for example, tenant reimbursements may cover items such as taxes, utilities, and common area expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TenantReimbursements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-based Compensation (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">135 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Non-cash, share-based compensation expense</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
        <td class="nump">$ 42<span></span></td>
        <td class="nump">$ 91<span></span></td>
        <td class="nump">$ 2,630<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Non-cash, share-based compensation expense</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
        <td class="nump">15<span></span></td>
        <td class="nump">26<span></span></td>
        <td class="nump">605<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Selling, General and Administrative</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Non-cash, share-based compensation expense</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
        <td class="nump">27<span></span></td>
        <td class="nump">65<span></span></td>
        <td class="nump">1,638<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Restructuring</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Non-cash, share-based compensation expense</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 387<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-based Compensation (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract', window );"><strong>Stock option activities of company</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of period</a></td>
        <td class="nump">144,019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, shares</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options Forfeited, cancelled or expired</a></td>
        <td class="num">(6,259)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of the period</a></td>
        <td class="nump">137,760<span></span></td>
        <td class="nump">144,019<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, end of period, Number of Options</a></td>
        <td class="nump">123,408<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, Number of Options</a></td>
        <td class="nump">136,208<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average exercise Price, Options Outstanding, Beginning of period</a></td>
        <td class="nump">$ 18.28<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited, cancelled or expired</a></td>
        <td class="nump">$ 16.53<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average exercise Price, Options Outstanding, end of period</a></td>
        <td class="nump">$ 18.36<span></span></td>
        <td class="nump">$ 18.28<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable, end of period</a></td>
        <td class="nump">$ 18.82<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average exercise Price, Options vested and expected to vest, end of period</a></td>
        <td class="nump">$ 18.39<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Options Outstanding</a></td>
        <td class="text">4 years 10 months 21 days<span></span></td>
        <td class="text">4 years 10 months 28 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at March 31, 2013, Weighted Average Remaining Contractual Term (in years)</a></td>
        <td class="text">4 years 7 months 13 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, Weighted Average Remaining Contractual Term (in years)</a></td>
        <td class="text">4 years 10 months 17 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c), d(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph d(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph d(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">The Company and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
			<p style="margin:9pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(1) The Company and Summary of Significant Accounting Policies </font></p>
			<p style="margin:4.5pt 0pt 0pt 12.2pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Description of Business</font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">ARCA </font><font style="font-family:'Times New Roman'; font-size:10pt">biopharma</font><font style="font-family:'Times New Roman'; font-size:10pt">, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Broomfield, Colorado and is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&#8217;s lead product candidate, </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:5pt; vertical-align:super">TM</font><font style="font-family:'Times New Roman'; font-size:10pt"> (</font><font style="font-family:'Times New Roman'; font-size:10pt">bucindolol</font><font style="font-family:'Times New Roman'; font-size:10pt"> hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, is being developed for the treatment and the prevention of atrial fibrillation, or AF, in patients with heart failure, or HF. The Company has identified common genetic variations in the cardiovascular system that it believes interact with </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro&#8217;s</font><font style="font-family:'Times New Roman'; font-size:10pt"> pharmacology and may predict patient response to </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> treatment. The Company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> based on genetic testing, which it believes will provide market exclusivity for these uses of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> into at least 2026 in the U.S. and into 2025 in Europe. In addition, the Company believes that if </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> is approved, a </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> patent will be eligible for patent term extension based on our current clinical trial plans which, if granted, may provide market exclusivity for </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> into 2029 or 2030 in the US and Europe. </font></p>
			<p style="margin:6pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">ARCA</font><font style="font-family:'Times New Roman'; font-size:10pt"> believes that </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> has potential efficacy in reducing or preventing AF, and</font><font style="font-family:'Times New Roman'; font-size:10pt"> that</font><font style="font-family:'Times New Roman'; font-size:10pt"> this efficacy may be genetically regulated. The Company plans to test this hypothesis in a clinical trial of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, known as GENETIC-AF, which the Company plans to initiate pending receipt of the necessary funding. The Company has created an adaptive design for GENETIC-AF under which the trial is intended to be initiated as a Phase 2b study in approximately </font><font style="font-family:'Times New Roman'; font-size:10pt; ">200</font><font style="font-family:'Times New Roman'; font-size:10pt"> patients with heart failure and left ventricular dysfunction, or HFREF. Depending on the results of the Phase 2b portion, the trial may then be expanded to a Phase 3 study by enrolling an estimated additional </font><font style="font-family:'Times New Roman'; font-size:10pt; ">420</font><font style="font-family:'Times New Roman'; font-size:10pt"> patients. The Company anticipates that GENETIC-AF could begin approximately 6 months after the Company obtains sufficient funding</font><font style="font-family:'Times New Roman'; font-size:10pt">.</font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">To support the continued development of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, including the planned GENETIC-AF clinical trial and ongoing operations, the Company will need to </font><font style="font-family:'Times New Roman'; font-size:10pt">raise</font><font style="font-family:'Times New Roman'; font-size:10pt"> substantial additional funding through public or private equity transactions or a strategic combination or partnership. If the Company is delayed in obtaining funding or is unable to complete a strategic transaction, it may have to discontinue development activities on </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> or discontinue its operations. </font></p>
			<p style="margin:13.5pt 0pt 0pt 12.2pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Development Stage Risks, Liquidity and Going Concern</font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The Company is in the development stage and devotes substantially all of its efforts towards obtaining regulatory approval, exploring strategic alternatives for further developing </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, and raising capital necessary to fund its operations. The Company has not generated revenue to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has historically funded its operations through issuances of common and preferred stock, as well as through the business combination with </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt">, </font><font style="font-family:'Times New Roman'; font-size:10pt">Inc</font><font style="font-family:'Times New Roman'; font-size:10pt">, or </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt">. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Since ARCA was founded on December</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">17, 2001, or Inception, the Company has incurred substantial losses and negative cash flows from operations. Since Inception, the Company incurred a loss from operations of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">100.2</font><font style="font-family:'Times New Roman'; font-size:10pt"> million and had negative cash flows from operations of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">98.2</font><font style="font-family:'Times New Roman'; font-size:10pt"> million. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">In light of the substantial additional time and costs associated with the development of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> and the need to raise a significant amount of capital on acceptable terms to finance the planned clinical trial and the Company&#8217;s ongoing operations, the Company is evaluating strategic alternatives for funding continued operations and development programs. The Company will need to complete a substantial equity financing, or a strategic transaction, such as a strategic combination or partnership to support the continued development of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, including the planned GENETIC-AF clinical trial. </font><font style="font-family:'Times New Roman'; font-size:10pt">To date</font><font style="font-family:'Times New Roman'; font-size:10pt">,</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font><font style="font-family:'Times New Roman'; font-size:10pt">the Company </font><font style="font-family:'Times New Roman'; font-size:10pt">has completed two equity-financing transactions in 2013 and </font><font style="font-family:'Times New Roman'; font-size:10pt">raised approximately $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">1.</font><font style="font-family:'Times New Roman'; font-size:10pt; ">4</font><font style="font-family:'Times New Roman'; font-size:10pt"> million, net of offering costs</font><font style="font-family:'Times New Roman'; font-size:10pt">.</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font><font style="font-family:'Times New Roman'; font-size:10pt">These financings </font><font style="font-family:'Times New Roman'; font-size:10pt">have </font><font style="font-family:'Times New Roman'; font-size:10pt">allow</font><font style="font-family:'Times New Roman'; font-size:10pt">ed</font><font style="font-family:'Times New Roman'; font-size:10pt"> ARCA to continue operations</font><font style="font-family:'Times New Roman'; font-size:10pt"> while it continues to pursue financing options, a strategic combination, partnering, and licensing opportunities. If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or discontinue its operations. The Company currently believes its cash and cash equivalents balance as of March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, </font><font style="font-family:'Times New Roman'; font-size:10pt">2013 </font><font style="font-family:'Times New Roman'; font-size:10pt">will be sufficient to fund its operations </font><font style="font-family:'Times New Roman'; font-size:10pt">through September</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">30, 2013. The Company is unable to assert that its current cash and cash equivalents are sufficient to fund operations beyond that date, and as a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern beyond September</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">30, 2013. These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> or to otherwise continue operations and may not be able to execute any strategic transaction. </font></p>
			<p style="margin:9pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">The Company&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </font></p>
			<ul type="disc" style="margin:0pt; padding-left:0pt">
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the market price of the Company&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the Company&#8217;s ability to retain the listing of its common stock on the </font><font style="font-family:'Times New Roman'; font-size:10pt">Nasdaq</font><font style="font-family:'Times New Roman'; font-size:10pt"> Capital Market; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">general economic and industry conditions affecting the availability and cost of capital; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the Company&#8217;s ability to control costs associated with its operations; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the</font><font style="font-family:'Times New Roman'; font-size:10pt"> terms and conditions of the Company&#8217;s existing collaborative and licensing agreements. </font></li>
			</ul>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&#8217;s capital stock and could contain covenants that would restrict the Company&#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company in the near term, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. </font></p>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Reverse Stock Split </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">On </font><font style="font-family:'Times New Roman'; font-size:10pt">March 4</font><font style="font-family:'Times New Roman'; font-size:10pt">, 2013</font><font style="font-family:'Times New Roman'; font-size:10pt">,</font><font style="font-family:'Times New Roman'; font-size:10pt"> the Company </font><font style="font-family:'Times New Roman'; font-size:10pt">completed </font><font style="font-family:'Times New Roman'; font-size:10pt">a </font><font style="font-family:'Times New Roman'; font-size:10pt; ">1-for-6 reverse split</font><font style="font-family:'Times New Roman'; font-size:10pt"> of its common stock</font><font style="font-family:'Times New Roman'; font-size:10pt">. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. </font></p>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Basis of Presentation </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The accompanying unaudited consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and Rule 10-01 of Regulation S-X.</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim consolidated financial statements. The results of operations for the three months ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 are not necessarily indicative of results expected for the full year ending December</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, </font><font style="font-family:'Times New Roman'; font-size:10pt">2013</font><font style="font-family:'Times New Roman'; font-size:10pt">.</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">The Company has generated </font><font style="font-family:'Times New Roman'; font-size:10pt; ">no</font><font style="font-family:'Times New Roman'; font-size:10pt"> revenue to date a</font><font style="font-family:'Times New Roman'; font-size:10pt">nd its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, and raising capital. Accordingly, the Company continues to be considered in the development stage at March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto for the year ended </font><font style="font-family:'Times New Roman'; font-size:10pt">December</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2012 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission</font><font style="font-family:'Times New Roman'; font-size:10pt">, as amended</font><font style="font-family:'Times New Roman'; font-size:10pt">. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values. </font></p>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Concentrations of Credit Risk </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, money market fund accounts and debt securities with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </font></p>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Accrued Expenses </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&#8217;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. </font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ETE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLiabilityRecorded', window );">Reserve for uncertain tax positions</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_IncomeTaxesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLiabilityRecorded">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated loss resulting from the income tax examination that has been accrued as of the balance sheet date, including interest and penalties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExaminationLiabilityRecorded</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 3,537<span></span></td>
        <td class="nump">$ 2,920<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">456<span></span></td>
        <td class="nump">125<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">3,993<span></span></td>
        <td class="nump">3,045<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">22<span></span></td>
        <td class="nump">23<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">124<span></span></td>
        <td class="nump">144<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">4,139<span></span></td>
        <td class="nump">3,212<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">377<span></span></td>
        <td class="nump">65<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
        <td class="nump">60<span></span></td>
        <td class="nump">103<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
        <td class="nump">383<span></span></td>
        <td class="nump">121<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent, current portion</a></td>
        <td class="nump">8<span></span></td>
        <td class="nump">16<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">828<span></span></td>
        <td class="nump">305<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">828<span></span></td>
        <td class="nump">305<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#x2019; equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100 million shares authorized at March 31, 2013 and December 31, 2012; 3,185,562 and 2,660,315 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively.</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">3<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">72,373<span></span></td>
        <td class="nump">70,898<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(69,065)<span></span></td>
        <td class="num">(67,994)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#x2019; equity</a></td>
        <td class="nump">3,311<span></span></td>
        <td class="nump">2,907<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#x2019; equity</a></td>
        <td class="nump">$ 4,139<span></span></td>
        <td class="nump">$ 3,212<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-3<br><br><br><br> -Paragraph 2<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) (unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jan. 03, 2005

</div>
          <div>Cash, Net of Offering Costs

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2004

</div>
          <div>Cash, Net of Offering Costs

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2002

</div>
          <div>Cash, Net of Offering Costs

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Jan. 03, 2005

</div>
          <div>Issuance for Notes Payable and Related Accrued Interest on January 3, 2005

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Oct. 14, 2005

</div>
          <div>Issuance for Intellectual Property License Rights on October 14, 2005

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Feb. 21, 2006

</div>
          <div>Issuance for Intellectual Property License Rights on February 21, 2006

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Feb. 22, 2006

</div>
          <div>Issuance of Series A on February 22, 2006

</div>
          <div>Series A</div>
        </th>
        <th class="th">
          <div>Feb. 22, 2006

</div>
          <div>Third Issuance for Notes Payable and Related Accrued Interest

</div>
          <div>Series A</div>
        </th>
        <th class="th">
          <div>Feb. 22, 2006

</div>
          <div>Issuance for Intellectual Property License Rights on February 22, 2006

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Jun. 23, 2006

</div>
          <div>Issuance for Intellectual Property License Rights on June 23, 2006

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Nov. 07, 2006

</div>
          <div>Issuance for Intellectual Property License Rights on November 7, 2006

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Dec. 08, 2006

</div>
          <div>Issuance of Series A on December 8, 2006

</div>
          <div>Series A</div>
        </th>
        <th class="th">
          <div>May 31, 2007

</div>
          <div>Issuance for Series B on May 31, 2007

</div>
          <div>Series B</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2007

</div>
          <div>Issuance for Series B on December 28, 2007

</div>
          <div>Series B</div>
        </th>
        <th class="th">
          <div>Jan. 18, 2007

</div>
          <div>Issuance for Intellectual Property License Rights on January 18, 2007

</div>
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2007

</div>
          <div>Issuance for Intellectual Property License Rights on June 30, 2007

</div>
          <div>Common Stock</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommonStockMarketPricePerShare', window );">Common stock market price per share</a></td>
        <td class="nump">$ 0.36<span></span></td>
        <td class="nump">$ 0.36<span></span></td>
        <td class="nump">$ 0.36<span></span></td>
        <td class="nump">$ 0.36<span></span></td>
        <td class="nump">$ 48.84<span></span></td>
        <td class="nump">$ 4.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.32<span></span></td>
        <td class="nump">$ 5.40<span></span></td>
        <td class="nump">$ 5.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10.08<span></span></td>
        <td class="nump">$ 10.80<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.6265<span></span></td>
        <td class="nump">$ 1.6265<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.6265<span></span></td>
        <td class="nump">$ 2.439<span></span></td>
        <td class="nump">$ 3.253<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommonStockMarketPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock market price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_CommonStockMarketPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVTAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Share (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="9">12 Months Ended</th>
        <th class="th" colspan="1">24 Months Ended</th>
        <th class="th" colspan="1">135 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2008</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2006</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2005</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2004</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2003</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract', window );"><strong>Summary of basic and diluted loss per share</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (1,071)<span></span></td>
        <td class="num">$ (1,407)<span></span></td>
        <td class="num">$ (4,320)<span></span></td>
        <td class="num">$ (5,364)<span></span></td>
        <td class="num">$ (8,420)<span></span></td>
        <td class="num">$ (9,138)<span></span></td>
        <td class="num">$ (19,431)<span></span></td>
        <td class="num">$ (13,994)<span></span></td>
        <td class="num">$ (5,241)<span></span></td>
        <td class="num">$ (1,459)<span></span></td>
        <td class="num">$ (511)<span></span></td>
        <td class="num">$ (116)<span></span></td>
        <td class="num">$ (69,065)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
        <td class="num">$ (1,071)<span></span></td>
        <td class="num">$ (1,407)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (70,091)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding</a></td>
        <td class="nump">3,037,546<span></span></td>
        <td class="nump">2,030,499<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Less: Weighted-average shares of unvested common stock</a></td>
        <td class="num">(2,783)<span></span></td>
        <td class="num">(2,783)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Total weighted-average shares used in computing net loss per share attributed to common stockholders</a></td>
        <td class="nump">3,034,763<span></span></td>
        <td class="nump">2,027,716<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
        <td class="num">$ (0.35)<span></span></td>
        <td class="num">$ (0.69)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_ReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedLossPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e2646-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesIssuedBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Merger with Nuvelo, Inc. on January 27, 2009 (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">135 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jan. 27, 2009</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract', window );"><strong>Merger with Nuvelo, Inc. On January 27, 2009 (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice', window );">Estimated total acquisition consideration</a></td>
        <td class="nump">$ 11,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet', window );">Net assets acquired in the Merger</a></td>
        <td class="nump">37,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents', window );">Net assets acquired, including cash, cash equivalents and marketable securities</a></td>
        <td class="nump">45,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount', window );">Gain on bargain purchase</a></td>
        <td class="nump">$ 25,300,000<span></span></td>
        <td class="nump">$ 25,282,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_MergerOnJanuaryTwoSevenTwoZeroZeroNineTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total purchase price of the acquired entity. This includes cash paid to equity interest holders of the acquired entity, fair value of debt and equity securities issued to equity holders of the acquired entity, and transaction costs paid to third parties to consummate the acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 35<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionPurchasePriceAllocationAssetsAcquiredLiabilitiesAssumedNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash and cash equivalents acquired in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph e<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 36, 37, 38<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6571-128477<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6527-128477<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (f)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 68<br><br> -Subparagraph o(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6393-128476<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6396-128476<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6387-128476<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESGBI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">135 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (1,071)<span></span></td>
        <td class="num">$ (1,407)<span></span></td>
        <td class="num">$ (69,065)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_GainLossOnAssignmentOfPatentRights', window );">Gain on patent rights assignment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount', window );">Gain on bargain purchase</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(25,282)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">10<span></span></td>
        <td class="nump">14<span></span></td>
        <td class="nump">1,790<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">211<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
        <td class="nump">42<span></span></td>
        <td class="nump">91<span></span></td>
        <td class="nump">2,630<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants for lease termination</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">377<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">152<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of property and equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">125<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Loss on impairment of in-process research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_WriteOffOfDeferredTaxLiability', window );">Write-off of deferred tax liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,281)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Gain on marketable securities available for sale</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(263)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss from disposal of property and equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">83<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">267<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities (net of amounts acquired):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
        <td class="num">(157)<span></span></td>
        <td class="num">(72)<span></span></td>
        <td class="nump">2,663<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="nump">20<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="nump">7,346<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">312<span></span></td>
        <td class="num">(134)<span></span></td>
        <td class="num">(1,813)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
        <td class="nump">88<span></span></td>
        <td class="num">(160)<span></span></td>
        <td class="num">(19,133)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred rent</a></td>
        <td class="num">(8)<span></span></td>
        <td class="num">(8)<span></span></td>
        <td class="nump">8<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(764)<span></span></td>
        <td class="num">(1,656)<span></span></td>
        <td class="num">(98,185)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash received from Merger</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,392<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payment of deferred transaction costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,186)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(9)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,888)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,369<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">358<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from patent rights assignment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
        <td class="num">(9)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,045<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of convertible notes payable and related warrants for common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,841<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of bank note payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock', window );">Proceeds from stock subject to repurchase</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">38<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from the issuance of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">32,316<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(60)<span></span></td>
        <td class="num">(60)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
        <td class="nump">1,741<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,850<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of principal on bank note payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of principal on convertible notes payables</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(105)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RepaymentOfPrincipalOnVendorFinanceAgreement', window );">Repayment of principal on vendor finance agreement</a></td>
        <td class="num">(43)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(323)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="nump">1,390<span></span></td>
        <td class="num">(60)<span></span></td>
        <td class="nump">56,677<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
        <td class="nump">617<span></span></td>
        <td class="num">(1,716)<span></span></td>
        <td class="nump">3,537<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump">2,920<span></span></td>
        <td class="nump">5,943<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump">3,537<span></span></td>
        <td class="nump">4,227<span></span></td>
        <td class="nump">3,537<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">116<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing transactions:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AccruedInterestOnNotesPayableConvertedToEquity', window );">Accrued interest on notes payable converted to equity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">163<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_WarrantIssuedInConnectionWithCreditFacility', window );">Warrant issued in connection with credit facility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">111<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AccruedDeferredTransactionCosts', window );">Accrued deferred transaction costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">482<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_VendorFinanceAgreement', window );">Vendor finance agreement</a></td>
        <td class="nump">131<span></span></td>
        <td class="nump">134<span></span></td>
        <td class="nump">131<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Preferred Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(246)<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common Stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
        <td class="num">$ (308)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (1,634)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AccruedDeferredTransactionCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred transaction costs accrued at the end of the respective period and applied to proceeds in the subsequent period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AccruedDeferredTransactionCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AccruedInterestOnNotesPayableConvertedToEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the interest accrued on notes payable that was recorded by the Company but converted by the holder to equity during the period that resulted in a noncash transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AccruedInterestOnNotesPayableConvertedToEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_GainLossOnAssignmentOfPatentRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gain or loss on transfer of all or part of the rights and interests in certain patents and patent applications.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_GainLossOnAssignmentOfPatentRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RepaymentOfPrincipalOnVendorFinanceAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Repayment of principal on vendor finance agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_RepaymentOfPrincipalOnVendorFinanceAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_VendorFinanceAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Vendor finance agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_VendorFinanceAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_WarrantIssuedInConnectionWithCreditFacility">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The non-cash value of warrants issued in connection with a bank credit facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_WarrantIssuedInConnectionWithCreditFacility</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_WriteOffOfDeferredTaxLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The write off of deferred tax liability associated with the impairment of the in-process research and development asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_WriteOffOfDeferredTaxLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 146<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 410<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 143<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 36, 37, 38<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6571-128477<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6527-128477<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (f)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 68<br><br> -Subparagraph o(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6393-128476<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6396-128476<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6387-128476<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16373-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 46<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 26<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 958<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 11<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6743430&amp;loc=d3e92212-112881<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Impairment<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7, 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27405-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 13, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(c)-(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27357-111563<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(c))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketableSecuritiesGainLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherPaymentsToAcquireBusinesses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaidInKindInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of preferred stock that is classified as callable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfRedeemablePreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems', window );"><strong>Statement - Consolidated Balance Sheets (Parenthetical) (unaudited) [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">3,185,562<span></span></td>
        <td class="nump">2,660,315<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">3,185,562<span></span></td>
        <td class="nump">2,660,315<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_StatementConsolidatedBalanceSheetsParentheticalUnauditedLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Description of Business</a></td>
        <td class="text"><div>
			<p style="margin:4.5pt 0pt 0pt 12.2pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Description of Business</font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">ARCA </font><font style="font-family:'Times New Roman'; font-size:10pt">biopharma</font><font style="font-family:'Times New Roman'; font-size:10pt">, Inc., or the Company or ARCA, a Delaware corporation, is headquartered in Broomfield, Colorado and is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company&#8217;s lead product candidate, </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:5pt; vertical-align:super">TM</font><font style="font-family:'Times New Roman'; font-size:10pt"> (</font><font style="font-family:'Times New Roman'; font-size:10pt">bucindolol</font><font style="font-family:'Times New Roman'; font-size:10pt"> hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator, is being developed for the treatment and the prevention of atrial fibrillation, or AF, in patients with heart failure, or HF. The Company has identified common genetic variations in the cardiovascular system that it believes interact with </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro&#8217;s</font><font style="font-family:'Times New Roman'; font-size:10pt"> pharmacology and may predict patient response to </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> treatment. The Company has been granted patents in the U.S., Europe, and other jurisdictions for methods of treating AF and HF patients with </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> based on genetic testing, which it believes will provide market exclusivity for these uses of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> into at least 2026 in the U.S. and into 2025 in Europe. In addition, the Company believes that if </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> is approved, a </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> patent will be eligible for patent term extension based on our current clinical trial plans which, if granted, may provide market exclusivity for </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> into 2029 or 2030 in the US and Europe. </font></p>
			<p style="margin:6pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">ARCA</font><font style="font-family:'Times New Roman'; font-size:10pt"> believes that </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> has potential efficacy in reducing or preventing AF, and</font><font style="font-family:'Times New Roman'; font-size:10pt"> that</font><font style="font-family:'Times New Roman'; font-size:10pt"> this efficacy may be genetically regulated. The Company plans to test this hypothesis in a clinical trial of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, known as GENETIC-AF, which the Company plans to initiate pending receipt of the necessary funding. The Company has created an adaptive design for GENETIC-AF under which the trial is intended to be initiated as a Phase 2b study in approximately </font><font style="font-family:'Times New Roman'; font-size:10pt; ">200</font><font style="font-family:'Times New Roman'; font-size:10pt"> patients with heart failure and left ventricular dysfunction, or HFREF. Depending on the results of the Phase 2b portion, the trial may then be expanded to a Phase 3 study by enrolling an estimated additional </font><font style="font-family:'Times New Roman'; font-size:10pt; ">420</font><font style="font-family:'Times New Roman'; font-size:10pt"> patients. The Company anticipates that GENETIC-AF could begin approximately 6 months after the Company obtains sufficient funding</font><font style="font-family:'Times New Roman'; font-size:10pt">.</font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">To support the continued development of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, including the planned GENETIC-AF clinical trial and ongoing operations, the Company will need to </font><font style="font-family:'Times New Roman'; font-size:10pt">raise</font><font style="font-family:'Times New Roman'; font-size:10pt"> substantial additional funding through public or private equity transactions or a strategic combination or partnership. If the Company is delayed in obtaining funding or is unable to complete a strategic transaction, it may have to discontinue development activities on </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> or discontinue its operations. </font></p>
		</div>
<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock', window );">Development Stage Risks, Liquidity and Going Concern</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt 12.2pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Development Stage Risks, Liquidity and Going Concern</font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The Company is in the development stage and devotes substantially all of its efforts towards obtaining regulatory approval, exploring strategic alternatives for further developing </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, and raising capital necessary to fund its operations. The Company has not generated revenue to date and is subject to a number of risks similar to those of other development stage companies, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has historically funded its operations through issuances of common and preferred stock, as well as through the business combination with </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt">, </font><font style="font-family:'Times New Roman'; font-size:10pt">Inc</font><font style="font-family:'Times New Roman'; font-size:10pt">, or </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt">. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Since ARCA was founded on December</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">17, 2001, or Inception, the Company has incurred substantial losses and negative cash flows from operations. Since Inception, the Company incurred a loss from operations of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">100.2</font><font style="font-family:'Times New Roman'; font-size:10pt"> million and had negative cash flows from operations of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">98.2</font><font style="font-family:'Times New Roman'; font-size:10pt"> million. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">In light of the substantial additional time and costs associated with the development of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> and the need to raise a significant amount of capital on acceptable terms to finance the planned clinical trial and the Company&#8217;s ongoing operations, the Company is evaluating strategic alternatives for funding continued operations and development programs. The Company will need to complete a substantial equity financing, or a strategic transaction, such as a strategic combination or partnership to support the continued development of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, including the planned GENETIC-AF clinical trial. </font><font style="font-family:'Times New Roman'; font-size:10pt">To date</font><font style="font-family:'Times New Roman'; font-size:10pt">,</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font><font style="font-family:'Times New Roman'; font-size:10pt">the Company </font><font style="font-family:'Times New Roman'; font-size:10pt">has completed two equity-financing transactions in 2013 and </font><font style="font-family:'Times New Roman'; font-size:10pt">raised approximately $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">1.</font><font style="font-family:'Times New Roman'; font-size:10pt; ">4</font><font style="font-family:'Times New Roman'; font-size:10pt"> million, net of offering costs</font><font style="font-family:'Times New Roman'; font-size:10pt">.</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font><font style="font-family:'Times New Roman'; font-size:10pt">These financings </font><font style="font-family:'Times New Roman'; font-size:10pt">have </font><font style="font-family:'Times New Roman'; font-size:10pt">allow</font><font style="font-family:'Times New Roman'; font-size:10pt">ed</font><font style="font-family:'Times New Roman'; font-size:10pt"> ARCA to continue operations</font><font style="font-family:'Times New Roman'; font-size:10pt"> while it continues to pursue financing options, a strategic combination, partnering, and licensing opportunities. If the Company is delayed in completing or is unable to complete additional funding and/or a strategic transaction, the Company may discontinue its development activities or discontinue its operations. The Company currently believes its cash and cash equivalents balance as of March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, </font><font style="font-family:'Times New Roman'; font-size:10pt">2013 </font><font style="font-family:'Times New Roman'; font-size:10pt">will be sufficient to fund its operations </font><font style="font-family:'Times New Roman'; font-size:10pt">through September</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">30, 2013. The Company is unable to assert that its current cash and cash equivalents are sufficient to fund operations beyond that date, and as a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern beyond September</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">30, 2013. These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the inability of the Company to continue as a going concern. The Company may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt"> or to otherwise continue operations and may not be able to execute any strategic transaction. </font></p>
			<p style="margin:9pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">The Company&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following: </font></p>
			<ul type="disc" style="margin:0pt; padding-left:0pt">
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the costs and timing for the planned GENETIC-AF clinical trial in order to gain possible FDA approval for </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the market price of the Company&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the Company&#8217;s ability to retain the listing of its common stock on the </font><font style="font-family:'Times New Roman'; font-size:10pt">Nasdaq</font><font style="font-family:'Times New Roman'; font-size:10pt"> Capital Market; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">general economic and industry conditions affecting the availability and cost of capital; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the Company&#8217;s ability to control costs associated with its operations; </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">the</font><font style="font-family:'Times New Roman'; font-size:10pt"> terms and conditions of the Company&#8217;s existing collaborative and licensing agreements. </font></li>
			</ul>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to the Company&#8217;s stockholders. If the Company raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of the Company&#8217;s capital stock and could contain covenants that would restrict the Company&#8217;s operations. The Company also cannot predict what consideration might be available, if any, to the Company or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to the Company in the near term, or not be available on acceptable terms, the Company may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause the Company to further delay, substantially reduce or discontinue operational activities to conserve its cash resources. </font></p>
		</div>
<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Reverse Stock Split </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">On </font><font style="font-family:'Times New Roman'; font-size:10pt">March 4</font><font style="font-family:'Times New Roman'; font-size:10pt">, 2013</font><font style="font-family:'Times New Roman'; font-size:10pt">,</font><font style="font-family:'Times New Roman'; font-size:10pt"> the Company </font><font style="font-family:'Times New Roman'; font-size:10pt">completed </font><font style="font-family:'Times New Roman'; font-size:10pt">a </font><font style="font-family:'Times New Roman'; font-size:10pt; ">1-for-6 reverse split</font><font style="font-family:'Times New Roman'; font-size:10pt"> of its common stock</font><font style="font-family:'Times New Roman'; font-size:10pt">. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action. </font></p>
		</div>
<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Basis of Presentation </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The accompanying unaudited consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles for interim financial information and instructions to Form 10-Q and Rule 10-01 of Regulation S-X.</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim consolidated financial statements. The results of operations for the three months ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 are not necessarily indicative of results expected for the full year ending December</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, </font><font style="font-family:'Times New Roman'; font-size:10pt">2013</font><font style="font-family:'Times New Roman'; font-size:10pt">.</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">The Company has generated </font><font style="font-family:'Times New Roman'; font-size:10pt; ">no</font><font style="font-family:'Times New Roman'; font-size:10pt"> revenue to date a</font><font style="font-family:'Times New Roman'; font-size:10pt">nd its activities have consisted of seeking regulatory approval, research and development, exploring strategic alternatives for further developing and commercializing </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, and raising capital. Accordingly, the Company continues to be considered in the development stage at March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto for the year ended </font><font style="font-family:'Times New Roman'; font-size:10pt">December</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2012 included in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission</font><font style="font-family:'Times New Roman'; font-size:10pt">, as amended</font><font style="font-family:'Times New Roman'; font-size:10pt">. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values. </font></p>
		</div>
<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Concentrations of Credit Risk </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits, money market fund accounts and debt securities with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </font></p>
		</div>
<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Accrued Expenses </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">As part of the process of preparing its financial statements, the Company is required to estimate accrued expenses. This process involves identifying services that third parties have performed on the Company&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to the Company&#8217;s drug product, and professional service fees, such as attorneys, consultants, and clinical research organizations. The Company develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time. </font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AccruedExpensesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for estimating costs incurred that have not yet been billed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AccruedExpensesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Development stage risks liquidity and going concern.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_DevelopmentStageRisksLiquidityAndGoingConcernPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ReverseStockSplitPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_ReverseStockSplitPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number SOP94-6-1<br><br> -Paragraph 7, 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 113<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14537-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6487554&amp;loc=d3e32600-158583<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 14<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13537-108611<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13531-108611<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>May 10, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DocumentDocumentAndEntityInformationLineItems', window );"><strong>Document - Document and Entity Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">ARCA Biopharma, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000907654<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,185,562<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DocumentDocumentAndEntityInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_DocumentDocumentAndEntityInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock', window );">Summary of Basic and Diluted Loss Per Share</a></td>
        <td class="text"><div>
			<p style="margin:9pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">A reconciliation of the numerator and denominator used in the calculation of basic and diluted loss per share follows: </font></p>
			<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:76%">

					<tr style="height:11.25pt">
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</th>
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</th>
						<th colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:160.35pt">
							<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> Three Months Ended March 31, </font></p>
						</th>
					</tr>
					<tr style="height:12.75pt">
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</th>
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</th>
						<th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">2013</font></p>
						</th>
						<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</th>
						<th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">2012</font></p>
						</th>
					</tr>


					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(In thousands, except shares and per share data)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Net loss</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(1,071)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(1,407)</font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Net loss available to common shareholders</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(1,071)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(1,407)</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:2.5pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Weighted average shares of common stock outstanding</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">3,037,546</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">2,030,499</font></p>
						</td>
					</tr>
					<tr style="height:5.4pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Less:&#160; Weighted-average shares of unvested common stock</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(2,783)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(2,783)</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td rowspan="2" style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Total weighted-average shares used in computing net loss per share attributed to common stockholders</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:12.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">3,034,763</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">2,027,716</font></p>
						</td>
					</tr>
					<tr style="height:13.5pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Basic and diluted loss per share</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(0.35)</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(0.69)</font></p>
						</td>
					</tr>
					<tr style="height:1pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:269.8pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:12.2pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:13.65pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:73.7pt">
							<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:1pt">&#xa0;</font></p>
						</td>
					</tr>
				<!--[if !supportMisalignedColumns]><tr style="height:0pt">
					<td style="width:200.7pt; border:none">
					</td>
					<td style="width:11.2pt; border:none">
					</td>
					<td style="width:55.95pt; border:none">
					</td>
					<td style="width:12.25pt; border:none">
					</td>
					<td style="width:56.45pt; border:none">
					</td>
				</tr><![endif]--></table>
			<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the numerators and the denominators of the basic and diluted per-share (or per-unit) computations for income from continuing operations, including the effect that has been given to preferred dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfCalculationOfNumeratorAndDenominatorInEarningsPerShareTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EBLAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (unaudited) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">135 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">$ 181<span></span></td>
        <td class="nump">$ 422<span></span></td>
        <td class="nump">$ 42,858<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">889<span></span></td>
        <td class="nump">984<span></span></td>
        <td class="nump">43,472<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Merger transaction costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,470<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,413<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Loss on impairment of in-process research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
        <td class="nump">1,070<span></span></td>
        <td class="nump">1,406<span></span></td>
        <td class="nump">100,213<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(1,070)<span></span></td>
        <td class="num">(1,406)<span></span></td>
        <td class="num">(100,213)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_GainLossOnAssignmentOfPatentRights', window );">Gain on assignment of patent rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount', window );">Gain on bargain purchase</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,282<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,028<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest and other expense</a></td>
        <td class="num">(1)<span></span></td>
        <td class="num">(1)<span></span></td>
        <td class="num">(443)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
        <td class="num">(1,071)<span></span></td>
        <td class="num">(1,407)<span></span></td>
        <td class="num">(71,346)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,281<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
        <td class="num">(1,071)<span></span></td>
        <td class="num">(1,407)<span></span></td>
        <td class="num">(69,065)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Less: Accretion of redeemable convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(245)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(781)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
        <td class="num">$ (1,071)<span></span></td>
        <td class="num">$ (1,407)<span></span></td>
        <td class="num">$ (70,091)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss attributable to common stockholders per share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
        <td class="num">$ (0.35)<span></span></td>
        <td class="num">$ (0.69)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
        <td class="nump">3,034,763<span></span></td>
        <td class="nump">2,027,716<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_GainLossOnAssignmentOfPatentRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gain or loss on transfer of all or part of the rights and interests in certain patents and patent applications.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_GainLossOnAssignmentOfPatentRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 23<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917927&amp;loc=d3e1043-128460<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 59<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationAcquisitionRelatedCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 36, 37, 38<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6571-128477<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6527-128477<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (f)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141R<br><br><br><br> -Paragraph 68<br><br><br><br> -Subparagraph o(1)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6393-128476<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6396-128476<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6387-128476<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7658586&amp;loc=d3e16373-109275<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 46<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph h<br><br><br><br> -Subparagraph 1(i)<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 109<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph a, b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph h<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestAndOtherIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 34<br><br><br><br> -Paragraph 21<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 10, 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 87-21<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 28, 29, 30<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A7<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 128<br><br><br><br> -Paragraph 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingCostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of accretion of the preferred stock redemption discount during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockAccretionOfRedemptionDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockDividendsAndOtherAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141<br><br><br><br> -Paragraph 51<br><br><br><br> -Subparagraph g<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 86<br><br><br><br> -Paragraph 11, 12<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 2<br><br><br><br> -Paragraph 12, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 3, 4<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Paragraph 5A<br><br><br><br> -Chapter 4<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(5) Property and Equipment </font></p>
			<p style="margin:4.5pt 0pt 9pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Property and equipment consist of the following (in thousands): </font></p>
			<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:94.66%">
				<tr style="height:24pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Estimated Life</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">March 31, 2013</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">December 31, 2012</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Computer equipment</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">3 years</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">87</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">104</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Lab equipment</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">5 years</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">142</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">142</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Furniture and fixtures</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">5 years</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">85</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">93</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Computer software</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">3 years</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">176</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">176</font></p>
					</td>
				</tr>
				<tr style="height:25.5pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Leasehold improvements</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">Lesser of useful life or life of the lease</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">508</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">533</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Less accumulated depreciation and </font><font style="font-family:'Times New Roman'; font-size:10pt">amortization</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(486)</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(510)</font></p>
					</td>
				</tr>
				<tr style="height:13.5pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">22</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">23</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
					</td>
				</tr>
			</table>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">For the three months ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 and 2012, and for the period from Inception through March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013, depreciation and amortization expense was $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">10</font><font style="font-family:'Times New Roman'; font-size:10pt; ">,000</font><font style="font-family:'Times New Roman'; font-size:10pt">, $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">14</font><font style="font-family:'Times New Roman'; font-size:10pt; ">,000</font><font style="font-family:'Times New Roman'; font-size:10pt">, and $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">1.8</font><font style="font-family:'Times New Roman'; font-size:10pt"> million respectively.</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Disclosures<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(4) Fair Value Disclosures </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">As of March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013, the Company had $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">3</font><font style="font-family:'Times New Roman'; font-size:10pt; ">.5</font><font style="font-family:'Times New Roman'; font-size:10pt"> million of cash equivalents consisting of money market funds with maturities of </font><font style="font-family:'Times New Roman'; font-size:10pt; ">90 days</font><font style="font-family:'Times New Roman'; font-size:10pt"> or less. The Company has the ability to liquidate these investments without restriction. The Company determines fair value for these money ma</font><font style="font-family:'Times New Roman'; font-size:10pt">rket funds and equity securities with Level 1 inputs through quoted market prices. There were no transfers of assets between fair value </font><font style="font-family:'Times New Roman'; font-size:10pt">hierarchy</font><font style="font-family:'Times New Roman'; font-size:10pt"> levels during the three month period ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013. </font></p>
			<p style="margin:9pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: </font></p>
			<ul type="disc" style="margin:0pt; padding-left:0pt">
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">Level 2&#8212;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability </font></li>
				<li style="margin:4.5pt 0pt 0pt 59.12pt; text-indent:0pt; padding-left:7.48pt; font-family:Symbol; font-size:12pt"><font style="font-family:'Times New Roman'; font-size:10pt">Level 3&#8212;Unobservable inputs for the asset or liability </font></li>
			</ul>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Fair Value of Other Financial Instruments </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The carrying amount of other financial instruments, including cash, accounts payable, and short-term notes payable approximated fair value due to their short maturities. </font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13504-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15C, 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44A, 44B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -Subparagraph a-d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 3, 10, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13433-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 17-22, 27, 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13537-108611<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15B<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32, 33, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Share (Details Textual)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EarningsLossPerShareTextualAbstract', window );"><strong>Earnings (Loss) Per Share (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average shares of common stock, Diluted</a></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="nump">604,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EarningsLossPerShareTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_EarningsLossPerShareTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
        <td class="text"><div>
			<p style="margin:4.5pt 0pt 9pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Property and equipment consist of the following (in thousands): </font></p>
			<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:94.66%">
				<tr style="height:24pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Estimated Life</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">March 31, 2013</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">December 31, 2012</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Computer equipment</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">3 years</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">87</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">104</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Lab equipment</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">5 years</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">142</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">142</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Furniture and fixtures</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">5 years</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">85</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">93</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Computer software</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">3 years</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">176</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">176</font></p>
					</td>
				</tr>
				<tr style="height:25.5pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Leasehold improvements</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt">Lesser of useful life or life of the lease</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">508</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">533</font></p>
					</td>
				</tr>
				<tr style="height:12.75pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Less accumulated depreciation and </font><font style="font-family:'Times New Roman'; font-size:10pt">amortization</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(486)</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(510)</font></p>
					</td>
				</tr>
				<tr style="height:13.5pt">
					<td style="vertical-align:bottom; width:211.5pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:99pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">22</font></p>
					</td>
					<td style="vertical-align:bottom; width:11.6pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
					</td>
					<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; vertical-align:bottom; width:54.65pt">
						<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">23</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
					</td>
				</tr>
			</table>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(8) Share-based Compensation </font></p>
			<p style="margin:4.5pt 0pt 9pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">For the three month periods ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 and 2012 and for the period from Inception through March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013, the Company recognized the following non-cash, share-based compensation expense in the consolidated statement of operations (in thousands): </font></p>
			<div style="text-align:center">
				<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:84%">

						<tr style="height:59.25pt">
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
							<th colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:137.15pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Three Months Ended March 31,</font></p>
							</th>
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
							<th rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Period from December 17, 2001 (date of inception) to March 31, 2013</font></p>
							</th>
						</tr>
						<tr style="height:15.75pt">
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
							<th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">2013</font></p>
							</th>
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
							<th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">2012</font></p>
							</th>
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
						</tr>


						<tr style="height:20.25pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
						</tr>
						<tr style="height:15.75pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Research and Development</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">15</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">26</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">605</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
						</tr>
						<tr style="height:15.75pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Selling, General and Administrative</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">27</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">65</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">1</font><font style="font-family:'Times New Roman'; font-size:10pt">,</font><font style="font-family:'Times New Roman'; font-size:10pt">638</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
						</tr>
						<tr style="height:15.75pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Restructuring Expense</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">0</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">0</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">387</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
						</tr>
						<tr style="height:16.5pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Total</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">42</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">91</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">2</font><font style="font-family:'Times New Roman'; font-size:10pt">,</font><font style="font-family:'Times New Roman'; font-size:10pt">630</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
						</tr>
					<!--[if !supportMisalignedColumns]><tr style="height:0pt">
						<td style="width:143pt; border:none">
						</td>
						<td style="width:67.55pt; border:none">
						</td>
						<td style="width:11.55pt; border:none">
						</td>
						<td style="width:68.5pt; border:none">
						</td>
						<td style="width:12.3pt; border:none">
						</td>
						<td style="width:69.05pt; border:none">
						</td>
					</tr><![endif]--></table>
			</div>
			<p style="margin:4.5pt 0pt 0pt 24.5pt; text-indent:-24.5pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
			<p style="margin:4.5pt 0pt 0pt 24.5pt; text-indent:-24.5pt"><font style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</font></p>
			<p style="margin:9pt 0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Stock option transactions for the three month period ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 under all plans are as follows: </font></p>
			<div style="text-align:center">
				<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:84%">
					<tr style="height:77.25pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> # of Options </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Weighted Average Exercise Price</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Weighted Average Remaining Contractual Term </font><br /><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(in years)</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Options outstanding at December</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2012</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">144,019</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18.28</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">4.91</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Changes during the period:</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Granted</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">-</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">0.00</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Exercised</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">-</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">0.00</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Forfeited, cancelled or expired</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(6,259)</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">16.53</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Options outstanding at March 31, 2013</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">137,760</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18.36</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">4.89</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
					</tr>
					<tr style="height:15.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Options exercisable at March 31, 2013</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">123,408</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18.</font><font style="font-family:'Times New Roman'; font-size:10pt">82</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">4.62</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Options vested and expected to vest</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">136,208</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18.</font><font style="font-family:'Times New Roman'; font-size:10pt">39</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">4.88</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
					</tr>
				</table>
			</div>
			<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(6) Commitments and Contingencies </font></p>
			<p style="margin:4.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">The Company has or is subject to the following commitments and contingencies: </font></p>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Employment Agreements </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The Company maintains employment agreements with several executive employees. </font><font style="font-family:'Times New Roman'; font-size:10pt">Most of these agreements provide for payments to be made under certain conditions related to a change in control of the Company and entitle the employee to wages and certain benefits payments not exceeding one calendar year from the date of termination without cause or by the employee for good reason. </font><font style="font-family:'Times New Roman'; font-size:10pt">The agreements may be terminated at any time by the Company with or without cause upon written notice to the employee. </font></p>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Operating Lease </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">On February</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">8, 2008, the Company entered into a lease agreement for approximately </font><font style="font-family:'Times New Roman'; font-size:10pt; ">15,000</font><font style="font-family:'Times New Roman'; font-size:10pt"> square feet of newly constructed office facilities in Broomfield, Colorado. The Company relocated to the new facility upon its completion in July</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">2008. The lease has a term of </font><font style="font-family:'Times New Roman'; font-size:10pt; ">5</font><font style="font-family:'Times New Roman'; font-size:10pt; ">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt; ">years</font><font style="font-family:'Times New Roman'; font-size:10pt"> with rights to extend the term for </font><font style="font-family:'Times New Roman'; font-size:10pt; ">two additional </font><font style="font-family:'Times New Roman'; font-size:10pt; ">three year</font><font style="font-family:'Times New Roman'; font-size:10pt; "> periods</font><font style="font-family:'Times New Roman'; font-size:10pt">. On June</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">14, 2011, the Company entered into a first amendment (the &#8220;Amendment&#8221;) to the lease agreement. Under the terms of the Amendment, the Company and its landlord mutually agreed for the Company to relocate from its office suite of approximately 15,000 square feet, to another suite within the same building, comprising approximately </font><font style="font-family:'Times New Roman'; font-size:10pt; ">4,500</font><font style="font-family:'Times New Roman'; font-size:10pt"> square feet. The office location serves as the Company&#8217;s primary business office. The Amendment also modified the annual per square foot rate of rent and allows the Company to terminate with </font><font style="font-family:'Times New Roman'; font-size:10pt; ">three months</font><font style="font-family:'Times New Roman'; font-size:10pt">&#8217; notice. As part of the agreement, the Company made a one-time payment to the landlord of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">200,000</font><font style="font-family:'Times New Roman'; font-size:10pt">, which the landlord agreed to use for the landlord&#8217;s improvements in the new leased premises. The original five year term of the Lease remains unchanged. Per the lease agreement, base rent is subject to annual increases of approximately three percent per year. The rent expense for the lease is being recognized on a straight-line basis over the lease term.</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Under the original lease, the Company received tenant improvement reimbursements from the landlord totaling $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">593,000</font><font style="font-family:'Times New Roman'; font-size:10pt"> which were recorded as deferred rent and were amortized as reductions to rent expense. The $200,000 payment made to the landlord in conjunction with the Amendment was recorded against the existing deferred rent. The net deferred rent balance is being amortized as reductions to rent expense over the remaining term of the lease. The unamortized deferred rent balance as of March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 was $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">8</font><font style="font-family:'Times New Roman'; font-size:10pt; ">,000</font><font style="font-family:'Times New Roman'; font-size:10pt">. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Rent expense under this lease for the three months ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 and 2012 was $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">12</font><font style="font-family:'Times New Roman'; font-size:10pt; ">,000</font><font style="font-family:'Times New Roman'; font-size:10pt">, and</font><font style="font-family:'Times New Roman'; font-size:10pt"> was</font><font style="font-family:'Times New Roman'; font-size:10pt"> $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">527</font><font style="font-family:'Times New Roman'; font-size:10pt; ">,000</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font><font style="font-family:'Times New Roman'; font-size:10pt">from Inception through March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013.</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The Company&#8217;s facility lease in Broomfield, Colorado expires in </font><font style="font-family:'Times New Roman'; font-size:10pt; ">June 2013</font><font style="font-family:'Times New Roman'; font-size:10pt">. The remaining minimum lease payments committed under the lease through June 2013 are $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">20,000</font><font style="font-family:'Times New Roman'; font-size:10pt">. The lease has an option to renew for an additional three year term under comparable terms, </font><font style="font-family:'Times New Roman'; font-size:10pt">and </font><font style="font-family:'Times New Roman'; font-size:10pt">the Company </font><font style="font-family:'Times New Roman'; font-size:10pt">is in negotiations with the landlord regarding potential renewal of </font><font style="font-family:'Times New Roman'; font-size:10pt">the lease. </font></p>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Cardiovascular Pharmacology and Engineering Consultants, LLC, or CPEC </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Under the terms of its strategic license agreement with CPEC, a licensing subsidiary of </font><font style="font-family:'Times New Roman'; font-size:10pt">Indevus</font><font style="font-family:'Times New Roman'; font-size:10pt"> Pharmaceuticals Inc. (a wholly owned subsidiary of Endo Pharmaceuticals), holding ownership rights to certain clinical trial data of </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, the Company will incur milestone and royalty obligations upon the occurrence of certain events. In August 2008, the Company paid CPEC a milestone payment of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">500,000</font><font style="font-family:'Times New Roman'; font-size:10pt"> based on the July</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2008 submission of its NDA to the FDA. If the FDA grants marketing approval for </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">, the </font><font style="font-family:'Times New Roman'; font-size:10pt">agreement provides that the </font><font style="font-family:'Times New Roman'; font-size:10pt">Company will owe CPEC another milestone payment of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">8.0</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">million within six months after FDA approval. The </font><font style="font-family:'Times New Roman'; font-size:10pt">agreement also states that the </font><font style="font-family:'Times New Roman'; font-size:10pt">Company has the obligation to make milestone payments of up to $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">5.0</font><font style="font-family:'Times New Roman'; font-size:10pt"> million in the aggregate upon regulatory marketing approval in Europe and Japan. The </font><font style="font-family:'Times New Roman'; font-size:10pt">agreement states that the </font><font style="font-family:'Times New Roman'; font-size:10pt">Company&#8217;s royalty obligation ranges from </font><font style="font-family:'Times New Roman'; font-size:10pt; ">12.5</font><font style="font-family:'Times New Roman'; font-size:10pt">% to </font><font style="font-family:'Times New Roman'; font-size:10pt; ">25</font><font style="font-family:'Times New Roman'; font-size:10pt">% of revenue from the related product based on achievement of specified product sales levels, including a </font><font style="font-family:'Times New Roman'; font-size:10pt; ">5</font><font style="font-family:'Times New Roman'; font-size:10pt">% royalty that CPEC is obligated to pay under its original license agreement for </font><font style="font-family:'Times New Roman'; font-size:10pt">Gencaro</font><font style="font-family:'Times New Roman'; font-size:10pt">. The Company has the right to buy down the royalties to a range of </font><font style="font-family:'Times New Roman'; font-size:10pt; ">12.5</font><font style="font-family:'Times New Roman'; font-size:10pt">% to </font><font style="font-family:'Times New Roman'; font-size:10pt; ">17</font><font style="font-family:'Times New Roman'; font-size:10pt">% by making a payment to CPEC within </font><font style="font-family:'Times New Roman'; font-size:10pt; ">six months</font><font style="font-family:'Times New Roman'; font-size:10pt"> of regulatory approval. </font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity Financings and Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsAndWarrantsDisclosureTextBlock', window );">Equity Financings and Warrants</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(7) </font><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Equity Financings and Warrants </font></p>
			<p style="margin:4.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Private Investment in Public Equity (PIPE) Transaction </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">On January</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">22, 2013, the Company entered into a Subscription Agreement (the &#8220;Purchase Agreement&#8221;) with various accredited investors and </font><font style="font-family:'Times New Roman'; font-size:10pt">its</font><font style="font-family:'Times New Roman'; font-size:10pt"> Chief Executive Officer in connection with a private placement of its common stock and warrants. Pursuant to the Purchase Agreement, the Company sold an aggregate of </font><font style="font-family:'Times New Roman'; font-size:10pt; ">356,430</font><font style="font-family:'Times New Roman'; font-size:10pt"> shares of its common stock and warrants to purchase up to </font><font style="font-family:'Times New Roman'; font-size:10pt; ">249,501</font><font style="font-family:'Times New Roman'; font-size:10pt"> additional shares of its common stock for aggregate gross proceeds of approximately $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">1</font><font style="font-family:'Times New Roman'; font-size:10pt"> million, before deducting estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">80</font><font style="font-family:'Times New Roman'; font-size:10pt; ">5</font><font style="font-family:'Times New Roman'; font-size:10pt">,000</font><font style="font-family:'Times New Roman'; font-size:10pt">, and the private placement closed on </font><font style="font-family:'Times New Roman'; font-size:10pt; ">January</font><font style="font-family:'Times New Roman'; font-size:10pt; ">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt; ">25, 2013</font><font style="font-family:'Times New Roman'; font-size:10pt">. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase </font><font style="font-family:'Times New Roman'; font-size:10pt; ">0.70</font><font style="font-family:'Times New Roman'; font-size:10pt"> shares of common stock. The purchase price for each unit was $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">2.81</font><font style="font-family:'Times New Roman'; font-size:10pt">. The warrants were exercisable upon issuance, expire </font><font style="font-family:'Times New Roman'; font-size:10pt; ">seven</font><font style="font-family:'Times New Roman'; font-size:10pt"> years from the date of issuance, and have an exercise price of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">2.28</font><font style="font-family:'Times New Roman'; font-size:10pt"> per share, equal to </font><font style="font-family:'Times New Roman'; font-size:10pt; ">100%</font><font style="font-family:'Times New Roman'; font-size:10pt"> of the closing bid price of ARCA&#8217;s common stock on the </font><font style="font-family:'Times New Roman'; font-size:10pt">Nasdaq</font><font style="font-family:'Times New Roman'; font-size:10pt"> Capital Market on January</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">22, 2013.</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The Company filed a registration statement for the resale of the shares underlying the units sold in these private placements. That registration statement was declared effective by the Securities and Exchange Commission on February</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">14, 2013. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">In connection with this transaction, the Company agreed that, subject to certain exceptions, it would not, while the warrants are outstanding, effect or enter into an agreement to effect any issuance of common stock or securities convertible into, exercisable for or exchangeable for common stock in a &#8220;variable rate transaction,&#8221; which means a transaction in which the Company issues or sells any convertible securities either (A)</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of common stock at any time after the initial issuance of such convertible securities, or (B)</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of the convertible securities or upon the occurrence of the specified or contingent events directly or indirectly related to our business or the market for our common stock. In addition, the Company agreed that, subject to certain exceptions, if it issues securities within one year following the closing of the offering, each investor would have the right to purchase its pro rata share of a specified portion of the securities in the future offering on the same terms, conditions and price provided for in the proposed issuance of securities. </font></p>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Registered Direct Offering </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">On January</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013, the Company entered into a subscription agreement with certain institutional investors (the &#8220;Investors&#8221;) in connection with its Registered Direct public offering (the &#8220;Offering&#8221;), pursuant to which the Company sold an aggregate of </font><font style="font-family:'Times New Roman'; font-size:10pt; ">164,636</font><font style="font-family:'Times New Roman'; font-size:10pt"> shares of its common stock and warrants to purchase up to </font><font style="font-family:'Times New Roman'; font-size:10pt; ">65,855</font><font style="font-family:'Times New Roman'; font-size:10pt"> additional shares of its common stock to the Investors for aggregate gross proceeds of approximately $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">730,000</font><font style="font-family:'Times New Roman'; font-size:10pt">, before deducting placement agent fee and other estimated offering expenses payable by the Company. The net proceeds to the Company were approximately $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">616</font><font style="font-family:'Times New Roman'; font-size:10pt">,000</font><font style="font-family:'Times New Roman'; font-size:10pt">, and the Offering closed on </font><font style="font-family:'Times New Roman'; font-size:10pt; ">February</font><font style="font-family:'Times New Roman'; font-size:10pt; ">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt; ">4, 2013</font><font style="font-family:'Times New Roman'; font-size:10pt">. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The common stock and warrants were sold in units consisting of one share of common stock and a warrant to purchase </font><font style="font-family:'Times New Roman'; font-size:10pt; ">0.40</font><font style="font-family:'Times New Roman'; font-size:10pt"> shares of common stock. The purchase price for each unit was $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">4.43</font><font style="font-family:'Times New Roman'; font-size:10pt">. The warrants were exercisable upon issuance, expire </font><font style="font-family:'Times New Roman'; font-size:10pt; ">five</font><font style="font-family:'Times New Roman'; font-size:10pt"> years from the date of issuance, and have an exercise price of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">4.13</font><font style="font-family:'Times New Roman'; font-size:10pt"> per share, equal to the closing bid price of ARCA&#8217;s common stock on the </font><font style="font-family:'Times New Roman'; font-size:10pt">Nasdaq</font><font style="font-family:'Times New Roman'; font-size:10pt"> Capital Market o</font><font style="font-family:'Times New Roman'; font-size:10pt">n</font><font style="font-family:'Times New Roman'; font-size:10pt"> January</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013. The Offering was </font><font style="font-family:'Times New Roman'; font-size:10pt">effected</font><font style="font-family:'Times New Roman'; font-size:10pt"> as a takedown off the Company&#8217;s S-3 Registration Statement, which became effective on April</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">4, 2011, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">1, 2013. The warrant agreements provide for settlement of the warrants in unregistered shares should an effective registration statement or current prospectus not </font><font style="font-family:'Times New Roman'; font-size:10pt">be</font><font style="font-family:'Times New Roman'; font-size:10pt"> in place at the time a warrant is exercised. </font></p>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold; font-style:italic">Warrants </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">As of March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013, warrants to purchase </font><font style="font-family:'Times New Roman'; font-size:10pt; ">1.3 million</font><font style="font-family:'Times New Roman'; font-size:10pt"> shares of common stock were outstanding at exercise prices ranging from $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">1.80</font><font style="font-family:'Times New Roman'; font-size:10pt"> to $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">116.89</font><font style="font-family:'Times New Roman'; font-size:10pt">, with a weighted average exercise price per share of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">7.25</font><font style="font-family:'Times New Roman'; font-size:10pt">. These warrants, which were granted as part of various financing and business agreements, expire at various times between October 2013 and </font><font style="font-family:'Times New Roman'; font-size:10pt">January 2020</font><font style="font-family:'Times New Roman'; font-size:10pt">. Warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using the Black-Scholes option-pricing model. </font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingsAndWarrantsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity financings and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_EquityFinancingsAndWarrantsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(9) Income Taxes </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">In accordance with United States Generally Accepted Accounting Principles, a valuation allowance should be provided if it is more likely than not that some or all of the </font><font style="font-family:'Times New Roman'; font-size:10pt">Company&#8217;s </font><font style="font-family:'Times New Roman'; font-size:10pt">deferred tax assets will not be realized. The </font><font style="font-family:'Times New Roman'; font-size:10pt">Company&#8217;s </font><font style="font-family:'Times New Roman'; font-size:10pt">ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets. The Company believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has </font><font style="font-family:'Times New Roman'; font-size:10pt; ">no</font><font style="font-family:'Times New Roman'; font-size:10pt"> reserve for uncertain tax positions</font><font style="font-family:'Times New Roman'; font-size:10pt">. </font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6IAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">135 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 04, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract', window );"><strong>Company Development Stage and Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AnticipatedPeriodToStartAtrialFibrillationTrial', window );">Anticipated time to start AF Trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (1,070,000)<span></span></td>
        <td class="num">$ (1,406,000)<span></span></td>
        <td class="num">$ (100,213,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(764,000)<span></span></td>
        <td class="num">(1,656,000)<span></span></td>
        <td class="num">(98,185,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Fund raised through sale of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,741,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,850,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
        <td class="text">1 for 6 reverse split<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RevenueGenerated', window );">Revenue generated by the company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2013 Equity Financings</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract', window );"><strong>Company Development Stage and Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Fund raised through sale of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract', window );"><strong>Company Development Stage and Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfPatientsCompanyPlansToEnroll', window );">Number of patients company plans to enroll</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract', window );"><strong>Company Development Stage and Basis of Presentation (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfPatientsCompanyPlansToEnroll', window );">Number of patients company plans to enroll</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">420<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AnticipatedPeriodToStartAtrialFibrillationTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Anticipated period to start atrial fibrillation trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AnticipatedPeriodToStartAtrialFibrillationTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_CompanyDevelopmentStageAndBasisOfPresentationTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfPatientsCompanyPlansToEnroll">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of patients company plans to enroll.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_NumberOfPatientsCompanyPlansToEnroll</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RevenueGenerated">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue generated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_RevenueGenerated</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 54<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityReverseStockSplit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComponentsOfPropertyAndEquipmentAbstract', window );"><strong>Components of Property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump">$ 508<span></span></td>
        <td class="nump">$ 533<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
        <td class="num">(486)<span></span></td>
        <td class="num">(510)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">22<span></span></td>
        <td class="nump">23<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer equipment</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComponentsOfPropertyAndEquipmentAbstract', window );"><strong>Components of Property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump">87<span></span></td>
        <td class="nump">104<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lab equipment</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComponentsOfPropertyAndEquipmentAbstract', window );"><strong>Components of Property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump">142<span></span></td>
        <td class="nump">142<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture and fixtures</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComponentsOfPropertyAndEquipmentAbstract', window );"><strong>Components of Property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump">85<span></span></td>
        <td class="nump">93<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer software</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComponentsOfPropertyAndEquipmentAbstract', window );"><strong>Components of Property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump">176<span></span></td>
        <td class="nump">176<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold improvements</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComponentsOfPropertyAndEquipmentAbstract', window );"><strong>Components of Property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LeaseholdImprovementsUsefulLife', window );">Leasehold improvements</a></td>
        <td class="text">Lesser of useful life or life of the lease<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
        <td class="nump">$ 18<span></span></td>
        <td class="nump">$ 18<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ComponentsOfPropertyAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_ComponentsOfPropertyAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LeaseholdImprovementsUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Leasehold improvements useful life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_LeaseholdImprovementsUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph b, c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJZNR">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) (unaudited) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Cash, Net of Offering Costs

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Issuance for Notes Payable and Related Accrued Interest on January 3, 2005

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Issuance for Intellectual Property License Rights on October 14, 2005

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Issuance for Notes Payable and Related Accrued Interest on October 14, 2005

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Issuance for Intellectual Property License Rights on February 21, 2006

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Issuance for Intellectual Property License Rights on February 22, 2006

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Issuance for Intellectual Property License Rights on June 23, 2006

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Accretion of Series A

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Accretion of Series B

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Issuance for Intellectual Property License Rights on January 18, 2007

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Issuance for Intellectual Property License Rights on June 30, 2007

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Common Conversion

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Notes and Related Accrued Interest

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series A

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series A

</div>
          <div>Cash, Net of Offering Costs</div>
        </th>
        <th class="th">
          <div>Series A

</div>
          <div>Issuance of Series A on February 22, 2006

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series A

</div>
          <div>Third Issuance for Notes Payable and Related Accrued Interest

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series A

</div>
          <div>Issuance of Series A on December 8, 2006

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series A

</div>
          <div>Series A offering costs

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series A

</div>
          <div>Accretion of Series A

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series A

</div>
          <div>Common Conversion

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series B

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series B

</div>
          <div>Cash, Net of Offering Costs</div>
        </th>
        <th class="th">
          <div>Series B

</div>
          <div>Issuance for Series B on May 31, 2007

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series B

</div>
          <div>Issuance for Series B on December 28, 2007

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series B

</div>
          <div>Accretion of Series B

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Series B

</div>
          <div>Common Conversion

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Cash, Net of Offering Costs

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance for Notes Payable and Related Accrued Interest on January 3, 2005</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance for Intellectual Property License Rights on October 14, 2005</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance for Notes Payable and Related Accrued Interest on October 14, 2005

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance for Intellectual Property License Rights on February 21, 2006</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance for Intellectual Property License Rights on February 22, 2006</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance for Intellectual Property License Rights on June 23, 2006</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance for Intellectual Property License Rights on November 7, 2006</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance for Intellectual Property License Rights on January 18, 2007</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance for Intellectual Property License Rights on June 30, 2007</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance of Common Stock for Commercial License Rights, on July 19, 2007</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Issuance of Shares to Executive Subject to Repurchase</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Common Conversion

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Common Stock

</div>
          <div>Notes and Related Accrued Interest</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Cash, Net of Offering Costs

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Issuance for Notes Payable and Related Accrued Interest on January 3, 2005

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Issuance for Intellectual Property License Rights on October 14, 2005

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Issuance for Notes Payable and Related Accrued Interest on October 14, 2005

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Issuance for Intellectual Property License Rights on February 21, 2006

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Issuance for Intellectual Property License Rights on February 22, 2006

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Issuance for Intellectual Property License Rights on June 23, 2006

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Accretion of Series A

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Accretion of Series B

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Issuance for Intellectual Property License Rights on January 18, 2007

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Issuance for Intellectual Property License Rights on June 30, 2007

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Common Conversion

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital

</div>
          <div>Notes and Related Accrued Interest

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Deficit Accumulated During the Development Stage

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Deficit Accumulated During the Development Stage

</div>
          <div>Cash, Net of Offering Costs</div>
        </th>
        <th class="th">
          <div>Deficit Accumulated During the Development Stage

</div>
          <div>Issuance for Notes Payable and Related Accrued Interest on October 14, 2005</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, value at Dec. 17, 2001</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash, net of offering costs, value</a></td>
        <td class="nump">$ 1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,588<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(116)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(116)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2003</a></td>
        <td class="num">(115)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(116)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2003</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,588<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash, net of offering costs, value</a></td>
        <td class="nump">7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,720<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(511)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(511)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2004</a></td>
        <td class="num">(619)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(627)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2004</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,308<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash, net of offering costs, value</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">44<span></span></td>
        <td class="nump">1,354<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">44<span></span></td>
        <td class="nump">1,354<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,922<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,978<span></span></td>
        <td class="nump">903<span></span></td>
        <td class="nump">31,095<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(1,459)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,459)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2005</a></td>
        <td class="num">(678)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,408<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,086)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2005</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">60,206<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash, net of offering costs, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75<span></span></td>
        <td class="nump">60<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,316<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75<span></span></td>
        <td class="nump">60<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,727,354<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,074,086<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,372<span></span></td>
        <td class="nump">13,907<span></span></td>
        <td class="nump">2,505<span></span></td>
        <td class="nump">38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(5,241)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(5,241)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, value</a></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">684<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">420,817<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
        <td class="num">(17)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(98)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(17)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">39<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2006</a></td>
        <td class="num">(5,744)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,919<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,583<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(7,327)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2006</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,222,257<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">102,047<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash, net of offering costs, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13<span></span></td>
        <td class="nump">7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,000<span></span></td>
        <td class="nump">9,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13<span></span></td>
        <td class="nump">7<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,688,902<span></span></td>
        <td class="nump">2,766,677<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,303<span></span></td>
        <td class="nump">642<span></span></td>
        <td class="nump">2,783<span></span></td>
        <td class="nump">13,915<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(13,994)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(13,994)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, value</a></td>
        <td class="nump">16<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,227<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(19)<span></span></td>
        <td class="num">(18)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(147)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(19)<span></span></td>
        <td class="num">(18)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2007</a></td>
        <td class="num">(19,689)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,938<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,871<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,632<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(21,321)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2007</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,222,257<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,455,579<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">122,917<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(19,431)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(19,431)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, value</a></td>
        <td class="nump">54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36,154<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(20)<span></span></td>
        <td class="num">(36)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(20)<span></span></td>
        <td class="num">(36)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">545<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">545<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Estimated fair value of warrants issued in connection with convertible notes payable</a></td>
        <td class="nump">399<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">399<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2008</a></td>
        <td class="num">(38,178)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,958<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,907<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,574<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(40,752)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2008</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,222,257<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,455,579<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">159,071<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(9,138)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(9,138)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, value</a></td>
        <td class="nump">114<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">114<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,521<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(42)<span></span></td>
        <td class="num">(93)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(42)<span></span></td>
        <td class="num">(93)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">845<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">845<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AdjustmentForFractionalShares', window );">Adjustment for fractional shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(102)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(7)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Deemed preferred stock dividend for additional common shares issuable under anti-dilution provision</a></td>
        <td class="num">(781)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">781<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(781)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock and convertible notes and related accrued interest, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,781<span></span></td>
        <td class="num">(8,501)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(15,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(18,781)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,780<span></span></td>
        <td class="num">(8,501)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of preferred stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(9,222,257)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(6,455,579)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">507,123<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction', window );">Restricted stock release from restriction</a></td>
        <td class="nump">75<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock and convertible notes and related accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(33,781)<span></span></td>
        <td class="nump">8,501<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,781<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(33,780)<span></span></td>
        <td class="nump">8,501<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares of common stock purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">145,465.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock', window );">Conversion of warrants for preferred stock</a></td>
        <td class="nump">36<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Merger with Nuvelo, Inc., value</a></td>
        <td class="nump">11,913<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,913<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Merger with Nuvelo, Inc., shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">447,826<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units, value</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">177<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued', window );">Estimated fair value of warrants issued in connection with lease termination</a></td>
        <td class="nump">377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2009</a></td>
        <td class="nump">7,412<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57,301<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(49,890)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2009</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,270,074<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash, net of offering costs, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,182<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,182<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">194,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(8,420)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(8,420)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, value</a></td>
        <td class="nump">139<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">139<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,248<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">458<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">458<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2010</a></td>
        <td class="nump">6,771<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">65,080<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(58,310)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,472,422<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash, net of offering costs, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">557,890<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(5,364)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(5,364)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">188<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">308<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">308<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2011</a></td>
        <td class="nump">5,732<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">69,404<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(63,674)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,030,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash, net of offering costs, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,189<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,188<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">629,815<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(4,320)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,320)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">306<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">306<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Dec. 31, 2012</a></td>
        <td class="nump">2,907<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">70,898<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(67,994)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,660,315<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock for cash, net of offering costs, value</a></td>
        <td class="nump">1,421<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,421<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock for cash, net of offering costs, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">521,066<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(1,071)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,071)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, for cash, shares</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">42<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">42<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AdjustmentForFractionalShares', window );">Adjustment for fractional shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(64)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants for cash, value</a></td>
        <td class="nump">12<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants for cash, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,245<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, value at Mar. 31, 2013</a></td>
        <td class="nump">$ 3,311<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 72,373<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (69,065)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Mar. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,185,562<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AdjustmentForFractionalShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment for fractional shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AdjustmentForFractionalShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount recorded to additional Paid in Capital account as a result of the conversion of warrants for preferred stock to outstanding common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment to additional paid in capital estimated fair value of warrants issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The adjustment to additional paid in capital to record the release of restriction agreements on stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_StockIssuedDuringPeriodSharesWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares warrants exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_StockIssuedDuringPeriodSharesWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_StockIssuedDuringPeriodValueWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value warrants exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_StockIssuedDuringPeriodValueWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A91<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 39<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 4110<br><br> -Paragraph 1, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Warrant<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 14<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656322&amp;loc=d3e4724-112606<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of stock dividends for preferred shareholders declared by an entity during the period. This element includes paid and unpaid dividends declared during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 14<br><br> -Subparagraph l<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 405<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DividendsPreferredStockStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 53<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 25<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418455&amp;loc=d3e16649-113920<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 25<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418455&amp;loc=d3e16649-113920<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Merger with Nuvelo, Inc. on January 27, 2009<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger with Nuvelo, Inc. on January 27, 2009</a></td>
        <td class="text"><div>
			<p style="margin:13.5pt 0pt 0pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(3) Merger with </font><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">, Inc. on January</font><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">27, 2009 </font></p>
			<p style="margin:4.5pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">On January</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">27, 2009, ARCA Colorado, Inc. (ARCA Colorado) completed the Merger with </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt"> in accordance with the terms of the Merger Agreement, in which a wholly-owned subsidiary of </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt"> merged with and into ARCA Colorado, with ARCA Colorado continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt">. Immediately following the Merger, the Company changed its name from </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt">, Inc. to ARCA </font><font style="font-family:'Times New Roman'; font-size:10pt">biopharma</font><font style="font-family:'Times New Roman'; font-size:10pt">, Inc., and its common stock began trading on the </font><font style="font-family:'Times New Roman'; font-size:10pt">Nasdaq</font><font style="font-family:'Times New Roman'; font-size:10pt"> Global Market under the symbol </font><font style="font-family:'Times New Roman'; font-size:10pt">&#8220;</font><font style="font-family:'Times New Roman'; font-size:10pt">ABIO</font><font style="font-family:'Times New Roman'; font-size:10pt">&#8221;</font><font style="font-family:'Times New Roman'; font-size:10pt"> on January</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">28, 2009. On March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">7, 2011, the listing of the Company&#8217;s common stock was transferred from the </font><font style="font-family:'Times New Roman'; font-size:10pt">Nasdaq</font><font style="font-family:'Times New Roman'; font-size:10pt"> Global Market to the </font><font style="font-family:'Times New Roman'; font-size:10pt">Nasdaq</font><font style="font-family:'Times New Roman'; font-size:10pt"> Capital Market. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The Merger was treated as a reverse merger and accounted for as a business combination using the acquisition method of accounting in accordance with ASC 805. For accounting purposes, ARCA Colorado was considered to have acquired </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt"> in the Merger, as the stockholders of ARCA Colorado prior to the Merger had a controlling interest in the combined company and the </font><font style="font-family:'Times New Roman'; font-size:10pt">Company&#8217;s </font><font style="font-family:'Times New Roman'; font-size:10pt">management is the former management of ARCA Colorado. The results of operations and cash flows include the activities of </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt"> since the date of the Merger. Pursuant to the rules and regulations of the United States Securities and Exchange Commission, or the SEC, the historical financial statements of ARCA Colorado replaced the historical financial statements of </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt">, and the disclosures in this report relating to the pre-Merger business of the Company, unless noted as being the business of </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt"> prior to the Merger, pertain to the business of ARCA Colorado prior to the Merger. </font></p>
			<p style="margin:9pt 0pt 0pt"><font style="font-family:'Times New Roman'; font-size:10pt">The estimated total acquisition consideration of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">11.9</font><font style="font-family:'Times New Roman'; font-size:10pt"> million to acquire </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt"> was based on the market capitalization of </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt"> as of January</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">27, 2009 and the estimated fair values of its vested stock options and warrants outstanding on that date, as this was deemed the most reliable measure of the consideration effectively transferred to acquire </font><font style="font-family:'Times New Roman'; font-size:10pt">Nuvelo</font><font style="font-family:'Times New Roman'; font-size:10pt"> on that date.</font><font style="font-family:'Times New Roman'; font-size:10pt"> </font><font style="font-family:'Times New Roman'; font-size:10pt">The Company estimated the net assets acquired in the Merger to be $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">37.2</font><font style="font-family:'Times New Roman'; font-size:10pt"> million, including $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">45.5</font><font style="font-family:'Times New Roman'; font-size:10pt"> million of cash, cash equivalents and marketable securities. In accordance with ASC 805, any excess of fair value of net assets acquired in a business combination over the acquisition consideration results in a gain on bargain purchase, and as a result, the Company recorded a gain on bargain purchase of $</font><font style="font-family:'Times New Roman'; font-size:10pt; ">25.3</font><font style="font-family:'Times New Roman'; font-size:10pt"> million</font><font style="font-family:'Times New Roman'; font-size:10pt">. </font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1392-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4926-128472<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1490-128463<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7008-128479<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e7000-128479<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1524-128463<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1383-128463<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1486-128463<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1500-128463<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 67-73<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4934-128472<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph F4<br><br> -Subparagraph e<br><br> -Appendix F<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7659399&amp;loc=d3e1497-128463<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4922-128472<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 88-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51, 52<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6996-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">135 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PropertyAndEquipmentTextualAbstract', window );"><strong>Property and Equipment (Textual) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="nump">$ 10,000<span></span></td>
        <td class="nump">$ 14,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DepreciationAndAmortizationExpenseSinceInception', window );">Depreciation and amortization expense since inception</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,800,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DepreciationAndAmortizationExpenseSinceInception">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Depreciation and amortization expense since inception.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_DepreciationAndAmortizationExpenseSinceInception</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PropertyAndEquipmentTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>abio_PropertyAndEquipmentTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>abio_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>45
<FILENAME>0001564590-13-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-13-000015-xbrl.zip
M4$L#!!0````(`.:*K4)H$/@Y]94``(":"``1`!P`86)I;RTR,#$S,#,S,2YX
M;6Q55`D``\!9D5'`69%1=7@+``$$)0X```0Y`0``[;WYDZ/(=BC\LQWA_X';
M?G;,Q*=2`]I[EA?555US^[E[NEQ5X^OW'(X;"%(E9A!H6&KQ7_^=DPD($$*`
M2`04X^N9DL22>?8MS_GQ?[]L#.&)V(YNF3^]DX;B.X&8JJ7IYN-/[SSG0G%4
M77\G.*YB:HIAF>2G=Z_$>?>_?_ZG?_SQ+Q<7PMW=M7"INOH3N=8=U;`<SR;?
MW7_]7OC/CW=?A,\FWJ@2X=I2O0TQ7>%"6+ON]L/[]\_/S\.5;L*ONF(,;5L;
MJM;FO7!Q$3SYRB:*"ZL2KA67"/2?#X(L2J,+<7(AC1YD\<-D\F&\&(Y&\X4D
MB_^?*'X0Q<@#_H/M2HC\\T&`'<+_3<>1ZVX5]0_ED0B?KR/7B9^NQ$OI<CJ;
MW5Q-)K/QU=7'^2?Y^O):GEQ=?AI?7XCPST*<32=C^%,:B=$G7EG;5UM_7+O"
M=^KW=,W"W1#_=VV9)C$,\BK\JW!OF0Y<N=DJYNM0N#0,X0YO<80[XA#[B6A#
M_XDO2]L0`$VF\].["/#PZZ%E/[Z717'T7O<A_8Y=^0%_-3*N-W3SCZ7B[*['
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M5CW;!K%XB!C]7U-N-!5===+OHC^E+,[1U0.;T=64RSW7/LB)B_?PZSN0(8)`
MI8CQP:&\=D=6`F7I#XBHG]XY^F9K(./1[X"8$>GYA`>]8VV3U4_OD`,N`KH?
MOCA:"=F27VR]9]OR3-T5=.VG=[_]W0'N`]5$OX=?-D1!9?0S^_K']\%G>MM[
MO&_O";[<^NW^>N\I_D\?X+>"C_H[[D!/+$[3GW2-^)_\.W]%1E9<RPZ_SO-^
M>M7[]/OI8Z^):6U`T1YX<!IX=L_<O_G']Y&U']@\4L(M*&]0^/OXP!\_!+_F
M@B40L?/GRMU[$GS_`7_(]1"*A2U<M/<8_+(H3G$3O\$O#40HA2^NK0*<JI;I
MDA>V_ZN_[TR>OU,VET3I[Z&>"QX%6-7=U]TKX;'PS4HGMD"%3URN!++MZO._
MO?MY]_P?W^]N"]<8>_*/6U!ZEK9[#Q@/MHNFXL_,1D0Q^>/[W;?AA<34(I>-
M0)3BH[7(13^^CSS\Q_<^$/)`9"*)9P<$LZ/<GT-36?SQ??#=J?MK`J+C^V/X
MJV9_LB0W:W_R!?ROPOT%'"LW`I$QCI7S<:Q<*<>",04BN#FD'84(@`/Q/ZM3
MAODNPKT+ST%O_=.?'JP6?51P_$%;7[[H3G#1I:;IZ)XKQJVB:Y_-*V6KNXKQ
ME6R6Q`Y@.\<_1K6P%8*//.*JHTJ1^11@\&\-7=5=MCI!T^$Z%O'P=_,A<\_O
M?@XNR]SUC^]37Q=1O_$5EB"'^1%R`%KP149U#%(C$IL.D2(,`M]N+//>M=0_
M.LX4>SOM&B/D0CO:W==DA=N]5%5OXQEPM7;MV;KY>$V>B&%M\5YXR"/I*$%0
MUZ,8#-XDJ>15H5V@B;-HSIT-O4-N!38T1SG0!50W@/TY(;XQ!M`Y"3O+KND"
M^=9FSC0`B4=5S]B/%8CC#F'V?-[;.%=X`RZKU'NK&8E-ATB20:X,Q7&^K2BG
MAZK[2G'6OQ+WV^K;:D50<5U9CNOXC%&$Q>[A;N)<=IRE8KL\QD*EWI_$DF]G
M9.&I:ZQ\#L+]^"8(]V-/N-TAW%3+M)/$6]A$[0FX#03<6^6%K?*>L!M-V.6"
M89TB<PY1L9[HST7T[27.'OV]Q&I/'+\5I)+;:NL`39P[C3=N1QJO"ZAN`/MS
M0GQC(N'G).S,8$D'R/<<:;QS(?&HZID$=LFD0Y@]7QIODL\2F52;QJL9B4V'
MR,E2KI-,46\19@/0GNJ\W^BVXWYV'`]/$M]8]J^62YQ;Y559&N32U.X(-67`
MJK$]`I+#)39Q7!Z1VD[26&,BM2>@N6>+@FS17F+NB>?LQ-/KZL:E;WOR/X'\
M_1\!;`@9PR"JZX$VM"UXN_OZ15<!&X3U<>FMBE9;%84QW3-'<>9H+TGW)-00
M$NHMC&9;&#T3Y&&">P+W:[V1W146.`6?/0/TD;O.VM@]8]3)&.TEYYY\&D`^
M'`ME6DJ6K2SQ[9FFEMJOGJ3?(*GDMBH[0!/GK@&=M*,&M`NH;@#[<T)\8\JH
MSDG8F<&@#I#O.6I`>2(QAVE_YLSD-#!^IATBGX9&39H54I_FL\RFY_5\2^4F
M6TK4/1$UAHA.UL8M)<'6I&9Z-BB3HZ>]<ZXL\PF`I"\-<D<T0C883KJUR8K8
M-M&B='Q2VZQ.<L#9VF:=ALDW2?P/:]VN(S/94SY7RC\!C5TG^][S:\X1PS.0
M0_U(;#I$>K/]_$<,&X#VX^9`'W5KF.SE9C'TCF(-S-%>DNY)J"$DU*ONQD7<
M>B8H'G"S/-M=]U;&&[`R3D1USQZ]G=$34=-E;&]I]+*TJ6R@KWHNZ!87G(31
M-\D$>T4!?8:[K7F^$U'Y1LD?853YQ+.>L*LE[`-(ZCK)]C17B.8ZB>YR1W$Z
M10P-.)/3"E(Y*!DZ0`.U"(3(H9;IF4XF'8])=PB9YSI/63MR2PKQ#J"Z`;*;
M$^(;4S/6`*F5'M_J`/F>XSPE3R3F*CR@*O8CSQA09,;R++!49QTBE[/-6#X1
ME5S-YED^LWG6C!!H3_]MI/]3<=EU!NA)LQ!IMAW=J?(.3_H0=+L"]J@BXMUA
M6CE#Q/L`BGIR+4FN1Z,JG23?QE3Z]>1\G)S;2X0]THLC_6/O.C3-=3B$HYY@
MRQ)LKW6;I75[@DXAZ/:288_V'+$]_:4QIXE:2F8MD7:G8;IGCE)GB5I*TCT)
M-82$3LXQMY0`&WR&HF>"$@G$)_BI-S/>A)EQ(JY[!NE-C9Z,6B!G>W.CEZ=-
M980=M"*X`YCA)V*KNF+TU-\*ZB^%R*Z3?&_]-J<IZQG(H7XD-ATB!77"_5JQ
MB?-@?7HAJN?J3^3>6_X.BO3!NB-;SU;7BD-ZE=!\E9`?CUT3`3U9GK\+<5/1
M7NXH7:<(H@%GZEI!*@=KE3M``W6?AYZ=Z63A?K%&YY#'J3ZC`<@[[JUU")GG
M.LQ>.W)+:N`.H+H!BI<3XAOC:S=`:J5[%!T@WW,<9N>)Q/I.M\T#]V'>(3)X
M4Z?;YOE\E/G9ZY)YE(1TDGP;4Q+2DW.NTVTM)<(>Z6<ZW=92>NE/M[T1@NVU
M;K.T;D_0Z:?;6DJ&/=I[2=2<>.NYR:%^)#8=(B=']#K)%/76"#05[>4R%)TB
MB`:D*EI!*@<COAV@@;IK!.9-J1'H'O+XUPB<"WG'C=<.(?-<-0*U([>D!NX`
MJAN@>#DAOC&N1P.D5KI'T0'R/4>-`$\DIH;+V.984VB$3E6G(1:!![%XRY10
M9;@O'5-</95%/D]ET90NW9TDNOIBNPU']U'SN)/H/U]L]PSD4#\2FPZ1\Q7Z
M=9*;WE2A7Y?)M5<&S2HYZ,DYK="OI438(_U,A7XMI9>^T.^-$&RO=9NE=7N"
M3B_T:RD9]FBO)6#=N[I]H+IEQ-I^V=90&[$GUBJ)M;</SVH?]L1\C)C;2X(]
MRH^A_%?+!7O'U.X(+3-"J]DC&C9/MHGC]M*L;=(L#SY[0C]$Z.TESYX<SBSW
M^H*N7KXUH-ZG)\.WA?9RA?*=(H@&5,RW@E0R)40'Z.`<I>>+IIYZZA)"SW7J
MJ7;DEA3F'4!U`V0X)\0WIBBW)L).#RPJSOI7XGY;?5NM"*+TRG*X3*^41-^R
M@7^WGRL:%UW*PB-/FTH2<]E4<%G=$?,LPFXO.?;HKUFNI1GE;26>!D>/WC(!
M]VJU,:?$SD$.]2.QZ1#IY?/9PZJ-17LI3[Q;!-$`E[P5I)(I(3I`!V<(J^Z0
MV+"P:J<0>J:P:OW(+2G,.X#J!LAP3HAOC!5;$V&?(?P@!=:,U`%.>-OA!RF?
M[22U-GYV5'%WDIC[O$`K";N]Y-BCOU>K#8@:-1SMO3*J-YI^!G*H'XE-APA'
M3[Q3[-(`E[P5I)*I0CM`!^<(JTI-#:MV":'G"JO6CMR2PKP#J&Z`#.>$^,:8
M,S41]AG"JG)@S<@=X(2W'5:5\]E.<J.B3Y4J[DX2<Q]6;25AMY<<>_3W:K4!
M8=6&H[U71O6&5<]`#O4CL>D0X>B)=XI=&N"2MX)4,E5H!^C@'&%5N:EAU2XA
M]%QAU=J16U*8=P#5#9#A;>#J4:"W1^*H]3@_OYD[RJ>IX;)18S1U)TF@7F>W
MJ6@O)_X[11`-T`.M()5L"=%^.CB'+1\BL7E:OSL(/9<M7SMRRPKS]J.Z`3*\
M)L377T(@=L'9>W.5`Y'^:SQ=RS.0XUA<C,2>'%M+CN,+<7$Q$KM"CA/PA48]
M.;:6'"?4W1K51XXWNNVXGQW'4TR5W%@V[3%_J[PJ2X-P'Q'04VM%U'H"%CM+
MS/Z/``W<L&$0U?7`Z;(M>+O[^D57`<CD3G]<5RA])5$:]_1<,3T71B17DL9.
M%^/Z2/J>P/W:&6EZ*LIR[V]50-,G8I(C44\OP"N3:W3)'M:Z?6Z:EGN:/IVF
M3T,D=Y*6:S0]+,]VUV>EZ:G<V])5V!ZG89(O44\OY%KMZ=5Y:5J2Q%E/TU78
MTZ<@DBM)XR'\68WVM/YR5I*>B9(T[TFZ`G/Z)$1R).D91CVD>9TNXA/\=%ZB
MGO9)D&I\Q--0R9>LI[4F2I(Q('@-<=C<<E=?&N2.:(1L,,)Y:Y,5L6VB1<FR
M"%&S9U]VTT&,;>Z<0;QB".R2<QASDSDF67HZYA[D:$QRI78BWHM?UBJ0)5GL
MBME\-D(^$8-\W4#Y0JS19DX&+BDD/O(DYH]1<WG2F1*VV.;.&7HNB$&^EO*D
MU@JW=+ZNC9HE6>Z6:#X#-9^*0J[D#+)9KDDV^Q>D4BFL19)D:=:^,O%]I`>7
MU('+Z'D>D3:4DV;G/,]S".E=.NUW&.-O[J1?$71WC\%K1?<YN)LV4ZD#5X6.
MKU=^Y.5.,1])E'R_ZJ:^\39ME53A?G:D&MM11Z72/AJ5EZZA,;JCCJ+Q1C?!
M3M;-QYU#_VS]/V);WTSRL+8)869^>)G35OS&-AIXOGFVVC7$4X3)HO_'2.1?
M9ET4(J!TQKD@@I=5`A'X2Y+YU\<4\!472!AR->4<;'^45QNRT9BIM<C%`SN(
M5"C\%-W^#\7PR,?72\<AS/B,Z33+)*]?%?L/XMYXIA83?FV0>8?V%]%QJ3ML
MUR'J((U_:\#S+DT-Y3@]%O[Q]>%U2Q*NTM9SB1U>TE9UEF//,=<I;===TVS%
MR>%MD4&/_@3Z;SS;U%W/QN3SC?Z"?[76OBU$"8<WWA-%("SOK97[K-CDLPEJ
MZA$3!U2'O@GZR`6#GE2^$,4A:\O0/F^VMO5$`YAO0X!D[+PGBTPCLVN44)-M
MV08/HA4-E1J.7`Y-C4[U![K&L6^%4]\$A[X5SCSFJG6-2>OST!K#K]DH[A[K
MG@7%Y^7B`KYUUQCZ+"YU8W@[-^*[Q^;G1OQY.?YHB*1K?%YC9*0QW'T$R=WC
MZ?,@N4I.ED5Q+M9Q$JQ`S<.<EGY44Q^/$[_%:0T]!`N-(,?C6=6TO*/XF[&:
M#OBC`56CL9H.0.4L1TT'O:RRNJ:&`").T;.*Q7+9@KV@F%PQ2'CGK:T_`=0_
MFT_$<5$F?39OO25(+?:,!ULQ'47%&0NQI$8+#D+[N_3K_(KNL\KS2HVI.XQ;
M"U+%)YX;0)9!KJVGSU;29\D\'R/DZO)\UV0)X'=<V\.U1ZW<ORDV("+13:*G
M^T806TN9;Y_8=CY&C-PZRFQ5<L\=>=0=;!FB7>LV4=U@W$",5YKOAS:11;)!
MR]M0::[]G(OD0O'<TU[S::^T7*SO5!;\KR?1`R1Z$#8]@59+H&>TDM\61;=1
MZ';;`CX/([4E5W8V?/)-AA64=WD.Q[<`F:>>B>\)YW3"V6^.T5+"*=(3HR><
M[3V@3_,,\FWU:;,UK%="[HG]I*OD?JW8Y*/B$`TK2P`:"L:F+@W#4NE?WU9W
M1+4>3?U_B'9+7T\'+GY\O2-;RW:_Z&:,P.Z(0Q1;75^"2ML-5/[T@D\FJ395
M"^B/-_!V%)8#?`VQ7"IO2U43@=X3PP#3\Q=B$ELQ`,Z7V@9D"3`\/.V)^*!N
M[;&K^DBU$"![HCU5JH)"4ETZJ/X*GOW84V@N87H`:CTYUJ'DY8`NZ^E#UR:Z
M/*N2E_,1J-Q>`BVLY'M2;;J2[S[19BOYGD(;I>3?!#GF4/)M:PS\5I3\.?N)
M-U3)]Z3:="7_!H@V4\GW%-HH)<^1'#6B?_A$%\)RXYA6^%79$$J?-Y0^1?&=
MX-]S1U9I77?C49_+NZM+X:-N;0$\&V4@?#;5X8_O#[THN8PK``LP_V=3(R__
M1EZCZY"*K2-*<0>?OWO]M:723`N>BHN^52[V5DF\^'?VON@#=Z^YA*\T_/K&
M4!ZC[QD5>\]*,1S"7A1[Y/Z&&&%_8B01?>.XV!NC!';P^?NOO]$=53'813?P
MG1-=PJ38$OX]\>J]9Q]Z_?\%$VCOY=/B^T][??CLW<NO/-N._9X"_5FQMU\$
MAR2SGI]DIAO=(/85_/!HV3%6FA=[^?U&,>!)`A.+(/H$E*>*^1KEK-C+]MAZ
M-^6""F7GF^=B2E'#AT46MCBVL(D$XD@CJ@Y+<GYZ]_G7FW>"9^KL\M_^[M"'
MO_MY),TGDZD<X_R,);#EAD?;%0?-9?P/EB@]*0;!05#NE6+;KW`U[3T<6;5T
M5$(B%".KOAC%%JT[UACT[6_WU[#PR6@&-__XOM!B3ES_$<G*#CKG6[^\D,53
MU__-71.;=A%P?$J/+O:H0,X/[/%D&EOK_HN++.R(!"\"14F>%%K8P34=E?$%
M*'.Q&,46568]1P1^$1B-Q/$D[WH.GH+_E<26=U0EY`>7+,<6E[6"<FL]HD`*
M,>VHY%HC=/FK9:K[^#ZJ:/(#5)+'AWAB]^Z"RSNB;@JQ[+CP\MBOD?7(%2J2
ML31:I+#'L154J`I&</'Q%:BJY8%"\,<E[XL,N4)Y/YK%=6OZRXLNL$*Y/YT4
M7E_@\OI3IK_HRE(W=!?G]NXOM4)U,(VK^:/+.&'5%2H-21R=LFS*U-F+K5"%
MC.;QQ1YX>^$E5J@YX.+B2[SV1UK>P2]7\%_=35EDA9IC'EOBP;>76&25^F-:
M9I69B!Y5J$[F<AR*QW"<O;`JM8PX*;NPZ(HJU#(9H,JUE`KU209P$BXC.,<Z
M/2;NH+,&KP?7C)AJ8FF@/UX<_8.I&S^]<VV/Y`):^MJ$]Z56,"FT`A]6^5?@
M!PB2'O*H2JD>=X\3+\V_I`JE>)$E76H@BW3+5(Q;1=<^FU?*5G<5([JR"D7W
M3![-$EYG^OL++[)"T3T3YXMY\47>$5?13:)]4FP3C[^!M>=M/&J'@/3''$)D
MO>,*9?G%="$F+,WC:SEE[16*^XOI;+$8G[1V2MG8Y8[8#CN"&%UKE>[&2(I;
M1_MO+K*R"O6"#+<56EE$<8!TSEYGA4[&GA-[;!WE5UUE9"KI^!9;=43^WBKV
M-YL.D=:H*+XE-HU=1Q=>5#4E0^:[E?\=4YAZ$$(7AR+6%158U4G;**K.SK`-
MEC:X]-RU96/*.+K\PCIOFIJW0'DAQCWKC`646FEAQ5?#2C\[CA=;Y:2HNCN:
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M;('9JK4<^B5,R(Y*+?&SJ5H;\L5R8HLL5O*6,R)S&,^[111:Y3%7L`RN+PXC
MN^0JL]5@.81?9&$\N4[:TNH713?QJV\F"`']T62BX19DL.G>Z8_KN(+@H?#D
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MV=&3`Y6(E-CK\ZUL?B2471%;EED9#W,C);F<L;1;VZ]SHN'92U6U27`P3R.;
M+?Y]K3MJPN:;\_"UY40Y>8&E9>WI6G_"\XZ:$YA;E]KOWKZ8F6<;+.6V-$MP
M6/Z591#0Y9.B&UB.^F!%(NM^/O.CXNAJ=%L\(N5'V/+X`BO;'8]X^A'6KG%W
M/*+N%["U187("XH^@N0MO00#^+KAN;&,W;QT!%[.E6B^$(>C2-;IR,)*[Z)T
M]#WW+J:+DKOX&T$''WS?)S!9'LFO'IZ`_K:B-T9R;AF;*ZW$#^8MQ=%X-AWM
M-E1NC17O<U':)#B8]!3EV4R:5KM/RGHL^WQ-`^;LI"TMEOB5/--?HCILD65/
M^`^E]18TK49M4SQ':IFTZ#/2G.!`^5R\/\$<_Q@5JOW?JW@ZMKD3X9'#3&G,
M+EAJ/'4;6:9)$;1&!'H>5!ZD]<E\?A0"B>WD,X@76=9*KIUB#-0O.HR6(=*%
M17+*\)!'<B(Y7TB)(P,E/(!%CJP%UX5EUN0ML@R02N7)B0Q8MJ1SD662<*2W
MD[!YVHZ/A!(*KFQ2;&49Y4>++-/C9"%75K9EERL5U$=29B>72OEI[!LPXKA0
M&7V]^EDZTE&F6;LXJ)\E;%&3]TQ,$LM7AN(X8!;2$$<@4+!7`\CL;ZM@/@ZM
MYDC,+LI#)_=P-W$N#]/%/@<D#^44A\:HV=#X6"\TBE@T?+>?*A@/L]@A"2DM
M9O)Q!LLT_XI#L<"ILWJ!6E@2\Z"Q:>.@4\XLJ@-6LSIA56I/!WP%*;-I5(U8
MR6<;3J13$S?2D694_!>694E+F4VGJA4A!;8WW[=^2KH*4F97*I[T5N@THESL
M'%WVCH_$BXJM3%H46]EAYTC*;&UUN@V0VSF21R(_[RBS5U:E##4)!,>D`7&_
MP_`X$AMJU"X.:]S,GEXGT^YA(!PDXH4L<S%?#R.R2)0IU<BXT6W'Q><JIDIN
M+/M7RR5!4Z)+4_-K_C%%#FL*JE%X6+.-HKG#`"]B*54.\*:!*8,UB\3<SDJ8
ME?'^[,3,15%2S.PH5QS$_H\`:02F81#5]8!9_7Z!7W05Z[98F7=CV#_1EZ\&
M_L]LHE<'T!L'JL,R(+.]7],(M"(QL!!'-4N!JF.B]P3NUYHB>/.U=RH,M)-#
MI[5!B9/=-)K4+SJSG`[^0&\@J#)$9Q'/I@5LG*<+A;B8U!S[EZN.V/('>KFX
M5X94+1@ISNS=6>,.\I;;3N*1LA*AXB.-0&M8669@,;,1:+6*IE#';+'"<'%F
M3U&>1%<$H[(XKZZ81CK2M+38TJ:S@LC(B!=GMC`]76_D51=341:GW.+%HXKM
MPS/[UM-`1$V+%+ND%&#Q-1!'%1N(I9SK9L'JL.V2V;:V<22:RNR'07VP0&0V
MFM4<8<_LQ5LJB$%+A:XL\PD`BQU>\,P9V:"%&#_#54515BEJ7HS2RD)YTW.U
M@?7&P/D0*4]F\FR$\^MX$3/][1L]R^A\>B&VJCO1@RI29I?D7`!_6.MV'1YF
M-50]3;8A*PJ[`@1^#/:9'9_;"OM#E#X&RQ@'7):'7'5$G]FN^OPVUZ@&"LT'
MIR/N1V-WEY/_N#HQQ5ED+DJ+>A@D3?5F=O4N+HW:Z.PD)A[5X.QD-B6O`^B-
M`]5AVS"S#WK3"+0J5V<$^ZO7U<GLTY[/!+<\VUVW61"D'3OC+`A.=WQ.A'KC
M8)4A"4XO*ZJ11"L2!?)$K#LSEMFC/Z<WOFH9F$<UUV]ECADH%\%K1L@CJ^.T
M*-9O/F1.2F@SH`]W1IF-Q?GT-'*.=(QZL`XHV\AS`^`D&I=+F;,?<@(?`5+Y
M>=52]'NQ-PRL/)!*@!OQM50<[,&^P3YZ"FO+SCJT$]CB$XA2AEN_72U>D!@O
M)V6.N#B_"9:<;<P9,.=#PY%#&!T%7@Z14=6QCFIX7IJ=D^5S@.OD3B-<V?FB
M\?`[TK>D8;L^5*>4.?&$8Y%,.?!,Y/')AWB/S43AO[+,$I[,J2>GB;%"E5B+
MHJ=%,S=5Q)8^3=@4BD3,4Y(+I?=X<G:@)"<5(=/9J,KCR4=FL!3DH%G:89.2
M]6:9PU>JY:*#9SID^&<RRU]MEK4=KD=6\T>715D<%]A1P=!&YIB74@%[UE^'
MI\<=:=XS"Q3'K$C5S#E"&YF3:MH,Z(.AC2D.QJNY!BQSMLX)`:3S@[EI])PY
M\:?5D#X8W)]-I]/9B9F^BCRAS!E%]5/@A31NN.N8.2PI%[E&9@\PH%41VBP%
M;:E$Y*A66)\<2*X"UD?=EI*4WG3@GUPB=`CXW079R04^>R#[>#9C0#IKVB,'
ML$^N$*H$V+RD0].A?[*[=Q#ZS8-94><A<\)6/I-6?VE,454YZ9&_\K<BCRUS
M9%@=0&\<J`[[7)E#S)I&H*EAK^)>%TZ9J3>&D#F0+:=G^P0_M5H0U-X&/G.:
M7#U0;QJL,@1!!:4Z-9)H1:)@.N833<R`\\G.U`[`$2``F/$3'@E1C(8`5Y[-
M3Y2S-1;D9([\.[_PG(C%+=HVUD4=FTW8/N`5EQ`G.U01$4S?\F!]>B&JY^I/
MY-Y;_@Z2^,&Z(UM_OOTY#;&%Q*>X/=<YQ\R1B^=G^0+G\%-W6B&@CG1!:N[V
M\IT(S1S;>`[%*<L5'ID^5$%U^E3'<I4N)4,ZH\4B7EA2HFCLV.#&&I:668E3
MV43&_:Q0L:JQ484-O$X?OG@PFEVHD'<^JV["GY0Y8+%:W5%(IH[D"O=X<KE2
M20%1J/.:-)*KQ&OV,.FB6:KIO+IA'9DC%JL5#G44PU4VF/&X6#CL_4\FD]FB
MBNW(E<U@3+<A<IO4LKR0\B.HFAR0G#EP\7RE$/-`G<\+<*U<PEFL,=\FBXTH
M.SFJMDK!_J+QP.=6A])=D%5?/5))*40I:(^F#0=V,^I..$F'QD.?7R%*2V%6
M25!8%FL[Y%@*QI/QI#B,6QB<ES,GA787>G]3;%LQ7<8147!4Y<'P(<O1HGB1
M9&RKU4$J<Z9I0_9W0H!</GVD*6<!U9!,@GQL$FISMY<KDR#S':AZ&#J'3TQ)
MN=L,ET\ER*>/6"T7*2QG$DF+\>C4\^?RL2FJ-2PM*Y`I5S8>=3^J4BR5,*DN
ME2`7FGA:S!LLE$J`-U:XJ=K2T(7"8)-9P7/<F7L\4W^*0LPW%F>3ZM(G<N:(
MSL)NW%RJ;HZ+7&B0Y6G"H894@EQHUN1I8J&.5(+,UXC(G4J8P"NEHSM"QHS8
MWC>6?6,K*I-#[);HUDX.!K(]L1.]#KRDJNJE1:"O%WGA<P'$>WSS<;1?ZT^Z
M1DS-B9\^IO^*@JG:OA<?\VPSL]_(/&Z49&VCW(:KLE:.ZL!2`."__R-IYYI7
M75$\M-"\P/K2@J6`.8Y;!HV+/6=.*FQ.6K"<_&DZ\`O-82R:%NPHR*HO&:@D
M+5@*VHM1PX%=?<T`E[1@.5)O//2K+QHXV:+C!K.LZ.O.:L>S2V%/GGNBPI6N
M'O,43I_"68&G4(WI(!5J?'X42)S@?7+E0&7P/I6XI7G2\FTBO$^N%:C?$\Z,
M7#<>X"<?JZH`X)PTX&A$@X,-1\#)WN`!!)P$MKKIED6%HL_Z#587@]/)GER]
MFB]_A+<01"J"YNG3-NO5:_D#S&>!YLE>6X/BMQ-:5G\:1!,!X(/&\QUQ7%M7
M73_F=D<,HCCDQK8VP2]P3Q30M;7:+A=:9#5;E>Z>,T"SG+#F@:%JY7OZF$\Z
M9+C*Z<)\*',^$1MOBIX^_C,7,EH$PGT9>Q2&)_M/E1-T17I)&D_&T[QM$7*"
M/Z^$BC[.KY5T;BP[GC"*8J&VRNQ2E.P7OU>Z>\X`/5)BW3`PY)$0ERHKR\:Z
MPNA.:ZN>+A=$DA8%VO%%]W@R9#+G;S9T/TP:'=I05>5&%4G8\7@VE_-.2-P'
M1:&*ET+S)^OP>B0<H%"T;J7&0R:%9D:>P;YL_'&5JO!P9"I0"Z%WRLF%S(&-
MYR=+26K,&8_,"8[-WE^^0QZ5S5RLRF$0)[*44YN=B/M/FZUAO1(?Q,\FF(EK
M?7MK*-%02^9,Q?.S2DJ)=^'=5@VQ(PW6FKU/1EFY-IHYM?$<K)-[^,XQ&.5U
MKCXY+JS))=J-HML4^CLG:^_<9&53)#FYU[-9(<?R^-YYPO+(T<-&02`@R4.G
MS\XUI;)DL9&4Z"=7XKS=L2&5_%>6>=BGLDF5Z8*MB*6T+_;+GF"J;%[E<?%3
MY+CO;)06GRZ]R9.MN9*L5*B:=T$;R56VYV-1QB(YL+%4\-!<QM&G0L,63V>C
MPUW40*S/H@>G*QV1*I\^Z?!*<=8@J[ZMOJU6!-](2S$Y9.&`TYA@A7\7(`II
MGM_\K&;<@UQH@&%QH#80%`=[B,NGSR:LC,#2.#$#D@=9<H&3V<_6+%PN-(&P
M?H:31BF-1L\3_\D<%]CL_>6+_Q0:[E<#:\SE\;RZ\$^-(>9"@_OJYZGQI,08
MN3:&^C-'^+43>H?<R$(#^:JS]LN!\&).3_&=YCAG3L.K9669KDBA`73%A>EY
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M[<Q^9SF(%K&)JP(J][1W65#DS]A5Y'>."LU&JY#)#C9M`/EXZH3K^NSQ4:'I
M9O5SUT@L,<NHA7[1*'-D6CNA=\!+&!4:6%:A,5<*A!?CT<GYN%'FD+!:5I9E
M:8XJF[65+D(+$6Q5YO,H<W!5M8*M2&68.%]4-QQC=/HXJI*L5,@OFB5GI9_@
M?8PRYTI53ZP'O8_I%-8RX>5]C&H;+R6-`N$#MD"!(2]I$[CY6KU'!DDU;B.'
M;5:N(Z,RX'`PTP$PF.8]')\`0I&3\:/3AT95N_&+Z3C_P7AZ719Y!*=Z4I(Y
MH\S940W@9Q8>*K[%*D!SQ#IJVH88363NB*M!59S,Q_)XD@V+`WLZFSM4VX"L
M<M15IM-^&[W2S!E>K03>(1<M<W(71TNZ%`0O)'%6R<C`4653P0Y(JOQ[JM#U
MJVPV6`[AD7^#,WDTJW*3YSD.7(Q.IPMQ.BFVYPS7K]`DL=.)]>"`56D^F4R/
M%SQ2?1M]E6+_0=Q;FTDJ>E-T<\TN<Q2/>L8[Q/_]96D;>@`N<3B:^L9'-C!*
M0:TY98VI4!N+"QP4U#2H\:U;/!EJV(QTU#RHG5SA>*/;CAL,4@$_D[8CO55>
ME:5!N'<E;2A03\ZRQX#J_PBP1?`9!E%=#[2W;6V)[;Y^@368#KG3']<5$BL8
M<.,R<!W/A_,Q-\">/I_L'@QI4SLC9*=L:FT)R`Y',C_`GIQ\?UCK]KGA*C</
MKB>?7[^Q/-M=GQ6P4[F4B)T,QR(_P)X\B^Q&7YT7KI*$.<JFP?7D_OKW^LM9
MX3H3)0RT%8>K)`[%.3_`GNP*W8/[:IX9M--RAC^`=EZ$9@,G--ZJ^U:QO]ET
M]2S,G0;EDUVGI.5%)]Y$.M+?$8V0#1JW\<55,9NHM`Z3AE,YVFH_']Q.A?7)
M#E?,9N#H.K0=T"?[:'M6;ZU4+<EB.8%\%F"?[+LE+6$V,XLGL#]&1?2D7$1+
M'HY'BYIA??I,LW3"K@W8$AT-7QS8HZ$\&9T&[&NRM>&]-&<$LO)R8\%^_T>)
M3XL:9<XY*YV&CE?H9:RDU)*/5,3LZ@H+5<1P7?*1F5R2!.LH#.79HB2<65[G
MWW0SU)G1M1[I/UIJK;(4S]SMKR`E(?(QF?J,KC++6JXH1YN^B*(+S5T%6V"A
M"XG#0K-/7I7$^W0D%EYJPH$!4HX,Y_&SWLXW&^2]OHEFLX^-%"JU@Z#Q<:G%
M)4H8@N'FGUYPYS%%=Z0O>CD!,4G4'"3>GX#Z9JOH-JJX;ZLOEOGX17\"T]IQ
MB.O\E1@:[.ZWV)*/#>\IMV0YGCC-M:B(M_TW6W<!-:MOJVM?8SXH+U]T^,V(
M)Y(S)_64IG;9G[*;8RUQX#-'5XD--/M%T<U$O4;FC)W3>'0'\ZRUQ%<=?/O-
MO%<,V&H06\!F\=10HJGTZ/IYZ,&+>7S]^585W\DW=TW`NS15Q5FSDI)]'CTV
M)Z;<XN5I7+X<7$F"6TW@91"CUX3]][-);[SR@,Y,EW%(=.T\U*4T28C&'&LZ
M;1<\=.E,KGD3//0LD%&"BRO;QS=@'E#2YN/^3K+U;<DJK\3QGGRK.G4G1RK^
M2A'667:2.7>D-'7-P(SEL!<P2"P/+"<_HA?=!@^W="0=8_7$@DY8/P\?]4(:
MC6O;`!=-+<VE8U*JX`[B9!=85[$)NJ,C$S7*$5/B_'N!E56RI2/ZO"1]38M)
MK*HW=62>6DF:6TBC7*JQS+8"R_X*W-K'^&:.-#(IIQR/$5UB/2<L_XAN+T=@
M]2V?AS]]TNI_)2Z6#X(S\J1K1/OX"HZK!I07:DS5U9^2')$Y/J,T$<WV.TOE
M7%H56SJBV<M*KLGTC'OBX99?+.;2?%+)IO`F.MT7B//&MC:12;_17?!0^7#M
M(FYU92PFQ2<',R`X),/N^>@YNDG`O(PA@(=K+DGS.$T=6U`RR)ZX,!:'N#2U
MM`!)YL2%L@P?;T^3?UU5[(>'2I?F">.K])9L2R5$<Y`,,58$5WY57`QYO7Y;
MI87!HCOCX<9+$]!<\:T576+V#A/1L$-8XQ)(3XQ)*+"T8WOZ;+J*^8C)W#U_
M^,A0@)(14U$4C^PEN:1<6N:S^42<@UHF<X!`:6,@3F[Y%U;%AGC$X,<3<9Q+
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M$0^83*>)*L&R>Z+!45/#_Z`[]P2.'>9":8N?9,)AMZMQ9K_QLJ0W3<Q3*K*V
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M'Y,"NG8L0]>"(U2WP+UP`_WX;>5;;XH1!DR<:]U1#<OQ;$S,W>N/IK[25<Q>
ML2HV[#0*SU/!SGN`77XT8I&T<69'Y'U"^OE?#?<'37_ZUT?WAW_ZQW_XAW_`
MSUO!<5\-\M.[C6(_ZN:'Q=851/;_/PA;Y9%<+$'%_W&AK$`6?5">+%U[AP_`
M>U?P[N!V_/MBI6QTX_7#ORI;R_GA0=^`Z?PK>1;NK(UBLB]_$.B%COX_Y(-$
MWT$_/Q/L(_!A:1GLZ=])WPL/:R+@(1_%?!444Q/NO0VL\56P5D($4L(.5$(`
M*P$7]QX?'*ST_39ST^/A9+=M09*'\KEV'UR!C_V`;1-UE;[PFCBJK=.YD`B`
MH&C@I(U6N1/ZK,N[J\M]V%?U=&#([5JQ-PJW-PP$,&R'`\&R!3="?/`1=S80
M%.&:&,HSGC%6+7MKV92Q!X+N"&NB:']ZBHT*&PP<4_AH6]9FI1-#&\"##+A6
MLR@9P\6*$.Y%)9X+=&S``]G+MD&DP7B%):H>]D@&G&NLM212^2,Q";W'>+UP
ML5(,3`%<KZULD?97L%Q5L37=>E(<U3,46]!T!ZUT9QCEJ7]5-ML?_GD.<N\'
M1S!@^?!J2_-4%^XV-91A9,`/F;\0$Q9I5?W\"?(4#9L!?"Z`>Q[-#XZW)39]
MZ<-7;OL1ON-']QYX_!J0D,%O]>M7S;;4-9"IKI'OD=)]\H37/C):0X7Y)_@]
M2^(J%TO41,2F!`UOU`2@-4O3#<6U;,H/2X*DZE,MT.?*YRD7Q"EM6TQOQ6^V
M-FT[XPLVQ;5!00HK?6GKAN'S%S+@S0"Y:@O?H-X4GL%N1*:S76&EZ`8H4'K9
M7V]B-"ZL%;02\?'`BAHRV0;>XW,0+-IFIYT=?#8N)L$XSJL#BAI^4<#N<&%3
MA@Z+Q:N!S\'Z8\O@SB013N5'`A&$,WV[45`:@6D.^_3A+H`]L[7P6)MKM4XV
M[+8:$N$^L2P)`?I`7P7(!79-B<TGCM^&]Z`</GE89C2@(+)0[`J_>[;N()@H
M)2&E;XB[MC0'"9J^"WGA\H;>\M>;!!&W%XRTM;@0X2>7%<0,A.>UKJYC'/,,
MW(P*!L.90%E8=R:0%]4`.^8)G5%?/@!E>5B:"8!K+UQ`.H"J=U&I.JX@B_(T
M2D',",!+X)<)_L(H:@C&AZ#XO;,',0,DA"(31*V&#5@_6Z0#HJ&6:>]&F&Q@
M=+TD`F"(5NM10O9_`QVQ`2*'OQW4;B&[6!Y8:.P<I:`:NDGM/Z;WMH8"(H2R
MSP`1[4NB@2^,,]FGO;`,N&&!*APGU(;\<D^Y)6"0HM[.E+.OPU&TQCB^O9A%
ME;JUD!N0NLD*?7;U%=$+A@7:M8^(\L`$I%J2:E:.NA\`RO/I(.#";2+3@FR(
M.&RP[4<V,2!N>C"^!RY`%<J>LG[=HGGAZ-3^4)*2HLT:<B#\85K/L"E'^.73
MKY\>/E]=(-Z9U>"F@47'T20`-F%+V'P#FZA$!]9&"PMN,.&CXV!T:.71"_8M
M.\Q4H5&GH)95MJ[^1,`_<<!#I-)SMQ!P=#2PZG:K80#7F=D/OVFX(L!KL"@-
M-Z((MVM,T\E+@)"G41JGFNY%W\`U@'H>X/Q!H`"519&KICOD<U'I;)"5*R#_
MVKH?;GAU``MJZ+O]]>;N$_AEUR1`GL6D.S@3GN$Z`0Y#^&VQ[U1@`S'@(R?!
M)Y.JVA?`J8^%`.HC'^C+5X&8MF48^!K`-!JD&X:B<"H)3T2,Y1H0,4R$1D&V
MZ&AR^-HB0LFJY8%OOB2/>\0X%<`1=M=`MQC9C(>[EJZB`]LY'LHQZO;Y3,5M
M:\.BFGW!4;,_6+#U+1(A"PE8J)D\("%M-]ZEY>)7-\%TI*Q((S`@94W87Y1P
MXLJ&^KKFHT69EYT6!%<W[J102]@DC"^YK=U6=(?P8S''6^(X&FJM1"2&3_^P
M7]OR'M?"UEL:X.]2TT5_0KU$6)+8W:4%'?Q9@54!M(`!50P^+763M4VC3H+M
MFL1VUOH67+]5#):@:S1B**\LE,P8$M\?K`-NATL\DU95`K@Q>&P06$;T?9&U
M#-`71QFZ5I[H#9KN!'0=(VME5_,$JVPMA2.`HEO44<N$=%O<D9!&+4@0[;!(
MAT\)=[KS!_#H%QU(4T/B1"[^A?+PE66JQ#:;E3UZB#.`[P)&J=.A^\)MP+=8
M$1'E5U!J\"\4S(AML,%!@*/M^*S8&(D+><BWP"VP%5DD0C$&:%-@[!M^WO&/
M8@!*D5^?_*S*"@<E@+*,Y&):RR$L?HG2%+>ALA%M$3,:9`0*FSW.25K5IN52
M_\:F1A;UXSPF85`J^ODNP-+O1'69P69Z>`(`\60C@0J.#AL`JQ&=G[4%MAS\
M8D7A'$$]2Y*!=(JJ,(W:E7B8"&76'P1-;PVDF.8IAJ^C$IJ;;GV?#/`GS!#@
M&$]*3T\Z%;!^7LQ_5J#BJ"8")0&2GVXUHBV"*LT4>"97@TO9O3/H_.H3\>[%
M_F5;\"/I!2O;V@@&)O_L'5#VL0-^).S0=SWQ_22)T5"EZ7X]OQ-``=Z";]T&
M)Z0`!9;ZQP!]G6<"C*;L[L5-+?V,=$S-\0UP_^HA'#FR"+='?S95CLOF&0OD
M#//BJIFG)W"OHU"A50W/"NH`QD%`V-?`V"C&N`&"Y?Q>%/$';J^09@,!JZ0H
MP0!%DNU^YH'F3TT:K-9BQK%AT18:*"%,\DB5I(`M)X6583T[3#Y%]08#Y8&W
MA&]0Z'.3=Z-$^E\<G79)%(<R/UL4[C)T7YJNE5SPXKWCQ;R&#3>+ES^;@H%&
M=!!M.N#IN?!`7]MBA:GB.);*8GQ4EZ48$ZTU`<,*C(1%(SB1ZCIE@\5UU";P
M;42D9!79F#F?Q-[0""TS>D@LH)`218BP?:P`Z5AT`</J8*)Y+)>>::0S%WD7
MMHFPE>\ZA.@#`^O15C8)RRD6R8BZUA&2\?W]T-0;)+W]F/?M>.J:!8GSA`/P
MM7T$*D8[*;*DPG`?^BK\]LJ/@;D].<IYW%Y"DS(^=P&K/5L^4UWL_*=8.$TW
M!2QEIDS,-[ZH)8+E7(V/_=AW=0\?<U?R`Q"45!99_DACICAKS!0TGYL>:%U3
M2-4IY>G5L128E=R>KAA@JW)[.N&8]*<N'%7F?D!X9Q/P>^GS6L>>!V[X5FHG
M;3W;\2+4`$OQS9T#QL$@,`VHE4$3KG3T(KL7C00\R4+#/YE9!%_49J</]E,>
M\,+W6:9-](6884B&W0]E%[(#]%%SS"^5,B)U<'@Y]9ZHI8Y_D-W92&&I&-04
M5:@?]56QU76;_?21Q#$2134JMZ<'U7&15')Z8)FG*<-BE/?@L;0^9#,2!]0&
MBC-(C)?!8R74;Z`EZ\ZNT/`@N^!QEA0$19"S)*\6]=W@F>Q<"#Z(^C.LAH.*
M`9R\%\O(")KE+8'KEY;G'G3\@M$Z4>E,G\S\095EJH(E=`^+#O7O_%.#>%`B
M."2(*0__E"!+V]+2]*U-0!U$PQ&`<&_##H91!.WEY+/`BG@,F#2@()M@(H+)
M9(7UPZ1^,XAKVIB:_F!$.["S3)UIV1MZD`DT',WBA"D!>KM%<T7,[\,0RRMH
MF]\]QV4[I.]=&31+A`ZAY3BLG-9SL<Z(@'6INLZN<DBUGH`\?=JA9(V]IVC4
M(CQ*PM;N'SQA@0SGP+71[5`HHBICM,UB<_@(P(S_0BNN:+-I-\ZL^&`$1!3@
M-.X28<&,4`N+,[B8ZAS$WMN5T`#%E\4R@,^Z0])LMO!X2@*0Y(6HGLN(*]5<
M.2DD64>^/YD(CQ_2"S+Y3/Y2_MQ)SR`?&5IP(179$0/O$&0&?AJ5LE@T2;N"
MWRT[FG`=`&.[%/2&OM&I[VXQ.W!EH8<`EWPX"F?/$-S7+0`*Q<J[!-!]8&OX
MM@LL+_P0@(;>3Q]@Z)EG>">+H41K-/!P](6.^6$WY;FSX7@>5EGXZ+I_W2PM
M(X89F4-`FD7V'%\DN0!*+/#QI=7QDBRL"[*Q3A50_ZC@T;A`9-Y<7^Y2VJT^
M&)#BD[\W]`[2@7^B8XN#ZA/*)28!:`H^C*,K3XINQ'0@D!/5?#LAX,>I`UE`
M=1EYT>DY+9;?#ZOS35BL3IL:`[^_&=`?L4EM@G5#%-R&#S6_.,.OD6`H\>T2
M?FEWQ=&4/_DIW2N?/EA'^#>!?%:U!!P"!H:UP502/9>G@4EJOZ+5P7@(*Z31
M]@Q2%0>9SF>Q-P&[G,Z<;1D'\JAQ[__-P(P!`ZTJW:"6%&AI!VU6^D$C*Q(&
MW01B@NY6V:?7X$BARF86[\X>XY$4`]TF3Z'G:^D`!,'&3+?S0WJJI).@Y2<:
M68:;<7HH$S)T=*A=5;"&E25M$O)$$H%;)>@EE%J,'$$0_>P99RN;0%_$40R2
M;E90UR)L4PL$O(27[J:=/-/C)X;^!S%";QJ4Z8'2"TTW/!;&L+(-H+5E@.&[
M'^^F'I"3#&+'RQ3]4B.3V5E(S$L02ABE8"Z,M33T1]_+M`D]J<?2\7B>/7*U
MOS>,;1)39SXKXSI\KK_"+#()++*=2<<.ZZ#<5&BX_HF8"@V-8#R"O0Z;P=FZ
M>CB:=BB&KAB.A7U=T&L+>CH\XW,Q]J1K_DW"AE;(+$,M9Q!Z"AF>,$A@A>80
MW#A"!BS-$+1V8Y(^PQ>_7]--'2CFP#C'OC,;>/S!^I++"F)1!"N*@7-IO&3O
MIM3`2C*3`7?LPJI!4.R)]GZD9G1U\3%VU!#>.<`P%9J85+9'P3$`"'@.28:=
M=B7I!MX=+X>G1VQ),M42D@ARWRXAPU2V0^PGLDNO`+W!:E5R\I&)9IV5N",@
ML@"8;#+!_1;P=%K+L,K%[C>.AV]H0DS@5QK`@MMMK*>II>QE5_+"+U'/\XBK
M=`%VZ<64GO5`)G*0?3B&@_>];7[%)<(ES9>P5X$P]RN<M^R41?AMF$SP)7MJ
MS@9O7%F6:]*#2KL,#LMZT,,RX"!1"8SF42(!$B8\5JP;0-GX=9/%\$<%FQO`
M#J-M,ALFB-&(`E.!"06TW,$D\#0:]3Z>MDNDB9XQ11HF\'1J@UBV1FL5J*WD
MAR3P)!NU3K`0;=?=TN\,:/B%KK0'F;Z)O%E'CW'#H,B"&6!:>7[U'-#7#?PJ
M2.+%O]-?[SRP;."3*.$Z[]AQ*+SU_N(_^559U9!>O:10!8@9KP._IU0J=I(9
M279XD#D)<4#NV-@F;/`H-AI(1TT*#H-F-B8E&]K\E=+&Y8;@V2R*S3!#D[;4
M5J/C,]L]GI?TDZUP/4@AW%DF?J*(\6UG=G`//3CJ1$?RQX$?0[1H+Q!:N+12
M=-IB9B=B&)JQI[[/0T=9F7E3D885D61DV-IP#3Y]T%:!]0GI1.T1*[JU">66
M`+CP,'K,4F71#3S-Z0.'O&Q!<T5:/JX\0.`K.F1^=*L+AZ>X%V7Q,W+:#/;D
M`=?=T6..%J_)L=IA[\0TMU<%%0,[EY_:I%1P4GL4>-@AY(^#9^11@E+7,7&*
MIOSI^>3AY^Z=J!\*26MD5]9J1:J"ER2JP0ZW/G"[HU*"ZK<B!K6S#J*N-C:L
M9N'&W_U>4Y&2N-P/C%MWM(@1HVJ^Y@J4%D]?O2O*$$=!!"9;2,%I(>I+T\1<
MU1VAY]L`;8%;\F^8%8M6-D;FIM,ND"_J6C$?Z5,WNH,]-7DR,[QT0W'/,]S@
MQQ%\ZQ3]/;"S;/^<N1_:QE@VZPIH>0X``AOET6);9GYA=U#R@JX&C5.P``60
MO,)"%T#!-&;=L1`N[6!CNI'STFR*#.UZTY`8PG$&/&MHXR82.,!`@5^(BUFA
ML"@(K/RP>4L\\Q`])*SN(4-ER,`.+X&%@4[RACD.M%KB0#EZ6HL9/%QVX9_J
MN'#6A!QYY>[`+4AR@AT>22`[:%F"0GNJL(,WL6_L\`8_2P@K(-HCM55P@-%C
MU!O<Y8ITDW7,.[2IX$3*+F"((@\S0(KY!ZCY#;.H`%,Z+@-<2/(:U(316GP_
MU!`<8$YD65%>KF+(U%TOZ.Y":YD#?WMW@H;.L*`0>P8QO'X="O<(LG"AF`##
M8G)*32A>V(P)?+I'.S50R=4MF>*/>`)%LR4F9I*;Q:^7#CT)%@2IMCC?VJ&D
MSV**2*5HX:<9.GN'Z<-`%I9-^TTRD<PH`(@/`*1SW0G?I)M/ED&/7[&)"C0>
MBAE#70W*YMVU;E.ELW,P0"DAN;.^*8>,@B59*P9KS.2O)JBW,M`(9KX)?5'D
M>6$=Y*ZXB!9CA>U$=DWEPU4J850V."7&Y`G:B$/`O+*A43RX)M(Z-`&6,#(5
MB(YP;2N"F=I0^,`G@,7K[IB=?SG@V<.Z:N`DVTE+FOOXU5CPEL7,,%*E&+&J
MA$/0U&SO,;A_X'=QLE:$FDQ(%JFK55SP]T#P8*H91(=G8"(Y:#T5U!Z'/J`5
MF7J5D(>^V^*$$'22)RP\)Z#5WSWMD0DFVAS=V_HT@M#QBVYT6_4VF-5&]/E]
M@YDV0N&4*8'HIW#@U6X@8-TCN^(#PSXI-C:BPU&:]VBLI4[V.C)2LLQDKR:(
M7OKT[^3OA2_8YX=/S";UG;=\/*P#;Q,H8ANF/V)G:A5#I7W(\;2LHZNL[]+.
M?UCB0=XGG89KZ4\@'6Q]Z;F1(\-A/C:H=EK2'LT"`P;*33RBQ;KV11*JEN<B
M-[/6?9X=M@"A@V4';*J!W\$E4F`=:2'XQ*:,L'$(#I,_UU@[!J],;$-G'2;H
M3Y5N:7<^IL#F4&_0<;D::VE.E0@ML&*E;T_$[S`8/CQ:`!5[3Z0F;)=9CKY<
M]XV$L+H_?C_VH:+WZ'0BY^'!8%%/(%AE\)!`#?HGV-EA0C;HLX2WN:CYE-4E
M/45HXM#1:%8(H8\A9<OVC6TL#C?I9SJ++1P4Q1C(OY$Q$2L#2Z5$=C3*.7XP
MBI&C2@S#V2I8_OO3.QP7"I_]:EOZV=__DAX!NJ"5IEN'?`C^^$%@0`T/3_T`
M=H7FKC_,IO\2.4?%_LU>:P?/7#-9)DE#>1([=>5?N`XNC%7_3H;C:$4P+84,
MODS,8UM:8&EL@A7)T\5PGGA/*GU4+!(/2.Y\SGI0F.NN>8.'M1JN'3I5P0((
M$LC8_.G=*$FS;)M(NI;]X9]%^L\/0OQ'YJ%1\RSY$X...)SLU:&7!_54'(Z2
M)'\(V'XU/'L.1B+\$8.<[8H'FF/^:M$<\Z==CEE(S4<>PQ+[QDY\LR\*Y.&L
MRZ*@9WQNL&@LL\]&C6;TU`J`\]#A:#C-*Q1[0BQ#B,-9TTEQOU=L8<V2P^`\
MI&6T;FB90\$06A_',GM.F,E+%!_ODGK?YT*%QAN(+=).W&&16Y5T'A)MTA4U
MD$5NP=XD6)SJ$W1$6K.N"\2E<9QF$%0W9&Z##;%S`9=+>^$(VJ2I>+:_^!7.
M?2<-Q)G4%'NH&YJOP<QY/F7:LV=)]AR+L^+LV=L?^_9'O-U!-)/GYRD;(@1[
M`R5=!OH_N=;VP//PE[2'X?>]J=/+TM[4Z=F\-YK>!*.G&DU5/3]?BK@WQ]H1
M8>R&O=5VDZ9ID.B(?FZ_"N0?A)>'G9>Y?TM6W@:%MJMX?7"D]K49E-<+Y^8(
MYVX:BZ.!.)H-)N-I,Y#<ZYU&Z9UNTKP,-"\.QHL%+Y5*D=MME?J%.,Z'"+("
M%7NQKV(].@Z":-GM%WO]VJ0H5*^RFRN^OI,'L_FH#^2^$1;J;8`ZF:C-05+;
M>F;GI.1W';(T'BQLV?]\P+X(CE.R$[IX:-4,\MV[FN?@D"X[,YMR1+<ALK03
MUD@W3(?F0*(C&K8KZK`+]="]H&F.H.FF>85AQ?%@-LUW_K"7H6]+AG:3YN6!
M*,\&,ZEX*#VO>AAU/U7W\4@/E&:P4#<4:.&@AV9Y2X.D1SUDVNFEB?5K??5:
MFZ3H=]@_I0]N]GS>(JNFY_22G#Y=\#O;TU5+J:%>Q3E,HH:"HGZ3HZ&`.(O^
M;"@LSJ&?.`0N\8N_7%S\E[X2_N)X6QR_\55WZ(:)=F49WL9T_CMX^IY0%N,0
MB,/9EZFBB(`*S(4/IF62Y#W[:TP^!1M/GOR0R62XF)R^E+C%5'8MT^&XT%,B
MF*,X^R^<F[;Z[XN+$/6T26AX0QHM\FTEO#]#[*R=C6]3F]3N)B38Q!^PDE8=
M7(/17\$K@N&[0WZ#X02XRPA&7G+<PU0<#\#;X+>/O6[-!VK&Z3Q6UF\Z,JZP
MVV,<`;78T(U.<\,YC73X\$!8$C9>GK5T]MM6;Z(=IA6D"U>_"/F+32C&H0[[
M:7MN&RG5[O]@P_UX7_Z/.):`.,Z5M5EBQV=@A5VO_]0F_9,N-^D??2]\)?8C
MH)2.I.`C$%)?_:N'`R1J?.%`^&RJ0R3E_Z.8GF*_UOANWFHC]:7R#.6!N&C8
MA()O7!%0E[`-@#L0+N^N+H4K#+$IFN43V7>Q+[\/!S^S43:\.8XS?S']FS+9
MG"I68F_"Z3O^1B\?0=FR(:)PU_-:QUDT\%\+3+D+ZQD<$YS\X.B:CO.<X=[6
M`F6#&_:'&[+A[*Z5)!#Z8^R[8$HH:F0J_Z/`4^C$2@"0_:0_L8D9-GAUN[GE
MG83D4/B\V1`-YST9K_Y<A6#.!@-,8LXJ'?S&AM^:RH8(*]O:M';WOA0):(?;
M>Y:ZM05;:<-O'C';"9LOI=,)[A'3?$D>P>!T@040M?Y0*'XX4QQ-^9,?[_]B
M6$O%0#<")_KA<$_&Q\[K!E0ROWTQ93>798[:[O+CYV_\-R#QVP!GLZ\VJV/.
MK(ZA`%94ZQU6:D))$I/DALX&/OFF0]J8HKA?CXK15DQG1=@80!3X'1(@_N2_
MUN[FBLU&][=3>E(4MR%I@1%.R8BP$9`.&%,V>2*V0Y@IQ\9#^8-9_?`1O6KI
MAQ&0)H,X@C_QD`ZK5/_T=(=.]8('N6M+HX.^PN&!:=;SY?V5,!<G0QR5';UT
MZX&]Y^`0Q[C1B"N/C),'>F$A'-6?^=E6XR<8OA68>8$!')W8!L",`V-KZQC9
MLZ*6,XX_4]@\3K`?&=3!N"9T>"B;[T61QTZ^4C,R&#;*;7-I8HW;RS:[D<"Z
M$XXD!LA$?DA"D@V)`R!YADOA;&U),'\Y''J\PBEGX60X1O`N>"<T#M]BKT,`
M!E;9AG!4;-R-'0JWGNUX.`K;IS/;,_SQ#39Y].?$A;[O;Z:.$H..%'5R3+FG
M@ZGQQOM/5TPCKD$C6C:=R)HV[7>?"6RR-135#S+DN+NM:!J$?*J%H5M_ZC8=
M>HQ)3S9!E\ICRY^T2RY\P1`*[[BM,0"CW<"O3<O7!DL2"/3H+6T%6YJ0'&`X
M'^>:!U]'-WI4Q#9/J^_F.;OT6&)4$0?*,ISGR*4L+,CA2</]]A6583)(X@$V
M?'W?7JI$.X8-AO8C`!MF`*O,@/0G.+>:\=@\\B[XGT%*(1#`.WY;*;HM/"F&
MQTP`#/;X;47\WETI\V-CPVPI]A4VI-VW^D":(W5H&#UF[]O@Z'<0[3KMD[TA
M"LK^0(['&9RE+FGJ,^8H=H%GHK#:+].H[#7<GAR=4AT1V3B8%SA?<1R"@^$#
M3R;F$"#^EH2K[![-AOO#T*J6W8-(&I[G9L:3X82_(L*J"_`,!LP_((`X$`74
MSD1^9Q*=LNRN8&<H?#[H!*.%]TK'I#%+9"=<\-,!&CG@E5M/?B#VL"T0N#OT
M(8]H#<&72[!8\$_PO\%8=PBS.OT8`5X?ST#@G&D;ZT@./X&WS2%/:B@<XICR
MR3`FZ:>4JH]\Y1SQ$I`;(*;_0%K:7>FD5GY,NUSY,?Y>0$`(%!)"!!0-*Q>X
MI`*@];'NH#@K+C0P1,55DW%\=HUJ):90J.@.<P4;RR2O@<NP\DS-88H$+(H@
MX,+)<_#!L!#!"GO=[U!3G:UG"QB58(&Y'>&P@)ZRU`W=?46CR-`!2#1L!3_0
M*C^TOUFP!T$"MC8J+M?65123\>=I!`LW4)1&=:U?+>F0$,S<MAG!'ZI91#AL
M*U+>2['ZA8!=+4BPMRUX#EC%:7F/:^%/CT9L?"K8P@X)@Q?8^+3^T[1"%X#2
M@V\]+(G[3(@9W3*W#:YUL#9`B/'S_X!,`#K@+@'(_+!5I,P5`SVZI76MV/6D
M$%0=^I<^ZV9'8#KZLRN:=?!YF-(K\^=8*>X2`_`J`=>5>JL.,0Q:F8M$B^)@
MJ^CTAX"DP>1$AYA)`K1A07#B(83`\54HPX?4'K")@J=A]"UUQ.'=U+UF#C7-
M#%!1\AUYT7V.^AX-=LIVM*<7O#]POR/L@]V\5`-6JJ]TXM<_L<1#4,$3\L&'
MHYCS#,%]W0+H,<S[+H%&<>]H:OSP"C[`T+-,%6&R&$KT%`J=N*T#8YANRG-G
MP_$\M*-\`KBG11TQ7,L<C!]?WH7I(OF'WTQ%^]VC<15?ZC%QQS**M&:;X=>A
MTEO'/=$D@"_R4)OXM**GVGJ&WDD8RN5AZ.CP7L5.A^`/@G?H:7'X'WL0OCQX
M*Y4%"M5;KK\B:@?X:L\"CD+%#'P>?V-XG[5TB/U$'>[@Q$,H/7:BXLT@?Q1#
M?@0X/D#+PHA^]HS&>WS!%?C8#S2HKN[4TG\$895OE*QNPF3A9Q.,18\9D,WR
M"=%R517;?J45LQNLE*"I:KJ!7;93WVT@&FUC@2J_PL(!A+PB+;#PCK.V;/<"
M;6&:!0Q_%93MUK9>]F+=8&P1/R>FV^SNB.M1*J21&9Z(1S)N;<S.NZ^W!BCQ
M2U/[!%;S%O=[Y$C+K,N!C<GW0@`7EFL/@'("$2]JM!5CBR?AXGVW-\AU[`RJ
M[VAXW/(<N-[Y_KA5Q>*P*AB5SE91X0D_O1/?T<^^T*:?_8WX/4%4>)NR=<B'
MX(\?!`:CT/(*CE$OQL/I]%\2=MC^3)M$_WUZ47BB-KNG@R2E=ME*.:?MZR7V
M%)5@\4_EV,I[=IM^D7&*F$.#ZTPP+A:-@.$!)OX4YH2^Z*LC/<6.03:[`X(T
MG.8#1$\Y/L@FX_VF$8TB'AK;$((`04\\/?$4()YKHI+-$LQ(GW[V$\'9\&5?
M)!IRY&DDS$<%5DYX5[2/.\`GM$PX,EA#E!0+.`JO1#G6B?ZMBY.J>+_R#?8=
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MH\I1'V'>]Q7Q^)^WP9ZM1!,TG!RGZKN1&MR0H6PL``KK:-CKY[<K"7OWHQO"
M];OQ?/I]3^H]J;\!4I](8E%2SVE)C%H:<>]][5[`E1!PFN4M#9(NX:1A9(CT
MA6MM#SP0?TD3E_A]+RO/+2OEODZ[9YGJP=^?ZBK%C!Q[(I]H#['/V(\E]E4]
MS93D0DQ=W[K"*OJW-:J='A7PM^RWZJ0C[3Z;*J&C$\)NIYW9_6`_\A8-D`GD
M94M,A]`9$%QGM8@<'SX`'<0-D@.^<-D_#ML:N"`Q<87-<#_94YE:"=I?V\39
M!C-,ZASS<;Q)79'.<_&>=73B&6M+#?==673((3%5G3A'NM;-N]RU;OJ]$($,
M)=\8;$[KP%A;\[IDCW)L6NK@3/+?@8Z%O6;`:F++:G3+QUO9-1&=AWIM?MIL
M#>N5MO*[?+0):6I?S0![&T4W<3`<V%R[E2N[E=-^[`X.2U4,T-1$]6CC7'8Q
M2>U]6=4ROUIA'T2P#B)KPK)776,];[?**_N2S0O:*/`]&\JM^A/O@-@TG0VE
MHL,"_=E0_BQY@5V!LT,3<P)98T8@5-=@LR*#/>/MST!R/BW[KUD2DZQTUFB4
MK0B[^N)L&^+/O<)FI@98MHI-SX#L1AF'0RAI;WYF%`6M_%7%<VB%Z_(UO@C<
M_*-EX5!*Q<$^_]SP@.02@?Y&>45(!XO%!N<NG>/CPA.#908PI.0#*XUOQ]OB
M#FW==8F)8**-T:W8_HHW?&^R5/C&IJL"&=#R[8;)@V^F<$.6MM?RJ75L:/H\
M/GJ%UJ$'+>H55AN^HV;*19&>OT9*)^@*C<D)5VM8</[TL"OXBA"7S<]ZAOU@
M0UG7]E1D5&NU0E9;*6JD&_E'V[(V*YT8VB`Q'G@W\PILM$!PLNEMS\%#7ADS
MZW1B"_`NH=(+'OM_/*/5U(2DQ,#`:&9-1X+1EM%\)\UPF;?C/YLOW/R7I!]P
MK(S*J4JQ4>12I0]^`O&G5%+D($=SW)S[#&)$8P8%6$0\WT0#8@A,CB_Q8U#\
MT#44OJ$L,/</Y+1(%DAC&LF2,E7+2K?!7E5`K6A4M7Q')\S3Q<UE6?SA,O@E
M_$[ZX?M`HB;TTE#XC=JP`56',ZS#APSV3%44P>"F:R#!-6'CN9YB@/BGC]R%
M'(,;7"N4ZLP.U>FL<*H>'$]G]FA<,3+M%54R`VI(FZP?/[L+F=.?X^DH:`YZ
MNH'F[X!J!UMW:"O_NA3N>#"I2=\R3>$#D,(5U2`.H$`WP8G"/D"_-/L!71D`
M@_T:G<>-CV"/"Y$M*(9C"1M+8^-VZ`P+TP0$(_N&R[#`W[!]5\*F=V&D%7UP
M)XG[T'AGTI2[%&-A?<XB@(+4=R>&PJ5#1Q\%C!.R5IQQJ+^HH'-V0=T7WWD+
MV3+@)]XC/461<Z#T>:VKZ_B>?-$`6T6?+)`0P<\Q,HT>-0WF]*(12,46SJ4A
M&]WQA[&!NZ>#SP+$N<)(`75U`[,)[V,>$-Q!HPZ>R?QP;2C<^@(O(0L'=&PX
MH^AXD,GG`=U4T0<FSK[,8M0'3(+G42FSX'+8,ND#@]Q#N'OZ;AUGQJ&DPFFO
MCR:`DDXM5P`5MH*6QX4!W(KK@BO#P;/L7MSJ>8*XJ9[C@J/?N--1(<HI#/8F
MYOHSSHBI(`YWM`2_Z9NE9SL^9841D9!&70N=:,ZSDR>+$5_'C#$?'5&XFQ],
M!\2Q6>6AM*:7^,DQ=@W\[*DL>D5U]HYF&17_+U]TA)*+2K2D^&)!KM^!V<+@
M4MR<H,FWW=IPGK'#9L61%W\*9VRU[.4XH3F^B:5BT"G/(0?EW,R.BYA@H),-
M(T*#TA5[J6?NGIG^<J5;LV2Y)T:YI+CJR/^=-!6R<G%X%Z5GSY>-P`A,+ZS>
M4IT#_US^?NE=2VB6YJPYJAJ%8^B%JQ*6][O0MP2E_%(O72\->B.&\L,![S^,
MH?MN1WHP'G6*;K-@/4<6P2!=^BBEZM3U0\S`V\!_-M[&WWV8-V75`IAN\$('
MP_>M?/H/ETJGH/)US#D;,(D$@RE8/JM3^QCS+)BA,J,QYUU@F)G(?KH;Z<NF
M0_]HQ'#`\7@KS[.S4=>1VTMTRDPF>;1<5I7H['RBT&FRR:-BT]S]UG*Q$`!@
M3W&B&+Q20"$$?'^G2SGP*P2F]:0XJH?3D6_7BKU1L(;_T1_@:<(."*%#[:\`
M(Y[A*G2DZY<O5P.L(;BZ_735L,QY2I0>`^D8)G+)HZX*L'GJ#NPRSI3.<"L#
M.L\=?\8=.][2T34=8\$\:>LS+/C)XV@B^F@E'CU;X:#Q,A2^4X3GM87I".O9
M!+D>W^PG$W1<XK[O!P+VN*.%,W"+[:SU;23I%];V&*!"<.RV:R-W:HJK<`7?
M+\14%=OBZ!S$BV<,&MWT;"P5)8Z+-43(*K;UJAA@-EA+0W_TY1=-P]-8G`HW
M@)Q2:2(@@!1Y0MTZ!'P(E]ZCY[@IM1);1=<8ERF1%P:!)<XA\`GG$#B-(M,P
M+FZY[=4)S(`6Y\A*&]UQT&3PA<^OUY=!_._F^A(PO@K^%AYMA55PX?SY,!/W
MA*%Z3EGS&KF&G[D3RFZ_\!#3:8K+]Z4Q&6`]$Y\O_61K[=PY'_+CS!K8):BT
M]]/3COX21."H6429(^`%9I/70$TTJ>NXBELK0:W];/1.=Z"TV"A_D'VJH@:-
MM\4+N(I^CL05'K+PLY;*XR/:]:Y?A`I_8W<@RWY-DXIPSR</CT!0K?M_%`!@
M;=11-V'$`A/[!H9@8Y;63]%Q#>P.N13`T8?_"U(RSV@!SZ73J@ZPXCRRRY,&
M!>U`KYA9V]DXBKK6B9]DA1OQ?!&K'0FN=!3@=7`SGX@!+A88F89'K6VE=:6-
M/G@"DJ4,0Y4EYN89_;(J!Q!J?JR$%CN%*>L]%ZW5QE"\=#>0]M1UHF<DO%=!
M`Y>*?4MAAG7`M(*-LCCGZM96\[?$)47A+WV)*N@/QH.1,B1*RK[=PG%K.Y.(
MGRJF$BS4MSM[*R.F0S^E'$PL=KR0'4U4EKKU`4\PNJ\WP/EPL?F(=_]-L:E?
M=.1<XJ++YQ)GWW,BKN3K#IZ;HW@1=HBA)E>`FN8?B\R_TUM;?T+[\[/Y!-8V
M97-@[5L/5)4J^&#X[O;S[:?OA0?8O*.PFIUF!3ZQJ%LQVWYB2):##@49==WW
MWM)1;9VE9<(SG7OEW;>>K:XQCQ->$JOSIF'?)\76+8]V)847Z"Y]"5*!93M\
M.Y+J*2-"*I/K5V!KKH1/X>'0;[2&V?:KSDP2*3I3L.*9DO_64-30/O6/#VVP
M9MI%N4N+X7SF'P)SV(ZG[,IR]V$=QZ"#XU$P:18Z>WR-FM%D.AB/>%::KQ6;
M.$<A1:W<`#;,;^?I[8P7@XDH\=MU).>9`0":(`T1_6A;#CTAC.=N4RJ"N18E
M<8]B#(0E@?T206.5E&`L@O2@>Z.G^UCVS*]!HT>1:4(X?BAW5[L9@LGGJS#H
M2,M0:X/;G&=C%G[>1@VM36B7H#V!B58J<_,YPHVC>J_S,*(\&?`N:BEJF?&N
M-#JL'BA?4^4(JMDSF2@U';_`&V0EQGZIJ*6IP^1SE.!),3W#$7GB<%:+4HWN
ME$G'<'?`?2HKWB6*NJ9`XU[<*@_G_%0)VU^<),@+L57=H;J"'>=VT-Y2R<"O
M/>,:><"@)C\LT]/(^[TV=CM$REXK3QCC#P`1H)WWJ:^AS+&[%#T:B"0.2/P3
MSTEQCHV)XK]P#1TA]E#SH:A:ZMH.19=W5Y>Q[$5,</D)?VY+^U5Q-.5/CLZ5
MLL7@`=;\_H%]'3KE>+^]^E]AI1MX&`HCH3JM$Z,'A3'9%^8>6&8',S0!W?NJ
MBF8OC%=Z.(J>A*+%9KX^9VV2]JQ%>BA3<0^][YF>0U,-!2,>!#P(VH<N\!CN
MP:6W6:<06J+WXC=-HN%7O^JD&\UC_"/^HV:9<Y_W(RCT2)&["PPF&@'X9WH!
MXX/H4=FP#.S%/TN`23_`ON4!\9B62P\(^WVN0MN`VH&>"\1BLC/\C#ZP%I/&
MR/P(F1E)G6%##G81KB90LGO6)#S!V9$6;)$V8T;S`Q\YB!DDR!'X1I_VPN]B
M#]3Q=&XD&H>1-GHE/1`?!5<D*N>?R]P0^!5[NT2BK?"\W8GI`+BX'>*PQ1N&
M0[<877MD2T2G=3K?7>[/4F@14V!C+W^'E->IRAWL64D[Y/C]!P!A=/OL=YJ1
MQ0.A-#E-[4L@J/=P%6*)1$JO`0.LWAKO0\N<UOW^Z5FN7^0(>!]$!>*>EQ+I
M1,8J>_!B'>0DEH=&R='Q`+GIR*,O_>YCJS'G!UMWN(M@+8JO.(8B`B,X_^Z`
MS0$_.A9`=.6YGNV;T-G0I;9:.F?`VP^4JE*\AH4*E,/]M)[KEZ\*&O@BJHMU
MQ"A\PD^1OGZ69T>::;`5LLH>)D@\.^'M?=Z=K3A!E&)<,I`/D<WZ>5MTJUG+
MO[`E9M2:]?<>Q.\&S-4,,@.^D*8N2BR5'_JH.NN)B,RG[-QW)5KU@0>F68DH
MA?)NA7Y9E(_:,(1H17JX^,=)(GT4T19@E.-71+(&,_ZSX+LM#5#%^"U\9;=.
M-=Q1LXKFBZXI.6+V@\&PS]CQ.SB8F;%SHAF[Q,F+@'NQOX'N>GYZ89>%2Z;U
M/@>_Q+)Y*9DM9,)]8MBRM&[(5\G'!\02??H`.3O,=^V;(75GMZ3I>#`=3=]8
M=FLZ&<PG_)('.9-;?F(FI,(&9;MF(]X]B_9R7;L4B$*M@A5AE;G,VNQ`)FPJ
M\6.SFM)5H?JK)4O%,_109YIJW&>I6IRE&K_%+-5X..;=*J!!62KL9?<FDU3C
M(4>QE)JDZA,]--'#[4T<DZT=\C"9!`JM&92FW-[)0N:$8ULHUKQ<^8/0LQ]@
M'Q_L2'M_,?+]6#]7=!_DBH(FHDNB8EAHERS"NEA@4J/-:`\[/$=];ZQ6M>AL
M)@^#H]NMX2?I:`XO#%N_H2Q9E#<",^O`9!:'N*X15OC&$DO4KK-WP1+?QG'6
M--*)*BZDK0-I2XP.T]"Q&T413ESAMO<E1_T/`*&^K>`?]F0)C!#"NA,J?:U;
MX=-J#GA4[J!<=JN#Z"`]AL8S9C@<!37+=;M&S%F(Y*V1J>(VLT./.N)/U.3F
M/$"0HW/(^6"^)$V'\P7'H)&?IF2"`LMB<,[8(TFZ.*&7P-O9F0TY'N&F6M/9
MJ<%!M"\T;<W"NB0';>N#TT*KX$P<M2["Y.9.[8;^+Q!Z<)-+E[4D[C,AIO!-
M=:TE`#%LTLIMD[X'`&^2>;;-^ULL,A`VKM9CC?*PG]$%IFI\SXHI5ST:*5XI
M\-'/#S\IAA=JX,`%IW@1/"?(V7X$-?W'Q;VZMO#\/&O6=X%42AL:6AHI=IZU
MQ)G4^)S-W07?5FC.$].AMM(=2XE?68[KW"/K?,3JBUN_KT?:`5=9[/(!U_GW
M`@7#!:M"B8+J!-MC4>/,S91!V<'TGN[VD7Z3X[(3TQ.""12T3B,L(#%![JB*
MLQXPS>C3M1JEZZ`7N5^7@4%TR]`U*O@BKM1*L-AX0BSM^(Y>#!H$(.]\?WPV
M*TB`8/,H.2[`LG\T/Z@T(_\NO))>ZM+(K8JE<UL%!=U/[U#DP.<M"FW_L_^P
M)0IT^T*%_2I;AWP(_OA!\)E0%!3/M7`<F.:N/\S'_Q)YVS_X_V&OM8-GKIE0
MF"Q`R_M`#RYD5ZZ#*_T%71AD!=</QXS-V7<V>PC[DE8XJ8KA[]NUML&*I-%L
M*.V])E6>4+&5#CV^4C&#JB-H#I;]WEVG@0PP`_@T?WHW2B)O:;FNM4$<6O:'
M?Q;I/S\(\1^91TCI,OD3@Z.(PG8'_:(88<]J$U(>J'S_:M'V9)]V@ET``7$"
MFDZD[`0<P:W)"\6VT+%M/3,ZEIM/Q]/Q<-1L*KZ-*.MKHI(-NA_2C':ME(3O
MP@Q7H,?I)+R0SM.3X<=QR;ZRDU_MJ0!I,ISU*J`RUFD\NS2<64I2.R_1+C4;
M6F^$9(=BPT4'.F@-HMK.&"3[2BR/5R.+A[P:[6PJK8&0UOC")[^F>7NP*:)9
MWAYT"@G\MP>><PGX)L*BB/?7+%B<[I]U0YGY1\<<0AU>#')?8R=F:TO[!IZ-
MQLIZ396#ADN.-T*^TE0\VU_\<J\2O]QU$\%V)K8XEQG3&$UT@J/:"XI&"`J9
MWRFS)H+M?(+B;9NLY7,6O9QHA)R8BKU%T3LP!U%X3PR#]BOYA9C$Q@([<&0N
M-1SKRTKV4X[,O3U?IHF$7IDAP6\@2A/!UGL<30#'>3V.)M)E9?J^5_>]7_"F
M_((FDF5EX4!N3]ZO0ZQ,`HWX=<1N(JY[CZ-HRL2U/=7UZ)G\3ZR^_71!UN`J
MH%XR<I`$O&=9-PMJO=?26>G0.T*]@&BS@.B&']1<`=&[5IS.:L[[P&=)-V4Z
M[+R7\F"YRGXS+/YB1;.\I4'2Y8K$Y(K_$\#JP`/QES0AA=]WR\'I4\*E^J3M
M'_GH,MAZWZF78<UVPWHQ5F9O"W[!\2:"K??P>C'6:&>QEV*ERF]:F>'K@VO'
M7&?\YB\7%_^EKX2_8-MARW:_Z@YE6FSI9G@;T_GOX`5[+K:8X.*X*/-ET'BT
MDT$?3,LD>[>DK#+YE.EL.)E4\!S0$Y4\9SH?5K(<>5@)=!;4+BSRG`@I4!KX
M+V)J^NJ_+RY":J)-M,([Z%?'FO#%6N4*\IC!B'8,T$V-F.Z'"_;EF51P,]8L
MG[SF14J70]UT=(VPCH"U=0J\9_,0_/YXNZFF3MA*;[^'8.=:"-)9R8)B&-A9
MVV3#;!7';Z#GM+6Q7:K`G\WV6S]P,><7DY2PZ@$3\:QL<.J9]J,2GI]_]";!
MV=P,FKP?B#N(H3TYT42D"?^,?=>^L<FUQ\S5^OB@8U!^`ZPQ&0\7^95!*[#V
MMZ`/_:7?A_Y3T(?^%OO0]\S2,TMY/=)Y9KDC&T4WL3#W"JZWP>?`@6X/Q-[L
MJYFE+;SGOT1L9DU'ZWU?F+#2@S(I5==<[.YH+4-KC.[>Q$X"[PI6M+3U5@"J
MD*7[E@%52/^^94`5,Q#?,J1ZDN)B1K4$4N<U-=H:XJ//"L(8B6EO0</Y#@2R
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M[WL4A_J-9:^([A)M(*B*B:U>B"98MD!>MKK=>R3=D`N]1]),J^*[Z4">+/;/
M='<9=KUAT38!TOLES94@.(5BU,N/7GXT6'[TCLEQQV1_Y&7OFQPZ%$U;>PI!
M?\QFT/@;]5`J;2<OT^:?#>PGWSM0C35_1K/!;-I'9GL#J$7RK??*\%G],?&2
MQ\1'TS<%N5[<]>*N,TYDLUBKJKV-A_/]QC-=!ESO]K=#GO6^_=F!UQ\W[\V0
M-J2M>NCUI'>FC$>+H9?;T.FMG$/)#<(.?]#)6WURHY.RH,\>---OE>318"SV
M71=[8Z+)`J0/]+>)ORH,]'-[]IS?N.TFHJ07>6T3>7VPO[F":3R<]N*C]X$K
M]8&?B(/S]Q13PW-'1,4/KD6_;H9`ZCW@W@-NDDRJS,H<30=R[P'WYF"C!4CO
M`;>)O]K@`8_Z>I5>Y#59Y/4><',%TW@X[RVF3`^8?8$IS?`[^I6F/\6^2"'F
M\W!V?'4_OO><BT=%V7ZXUAW5L!S/)M]65]9F2TQ'09?UCA@*.*E7EN,Z]VO%
M)A\5AVBWRNN&F*[S`.SXT;#4/W[^IW\4A!^#AWTV56M#'I27W5/#*P5=^^G=
MS=]%41S+TCM!A57"3W=D]=.[*_Q67(BSZ63\=TP*BY(HL3]&(^G=S[CV8X"5
M1G@@2A#9_]<A!0X-LE]\+S`X"``(>$P6L:7M9!S=2.7$\MD4%%6U;`U;H8`H
M=M?";R9V1Q'N74"X(_Q"3&(KAO$J7*HJV>(O\(?EF2X>3KRU=5/5MP9Q!H(B
M/"F&1ZE%@!NL9_I(9VUYAB8LB;"UK2>0RYJ@KP3=%71'V%@V$0S]#P)/=]>*
M*9B6BW_`SA!>EHW/$:P5'<C#30`AF2OF*V.;N2S-?DA!4E4OT\B*V#9&>Y07
M07$<XCH`==@E;AV`!!1JP`W:4'CHS)Z5I6[H[BL&N/SM480N@;)60`@6DH,C
M'(2,1D`*:0)0%=[U2.F1$AG<N/)<$"IX"RTGT2FC#85KC^#;\'H/B-!V%=V$
M!>QN`%J$5]-[K*W_/(>&X^*/&M!G^-`2UHH#.T!NP=@=/`M6ET;SRB.\SW'I
MMDSBIFV-X3=X\)(8.GD"<.(=>-$*(`;L!2#5=TN#MWHJ^V@S<4PW"9>S856.
MX'C+WXGJXM?D!9!ELI51,`)Q.9Z#D(#[O"TNV-,`_/!DNDN;K(`=!W23/$CA
M!X$2@VEQHS.`BD/L)P*_V3N\,P`%@.3V\F&68#^D;;,49%R5?O0<0)SC7!-'
MM74:1;XTM9TDOK4,7=6)DZI?Y>KU:TPK"9(\E,^E98,KZ/$<X&F``WUA!%+(
M^`$`FZ5^+^^N+OD)WJ5N;<%6VRC<WC!`VV8X0%4=%93P$7>&-L$U2*IGL!>!
M`NVMQ23M`)7_FBC:GYYB`YF@36`*'VW+VJQT8H`\NL*36(IF4;D'%RM"N!>5
M>-2+A`>REVV9#4)ME)6E>@ZARD(#@6I86Q2CJ#/H/<;KA0MH)51T@LA3ML`R
M5%RHBJWIUI/BJ)ZAV(*F.P0,W+B8CFE+`Y:/:@1%,C:2TW0-)/*`'S+!$(-%
M5BX])RF>N>.!0J$O??C*3UI_QX_N/54W-2`A@]_JUZ^:;:EK(%.P:;]'2O?)
M$U[[R&@-=)#^IX>&CJM<+%$H$YL2-+Q1`\/!L30=U+AE4WY8$B15GVJ!/E<^
M3[D@3EWTLIAY@J,I;;C(#`2;XMHZ<,-*7]J@YGW^0@:\&2!7;>$;=-&8;0],
M9[O"2M$-#W4]7/;7F[@I@NH?=@2/!U;4D,DV\!Z?@V#1\#)F@NC,'DLPCO/J
MN&3#C'C=C1@VH'YL!5B%+H,[DT0XE1\)1!#^RO"JH#0BF@[[].&.-@G86@ZU
M1]LF&W9;#8EPGUB6A`!]L%%BN&M*;#YQ_#:\!^7PR;.!H@<41!:*7>%WS]8=
M!!.E)*3T#7'7:,&BLX?O0EZXO*&W_/4F0<3M!>-2\953P$_@8>-6!\+S6E?7
M,8ZA1KOO,P-EV7^`(T%>5`/LF"?TIGSY`)0%&H\"KKUP`>E@X5D`4*K@-LFB
M/(U2$#,"\!+X98*_,(H:"AB]T#2=R3PWS:%B@JC5L`'K9XMT@!UKE19OA,F&
MT!D%##WJZ&DC(?N_@8[8`)'#WPYJMY!=+`\L-`]<:+A&!<^8VG],[VT-!40(
M99\!(MJ71`-?&&>R3WMA&7##`E6X+([$D%_N*;<$#%+4VYER]G4XBM88Q[<7
MLZA2MQ9R`U(W6:V`UM571*^-X1_4B\@OO@E(M235K!QU/P"4Y]-!P(7;1*9=
MDJC#!MM^]&BP*VYZ,+['^!>H4/:4]>L6S0M'I_:'DI04;=:0`^$/TWJ&33G"
M+Y]^_?3P^>H"\<ZL!C<-++!UH"`7!]FS/H(V48F^=8-PN@D?'4>Q01)Z]()]
MRTY%0XQ6*8*65;:N_D3`/W'`0Z32<[<0<'0TL.IVJV$`UYG9;VHL4+DDX:(T
MW(@BW,);B"`O`4*>1FF<:KH7?0/7`.HYAB%ECM,MLGPN*ITQ4RX@_]JZ'VYX
M=0`+:NB[_?7F[A/X9=<D0)X?_`9GPC-<)\!A"+^M9>]L(`9\Y"3X9%)5^P(X
M];$00'WD`WWY*A#3M@P:;P9,HT&Z82CR+2MX&$=$C.4:$!&G;3`0=`P8N8&V
MB%"RZF>K'O>(<2J`(^RN@6XQLAD/=RTQT(SA=Y1CU.WSF8I?N+FH9E]PU.P/
M%FQ]BT3(0@(6:B:/:$$T@T8OVBU^=1-,1\J*-`(#4A;3*%'"B2L;ZNN:CQ9E
MWC##%'=26-Z/,+[DMG9;T1W"C\4<;XFM:JFU$I$8/OW#?FW+>UP+6V]I@+]+
M31?]"?42^=.C24&PUQW%CP1@QA=6!=`"!E0Q^+0,<EC42;!=D]C.6M^"Z[>*
MP5+'!**AO+)0,F-(?'^P#K@=+O%,FML#<&/PV""PC.C[(FL9H"^.,G2M/-$;
M--T)Z#I&UG@Y.!081X95MI;"$4#1+6(B<D>WI9);A5-6+..E+'7KP_4.PO>N
M\DCN=.</YXL.)`,4]@J/^04YZ\K"))])'_2:FOD:\:XL:6CJ:T>?%'P"A=]`
M""%(Y1.%H>`#L5EYL8<X:_O.;93O'+HOEA9_LE"51R01J&N_<@3I&+P+4$UH
M%3\K-L880^G@^Q866,$LQJ(8`[26,*H//^\D@V(`2E$2/?GYHI5GTTAF),O4
M6MYGD5G4$[@-5=DB*44<!)!^*$;W9$+27\`2%K\\`\0P]5!9'09FQH),7J1$
M01%,;[,$(`*>;"10P=%A`V`/T]H-"ZQ4^,6*PCF">I;^T['R:*><6:T(P2(,
MD,9_$'0J@*%US5,,7_LF;!*Z]7TRP)\P]X&M2B@]/>E4=?@9/_]9@?*F.A;4
M'^@TNM6('@3]95*O?1^>R=7@4G;OU/\GK')!P.]>[%^V!0^97K"RK8U@8%K3
MW@%E'SO@(<,.?:<:WT^2&`V5M>XX'A:R.`$4L%C$Q'1G4,@"CU+_&*`7]TR`
MT93=O;2RQY?\,07.-W3_JX=PY,@BW![]V50Y+IMGE),SS(M'+WGZ./<Z"A5:
MK_&LH`Y@'`2$?0V,C6*,&R`R"GJK>H4TP_9+HD0)!BB2;/=S*C0S;-(PO!8S
M^PW+P0P42@B3/%(E"5K$60LKPWIVF'R*Z@T&R@-O"=^@T.<F[T:)Q.5TD1^.
MD$1QR.^T-V;^#=V7IFLE%[QX[W@QKV'#S>+ESZ9@H!$=Q-$.^+`N/-#7M@XH
M2L5Q+)5%+ZDN2S$F6FL"AK4E"8M&P&BOCL%YM$\VZ+E1F\"W$2U:/0YLS-QJ
M8F]H[)D9/206*DF)CT38/E9:=2QN@@D#O^SVF)'.G/]=0"I1[!M%'QA8C[:R
M25A.L1A--&@0(1D_DA&:>H-D'",65W`\=<W"WWD"'?C:/K86HYT465)A(!-]
M%7Y[Y<?`W)X<Y3QN+Z'I)I^[@-6>+9^I+G;^4RQ0J)NT6R1E8KZ14RV1!N!J
M?'`Y_QLD6K@K^0$][(`N^PK<1"9X07'6F`-I/C<]T(JMD*HYGKJA@6MN3Z>'
M7;@]/64,=V6HI2X<5>9^J'MG$_![Z?-:QS-%;OA6:B=M/=OQ(M0`2_'-G0/&
MP2`P#:B505/)NHK%4O1>-!(\D^8BCN1'?%&;G1C93^;`"]]GF3;1%V+N))E0
M.)0WR4X]1,TQOPC,2!R9HMX3M=3Q#U0=8!_2#/Q2,=B1+.I'T5[#;?;3L4TR
MMX=3C<KMZ;M#:&&2/#VPS-.483'*>SS'VO:0S4AD';/C#!+C93QJ:+M!,;ZS
M*Z$\R"YX4"<%01'D+,FK17TW>"8[\8(/HOX,JT[Q#Q/ZL?[02<+!2<#U2\MS
M#SI^D8.BH32@3V;^H,HR5<$2NH=%A_IW=,0G#3/XB@&@Y^!A;'K4GB6D:=']
MUB:@#J+A"$"XMV%'WBB"]JH-LL"*>`R8-*"@X+RNSN(?>":7^LT@KM>8<:`_
M&#I#G$["3)UIV1MZ1`LT',WBA"D!>KM%<T7,[\,0RRMHF]\]QV4[I.]=&31+
MA`ZAY3BL4)B=W25@7:JNLZN)4JTG($^?=BA9&[!6&K4(#\FPM?M':E@@PSEP
M;70[%(JHRAAML]@</@(PX[_0BBO:;-J-,RL^V#_W'0*<QETB+)@1:F%Q!A=3
MG8/8>[L2&J#XLE@&\%EW2)K-%AZ\20"2O!#5<QEQI9HK)X4D:VLK<_#X89#)
M9_*7\F?DF+V?CPPMN)"*[(B!=P@R`S^-2EDLFJ1=P>^6'4VX#H"Q70IZ0]_H
M[$0ZLP-7%GH(<,F'HW#V#,%]W0*@4*R\2P!=W)NH%X!FUWG%T#-/)T\60TD.
MNP;IF!]V4YX[&X[G896%CZ[[U\W2,F*8D3D$I%EDS_%%D@N@Q-(E7UH=+S;#
MBB<<1XBHQ]8#.Y%Y<WVY2VFW^LA#6I<>0^\@'?AG5;:VKI*$<HE)`)J"#^/H
MRI.B&S$=".1$-=]."/AQZD`64%U&7G1Z`HWE]\-S!R8L5C>Q'2WP^YL!_1&;
MU":LG\0:F]8PJ/G%&7Z-!$.);Y?P2[LKCJ;\R4_I7OGT\942XIM`/JM:`@X!
M`\/:8"J)GCC4P"2U7]'JT((V+-3V#%(5!YG.9[$W`;N<SIQM&0?RJ''O_\W`
MC`$#K2K:ZV>`"4@';5;Z`5L&A4$W@9B@NU7VZ34X+`F>B[YQ(J>J\;"-@6Z3
MI]"3PP!3@#_MC^C\D)XJZ21H^8E&EN%FG![*A`P='6I7%:QA94G;GSR11.!6
M>;0)\^W37)((@NAGSSA;V03Z(HYBD'2S@KH6)NTD@I:G1I;P4J!GFWG2S_1@
MC=_LS?>F09D>*+W0=,-C80PKVP!:6P88OOOQ;NH!.<D@=KQ,T2\U,IF=A<2\
M!*&$40KFPEA+0W]4]AINT01^]&I_;QC;)*;.?%;&=?A<?X599!)89#N3CAU#
M0KFIT'#]$S$5&AK!>`1['<`0SX\=CJ8=BJ$KAF-AQQKTVH)N%<_X7(P]Z5K0
M76U#*V26H98S"#U?#4\8)+!"<PAN'"$#EF8`QT7=57]F^.+WK$W@@6(.C'/L
M.[.!QQ^L+[FL(!9%L*(8.)?&2_9N2@VL)#,92Q()JP9!,:Q!(<R,KBX^Q@Y1
MPCL'&*9"$Y/*]B@X!@`!SR')L-.N)-W`N^/E\/3P,$FF6D(20>[;)628RF:]
MU,+T"M`;K%8EQ0Z#G'R:(W(HY`X>`^"Z1S*[WP)`,PY^C+O94O30B0\?-`*%
MC4"!T[!&H]\X'HYB(T3Y%3@<&$U:V>,Y&BQU%._L"G?XE1OP/((L78!U?3&E
M)U:0B1QD'XY![?V8`;\2&>&29GW8J[!O,U-06W96)/PV3(GX^BDU\X0WKBS+
M->EQJUT>BN5NZ)$?</.H'J$=?>-IG#!MLV+=&G)$X5.5R3$MD.B;J3BZ\VV5
M.'7XFJ$Y)F]+<U``(5)NL7LJV)O47&N6[D#K%;M44SF&+A/88MB[EO:G.Y8O
M3>3GG@EM_^MG3O7]]M>/8<-K)6AXK>P:7F_#AM<TG$[;VNF;R)MU=-4W?D=@
M&D4"FS9HVPLL<0._"I)X\>_TUSL/3$KX)$JXSCMV#@UOO;_X3W[E;37DM2\I
M5`%BQNO`;U.6BIUD*GC7[SL)R)WDL='C1.PM7P^@)@6'07^D6'-S>-7EAN"A
M.(K-,#66MM16H^,SVST>5/6SW'`]2"'<629^HHCQG19V8A)=9QJ]B"3N`P>2
M:-'V,K1B;*7HM&O13L0P-#LDY*&CK,S<V$@/E$@6..R6N;8)"3IUL-8SG2CZ
M8M7.-J'<$@`7'D;/MZHLK(3':'W@A$,%`[C07N6OZ`G[8<4NG%KC7@W'SRYK
M,]B3)XMW9[XY&NE\^\8GCJIS>U50JK&+M5`SF@I.:D(##SN$_'&P.0%*4.KM
M)HXOE6];D#QUWKU6!D,A:8WLZHFM2#GVDD0UV.&>$VYW5$I0=EC$H-Y-=+&Q
M!SJ+\_[NMR^+U"+F?F#<NJ/5HQC.]#57H+1XAA>ZH@P!I7)@LH44G)8;N#1-
M3!+>$7JP$-`6N"7_ANG(:$GI_2Z%0QN+OJAKQ7RD3]WH#K9IY<G,\-(-Q3W/
M"(D?^O"M4_3WP,ZR_0/^?DX!DPBLT:3E.71DRC.K<F;F%S:<)2_H:M#0"HNI
M`,DK+-H"%$R3!24;*>6*8<3C'C28;KK,/,9X^Q5F>ES\*QKLF+ZM8$<,*M2%
M8&"A_9$:$O0X+C'.&HNYB40Z,++AEVQC_C`L'P.W)&SS$\]118^3JWO(4!DR
ML!=08!*A5[]AG@ZMJSEP<"&M&1$>0[SPS_]<.&M"CKQR=S0;!R%AEU,2"#M:
MP*+0[COLB%;L&SN\P<\GPPJ(]DB-*]O&!VSVU[C!D52T:^2A305GEW9!6931
MF"M4S#_`+MDP$W"+HXU@&>#SDM>@>I">VO!C(\%1]T0^'@7\*H9,W?6"/D"T
MZCT($.S.6M$Y+A1BSZ`WUJ]#X1Y!%BX44Z5X[(!2$\I#-F<%G^[1GAY4U)82
M@AD"+9(B!!EI>T3[](*#"XF3$>:=O2W)YP-&""#3$&$7A@L=>K(QB/V!MX,1
M#OS(0K7(2^@XI=F/>\TAPO@@'@/PV]DB,U``$!\`R(VZ$[Y)-Y\L@QXG9+-/
M:)@9,^"Z&AP#<=>Z377YSF\#78],2<+I=&FVUI*L%8,U&O-7$]0/&NA;,)>/
MOBCRO+"N=U<L1XL+P_8XN_$/X2J5,-@=G'ID4@]-[R%@7MG0X"A<$VGRFP!+
M&/`+!%RXMA7!RH-01,(G@,7K[MBH?SG@V<-S`L#OMI-6!.+CUQ]EQT*1&`!4
MC/A8NP/0U&SO,;A_X'<ELU:$6J)(%JFK55QPHT$\8ND$"#C/P,*(H)5:4$L?
MNM:6_:B8?ONUA-3VO4$GA*"3/#'D.0&M_NYICTQ\TC$&=.0>%>.H-MBK=5OU
M-EBE@>CS.WPSG8DBM'AN+%O\Q2W$>Q64E&?@G%?%4/V\P[?5KZ#1;8PZ7)K:
M-<%J6!,_?38_*3;V3'1NB4T'P#X@ZE-%Z[QZT;JH^=C-)3U6!I+&T*/1:CP+
MPZ#CZ]00/@(=.Q;.1`H!RO2UXY<4T[(VN(YVMMHY"NRLC'/\I`RK45*)83A;
M!>M!?WHGOJ.?_?)+^MG?_Y*>";F@I8=;AWP(_OA!8$`-3],$([AGTW^)'*R)
MC#IV[>"9:Z9I)&DH)X=UTPO7P875#`67IXOA//&>.N8H[^O5`C9Y.`YZS1L\
MK/=L[="I"A9`D$#&YD_O1DF:9=M$TK7L#_\LTG]^$.(_,A.'AI:2/S'HB,/)
M7F%R>5!/Q>&HU'QZM%K]:7I\J1,4%>:^OEHT]_5IE_L24O,DQ[#$OK$3W^R+
M`GDXZ[(HZ!F?&RP:R^RS4:,9/34S>1XZ'`VG>85B3XAE"'$X:SHI[C</+:Q9
M<AB<A[2,U@TM<P"\W]&Z'99Q<,(,0Z*.<Y=L^#X7*C3>0&R1=N(.B]RJI/.0
M:).NJ($L<@OV)L'B5)^@(]*:'<,G+HWC-(.@NB%S&VR(G0NX7/K-1M`F3<6S
M_<6OH.<[:2#.I*;80]W0?`UFSO,ITYX]2[+G6)P59\_>_MBW/^+GWZ.'^ORC
M^`T1@KV!DBX#_9]<:WO@>?A+VL/P^][4Z65I;^KT;-X;36^"T5.-IJJ>GR]%
MW)MC[8@P=L/>:KM)TS1(=$0_MU\%\@_"R\/.R]R_T9UB%3,.`'@D069T-[78
M[\CKN5ADBUMK!N7UPKDYPKF;QN)H((YF@\EXV@PD]WJG47JGFS0O`\V+@_%B
MP4NE4N1V6Z5^(8[S(8*L0,5>[*M8C\X'(%IV)[M>OS8I"M6K[.:*K^_DP6P^
MZ@.Y;X2%>AN@3B9J<Y#4MI[9.2GY78<LC0<+>[@_'[`O@N.4V)*1CL2@LZ43
MYR85U[7UI>>?&(Z:(7WJN[&^3P^)3FG8KJC#+M1#]X*F.8*FF^85AA7'@]DT
MW_G#7H:^+1G:39J7!Z(\&\RDXJ'TO.IAU/U4W<<C/5":P4+=4*"%@QZ:Y2T-
MDA[UD&FGER;6K_75:VV2HM]A_Y0^N-GS>8NLFI[32W+Z=,'O;$]7+:6&>A7G
M,(D:"HKZ38Z&`N(L^K.AL#B'?N(0N,0O_G)Q\5_Z2OB+XVUQ+,!7W:$;)MJ5
M97@;T_GOX.E[0EF,0R`.9U^FBB("*C`7/IB629+W[*\Q^11L/'GR0R:3X6)R
M^E+B%E/9M4R'XT)/B6".XNR_<)[3ZK\O+D+4TR:AX0V-,FOIIY3FWM7VHHWW
MN;VU<4R8^WIK**8+#_KTIZ?3<2ZIO6L7U?>NW77.7C`14TL'VV#;K.]TL.>P
MK;[?SY9UGL7TZG=ZI-74]^=N1;L8#Z>Q;K2I8D<>9\F=;!,/)$E:T*W^SFJ%
M1/DQH<*AWB43C(M%(V!XH'W:I[#-^1=]=23$>`RRV0:1-)SF`T1/.3[()N-]
M&[)1Q+-KG7N\WV9//#WQQ(@G&"@6T,^1)IE95EZ&_DNI*^"C`BLGO"M:U@7P
M"2T3C@S6$"7%$NATGMV1PK2W+DZJXOT^(-R(@/!\UI-[3^YOAMPE<=QK^_BA
M,F7YYA3]I%?T+99\G99/XZ+>2$^5/54VCRJ[KC5O/-O4<8XB&Y"NO^#?/!5*
MKSY[0=4+JJ/>[*0GRIXH&T:4BZ()BJXKSS#`[%@K]_GH`8/.Z,T^OMR+J&:*
M*&EVY`!53Y4]5;:`*O-I3GF25'TM49Q?B.+0R1&"OMG:UA/!F.U;\3JQ^QG8
M#-C<S"$KSQ`,?44$R_;_RVKF#(10+\I:6@_22\<BTG'>TWE/YSV=OSGWN1:;
M-J_F;^?N.B#>>EET!EDT$7NEVU-EXZARU$>8]WU%05%5;X/GU8@F:&1K$U6G
M9]=HRI8;,I2-!4#Y'_JF7C^_74G8NQ_=$*[?C>?3[WM2[TG]#9#Z1!*+DGI.
M2V*OBUY+#(G>U^X%7,7-O*2J9\[VLO(,LE+NZ[1[EJD>_/VIKE+,N!__J.K1
M1V:*'+6'V.>C77]V?6BJI"JY"%/33RG]?X[WZ(GW]-GU"_JTV1K6*R'WQ'[2
M54*[`7U4'.Q9M=D2TZ$QDDL#'N'W%+HCJO5HPM*U6V+K%ESGN$Y:*Z"1V)56
M0#>630L7W+5-B+"!"];8>!DV[PC$U(@FT%X7G,5"*FE4]8J@30>-NV&_!79F
MPM\XVZRPLJV-\-E4R9:&Z``<EO>X[L[F!W2S2/B*^2K8(:$G.CV9EGFA*LYZ
MP#IO7RR17>B@G8!?!/*"?Q.!]H0BM&D4*CL:YG1<^`_M)66M!&1;>HM3N($4
M\$JP^?3"GHBO5V6OJ0^BH'BN%6CB^3C:9NH?HLIX?_[C@K9\BVEM=N4ZN+)L
M4T$P'W;=%6=#:>\U9RJ+.M#?)*\)%RBG=1K(`#-LKM4HB;SFS6MK`U(>J'S_
MBO+=$3[M!#LVH3D!32=2]I[;L==9MP[+ER<=I\QG:RP=3\?#O2ZVS:+BVXBR
M#MLH23-4<:(D?(=*"#6/'NCQ[W'V6Y%F7:FXW(LQ'HHR3O9'.?4JX%39TEQV
M:3BSE*1V7J(]V9R]8=!Z(R0[%!LN.HXWQ.L-DC(DNJ_$\G@ULGC(JSFY57II
ME=9`2&M\X9-?T[P]V!31+&\/.H4$_ML#S[D$?!-A4<3[:Q8L3O?/NJ',Z+/N
MB$.HPXM![FOR1`PK1VL]GC16UFOJDYN-2&Y*^SUMN@RV,['%N<R8QFBB$QS5
M7E`T0E#(^]T2N@RV\PF*MVVREL]9]'*B$7)B*O861>_`'$3A/3$,6.U`^(68
MQ%8,ZLA<:AO=U!T7"TJ>C@V$?PN^3!,)O3)#8G\F1)?!UGL<30#'>3V.)M)E
M9?J^5_>]7_"F_((FDF5EX4!N3]ZO0ZQ,`HWVVZ9T&=>]QU$T9>+:GNIZ-I;`
M?V+U[:<+L@97`?62D8,D$'L9TWLM79`.O2/4"X@V"XAN^$'-%1"]:\7IK&;*
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MK&N@;CJZ1EC;P-K:"=Z[N%G+;Z)G*P`4E;6`6QUL--BY/H,>[,<6%,,0M@9`
M0``R$13'[[+GM+7[7:I6F,WV^T-PL?D7DY38ZP&Y=%8V./7@^U$UP,^)>I/@
M;&Z:3=Z/UAW$T)Z<:"+2A'_&YFS?MDPA-(8/.@;E-\`:D_%PD5\9M`)K?Z.?
MP0RZA)W#(H1/+\16=8<(MS;8L#VS],Q27H]TGEGNR$;13:S>O8+K;?`Y/,40
M'HB]V5<S2UMXSW^)V/'ZE2BV\WUAPDJ/W*249G.QNZ,%#ZTQNGL3.PF\*UC1
MTM9;`:A"ENY;!E0A_?N6`57,0'S+D.I)BHL9U1)(G=?4:&N(CSXK"&-8GNNX
MBHF;%10W[$K?@4#VL3;,;\&,:KL-6C:(2-_0%'`V*_5>U=ZD\7@@2HMFT,E9
MS8"V,UGI<&1#N*PODRK%O_.A_);;"O22J?F2J73LMR&2J8E<4-7>0&F\Y7+Q
MWAFM$-U7:\5\A&LUUL)D-]?T0S/D4._#M34\WG;@]>9#:\/H;8=>3WJM#;?7
M"+W>ZBD-]5]LQ72)U@R"[4V</DS=)&^KJKU=]#YJ;R@T6'2T/?C>1"ZH:F_B
M4'S+QW)[\=%\\=&-"'GO>=0+]>!P1N][=$("]+Y',^V'WO?HC8<FBX[>]VBN
M[.A]CUY\-%Q\]+Y'[WL4A_J-9:^([A)M(*B*B:U>B"98MD!>MKK=>R3=D`N]
M1]),J^*[Z4">+/;/='<9=KUAT38!TOLES94@.*IBU,N/7GXT6'[TCLEQQV1_
M+F;OFQPZ%$U;>PI!?\QFT/@;]5`J[3DOT^:?#6PZWSM0C35_1K/!;-I'9GL#
MJ$7RK??*\%G],?&2Q\1'TS<%N5[<]>*N,TYDLUBKJKV-A_/]QC-=!ESO]K=#
MGO6^_=F!UQ\W[\V0-J2M>NCUI'>FC$>+H9?;T.FMG$/)#<(.?]#)6WURHY.R
MH,\>---OE>318"SV71=[8Z+)`J0/]+>)ORH,]'-[]IS?3.XFHJ07>6T3>7VP
MO[F":3R<]N*C]X$K]8&?B(/S]Q13PW-'1,4/KD6_;H9`ZCW@W@-NDDRJS,H<
M30=R[P'WYF"C!4CO`;>)O]K@`8_Z>I5>Y#59Y/4><',%TW@X[RVF3`^8?8$I
MS?`[^I6F/\6^2"'F\W!V?'4_OO><BT=%V7ZX5]=$\PSR;76_5FSR47&(=F5M
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MOI.M-J#>6]M2"=&<&]O:?'8<#_N[?%O!+C>6>>\"H4:7.#F.DQO=A$>`(J-X
MP?4]/%O_C]C6-Y,\K&U"/OWI`3.$ESEYD'4QBN%*=ZRQ+,U^N[]^][,TIJ7G
M.W8\NJ'X_NE7:\O0B.VPI=T1T+H.H3_<;PW=C4)@>@Q)LNC_,1+'L#J0-K8P
M%6SV3,'!YT5$Q_&71V@+?S,]\@LQB8W(CJYK5HAX(J`5#T(VX(#D:^/P^QN-
M7!+M$M8-9D/`+E04.M]VAW)!+.IJ=,7S:E;LT!>]^QDNFTW&TQUL"RVLHCTM
MLO<D!WN2\^U)1B):+/CMZ5HW//AN[_Y+[7?/<3<@[R*[&XO58NQ"GLU'1_9V
M?(&5[U*J%H>U[3(@`Y1Y1$N2YCC+:"C';N/9]-C&4M9T^DZR#(-23";/9E)>
MP7%P)ZB$-<2C_D3NB>K9.M@+SJ<7U?`THJ$R0LO!<ZD>_K;ZI-@F:C]0V/3!
MEQO+B]-A,7,@JBPGJ?N$"^.*LI(5<P9"EL%1`M=3<<P;!!\]1S>)XURJH,\=
M'6^\LASWVXI^81/M$[S3?;WU;'4-GL*MK:LDNN-L`P/^DN19!K9CII&T2*"\
MS.*.;B]V]:4!S@US>QR'N$[PX"\ZV!(&!2_\X&V(]BN)83K;@"FT[]%,/K[O
M\JLN"Y`KS[9!E+,W7"G.^M+4\#]H^#TI!CH748!DVT>%`#*>3$H#),>JTP$"
MG+,$(Q^?\1$\=T4/W_`+_'U'5.O1!"=<VV?Z;"L*=TZ9OA`(Y$E2_)5;9WRO
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M0+]@X.?S9FM;3P0O=-(WFV48%=]LZHL/;_$+*$AB"]9*\.CB!`-79]G^?U=T
M[K>!S_0%UY&-Y43[+[;EQ/1#EC%4L7C*'WJ<SY*!QXS=E-UYEC%4Z<YE2<X?
M=$WX45RV/LUA*)TJK8O$F>4:MIQE!U6RY4)8KF7+.;)9%6JM`MP]J6'SU9I=
MV9LO@OK%J(;-5VN-%5#C!;A^-JT!$-4:;KD!44@6U`*(:@V[H[9.`3J8U[#[
M6BV]0LBO8_='\X'YL341ZUCPL61?`0!/1N7E[:6J>AO/P,SL-=G:\#H:RX*_
M#4(CFB:&KFQ7_Q_Z_<%'1[8V.YKIRX^+\3PN.*I:+G\@'$L$%L&O)-8`A#R/
MBFZ00_PJL<\\*SIM#Q4E`_<J2LKL@3K`T<L35WUZP9HP<J^;*BAEE6R3F\E.
M^8D2T-RL:(R7RNZP9JOHZA)<9A/EV^J.*,8GQP7B#>@RNH?LC!T(9EF<'\:#
MY]K.GRL7EAVWO@^]N?CZCA3P2.)4&N=8WWB2?WF[P,@#L3?1Q12KVF%!MOC3
M(F_X].(24R-:ZIN*5=NPT%;Z4Z,%29@HQRHX>DWRE4?T8_*5#\^6@"702':*
M(;A8*R:\$L46MK2HS0G*D?9>&BV_,PSK^<'";S&G0RX?X2D)P3XO5L<"L`@+
M[0X]/;("+'/3-^16><4?'JPOBJD9EJW=6/:OY)E"4;NUR49W8AF0^=$,2'%A
M+$<YO\BZXESU0$Q0.W=$WRP]VV%V9'3E'-3().%_IBTAJ3=6Q+:)=@<_7<%_
M8U5[\R-:HL#*XH;E_EOCJ_JVQ9(YW7RD\'7P,E_,QK/?\]+%'AEJ+!Z\R5Q*
MR5575)U1\ZJ/5%@<UK(9]"K/BBY[)\:_PF+6GW"4(K,Q0+!$EUM01^!?%^(T
MJB=27I`)NAL/(T=^Q;@O,)QKC_BE`-'%%77:C@BK@Q`\LJ0(2+_J!G%<RPPD
MW5=%(Q]?_:KMZ-*/5!G,Q1FK,H`_<I-!5.!F+B2FMMEA]N3USF];L-&VZ+O'
MZL07V>IK?[T9QB&S#<50U>=82:S6W7+7Q"Z\@6Q55V@#D]@&BBPH1C*,K(BM
MPE7*(P%3SGI5#/?UV]+0'Y,^QR);X6503O+,P<O2-O0M$/:[G\6A)$]"RCF^
MGNCRV:&'W,O/5H9EE[];?8[E1%9_^#JB/5B`N=_`^K0_N\XW6W\$J\OXHJLH
M2-,LN\41!^KPUN3#&Q.#C9V\TB,DAX=9@B?KQ'E8*^Z58GXD'[W7:^LYAL*C
M3A8'"CRRO",$66!S1_1SV<W-,NBSP-X2,@5T$#MS$]W!D5K&Q`XB)WD./CU1
M=K8[S!*M2HXN(4?"O.Q)'?_V>\4@X9VWMOX$?/#9Q'8LN/+/YJT'S*&R9]!*
M)45%UH_5&LAR%O["6O/)=#R*5JFE;S\!(RR9^[;ZFV+#N]UO-G4;PUKNL-;W
M2L%AUA]?_>L<_\*H@[/(D8)O#2QE$!ZB%('E:6`Z2)>?3:RAIF<8`I?^5M&U
MS^:5LM7=J#T`*KR%\+V89L=`Q71Z/0:6TF?S`*FM@&+@JR3!F9&'%_<2\7G.
M]S&5G;W(;RMPWV&?5X;ED+C?-1%SU"4T`)X`1M_EDRY"]5UTVRDG(IE(O?;P
M.J:"F*B]LDP\H$B/0["_7<PL[R1%%(0YJANNR1)6Y[BVA^N,YB]]41,'60,@
M?H""Y51Q*PYG$=(]#;)1NH[6ZL>(_S<S&OF:B#EJ+-H"TYU0H*_"G0+M#^=2
M0/690(E6K*?IO$^[%NN[4$G2M)N('$]`<X+GS[>S()9?=.,Y819`G-)QU*Y&
M`8.G474MCA-*[U&HYJC[:`!4X\0I'O(UI!S0+@>R'!9NXOF'S=J)F*/<I'%`
M3YJU!V2"/#]BX1X!4T%W:R+6[&[=D4?=<8D->D2WB>H&&CT&N3P'(J7I>#J:
MGLNUFH@UNU8EX';(D9I.YI-)H_PHJ68_ZF0BC%KYL]$9?":I9I\I%\1"W9V[
MNF@J[=5FYO:0#BTIS2623G2)X'\\@>7[0?*%.`X[EQS9'"?'1VJVXW,*&1X2
MA^)P?%9'1ZK9T3D%ACG<FO%P/*K1K9%J=FN*\_:N]*F<$U.1T2S5[*E48+`<
MH"]I5*F)G/:$2">;*`AS^!UYA6.>QFZ)_B=#\<B^(ZNNEG1R^`BG[#N'5)G1
M+"UGK!>`2`[KOZ":S-,1L#C<)&DZG"\:!#DYAZE_,N3V.T:6@-QP?HS?"L'-
M[TOB]\K::[7I%UE%(97#Q-\U\/RTV1K6*P%;Q'Z"U1SHYQGV1L&2WZ`]"%,V
MV$W'^?AZ1[:6[7[1S1A$[XA#L'W#I:E=8P,'B];P^VL^M0UBHEXZ%YQ.A6T.
M?Z`NV-X3PP")S9H4&EC:KFV`@('\%6SNY"_^U&:3B3*_>J"<PYFHD8)!GJ@N
MM>FOX-F/)X.T=G"6[ZN6<<A)/@-=Y+#9&R;9#A<$9_'<]`RPS6'F-U:RE8+R
M]!SZ(X<GT`S)5@JDM8/S2#%VJ4TLI#/010Z_H%F2+>MH7@;/B6=@NE$.UZ&I
MHJT<F*7I:'X&.#?+\3@LW,H!=30_@RF<.?F@[$[D:2+U5&8K!Q"&KNPC8?T9
M=I?XQ;V7SXJM^=,-(T$GEC2,[OK8&>?D0?2#$;#Q6)0B88S*%UTM3'ZA<8#/
M?A@WT7YA@N,27AS]@ZD;/[T#ZB;%S/I]\`CO"V2#Z(_^.H,`1C2@CI,2^*[N
M1.#>6/:*T%Y!#C84"&/F(;RCFSDZ]"#OD(TP>2Y/*J3#HWNID5>/GM;+':V>
MS:9B:W@UDG_9ATG10X('82*/QN*\.ICL+;I:F/P''5C+*)*>1WNP\*M,\CEZ
M9CXW^4SE*D&5=R_<."W1E#\6-(X`\-B,BCU=>3"&30OZ0G#.8R5E->VK(#"=
M0OHT+T!+]R7(!UEQ*!:1<M7ML6+@!L\N#-_2W1/.`M]"VZS98LD+\:/-($Z#
MN#0=3D8U&C?U8:"$.#X:;"\'XODP6K3:3'&<W_C("\PC[3;*`W,N<S&JZ@/F
M<?,D+XR/NCJE";9"A^>T[::`?GE\+<O"S'-'-HJ.\W*N`*"VHKJ>8F#K)#D*
M[R/^TBYF30VWGV_'_U<2O\KSZP0PZ]U`HR!8M+,7@Z#4)0@>ECF'%B!%(5BP
M41E`</95&E4(P!+KKQ:`A05*'KAF#KHY2)G2K$+`5K>O.+P_FZJU(0_*RZ<7
M9>,/#PIF1;UB:-[68N'`?/-M\DZ(*;2*GW%4,2HC^./_!U!+`P04````"`#F
MBJU")M)1`N`+``#VFP``%0`<`&%B:6\M,C`Q,S`S,S%?8V%L+GAM;%54"0`#
MP%F14<!9D5%U>`L``00E#@``!#D!``#M76UOXS82_G[`_0?5!0XM#HYE.]G=
M!)LK'#N[%URR#IQ]Z;<%(]$.;R71)24G[J_O4+(COT@R29MRY'1;((DC/9QY
M2`Z',T/F_6]/OF=-,..$!N>UYI%=LW#@4)<$H_-:Q.N(.X34?OO//__Q_J=Z
MW1H,>E;'"<D$]PAW/,HCAG^YN_G5^OUB<&U=D^#'/>+8ZE$G\G$06G7K(0S'
M9XW&X^/CT9`$*'`(\HX8<X\<ZC>L>GV.W&48A2"$U4,AMN)_9U;+;K;K]DF]
MV?[<LL].3LZ.3X_:[7>GS9;];]L^L^T%@*^)$M;"OS,+%(+_WAPO/'>+G!]H
MA*VKWL)S]F77[C0[;]Z^_=`].7E[W.U>O+ML]3J]UDFW<WG<J]OP[]1^^^;D
M&+YMMNU%Q"X=3QD9/836+\ZOL<S6X$C\WZ-!@#T/3ZU_67<TX/"D/T;!],CJ
M>)XU$*]P:X`Y9A/L'LT0O3F)T#,!/Z\M$/ATS[PCRD:-EFVW&_,':\F39T^<
M+#W]V)X_VVS\?G-]YSQ@']5)P$/HA?0M`9/U7O/T]+01_Q8>Y>2,Q^]?4R?N
M)@FYK-PGQ$_U^6-U\5&]V:JWFT=/W*T!!Y;UGE$/#_#0B@4X"Z=C?%[CQ!][
M0O#XLP>&A^<U=$]H75!NMY/W?_Z,X2D80]>QY`+GR^!J25S$'/':^`$Q'\7C
M<`[0$(\WEA$:RP(I`H;HB0;4GR;(=R'`BHG1A=%`/>+"C^X%\D2'W#U@'/(O
M`8I<`I]N4G,`>-\U\):IG"GG(,^)O+ACA=)+C^*G$`=N"B`4,:]]+!=(YE%G
MB8A9N_%X&B)^'P\JL%,CA,:BW58#>R&??R(H:]7MYFQL_3S[^'L_?,"LPSDT
MV8T8`Y&6Z?'$**=L_J&'[K$7F\/<MQMF!>XB_M`)7/'E\H^(3)`'K?).V$6,
M3<%6?T5>A%5TD`0TK-8"DY]HX&S5%8L`AL6^972,63B]A:$;`HN"P;$8V)^P
MDO3%.(:5T![^Y8[\I#5U^8P+UL-##!2X`V'0X"L)-;@L`"ECZET3L-P>"0G6
MMH-9$(9%OX2UBTXQ+,=BE7:W4T("S/0(=QP:@?&]15-T[V&=&9F#8%CP[8C?
M`],#'"(28/<2L0#6.`Z\17X4]SM,1.(0)05DT$P/'1<L!CAMR+M%Q+T*NFA,
M0N0IC9T\"-,>#?5]&MR%U/FA[KRLO6M8V+BI!^JYL,<4BW0X51$WZ^T2V"6A
M'_MTX.71((01"AM[F&RJ1.?"E&==-,U*F2("/=L-DLU8S\HL[-8ZS%EJ`_9B
M<WSX=FVKMKP-GSW1X)'OQVAUV'KY\_>'C/HJXLW$H#E=01D\?%YKVG;3/K+M
MFC5FA#)X\[S6JED1!T'I.#%$->L1B]A('(^R*ZAXX;1)B6@=/!%93Z7ZMRNE
MOWS7+R]-J;['!ZAOKON0JGUR@&K+^'XI`V\JQ4#6PIMMU9_]]E35MU55=74'
M0S=OKU*MWQV@UA(;XY2`TP,D(#>\\:PV*'YX:A>$I%+%J^7#K<00Z>IO,A2L
MEF^6KV!QB#G5MUJ^6+Z^.0F!5-%J.6'90?I%?U,NCY/J7RUO;*/^6;FX5%E-
MQ^M]8R4A:CH%_/PA[P_[,%_CAI.]HS]F^`$'G$SP->6[R`]OT=A+2Q[KJ&(V
M)'3ECQ%A0J3^\"H(43`BX#(F`_3RR?$B45GSD5+WD7A*<5I%8..1=!ZRR`DC
M!JUVH?-&:E&Z[/<-"WT1<=BS<0Z#XYX$B2%SP&CR>`<[\W.[E*NE&U5038>I
ML>>)48`#F`H>3(..ZY.``-5(E&Q=/HUA0BA%VF41S0\W#)9"K'0]/,$>C5T8
M#7TV`)G.N28F*AC-&E0:9QDO&Q87S`QF,%%G#?;PO5)^+//UDD2&_HT]@ZL`
MEA2E$9*'4+YMN@"KB$AP&\%X11Q_A.\'V*&C@/R)W8XO0A);VBFI%G(57_<Y
MQ"??!8I8<?L!+$YD%"1+UBU8P2!,2AYEI):&*FO*)N-`2*,U:1=?-SX'1%.?
MT=-LXEV`\1ZJI;9S(4H17;#T`;8!2>(D`O92W^X"#RG#S_)A?D."V+=?F+?+
M*$D0]P:'#Q1^,X%'8H=1G8Z2Q#)>NS:+[\2![AZ9$!<\=#XW=QWW_Y$&0RJH
MI2K8<1R&11?UAP/L8C_>]XG:=57SJ01K6,5/.-0S1RLOEBEF9X*()\+GG^E"
MCFR6:+E`G#C:BLA`[S6*H4L$S>VYJF;3=\"$TD342K;7#Y&H8INLE91_<3QE
ML5#JVEW57+\DBQD.H5::_R4,G'VXFG3#QJ"J%0-[XE)ZCUC5\H0]CU'=B$%5
MZR+V3'=>Y*FJ518OA,ZE\*-6Z<9+6*Z*XE!9RTH:)-8JVGA1*J]%RY<*\0H#
M^E4MZ)#2738Y4]4J#RD25-)O5:T"D9T)&2G5JA9^2*FLF!.O=EV(*/'YX-''
M79>`Y..^Y&J/#*F-IR881L*/2+Y>!?-"28WR!PDP\YF6%0EBG_-YVFF>OE*"
M+5W%E4+N[11;`]MSCZD?E)=%W(]BLW*^G:FU@E?&\7I1@0IV*G'9-:I5"D`,
MBY]&5>Z0A_O#I3+BYQIB%5UD$0TK=H/8#QR*"7N''7"5A"6:BZ:B3C&.:LW$
M-P``3H;]X7P=@.WPW%9*'2.5@C$]D5]'[>.B--=4K&D3[";"_!=[[@?*OJA-
M<TE`\]=0))DT#4.U_J[I/N`\$M=&]8=)%C!POR'&P))P8.L.LPEQ,.^SKH>(
MK[9XJ`&;+N@$;Q!?P!H6%S0#L['?K53`F8-@N@@C/@SZ/R+B=TD83JG6(N-M
MX[?YC!EV2++)#40HFX7D3V6Z"V'^+B%\E26$%:G6`8?,P=B-P^R)B[:ZU*J5
M2VU&*UVAW,-PVVE6`%NRBM#X#1(1P'#:'V:YJ-LH*@%N?%69QN&?SS0.\3*\
MFPY50"UCU[@FS]SL*IX7V(A5QIV52:NN&$,+87D5/0IA5%>6`1XGC(A92P*'
MC)'7#[[BP*7L0WP],>Z,&,:R8T@#U/A1F9DP(DA*@PD,9&%S50]O%,*4J,(G
M&F*=>%T^1HDF.=U,+)3MZ9K@'+"23.YL/S070OF47#'.7OIDI9`T<),/L+B-
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M6+W7,2_K4=6B_NTHV9S0TBKPK_Y844E@IA0IN#`'0)%Z+CMEJEJG6'=+5&%U
M0TK107@XVA2ME[8\,].JUA7A&G%?B4MJ6M4*^NF1H'X;0>LP_&#)P;'U;0*M
MPW"1)>DJK"1-.3F(8)\D)5EEP2D3!^$*2S*15]6=LG$0X3Q)-A1K]E.2#B**
M)TG2^A&-E(>#<'!E!XO<89N4G(-P;37(43E0WWX-7J[4$;N4DHK=MK+=P"D^
M#IF2\JH\7MDCKRD]K\K#+3C=G#)R&$%?6?,K=7(]):=B5RX:(6?MMH*4GL,(
M`FO3LW9!1<K,:W)\E:XD22EZ53[QYNMH4F(T_6&3=R>)^YX]RB,6!QYO,8OW
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M#W\!4$L#!!0````(`.:*K4+K^<*4XBX```)M`P`5`!P`86)I;RTR,#$S,#,S
M,5]D968N>&UL550)``/`69%1P%F1475X"P`!!"4.```$.0$``.U]:W/<N'+H
M]U3=_Z#X5*62NB5[9F19MFLWJ='+46)K5)*\FYLO6Q")&?$LAY@#DK)F?_T%
M2`XQ#S[0($&"-$\>]I'%1G>CT6CT\Y?_>%VZ1R^8^@[Q?GTS?CMZ<X0]B]B.
MM_CU3>@?(]]RG#?_\>__YY]^^>?CXZ/[^\NCJ14X+_C2\2V7^"'%__KP[=^.
M_N?\_NO15\?[\PGY^.B26.$2>\'1\=%S$*P^OWOWX\>/MW/'0Y[E(/<MI?9;
MBRS?'1T?;R!?4(P"AL31)0KP4?2?ST>3T?CD>'1Z/#YYG(P^GYY^?O_I[<G)
MQT_CR>C_CD:?1Z,M`+_%1!QM_>?S$2.(_<^']UN_=X>L/]$"']U<;OW>Z.IB
M-!U//YR=75^<GIZ]O[@X_W@UN9Q>3DXOIE?O+X]'[#^?1F<?3M^SOXY/1ML0
M+\AJ39W%<W#TK]:_13@?W;_E_WM)/`^[+EX?_<O1`_%\]IO+%?+6;X^FKGMT
MSS_QC^ZQC^D+MM\F$-T-$]G.>/ZO;[88^/I$W;>$+MY-1J.3=YM??!/_YN=7
MW]GY[1\GF]\=O_N?;U\?K&>\1,>.YP=L%\17'$S6=^-/GSZ]B_XU_56VO!VD
MO[N-S>F[^!_9K_K.9S]:ZBNQHAV5(.$H]S?X?SO>_-HQ_]'Q>')\,G[[ZMMO
M&+N.CGY!U*+$Q?=X?A2A^SE8K_"O;WQGN7(YF='/GBF>YR*RP9[#/^60_X9<
M]\U1`OC[_<TAS8X7O+.=Y;OD=]Y%'[S3AQ!;"WM<OH]M/$>A&\#0R_B\&63)
M$CF>,J[)USI1C98X7N+E$Z9`/'<_U8CD,P-!K?`)'Z>\@:&:"2!!6!9;].20
M8Z[<1B?Q\?O;(V:_Q;3UUTA'["/#R6+K\\]6SX@N4:3Q-P#>17CM0MA#"`@P
M0*_$(\MU#'ES`VW^G'KVE1<XP?K&FQ/V;1"QH)B^>P;H#PB@7>8EY+`#YW@.
M_S5.Y<YOXM<`>S:V-]]SS#62&^'#,'*)E26'D?3XV'J[("_O;.SPM2;\+YPK
MD^/1.%&[?V,_^B.&SNZS)?$>`F+]^<!PQ/XL#/CUPLV'7::X_#(@=/-#%SUA
M]]<WLI#>U8_ZM>-B>L%D;T'H&H;KWJ>U(G<14LKV[YI95\C]?QC1*\_F%I$L
MAOG?UXKF1L[$.M?L)[XLEKF?:T3R#E.'V!70W`&@!=%X!>".YWQ<*X)3MH`=
M<<)%T@=[[R,M''MD.$`9%7^C0:5<,.`4N3=,I;_^-P8JE8./-2!XCQ>.SU;Q
M@ENTE.9;]K<:T+M,S#T(6O$W?TP,0ZAF=+[B!7)C^--71UI_'7PFA=0<^4^1
M%<F>_PN$5C%FV`W\S4_V44Q^_,=#P%1/=,30DRLE7WE?YB)Z:*7QGTA9:<S\
MPC=L%2GVJ4!-D18FWY1:.XLQ@VZS4&*;2SXMXV_FE"S5<$N0(/DL)]3&]-<W
M8_;H&+T=C=X<K=A]0AG`7]^PTQ7Z#%.RXE`11R=ZH7RVB!<P(_;*C0`QTQ<O
M^%_$O[O$Q_:O;P(:8FW\R7S<;/.K1#Q)SF$1#/E0SA!-M&6\V[<I*](-)%M-
M"JK.3*!J1\,J$64(2;O.@/J.:_X-+,C^U&>R#PRCE.ZQA*+J(MV[AFI*[F3<
M3W+WW@F"WIZ>YIP'6TKWR4F_Z<YX30O:>ZK*<AT>*>7O>ZK,\AU2*>FG/55L
MF=Y"075/U9N,/S=EP@=I7??+NUU'>HVQ@O1=<$$\G[B.S?ZK?8Y<'B9]>,8X
M\+][*+2=0'CJ"T,&"O#:BQQ`D-7K/?CJ,(Q=1B_VF<!%HO-,7"8H_M4_0B8;
M$']".2SMKI`JZ+>`\#T.F$[`]A6B'CNC_M1B9S_DP3G[DLFAY000`F2@:29H
M:MM.K$+ND&/?>!=HY03(A5"1"T(SZEO*\S?DAB!/VN&WC4OZ](D_4RV0P!1!
M:8#;3L!5(-<53`T&3&*Q9S'=`65\+AC-)&RI.T4MV22*B4FHB&GZM6:$F9["
M;"7[GM^-[$\G4,"[`(AF]&?!,Z;5F)X+0C/J5\P*(FO,#+OHPJA&A`0PW1>1
M99&0:84[M.9^9P4:\B`T?F15-'L1E.8(R+0"*Y)3`E.W6/D^,\Y!8I1\T83F
MB=>Z)9ZEJ'<.`6A&^XZ2%:;!^HX]?:(7+]O.%;_.;S$(^V(XC0B%BHK9_;`Y
M$5&]EYI%^`+YS]RJ8W_P_7Q!;F3G!1>(TC6S\^!FNAS`)L5%11OF`&@$;75\
M@8@.22/]3!H!N+X.O9UEN2-JP!M-(:E$OTPFB4S$\J?*))E,>I=S,3$W6EF7
M?.]?&H)V(V-V);?D`6$'M[?AD6@YXX6`;2T1BC4R'@DF.\M,%C0:&6@'TYA'
MGIG!5?F36?R(%.'3CBN@G)=^2M]9!Q10N7AN$?312-52ZVTI[R`37#%:&8&]
MB-G,R+]F/QFMK"2\P-L2G^.JWA`[ELDN[PJQ$K&%E.ZQT:H,1G=N8"BEULQ<
M535J"V)X@MZN:#`)>@LW]J0KNJJ*JMZBU\RTS#KH+<Q72.D_[8K:`M,O8YF,
M/QBMQ^`;OIL9),@T6GW!R,Q-VDJI/3-:A\&HE4FT2PG_:+0RJWI\MPC]U%NM
M59[8NF'"9"2MNUK-K;Y#W,1XQH%C(;?N1.MBX"9G7>=@WECBJ5(_%SDXS67/
MQHO?^'ZXO^E`_#<@FD9]&@;/[/#^51'];3#-D<!$>$8C2;<C@^,.TP@=15+R
MP0U1_`.,ABA^F2H]=&)6#^F7KF18?%^6,T/;B,ZVC?A9&BQH$7:IVZ<+?1AT
M<^?0S!!=&GY>F=FU'0U/&VF0(]FUP/+9)DV_5],?^K/YC-T:40%T[#5=KBA^
MYKKV!7\E?AV%PA46,^P]JT*)7BOU=\Q[;F-[^L*P6>#;D!^#V3R2RBVA/$>^
M8S$\+QTW/&!OL36KNH)F\[P(K>WCJ))3#8>MNWXL\85NKN@*VUD*JF%25/8G
M'X9FY&]Q<.,QI1$=\>D+<EQN0#^2K?L@\5U&;(70!`:MO7@H"1)'2U\Z+X[-
M-"O7=7&*D_WWT(]C;1`J(5`;)7!J611S;3Z;WV,;+Z/[F4^$X+D?ZA26@&U2
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M]OX70NP?CO!,2YUD&&#M/9&8I1Q:04C9JA?,=E[`-B;[^^:UTM1BMY$?^0"2
M5-4+XL/N2`A4W:$F[+I<"IC10I'+=/[47CI>U!J7#R9+#@$H!"4)4;^X8<34
M.G]?XA?LDJCB0X&>$D!-Z;)(''CQ2J*65!ZO$L"&Z.\0_:WL>*PI&EQMY?:C
MP[5P;B@-'TK#NU@:7K?P2]Q=AL<$X5<ZD;9"1-S/R`!Q)=)E#<J.E&,K\0#R
M8A`%S4;76Z@>@XQ'H*"X?SL/?,2+:N_^*8(,UXRH>C92Y;=P/6[[V0POBM;/
M'6DGJJBH-E*#-"='JDYR49K]DXI:6?A$5#?_Y)HJ,RHF2J)_\F=.H^%3PPNS
MF^9Z1@Q?E&[_Y&IM+RU#%#O_Y)(#RKDQO&BZ+:X5YV(97G#=TA&42=,SO(*[
M.<[E)VV*^FXCA4LZ<[6`V(,LVY3FG]U4A^=:IZPS<YQFY01U2>84Y=ZG+)*?
M/MEF!<K>_9W5!2)I_5%S-4J%A0VN3%&A"ARD9A#C,K#+R`T<#S^-A?MW1/E,
M9__J%5/+\>7J$Y3`PF/KF?"C\L?:L<Z#"D5:&&*/)*<5T)4?.$LN!M?(H=&Z
ML_EF9?E>$76NUL2(MCQ!V30QC'YI]L-C4O_LK'CC65@>A^(2[9`>[8-6RDM7
M:'//MP)QH"Q``-`6][5FZC)@:E!*['IB9HL?/<0WZN&:T-W;J4Z])+E@FV*Z
MC6+\]X!'$A^PQ7X5.NRPZDH:]CP*#3M6D##['KL8^9C[/S?_LI5F5,>>2RYH
MRIY_9]:AGCU.(+>HI)J0;=F%=$_2W#C+=G6+M$:3@Z-^/IG6N^9ORNB\Q+*B
M<.@RH>@>A"6\CKEG/M'M\"9H"L`-(#?B_!/3:I&+!7L^BM.-XNN;B3U]<2P<
MGX\D)LQ_`3S`33\N)C!3Z!7^_WD7$'#E2+5UVKR*8JL]\OS`WKE5H+=X)>FB
MMPCX4--=*BBW^$?T3_590EL06Q2W.NG:!ZB;K"K-49OOB)K5)AC(\KVOAYJK
M`XQ:J[DZ#!A!ZJZ^9I0?25K0MR2(NE`GN=P\DX!?X$E.S[>=:$^I(2T'#(IB
M'&@63R`@4GF?0]'8&#6;@-8C85>@%?):@(?PZ>_88D_V>[Q*TA6!2*H!5R=A
M*WC/WCS\O_';'+E?F2WK^3C.3U6F`00='-'`+[QYW1;'DG6XG+DN8U7(+--D
M]EH5>JHO!";->6V$L(K+@%_I(CV)/9<<[)\#$<X'4!F5JIBH2[%%/'MK$V*Z
MMIP[/),++WFNS:ZK!"S%51>"DO;X[-`F**N\#GS/^`JS.0.U*2$!;T8NA'H$
MJ"GYT<CE:V?>A!*LN@R8+!+21NBJND[5XZZ)KJK+5"*++139MLE$Q+KLY4IK
MP,\5]0/]^J+J,I7UH#9KL.(ZU0C3)('5%JDJ@MI4>[5E*I&E::,JK0%^<2/_
M^18'LWD56Z<8B.X)-B[R_63KY9U2^5__,>D<RLTYK[;7EO6V20"!2FV2X;D]
M/2_R+F\UKF"K+:"N&2A8[2&_S.B;/%&2@)H;,05'/>-C[?WJ@'Z+G`\;07.J
MBN:T(33C"`2/IQ./'1^XMLL$T(".UH-X<YIZ;WE?65MG`^I>ASKC&HQ)<EK,
M*WIO0LLQ/$>A&Y306BA\1.)PFS^5JUZ:#:%8HDZP4"V2W&M&D/>Q1^2='Y`W
M;K$O8(WD99A=@L1^"&B)42Q:_8TZ3:[2P\:$-I<Z;MC#EZ<1W2^!MVON(YR4
M^36,Z%\)NU;5B#6$U/+S6^`*(E+>-4&GT07C$G16\GL*-AC97DV5#0HN;84!
MC89RHEK$HB,-:\%\J"(2[XWNUZIP.*`A1\&)KM\*E0+*'6ED#&5#E:-QVG5M
M63D;1+"BZPJS:L)/1_I;JUP=R@KS0]?/1T%"GB"RZY)?.5&R(XW.E45?B1=G
M79?]W%SFCC1S5R'QT#=[UGF1KIC-+WK9=_]>JUJP87A??P`O%(MQ!`.Z?BS4
M*JK$Z(*N'X:\LC?#AS,`*)2K-A0C%MJC]V!XFT3]I\0`MO$P@&TW7C/NWP"V
ML9D#V*`"?%A];OA@"B"!A^T`#!]RH+"!Y1T;#&_/7PO-!]TW1*-XHTTF.:)S
MYBU,QD:;0]6%.*>SS8;^,[-]?C4(=!D#/O;@&JK6Q2IAQ61DYJPN#:RHU/DL
M9==)#XZ.0AN]#?T?S':K%-,OTQYQ0^C'/FQT<7O*E%2SXX+5KT.)?J,;7GSJ
MP[9#>\ZFQ'?9+JBYX7#*DX]&.Y9J%HCBTW$R.NGP2ZCF+N0I3\Q.):BN/7?[
MS*=D=]D0D#H7V72/S9YQ57V[BP9$;)@P&??@T5"X^5)<>-]ANZG.63$I0[KL
M*%.9!+0A_).9LP&K$YX[N"FA_/U(?OQ=QP:4W3'*O>`9!XZ%TGA7X]/*,K'H
MU^BR71+UUESOHL=6GM$(^_B$;X8][O*YN!9;%J):F]@X5PO1/W%P1V/WE#2&
M4F"&KLD'&/6X:_+0/<2\[B$=:QTS]`Q1ZQDRM'_N2?OGH=5Q%UL=#]V%A^["
M&70-W86'[L)#=^'N=Q<>6O$.K7B[V8JWOWUMARZ).GHXF=$AL9&N1F9W":RO
MJY'9[0(;ZVHT;E&RS>IJ9';WP4:[^8Q[=3:J-*<PNT=C8]U\VJR),ZN;SZ3S
M^K*V;CZ3KBO,VKKY3+JN+^OKYG/2*X59J;G+2=>59HV-;DZZKC9KZY!RTG6M
M66.'E)/V]&8+8Q9.6DS?;6?B@-E=06OI66]V-G+EH0JG1N<65QZJT&);/DW]
M7$9G$COV,_5S&9V9.NA%N9^+X3WU)!+?RQ)D.])93^ZHRB8KITU`Y/NKMYG=
MS_WLUR[YX:<YY1OBJ^7KY\,U.`,_`VE@D/8WABJAUX['C>KI@F*<Z&*Y\&S>
MY]!8<>()O$Q$]I$BSX^K]9,6%I+XE,*!(K;3&N&&-Z7S<`3O=R=XOF!+.,$U
MLAPW:@PEB20(IB(G-S[5F;?M>DW>T(PQ9-/,"L98:;"Z(_.)X-\2SV)_O6'K
M^X'C+::>'0LC_SOCZ4M4U'SI^-RH""F>/OD!;P,!BN-77DLS,S:;PFOY((3M
M?J<[MA^N5K'%A]P-1V^\.6$J,+HZ%39&&F0#PLB$@?_!Q?\%N='K-;A@YWS-
MA"-I*P.3.`F`K9`5UPK>>!;EK10N<?QG=>KRX&HF\A8'')$[2GCW%/M\_=WG
M6B[C8$-(A$"%*OA[O$)K+O2\`,]AX%;(G7D5[W$84,U[DB+C[S2IN,1/(/50
M"*9!$K9O2E7\=V%H1IZ)K86Q[?,^*9G-F"%42`#334[*Q;3P>:LW&H"20CBM
M[,E!!6[\`\S^L::-*E^A%<+S(D#5"<Z'W""AJBHC'T8;NT0?V-4^F\N_-"#0
MC+$+5"Q7%>CM$"Q>.W4:0IE0&Q316)38^P=Y"VX33'T?`R\#"6B-$[0)?_+6
M-0'3U?RLK&3M0"6P#9/(%O^&`MZJ;#V;QRY<M->^3)U0">`-62J/).I'17$]
M&PJ`JIG`6?",Z0$^YZ'O>)@=&M#VE<-JXGT<KVIS&=KJ(09^#N>!,4;IUWC+
M%4)OA^`9.P^H]ELN$ZIV7^"N`^7&V_C"+YX17<#HD@#6.#G1L4\Y^]5!3]Q1
M#MPP$-C&29Q:%@FY2PS^`)``UO*.P4TM68CM$'814M[2JC:R]N`U3]2&K4E/
M0!7%#X':A,611F[X>(BK5]X0'G2J"H!H1O\+<CP^SV+F99CB2M:@+$3-A&79
MUQO4(.04PP%'>QD`QI/Y;)Y&D-'KYC(`!'A+P.@^U,L5<FCLS=]_E5Z]6F[(
MQ_Q\(<3^X;@NZ%S#`#=(YE?"+^T7;,?(_"=V[6M"O\..N21`S62E@S\5%-7A
MM[KW8#<=FSTFM[IH)V,V_!F]<)$#:W4'!*P[>,U3I<[WYXF`8M4Y$+1[%'A[
MW_]VO#1S`^8Y./Q:,\*7>$6QY<0!?,^>+@D-G+_`["X$HYF$C0N";?23XT5K
MGK/7$KN4[I*1G?R"2L;._(4Y<B'L#E==`7H="EN!:4%GX24!8A2P/^/:"NDK
M40:4;L6Z/0F',\>S'!?OC`U[))+O>!6K6,_Z^ATFVU/50#Z1[0^-\>O4Z,BJ
MOB]#L]VAV6YWV\.JMD,K_G[HZ33T=,K\TMQ*(`DN&U&YUW!/)[/'!Q?7'!?K
M*$&BT251<B06UIFV5PBEJU+Q=)@\OZN13GLW>7[4AR&7*H^.CA105WBME0_\
M;K.ZNC':]?@21/VKT>='JR.'`!Q6*;\^&GW<=/.KJELR9>,GHQMW-,7&0M^U
MX)716JXI7F5%*-*"=K.GW3?%HKS(4\HF^:E^?683,."8<F\R"%EFX%FTE1C$
M2SZW(.6:V;Z3-K@FD7"2<L_L]U\C]FM9#I+@U:#`2O/(4F:9_;9LBEFR.80I
MVV2Z@_6?;05II"FG/AJMN>IQ7D#2@U/&F/TV5,BC+F9(1BKXAA63D=$RHH45
M!\G^*3/&1JN6NIEQ4,V1\F%B],VD5RAVRG52CK39^+9YCAQ49J5\D`EX=?U*
M@53@I8SY8+0>K10E*JRQ3!E@MEE6H3AU.[I=5%Z;<N*CT=JS'DZ4%TRG[/CT
M$P@&I"Q^PY@3LTVOFA@#[XN0\F?\$_*GL$%&RIE)%V_ARIPY;(HB&&*T>58/
M0R#M;U+&F.TPKV26%#8X2AE@=E)=A<Y0.4<EK\55RA"S7;3U,V2W=5G*!K.=
MKQKEHJ`I7<J<3MKRM3"GO$5ARJ1.>E>A3"IL4YFRPFQ_JDYYV>D]*OCQ$^C8
M_(ZR&S:\[Z155H$-!XV!4TZ8;895XX1"S^>4+V9G)M0C(9#^W2ECS,ZYEK/;
M8;W94]+-MLRJD'[0=#^EN0\S@J0G**14F^T9A`Z9V(FH;`_#V-![.NJ)9%<;
M8)*RP^Q<T=JFPFRN2.C4FY1/9IM1M?,)--$H99+9%I8N8<J?394RQFP3JW;&
ME)F<I_+IG!HGTPE"'I\Q3Z5'WIJ1_!`NEXBNV6O;67C.W+%X""#.TF!\N".N
M8VTU)RV<45?+"NU-JZN&ON8VD'2!O*2(1@S3BPML[IAJYQ8#_Z^S>2+"R!5S
M]K9$F)%31,4CX^:Y"YQ#T3QN0V^:`XQ:ZTU37UN,SC71Z4:_@-$PV7BW7\"H
M?Y.-^_#*:_X:$>R3?NTT8I_QA'TQWQAD>&5]:H)%M8.77H5_A:C']CM=3LFF
M*0`R&!^#\3$8'X/Q,1@?/3(^"O2]J5;"-TP7F'('Y6WX@EURXUDS[[^0%R*Z
MGIQ-&+I`VT$>H`D6A02VC;?)WO(@J1@=LA`'"V2P0`8+9+!`!@ND1Q:(K/(W
MU1RY1@Z-4DS$CZ!1HR(0)I@<F?CI5=]92RK9%B6`!I-B,"D&DV(P*0:3HD<F
M18G.-]62V%2C9LT+E[0DBD"88$EDXJ=[V$E.C6]%IP4,[F!G#';&8&<,=L9@
M9_3(SH!=`:::';RLTHF[*/(R&A)EC6!/(?M5`I()1D@1FOKGQ.6L7-$:@4(>
M[)'!'AGLD<$>&>R1'MDCT$O`5(LDKLI+:Y+\K9D.0(M$`I()%DD1FGFZ/6?T
M=P$H11-#">Q@7PSVQ6!?#/;%8%_TP+Y0N@%,-2[RQFJ![(IB(":8%#D8ZM7D
M8OFH6U>Z[#UVF7S94;F\0"QMY*OB\*B\U&"A#!;*8*$,%LI@H?3`0JGM5C#5
M:HG'3CVB5W!0)N-+$^R3;;3T*N]TI8HAEF(X@SDQF!.#.3&8$X,YT2-SHECE
MFVHK*'3Q:J[=64_:GI6V/\L)SR2]!)/YH3&8-3P<4P9&\P5V03R+G1T:V]:.
M_V?<*I+_#9:T4@!&,PGL`>#XL_G>SJX5-@0*,9>P')&YQR^8^O%(A(>5ZP2J
M0E,."(K:)>85Z%'*&U.H"\QWSO_J_"-T;"=*\OY"^%A$OLW44T6[VB*ZQ2BI
M7KS$OD6=5=*VJ:8&@PK`AV?(\`P9GB'#,V1XAO3H&:)P#RB\3<RCOX;K/^6#
MV0WP)?A0;KVEM$Z,;D,N*?.2UG1*](G1(\)D$S@+'D0II>^-G@`F(<IEKU=!
MJ5F.E>UFGM'-"O67Y`,PP0V2@9UF`]1ZQG;()V=>(-<*W:3-[6VXY-/?"67*
M_1(S3'E;&$)OO(-F=1Q)I9=5W2L/SZ[AV34\NX9GU_#LZM&SJ^Y+PM1X4593
M#B7SIAR0"69.`98M=2*IM__(8)8,9LE@E@QFR6"6]-,LD5'\IIH:V54I2L:&
M#"@3S(U"/)ORKV0CD0Q[7-?A1X&MH/LN2]&Z8EM/UA@_8/KB6#F;,74C*B/K
M_AY;9.$Y?V$['IX=I8Q7Y$WM2`QVW6#7#7;=8-<-=EV/[#J-]T4OL@&JVAP*
MJ0"FIFM?X@`Y;@/9VGL+F6!/5Z!"(?'6"_$7['%_KZ!"*M%V]T/M=SR3\&?B
M,@'WXSX-!]DBL$M?`IQFDM@KU\+8]J^9AKCQ_9"/F(]J.I?$B]``^DK+@$%3
MGQ]_D/_%E,P\)I`4'W1P^K:CYDHE1A*:9IZG"\H_!G(^_6/2(62;0U7V09/S
MH68T;W%P@?QG=EA>'*:TS]??V<UZX\U67(MQ).*+]:!XIY@&"%3-!*9KQG5=
M/-\%0DGFYU"],64WD^6L^+40VVJ/A)D]-)@&U$'NM?-$'3>.-#[R'TAK$#!<
M*.*W(==!L_D=`\*+YI-+F'LA_4=RY;%K6AY;.6!0%!,H^QFCS$Y(L@FWQVES
MRS!$[O3)#RBRI.['&A89/#<5/#?%VRYM#D8/`Y`WI)9E-"NW;^C5689+><,C
MYT/=:+*W@AJ:NQ]J1O,>>0L,1W+KLP9,H.I(-H,BU.S9^J@17:!7!;3G**R!
M(R1S5X0_Z;T)KD0\1Z$;[-*>+X#[)(GC:KZ'%$J5(325N_ZR5!G)5?Z"J(]=
M)FKWXA7^R5%K1!W$8.HTL$@UC23X,^E90*<>/5T<]!FW6!ZE*>@S;O'RR3_\
M&D^,XIM3,,S(*Z"^ISL!>1=$N61[^K91MH!=1**V4D+C=IQ#A4X^49#8_Q.D
MXK<5_&G/'FOX-;3GFD\Y<-IB<:[<BR@[&I%%FHCE"/),-2-4J3.$MO+'1%Z\
M:Z/=)4.(@EHCFP1H4642X=^4+1]^'K9(A?E3QIP9F3I4OY5TF+R1LN"3M()H
MO!V!6D90`0034GVRT-/KKMXOX>3R8_$Z3\<-)3.`I$%I]KS_CIW%,UMHRHXT
M.PR;-U&$B\^U((Y.AP6A21YF&\0EG(VQF86!'R#/YI:`_??0#Q*_3S5:999H
M<U^W4*IW<P\!ZT]&$2^PZ0L[^U$Z)]FZM9.K"TPH&'23I"H3HM)8U"+,.'2=
MXL+V^-VW4P*_I\NV]30XGT(S%D/"Q0%&/2R5R>M/6V1*'+I;2SO12H)K-#@#
MI%&J8D;"B].I`$OEBID6WSZZ@B?F.KWA$MW$10(*/[;$N69N=))K@70AI-(N
MCV3,3<%%<P.<C7,1^#H1/#0R0\0@'LH\:44@T-SXEQG<S'2&B/#8<*#E_6,B
M4B%]X;;E=DU\RM6]KWN`#'7";K#4^VSDZ0HV%P;G!3]@*Z11L/GJU7)#1B*/
MY7"_?Q@D8K@O3],E#^5"7ILU+0A]I&[@[+3?52Q.D8(UN$0&ETCAP:[9,W((
MU1P'22[%0V>1H;.(N9U%J@FV_%5AA`>LA`V0^Y/4?MN;VE7D&Z8+3']W@N?;
MD*=%W'C6S/LOY(6(KB=G$[:A:BD#8+@FV+#R2.N]]C>#?)AD/?'W%*/_'-$%
M$^^[D%K/R,=?V-]%-Q^X#:NZ0D-C\J;6/T+'CS9^@\\==2PLFAE=A)2RBV?J
M^SCP>0(J>Q+R/WB"T@MR>3JW"C]J6M@8-L5H1K]'V9O;82?"C108^P?V<K=O
ML9+8U+1P\VSB':_XM*`8K?@NWZ&@(C<DX$,M\5@II7KH\0=YX*EG21XG_[];
MAH7J2U`1^O`V'-Z&D`NSRE-199&67HX5^#$\)(>'9&<>DM7DO,K%TX679K4;
M.V.@)\S`,**6MT465;%(1033R.&);?%.ZM$C>&>N"JN==]`'M(CQFE4D<HT<
M^AMR0RQ^I-@^5@*2";Z>(C2!]G`**CX?YSCX@;'WGPZF#*_G]5=>;^0_4N3Y
M<TQ]>6=-!>#@?DB[A_F",-/&YP6NL_DWXN'U-T3_Q,%UZ-D^O_6_H2!QA$K3
M46$%*#%96SNU;2<^5JHO92!4S:^_;"6<@2/D80@`6L>>U+D3@X?"/`]%ND_G
MR.6UM`_/&`=?*`E7[-@G)<?(3=]^%RBZ^&"^@OK6TMW0<$_)*70VS('0U"[&
M%]`WC/B!LV?<N&%F89)+Z7_WR)./Z0M_P-]XJS#8S10[7T>?7[C(]Q4Z,6O"
MH8G^TSUF7X,:9&MM<'?L?"#-H9^EEL".6SEX;3OS0%03J7WJ4"/)<I'-(EF#
M7C/?26H4RPQAF$2#%]T7"BDW.4QHK)D[!ZPVLS-;-Q7H-%#57"<#-5#=7M)L
MTH@F6/762QI9]:?C:,@_Q;O0B1/BGR!*'A-1:C:(2('?K`L5>6H.1E+=$]J%
M`KMJS%%S=XNHBEDU8)L9W-OCM]6B*A*03(BJ%*&I?1!<]KAS8(IC,1S-#H.I
M985+7C&)[4N\HMB*C77V=Q='Y]?C@40:.']%/\_%%4)P?6OJ'_67O3*[G6`-
MD<H@08,;7]D;#//B_)OEBI*7Z&+TO_MX'KI?G;G\W)!2.&UQ&$8+")S*Y!9V
M2S+&\'Z-A]I&:5"7',`AI-1Z2"E7I)2"1C+0-!.4>>3AL:%",+I#T5']$Z8/
M9![\0!3?>`'R%LZ3&]MP<&(D`>IVWH>4&4[,IF&"<>V\\K\I;$P1%,T$I-(,
MQ_K@TX9$J`+*N2#:TDB/#&EXJ$X"7`-!R^:):H^D\S7'`AI4E`*GNP(DG7"?
MSV!P;8@TS+9=T6#J"7#W.A1TA`BW#!MVE8T1@3&I2*(^/AC"A7+_+41U$XGK
MTX10GSZR\\DUL_%E17*+K-&.A+`JRG?)F\+P4%5%)A2^$DT8_Y8;TP>\^XF*
MB2"([VU/8P5SJ21ZW[]NQV;VHU4[!$#GIN'A:37?KXR-M^V,%DPPTL939H)<
M=$$ABMH)ZF7#/F*&E=G#O53IKR_2M^'4>&)NB;$62=DI$A[+%PFWG6V@UGE6
M'J#AN0=EG6CS&IULG9*]PW'UNF(6"'YP/(N])2P<[;=TS!$.6+,K448?0-R(
M<O"@L=^L'58M(I2"-41\6X_XFM#FJ%RS@,+/5:"WU-A(A0-#1Z.AHU%G.AHI
M"KC\5=*%QD60^Y5`+WOQMC:WM0Z0`8JVG$*3H4;>#WS2D!.-<O%Y30.))MQC
MC\^W5TM:E@=HPOM!`EMHZT['Q7[`'J%W:!TIE!#?8;;74@."RR"`^XBB5V<9
M+MGG%@.$%G@VOT=>]`=9(Y<7&#P^H^`">>?X/&1J_(?\>T8)-I@`)@S:"%"!
M#7Z^;$./P*YG3ZZSX`Z91\)V^#L3:7H3^#/J+!R/7SD6UQ_3!<58-JV[KI7J
M$*^=E2'O8SE@=0B0.HI2P*`H3CT2/&/*+PZ+[=7^\?>_K]@EL^+NVWW?2P&J
M,*#@N32UXJH)R7UPWY"-S]?<18B\M;(VWH.B^24\6_%)6^Q.BASY_G7(P_<;
M,4RXQ.Z'I%<?Y*4,A:Q4'_&-7:C/;'L=&AN*3!=),SX?0+,\OV?D)T8=L*RH
M!)!V]]X<L[VS^;(7[$\'A'O6UYH1?L0>\H)[["R?0NK'H2H(RMG?0^5VYN%'
M]BA.CL`C^8H\VV76^S6AM_A'M)/V'<5+QP<TPH,!!5\@KDM^/))'3*-)?`JV
M0P$$*#+W?/*A_TBN(FN=0Y3&(NM3^,T4/Q(BGH)6S_A22>>!%I59K*8R0XH1
M,U<P<J]\[J?:/'LA)RP?AD)%5]Z[2]6Y#P$Y^/@''[_4Z[^*CQ\$O24?OPH'
M!A__X./OC(]?4<#!-TH77/T*ERZ1N?R[X.57HWW?1NO"J(`*E&:8P(+BOLEU
M[I-#I$2:J^`JD%SPUA-CU8U.AE2E'/8*3YGQP>A\QPH:/=MADM+]L6]"4.3;
M2JG^U#?-+NF-3!-<QWW;]A)O<DKX^Y]DYTM=_8(CO;P`2R(Z*?4?>DF]9+`M
MY<)9WVX_A?"H8$8OC6"YL';*A-[9!8#T@Y0)O3,3ZLHA$1SJI?I42AK:\&0R
MZJ4R5<H$$SSIJ4[-3>)+*9>WM!M)!>79K\$Z:??L+3C)OR-*$;<.E5)!Y0&:
MD`HJ@:WFAFA\+L-LGBPZHY%O:A8&?H`\FV$$B9&5P](]^BK6DPH3KW8_U(UF
MK+H4T-S]4#.:D3J%([GS61,H0CNJ;7T$SC/!"\</,,7VI4.9$3^;SS$?A'+!
MPX6@1#,)2%#DDMFR,P^S_]U7+/+[*`^K+NX!<2L#H[N%9):6NWIE=HB3C#-.
M_]%/_A4DGFKPP;DP$JL\L(L,;QM87#CYV!_'3GZ#VRK$BWX/,*!5P])UDL]C
M[,)?!ZRC@`,&)_=O3\Y.^1`0Z\_OGERZI108[9DX;*4;WP_9*0[YZ8W9$>\G
M,WI?,.79`QPQ_O>`-]!ZX'.GI(<!U[629D8DD@*_9_<^U)[8^Q3<>.S=$4;=
M*=!2H3MK'HP&^LSJ1+]AY*'F3M;7\'X(S@NS26[8`?&CI^F-=Q<^N8X5FP;J
M9A`<L/[NO1;&MG_-'N1<:?#)1#O:$<)Z"6#Z^UUOUKKQ+#?DSS`Q(^<..?:-
M=X%63B!7.:,$M@U[[#;D6I'9$:DBOT"NB^WS=>VF&62IYG8[OM[B:T]Q9W=!
M@'/B\ST;JLG6$)!#LO4!1HTG6X=//OY'R$/^+UAQ<$8^#/77\2/[O?K>QX70
M=$^.V"RH,*E[_].F4`4/U=[]L&;+)1KPQA0&N[>`$@`'K/NX(5?!J!5?-6"%
M5T6Q$02A`BJ^:5:?PDM8,K]OO;:AB"J2Q>8.C4LXD">2=_+,K]F`T60(1>6]
MCC-T$E%6\2;,,*C]Y.W=P*(M=XNY%E*2FFUS9%%V.%W;R/R`,KN/P*Q3$TIH
M<AOQE[X>2)DD@^IFNED76'*"BZL#3UILOJVI.O#$W%0G!7\(D7#+"-+-39"L
M2'I5IYLHK3(W?;(VZ2AWQW:ATJP:.R3<[J+HK&\:0S&L(AC2GN53N^6:%?H2
M-5=&7']%K\>"N%\ND;M154&L$4_E`EN]&JV&4%INN9?&H;>(W0OP"PK-?D]+
MV.U@]9;F]X_,'1A3[<ZJFJ4B*BF-G"Q5^4(KR582Y!MY.*J2#\\J$X-S^G9B
MM.40"I89.8!4UU.J-+543"$R^FHM<.2690R+VF,C']%PMU]!TK:H-.ZEII3(
MJQ=%8.W)<^U/G:VBAI2^,]-#28?E&_L4[4OMY,Q(W5Q4,K-%TE[]3DK41R-M
M-EFB=FNG!%%],SSDR]PV/#B1+S-MI-@RLG3.><<AWGB"'=!DDHI*G:44+!-*
M+(L1U=S_UHU2,K"=C432"@>2Q"$+47,NRA7;4;+&[`E*7YC9F(W,=+&@F)?Q
MB\WP(4F?-2XVI(,>8-1T.JC<+L;B'7DZ[K%%%I[S%[;C1^T%\0-8;UQM2^LN
M:\7<0V@%D2/H@F&[P(`$51DHNE/5L,M@+KY@#U-VF7KVU%XRG<]/8^"\X$1+
M*=`$!*Q_GS"[D9X9'I?X!;LDFN.5(*&T8>7@.G%*[_&*T,CW"T_WU(-!`]FM
M?66=?FUA/6,[=/%L7@\!YVM!`CB;5SLN'6,F/,U8#P*M.V*T\I4T*8%=2J!N
M2C60)BX@(U*BY9*\>\-W0[A>[F;3;#X0H)UI0BJ[45P#/CU$*KG1SMU&I2[W
M.2J8U9[3.#<379?C0N.=OY\!/Y:XZ+N9`:_;*BM.H6^S;;FF%'HS$V@:/(LU
M>)L%,WMP=\HX\0D\0"'2T*55?OLQLG&=0;(4F/%1LK'F,%FT^-.!Y/'XZB*Z
MAL[7XE>2WK;3'XC:LTA"_-^8:8%M9I)M6JL_$OZCK9CL[Y@':=GOO##C;<'D
MA1\.;H>PVXY+<HA</IMF;TM*'!T&8:W;J521U*U411-W0@D]PUD.%Z-)DRQ7
M0J\)EA]>@`<TG==UH'=2+\'<;Q%3PS<B_SRWQG%IE`QG[36A<^P$D148B4^2
M=^[?)*GGIC"\(J)M;X,O)T^X>;[7C)GIC/X2I04:QV4(6FVSN(04`^_'OER$
MY?=\7$AOENVQP<EPYFY=Z<US,6-QP]E5>B$;91VTVP`]^L>]^Q3&'P7HALO/
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MC_T:?D2OV%?K%9@/P(32IPSL]`:)TP6O7M'2\5!,*4/;97O-"Q:I#<OVD00(
M#2EO,49U9',1B"%=84A7R#Q^55(4"J&UE)8@0^&0BC"D(G0F%4%2H$MO`,.3
M!60O00*^B46#@"J6WB_O^/K<,F7_Y?\#4$L#!!0````(`.:*K4(<K%@_2%4`
M`&Z_!``5`!P`86)I;RTR,#$S,#,S,5]L86(N>&UL550)``/`69%1P%F1475X
M"P`!!"4.```$.0$``.V]^W,D-Y(?_KLC_#_@*SL<4IC4O%:KE>YV'<W'Z'C'
MF:9)2K*M<%P4N]!DK="%OJIJSG#_^B]>585Z`RB@@!YY'Q*'TYV9R$]F`D@D
M$O_\/S[O$'B&69[@]*]?O?GV]5<`IAL<)^GC7[\ZY*=1ODF2KT!>1&D<(9S"
MOW[U`O.O_L??_O-_^N?_[_04W-Y>@-6F2)[A19)O$,X/&?SZ[L,WX'^=W5Z#
MZR3]_2'*(;C`F\,.I@4X!4]%L?_QU:M/GSY]NTW2*-TD$?HVR^)O-WCW"IR>
MEI3/,Q@51"IP$140L/_\"-Z^?O/N]/5WIV_>W;]]_>-WW_WXIQ^^???N+S^\
M>?OZO[]^_>/KUQ*!7_BH@/2?'P$9(?GOG_\D?>XFVOP>/4)P=2%][O7E^>O5
MF]6?O__^_?EWWWW_I_/SL[]<OKU87;S][GQU^:>+T]?D/S^\_O[/W_V)_/CF
MW6N9XCG>OV3)XU,!OMY\PV0&M]_2_UW@-(4(P1?PW\`=3G/RR=T^2E^^!2N$
MP"W]2@YN80ZS9QA_*RBB4HD$JC3_ZU>2`C\_9.A;G#V^>OOZ];M7Y0>_XI_\
MD?Y9X^.?.Y__](Y]^LT//_SPBOUM]=$\Z?L@(?OFU?_Z<'VW>8*[Z#1)J=EL
M*(,\^3%GO[S&&X:J@EQ@\!/T3Z?EQT[IKT[?O#U]]^;;SWG\%5$9`/^<801O
MX1;0?_]\>U6Q8X0.^2MBVH]1M']%__X5BAX@>I7"1V)I,9&6DO[Q*8/;?BE1
MEO'OB6]0"?YR2H3@$OR7%J'B94^\)D]V>T14\6JN?/>XB)`U(1O4+$MZ`[,$
MQY>I/95V*#J1^*Z(LL*RS`V:6E*WS?^'!M-K*KZ9K#]0IWGS9UG6!C6+4GZ$
MA5U!VP0MREK9F%V)^\E:EYO9F0O)NX0MRGY/IFIH5^HN29ORTJAI6=X.23OR
M&AA#T151`7D62.F"3WR($AN9Y7GPY6L*B2C\7,`TAF(:IV3QID]V1BR'FV\?
M\?.K&":$Z)NW](=3^L/IZS=E%":_^O?+M$B*EW.R_LPB=$7(?_XW^-+DB^BZ
M!&?E+]E@_OK5R)=?50+2C])U$?D2733#]/3G.U4Z_XX>6EK-8(X/&5LT*:NQ
MJ&W];YP-$'P`8P0(IW_F,UU#ZE6V:?".LDW)EOPXP5E\XM4&DR7>OCA%LH5L
M,[P;59]@BR=U\VK($**'!%.PW[U^)Z"FO_GW<J>Q2F-.]2K=XFS'%IVKAYPP
MV!0JT&L0TS(%9;IV3",6G!CIK_Y6[</(=HYL])BI)#7O;WU8B3YL6%N-(4,D
M>V^%#V$+A"M+C,%O)>O_VT9*SSO&1D=B.+PJX"[7=A-%JN9@*#%PB,HI:#A0
M'T!4#,#DZ$"TN#/IH=SV*@UE#P9I>;;>1OD#&TNY_V)3-D1%M2-KS]WBU_].
MUIZ$%Q'E/GI`4,4LA[ZI97K]1.R;5T4?_,8X>#&<"5WC<74$HU>DJ%(+J\IK
MLG!'W#-6GQ.E:-G[->V59(N"?8-D#,KH]AOEX<4DQY2,1U01AD*1LBZM[7`N
M\"Y*4KV-3?D=P_T,_[JS;<QOG+XW\^O5*QY20``Z1,KJ"W3=A5I+KLD5\<B"
MRYICW<+'A*Z[T^)CM%-:@`Q_U]!(FF2<.5S-!E`^?OUN0.UX2B\!J1CI:M=O
M)JDI[F02R8*#E?Y]3V16=:SF=[31EK_N<+-(R?ORGUZMXJ'A!Z#!=MCO4YX%
M:UL1XC%E\!Y%CZKFUOJ2MK8:W[=O<!5Y0.G[LKA^S>)!#82@1:2B0(LQKCH#
MI"4MNL&N]65CGVW0<1C^.!^R9(M9!8_O2-BO>SRIFY#TW`Z2$RJV:+GODWP3
M(<[O/?F=<K9CA("Q9CNT'%HQYU5JFG'S;<G#6&`E/86F][95*ZC<NF7_;QAE
M,^Q:^OI,[5:4W-LT916217<QZ+7GEH;"TO>`+0^KVH(EGQ^RK#$>S07&\/>U
M=3M$RKXQ"TX-!?M>:DP"@56T%)C2D;Z^K:7=WB<(9N>$PR/.-.MU6E\US`@U
MJ#C+N3$NH&3C-^76KW(\H91PU(LT-&NOL@SO=CB]*_#F][NGB(B]/A3LQD22
M*B<95"B9UIR-$'57@,:8`L;U!'"^0&+LN1Y-!3&LI\1@T4&#P"C@XK:@8[U]
M7]X!NL%YHENDIT=O7I'""&F7)2'K+:CX@I+Q2!W8$GYD!&-?!<FD3G6K/RO*
MYSC-,4IB6EI]%B%Z#>GN"<(B_SF-#G%"[SIHE[F9$=>O=C/AX]($Z86V6A`@
M)`%<%/#UH13FFS"JWV;9`)Z-P3'AC=I0CP%="6%ZYFX^7ZSRG$A@,C.TOVDT
M!S2).#C!N;N[O+_S&<D'%(S'=1",,LN#'$9:O4C:IG&*#;*YC78(S-!NBY:[
M]$O$V/WHWW2'U-^QX%[5A*;JICV7RE[8KL^C_&F5QO1?E_]Q2)XC1(3(5\5Y
ME&4O9*?P2X0.6L78B@2-P%"B[<`/"#]V%6!#?X`U9Y\>H0<<-E)BZ"`A"1]:
M.<A^D)B"%5GL"+:`\5W$I];%$\P:@4/'@?J^;01$EY!]UV`\P*8Q4?CTBA'5
MXVG-!*5F)&NX.4DLO^(Q7NG8F'8MF6U]]_IO[!YV0&8[:;&VC-6=G7JPT)L,
M[V%6O-R0<;.J=1+Y]W2'^Q%J&>PX'2,]CY&T'X5+;OS";\GJ!*2P`\225JV$
M#]916J!8H!8,C!._RU#R`A^[6+A>?'PD$,U:?\@$YLZ--2U7JQ#_87Q<]_T+
MD+9>0M-SWS*DYK'@2D1_"3)KCG2UZ/!OI2UU=E89LY<7#M85B]C9=1(])"@I
M$IB3V,W.3I\PBDF@H6&\>#%)^ZG3-%*X*GD'UX>O5F=7UU?W5Y=W8/7Q`MS=
MK\__[5_6UQ>7MW?_[;_\Y>V;[_\)7/[/GZ_N_[=/6]>&%)OJ]@C@$QXE,65K
M%)DMX'R7SD)*(LU(L8]1F0O/8LEV5//TFG%7@*3?5^SEWEVKO\<?/&7A5YL-
M/J1%?A.]T$86)DF7`0IFTW@O,0='HH(/V'-&7E=%XQ!@->T$IV[4TK3@L6B>
MYG*W1_@%PEN(6/_1CEOK&+H",2,0)NDZ,?_L`&.PP;L]3'/>ZH"E<(0LX`&F
M<)OXW2ZHHX>UM1DR4L)S2FY`L`,]T\5RB9UYOC-(PCSIL*2?P,_438C:J8]@
MEI"05DO>$S]JGC&JM?!P:*1_?)G^!=Q"PBV^I>5SY-])86#\(T2,U#Y(S\&E
M/L$*9"RM7YY;[7%&IPR?AC^-#%;66(@HH!8`MZQ^DO%9U`/FQ7UK(=]9M!\\
MFPTDP*O%=JMAW7%$]Q7+);Z&)CQ?GZZ,-CQCG;!2.^;IRBZ7*8#$NUU2[%B-
M6AJ?X[1(TD>8;C3M<Y2,61W=,$4'V<>:&:]TE-EY+7-4@`=K*"U,*%`7!5;/
M.(:"HSM[-@Z]K!]S+7FP)?,J#[(@X^DU'Z]W=N7DM&JA\ZD`SJ.DZ[KZ!?"=
M[QK'')F,FYB/4Y#SR]O_]?6WKU^_`?LH`\^4WS^!-Z]?@UV"$,U*YOP*<70H
MGG"6_(/LA*("?"#F^P3>O3GAK]_1>>,";N#N`6;E;]_^$WAW\N8OWYU\]^>W
M[`-O3_[\Y]<G[]Y\5Y),\ISF=EA*I[Z@K$K^A&R)\SUD;Q.B%R\O6TS:#)X"
M-2#[0`W3X-?'ERN<7\4QNQX<H9LHB:_2\VB?=%ZNFS@'&R)A=C+33\U!BK-B
M1#PPB4^3%&PX+Z]G8A-X8$5-A:=[U%$[90*N4G#>KW8G]GX+BRA)87P992D)
M>OEJLSGL#NR8X0)NDTVBM>I2H6:$Q#1A)RE/2AA$-2\0'S(Z-11/$,20Q'O,
M*VO)G/'H]>A8`T:LK]6@(1-^5+(#)3\@,02"HZ<-S+R-B[6ELJN<4SZX70EK
MMZ*V2[&Z.W&]*PFB*-4PB3I`RTD5XP+I5K8["-,5E`'4*#UU6'*Z=*FIV1-W
MT]U4;B)ZI/$$BV03(:?]@"8YN6@6,\'48Z>@AF3?'&/G(%7346\CI(36T9H)
M:EO(F'TT)/+9;DA*H!"9UAD3/V;)CAN8L9YYAFF_87)S,SU#E%TG!ZNL8"`)
MMDG`^G-NX^H+&YR^S!SA"-89X#QYGHYV5.<-'Y=V(MYE<E5EB`V=ITMF+BYM
MBJZ=I9,K#\1I!@'J=Y9^M84)1I]SB*ZGJT$8EG&(*W:^,<L92A)V=,^I+>0$
M_'0G*`=H`3)F_+*JPE/^B-%?]:I]&8/7;(NM1L>.]IVVQ.ZU?^RW%[862&.>
M,*\/]G*`C/B$>OOK@9S#3U&27N,\7Z>K/$\>4][;^(:LO=+B-GE\4FM1H$Q*
M?SLX3=6.DF/Q\`F[L/35W^Z?('@DK`'.`"+L`=$\??XRWY*E*-Z"""'Z5V0/
M4=`_TN.;C$G#DG9)2IP(YN1/],P39O0@@7RVJ$K1^,\@VN\1V3)2EKF7<WY=
M&\":J`QVP;83IZ_2#=[!:H]N4M8U2,(H&`Q0LQ^8.2,@O18?1%_U*4"PHJJL
M=$^O?IFOM^L]S+B?L6+'W3Z#3S#-DV=(S=AV*G4>9TLYLSE"+)AJK<6D@;06
ME,7)AJB`RGHDN5<KMC>:BYT/[Q=C9^.Y6LG`U@T#6_4;F,?TK1`N?3S'.2O+
MOA2W0TUF-@5B9E<SI^BZV(;D8N%47I?U6K:L#A/65EO(D`@_J[@!C@OK"5A>
M8UZXJ/D6YI"6U!(9+NKR*2&-7J'9*"'#@J41FO:]I&3''$4J)O-;1J:"#];2
M6:A8H!8,*U;<7=?T"6;+E(Q!1&@^_@13XJN(2+**=TF:4->D9>4&#J)*T:S.
M28FX@U4IYWL"'CEGYCI1@[?7BC,]%+&90H-'##7``H(G\Z\FUT5=[.R0D^5A
MGI,EY$.2LC7E:O,?AX2_!B8ZJ[`94L?-=*@:`:?.P+Z[?8#9(\QX(HTL$>@E
MG`WEY-/'#&#$YMH\"LB$OY5L@<072(RK[D'G?1BZ6NX5V6%3L*+Y\Z>(F).6
M=_5_WW1!T2'E9$U7<REW/]Z;H(_"@%5T%)C*49^V!8=%#/MJMX^2C*?1K]*"
MJ")Y0)#W";[\O$$'>L3S$\;QIP1IW1W3)&R6]=;AX:!KKSB?22HQ:"8Q24_W
M&=[0^)4%N#$R`QS/4OJQ@"N\L>9,$W<U[[)C>\4=E.R73=*5.0^CI%S]Y7D9
MGY*.LYY%G=1;$)FWCN[[,FU-W82DYTXF[7)`N6XMF)_!T?AI9,/RU^=IMZ9D
MWX[9]$#-".`J]Q^$#?=HO\^*V[H)2],=2Q8GTY1#GY9#JOF0%Q$_L6*/E#YE
M(3C2182HT^"E':$/!TDC84:_3D'-D<ZAG">X[1W.4DF2,[*J)B+>D.$]13FD
MXM["#7Y,:3WK:D=;.L],F"AQL+435V#FSEH?.'.P%]P#2Z3H0#V>5%'6\M'!
M.I9L$4*`4@K`<*_E`%R097:HHJ9ME<:L<2Z/\WJE5OT4#"NM^HBY*+3B?*3^
MS`ECY;?,:A0+K*:FX/2.6BJG"7[>I/FJ5^5.[5RLR"_@@V8]8<_79VE:HJ2I
M9J:)0S5B2<FO4OA(4[>]]@W[#U%\&'@?"#W6W5&1)X4KVK5@`"B'A6RZ7/2_
M)VKF'1@/9+%>%T.=P2W.(/_<??09YA^2%&=)\2+Y>Y,*O^G^`19/F/S-,_D(
MJ['2\Y4%Q9I1S[N(A(XVO@],/C%G@8)*Z+]`>%E+[!0=+XCG'\/JJ@!7;?T!
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MLE_WJF".?$AC2#Y'UN.G<8(.S`#V&7Y.<M_GH0:6,>C*TP"%905ZCEPQEC*C
M$N_EUX2KYRA!U+SNL=0&0?1"/(OR9*/CS-JDYR]ZIKFX7'D6198\'`KFGP6N
M/%<2(9AEJ`;20PM555T?#ZK]BUU0L0?W&,A=.\HFH4R$95XI%JVKR[9M)O=(
MAVF8O70[0,[^T9V.HX$]B:5LSO1ZLW02+ZRJR`"Q$>Y2M5.ONOHM?6FT/4SF
MC_1B(%T8Z?4UFR1E!8<65?NNPACP\FC.(B0G&()GQ!=Z%18N%,.>P8%A-TG[
M@7'B(+]"6B$&XQ79^T>/\..!OD^TWG;Z6YE,)_JTC7#396/?ITH)0,1%Z&F?
MYG6N,089S]7R$0&*6E@*[H"SIPF5;B>VI:>S,<U(8LV8Y4PY6`=ZF-D7/B?.
MQ%C19:?4>W1X*KIOPWO]3+E5ER*B&4OOE2H1-'R61H&VRQYB%#BM%S67]%4]
M*+&16ATW5JPDX;QIERR<LJ>"/R=:"?H)0O.LKX^F?:L3ME6S"<*V1H'ILZEA
M984*`FI[?0<)XO"$VT))@^8X+_`N2E*M5$$_`;-=:1\M]Z;O-2LPJG^LI)O0
M=(WZU0Q^XTR6,>P[F-%WLSZP1XBU8GOSBX9MA"0:+OH[9>R9+K]-G/KTBT=U
M$(HN45.-X#=.?$G#/#,US#,+AGGFV##/_!MF6[\=PSRS9)A6==DTS+-E#5,Z
M5-0WSIXOSWUWP)61RF>7@;ST,&RL`_H(2;>HJ]9E#7?@^7%](YX@9/-M=%?&
MK?Y,^I*FKH;0]!OULUU@`330%!"JSC'P*(!XHEM^)IPU]I)ZLM[19];5S=^(
MK'Z;=3T.3MX_&7FJOO-,O;^72PP1QC/T?!QHRH&NA++Q>CV'DCY;(W<H9G*8
MMCGQ,4XT.<3.\!;>PU0O)J`HST5>USB)VB4R+W?7IN=@"4DYT#L%WA>1TTCT
M94W[-12BUCO94J[Z\J1DR52I/$#]/&G?M\U6\1U"7[)]CR@=3^LD*`4C6;>U
M`:LE10<6@^=1_O01%NOM>KN%6?E4AN;2;YR(_M)@C)Z391UER+H'4Y/%@BGO
M\>AO%:<$#59668@P-$(&P^`CQZ#DV-]#.YP!H%IV)OJZ+?K,O=K[),L+^L)K
M1&SE/<X^X@+F-]$++=E>I;'H-$YOLAU@7/8(T/3>63STK6H&.R>^S^3A%\*(
M0.S:6$I%`GLN$RMURD1+]XB+5;UDZ2\ZV+`,;`N2([2"1C,S&7PF";B1P"_[
M^0MIZEX<.`7_&J6'*'L![TX`H?V=::3RK@X1R+@S5/IXW]'':DP?%F.=6#X1
M`2AUA."F.$3H)J.]:HN7ZV1#NS[PAIUSPIT!FYFVKLUQB:!'9EQ^>Y8Z0"+)
M1>_",L$`XI*)GJ^!Q#US*^D-?8;8'*=%#`9`60I0B@&$'*))+@U]ZTV!:;7H
MFS]9C'V>E-$?_JH]UGM5M<R+@'>06'_L>+DWCXG!XZ@S^#F)?5R@XUOQ6;$.
M;`V58[0$2XL^6Y'/OT*J>A'F$G[6?4TMN%OXS>8SU^+#6/JUP]\1K?UL64I_
M$%QL]1>$5<Q>_KV'#QG;^KY]PZ+@G^U$0;\+P'8@7'H%V%X+LSJ^\[K9V&W5
M@JS9>V?F'EB7S?P=CQ['I?;`O&Q2;NXF]7QK=9H*9PML:"1#6V`3:([3('IC
M(#VT+.NZ&V'N[;PP%\*`A[>Y?,22.*"6![0;;LV+<?=/2>9ZDSN+A[XQSV#G
M)+0Q>8YOAVO#,K`M2([0"N1XQDW`<)-K&N.\:P#U#G[1[6Q#!^YVLW/9S#3O
M,/:RK3AW1%M92U;2&^T6V\B&8!$6][$S%W@A:*,__BV^BR5R%T\+'.7.Y6.P
M;9G'TLU&ELETE&'0EJ5@F_`<J57,CH3_>D@A>/MNYC8W!%64^USN&!ZS>=M%
MPN!,-B;)FSD<'67SML<:`^U8";:(S7%:Q.P`^!$_,W'`]W-3??Z54:7ZMCXC
M8.=LQ]&!QFP^%D[Q`CC2Z#O;/8XS#5N&,GBTN\RI1A!&H7*L<0$W/-3]Q?+A
MK<=CC;[#VP7/-3BO.?>H1BB8F.(`,4>1I[2MYNTIGQ%E"@ZLIJG@5-_7R:NE
M=W-W=BHY:@AM]:94._O&>RO97VG,YC,_S:K)<JG,>]ES*O2EABU+&<J]&\%S
MI%8QN.6J.I"1M<:'Z`6\XT5BW]M*KGL9[7!VO1SM0@N-OC67@U@WGY&M%;3G
M:#>\KPH_W%FSEO&ME?N`%X9E*$6\:G?U]B_SPEX88Y[<7RT4^*2W8CECS7@V
M^'U]8QP@Y23Z-!XA%G%GY2^@3*&`5504F,8;'1!E=8]U2O8N-6H+7'ND94?3
MZ#8\0<`"\%8[YBKXVEE`OM;3EEA!2:$I?<K=>OL_^Q=[Q-^46RT/K>F3STL<
M%<]E8[!JF\71S6J>BG241\66K`1;Q.8X+6)^K8SH^_)F[@(_`&64RWOF%AZ/
MBI^)BRX1`V<S,MF[SN/I**O!A#K.2&C+6K!5A([5,NS4#KY[/3?;$8(NJFP'
M]PYO`;%6@_3N`N%-_P2S31*A.5'0D+J^@1LQ<A+OY%H(^:U[9NB;2IQ@8MP\
M`\#S]7]48`]5O32>%:%(U[*T_/6$!S)$5G4_S`MD'M6`6AI8MS3P?DP#UB(6
M?_WY'E]^AIM#D3S#N\/#WTFTO,>W<$^&]!3ENN]+F!&?8\+J?)R'*_%&>H$!
M+(4!.9>&_C*KY`DA6AF`WPU6NLH_)J`'"_0JE"M)P%V-<BW,_+BT])![PI(8
M[7W?:._ET<Z,2CS\\0.JG'B69MP9^KI!/^U>2FX:FO.0OZEX>6QC/JY^K*"<
ML%3=\Q1<S<BX5;E#@=&`K#/]BMVHM]6P0XV8OB&HT'7B@;S?0)A]-K20P]J:
M#!DEV7EKB&SWP5AN/$@>BHVN%I;?=[I.4GA%?C1[V$GZ]KRWA2I"#BJPJY>%
M?J-<`&/3T?(2OJV@_+ZWG%JZ"4K12%?'RO*2O?`31C$!DC\S;D?>/<P2'!-Q
MLT*8QQE\3-*45KF?18@N?4_`<X0.G26\&S=D2^SUH<@+$N:($%I>V/VRF6VT
MZ2RH:KYO]NJ,@Q#@216%I.[2$_FF32*_T'Q"_)5N'LO7$V\8^K]03_H(/[&_
MT9QBE`@:!D,%VFXS"5)>>_AIJX%(M.Q4I8,K-M)QZ!A6<QR%C+,L7^GD3`'C
M"@A;_M>=>+:DR_$`8-/G.A1M`M8B'H37!3`IZ6$[[7>]:@X>QVG/$]/=L.MI
MC.PC+*[2#=[!:YP[,$3Z_!PBE(-=%5^FL1#UDBT<)A;$_I<\4V+W^_'BZQ_V
M=^L]33OEEY_IN5X.8UMKH0'BUN?47CYNHW6C!."P)S]"P;B.Y9A+="(%]:#7
M3..VH+A^&L'BF'!775?Q#P@90"6$_T66*\<>I6Y_TCX>UPY\83;7N2?A."KL
ME1=O/OU[%?_]D!<T<YG?XU4<)U2("-U$27R5GD?[I(B0I,#2AEE##!U/G\?'
M"/<Y+.U[_WJR_<E2+FP%<FQ3ST<*KW!P21!:%E*+`J@LX"H%0AK0"`75=-#[
M@K@_9Z<QZ2$B\><<[_8PS=EQ\2TDNZT\*>`=S)Z3#>0![!9N\&/*J+"5BO6`
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MW[&*^\`/[]3M1_$@3Q&SX&UEY@&?9$;L-FQM,K5$_D_[9*7]3';Q]DJK>BC;
M/^GI,%DZ'@1_?#<,L.K1W8".PP-S[I%=TV.9!'/WN8-;^ELR,63)IA#+EEN(
M8)3#]P37\F_H1E%_2SR7X9SMVCS>CAK&0[+6KK9'!997WGN:XJ")+9'B8%?:
M-SB+0?%$NRHS*:G/9[64('K,(.0)D_*L/X3=NB5#ZV[L;8!Z[$8EIPMJMF)!
M6-H)A46VE/EY@Q"&WDTQC*<))?7P@"N$`U0Z<#M+/0$M`INWL>WN%\):%+K:
M4BIS<KO.6,A&Q`JC7216]IKHY-.#7#[.W1UJ:?]H83=<;AIM$,W7G[(RQ-%.
M_AYGS62:S?6G(D,G2P4EWN[6GSM\(/,F7UH28V@N0F_$(K2<0,ELP#X>D4F"
M+B<.B-WFH2O236.BJ4YH:3ZY/>L0'KB^F-`(.D&O5O7,4F.UJF$"QVZ"PVN3
M,9-QN%Q=<.RZR]5F#"Z%8\=HK6R_]SS_:L,+<&@]L:V4?I.F]8RL3-Z^;7^`
MV2/,>"W*Q\,S1/B$0+OY-O!\>R^.BJGUKD*/`#/5A+G,V?\>R+*[]1&UO\3U
MY7"!Y\`-76Y(I\>`F_(N)!2O8S'@<K='^`6*^WF?4F)\3\G^AFC7UHPWQL%Z
M+!UFMN1%-%9(`H4HK<0#V!-A6#:*W5=[AGE!343*>5=;B@,]#PE\;E6P'\69
M=@JZH[,5U5FXE*.\P%9*`J@H_J=EIQ%BFH7]T/\EQHC`EP-6HH0:>L=G+\H+
MASF!PCQO6=U7>!\E&8M8=4Y!_:*'36Y.TD73C%W7I8\?E4.U:R-!YQHU3$DC
MT:B*W%&;C:4;1/QDF!#;)>G@]<8C4XUN!K)6'Q5,+,+D7.2<"S=C"\Z2@5:/
M#Q.J!J]3Z3!P\T@9F].$Y<9\^N.-F82!5]9=MOCP&.O,4,;FRCX*1,VZM#2.
M2"9:+P4Z<-6=7A5A5)N3Z`49ODRT'F4&R5HSR@$.2\<9<2'H"`+-%-(3D694
MW\>!JK58,^_*H8^A*^\7;84;Z6VS#U'V.RQN,MY#@?%1#B]39$Q??QFBZ/+!
M'6Y?.\84["E7&D2X,?E^@F<2**RAOC!!Z7F:9PR1>8_UN!T*:HR".S5G!A@W
MZM/<H1=)!3=+1&ZB;)VQ1QGX^DG'YW4I&B7NU(C;-[J;]IVD?93Y/ZC1!`^;
MZ3%XH%`;(^Y5A"E8$U]B;,6*7-6Y!F;&6[B/7NCLL-X29TTWR3Y"Z_07F,8X
M>Y^D=%&R*F^O*,^3>D3U`[0.?2=S:"4`K]X7(@!VTD&%`%LN17WSQ]^4:H0P
M-M;T*TT#_#5+"KC>;M?;"V'L]]'GZX3\'4J*%V63FR*C;V3C%)U5_GZB;&DC
M?FI:<>G_1?09H)(WB/(<;Q(6!%A.E!;Z)KM]E&2E3;+?I*?[#&]@GM-#-TCL
MY8F=R,60EN'LV4<))>C1-A7!QQJ0#-J?Y>?"UMMSLOMZC_"G?/60%[1_BMYI
M\AB=>2];]9!T^9@8O8A`^`'&$/Q6L@SC8;$QF/J>&!O4G6.[:JXNU)^D'/^^
MA86.JR<-)TJE_2TZNX]*3BLF,#T/+!\7?5?Q(RRH)]W0]D,QC,]>?L[INY)K
MLJ6-:"W(:E,DS^R^DDGX-*%N!)(^(P?Y`1I=MRRZ'G)^*HI+_B"J!/C1IP_-
M@!O/U_9102N\D[Z"PY`M!0!G+X"*0$]Z*R%`+<7(U.J^72KMV$J6_P@VW@:Z
MQPY]W`W_^0TW+8GBLBMA7O:E8'*RU[WH@TOTM_1G>FX0;BAQ:G=#'5NM@OJ%
MV5BG/(7U?:U$!#22<2$!E9+^I:W`IKI9_RE*4LI[G:[R/'E,1<J"+.K3XC9Y
M?'+2Y(DRI3F?/6,#,L:';JF%`#/:59P=\B0E._=SO'L0=4YG4?9(&-Z("EO*
M7+31_@>,5^R^L,,Q/G#N58'O,OU!X9X$L80-?Y72069%\H](M<V1$AFS1I+#
M%.V'=9D92^!$$CNO73T5X,$:2@L3"M2#`GV^?C6"@IL4`2M-_+<D)?_D75^T
M$@0]WS;;MG8(.7@A$J>G;)%2]K<!\#-]5L#OV=2P_O&T>H+2=9D@$'6EE`&X
M6K25$#VQ.FL_<J&50!V@8/X2>8?8'^.)E@DHVF^_#V@I.+4C2>/@K/,VR2)6
M7I9UK;<L`4=F#:F5A7@2)5]GYRA*=EH7QC4)&X&CQ<-M25RCZ$WI`L!2SF.&
M,)ZEY6-!$[6`7&]%'IJNGAIM4TK^M+B!2[!,@FNSR2"UH$N^N-!*3G6^:[;I
M;Y%QD!0J.5!'*H^0>[J$+9KA&5(\GM),0$I&;?U>]B]1W<PLU6G_>GN-T\?K
MY!G&*WJ8G_\+1#%QJI_U[%F1H%GL4:'M8`9I5$3L,YKHI,43)/K0=\GV0RF:
MQ>8.+0RQD3Y#QPMUH"*S!.4)&%/`N0+*ELT4/_=O`1>OYU%)G3&&IZ.5/$&,
M91P:QHJ@LJ7(E-P`80>NAT;A).+QBN*HT7RSS/KJ!+IQ.D;^,D;284IV5[$%
M><471,]1@M@OZ6(YC_P^K:>$&M91I6^$QKVE9B0U9`4,,<IK$4^IST+N"/JT
M<)//?+3'0G%9SGPZ/J-*T0@;->(._.AKROD;?C#*&K''2;['.:WC#7&YH`DK
M-M-P.!"..UKE4F"=`LJ53D\E7]9.I`"70[`Y<;MU\02SCP3'*'_BIZ$&V\H1
M(D;(#-)SX$^,UPDM,/#I)M,P8&7U>%7YN/TS+D"P*4_?%]V!IF3?&^7P`O)_
M2W4(HDV%2<V/#E6SO8TR`P=U?$]$/-BJN>$;'#K+2,D9\#4MTR'3$.\#3OZ>
M=EPD"^]OO%;F&&".S55_%/B6&UC!%I1\F[4N9>.6A2OX>I1!P\;Y@>SATH+O
MK6=Z9P\]6[AU2+N:L\"&<Q'.&)B'#2,V[EL#Z@L%'1-_8F`)IB(UY-./ZL([
M6Y[4H6@3K19Q9]X4K!<-X37M1[VJ"P<;8U^2JC%]>M.*OU^2WT0O-'4RSY$Z
MQ"SAU*+KY*2.+_;VG$-8'C2$T:CS].HL9#S&7*;"YZ8?'R]3SW6]:;`Y_S3(
M.@ET$@<WA]ZTJ9"H&N3[*\Q"7B!'X":X:LQ3'>T>!X8Z,];U,)`+>6)Y&D;V
M]=GC7/_K$+.$6(NNB_)T<2:8^3Y/5P9HU)%Z%18R&&-.4X$C.`9V]5?'972H
M.KX/:LF)<!$AX40?56[E'<?]WCXOTU7M4>"':NBTKKOY],&K5#S%X.3Z_2AU
MFYB.,')Z_7Y?0OSP`KX6KOH-^7_YOD4@-VAG@#_MM).Z/RJ@59RX$L+C97PJ
MW$H<`M%GT:4GN'0<=Y2,$7`C%!VY8@8WD!4'LJ(-_L"<3V]3@09K*"Q,&)"$
M0,D(4$[R:W#+%5K<\+9T^3T6PI0WIO46E=.TS&L`1L@ZR+W?U`T)ZUK3+$KS
MB#^>L<&YWZ2\,FSM^HQ)/88`D4JU1LF-O>[!^8&:X4)WB%L#;I1JK=+8J#Y0
MAZKA/5A5!BX\JWS3+,BR0`-$L;EBPT)OZG9SU]U:%8+T)MJR58(WM",GC',Z
M<]*R12+!AZB@A<(OZVU?F;*6'^H3-^Q<I\G'1?M`+@)?!-(R=^J>O27Q?EL+
MFL*-9ZO[F*!%+539PI*5]5(7+26@-;Z]%?9>7+=5YVP\>>J0M8+I"(>E'#7`
M>=0`W1$?G=3Q<2`Y[)?=<GO_D^EZ>Y461(D)B0[Z-5DJU"RAUB;LVNUT.I3Y
M<[A!\$;]K%^700,UZE4URR6+LM3SKV[."9RGC1V>V:F?"AS'H<"\PX!%#@'\
M)O]]>B1_=</5"=XH=9N8CC#R<(*W+:4)_`1/!?QIIYW4_5$!K>+$E1`>3_#D
MQ475C2GCRPRZ;%9[[$:'VNPU4#]AUXO5I/$8)@F_6<%60RDN8%4<S3:.&43\
M$9S&HYC2:WJAK&\G\!Y8WXZI/VAL>]>W=1^PK%KK<J:+N]]':DD&EPV&:<R&
M0R:WI(,]1.GOS+-"N'4PB=&`HW25%R`>O4[!V"QZH:`W!FQO80SAC@K1?)5F
M]I0T0ME>"!MDXCR=R?H9YH>'O\--P=]<&&J0[GWJF<9X:AJ:4//1X#DQ/6U!
MS1Y,/%.UH(LV-;%*8_X+2/[2DJM.<[`(\10SUZ[+7DB4)L)]\SW<\-Q7&?])
M-U93_=%A/>G6[??0Z(%%+<F2#BXJ$T0SWE+&<UJB95)WTT]G5JU&'TFW56MX
M2X"@6W3OE6I*\/04T0SKS#<4BH4R58?FRFO.^[!8<-*3WJ^?/[\UB%D,;Q)=
M.[@\P^P!*\Y;0:<[>O&;G)\Z^@P9J\E9AW-<<':IWNPFD<,TTS%,PPB+(7(.
M9I3AI]F#2G5,@H15M><3D'&?J)E0/U@^U2$/\KQ.)%_`!ZVCLE$RL[7?HKBH
M1PQFU[TNOU1@&_".7F5ZADC'1R1.@+(R[0]>4:5[+P'X.OT%IC'.^%D87#UF
M$#JJF!^VN&<F@CAOA2`JA0APH(JX\8UE.<1U"CAS<>0(P6IHB)Z+!MP4"S@_
M.UZ\C*>O-.`X*@/F500L4@G@MP)@N8N[:4S_14\[GR-$@_T-S!(<MQN$Z/BD
M'EWS.Z6*+-SXY=>Q($_+Z417DR3E[DH+`-@/L);-^S5@7:#;]X*UM'TDH"*I
M"(NF7-D/$F_`F8-.`YL9[R?WCW)%XE*6O9`H\$N$#I:&MV?2WQ515LCE9GWF
M>0(>X&.2IC0,T941^^8QC?(RC:?'"&FOM:'1N7E-]+#?([;(BA`5[#W"GZ[2
M+<YV_%E@@_I(99)F#U^J47?P`*G$F$-'RR))3*UX>RU[U`42&ZHT?-!0#U[,
MYRA7(+%=OJ<X?R:8OAVLXU#-[QGV4ZM).'@NKGQJ>D_(^^UCUZ-A/*:&0+2)
M6HJ\Z5&DLS4V]8OJU8WROD`:]VPZ+I)\@W!^R*#)Q#"?E_&R;0Y;QU-)7#&D
M4W\JGB61KL"0-4&]DY;ZDO@ML[=F.-@V4D=L)/)ZG\U6]2LUU54:8@Z]-?FU
M3.KS&DT$TLCP[O4[$1=8:E#T`"ZCT3J5SSE$HA7&]UB]]MZ(K!:0!ASL8!;C
MS8&Y,NM:];?[)RB>GJ'NS(Z<RZ`>B=;*9.71+,@OGJ("?(IRVI\+9R*/1K]*
MGUV/TA?P<"C*$X?Z+Y\PBF%&2R<A&PZ(#ZP(A/X=WT%PPH3W`16\-V94!1@I
MD'SK(X[,,30\`^[C,*J^CMR5'77LIS:-RAA,3P5\#!8UQUDM@M9I\^035/QI
M7QJE"Q`#`4X\H4YK#>A8"=T4,E?X-2F>SC,8)\7[:,->:%6.;EHT]:U0@[RS
MN$9BQRD+'L\T.T+C6W5]*&%RL0QC)1GX1$0C(8=5#VR8B&`K9/07<TRPQZ8@
M'`'.<J@1S$?0;,%H_`KSTJ-$S0%RQO1THV8-*&_`F8/W`P/46D!5+TS7<ZUR
MH:H:'>/9;(BDD]AQ,=A5L5H3D74*7;>(!"C]D?#=4V">J]4,W0E%9.>4\(EN
M7]:-$3.E7\@/#SF9_.C!,O^"]W7-)/Y8!Y1`L>Y;JNBUT0QF**V%2/UDNS0*
ME;+>@:C07UNA'`R&OJYO%RZ+/%JN_\M`U8H_WYQ``2OH*"R-RPXXI&Y3MUN@
M',AKT<\]_%R<(7JSQB"?V?-EH]Q3AXY5_5+J@)$?R0LMF3D<UCF>U,DKM^:P
MSAZC-/E'Q.>5-,<HB?D)%;MXE9=Q;;T5*;@(W9'?,'N5DX)I?)<\ILDVV=#6
M<OSQLR1]O"'T-@G,J\'I6-ORLIDUAUY83/LQ]%Y*O-$EY]UAMXNR%[HNE40"
MM4R@%,IKCW!?IHM]8_\',E,1TF7A04/Z\F)F)3^ML:U&`.HAR,<%]#L3E@U^
MJZ>190[++Z.,%OO0\JJ[IRB#1C%SA(B1U0S2LQ^%KG'.RKL`8^0SLDPC@94U
M%*+6A5.57&JE+V_TY9,&9/IY($Y+';CV4R,/4*5H!(P:<?N^P1^NX0G)CX=G
MB/`)+8'\EIZ,_&N4'NAL_?;[$T"^_8-/S]&$$YMI-GCHA(.5+('$LW%JO;2W
MO8^2C-5YUD*8+<TG"!D!-$K3ODM1=H#QDR#QNJ!50P=K:2Q4)-`8",L[QF!G
M])F3D1Y=TZOKRBR<],FI>_,/-G1?THN,H,1S]'DDL*$68CV-^+U.3K3W05*P
MO1J]IX#9?@RFFT;UF9$7ZE(VJZ?38N*@;W'-GSEC0P*O=9-FN.)YJCT:#%$7
MOE4;/D._'#B5XW5$54DE':JH$C!U-".R^F=*>AR<G.YQ$>KR9.YK95&0OS,^
M0TSQ#,T>!WYRB!3@O6^"5XI@>F+H8U1H:$`K:4!>9_.:-^NCM(=ISESHEK?A
M9D4%+.=T%N4PKE[],YG>9[,RFBMF<G5PQX(R.WV@W(`LD,^YWY858,MZ/U[$
MA>=+KLW;AE72`"$.K]L1>5TF4?VF[.+1X"K=X!V\CS[/7,F/TS&\VC9,TL7%
M0<H-$'9^%^5*@&`=+06J?-36N]=9L<P(7\!\DR5[<?QJJ5["@/BL3+HR'_MN
M)+&F50JE1"$<?>A#VW,*HJG:8X*Q?38B0TE7KS//X@?VO!>0'IJQ)-==$3W"
MVR3_/;].R/HY)BMHPO<G3#B>4YBSE/%]T=\!SV.BOY^:P\]1V7LE$,BI1""C
M(@%4RL0V7(^8=VYF8OG;,ELQ"6P-BF.$OQF2:^R9.(#)<P*N&^`SF8`0RG3+
M[7_D:'30TIA7[3'SJ/9B(:;=$N9$_ZQ9\-T>)85IW)HFI&^<4S2=Q!_!M'QJ
MA;+U%U^4X<%:*@L5"CD6E#CP!O&,IWG3SB6$1X-R&[BKI:U"E"?Y>MM:C[T8
M^+@N1;/5I!)Q^Z;&^-(]@%P#ZG4?H(<;-E-A\!@A&9[UMK.L?_'F6&P>3HN,
MY^[(=,TOP-*?]`Z51\@8GCX.4G1Q7"PQ8PXD[@%3=GZ/BZ?AP1I*"Q,*U(,"
M4_T8#%I7L2\_TY0PS$T7A5-DC"_G#E!TLR%MM)J*ZABTY\&'O@%+VPS1]GCE
M:T*T>^R!W^6ES62>HF?6\!Z\P`(\0)B"AP0AZ/^N]13`6$/M88+9=]&Z9#CS
M6K53N5&_R-YFO+O-$XP/].'>\PAM#DC<\_E(/"6C[D_VJ!<PQ3M:HHRSJ[1S
M_8#VHC%:<MKF;-:+TZH0+IKC5=?MZ')IP_(D%PDZT%.\<&[%.+(B[!:H+\9B
M1%`I16/'OK5P[-&<4CR6=)($I%U?>B[[,"D#JK6V6V'MK*YZF4AP1(759N74
M3HNH/91.>YS5+W=[A%\@O(/9<[*!=0V*7!>R0LR16""[A1O\F";_@#%OI\]*
M169.\-:%F!FY+<MCW]D_BMYR)SP<GYYU*K?*E6,8L[XK*^M=`#A![TNTJ)YE
M02DG$((V:L`:]E4+RU\R+\4M7]G@)60>(]N`CGD/X!<;^Q(]#C,M2(>9T]4%
M/^!8BZJ+(-ZJF@EZ;Q31U_?1`=SC_\/N+N3PM?+OUA:9-*$:HV($WS!!)VFL
M;G53$$VJ%,#!ZCH;;%LUD+06[8=H=QD>I8@OC;:9H19\G:3PJH`[]?:B<]GH
MYTGG<722%#=K]50&#2H;8,)Y,5>;UH(M8K2(P;NU\\7,V[E5Y[55YY)5M\]_
MB#S^3G'F&<`LTS4]\_$(=NNF,T-Z)<6O]73\^HV)TQNT`A\\<C%N-Z^H$QW"
MU>=$Z\5@Z4MFSV^7WW=0R$9)>WW?O*-0/#CP$)2')+V1A2VANZ#A?8"[!YAI
MFU[Y-7/]<0I?JOFUU-HV0'GP8:BP:82<\C)F^"%)D]UAIV^(K2\:Z;%!PT$/
M.D[>ISGVJQ>/JB`45:*&%A<VR^BSH5DVOVBF2YF&`[/DY+V:9:]Z\:@*0E$E
M:FAQT"R/*=UA8:^@ENLX%H7,VS],ZT(KX]&^NT6D$77I<@4_34T?(J23'[;`
MQ'A+;,3/:1HD;E_%/&&9D8?RNL1>DLM[$F2>36!K6!PC_GW1KGLMD6+?>U4&
M?"VD^F;B'.(XM(&F%+&J%+%N*4+(,_LMV8\'.H.2L1*RM-N*D(76#.7W^#(E
M<B+E>*9&3-]N5>@ZB4^<,8M`@C78"+#VE#E[T).Q]Q>5M!#$VAH-&:U&@9(R
M5*;Q8KEQH<:0J.N70RI#!6/*GEGM'9+BW1NR=MHD>]I_B9?0W&,2=K)B561)
MA-XG#UF">,'N/?V%<AC0IFMPH4./A9/@(,E0/>B,Z?(E*T#$Y`!;21#`?N7Q
M(HXAVGB.RH\$V4;1@P1KD>Q@#>KJ/6`\C6_S^!@:ZHY*U,N1Z'''Q\6-51;`
M>*#EYG^]I]7]9&O&>UG1BR&.'F&A)@XP9X=3DZM6I<P?87$>Y4\W&7Y.8AB?
MO?R<T]=OJZ'4I6<.%L/TW>8MPI\F!^3FK86R*:?N<5CKBV8=_&4:#MY.*,E[
M?2ZA5\%X5`FA*!.U]+CD45G%]`+OHB0U,LWRJ_/TR:E\Z>;94G.?@<J*"$>E
M72/EU`WWQ?>?\/^!&5ZG\)Y\#K;;)JL?3NA0TU\M*1%VLOJE*@.=EL[^EK=Z
M@&%]_04-CAQ0^I$Q7;0N.`CAPH0CH"P!X0D8T^YHYAS]2/?QV`/U[XD17>7Y
M@;YOS'HE[W#*KAPXB/6'-`99E.2L7T.&#X]/((\0Z_>P88QY-[!E+JY03D\8
MQ41`KN!.^RJ=Z5:)G-F-A6G*[KJ"2=W9O%XXT0`+&Z@N;&!$9)#YE3%!H7N;
M>H/"]`!_@BG=><%8>7+O?M&LZYU,PUG#0<($/)9<_+8;[%4V'E5(*(IM!XJ&
M5L'#"PGNL$P_S^DE:%]RU!2ZHF[8J+CJ6$13,65#B0M81`G*K[4OO*B2,^@^
MJT3909_9NJ73::L["OA:L/\FC&LJFEAB`\V&C1OJ0-8"3+"U4%U"+R^3A2Q*
MQGNU\/QCHZL+Z[E#/\4[[LA:T2X_<2R%2;!V*)"C*566F"[CTZJO#:UBB*6^
M-@>ZZD]2/C=(S7#(EQZJ3DJQZ*2$J.GMB>GE=`P^)^HE+!4O9P!?I%4.7)R?
M,BOSI4GP&JG6.0W_'.T[1<6ES:=:C:IXE[/58)<S]1(<.]OV7V'R^$3$6)%]
M3_0(RZH$)DN^/A1Y00!/TD<FM\X&7I.PT8Y1BX=]WRC9@XCSYVZ0M],O`->2
M^-STFT&-9ZG[6&!%+40%:U`7S7#N0&+/?=F?EXH`TE'+*O[[(6?/J<[V5Q46
M]B">YN;@T!_F^8^@%.>TZ\F']!GFU"3&,JK>W5C#%J8<6A6%X\-]PLG+";G'
MTVM)_$_*]'`!QG;GXP9-^S%;(F_)@W$1(>'!]_1G\&G`@\MM$DV?'=CECA06
MK84KB(HB2QX8^`5N.+I(#P?G[V/&H#IC=U`Y`N"5YVG.N7^*UAA=N[MM:\=A
M9U!D#`^X\:J'SC;+0FY5E/];3K%VJ5K.V+49^$FX@OH22?")UT&@E?*O_?H^
M"E"5L['539C96=DR=,AC-+W:IT3+X%'Z:;).\IQ50^Y0\I(Z6&%=Y06,BQSK
M*E"^IFR_D2.=Q6MRBPT-M4;5\G?M&V^6VD"F1<*F]>09WL'-(6,%X)>?-^@0
MPYC6#IVSA:I(<+:7'ZL=O:*LL^RWQ-"LN:0-WM[2=B?EAM!K9TJK]H*=8'/L
MMB$BA2P1J$4"I4R`"@4DJ5B_Z>[3$ERT19]4)T(]T&,'>L'#I*WL.)U9+VSW
MD73P$F+YHK;,+I#FLDH@];R#/JPYW7Z;]:KW`\P>8?9K4CQ]/-#;X5?I9IW^
M:Y0>HNSE[?=D9#]8J+8Q83)G$Z'/S_%&D0L$/A&)`!?I!!"AO@4D9@BYP-OO
M3P`5+=RZG1FVTMU-FF)TC';1W6L*@_BU-@AJ#V!=F0,7QV))$.=8#??^$[ZC
M-7JB_)[^_R-A8;H=-:2N#Z81(R=;5@%ACP?[V[7.`QG/U_%1`=IHG#84H==]
M$=KB]M?C^%%CZ-)`Z0T9)@6H[LJP?U!)?.V3RT70:O,?AR1/J`_2!UGH`\[D
M%QF,+\EJO7BY(4IXBG)XDR6U,G16O'KT9ZV$=5@YR.[PEU[9"1<]+XMJ:<BN
M-\V36-P0#V&I;(1ZSQ):7^5'AC!J;7\D"=@#1OSU<2X$X%*`4@S`Y/#ES0UE
MU&\QK?(<%GDI\G5"@B9BVW#R%V0ZCC]"HXVM)<:VK,-<!@>=CF`!(L:8QX2L
M+BOF4T5@`<&"X8Q'BKG@?"E&,A9;FC%$?DN-BU<''4E`("0$1,3`PLXY??0\
M+;CPM'G**HWIO^BMP.<(T699;L*.$F/'%J4@PR)AYX2^/H\.K."*/PY)_PE@
M+0:KBMA%V>]DGTP;L^95EO8X@I2.F1D%*64HOQ23,@M20KPR6+%N2;0DG_T@
MR;A,3YHHR7Z)T`'6"2.C)/XX';/6*B,D';0S(-P`8P<D?H%D\950PCJJ&\SB
M6S:KLY>S"-%N%'=/$!8_9?BP)Q%6^4TM/7KSS&R$M%-S.WL!@C%@G$')>NSA
MI,4M3P7(/@N<U&K@H*'Y>+GV,#:1G".RH-'N>#=,9"XL37H.6EM2^H`Q",0_
M!F#H=XH^]82H\E[SEW2_:/^\<JA\Y?0!1G1BB]?I+5V)9^).5OYSBA]RF#U3
M7[Q*]X>B>7%2UI-!(SYG,LQ#W[(X3B>\AX8%!>&]KBRJS_F=0/4%6D\W](@=
M4RDG/4:J)!5O"\BR`B8L:-V;;L<OM=:*EIZ#PBE\^<!2"+1]FD;KQ2D*9J\:
M]1)S<.!)^0#."#!.7A^-&@<!J^DG.(6C(5TO^^)9O1[I69>+IH<1NBNB`M("
MA_-HSVK,NF4\6LM74UXSEUQF;-WN)ONW)I58H)(+E()YK_VR;CN]:^XY8!VQ
MG?2LX"V;B%I16%].RK0$3(F6?GV0`MG%$H^J=3^+U'KI8(=UE1DP3EW?D2'R
M5)W4?Z+1HQ.=J52#J%$L5*;OZ#D*^1R/51SE[#H^WH(=6S#Q<SVP];TXU0<7
M&ROY&(!$$H9]AV2@US?MS5"K.&;G>1&R.5>-4+43#0<9."E/'IK":BE`Z+/9
M-,YC\]J$NH\"4Y4UB3Z@@0YV?&+O#G/VVY2M>'E>34'K;3LI0"]J?(@*45NB
M'&=F<#!X?=64F9NG=W5G>%Y[OZND\O@.[VR[P'8@.3H;F+7$:QN`\;N[?G4@
MKX[D15$M!ZW![DD)LLM@'P:'K[E>XGGY,UA\@C#]EP1FQ/J?7J[I$\#Y?1:E
M^99@I=X]8`;Q&3.M!A]WBZAG-A>)TL0'+@MX*H4!B$D#BE(<$#%Y_(6O62;0
M65%I0W!,<,OQJF)`HU,+[6UM!VW@9R^P%A_TX!F>D`%40@`N!:A5LV`K@YN,
MOE%9L/>/"[+-I+&4O5UN4@JI0,QHYSU)U[Z=EBS9&\T%VX!77`,IC52'#FNK
MTG&1Y-WF"<8'!-?;07FT"R75:9J]DJ1(WD$K>,&9/2$^:I;^BR:U@<6F&CX"
M$)$=_):-^V<O]V3`NN642N3LQOZ:LKOH?R)PBF2<3@!E'&3D[P%/)?:W51DV
M4$AAACY[82`M6:,Y'%&((/KEEDKD[`)54_Y_'C4"GHI'M549-E`J'L7=:<F2
M0=[R#6:5#/HU@X,DS`X`^ZDY2.H)1BRQM^]K?[_HP>P$#EA10^'I'+74+2W%
MEBP<G&'@=@S;N4&3?X5ARPHV;,]V7=JL)U-]?\C2I#ADD$P.[Y//]">#4NXQ
M*F;UAH,$7;S^+7BQ-<Q6</-:/#H-"E;759``H+;NZ>*D9+2L"Y2SQ1W>%I^B
M#%ZE!5%/0G;N+,%KODB9(#AK^ARE[7`!DPN^(:Q?U`#K6<TH*"]T<-HKG9(E
MJ'F*NT&+^M(UC')(W_JYVNTS_,PJKPWFDU$R1M",4'3Q%II@!A*)FT^74<$%
M:V@K3`Q06_TRHV4=87"K?VUR.TB%FMV,Q+6[&S[C*?/K,.[O:."GDCZZMG`'
M9RFL5))'\^_0T)D+I]0QZ[,;T^-J38(&]6&*M-V4!%;,:8E%!0O=K%1;<(]5
M?[HX8B.=AHY9>[$\!9AQE=ZBHT*=`<E'GJHU%,M.L#_G<'M`U\E6J]A`B9S=
ML%U3=MFEF-(/<B+MP4EE)FUK+6Q,5.92SK,7*+6IM'==K><&:G3T@_`$22?S
M9?_NBSY@2]6,"%M_LZ4J5%A'?X'"8K8C#D;\\<VDNM,ZGNY^RG!N9R\I*-D-
MJ(RHPSUDJ^R`L0MRNFOBI#+32:H+%A.5^:T7$S>/0F[(1'!`=-US`?<9W/`^
M2>1G!%G+[S1>[7!6)/]@OQ]4D(X[V>-I]OR?)?::YL"`.E2`2,;P*H6/5!H:
M.7/:D[J2#\22@,QQ(TDRKX]#VK8;[`J@8[*1B5<B)<.0I0*56"R,R(*-%MO.
M>)M^<,#VWHF@3\7T35VPGKK2R6;^DZ\2]B4$[+U,KT5]SGMS&HP</T#8O\P(
M_\5Z$T/HOC6HC<-1@8XZ>`\DMNR_:-\W5M.>'$JT](%1(.MD\QY:>EL'*JRK
MNX!AF=YL67W.;[%QM3<LK9IH/VVP5%9E.GL2-7I&:TD5T@XFY;&=`X"?]S#-
MO6:YM1#$)NH,'"W4`]3P2MYPH2L1;PWBDIO`74*0NF)H*;J,(6&#E8XF#R>S
MJY(?@9P*0M^0XI+XFWR-`<>SE'XLX&I'R#:RIK.UG^'VA9A.BD#P!TP`<#4T
M4E>%Q+ND8.<#M*T@3FG7&IAN$IC7NPR3-@R:A$UK5]5Y.*F9*-GSYHBR`%)'
MLT!:-9A!C6>I>["%PV1>:(P9W]S.R0MI49^3(M!@Y#@O)%MKU+'6,CT47%K(
MQ`ZZ:2%M&(X*\VY::"(TB>R0E8K(H:&:)H=T2!I5V"E2=U47V7#"C2R`UX)(
M71BQH4+#AVQHBN\)FA:S24N/$JFL83SEEE89C-;;6QBARYR^A5!FOK3.N`=I
MF)U'#I!S\+(>X41K</%V2U^NW4:;\@GM(OH=IH!L&!"M[_%Z^#P%$%;57(!@
M(`F']190-H#SJ4Y;9M0\WL-LISP72M\P+)BC7W97L0B(X>X\5R8V%(K[Q^Y=
M>9VZ0J:Y6;6$]H1#LESW/7*IF??EYP*F,8SUS;SGF_J(=8@X,?N2"X_!GNU_
M6.-X7"G!:+=1_]]5K:F#.)(6M02=ZS&WR>-3D=]C3E#+9?J^JH]JEXH3I^%L
M0($!9(P\N\V(VO&$8L)1L>PYO?HU]1U7`J.&K/<8<`8SW&>%$/YTCRF!)"7+
ML]5C!J%J+>P4!7VD!XDY\2G&C4)>E/Q`5#+TYUK3D&`U;06G_L86;43W(,4%
MW;>1?4*"8U,G=#P8)(^#N&+%!U2,S%QRG<+[9`=OHA=6#8.OHS1&.(O?X^PC
M_,3FR_@F@[LDUWA:18^HON7HT'?BRT2`TX)(`/9<!&I:2`@!MC@#*?S$5T4Q
MV`M!_/FX$<;86-?'@&=W>U?'`X&I:218?C`B.!#&@'(&@C6-$R5S0+@#PIZO
M@&-0"K!(=O`>IE%:W,)D]W`@:F>Y2YW,8/_WC1)1?:0</%?!N,BW$$'68.DS
M%3B*!E9156":1PVEWXXJVE%EY19F&8QO"<=S\N]$J^ZB[]N&=7AM0O8M^^=4
ME/RPFU:<'[%MO^TY1_2/I]43E*[+@^%2M90^X`P6,>4U605']#R)S1,Y92^*
MG3Y"+:N>(&2D]%&:#C;I5/<!E/VJ88*U]!2J_LNE3,F)KU=R[@=EV=U'TTML
MC-@'G!9/A%22\8IELHG2.][I)6!X8-%#R^'ASXYRHR8MV(&8\/-\&C0&!U92
M56BJ[^XMF,9?9F88W`K=.%)B7$#-!E`^/N:?]P?:JO=#DB:[PTYL:_*+`SP_
M9)GF%7I=RC8BY`03^^8F6(D#&;&1];K;,`1T>#93TNG1@#<TWW'FH,2S9`\(
M?R`$,)L"/R0(Y@5.R_S$ARB&9R^T]UJ4*I7KJ%#1C\BC!)W,B!7'*H>W(SS!
MPPO8<*[^YD4UC+"ZZH+$HQFW6F"83I(+R(W:(I?I-LJ+/B$EN)G69.SAIH!Q
M>R#YSWN<KO8TH10A93]5I&927:!`V%$]!^<,=FV;R<%A3^\E">X^JSQT,,3Z
M*@T:KV:%B")8YG4CBXT+M8;4"0`YH$S!:F!(BD?D*2Z>8&8W#.@1-3C)U:#O
MYFR="\"R-8$'!R.`L;&BCP',QDF]+I+&!_:+#Q,U1^@XD)0;%TBD)'[R"-?;
M6_P2H>)E_8"21^5V#QK$3):9TW0=K?[YQFI?<:85_!GG#7#%W.<F0`,_K*W/
MD+'JRVA,`66^85AJ5*@YH)HCN[,@!K0>')"BUT>?+7J]$C$#2U*@Z\;K.>.0
MO5X'/ZRMSY"Q:GB](E#&7K_8J%!S0&Z\?G@<,+['9%7Q<QK#[*K(UUGRF*2T
MR]V&GJ3IU]]:X&30CVPN4S=-Y,9LDRSK"DQ7K.!`90,)?:9#2`<0%R^$\E][
MEH/M@G6T5M+J:1<?-@7(([+"!P@^0Y27EF+<Q"Z,88JX-AK/B!/<8[JI`4PF
M<$6?=BF=0(@UMWZY;_U&%%@IA][&?HJ*\R@]@V>'EPO\:=ZN9Y*VG87U!)LE
M]T14E#K"L6O-1!JPB5+P`,'#X07$1**P-DJJ%C"V;U*"X(C05MA5J4%M<ZNU
MR,C'=UYLT%7P8DT4Z*")&.`,`B((N.@9M/EVS%IT,J%M9P/@)3KU;PF"CTXS
M+&!L?^<J.OE"6V'WYS@Z^1KY^`[1:71JY;PO#O"&E:@9UX%(%.;7'%3$%JK_
MB`_E)<!P2C^ZD`R5?;2T%9SZ1\L])-W;JORP+/Y@U0>MR+KIE=Q)@21M(UZ\
MF/3W;'_3J$:N2<1!P0"C'TC_S0%=XW%U#';0M&,`=X>''/['@=;>/Y-_W$</
M2.L-TO[O&QE#'RG[)E%S`8P-^(TQ\FH9HR!@%0T%IG"DIVLWEATAN/J<:%T-
MK;]CIE#Q=0=62RA[M="V,O'0J`-0'*IU1D(_(;N<P5W@791HO7LA?\M8=YS`
MEVEV+97BX9$'H;Z&\7'"QB\N)<]1`:_29[)&I(O#J_3F\("2#5\FW),=;$Z6
M"63[\0'N'F"F8G6&A$T>_='CX>AA)B8$2"HIR(]@S^1@#S61M6%12^+SQ29#
MJ/$L=1\+K(U#L*N;2R#Q,7^]R<=(RG,N89@U=_(CX/R!V+1($H#?N`P+S6/-
M9>&U3IO]:1HV5JK7[EKF=Y>LUW[;X2NC,KQ/N)[1VGX9!`;W"R/*5[P`PYSI
M?9)&Z29)'VEO[5^CC+A68=R@7H>DP=4*9>IN[L/PX%/S9UW!2PF4.YXO<S%&
M'UMLJ&7'69AS%.7Y>BM$6&>L2>+'`XWYZ^T=W!PRU@'\/$((QF<OI:CB@UJ1
M>38KLY=ZYG%U<#$@CA-J\1$"^5-$J)%E8;9YHMVLO+[18\D0L&75'R_H8FIA
MLM"3+\$%K#/`V``N$/VK6B3`9:+7+ZO05WYAF290]%T&G-X5>//[5;I!AYA$
MJ=IF;Z(DODK/HWU2J-W;,B)K_":7(@<'7OWXF$%:*@8>,TSPWF=X`V'LM66!
M"9)XACZ/`[72+1E?P!B#BC.0HC/E33='@KN35,IZNX49X7N.<`ZU.OCH$[:^
MY^[P\)9*P4(20%^A@IZ[`1E#KIA2&5#[L<#;2*DT\@XE0\`X]O;J"7MH&CD6
MA;$Z:O'X0'1!-AC,Q71/J?J^;=AVL$W(Q2.O#U3Q)1._C1T'M8ZGE1*4AE&O
M<I<\[6J.[&.T,SC[&J9A0=DU.>=&?0(HLW!,NP>-00-OJRE`S0\8.V6C>L1F
MQ^;%7E#]N&W@BT8Z;M"P;]*"O$\C[E<O'E5!**I$#2T.'MB$F@7N*9K;UBE@
M^O+E)]T4<(C#1(T1#B6YM5^]'-IUBHPB68ENX'HK[;%_3M6:>BN1,=ARC%)T
MLW\4+,&>\J1U]QN^]<_9UO]`^'K<*ZH!A374%R8HS5U?`Q'ZS$@'$N.-WP)C
M0:UA,%XTC=O(*?W<,PK%IZW[LM>7GV&V27):Q5CWL]6\Y:!/V.#-9$T>;AZ[
M9CEWXNIB[@#$Q#*6<X>U)'+_:-_7)8PAQ[/4?BSP]BP7<_`)9K"!)VNGE>3Y
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M3"R:#X150'"&U?&T\5/>"XP`30FO>GEAP%7O/^'_`S.\3B'Y7SM?K.FO2K3T
M#46!K!//)<IZ`SJY;']>JP,5UM5=P+#(3MR/B:D#+S8$X<6$'Z`,`7W\E_Z_
M>U(RSYN'(I)^Y9T")7LAWVUMW?`,'$0EG3IF4_/Q[%JYA?!1FY4M%,@M-)[I
M.7KA^K?>3<?Z4.1%E-("X-E[WP8M>_LBB:Q]2Q,7$>JL8@YPS2^XK6T?7%/;
MV([^`H9F<GNZ'@;'3<5=DM/IX)#QA!M]O)9-(+<0T>:XYS@O<I;3>J"WF,K'
M/TQZ.\WE9%9#-HNI@QJ_2AZ1,ZPD`D(DP&0"M5#UBRMA=)RR9#'8+DBN.UIM
MGF!\0$3`R]T>X1<([V#VG&P@D^N,RB5+OD+,%\A/Z^TMW.#'E+Y&SP_QV'#T
M6V*Y$<#LVK8+61S<NA=B4D\K!05"4I'79[(VW;"6EK6TK.051[#"/4/H[^74
M)/$B<']IYH>\6=Y11+VSEUNXQQEK]*#=1<VY+$$88ULLAV$1#QGGZ4/'.$]D
MZ\2#UGE"WR;F`P!T!%]2?!PT7H>ALM\:OF!#72"`GC4L=,G;37847ZM=_VZ4
M*PG,^O0Z$<;!U07K03*0".G8'O$R4']QMH?&S,X\[C6"WI(7W&YA#HE5/JW2
M^((^+X7W=/].GY9-<ZA_[4V)G)%1*%"V@_`SS!ZP=!C`V;(;41)CGZ%!!S-L
MH,&P\4$M8%9-8(!@N7`'18@(S<>?8`JS"!&15O$N21.:!"N29RADTJA>,"1L
MMOK4X>'"R80`)T"(P)RM*837S8H1N'B6@H\%2-1`L`)PU0&P]$OE>@)K\UN1
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M:77@Z>`I$_A:2`+>?.-]03X3>#Q/]T<#,NK@.^B"I03++X4'%@,9>]2:YKW/
M7NJ/B"K,U:<HB]=[^L'\/<ZV,"G8:B&-Z^8E^95HH6*R9%Y0*+-\Z%+R.2@$
M8KVL,),#T#>AGODS!;QKR#Y*7[QFQ!>W1NP-U3^"Y959_,$5?BTX+=&1/U<^
M8\VD!T)\(,G/S@*D$;">W#RML/`682XHTO4/?G-GR5C9P]R+97;DL&.!O!'<
M71%EA8B`I2E)-Z+``WQ,TI3^1.+@\'/OQQ(&APW*8K@;`.Q+,A[KX4N24[P6
M=!0!ZB=VA["<(GZB#^(L&:)ZV7NQLQY)7-[>+,V&L?7[G)A+$[(8E`8!^K+,
MQ7I@XI)*2R@F[%$$I\DE;5`[SU#7_9IVR3`_5-A*5ODJ92G[N"^."2E@?`(V
MM*<K>QD/9[RSZW''-W4K7'+'&?).,]!(J+3#-.C2$?A2EV]Z+M-X9)<$B3I$
MP]#^/5*0\X/47'GYW74/<R_>V)'#_K*UM!BI@_=):3+<7$Y`9THXYI`_;%@6
M0_P`<%^2$5D/X7([]2/:9?\"<[(TXI,EW)`?[S']E=?LH+I,7BQ253QWT>Z9
M2<`N%D`A`R@P^_47%NZTS=-B%-3#^0]@BM9C)A>_7/%R.[['[-?'FK64Q/X5
MTCY;!)YGF$6/L-&4VM-AR[A(OK/H8]*Y.I@I>0+!M'X!@[$]Z<NBGX"S+_;H
M1LEHW1SH3,/_Y1NHT\.?CJTW.]2'$5]SK?3V8C'6IEANS-B>A`[>NR@M+VI'
MV3V/LL=PV.3`,G4"J6U\_QA6J!%0<\-3JR\BK)8RAQ=9-27S8]9:0GJ(KR7_
MXXZP9D9J,\@:X/R',4C[H;8:Q+%%V[G'E*&D#F8*&N89<&"A^8]<G[!TML&"
M;?Q1;=I35;UFN/]2\T+M2@FSM&7C8/PH9DKI5#64.5%9)-_'Y8'-<].E&L<\
MU>D:JIMJC4"GKT6-TFEEQY>P^Y@^-`XEU,Z5--`S>4^!>6JI,%I5\L4$:DO6
MOVB=2:!A/01+]U:3$LQ,\#`-X(/V%N86TJ[=M*TD3MFEYD.$[F&V>ZL=_I<6
MS]P3EI5TL8*62@(@B0"H#.#K)`4O,,KR;_KVB]ZCO"?+;H=V'W;QQ[)B.8@_
MJ,7P!].:EV%W>'L4,7MX+S4$TILE8[:1>%ZLW4#21>ZO@*@`']AC`._>G`#:
M_.Q$QXJEH'[,`7R.F5L,X,9&\L<R:<L!?#3C,FSZ;XXB@&OOFH*(ZS:E]N(;
M]@;@Z5[/'V\.<.`I%J<&VP;U_[S"_D1BG,SQ/<E<I1N\@_?1Y[J1ITE/RU$R
M1@8W0M%^7.3,`.$F->,.Y'%Z%82PAMX&GY6?[(%<D8:Y:.EZ/:/O\2BU.6UP
M1P@[[F]<FQ',JY[&P74T5H&QV\5X4JM!0X8Z:#6P*MM/:S0H'O`6:23W\#,-
MYCKA=)*$OI*'J=G1;(PW!SHALGE3CJ34!03';SR'4E5DL*+.PD.A?S+3@""$
M0:`>^06CI9O>5D.]_!SMDI09]W5"M("2XH6^])/%4*OUFB+!>4NE,=I.7LB#
MV3,$6YR!`_&]C,30%!1D#;7'><+6Q4&LFY0@[%M!3:LS=+@Z'@4DGJ!B"DJN
M,E[B9S(C_D[^3/Y$?J!;(/*'_Q]02P,$%`````@`YHJM0I"0X@QU,0``P0($
M`!4`'`!A8FEO+3(P,3,P,S,Q7W!R92YX;6Q55`D``\!9D5'`69%1=7@+``$$
M)0X```0Y`0``[7WI<]NXEN_W5S7_@U^FZM5,327>XCCNZGY3\I;QC&.Y;.?V
MO/G219.0A-L4H<O%L?JO?P!)D5JXX&"A*`AWEN0ZYL'!#P?`P5E__??WJ7_P
MAL((D^"W#\>?CCX<H,`E'@[&OWU(HH].Y&+\X2"*G<!S?!*@WS[,4?3AW__O
M/_VO7__WQX\'3T_7!P,WQF_H&D>N3Z(D1/_R_/U?#_[[\NG^X!X'?[XZ$3JX
M)FXR14%\\/%@$L>S7PX/?_[\^6F$`R=PL>-_"D/ODTNFAP<?/RXH7X7(B2E7
M!]=.C`[2__QR<')T?/KQZ.SC\>G+R=$O9V>_?+[X='KZ]>+XY.C?CHY^.3I:
M(O"W;%8'2__YY8#.D/[/E\]+O_?HN'\Z8W1P=[WT>T<W5T>#X\&7\_/;J[.S
M\\]75Y=?;TZN!]<G9U>#F\_7'X_H?RZ.SK^<?:9_/3X]6J9X16;S$(\G\<&_
MN/^:\GSP](G][S4)`N3[:'[P?PZ>21#1WYS.G&#^Z6#@^P=/[)/HX`E%*'Q#
MWJ><HK\`D2Y5$/WV80G`]]?0_T3"\>')T='IX>(7/V2_^0O[[X!??]_X_9^G
MZ6\?7UQ<'*;_6OQJA*M^D9(]/OSO[_?/[@1-G8\X8&+CL@$B_$N4_O">N.FJ
M<O!U4/L;[+]]7/S:1_:CC\<G'T^//[U'W@<*V<'!KR'QT1,:';`_?SS=K0SG
MA*[SBLELXH13)Q4[MD1'IZ?'A^S7#U_0=.93H;O/9LP&^F42HM%O']AG'Q>_
MS$;[YZK?C><SNDTB3/^%SOU0BJ'8>2<!F<XSSA;;:/'G(/!N@AC'\[M@1.BW
M#-DVCI\HH3\@A"JG,PNIE`9Q^HML[BN_B]YC%'C(6U!@O&N<<,H1Y<DG[LK<
M\P%3V8F0^VE,W@X]A-E8)^PO#)>3CT?'N>3\,_W1'QEUNBVG)'B.B?OG,^41
M1<,D3H]`>BRNPN(S>2;AXH>^\XK\WS[P4CI4S_HM]E%X125R3,(YC->U3Y4R
M=Y6$(5V_6WI)./[_0TYX$WCL8.?EL/Y[I6PNY*P<YY;^).+ELO9SC4P^HA`3
M3X+-%0):&,U&`*YXS<=*&1S0`;P4"=_AWMAK'VE![(7R``4J^T;#D7)%B8>.
M?T>/]/?_0L!#9>-C#0P^H3&.Z"A!_.!,N7&K_K:6O<V;E/V$ZR:E%R2ZB]&4
M:X.*4-6`Z369.CB`8;GX1BD[]VCL^!G]P3OF/N,V/N-B:N1$KZF>29\^8\>9
M99PA/XX6/UEG,?_Q'\]4%T+I-G1>?2X9K/M25`*K9&3PRF3;C<&"UTRL8'%9
M#1R$[LHH5,E;C$#_NJ$#KJKT^6\<SAQVS7]T)]@OU,=12*8@]G(N2#W&)/10
M2-^[],%"WX/TT3NCETQ(Z?WVX>3#01)15LF,$75\]F]HA*CZX=UG0-5.(IU!
M3)^=*/W-[>#4(I"D9GN4B)R8ADC3*4*JSJ\2BU/3L&B7#I'[IP3LLVF`25SR
MI$G/*"'[:B&KAFQ#=2PP.[9BMH'9ZC.@@(J.;Z%:@VKM!5=B]<5B52=6:\_P
M`K-3X]0%=9A5V%=*W.RQWX+;DOFL0.VS/?@W4*LWC1:PG=E+H$;'6+-YEXC9
MJZ!.*VOT:!0`?NG@7OCU<-T-I=#75KR0KD@0$1][]+]ZEX[//)K/$X3BZ$?@
M)!Z.2S]7H\M-@-XV/6\0=O5:UNXQY=C',481%==4\";$IV(6W?PCH9(%L;6U
MT])N)I1A?PL,/Z'8H0>"=^.$`=WAT<"E)T?"7-[>-1IA%W/9%B'4-$]HX%&A
M30^@1P=[=\&5,\,Q.XWX9U%+0C/K2T?OWQP_`5F9-[_M7-(AQF@>*AV@C6-V
M!+*S@AZ#,958%+CT[(`"7TM&\Q26CCO!4[)+%G-%5I#3XFO-#%_G.LL3NQOI
MGS@6X+N!B&;VA_$$A7*@UY+0S/H-U8/('%'5+KTPY";!04SW1>2Z)*&GPJ,S
M9S9X@3G44>A\RXJ<[$U4NIM`I18H.9T6FKK%*HJH<@X2H_R++DZ>;*P'$KB"
MY\XF`<UL/X9DAL)X_DB?/NE[F2[GC%WG#PC$?3.=3H1"Y(A9_;`[$1&]E[IE
M^,J))DRKHW^P]7QS_%3/BZ^<,)Q3/0^NIO,1[%)<1$[#&@*=L"W.+P>C-3$X
M`&O)IGFM+29'C+B-"=O@R,"8,,6,#D>WBYR<1Q)A:`@9C%XOXE]X9LP32'9\
M;IK#0#:0[-@X#Z=X(-GQA6E8<`:2B=U=ID>O2*D+I%YM*7$SSD_>HN-M@+*A
M>QH<L<*GMA/P*Z,,NS!N&X(AJWI<EO@8=]6!\:F#1D,@!8D=OS?0-&'2;/(I
M0R7V^+"NL>D5V)P;?EBW;ZDE,+ZJ/X:WO)>4:D/\)O@246,/;K"/HQK(>C7J
MPK@(.8!_:WF7UCCA%D`=FY<3(P84A\>UP.S8V&,?AEFMJ[U`RKP7LAA2#1$5
M)5;[<-IS8-4H4*?&*NR*KL0EK#2D(QB`56/$6X'=V3X<\6#L>+36XR_&GOEP
M05N-:2TA,O:HAT%4&ZI<('5NK!X/0XHG-+T`[:NQ.KWL<;4$TH7Z$]Z`V[$]
M!64!(&5*/X!;SJ%Z3+&>H!B[CJ\ZH:J9>+^SJVIX[RS!1*CN(1^=[K)DLL'O
MHBA97W8@_PL27;,^2.()W?I_2;*_3*:[*5`1'H:II'NI>O:(PI0=P:G4DU,?
MK5>]^S:MS_*A>ZTCV3B^#8YL')^-X],5QV<+PMF"<+8@G$`<7^M%9GJ1.'5:
M1;6)JU[_,;V6G&YD-Y7D,G#7..M8AX@N7DT&AZ5VB&9UG9TNHEF[MQ$5/XR&
MH^$,A>G`F3=I2GF9H"#";^B>1"J*\$@,UCL;DLA<]+Y)?D>LK0WR!F^4FS%Z
M2*:O*!R.4IE>$NE+)\(NY?,:^\D&P,VO%-$1-#_&FMA:WLPB#S,X;=VU&7*O
MR4(ID5C.5E(=3T5D?>II:&;^`<5W`3TTTBT^>'.PS]3Y%[)TF^3>AA16R)S`
MI+4GYN>W6CKT-7[#'CU9V5F7!15[?T^B+`H!,DL(U4XG.'#=$+'3?#AZ0AZ:
MIK<[:[K&H@_%9]A"MDMQ%19&[6QF0[TX[S?O,WJ#HDL4H!&L\EDMB4Y89RC=
M4H4U"\9)Z-%4*@>7:$1"5/"'HN\X2%7)NX"J@BABF0NK5#)'Y7=$WTOT7]Z0
MP#;KE"WM$&<,Y2M[C5Z!DE'Q>4<L+XZU#$@1KM<I:&;\,HGHHRF*Z*7SBH-4
M4BZ=<.S@X#$)W8D3H6_T[T_()>.`/>4'4^CQ*#H"U`G%J##)'0:#*,+C(#-B
M/U+U/8BS3I#<7B8>4KHKMV3[-AB+'>>5GW?%<K[QQ!@N/]:]9:<S!X?9TM+-
MYP1C3-6O+$?HYMWU$Z;O?R/$^XE]4#5+(&'M]4:IIIRX<1+24:^H[CR&+4SU
M]]V?2@.7WD:9'RI/>+@B$>R.A%#5[5A$OL^D@"HMH>/3,W_@37&0-C1AO7_S
M30!R+7)2U"]NR*''.GM?HC?DDS0_4V`^+82Z.LM2<6"IIOFQ)/)XY2"F).)"
MP%:E*`)#;F0;D6$C,F#/KV)0D>U82V*;[N*V>=F22;9DDBV9I"[40N[&VLMZ
M2DK4"P)2BPQV=,,U3<*M')?.;..B+:1@XWTC[4$=(B'\(`_HLAJ/<4>D[-:M
ML*>4:%F)6T8+:$LKRQS9@Z_RJBVMJV7)'N-R[K>@PBR;V756]#$>66[_2UD.
MR+@3LSOY%?7-E76%C#MGNP._SN-;EM<Q[M'3/;@K00!E31[Q(-]TRDEAI\QP
M32V,AP$:.ZL!=89"VV&HB<&E@;I>L8I8J;)XD/@Y;C?$6NQ<63/'BJPPIJ"@
M2A6U=ZP80R)U513NL8B#(\`-+@74'>KUN01EH2#C-&_N9(P&H#821PJ\[#-0
M7!SAJ4<%["?&P2Z=Z\4);%,:6P'O:0>6I>VF@JYI657ET_):?8K30B4&[G6*
MJ,B\P*%_E&*6"7Z=.I'H\8R)EVV-WYTP=`+F&T&ABR.^1$$ALO"(Q4KZ:>4%
MY5S7484R7>J\+Z2F\N=-%.,I$X-;!X?IN,/18F3^0FDJ1],>*M@@*(N:].DO
M#7\&5.HG>,;ZM<!B"@6'V,[4TW70.O/6$;:YYDLA`*!P?`#1+:ZKXME5T-1P
M*-'KB2H]46HP61P/MR1<O9U4GDN<`VY33)=9S/X>LUB"9^327\WJT"N278Z1
MMBC07>#`-]`?/C[R3[1L@#3*!KMQ+GE/R$=.A)BG8?$O]!N5&X!SP+YL@!\!
MAN5.02E;`>]BGQ=&VM6#EOMXYZ,COC_I%7#+GN?I?LED16#355+1C.R2M;MV
MS^<7';P<L@#Q'DPW1?Z5GFJII0L%D9-%?6:Z#!7[\`V[*-L?><@(^X6\DX1:
M=.1XZ0.8Y;G"_C^K;`;.9Y4;9YM74?:$28UHL$>_#/4M7DFZYMM$7/=T9>K9
M;WS<J@HJ7*.U[A#`15CYNB.V=Z2J3^.F?$`_TW]2IW4N4=SBUE8YKW6".[6%
M=V[S=I=4O>G_@R16WW-DRM=HX@\D3KOBY*DY+(R&*0)Y%-YWQ#QBW`HY'S$H
MBUFL0_F4`C)5]SF4C85RM/`QOA!ZE;H)2PM[3E[_CESZ]']"LSPJ&LBD&''Q
M*2S%C]"W$_MO3"MP_'NJ$P<1RD+HA><`H@YV$Z$W*O*3)<3R<9B<^3Z%*J$:
M;MX'7F8^\@.!IX;?.YF8Y##@UWX9FT>?71A%ET"&ZPE(LR++B;@4NR3PEA8A
MF]>2D8B%,:(I"_=:-;F`I5AV(.C47B8X[&)FTN/`UXR-,!Q14HOL.O!BU%)0
M(T!=R8]&E&_QJ(M#4'88\+1($G8R+]EQ9+>[IGG)#B,U+3I0JML^.G,FZ*KT
M9:DQX/LJC&+]YX7L,-+GH#9M4'(<N8EIDD"Y061%4-O1+C>,U+0T+934&.`7
MMQ--'E`\',GH.LU$=/?$])THRI>>O])?T]==68*6Q^:M!\A!!"H">0SJ<DON
MU`RY5$R(CC:&VCF@9+7[X2I=8OR3XB3470=8..L5'VLO;0LT`M1\V`F;`U$V
M!QVQF9FJF9.;!'3[P$^[&@)='7AKPT?"AUXU(5LZ=H,C6SJVC='\ZEQQ!DEV
M\VTBV(O2F%QSMOU\;3]?V\\7*AV<5]6JO)P8C5'CK4]:E9,2JC-3Q:E9KR.U
MZF8)C;'%OH'07&Y`<VSL%<4-3<6SKX3';JJ6!_T>U$QOA4K(H%/6ZS9V"P+T
M@$T[W:H.\-EH?&I-G:39%+L'-=\;[->$R[Y>8F1L!1`.C*2\)B6$QM6/%850
MP)E6=AHP[A$,0%'.S[H'W1K`&,J(XF=C&PX(;&AH@$:)XC[?OE*A.WO0/00*
MH<QV/MOGFT4ZWJ^$<9\O%]EPT#UH9B-R10M?+E_V>4\WA(F7`.WS;I4._=^#
M;DK"VU4(Q_-]WJ^U64%[T&U*!)Y-A\SY7F]#R7R\LE'7?NL>LNF:.AN>[0Z.
M@FF\)7C[O)7%\KC+?G#[O('K$O5U=LO;'73X:BN4/>^,Q0K@7KW?[,=];%X_
M;HYB(BO@;%8YT=A/;I:5XXF=,-X=B#8+UVAL,K:3"/%5)]+9YVKW-AU'E:JR
M:9*Q2A0?8#4-TTZ.[>E=4V"N[$FBZ82Z";S=@:FN>F"!DGHS_0ZB!"\9N<#O
MW%PWAX(3O0V\K\8:2_G`DRM+F\-(.=OS2U)_&>0"ZM,]W^X"];@7V'TQURK;
MC!U/C?8%2%_W7<":Z^L7,$F$NJ3\]["9JCJ=A:/;P@+("PEY,QK(VG8=!7(2
MFM]N(Z>XT4L!Z%?S3;7ZMO3:P^[TR%H(Y/I.%4"JMR/L!I"*&YH5>)H;7BF_
MS5?;W160[:OFS+67JS$[-K<QN;R8-?7'7`!X<KSG5H5&H>-"\/.>FK=4MN@M
MP-Q7UYE(\^8%:!<7^RR!C1NX'K7/1\<=:"@[U\W^,5V2"8JQR^:?8=UY:_M*
M+DSK<[\Z2;VEWE;9HR,/PY3[[&RA.R;=+JM(-]=ZXZ4HUOXFB[IWPC]1_!AF
M%GMN#KG(F-/I2!'#MDCI_E:HM355Q6JJVI9-AK1LLNV)=K$]D>T(9#L"5<S+
M=@2R'8%L1Z#=[PADV^?8]CFV?4Z_VN<LLV^[2-@N$K:+A.TB(9S`:KM(V"X2
M"JM'GQB-CW3U:'-;1ZBK'FUN#XG.JD<?&WM4=5D]VMR6%)U6/CZV^UE!<4IS
MFWYT5OG8W/8?758^/MGKNT59Y>.3?;Y<E%4^/MGGNT5=Y>,3>[FH*$A[NL\7
MC,+"OJ?[?,4HJ\QZNL\WC,+*K*?&WC&*N\>:W3E.5?=8<QL!*>D#:FXBEW1S
MW3-CT[*DF^M^,3_16:CT[-&YL3+#D976EG^R!ZT`^/)O>?.(BEJA7316W&[:
M'G-6W?KD9U2DBBV`DTO$JZ?;Z]2Z"K:!$6I_HZR2\!8'3!\?C$.4DN:.3:O[
M'!HHEQN)KW/9?`F=(,HJA.6E_CCY::4#96REE-L=JTD?H)3>[SB>7-$A<'SK
MN-A/JV=S,@FB*8CDPMP^#):M\OFSGP)#%A6_8<!RD]4=EI@+_@,)7/K7.SI^
M%.-@/`B\3!C9WRFF;VDMFVL<N3Z)DA")!%W)CZ49C,6BL-("D(FM?J<[%BZ9
MT1.4G0Z.OT#T+A@1>@2F%Z](-!POR0Z$D0H#^X.)_YOCIR_1^(KN\SD5CKR$
M)DSB6@DNZET9.;DM32NKCW`7N"$KU':-LC_E9U='5_,D'U#,&'D,"2LIZ5W.
M?T3L"*\XM2!3A%"%WEY/:.;,L^A1^BJ@Y&:./PPDE1084<UK4C`3K11>NT:O
MH+.OD4R'4UA6`T3Y7Z6AF7DJMBY"7L2J,%8VN(+,@H.8[ND4*!;%7I8*9`-F
MTDAG*VNR43<D^P&B_ZAHH=I'V,K$ZSQR\A.NI]SA1$6/C'H:VUBE\)E>[<,1
M_S,*0JTW>H&(6BY"?3L3+I]R*A6A2JH=BF@F2O1QYP1CIA,,H@@!+P,.:IU/
M:.$69B4&8WI6L[TRX]4#A<AV/$4Z^'<G9N5WY\-19AEWUDKRBD^4@WA'FLH+
M2>N5ADC-@@*H:I[@,)Z@<(.?RR3"`:*;!K1\[;2Z>!]GHWI,AI9JS(*?PW5D
M>G/H*[SE&JEO9\)#NA\<Y;=<)57MALY5`\I=L##T7TV<<`R;%P>QSJ>3;OL"
MV7OLO#(O`'#!0&0[G^+`=4G"3&+P!P`'L2VO&%S5XJ6XG8E=)2%S92N;UAJ]
M[B>U@#6OORQR\$.H=J%Q%&XIUB3SYIUU]@+MJ@8BFMG_YN"`=?4<!A6JN)`V
MR$M1\\2J].L%:Y#I--,!N[(I`8K):#@JW./.^^(R`'BO6\CHWM33F8/#S)J_
M_BJ]>7?]A#7Y_$:(]Q/[/FA?PPAW.,U[PB[M-^1ES/P'\KU;$OZ`;7-.@IJG
MQ<(($-/^!0ZJS6]UK\%JF#I]3"YU=\G[)4;#\,IW,*R(,9"P;L\\BR*[7&\,
M"7+$UU#0;E%@K13^"P=%6`K,<K#YM6:&K]$L1"[.HA,";S`E88S_`L/=2$;S
M%!8F"+K0KSA(Q[RDKR5Z*3TFH3NA,L`NJ+Q_Z%^(,9?`[G#1$:#78:DKT%,0
MCX/<0>S$],\LYX3[2N0AI?M@76Y+RL`)7.RCE>;I+X3S'2^B%>L97[_!9+FW
M/,@FLOQA;^PZ"@U9VUR7G6L1L&-%[46+N#9_;RM1VDJ4JMBQE2BU5:(L<@8D
M"U!6T.E%2DW3#'G*39J;"2I:;O*S<044Q,M-FIL(JZ;<9"HKMMQD8[G)S\9F
M?S:7@&A6'TMXC,T:YH.G,0_?_)18L8SJ,_-O[<W',)%[Q>]!"0,)TPFI-??L
M07T#-;CI,0J6]0&,U<6T6G,)P&I=8/U5_(A(04B*)VJ&=/JN/`RH#I[FVIL,
MMJQCHUB#"_$[SJX!A^NL!-K8<[TKG*N<JT69DB-CE=BNX*USN!<0=]'`W6R(
M@3$:!?(G5KAEM<:-.)^RP)$5:UFQY@L#*Q`WUU:U#<0YX@H+Y,_LZT;F==,6
MIEKB+'Y@6ZV:)TZY0%K"7&*1A@6X%YA+5)JTF+<F2!0P?Q4_K/L.LQI3("1K
MID!5PN#1\RM0(#6I&<R*[*H%C"<2[2+[+IQ:<-Q(OBN0/#;W-%6-Y$9J9@'B
MB;&/.+W2N)*W6Z!Y:JR]036:&^G=!8;F.H^5^3^Y2P`4H'Y1_WXE=,U[`*J4
M1[ZQ0$0!GKD%XB6J<BS'R#35%2E0_&KL3:,&Q?8J,P64%^9J/FJPA!0B6J!Z
M:K!FK@A5>!FK`MQC8PVH>K!MK(56H'JR;[J2-*J;M?-*,(U5WM6`":FP6("J
MP4EH@N+96'^S`,_<X&N)HJ<UV[NN>FL!IH1K:>_`7*WH6T"X=R&V*N2QH<YS
M`>S>O3"5`-M>,;P`6,(EM!\`-U:<+V`T..A5IZ"N]"`HP51^(;VA\)48))7U
M?2D6('Z64-KW0R(;>Y,4,$JHZ6;#*-"SI@!5(ES/;%#A5)90U9`?MU,O2EA3
MJP(V#;J[`;!M=#HK\%+?[W:6+A'E-HS-0FW1_*[`3KVK)\/N)O!V!CGN?H@%
M:A)>G9Z_4:#M)E<B!Y;;8BZP.CLRUA+!OR_EVJ`64)J;G:2L+^U"#X3VW2TP
M-M>UH!QC4#_F`F!S<Y%T"7%]5^X"5'/3C92#VO86/.LB@>C7PV4HZ?WQ9_9C
M]NM/:'3`_OSQ=+="F&+&)C";./0R_N22Z>&B..]A[+R3@$SGV7`E""\3Q!)=
MG6!.X7I.IE,GG`]'SW@<X!%VF;,ZBS:E&#X2'[M+'5/J:@`_T1'^4#)")C81
MGL[*0GZ_KL.R\KOH/::+API)V1"RCB#2W)TB'#M!GEQ/S]2(CNHM$N\?E^`9
MCO(-X/B%)K*\`>ATFF;Q0M&\]('M,;OG;1>K=>Y<!5];7K3F2\V,%G(N4E.T
MXN-M7M3U<^&I'GID7*W,%F%LK1XJ$>.XLX@T'60E,*>F`2->5O7(6+V?S[C2
MO3Y20M^!H:"C9P)+^7U$85H=!ZC_5WW:#\5^A3.]U_B-$P946HKAA%3K!B)6
M![8ZL-6!K0Z\^Y>YU8&M#FQU8+4Z<(/B8**R^AV%8Q0R%]-#\H9\<A>XP^`_
MG2!QPOG).67P`JC"\A/LAV++P6_GO0R7[.DBNB\O1:L(6T78*L)6$=[]&]TJ
MPE81MHJP6D685XLP42N^=7"81OB6/X*&<C21Z(?F6\FAWDNY:D@A%;>%D-5L
MK69K-5NKV>[^%6TU6ZO96LU6K6;;HCR8J-`N:FJMEM,"*;1-)/JAT%9RJ/<N
MKJU5)FG"A=&UZJY5=ZVZ:]7=W;^WK;IKU5VK[JI5=V&ZA(G:+RM#A;,>/:RF
M`TFCD5$@D*#'0:D?NG`3HWKOZX:1)95B*&6K%ENUV*K%5BW>_?O=JL56+;9J
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M:#A:6]FYP()`*=9.K$9DGM`;.TO2+M+/,Q_'HD+33@C*VC5B)0/39`IZ'(\1
M6[GH'O\CP1Y.\U"_$8I#NLQA(,JVW""ZQ2BO$G2-(C?$L[Q8O*+^.`+$[6O8
MOH;M:]B^AG=?K;>O8?L:MJ]A/34-`0I%IT_D/F*G0`<M,#2WY3('ANW/CP*G
MDWW?IYQ/R0*P4_-OOT;`&BT)!4J?C_83)2Z348F2.;;0Y:Y=J?8$-7'6$^B'
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M#[6KIW1_3(A/MT>4U9W<"'B%Z:P<Y#1/Z3$D+D)>=$O/E[LH2IS`S8H#34F0
ML@'T.K41@Z8?OOPD_X-",@RH0(9HH[3Y=S1]12&WQ'!2TXQY,2#_>[;VTZY8
MY7TUUGRHF<T'%%\YT83*WQNFY^#E_`>]ZNZ"X8P=#(R)[*;;R$IOG@.$JN8)
M%F-FQ0Y83"AD)I6?0[?B@![V+IZQDS93O%X(U4/">!"'V/%O\6N(_2R(XH7]
M@'M3@NE"&7](V+8>CAXI$7J'1OF]QBS;T0NY">C-Q\\M'S$HBSF5]1P4>O7F
M>0*/2_<_4]42QX>8'A0,(C@E;NTAU4)!UC,EPVC>N-^==SQ-IOSW5,V'NMG$
M@2";JQ]J9O/)"<8(SN3*9UVP"+TMES[:1;-Y;ZS0*H\BO2>0=CG<'%?$5-U$
M99L&$([9$;GE,=C`K6!/[*$17,+6:YS=6XT$5=Q^J_)S8A)F]0K".A0+3:4$
MX\PT`6I2Z$BM=ED"<KZO@*R^"DI`+DP#1,T1H^2)6/I#K"K0\%(G2LP,)=C&
M'7KJ+#T$9(PJ(37ZE%`#*=@:61;H,/ITD$:WT19=5J:PNYX'1(AKHL36.*U)
M[3MDS6>U^A;Y;!)NS>Z]*D@V'K5GQCWPV]RSBQN"TXE<(F5<J)>6(XTC>*"`
M](N%E`=2K@"3`M1SX\+EU&N'FR%'!7P7'1R(6ZBI)18%UT"A'^%M50SJ=<BL
MEX]@TN>R&A/83SBCWKA):?8M_8[P>$('&M##A&ZEQ2LTY25B9S=*]Y8+F1,_
MS6U,+D<VXV:8Q%'L!![3F[R_)U',#A7IN?(,L<UU76))[>)N$M8?+5:^/0=O
M=.^G`=!D2=?(+TWP1,&DNYRJ\$1$&EJXA*K#/FXNJI.]6E?*[ZR=9<OG-#C@
M23,7X%8:3;?/ICVUM6D&)SD;42(14;)G>8WKFH5(S$@]C6V^ZEMGQI7L:-R[
M4SK9T3A[K42<A_FEWZL=K+PWD<'^>Y$+GG2CIICNONY&UR2UNK'I[M7MXLOS
MB"J;2JB/M".QX^_="@#?ZR7^9I[K_<"?QT!4!B,8IY?U:"4JS9*EF]T>0DJ@
M;[5REQY6Y8H-7>U7TAOG2^Z5DO?!K!'JK2MFP:?F%!GZC/.8,.$W](S<)$P#
M9F[>73^A4V1^:.8[3.)<C#<L"%,66`+*IE$S(-3NN*"STDE&,(>4BY92PVA.
M7;%]=).J-9-:,ZDUDZHQDQIG:+`UX6PZG%XSZ>:%9+#70>+6)Q!%Q.!2<&#-
MCBC70TVL$_<=A6,4_H[CR4/"`@;O`G<8_*<3)$XX/SFG#%Z(!<2!Z?;C;<;/
MMEZ%:]'5FLKE*[,ST/E?.N&87BR/2>A.G`A]HW\O*T/"WV:B(VC6-!=L#=Q_
M)#C"C*T%/X\A=E%9&/,J"=E9,8@B%$<L.600>.P/%OC[YO@L/4P$#T4#]P:F
MC,WT]]AAA.F.\-/CC_Y#,D7>`Q(2&T4#=P\3JY[*VE!G;&4JV\H,)-'@H`\U
M%V2'4G$.O?PDSRPL.\_+8/_W0+D0M7`(4A>W>7"?L3(F$)%!K$7$6D0D+FBA
M@D/-=+;YN..:H;6.6.N(M8Y(6D=$[JK],99(J`M$3L4QW9HBIU<2636X-*<8
M=QQJAU?FS57&S!Q9W-7@SF42*'$W+FY:#^Y0TU09D61.:O*M@\._.7Z"RA\)
M-NK@H-0/&VP3HT"C0T$JVYF7*/Z)4/`?&(64K\G\GN7(1R^A$T14%B)^(ZH$
M<7`MW]5CY(J^PG#$RKL,1]])@.;?G?!/%-\F@1<Q'>F[$^?N#>YY2(P`G4S5
MT@X\#V>;4M2"!:2JV3)0??Q7\`@Q$P"(JE@3E2O1-?X%#Y>.SVJJ/$\0BK^%
M))E1D<[+UCA^\3B[<M(K`69L5#>6[CKW:QM8H.!]#86N5C$[7+\CAPF3-V37
M/E6V\EC\Z$=`7B,4OK$7]ETP2^+5J-W+>?KYE>]$D4#S&6T\=+8%EL8&=[2I
M)V(-Y5LWE"^M3M79`S:?\]'K:E++%[F`4;V9SE9KK?',D$"790],[2!YMP9X
M:X`7D!F.FV\/ZO6W*P]54"E7D0RNN-"9CDO:U7B#2Q2H.P9$'W<&MRM0_MHF
M$!-"Z3HR[O("VV2(D)6H3&'?`Y51HV@VV!E-KQ(@9LPE\E9GTY/^Y8`5<TN4
MOK,.SH..?&>/(9FA,&:5\IFDI;60Q7QG')3ZX3MK8E2O[68Q,NO%$B\/#PPP
M;Z:COXED,F5U')!WC>CBN9F*3?_NHW3W!\S9',;XK_3GM;Q")JQN3,W@U(Y,
M[U18L=4V2E`7UCU].2%6(NEN.@O)6WJ=1S\B-$K\>SSB[VS:2F=;",/F`B(G
MTEN6WL\4&%9)?O.T$>K2S4=P6^@+N09YJ&F>4*4XPSV`C61T.]/3O$P4/I-1
M_)-J37?T,@W&F+[84^T&/AE.@KH='4D88*K0LJX,M_B=_4U@89JHZ"X(L9!F
M.-<;GW8D0A(LUY+8UHGT0IF&^[.YR&UK2I=SQ@742<U%SKJKM^ZN?G8GR$M\
M5%[QFT((SOCBIKDMF1;Q77,0VZ91C7^N1&2E]L"3#=X*UIMMO=F"<@.Z)O?`
MMPW1/GC@6U:<]L!A#=%'"8?ZO`?.9T'(&J`RUI4L"%73*]C@5@"*]F2+'<1@
M1[LD@(U6L1(V8^\"+>K(?47LS/'^W0WU(0C\QG*#`SS$_!`\\K?L&"D!-&X/
M"P/(YR7K-)9@1Y#C=7V6W:G-K.LA@YTZ3_D"Y>,3<=-).OVD,`YF&*?&O,,`
MC9W5OL2[!'-S!$8!G8;J$1MM/[8?*"36BH*?8._#AMI:4]25^UO:H&O[\N9]
MAH((/>/`I<\.%Z72PATN`">LV?K/<Q1!'`!\]*!A&U4K+)KES45+O#YDNS""
M`C)DJ%O/X?8]A[M2$=)Z`=N\@+9`I/7H68^>0(%(T)VU/Y4A110%`M%A3"\`
M"5$*"51#+>UG9I89!((G^'CIM%AC1\]MUM<8IPU<(Y:M2`*6]H4"%XN6MN,G
MV(_G-@>_T!8!V$=13`+TZ,S38S!!CXA*BL>C=+91`/<K<-[Q-)G2SUT&ZQ@-
M1T].D/Y!YH[/DOA>)DY\Y027Z#*A-_Y/_N>_$&WP!'"@;P(BM,&O_67J*=GY
M\-7'J57RA=`5_D%%.KR+HV&(QSA@%Z7+3I_!.$2(-X%)U4@JQ&ME9(@YB8^8
M"@$29Y&+&)3%04#B"0K9M>/2M5K?_M&/&;VB9LS!LVZL;&`51A3<UU4IKYJ8
M7"?WW?'0Y9S9XYU@+GP:KU'1;,H8SEBG:WHGI:Z^Z#9A034+,<Q1HO=#7O48
M8M>`4A;*!/Q.+]0)75X<9BHJ/8NX@:\GT"WF3W3ZN4H(3*!M(:3=&IYIH&S8
M*_HG!O%>];5FAE]0X`3Q$\+3UX3JPZD$0EBN_AXJM\,`O>#I8K>_D'LG\'RJ
M^]^2\`']3%?2>PS1%$>`PKXPHN`+Q/?)SQ?R@L(I*](MH#LT4(`R\X3'DSAZ
M(3>IMLXH<G-1]2G\9LH>"2FFH-$KOA0Z\T"#\@RF**$^1`Y55Y#CWT3,VK5X
M-$-V6#T-@=SENG>7J"\,0E+<)=;^8)1QB8&H6Y>8=8D!4F]K!:N0/A'W&)#P
M-HW\8AA8MYEUFUFWF:3;#'2O[8_;3$29(`+JCNG>,P%MDO!HM:8[SL1P6W^X
MF-[%3`*EBC=EB9;=BVMH5;W_RPP&,UNU2<#58+0I4#LS\PJ50`UFBBN`_&*<
M0JO@YJRVN!:8?;7"MXE9E6&]0.S"WJ";B+6X48HTF&,K;E5*6J4+K0#MLY6X
M5HEK]8V6:%HE94T$6]SG!7)?+'(;;P>NJ(@"P7.KH:PKR*`8F!)(^S#;V,0\
M<4\%@%;OVP"0*[:M`-"J@>L`*@AN+-&U5PW'_FZ-A%W@>6*>KT?'=@?@:>^?
M%B5R*2*^0*V+UU]'61DLB26>YWV1@C&#ZW<G#!WVZA#*RN`GV(^L#`Y^-8=+
ML!9^PU$^Z#!,+=/#)(YB)_`H1Z`(B59:NCN/9Z>[0,/QU0]ULYD=F@)LKGZH
MF<WT((<SN?)9%RQ"Z[<O?00.^41C'-'3$GG7.*1/K>&(GK)4LJ_H;D:@F&\.
M2E#F7GZ2_T$A&0:(_N_ZP<*_CORT5*$'Y*V-C.X`LZI3[N:=:D`X0H\AU<:+
M?XSR?P6)IQA]<%@JQRC/]")#RZH=$T[6(19[^6\P38<$Z>_Q!X'J&%KE]%F$
M3VE%!J8TP@F#\^R2T)TX!5(Y#C%Q__P1\&4^<)'1'D]*1[J+HH3NXH3MW@R.
M;#VIROQ&55(*$F.,_3UF56*?68OBO!\C_WZ2'4DS$+FDP._9M0^UY]B\QG<!
M?;4D:54V9RK0"Z:>1J?,0_6%JJ_AI;#P&[W4[ZB$1>G+\"YX3%Y][&9WJ[@>
M`2>LOR21BY`7W=+W,-MUK`ONRO$"@9Z#6`?AY/E8=X'K)^P=4_9%?72P=Q=<
M.3,<\V6!"I'=AD+SD+!CA5[$Q4EXY?@^\B[GRG4;R%#=K79V/V3WAN#*KI(`
MYW?5FP9$$X<@)'7?_\EKA/Z1L`B'-R38[K">AOC3Z87^GKK'4R,UW?W^%@/"
M+^J-3[MB%7HUKWVH^%9.&U;3S4#/9*`$P`GKWFZ.+Z"P+7_5`8/0U2^_L0F"
M&QQUGB"X>AC#TP0KO^^@I2C%1R`;</W+;28GU<R"M(&[#UE]35)I<_ML;A^'
MC&Q>-WO0M6[C/B;5:L$>=*"KT)V(L)ZW!^WG>/?3FO*^NJD^FXA,]3NG"I*-
M[75L7*A,VSN5P%[3!F>P@B^J6KN(Z0FL`C8SPF&Z*V$S,]Y7$C99HVZ9^6JE
MLE$JVUT%IB<1RT')X4XJ\XF5O_W>4/A*=A5"06=C":>Q^@OOK5SE1E[5>;^8
M"$^#[[T6G.70@#)CV%@#1&MLQ1)0:U$?)3KF/K_;/(5$X&`K4F3,,WTJN"=E
M0Z9*=(UK'"]]A;:$W94Y_L9M:%GHX*&59<M5N\L!8(H&X99P&V?;U/5,;HWK
M+EO?&JO^--C7VT+]RW(4QAEFX.;1ADR-LOB$O54X1:SB$7MB?:!+N5.K;]>O
M)J*RF5ZV#L7Z!CLY-^[J:TH'7()C+3>Q!,2X)P`O(*LYI04@7ZTNRJD<K:0.
M+_`[[:)H0$?I[ZGB?,GJ,+(R42B(\O:6(IGO7+3ZD?3>S*KFYB!^&M>'O&HF
M\G)[D$A`7HJZ0QGIFI(Y0L\H?*-OB6IF!N-QB%@IF7(Q(J'H1_G!>@%'MG2I
M*>L)N60<X+^0EUD/KD@4PSJ<:!M:=Q(]8J9G-TXM?5>4VS$"9#SP4-$=>HQ\
M2G/\#04HI-=,X`V\*;U\F:3%^`WE.U!@3D#"^M<)T=-V0OFX1F_()VG[WYP)
MH05K)[<3N_0)S4B8.@;@*0ZZ.-`M\NX$>8F/AB,U$[B<EU,`IV%HY\6F=VQP
MU'EZA^)%AN>'Z&%`=^9YH?JDQO*"O2?D,Y4QY22=P&M:C3TOURFBDLF.M%4'
MN!J4B'9IV8>,&:T;W:;<V)2;+H2L.]UD'W*!NE(VB7Z]?`_RE30_J@CP":DQ
MXVG[$;7=8PZT293H*_?#["/Z35:N,E?+*H>R][9R&VJY.,8J5;I,WN!E:;3[
MEPMAK*=<G2N&P-U,9090!Z=0'_RDQRH=I06Q'?"4'FMVE986EQ6Y91[Z<=II
MXG*^8909_'1";YC*5_0W>E<BCVHHB[8T+X3]:,FK_SMB;G[Z.U25<,948MBU
MRRY6$J3[('%\UO-Q;5%:[(0]XEJW359RJDNQTWU<"2'V>@XY7(Q.NH1<B+TN
M(-^\/C?F=*EJ0Z_$9(/1WR*G/5^(^OV\-<2Y6>HYM#T49DZ6_O#QD=__0^26
MA".$XU1)3_=GGFD4W>7)1GV!79+1;2]#Q+=A4?>X*^:L[T!_2R-W>X<RA*UM
M0VSLF=U[:-L5J:P\3;^4NP5//0=W26?J'L6*P7L.UU:%;F-P4]2M7JE4VVV6
MD_[CFA("PT>`>L_E9U5-^!:2"!;1JF/XGD/6KW.J]W"U'@HB,9P=,@5ME<#K
MD]AT'[;U2A"@;./!MQ\/'CMQ*I+P0.ZU+VT$MID1V&O+O`^AT]5[PL8\VYCG
M1ND0O09+T(RK?B.I<Y"MZ%3E>IA;[+1SM5GA4E:\,LJJ\<JWT"Q[1<=.&-N%
MT_">-K@H>S\63<`L5`8?VC7IXT;B,&66%;O%ES#%-BF>9MD"IJ^EPR"->?7L
M&JJWZ1<K]T737783>'8#*O=?%<MV;L_,/BX9O^.V6,FO=B7[N)+<X0UE$6[E
M753LJV`[P4!E;6KC&N.8L9C`^+FR+K9=SSZ>M9)QJ&5A;[N\?5Q>8'1WL9QG
MFBY4^S3I+A>B+"9O]V8?%U(VC:A8WW.[OMK6M^LDO:+\^+%R9[-]TFPWY;58
M6H,['^_RHJK,*"_6^K2#F)&.JCO<!?37T(OSCB*QTO?U!/I1Q:&"/[TQ;\6`
M-^_.%`?Y3"G;/I445O4E]&`AXIP$H4&E2\#4]8AHBQYM(B$>X[JY8C)QK8W4
M;"RKC64%[^M2MD0"51O);/.:YYF?#3&U(:8VQ%0RQ+3Q1MJ?L%*>:YYP*!H&
M!W[RZFD$K"R6A0"W]93Y]9#QSIYM]+_\?U!+`P04````"`#FBJU".,=QKI<0
M``#KK@``$0`<`&%B:6\M,C`Q,S`S,S$N>'-D550)``/`69%1P%F1475X"P`!
M!"4.```$.0$``.U=7W/;QA%_[TR_`ZJ'C#T-15*R[%BUTJ%$*55',CD4G:1]
MR9R`(WDQ>&#N#I+83]_=`T""!`C@",HZM72<,0GL[NWN;[&W]P_\]/>GJ>\\
M4"%9P,\.VH>M`X=R-_`8'Y\=A+)!I,O8P=]__/.?/OVET7`&@Z[3<15[H%TF
M73^0H:!O[F[?.K^>#VZ<.W="I\3I!FXXI5PY#6>BU.RTV7Q\?#P<,4ZXRXA_
M*(1WZ`;3IM-H)'(O!"4*5'"Z1%%'_SEUCEKMXT;KI-$^'AZU3D].3M]]/#P^
M_N%C^ZCUUU;KM-5*"?@Y,L%)_3EUP!SX[_V[%%V?N%_)F#K7W11=Z_*BU6EW
MWG_X<'5Q<O+AW<7%^0^71]U.]^CDHG/YKMMHP9^/K0_O3][!Q_9Q*RWQ(IC-
M!1M/E//&?:MU=@:'^+<;<$Y]G\Z=[YR[@$N@G,X(GQ\Z'=]W!L@BG0&55#Q0
M[S"6*",7`BI<GG*0$$[/#E)>?+H7_F$@QDU/B:::SV@3B!I`105S#V(^P`UO
MR07GB,A[S97<:8*>1XU6NW'<3IBDFHD%@VY&4O=P'#PT\0XRM-<8F+N!GKDY
MY(P_4*GR.:)[.4HAE;?&A'8<M5HGS>AF0DKN6;#B*B)<O#:;$#$E.N`0G-;Q
M4CIX8TS(+-=->"-'(8^R?!/@Q@;]63Z`8,(Q&"X5/!4TH7>#D"LQSV\BOIG3
MC,_XUX)6\/8]D8M6GC+TC\>:NOWQX\>FOKM0*!0"$L(FC>*[.2IQPER9SZ5O
MY40(?7(G^1QX)Z^-\H<C>3"(4H+=AXI>!6+:I2,2^A!6(?\C)#X;,>I!WO,I
M9JT5@M1M1<28JL]D2N6,N-0LU/*<#="TF[_>WD19\P">?L?YQ*:S0"@G2@,W
M@:NS8@&T^*V11%$#+S7`2\?MPR<).O-<;3>%8+.&"DF(;:7",CZW4B')!-CV
MR:96\U-'I?8T:VYN:%)?R452;2PC=),6Q8G8W/KU0$<7?$3WM]]7<G_V0:FC
M0\`_UU4CW9GM"AR\8HA-)OM7UR4O6R=?*FA1FO'--4GUKO%G4SUR^F=S-9(>
M$C^8*K#>NYJWOBAB]*?&LO>IU'ZF!#)78-&'Z4^F#LCT@%L$9+JS7GPS#LF\
M+M]<F64-$'TT!21;0VP1$G&=BA^,`V*MQHU;)YP'2C>IO^.5V8SQ41!_A0O8
MV9V*P*=#2'@.\\X.AG0Z\V'<<Z/K+KSU97!=L;YH(GES58)93;C0+-'-HS!4
M8]H&'/?`*"L]HDN:<K"M3\UUCG5AH:1>C_^H/\\$#'9XY)X4=TQ2Q.D2WPW]
M+1B7FFWFBZ\FD*PAE?AI0$>.KHQ/`0RD+:Z?FS,1S*A0#+KX5/FM!4P$'9T=
M(*"-!,;?P,)#P"TAR32P"IX&?<TIL9*)!,44BKA8$FG$Y/<.\1?-8)][=B#A
MF?'I<XXEFB_C5$#?U*FK`9/OT^Z"IM2E+V2X3^Y-#0<6ZF^V^09OVVHN)!93
M<]=S4;[5_125L?&+'&^8T15Y"G@PG4>*)JDW^;?#O4L.ZLVOH5<!7E3M0'<C
M`R#_K1)Y4<IOY^3\Q4?"/2<2YZ3DF?4"6^?R[;N/^KW`;K"\`^7U',-%P&7@
M,P^^>N?$Q^'WW812);]P$GI,X7S#`E(3KC)DVXCL0J"#LY=+F4XLU(FD.F_"
M1.[;/<0[@[A/H'Y6$ZH8N&D[O#>(*`/_R`C\E4;>[H-A5\&PN"A[HQ[T<MH^
M"7D:EP<$G5`NV0.]"63U9+"-R+)@.2X,EF6+3C!REFWJ'F*E50>;W4?/<T0/
M5"<C"J-QN!BX7P%N_>\D\#TJY.4?(7336*JZ3&T52=N(+XNJ=P91M6C?T0WK
MT$JK\!V9!?)O3J2)\R;699^I;(FUE0[DF0-OM:VR*#SYME&XWI?NHW)747E!
MY.3*#QZWZRISN,LBY[U!Y*!X1\O?IZ1M!KZ+#2;#"8VW3F`N"*=3(N:]T1T;
M<P8/&X%!KJL72A@?]P$+EU&9'A'7DE,6$!_T4'G1!$Z03FBRTR-*%E%#&!&I
MIIQE6T[2V#XTC$,#B\L^%7?`0G,Q7R$H`_.'#)BZ>`5^1PO8`V0,T"T58RI^
M86KR.7R@?G#-W1[_)^$A/!)''W"9.!>V"FQE8'[,@!D)=1Y!JA.)_=X!P8=.
MP)U8MG/TX7L'Q>^A-H;ZBC#Q,_'#U-;`_#R<2U@"9[N5@1/%.%I.ZOH^B9H#
MUX]FV[%7Q#)VAA5,+G"YA&7`M3/`)6*BZ>1$T!XX8^"@S)@RI0M./=FCRPG*
M-Q9`1?1E,!YE8$Q)BZ=]4O+V:!JC&0TAKZ)MTGR,$/U"A(!B,1_-(OHR-(\S
M:,8#V*4XC6DB<`^G,9RZ8CPGH`*.!BB7F:6Z,M(R$-]E0-2"&EJ2DQ:UA\\8
M/B@,@RD=DJ<-N31]OPRHDPQ0$;>CV??@?(L9@5W/#%2=(6B_W^$,@?,F^;2?
M1ZHW63`D]_Z&8,@A*\,X.PNT.G'@O(D$[5';S>BD`+T"\C(4L],_^2.5/9J[
MKHH*\"QD*$,T.P<454CWF0IIC^DW[8V[5!'F[ZPS3L25Q,-1=A*I3E\<M[H/
MF7I=<5$LY-&5@9R=<%KOC/?`[1*X(7U2X<H*?R7R,ABS$TX;8'1BB7LXGV-Y
MINCIK,Y=!G9V/LIDL6;_1.]XV:8(]"+Z,IBS,U;YBSA[0'<\8"H"M(B^#-#L
MS-:F(=,>T.<`M*COK<!6!F]V[JH$WGU?_"RK>46/;P6V,IBSTU>%:WO[A_EY
M5OF*4*[`5H9R=GJK>,UO#_/.Y[F*$"[F*`/79*9K#^OSP-HVQ[5=!NQQ=LJJ
M%%BGO8>VUH)OT6.:0U8&879"*KW\^W_Q/'YJIM^#`=]6WY/Q*7[WEG8X`O=;
MT?GESKU4@K@J>DG'V4$UVNBPMGXAVRE<@^[N6M$IZGC@R!#(F`J1XR<1A+.$
MD`')@1-]AKJ7!=Y0B_%"$6_GX,SW<>7@[$")$$21N,'D>[/$P"+EP<L4E93K
MEE9DLLQD@X/,&<NWXWUU#L@_V;N%-TH%6>::GPCC.+_;XQTIV9CCW=ZH#W9Q
M%;TJ,[&]"F7:N&G`(;^*^3.;-R*^?DF%9KZ/H#@[<`4%QQM&Q!;'>:M%2#W!
MED5,?-*NXT(JQ'Z0>MT0E>I2G"S6TQ)@[YC>TND]%8L,:L@5&1V]B/74"Z80
M?"]J-1XJ^TPAX'NC$47%+P*IY*J-Q32V673%A%374H;XQ%P%XG.@**2O.<J"
MT!Q0C1(`!E*\:ZXHE"]JU>!:(JSV1V^DSYJ"3:BV[U,79]>22;@;YL(C2Z.L
M5^"2+:38YI4[Z@;<JQ<F]638[9&M`Z6V&-O\LA[Y()Q*Z`4?\(52(&]`/4JG
M*'GUG'GQ\V,JQ3:O#"=,U'Q\:HFPVA];/SQUI=CFE:L@%&I2O_.I*\8ZO[#1
M+MQ24XIM7LET'=NEVMIB[/,+&E!0H!<0V&;+>H;3FI\;8UQ;C&U^R0]:<\?4
MEV.;9[``H"@B,6;5X(VWK;?CO,20<ULMN6-/.^B]ZDJQSBOT`6=(=S"`JBO'
M-L\L3<%M(`%/#,)O5.!/.!6X8TMF>WV@EUOE,+A\HFZ(OWQU%][_#J@.@P&=
MA<*=$$DWN<"$US8/1/!%'1'^M-;:'..&N[99H0>I%0>XU6AML[#C_1Y*%?]R
MT15R@#CB1Z&WZ*R*B5:F]O6U;[-:4F[3,.AX'HNT[1,&:%R0&5/$'U!<@W!5
M7`T!9A0>IBL13),[D0IKYM>5]VI6EBJ8O'QZ>Z-DTQ>$QVJ9:>#"BO+^EUQX
M";I.,5DL=L4O3<=N@'H&_JLB[-4X3X,=:1VML/5UL]JLQ"CH%J$BD$LG&3*]
M=F=$Z=?4&QNY;,OBJ0+PEHBO5/4AC=+EZ_K2E<1FJKB_A<YV%E^K857T8W>J
MAE%0N)%YO.<`,''9C/@]_C/E'G2L>B,M[8P%I=%+M"(3S7A>353_(J#-WFC4
M&W7C##\D3S<,[OE,S1/CRZA>C;EK]6"/IQ=`X@D;,"Z(=E6GIPE,N*QQAT?O
M"\&/\D^4GJYQ),"IKI'P.."%=N45<5<CP83EM?@AQG<1VV"AC,IK/:^[%@:;
MR5Z+O<69SOJ<5F)=T3&+Y0L*Z),Z]U.UL2G7RA!2)==?MK->WP`U8/*KO&%@
M&3R6>(;LIT"O58`7!=?O0)AG_%!/AHU>&5`<T5!=G=S-(#-ML+R<SD;KXJ1T
M^81G".)76F5M*Z.RT3+3%XCHE[]D-E'6E6+9CLFMS*GEBZU<X*G3"=P7;GBO
M'?FLSEA/66#?.9$L^A6*Q3&)^%3K^L&#>C(LBX[/(<YOZIW4#+<(Q\;UH>/$
M&6PN`OSANWBFM!)MVD`&]>^8BA?.=Q"A./C"'PR))`<`F%`=\#[QK]B]0,D:
M++RP2("F;&G#$[5?UO+A8_!O*H(>I\,)%&7K!<O:8GTU8MLFPK$/YB']B7+<
MV;Z<1LE>MZ8:+1MR%KY()WLZJ"*U98EG@%L@<-A'HM5T_1OR1`4"\FB7\F`*
MD0??OD@]:%R>>NN-,,NZ2,7\$,\JI*Q>3]7/W(AE+JWR`B:S\,DR66;R)1$<
ML]/*VSOSN^U*I):9M\5+EPH`WD:&90Z)3%AH#7V6WH@1]UWX_V?0?4,$;,EL
MF0ORWL2TP>!*I*_`O.7*F8&A!4R6F8PGM[#<>B!^5%9S&$;@J*HWNH4Z91XM
MD%R%W)/X\-X2%0JFV'*=OX:`'1>M]5=:%E!VI*1*GE/U2"G_!X-^6[B3^0V.
MNJ2>2!U1(3M3'(!FPL"(]]74A3C>`OWB7TO,ON8I;Z!:C=ZR!^(&-V'@+RU>
M3V<B>(@.KT*1-@JA%!DM)B=*R;ZY666SK09OZ2KHQXV8+8,V]T7=^4F]$JEE
MYG7I3%`W&FZ`WI!BA&+_T5_CF=0[!L\Z5%YTEMZJ9,YG3=8J65LQ>6590<P;
M,5L6%`6Z;YYBK,QAF;$Z*0^IF*YDZ>B"?3-DET^*<@_&]^M:Y]RP3_MH,S5N
M-$9ET^KGW;&M-^SX?O`X#%`YG(;)+BL7$-B'!<Z;LBGM1UM^AL$-X9X?"`^/
MS-)''49>7]`ID\NZW8S'FHQ?5J=JQ6'@H2;0=[&HE2[@MY(1<N^G31S_BQ*A
MJ5X6V%OF4ZG`WS%,M\2CY_-X[6,QM5!,]&J@PV(#=T.OVR._P$BB,\,R>[E"
M4I%XQ\97'V*:[O3B@9I08>0",Y[7XHE;QMDTG/:I<'$=<TQ[HT$P)[Z:]^Y]
M-B;IRK4:;;QJ%&WG1,(7?J;)4W4#*]%:9N!F;7'7(43G%RANQ+62/<'&T+DF
MQ[,R??`.!%GFFKR`)7QI'];8$Z(N"#^GY^&\&SP6QGHIJVWFYX1S5?.W8;7-
M_+4,W0UIM+J_J2=/$=A7=/8%>X`G\9H_T.B4R37OA_!XNM'J?6J_Z>I:OSF?
M;<O^!9LO-ZW_&7!8-J8N@6OQ2@D_D#1=:)OSK80XLK[D4D`_/BNKCX:LG"S^
MPMFRARJABDP*90,_2%01K[_P1D6?2+DXYM43>K@>G^E!@<MQT6IR,N>S+V<5
MV9"`J!?GT_T,ABA$ZCGS5F%>.>[Z'))WV7WMXAC2F$D\4N)UF8`11_($KV;W
M,BK;<OERYQG\K;I)K8#4-OLVX9')UQ4(=YB@=[J@5?R^^X*)_<J,EO7)1>^&
M+S"WD-@R$U.Z;JBIBBA>T)A/3>E.Z)3`Q_\"4$L!`AX#%`````@`YHJM0F@0
M^#GUE0``@)H(`!$`&````````0```*2!`````&%B:6\M,C`Q,S`S,S$N>&UL
M550%``/`69%1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`YHJM0B;240+@
M"P``]IL``!4`&````````0```*2!0)8``&%B:6\M,C`Q,S`S,S%?8V%L+GAM
M;%54!0`#P%F1475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.:*K4+K^<*4
MXBX```)M`P`5`!@```````$```"D@6^B``!A8FEO+3(P,3,P,S,Q7V1E9BYX
M;6Q55`4``\!9D5%U>`L``00E#@``!#D!``!02P$"'@,4````"`#FBJU"'*Q8
M/TA5``!NOP0`%0`8```````!````I(&@T0``86)I;RTR,#$S,#,S,5]L86(N
M>&UL550%``/`69%1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`YHJM0I"0
MX@QU,0``P0($`!4`&````````0```*2!-R<!`&%B:6\M,C`Q,S`S,S%?<')E
M+GAM;%54!0`#P%F1475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.:*K4(X
MQW&NEQ```.NN```1`!@```````$```"D@?M8`0!A8FEO+3(P,3,P,S,Q+GAS
M9%54!0`#P%F1475X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``#=:0$`
"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>238</ContextCount>
  <ElementCount>198</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical) (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticalUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical) (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficitUnauditedParenthetical</Role>
      <ShortName>Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) (unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - The Company and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Merger with Nuvelo, Inc. on January 27, 2009</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009</Role>
      <ShortName>Merger with Nuvelo, Inc. on January 27, 2009</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosures</Role>
      <ShortName>Fair Value Disclosures</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Equity Financings and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrants</Role>
      <ShortName>Equity Financings and Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureTheCompanyAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>The Company and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Loss Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureLossPerShareDetailsTextual</Role>
      <ShortName>Loss Per Share (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Merger with Nuvelo, Inc. on January 27, 2009 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureMergerWithNuveloIncOnJanuary272009Details</Role>
      <ShortName>Merger with Nuvelo, Inc. on January 27, 2009 (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Fair Value Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureFairValueDisclosuresDetails</Role>
      <ShortName>Fair Value Disclosures (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosurePropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Equity Financings and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureEquityFinancingsAndWarrantsDetails</Role>
      <ShortName>Equity Financings and Warrants (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>Share-based Compensation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Share-based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureShareBasedCompensationDetails1</Role>
      <ShortName>Share-based Compensation (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20130331/taxonomy/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Element us-gaap_CommonStockIncludingAdditionalPaidInCapital had a mix of decimals attribute values: -6 0.</Log>
    <Log type="Info">Element us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">'Shares' elements on report '100020 - Statement - Consolidated Balance Sheets (Parenthetical) (unaudited)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '100200 - Disclosure - The Company and Summary of Significant Accounting Policies (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '100230 - Disclosure - Merger with Nuvelo, Inc. on January 27, 2009 (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 100010 - Statement - Consolidated Balance Sheets (unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2006'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2004'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2003'</Log>
    <Log type="Info">Process Flow-Through: 100020 - Statement - Consolidated Balance Sheets (Parenthetical) (unaudited)</Log>
    <Log type="Info">Process Flow-Through: 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss (unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column '1 Months Ended
Jan. 27, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2006'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2004'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '24 Months Ended
Dec. 31, 2003'</Log>
    <Log type="Info">Process Flow-Through: 100050 - Statement - Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) (unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 100060 - Statement - Consolidated Statements of Cash Flows (unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>abio-20130331.xml</File>
    <File>abio-20130331.xsd</File>
    <File>abio-20130331_cal.xml</File>
    <File>abio-20130331_def.xml</File>
    <File>abio-20130331_lab.xml</File>
    <File>abio-20130331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Non-cash, Share-Based Compensation Expense</a></td>
        <td class="text"><div>
			<p style="margin:4.5pt 0pt 9pt; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">For the three month periods ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 and 2012 and for the period from Inception through March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013, the Company recognized the following non-cash, share-based compensation expense in the consolidated statement of operations (in thousands): </font></p>
			<div style="text-align:center">
				<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:84%">

						<tr style="height:59.25pt">
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
							<th colspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:137.15pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Three Months Ended March 31,</font></p>
							</th>
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
							<th rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Period from December 17, 2001 (date of inception) to March 31, 2013</font></p>
							</th>
						</tr>
						<tr style="height:15.75pt">
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
							<th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">2013</font></p>
							</th>
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
							<th style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt; text-align:center"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">2012</font></p>
							</th>
							<th style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</th>
						</tr>


						<tr style="height:20.25pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
						</tr>
						<tr style="height:15.75pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Research and Development</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">15</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">26</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">605</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
						</tr>
						<tr style="height:15.75pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Selling, General and Administrative</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">27</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">65</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">1</font><font style="font-family:'Times New Roman'; font-size:10pt">,</font><font style="font-family:'Times New Roman'; font-size:10pt">638</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
						</tr>
						<tr style="height:15.75pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Restructuring Expense</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">0</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">0</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">387</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
						</tr>
						<tr style="height:16.5pt">
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:137.15pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">Total</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">42</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:63.05pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">91</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
							<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
							</td>
							<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:1.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:64.3pt">
								<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">2</font><font style="font-family:'Times New Roman'; font-size:10pt">,</font><font style="font-family:'Times New Roman'; font-size:10pt">630</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
							</td>
						</tr>
					<!--[if !supportMisalignedColumns]><tr style="height:0pt">
						<td style="width:143pt; border:none">
						</td>
						<td style="width:67.55pt; border:none">
						</td>
						<td style="width:11.55pt; border:none">
						</td>
						<td style="width:68.5pt; border:none">
						</td>
						<td style="width:12.3pt; border:none">
						</td>
						<td style="width:69.05pt; border:none">
						</td>
					</tr><![endif]--></table>
			</div>
			<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
		</div>
<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Stock Option Activities</a></td>
        <td class="text"><div>
			<p style="margin:9pt 0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Stock option transactions for the three month period ended March</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2013 under all plans are as follows: </font></p>
			<div style="text-align:center">
				<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:84%">
					<tr style="height:77.25pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> # of Options </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Weighted Average Exercise Price</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:center; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Weighted Average Remaining Contractual Term </font><br /><font style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(in years)</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:Calibri; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Options outstanding at December</font><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font><font style="font-family:'Times New Roman'; font-size:10pt">31, 2012</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">144,019</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18.28</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">4.91</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Changes during the period:</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Granted</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">-</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">0.00</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Exercised</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">-</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">0.00</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Forfeited, cancelled or expired</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">(6,259)</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">16.53</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Options outstanding at March 31, 2013</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">137,760</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18.36</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="border-bottom-color:#000000; border-bottom-style:double; border-bottom-width:2.25pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">4.89</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
					</tr>
					<tr style="height:15.75pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Options exercisable at March 31, 2013</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">123,408</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18.</font><font style="font-family:'Times New Roman'; font-size:10pt">82</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">4.62</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
					</tr>
					<tr style="height:15pt">
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:195.15pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">Options vested and expected to vest</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.8pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.1pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">136,208</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:54.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">$</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">18.</font><font style="font-family:'Times New Roman'; font-size:10pt">39</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:11.1pt">
							<p style="margin:0pt; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
						</td>
						<td style="padding-left:5.4pt; padding-right:5.4pt; vertical-align:bottom; width:62.95pt">
							<p style="margin:0pt; text-align:right; page-break-inside:avoid; page-break-after:avoid"><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:'Times New Roman'; font-size:10pt">4.88</font><font style="font-family:'Times New Roman'; font-size:10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></p>
						</td>
					</tr>
				</table>
			</div>
			<p style="margin:0pt"><font style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</font></p>
		</div>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
